<SEC-DOCUMENT>0001193125-22-203392.txt : 20220727
<SEC-HEADER>0001193125-22-203392.hdr.sgml : 20220727
<ACCEPTANCE-DATETIME>20220727160523
ACCESSION NUMBER:		0001193125-22-203392
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		89
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220727
DATE AS OF CHANGE:		20220727

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TEVA PHARMACEUTICAL INDUSTRIES LTD
		CENTRAL INDEX KEY:			0000818686
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-16174
		FILM NUMBER:		221111035

	BUSINESS ADDRESS:	
		STREET 1:		5 BAZEL ST
		STREET 2:		P O B 3190
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			49131
		BUSINESS PHONE:		9729267267

	MAIL ADDRESS:	
		STREET 1:		TEVA PHARMACEUTICAL INDUSTRIES LIMITED
		STREET 2:		5 BAZEL ST PO B 3190
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			49131
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>d360666d10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:teva="http://www.tevapharm.com/20220630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>10-Q</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style=""><div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P01_01_2022To06_30_2022">false</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="P01_01_2022To06_30_2022">Q2</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P01_01_2022To06_30_2022">0000818686</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="P01_01_2022To06_30_2022">--12-31</ix:nonNumeric><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="hidden52307726" contextRef="P01_01_2022To06_30_2022">00-0000000</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressCountry" id="hidden52307730" contextRef="P01_01_2022To06_30_2022">IL</ix:nonNumeric><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" id="hidden52308335" contextRef="P01_01_2022To06_30_2022_UnsecuredSyndicatedRevolvingCreditFacilityMemberusgaapCreditFacilityAxis">2026-04-30</ix:nonNumeric><ix:footnote id="FN_170208" xml:lang="en-US">Represents an amount less than $0.5 million.</ix:footnote ><ix:footnote id="FN_170214" xml:lang="en-US">Accumulated goodwill impairment as of June 30, 2022 and December 31, 2021 was approximately $26.3 billion and $25.6 billion, respectively.</ix:footnote ><ix:footnote id="FN_170217" xml:lang="en-US">In April 2022, Teva repaid $296 million of its 3.25% senior notes at maturity.</ix:footnote ><ix:footnote id="FN_170218" xml:lang="en-US">If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.125%-0.375% per annum, from and including May 9, 2026.</ix:footnote ><ix:footnote id="FN_170219" xml:lang="en-US">Interest rate adjustments and a potential one-time premium payment related to the sustainability-linked bonds are treated as bifurcated embedded derivatives. See note 8d.</ix:footnote ><ix:footnote id="FN_170220" xml:lang="en-US">If Teva fails to achieve certain sustainability performance targets, a one-time premium payment of 0.15%-0.45% out of the principal amount will be paid at maturity or upon earlier redemption, if such redemption is on or after May 9, 2026.</ix:footnote ><ix:footnote id="FN_170209" xml:lang="en-US">Contingent consideration represents liabilities recorded at fair value in connection with acquisitions.</ix:footnote ><ix:footnote id="FN_170215" xml:lang="en-US">Teva uses foreign exchange contracts (mainly option and forward contracts) to hedge balance sheet items from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, Teva recognizes gains or losses that offset the revaluation of the balance sheet items also recorded under financial expenses, net. [Ruble -to check 10K language]</ix:footnote ><ix:footnote id="FN_170216" xml:lang="en-US">Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on projected revenues and expenses recorded in euro, the Swiss franc, the Japanese yen, the British pound, the Russian ruble, the Canadian dollar and some other currencies to protect its projected operating results for 2021 and 2022. These derivative instruments do not meet the criteria for hedge accounting, however, they are accounted for as an economic hedge. These derivative instruments, which may include hedging transactions against future projected revenues and expenses, are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. In the first six months of 2022, the positive impact from these derivatives recognized under revenues was $35 million. In the first six months of 2021, the positive impact from these derivatives recognized under revenues was $13 million. Changes in the fair value of the derivative instruments are recognized in the same line item in the statements of income as the underlying exposure being hedged. The cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows.</ix:footnote ><ix:footnote id="FN_170213" xml:lang="en-US">Including impairments related to exit and disposal activities.</ix:footnote ><ix:footnote id="FN_170212" xml:lang="en-US">Includes adjustments for foreign currency translation.</ix:footnote ><ix:footnote id="FN_170211" xml:lang="en-US">Amounts do not include a $68 million loss from foreign currency translation adjustments attributable to non-controlling interests.</ix:footnote ><ix:footnote id="FN_170210" xml:lang="en-US">Amounts do not include a $150 million loss from foreign currency translation adjustments attributable to non-controlling interests.</ix:footnote ></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="teva-20220630.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="teva-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="teva-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="teva-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="teva-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references><ix:resources><xbrli:context id="P01_01_2022To06_30_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_01_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-08-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_21_2017To08_21_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-08-21</xbrli:startDate> <xbrli:endDate>2021-08-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_31_2008" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2008-07-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_28_2005" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2005-02-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2013To04_30_2013" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2013-04-01</xbrli:startDate> <xbrli:endDate>2013-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_01_2013To09_30_2013" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2013-09-01</xbrli:startDate> <xbrli:endDate>2013-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2010To12_31_2010" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2010-12-01</xbrli:startDate> <xbrli:endDate>2010-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2012To08_31_2012" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2012-08-01</xbrli:startDate> <xbrli:endDate>2012-08-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2014To12_31_2014" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2014-01-01</xbrli:startDate> <xbrli:endDate>2014-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_05_2021To08_05_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-08-05</xbrli:startDate> <xbrli:endDate>2021-08-05</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P06_02_2022To06_02_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-06-02</xbrli:startDate> <xbrli:endDate>2022-06-02</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_08_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P02_04_2022To02_04_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-02-04</xbrli:startDate> <xbrli:endDate>2022-02-04</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DemandDepositsMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:DemandDepositsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DemandDepositsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:DemandDepositsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:EquitySecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:EquitySecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >teva:OtherRestrictedCashMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >teva:OtherRestrictedCashMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >teva:OtherRestrictedCashMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SeniornotesandconvertibleseniordebenturesMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >teva:SeniornotesandconvertibleseniordebenturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SeniorNotesAndSustainabilityLinkedSeniorNotesMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >teva:SeniorNotesAndSustainabilityLinkedSeniorNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis" >us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:TradeNamesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >teva:ProductRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_InterestRateSwapMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:InterestRateSwapMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_InterestRateSwapMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:InterestRateSwapMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherCurrentAssetsMemberusgaapBalanceSheetLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NondesignatedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:ShortCreditAgreement2026Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_SeniorNotesAndLoansMemberusgaapBalanceSheetLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NondesignatedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >teva:SeniorNotesAndLoansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2028OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2024OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2046Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2023TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2026OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SubsidiarySeniorNotesDue2027MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2027Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2022OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2022ThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SubsidiarySeniorNotesDue2025ThreeMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2025ThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2036Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SubsidiarySeniorNotesDue2022TwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2022TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SustainabilityLinkedSeniorNotesDue2029MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilityLinkedSeniorNotesDue2029Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SustainabilityLinkedSeniorNotesDue2027TwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilityLinkedSeniorNotesDue2027TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2025TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2028Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2025Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2025OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SustainabilityLinkedSeniorNotesDue2027MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilityLinkedSeniorNotesDue2027Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2023OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SustainabilityLinkedSeniorNotesDue2030MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilityLinkedSeniorNotesDue2030Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2024Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_OtherDebentures2026MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:OtherDebentures2026Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >teva:OptionsAndForwardContractsDerivativeLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >teva:OptionsAndForwardContractsDerivativeLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CrossCurrencyInterestRateContractMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_DemandDepositsMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:DemandDepositsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_DemandDepositsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:DemandDepositsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_TevasApiReportingUnitMemberusgaapReportingUnitAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis" >teva:TevasApiReportingUnitMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_InternationalMarketsReportingUnitMemberusgaapReportingUnitAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis" >teva:InternationalMarketsReportingUnitMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:EquitySecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:EquitySecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >teva:OtherRestrictedCashMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >teva:OtherRestrictedCashMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >teva:OtherRestrictedCashMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_SeniornotesandconvertibleseniordebenturesMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >teva:SeniornotesandconvertibleseniordebenturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_SeniorNotesAndSustainabilityLinkedSeniorNotesMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >teva:SeniorNotesAndSustainabilityLinkedSeniorNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis" >us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:TradeNamesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >teva:ProductRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:ShortCreditAgreement2026Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_InterestRateSwapMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:InterestRateSwapMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_InterestRateSwapMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:InterestRateSwapMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_ActavisMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:ActavisMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherCurrentAssetsMemberusgaapBalanceSheetLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NondesignatedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_SeniorNotesAndLoansMemberusgaapBalanceSheetLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NondesignatedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >teva:SeniorNotesAndLoansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2036Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2022ThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_SubsidiarySeniorNotesDue2025ThreeMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2025ThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2024OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2046Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2023TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2026OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_SubsidiarySeniorNotesDue2027MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2027Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2022OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2028Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2025Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2025OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_SustainabilityLinkedSeniorNotesDue2027MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilityLinkedSeniorNotesDue2027Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2023OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_SubsidiarySeniorNotesDue2030MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2030Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2024Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2028OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2025TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_SustainabilityLinkedSeniorNotesDue2027TwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilityLinkedSeniorNotesDue2027TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_SustainabilityLinkedSeniorNotesDue2029MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilityLinkedSeniorNotesDue2029Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_SubsidiarySeniorNotesDue2022TwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2022TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_SustainabilityLinkedSeniorNotesDue2030MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilityLinkedSeniorNotesDue2030Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_OtherDebentures2026MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:OtherDebentures2026Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_MeasurementInputTerminalGrowthRateMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >teva:MeasurementInputTerminalGrowthRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_MeasurementInputTerminalGrowthRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >teva:MeasurementInputTerminalGrowthRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_MaximumMembersrtRangeAxis_MeasurementInputTerminalGrowthRateMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >teva:MeasurementInputTerminalGrowthRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_TevasEuropeReportingUnitMemberusgaapReportingUnitAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis" >teva:TevasEuropeReportingUnitMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_NorthAmericaAndMedisReportingUnitsMemberusgaapReportingUnitAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis" >teva:NorthAmericaAndMedisReportingUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_MeasurementInputProbabilityOfSuccessMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >teva:MeasurementInputProbabilityOfSuccessMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_WeightedAverageMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:WeightedAverageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >teva:OptionsAndForwardContractsDerivativeLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >teva:OptionsAndForwardContractsDerivativeLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_CrossCurrencyInterestRateContractMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_NorthAmericaMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_EuropeMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_LicenseMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_EuropeMembersrtStatementGeographicalAxis_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_LicenseMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_DistributionServiceMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:DistributionServiceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_DistributionServiceMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:DistributionServiceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_DistributionServiceMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:DistributionServiceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_DistributionServiceMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:DistributionServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_NorthAmericaMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_EuropeMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_NorthAmericaMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_EuropeMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis" >us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis" >us-gaap:OtherRestructuringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:OtherProductsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:OtherProductsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_COPAXONEMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:COPAXONEMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_AjovyMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AjovyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_GenericsMediciansMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:GenericsMediciansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:OtherProductsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_RespiratoryProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:RespiratoryProductMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_COPAXONEMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:COPAXONEMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_AjovyMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AjovyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_GenericsMediciansMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:GenericsMediciansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_AndaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AndaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_COPAXONEMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:COPAXONEMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_BendekaAndTreandaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:BendekaAndTreandaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_AustedoMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AustedoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_AjovyMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AjovyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_GenericsMediciansMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:GenericsMediciansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_ParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:ParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >teva:ProductRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_GenericPipelineProductsMembersrtProductOrServiceAxis_InprocessresearchandDevelopmenttoProductRightsMemberusgaapReclassificationTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ReclassificationTypeAxis" >teva:InprocessresearchandDevelopmenttoProductRightsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:GenericPipelineProductsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_CorporateMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >us-gaap:CorporateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_AllOtherSegmentsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_SegmentsAndOtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:SegmentsAndOtherActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NondesignatedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:NetRevenuesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NondesignatedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NotDesignatedAsHedgingInstrumentTradingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:NetRevenuesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NotDesignatedAsHedgingInstrumentTradingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:NetRevenuesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_SettlementOnAccountOfProductLiabilityMembersrtLitigationCaseAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:LitigationCaseAxis" >teva:SettlementOnAccountOfProductLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_DistributionServiceMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:DistributionServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_DistributionServiceMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:DistributionServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_NorthAmericaMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_EuropeMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_NorthAmericaMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_EuropeMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_NorthAmericaMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_EuropeMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_LicenseMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_EuropeMembersrtStatementGeographicalAxis_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_LicenseMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_DistributionServiceMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:DistributionServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_DistributionServiceMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:DistributionServiceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis" >us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis" >us-gaap:OtherRestructuringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:OtherProductsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_COPAXONEMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:COPAXONEMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_AjovyMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AjovyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_GenericsMediciansMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:GenericsMediciansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:OtherProductsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_RespiratoryProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:RespiratoryProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_COPAXONEMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:COPAXONEMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_AjovyMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AjovyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_GenericsMediciansMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:GenericsMediciansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:OtherProductsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_AndaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AndaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_COPAXONEMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:COPAXONEMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_BendekaAndTreandaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:BendekaAndTreandaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_AustedoMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AustedoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_AjovyMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AjovyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_GenericsMediciansMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:GenericsMediciansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_ParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:ParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_ActavisMemberusgaapBusinessAcquisitionAxis_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_USsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:ActavisMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >teva:ProductRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_GenericPipelineProductsMembersrtProductOrServiceAxis_InprocessresearchandDevelopmenttoProductRightsMemberusgaapReclassificationTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ReclassificationTypeAxis" >teva:InprocessresearchandDevelopmenttoProductRightsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:GenericPipelineProductsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_ActavisMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:ActavisMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >teva:ProductRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_CorporateMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >us-gaap:CorporateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_AllOtherSegmentsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_SegmentsAndOtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:SegmentsAndOtherActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NondesignatedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NondesignatedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:NetRevenuesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NotDesignatedAsHedgingInstrumentTradingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:NetRevenuesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NotDesignatedAsHedgingInstrumentTradingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:NetRevenuesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_EuropeMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_NorthAmericaMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_EuropeMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_LicenseMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_EuropeMembersrtStatementGeographicalAxis_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_LicenseMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_DistributionServiceMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:DistributionServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_DistributionServiceMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:DistributionServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_DistributionServiceMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:DistributionServiceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_DistributionServiceMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:DistributionServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_NorthAmericaMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_EuropeMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_NorthAmericaMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis" >us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis" >us-gaap:OtherRestructuringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:OtherProductsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_COPAXONEMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:COPAXONEMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_AjovyMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AjovyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_GenericsMediciansMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:GenericsMediciansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_GenericsMediciansMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:GenericsMediciansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_AjovyMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AjovyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_COPAXONEMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:COPAXONEMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:OtherProductsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_RespiratoryProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:RespiratoryProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:OtherProductsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_AndaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AndaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_COPAXONEMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:COPAXONEMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_BendekaAndTreandaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:BendekaAndTreandaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_AustedoMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AustedoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_AjovyMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AjovyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_GenericsMediciansMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:GenericsMediciansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_EmployeeTerminationMemberTEVAExitAndDisposalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis" >teva:EmployeeTerminationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis" >teva:OtherExitAndDisposalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_ParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:ParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_NoveTideAcquisitionMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:NoveTideAcquisitionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ReservesIncludedInAccountsReceivableNetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:RebatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:MedicaidAndOtherGovernmentalAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ChargebacksMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ReturnsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:OtherSalesReservesAndAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:TotalReservesIncludedInSalesReservesAndAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_ActavisMemberusgaapBusinessAcquisitionAxis_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_USsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:ActavisMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >teva:ProductRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_GenericPipelineProductsMembersrtProductOrServiceAxis_InprocessresearchandDevelopmenttoProductRightsMemberusgaapReclassificationTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ReclassificationTypeAxis" >teva:InprocessresearchandDevelopmenttoProductRightsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:GenericPipelineProductsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_ActavisMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:ActavisMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >teva:ProductRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_SegmentsAndOtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:SegmentsAndOtherActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_AllOtherSegmentsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_CorporateMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >us-gaap:CorporateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_AccountingStandardsUpdate201601MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis" >us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NondesignatedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:NetRevenuesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NondesignatedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NotDesignatedAsHedgingInstrumentTradingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:NetRevenuesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NotDesignatedAsHedgingInstrumentTradingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:NetRevenuesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_CostOfSalesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:CostOfSalesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_EagleTransactionMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:EagleTransactionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_ActavisGenericsMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:ActavisGenericsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_NorthAmericaMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_EuropeMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_LicenseMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_EuropeMembersrtStatementGeographicalAxis_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_LicenseMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_DistributionServiceMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:DistributionServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_DistributionServiceMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:DistributionServiceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_DistributionServiceMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:DistributionServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_DistributionServiceMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:DistributionServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_EuropeMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_NorthAmericaMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_EuropeMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_NorthAmericaMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis" >us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis" >us-gaap:OtherRestructuringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:OtherProductsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_COPAXONEMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:COPAXONEMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_AjovyMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AjovyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_GenericsMediciansMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:GenericsMediciansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_RespiratoryProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:RespiratoryProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_AjovyMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AjovyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_COPAXONEMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:COPAXONEMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_GenericsMediciansMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:GenericsMediciansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:OtherProductsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:OtherProductsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_AndaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AndaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_COPAXONEMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:COPAXONEMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_BendekaAndTreandaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:BendekaAndTreandaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_AustedoMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AustedoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_AjovyMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AjovyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_GenericsMediciansMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:GenericsMediciansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_EmployeeTerminationMemberTEVAExitAndDisposalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis" >teva:EmployeeTerminationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis" >teva:OtherExitAndDisposalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_USsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_ParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:ParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_NoveTideAcquisitionMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:NoveTideAcquisitionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_OtherCountriesMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >teva:OtherCountriesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:ShortCreditAgreement2026Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_TakedaMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:TakedaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_AlvotechMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:AlvotechMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:TotalReservesIncludedInSalesReservesAndAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ReservesIncludedInAccountsReceivableNetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:RebatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:MedicaidAndOtherGovernmentalAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ChargebacksMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ReturnsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:OtherSalesReservesAndAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis" >us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >teva:ProductRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_GenericPipelineProductsMembersrtProductOrServiceAxis_InprocessresearchandDevelopmenttoProductRightsMemberusgaapReclassificationTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ReclassificationTypeAxis" >teva:InprocessresearchandDevelopmenttoProductRightsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:GenericPipelineProductsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_SegmentsAndOtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:SegmentsAndOtherActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_AllOtherSegmentsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_CorporateMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >us-gaap:CorporateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_EosinophilicEsophagitisMemberusgaapLossContingenciesByNatureOfContingencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis" >teva:EosinophilicEsophagitisMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_EosinophilicEsophagitisMemberusgaapLossContingenciesByNatureOfContingencyAxis_USsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis" >teva:EosinophilicEsophagitisMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2024Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_SustainabilityLinkedSeniorNotesDue2030MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilityLinkedSeniorNotesDue2030Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2023OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_SustainabilityLinkedSeniorNotesDue2027MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilityLinkedSeniorNotesDue2027Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2025OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2025Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2028Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_SustainabilityLinkedSeniorNotesDue2027TwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilityLinkedSeniorNotesDue2027TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_SustainabilityLinkedSeniorNotesDue2029MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilityLinkedSeniorNotesDue2029Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2022TwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2022TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2036Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2025ThreeMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2025ThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2022ThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2022OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2027MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2027Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2026OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2023TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2046Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2024OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2025TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2028OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NondesignatedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:NetRevenuesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NondesignatedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NotDesignatedAsHedgingInstrumentTradingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:NetRevenuesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NotDesignatedAsHedgingInstrumentTradingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:NetRevenuesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_InternationalMarketsMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_CostOfSalesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:CostOfSalesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_EagleTransactionMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:EagleTransactionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_ActavisGenericsMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:ActavisGenericsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_UnsecuredSyndicatedRevolvingCreditFacilityMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >teva:UnsecuredSyndicatedRevolvingCreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_InterestRateIncreaseMemberusgaapDebtInstrumentAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:InterestRateIncreaseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_InterestRateIncreaseMemberusgaapDebtInstrumentAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:InterestRateIncreaseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_MaximumMembersrtRangeAxis_OneTimePremiumPaymentMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:OneTimePremiumPaymentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_MinimumMembersrtRangeAxis_OneTimePremiumPaymentMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:OneTimePremiumPaymentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_OneTimePremiumPaymentMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:OneTimePremiumPaymentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_InterestRateIncreaseMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:InterestRateIncreaseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_30_2022_UnsecuredSyndicatedRevolvingCreditFacilityMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >teva:UnsecuredSyndicatedRevolvingCreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-04-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_30_2022_SeniorNotesMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >us-gaap:SeniorNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-04-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2022To12_31_2022_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2023To06_30_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2023To12_31_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-10-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2016To09_30_2016_RegeneronMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:RegeneronMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-07-01</xbrli:startDate> <xbrli:endDate>2016-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2016To09_30_2016_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >teva:SeniorNotesDue2023TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-07-01</xbrli:startDate> <xbrli:endDate>2016-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2016_SeniorNotesDue2022MemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >teva:SeniorNotesDue2022Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2016-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2016_SeniorNotesDue2021MemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >teva:SeniorNotesDue2021Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2016-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2016_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >teva:SeniorNotesDue2023TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2016-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2019_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >teva:SeniorNotesDue2023TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2021To10_31_2021_ModagMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:ModagMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-10-01</xbrli:startDate> <xbrli:endDate>2021-10-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2021To10_31_2021_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis_TaxYear2008To2011MemberusgaapTaxPeriodAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis" >us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis" >teva:TaxYear2008To2011Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-10-01</xbrli:startDate> <xbrli:endDate>2021-10-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2021To12_31_2021_ModagMemberusgaapBusinessAcquisitionAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:ModagMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-10-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_08_2018To01_08_2018_AlderMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:AlderMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-08</xbrli:startDate> <xbrli:endDate>2018-01-08</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_AlderMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:AlderMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_12_2017To05_12_2017_OtsukaMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:OtsukaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-05-12</xbrli:startDate> <xbrli:endDate>2017-05-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To09_30_2020_OtsukaMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:OtsukaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To09_30_2021_OtsukaMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:OtsukaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_01_2016To09_30_2016_RegeneronMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:RegeneronMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-09-01</xbrli:startDate> <xbrli:endDate>2016-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2017To12_31_2017_RegeneronMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:RegeneronMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-01-01</xbrli:startDate> <xbrli:endDate>2017-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2017To12_31_2017_CAsrtStatementGeographicalAxis_VireadMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:CA</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:VireadMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-01-01</xbrli:startDate> <xbrli:endDate>2017-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_RegeneronMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:RegeneronMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2021To08_31_2021_MedincellMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:MedincellMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-08-01</xbrli:startDate> <xbrli:endDate>2021-08-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2016To12_31_2016_TakedaMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:TakedaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-12-01</xbrli:startDate> <xbrli:endDate>2016-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_01_2022_NoveTideAcquisitionMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:NoveTideAcquisitionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_31_2019_AndroGelRateAtOnePercentageMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AndroGelRateAtOnePercentageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-08-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_01_2021_AtripalaMembersrtProductOrServiceAxis_CAsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:CA</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AtripalaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_01_2021_CAsrtStatementGeographicalAxis_ColcysMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:ColcysMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:CA</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_01_2021_CAsrtStatementGeographicalAxis_VireadMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:CA</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:VireadMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_01_2021_CAsrtStatementGeographicalAxis_TiruvadaMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:CA</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:TiruvadaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CAsrtStatementGeographicalAxis_TiruvadaMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:CA</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:TiruvadaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AtripalaMembersrtProductOrServiceAxis_CAsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:CA</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AtripalaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_01_2019To05_31_2019_OpioidLitigationMembersrtLitigationCaseAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:LitigationCaseAxis" >teva:OpioidLitigationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-05-01</xbrli:startDate> <xbrli:endDate>2019-05-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_21_2019To10_21_2019_OpioidLitigationMembersrtLitigationCaseAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:LitigationCaseAxis" >teva:OpioidLitigationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-10-21</xbrli:startDate> <xbrli:endDate>2019-10-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_21_2021To07_21_2021_FourOtherDefendantsOtherThanTevaMemberTEVADefendantsAxis_NationwideSettlementMembersrtLitigationCaseAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:LitigationCaseAxis" >teva:NationwideSettlementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="teva:DefendantsAxis" >teva:FourOtherDefendantsOtherThanTevaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-21</xbrli:startDate> <xbrli:endDate>2021-07-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_04_2022_AttorneyGeneralOfLouisanaMemberTEVAAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:AgreementAxis" >teva:AttorneyGeneralOfLouisanaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-02-04</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P02_04_2022To02_04_2022_OpioidLitigationMembersrtLitigationCaseAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:LitigationCaseAxis" >teva:OpioidLitigationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-02-04</xbrli:startDate> <xbrli:endDate>2022-02-04</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_30_2022_AttorneyGeneralOfFloridaMemberTEVAAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:AgreementAxis" >teva:AttorneyGeneralOfFloridaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P03_30_2022To03_30_2022_OpioidLitigationMembersrtLitigationCaseAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:LitigationCaseAxis" >teva:OpioidLitigationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-03-30</xbrli:startDate> <xbrli:endDate>2022-03-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_24_2022To05_24_2022_OpioidLitigationMembersrtLitigationCaseAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:LitigationCaseAxis" >teva:OpioidLitigationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-05-24</xbrli:startDate> <xbrli:endDate>2022-05-24</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_24_2022_AttorneyGeneralOfWestVirginiaMemberTEVAAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:AgreementAxis" >teva:AttorneyGeneralOfWestVirginiaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-24</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_12_2022To07_12_2022_OpioidLitigationMembersrtLitigationCaseAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:LitigationCaseAxis" >teva:OpioidLitigationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-12</xbrli:startDate> <xbrli:endDate>2022-07-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_12_2022_OpioidLitigationMembersrtLitigationCaseAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:LitigationCaseAxis" >teva:OpioidLitigationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-07-12</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P09_28_2021To09_28_2021_AttorneyGeneralOfLouisanaMemberTEVAAgreementAxis_LAsrtStatementGeographicalAxis_OpioidLitigationMembersrtLitigationCaseAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:LitigationCaseAxis" >teva:OpioidLitigationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="teva:AgreementAxis" >teva:AttorneyGeneralOfLouisanaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >stpr:LA</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-09-28</xbrli:startDate> <xbrli:endDate>2021-09-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_28_2021_AttorneyGeneralOfLouisanaMemberTEVAAgreementAxis_LAsrtStatementGeographicalAxis_OpioidLitigationMembersrtLitigationCaseAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:AgreementAxis" >teva:AttorneyGeneralOfLouisanaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:LitigationCaseAxis" >teva:OpioidLitigationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >stpr:LA</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P03_21_2022To03_21_2022_OpioidLitigationMembersrtLitigationCaseAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:LitigationCaseAxis" >teva:OpioidLitigationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-03-21</xbrli:startDate> <xbrli:endDate>2022-03-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_21_2022_AttorneyGeneralOfRhodeIslandMemberTEVAAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:AgreementAxis" >teva:AttorneyGeneralOfRhodeIslandMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-21</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_01_2022_CompaniesShareMemberTEVADefendantsAxis_StatesPoliticalSubdivisionsAndTribesMembersrtLitigationCaseAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:LitigationCaseAxis" >teva:StatesPoliticalSubdivisionsAndTribesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="teva:DefendantsAxis" >teva:CompaniesShareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-07-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To07_31_2022_CompaniesShareMemberTEVADefendantsAxis_StatesPoliticalSubdivisionsAndTribesMembersrtLitigationCaseAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:DefendantsAxis" >teva:CompaniesShareMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:LitigationCaseAxis" >teva:StatesPoliticalSubdivisionsAndTribesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-07-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_31_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-07-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_31_2022_CompaniesShareMemberTEVADefendantsAxis_StatesPoliticalSubdivisionsAndTribesMembersrtLitigationCaseAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:LitigationCaseAxis" >teva:StatesPoliticalSubdivisionsAndTribesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="teva:DefendantsAxis" >teva:CompaniesShareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-07-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_TreasuryStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:TreasuryStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_ParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:ParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_ParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:ParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_TreasuryStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:TreasuryStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_ParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:ParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_TreasuryStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:TreasuryStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_TreasuryStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:TreasuryStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_ParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:ParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_TreasuryStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:TreasuryStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:ParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_EmployeeTerminationMemberTEVAExitAndDisposalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis" >teva:EmployeeTerminationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis" >teva:OtherExitAndDisposalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_EmployeeTerminationMemberTEVAExitAndDisposalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis" >teva:EmployeeTerminationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis" >teva:OtherExitAndDisposalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ReservesIncludedInAccountsReceivableNetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:RebatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:MedicaidAndOtherGovernmentalAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ChargebacksMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ReturnsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:OtherSalesReservesAndAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:TotalReservesIncludedInSalesReservesAndAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ReservesIncludedInAccountsReceivableNetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:RebatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:MedicaidAndOtherGovernmentalAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ChargebacksMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ReturnsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:OtherSalesReservesAndAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:TotalReservesIncludedInSalesReservesAndAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_TreasuryStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:TreasuryStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:ParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_NorthAmericaMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EuropeMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_InternationalMarketsMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_OtherCountriesMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >teva:OtherCountriesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EmployeeTerminationMemberTEVAExitAndDisposalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis" >teva:EmployeeTerminationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis" >teva:OtherExitAndDisposalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_EmployeeTerminationMemberTEVAExitAndDisposalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis" >teva:EmployeeTerminationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis" >teva:OtherExitAndDisposalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ReservesIncludedInAccountsReceivableNetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:RebatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:MedicaidAndOtherGovernmentalAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ChargebacksMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ReturnsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:OtherSalesReservesAndAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:TotalReservesIncludedInSalesReservesAndAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ReservesIncludedInAccountsReceivableNetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:RebatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:MedicaidAndOtherGovernmentalAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ChargebacksMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ReturnsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:OtherSalesReservesAndAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:TotalReservesIncludedInSalesReservesAndAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_NorthAmericaMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_EuropeMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_InternationalMarketsMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_OtherCountriesMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >teva:OtherCountriesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_USD" > <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year" > <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure" > <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares" > <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_CHF" > <xbrli:measure>iso4217:CHF</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_EUR" > <xbrli:measure>iso4217:EUR</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><xbrli:unit id="Unit_Segment" > <xbrli:measure>teva:Segment</xbrli:measure> </xbrli:unit><ix:relationship fromRefs="Fact_52307110" toRefs="FN_170208"/><ix:relationship fromRefs="Fact_52307132" toRefs="FN_170208"/><ix:relationship fromRefs="Fact_52307165" toRefs="FN_170208"/><ix:relationship fromRefs="Fact_52307391" toRefs="FN_170214"/><ix:relationship fromRefs="Fact_52307392" toRefs="FN_170214"/><ix:relationship fromRefs="Fact_52307393" toRefs="FN_170214"/><ix:relationship fromRefs="Fact_52307394" toRefs="FN_170214"/><ix:relationship fromRefs="Fact_52307395" toRefs="FN_170214"/><ix:relationship fromRefs="Fact_52307401" toRefs="FN_170214"/><ix:relationship fromRefs="Fact_52307402" toRefs="FN_170214"/><ix:relationship fromRefs="Fact_52307403" toRefs="FN_170214"/><ix:relationship fromRefs="Fact_52307404" toRefs="FN_170214"/><ix:relationship fromRefs="Fact_52307405" toRefs="FN_170214"/><ix:relationship fromRefs="Fact_52307410" toRefs="FN_170217"/><ix:relationship fromRefs="Fact_52307411" toRefs="FN_170217"/><ix:relationship fromRefs="Fact_52307419" toRefs="FN_170218"/><ix:relationship fromRefs="Fact_52307419" toRefs="FN_170219"/><ix:relationship fromRefs="Fact_52307420" toRefs="FN_170219"/><ix:relationship fromRefs="Fact_52307420" toRefs="FN_170218"/><ix:relationship fromRefs="Fact_52307421" toRefs="FN_170218"/><ix:relationship fromRefs="Fact_52307421" toRefs="FN_170219"/><ix:relationship fromRefs="Fact_52307425" toRefs="FN_170219"/><ix:relationship fromRefs="Fact_52307425" toRefs="FN_170220"/><ix:relationship fromRefs="Fact_52307426" toRefs="FN_170220"/><ix:relationship fromRefs="Fact_52307426" toRefs="FN_170219"/><ix:relationship fromRefs="Fact_52307427" toRefs="FN_170219"/><ix:relationship fromRefs="Fact_52307427" toRefs="FN_170220"/><ix:relationship fromRefs="Fact_52307452" toRefs="FN_170220"/><ix:relationship fromRefs="Fact_52307452" toRefs="FN_170219"/><ix:relationship fromRefs="Fact_52307453" toRefs="FN_170219"/><ix:relationship fromRefs="Fact_52307453" toRefs="FN_170220"/><ix:relationship fromRefs="Fact_52307454" toRefs="FN_170220"/><ix:relationship fromRefs="Fact_52307454" toRefs="FN_170219"/><ix:relationship fromRefs="Fact_52307455" toRefs="FN_170219"/><ix:relationship fromRefs="Fact_52307455" toRefs="FN_170218"/><ix:relationship fromRefs="Fact_52307456" toRefs="FN_170218"/><ix:relationship fromRefs="Fact_52307456" toRefs="FN_170219"/><ix:relationship fromRefs="Fact_52307457" toRefs="FN_170219"/><ix:relationship fromRefs="Fact_52307457" toRefs="FN_170218"/><ix:relationship fromRefs="Fact_52307481" toRefs="FN_170209"/><ix:relationship fromRefs="Fact_52307482" toRefs="FN_170209"/><ix:relationship fromRefs="Fact_52307503" toRefs="FN_170215"/><ix:relationship fromRefs="Fact_52307504" toRefs="FN_170215"/><ix:relationship fromRefs="Fact_52307505" toRefs="FN_170215"/><ix:relationship fromRefs="Fact_52307506" toRefs="FN_170215"/><ix:relationship fromRefs="Fact_52307507" toRefs="FN_170216"/><ix:relationship fromRefs="Fact_52307508" toRefs="FN_170216"/><ix:relationship fromRefs="Fact_52307509" toRefs="FN_170216"/><ix:relationship fromRefs="Fact_52307510" toRefs="FN_170216"/><ix:relationship fromRefs="Fact_52307515" toRefs="FN_170215"/><ix:relationship fromRefs="Fact_52307516" toRefs="FN_170215"/><ix:relationship fromRefs="Fact_52307517" toRefs="FN_170215"/><ix:relationship fromRefs="Fact_52307518" toRefs="FN_170215"/><ix:relationship fromRefs="Fact_52307519" toRefs="FN_170216"/><ix:relationship fromRefs="Fact_52307520" toRefs="FN_170216"/><ix:relationship fromRefs="Fact_52307521" toRefs="FN_170216"/><ix:relationship fromRefs="Fact_52307522" toRefs="FN_170216"/><ix:relationship fromRefs="Fact_52307555" toRefs="FN_170213"/><ix:relationship fromRefs="Fact_52307556" toRefs="FN_170213"/><ix:relationship fromRefs="Fact_52307557" toRefs="FN_170213"/><ix:relationship fromRefs="Fact_52307558" toRefs="FN_170213"/><ix:relationship fromRefs="Fact_52307612" toRefs="FN_170212"/><ix:relationship fromRefs="Fact_52307613" toRefs="FN_170212"/><ix:relationship fromRefs="Fact_52307614" toRefs="FN_170212"/><ix:relationship fromRefs="Fact_52307617" toRefs="FN_170217"/><ix:relationship fromRefs="Fact_52307618" toRefs="FN_170217"/><ix:relationship fromRefs="Fact_52307619" toRefs="FN_170217"/><ix:relationship fromRefs="Fact_52307779" toRefs="FN_170211"/><ix:relationship fromRefs="Fact_52307780" toRefs="FN_170211"/><ix:relationship fromRefs="Fact_52307781" toRefs="FN_170211"/><ix:relationship fromRefs="Fact_52307826" toRefs="FN_170210"/><ix:relationship fromRefs="Fact_52307827" toRefs="FN_170210"/><ix:relationship fromRefs="Fact_52307828" toRefs="FN_170210"/><ix:relationship fromRefs="Fact_52307829" toRefs="FN_170210"/><ix:relationship fromRefs="Fact_52307908" toRefs="FN_170212"/><ix:relationship fromRefs="Fact_52307958" toRefs="FN_170211"/><ix:relationship fromRefs="Fact_52308001" toRefs="FN_170209"/><ix:relationship fromRefs="Fact_52308002" toRefs="FN_170209"/><ix:relationship fromRefs="Fact_52308225" toRefs="FN_170212"/><ix:relationship fromRefs="Fact_52308226" toRefs="FN_170212"/><ix:relationship fromRefs="Fact_52308383" toRefs="FN_170218"/><ix:relationship fromRefs="Fact_52308383" toRefs="FN_170219"/><ix:relationship fromRefs="Fact_52308385" toRefs="FN_170219"/><ix:relationship fromRefs="Fact_52308385" toRefs="FN_170220"/><ix:relationship fromRefs="Fact_52308389" toRefs="FN_170217"/><ix:relationship fromRefs="Fact_52308397" toRefs="FN_170219"/><ix:relationship fromRefs="Fact_52308397" toRefs="FN_170220"/><ix:relationship fromRefs="Fact_52308398" toRefs="FN_170218"/><ix:relationship fromRefs="Fact_52308398" toRefs="FN_170219"/></ix:resources></ix:header></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;;display:inline;">UNITED STATES </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">WASHINGTON, D.C. 20549 </div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">FORM <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentType" contextRef="P01_01_2022To06_30_2022">10-Q</ix:nonNumeric></div> </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 12pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><ix:nonNumeric name="dei:DocumentQuarterlyReport" contextRef="P01_01_2022To06_30_2022" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the quarterly period ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="P01_01_2022To06_30_2022" format="ixt:date-monthname-day-year-en">June 30, <ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="P01_01_2022To06_30_2022">2022</ix:nonNumeric></ix:nonNumeric> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OR </div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 12pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><ix:nonNumeric name="dei:DocumentTransitionReport" contextRef="P01_01_2022To06_30_2022" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Commission file number <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="P01_01_2022To06_30_2022">001-16174</ix:nonNumeric></div></div> </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 24pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 24pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P01_01_2022To06_30_2022">TEVA PHARMACEUTICAL INDUSTRIES LIMITED</ix:nonNumeric> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exact name of registrant as specified in its charter) </div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 50%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 48%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P01_01_2022To06_30_2022" format="ixt-sec:edgarprovcountryen">Israel</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><span style="-sec-ix-hidden:hidden52307726">Not Applica</span>ble</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(State or other jurisdiction of</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">incorporation or organization)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(IRS Employer</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Identification Number)</div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2022To06_30_2022">124 Dvora HaNevi&#8217;a St.</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2022To06_30_2022">Tel Aviv</ix:nonNumeric>, <span style="-sec-ix-hidden:hidden52307730">ISRAEL</span></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2022To06_30_2022">6944020</ix:nonNumeric></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Address of principal executive offices)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Zip code)</div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">+972 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2022To06_30_2022">3</ix:nonNumeric>)&#160;<ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2022To06_30_2022">914-8213</ix:nonNumeric></div> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Registrant&#8217;s telephone number, including area code) </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Securities registered pursuant to Section&#160;12(b) of the Act:</div></div></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 34%;"></td>
<td style="vertical-align: bottom;"></td>
<td style="width: 32%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 32%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Title of each class</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Trading Symbol(s)</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name of each exchange on which registered</div></div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="P01_01_2022To06_30_2022">American Depositary Shares, each representing one Ordinary Share</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="P01_01_2022To06_30_2022">TEVA</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="P01_01_2022To06_30_2022" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="P01_01_2022To06_30_2022">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744; </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-T</div> (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;<ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="P01_01_2022To06_30_2022">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744; </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-accelerated</div> filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act. </div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 20%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 55%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 20%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 2%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P01_01_2022To06_30_2022" format="ixt-sec:entityfilercategoryen">Large accelerated filer</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9746;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Accelerated&#160;filer</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9744;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 6pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 6pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 6pt; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-accelerated</div> filer</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9744;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Smaller&#160;reporting&#160;company</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="P01_01_2022To06_30_2022" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 6pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 6pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 6pt; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">Emerging&#160;growth&#160;company</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P01_01_2022To06_30_2022" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744; </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;No&#160;&#160;<ix:nonNumeric name="dei:EntityShellCompany" contextRef="P01_01_2022To06_30_2022" format="ixt:fixed-false">&#9746;</ix:nonNumeric> </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">As of June&#160;30, 2022, the registrant had</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;<ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="PAsOn06_30_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,110,564,656</ix:nonFraction> ordinary shares outstanding.</div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 6pt; text-align: left;;font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED</div></div></div><div id="index" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">INDEX </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 7%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 89%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART&#160;I.</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><a href="#tx360666_1">Financial Statements (unaudited)</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;1.</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx360666_2">Financial Statements (unaudited)</a></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx360666_3">Consolidated Balance Sheets</a></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx360666_4">Consolidated Statements of Income (loss)</a></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx360666_5">Consolidated Statements of Comprehensive Income (loss)</a></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx360666_6">Consolidated statements of changes in equity</a></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx360666_7">Consolidated Statements of Cash Flows</a></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx360666_8">Notes to Consolidated Financial Statements</a></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;2.</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx360666_9">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">50</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;3.</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx360666_10">Quantitative and Qualitative Disclosures about Market Risk</a></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">81</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;4.</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx360666_11">Controls and Procedures</a></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">81</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART&#160;II.</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><a href="#tx360666_12">OTHER INFORMATION</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;1.</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx360666_13">Legal Proceedings</a></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">82</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;1A.</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx360666_14">Risk Factors</a></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">82</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;2.</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx360666_15">Unregistered Sales of Equity Securities and Use of Proceeds</a></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">82</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;3.</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx360666_16">Defaults Upon Senior Securities</a></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">82</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;4.</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx360666_17">Mine Safety Disclosures</a></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">82</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;5.</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx360666_18">Other Information</a></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">82</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;6.</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx360666_19">Exhibits</a></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">83</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx360666_20">Signatures</a></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">84</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1 </div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">INTRODUCTION AND USE OF CERTAIN TERMS </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Unless otherwise indicated, all references to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;Teva&#8221; refer to Teva Pharmaceutical Industries Limited and its subsidiaries, and references to &#8220;revenues&#8221; refer to net revenues. References to &#8220;U.S. dollars,&#8221; &#8220;dollars,&#8221; &#8220;U.S. $&#8221; and &#8220;$&#8221; are to the lawful currency of the United States of America, and references to &#8220;NIS&#8221; are to new Israeli shekels. References to &#8220;ADS(s)&#8221; are to Teva&#8217;s American Depositary Share(s). References to &#8220;MS&#8221; are to multiple sclerosis. Market data, including both sales and share data, is based on information provided by IQVIA, a provider of market research to the pharmaceutical industry (&#8220;IQVIA&#8221;), unless otherwise stated. References to &#8220;R&amp;D&#8221; are to Research and Development, references to &#8220;IPR&amp;D&#8221; are to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> R&amp;D, references to &#8220;S&amp;M&#8221; are to Selling and Marketing and references to &#8220;G&amp;A&#8221; are to General and Administrative. Some amounts in this report may not add up due to rounding. All percentages have been calculated using unrounded amounts. This report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> contains many of the trademarks and trade names used by Teva in the United States and internationally to distinguish its products and services. Any third-party trademarks mentioned in this report are the property of their respective owners. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In addition to historical information, this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q,</div> and the reports and documents incorporated by reference in this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q,</div> may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management&#8217;s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;target,&#8221; &#8220;may,&#8221; &#8220;project,&#8221; &#8220;guidance,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe&#8221; and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance.&#160;Important factors that could cause or contribute to such differences include risks relating to: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; consolidation of our customer base and commercial alliances among our customers; delays in launches of new generic products; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products; our ability to develop and commercialize biopharmaceutical products; competition for our specialty products, including AUSTEDO<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>, AJOVY<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> and COPAXONE<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>; our ability to achieve expected results from investments in our product pipeline; our ability to develop and commercialize additional pharmaceutical products; and the effectiveness of our patents and other measures to protect our intellectual property rights; </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, may result in a further downgrade of our credit ratings; and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us; </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">our business and operations in general, including: uncertainty regarding the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and the governmental and societal responses thereto; our ability to successfully execute and maintain the activities and efforts related to the measures we have taken or may take in response to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and associated costs therewith; effectiveness of our optimization efforts; our ability to attract, hire and retain highly skilled personnel; manufacturing or quality control problems; interruptions in our supply chain; disruptions of information technology systems; breaches of our data security; variations in intellectual property laws; challenges associated with conducting business globally, including political or economic instability, major hostilities or terrorism; costs and delays resulting from the extensive pharmaceutical regulation to which we are subject or delays in governmental processing time due to travel and work restrictions caused by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; significant sales to a limited number of customers; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; and our prospects and opportunities for growth if we sell assets; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">compliance, regulatory and litigation matters, including: failure to comply with complex legal and regulatory environments; increased legal and regulatory action in connection with public concern over the abuse of opioid medications and our ability to reach a final resolution of the remaining opioid-related litigation; scrutiny from competition and pricing authorities around the world, including our ability to successfully defend against the U.S. Department of Justice (&#8220;DOJ&#8221;) criminal charges of Sherman Act violations; potential liability for patent infringement; product liability claims; failure to comply with complex Medicare and Medicaid reporting and payment obligations; compliance with anti-corruption sanctions and trade control laws; environmental risks; and the impact of Environmental, Social and Governance (&#8220;ESG&#8221;) issues; </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; potential impairments of our intangible assets; potential significant increases in tax liabilities (including as a result of potential tax reform in the United States); and the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business; </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2 </div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">and other factors discussed in this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> and in our Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the year ended December&#160;31, 2021, including in the sections captioned &#8220;Risk Factors.&#8221; Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3 </div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div id="tx360666_1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART I &#8212; FINANCIAL INFORMATION </div></div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx360666_2" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ITEM&#160;1.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FINANCIAL STATEMENTS </div></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 20pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div> <div id="tx360666_3" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED BALANCE SHEETS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(U.S. dollars in millions, except for share data) </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 84%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ASSETS</div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current assets:</div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,058</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,165</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivables, net of allowance for credit losses of $<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:num-dot-decimal">95</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:num-dot-decimal">90</ix:nonFraction>&#160;million as of June&#160;30, 2022 and December&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,471</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,529</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventories</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,049</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,818</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,052</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,075</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">518</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">965</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets held for sale</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">19</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">12,164</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">12,573</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,595</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">596</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">454</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">515</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property, plant and equipment, net</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,740</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,982</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">441</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">495</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Identifiable intangible assets, net</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,466</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">18,837</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">20,040</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">45,932</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">47,666</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LIABILITIES AND EQUITY</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term debt</div></div> </td>
<td style="vertical-align: bottom; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;"><ix:nonFraction name="us-gaap:DebtCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,719</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;"><ix:nonFraction name="us-gaap:DebtCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,426</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales reserves and allowances</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:SalesReservesAndAllowances" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,880</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:SalesReservesAndAllowances" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,241</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payables</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,901</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,686</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee-related obligations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">467</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">563</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:AccruedExpenses" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,112</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:AccruedExpenses" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,208</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">916</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">903</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,996</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">11,027</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term liabilities:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">532</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">784</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other taxes and long-term liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,842</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,578</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes and loans</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermNotesAndLoans" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">20,363</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermNotesAndLoans" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">21,617</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">371</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">416</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total long-term liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">25,107</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">25,395</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Commitments and contingencies</div></div>, see note 10</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">36,103</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">36,422</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva shareholders&#8217; equity:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares of NIS <ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn06_30_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.10</ix:nonFraction></ix:nonFraction> par value per share; June&#160;30, 2022 and December&#160;31, 2021: authorized <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn06_30_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">2,495</ix:nonFraction></ix:nonFraction>&#160;million shares; issued <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn06_30_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,216</ix:nonFraction>&#160;million shares and <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,209</ix:nonFraction>&#160;million shares, respectively.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">57</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">57</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">27,625</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">27,561</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated deficit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">11,716</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">10,529</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated other comprehensive loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,801</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,683</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Treasury shares as of June&#160;30, 2022 and December&#160;31, 2021: <ix:nonFraction name="us-gaap:TreasuryStockShares" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:TreasuryStockShares" contextRef="PAsOn06_30_2022" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal">106</ix:nonFraction></ix:nonFraction>&#160;million ordinary shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,128</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,128</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">9,037</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,278</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div> interests</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">791</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">966</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total equity</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">9,828</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">11,244</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities and equity</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">45,932</ix:nonFraction><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">47,666</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts may not add up due to rounding. </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of the financial statements. </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4</div></div></div> <div style="clear: both; max-height: 0px;"></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div> </div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div> <div id="tx360666_4" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF INCOME (LOSS) </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(U.S. dollars in millions, except share and per share data) </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six months ended</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenues</div></div> </td>
<td style="vertical-align: bottom; width: 1%; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,786</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,910</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,447</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,892</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of sales</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,992</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,037</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,913</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,141</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,794</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,873</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,534</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,750</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">228</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">248</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">453</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">501</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selling and marketing expenses</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">594</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">615</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,178</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">313</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">242</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">609</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">532</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets impairments</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:IntangibleAssetsImpairments" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">51</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:IntangibleAssetsImpairments" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">195</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:IntangibleAssetsImpairments" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">199</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:IntangibleAssetsImpairments" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">274</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill impairment</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">745</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">745</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets impairments, restructuring and other items</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ImpairmentsRestructuringAndOthers" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">118</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ImpairmentsRestructuringAndOthers" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">28</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ImpairmentsRestructuringAndOthers" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">246</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ImpairmentsRestructuringAndOthers" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">165</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legal settlements and loss contingencies</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:LegalSettlementsAndLossContingencies" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">729</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:LegalSettlementsAndLossContingencies" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:LegalSettlementsAndLossContingencies" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,854</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:LegalSettlementsAndLossContingencies" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">110</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">34</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">43</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">87</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">48</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating income (loss)</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">949</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">582</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,662</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,015</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial expenses, net</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">211</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">274</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">468</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">564</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income (loss) before income taxes</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,160</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">308</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,131</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">451</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes (benefit)</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">900</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">98</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">899</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">159</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share&#160;in (profits)&#160;losses of&#160;associated&#160;companies, net</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%; padding: 0pt 5pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">11</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div>&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">259</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">221</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,211</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">306</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Net income (loss) attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests</div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">27</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">24</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to Teva</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">232</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">207</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,187</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">284</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earnings (loss) per share attributable to ordinary shareholders:</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.21</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.19</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">1.07</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom; width: 1%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.26</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.21</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.19</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">1.07</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.26</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of shares (in millions):</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,110</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,103</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,109</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,101</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,110</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,109</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,109</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,108</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts may not add up due to rounding. </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of the financial statements. </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5 </div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div> <div id="tx360666_5" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(U.S. dollars in millions) </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months&#160;ended</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six months ended</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div> </td>
<td style="vertical-align: bottom; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">259</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">221</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,211</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">306</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income (loss), net of tax:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Currency translation adjustment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">219</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">79</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">282</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">130</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized gain (loss) from derivative financial instruments, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:UnrealizedGainLossOnDerivativeNetOfTax" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:UnrealizedGainLossOnDerivativeNetOfTax" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:UnrealizedGainLossOnDerivativeNetOfTax" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:UnrealizedGainLossOnDerivativeNetOfTax" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized loss on defined benefit plans</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total other comprehensive income (loss)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">212</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">87</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">268</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">115</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total comprehensive income (loss)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">471</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">308</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,479</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">191</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Comprehensive income (loss) attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">125</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">13</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">174</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">47</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive income (loss) attributable to Teva</div></div> </td>
<td style="vertical-align: bottom; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">346</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;">)</td>
<td style="vertical-align: bottom; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">295</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,305</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;">)</td>
<td style="vertical-align: bottom; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">238</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts may not add up due to rounding. </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of the financial statements. </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6 </div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div> </div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div> <div id="tx360666_6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 42%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="26" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Teva shareholders&#8217; equity</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/>shares (in<br/>millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stated<br/>value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div><br/>capital</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Retained<br/>earnings<br/>(accumulated<br/>deficit)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated&#160;other<br/>comprehensive<br/>(loss)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Treasury<br/>shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total Teva<br/>shareholders&#8217;<br/>equity</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div><br/>interests</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/>equity</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="34" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. dollars in millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2022</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,216</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">57</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">27,587</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">11,484</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,687</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2022_TreasuryStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4,128</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2022_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">9,344</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">916</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,260</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Income (loss)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2022To06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">232</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2022To06_30_2022_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">232</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2022To06_30_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">27</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">259</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income (loss)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P04_01_2022To06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">114</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P04_01_2022To06_30_2022_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">114</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P04_01_2022To06_30_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">98</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">212</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of Shares</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_01_2022To06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">39</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_01_2022To06_30_2022_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">39</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">39</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at June&#160;30, 2022</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,216</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">57</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">27,625</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">11,716</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,801</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2022_TreasuryStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4,128</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2022_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">9,037</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">791</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">9,828</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="clear: both; max-height: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P04_01_2022To06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction>&#160;million.&#160;</div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 42%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="26" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Teva shareholders&#8217; equity</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/>shares (in<br/>millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stated<br/>value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div><br/>capital</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Retained<br/>earnings<br/>(accumulated<br/>deficit)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated&#160;other<br/>comprehensive<br/>(loss)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Treasury<br/>shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total Teva<br/>shareholders&#8217;<br/>equity</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div><br/>interests</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/>equity</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="34" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. dollars in millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,208</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">57</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">27,474</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">10,869</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,534</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2021_TreasuryStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4,128</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2021_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">975</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,975</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Income (loss)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2021To06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">207</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2021To06_30_2021_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">207</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2021To06_30_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">221</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income (loss)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P04_01_2021To06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">88</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P04_01_2021To06_30_2021_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">88</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P04_01_2021To06_30_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">87</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of Shares</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P04_01_2021To06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52307110">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">*</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_01_2021To06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">29</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_01_2021To06_30_2021_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">29</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">29</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at June&#160;30, 2021</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,209</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">57</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">27,503</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">10,662</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,446</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2021_TreasuryStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4,128</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2021_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,324</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">987</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">11,311</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="clear: both; max-height: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P04_01_2021To06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction>&#160;million.&#160;</div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 42%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="26" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Teva shareholders&#8217; equity</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/>shares (in<br/>millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stated<br/>value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div><br/>capital</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Retained<br/>earnings<br/>(accumulated<br/>deficit)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated&#160;other<br/>comprehensive<br/>(loss)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Treasury<br/>shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total Teva<br/>shareholders&#8217;<br/>equity</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div><br/>interests</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/>equity</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="34" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. dollars in millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,209</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">57</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">27,561</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">10,529</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,683</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021_TreasuryStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4,128</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,278</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">966</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">11,244</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Income (loss)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2022To06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,187</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2022To06_30_2022_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,187</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2022To06_30_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">24</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,211</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income (loss)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2022To06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">118</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2022To06_30_2022_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">118</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2022To06_30_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">150</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">268</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of Shares</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2022To06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52307132">7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; text-indent: 0px;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">*</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2022To06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2022To06_30_2022_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2022To06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">63</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2022To06_30_2022_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">63</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">63</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at June&#160;30, 2022</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,216</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">57</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">27,625</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">11,716</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,801</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2022_TreasuryStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4,128</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2022_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">9,037</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">791</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">9,828</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="clear: both; max-height: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2022To06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction>&#160;million.&#160;</div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts may not add up due to rounding. </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of the financial statements. </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7 </div></div></div> <div style="clear: both; max-height: 0px;"></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 40%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="26" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Teva shareholders&#8217; equity</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/>shares (in<br/>millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stated<br/>value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div><br/>capital</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Retained<br/>earnings<br/>(accumulated<br/>deficit)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated&#160;other<br/>comprehensive<br/>(loss)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Treasury<br/>shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total Teva<br/>shareholders&#8217;<br/>equity</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div><br/>interests</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/>equity</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="34" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. dollars in millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2020</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,202</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">57</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">27,443</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">10,946</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,399</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020_TreasuryStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4,128</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,026</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,035</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">11,061</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Income (loss)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2021To06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">284</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2021To06_30_2021_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">284</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2021To06_30_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">306</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income (loss)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2021To06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">47</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2021To06_30_2021_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">47</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2021To06_30_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">68</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">115</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of shares</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2021To06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52307165">6</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2021To06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">60</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2021To06_30_2021_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">60</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">60</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at June&#160;30, 2021</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,209</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">57</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">27,503</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">10,662</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,446</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2021_TreasuryStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4,128</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2021_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,324</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">987</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">11,311</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="clear: both; max-height: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2021To06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction>&#160;million.&#160;</div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear:both;max-height:0pt;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts may not add up due to rounding. </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of the financial statements. </div></div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8 </div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div> <div id="tx360666_7" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF CASH FLOWS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(U.S. dollars in millions) </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 87%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six months ended</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating activities:</div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div> </td>
<td style="vertical-align: bottom; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,211</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">306</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to reconcile net income (loss) to net cash provided by operations:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">681</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">681</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Impairment of goodwill, long-lived assets and assets held for sale</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">975</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">354</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net change in operating assets and liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingCapital" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">913</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingCapital" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,679</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes &#8211; net and uncertain tax positions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:DeferredIncomeTaxesNetAndUncertainTaxPositions" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,258</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:DeferredIncomeTaxesNetAndUncertainTaxPositions" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">63</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">60</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other items</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherOperatingActivitiesCashFlowStatement" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">77</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherOperatingActivitiesCashFlowStatement" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss (gain) from investments and from sale of long lived assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:ProfitFromSaleOfLongLivedAssetsAndInvestment" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ProfitFromSaleOfLongLivedAssetsAndInvestment" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">93</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by (used in) operating activities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">74</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">187</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investing activities:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Beneficial interest collected in exchange for securitized trade receivables</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">592</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">881</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from sale of business and long lived assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromDivestitureOfBusinesses" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">43</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromDivestitureOfBusinesses" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">254</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisition of businesses, net of cash acquired</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchases of property, plant and equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">284</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">263</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchases of investments and other assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:PaymentToAcquireMarketableSecuritiesAndOtherAssets" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:PaymentToAcquireMarketableSecuritiesAndOtherAssets" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">36</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from sale of investments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">153</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other investing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by (used in) investing activities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">341</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">989</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financing activities:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Redemption of convertible senior notes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">491</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repayment of senior notes and loans</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfSeniorDebt" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">296</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RepaymentsOfSeniorDebt" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other financing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by (used in) financing activities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">336</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">494</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Translation adjustment on cash and cash equivalents</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">185</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">49</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net change in cash, cash equivalents and restricted cash</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">107</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">259</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance of cash, cash equivalents and restricted cash at beginning of period</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,198</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,177</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance of cash, cash equivalents and restricted cash at end of period</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,091</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,436</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reconciliation of cash, cash equivalents and restricted cash reported in the consolidated balance sheets:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,058</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,436</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash included in other current assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">33</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total cash, cash equivalents and restricted cash shown in the statement of cash flows</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,091</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,436</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> financing and investing activities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Beneficial interest obtained in exchange for securitized accounts receivables</div></div> </td>
<td style="vertical-align: bottom; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;"><ix:nonFraction name="teva:BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">590</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;"><ix:nonFraction name="teva:BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">878</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> </div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts may not add up due to rounding </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of the financial statements. </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9 </div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div> <div id="tx360666_8" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></div> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <ix:nonNumeric name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" contextRef="P01_01_2022To06_30_2022" escape="true" continuedAt="TextSelection_52308150"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 1 &#8211; Basis of presentation: </div></div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">a.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of presentation </div></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The accompanying unaudited consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements. In the opinion of management, the financial statements reflect all normal and recurring adjustments necessary to fairly state the financial position and results of operations of Teva. The information included in this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the year ended December&#160;31, 2021, as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;). The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-end</div> balance sheet data was derived from the audited consolidated financial statements as of December&#160;31, 2021, but not all disclosures required by generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;) are included. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In the process of preparing the consolidated financial statements, management makes estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. The inputs into Teva&#8217;s judgments and estimates also consider the economic implications of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on its critical and significant accounting estimates, most significantly in relation to sales, reserves and allowances, IPR&amp;D assets, marketed product rights and goodwill, all of which will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and the actions taken to contain or treat it, as well as the economic impact on Teva&#8217;s employees, third-party manufacturers and suppliers, customers and markets. All estimates made by Teva related to the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic within its financial statements may change in future periods. Actual results could differ from those estimates. </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">In February 2022, Russia launched an invasion of Ukraine. As of the date of this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q,</div> sustained conflict and disruption in the region is ongoing. Russia and Ukraine markets are included in Teva&#8217;s International Markets segment results. Teva has no manufacturing or R&amp;D facilities in these markets. As part of the Company&#8217;s annual goodwill analysis, it identified an increase in the discount rate, which led to a goodwill impairment charge in its International Markets and Teva&#8217;s API reporting units. This increase was a result of an increase in certain components of the discount rate that were partially attributed to higher risk associated with country-specific characteristics of several countries, such as Russia, that might be a consequence of the conflict. Other than its impact on the goodwill impairment charge, during the three and six months ended June 30, 2022, the impact of this conflict on Teva&#8217;s results of operations and financial condition was immaterial. See also note 6. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The results of operations for the three and six months ended June&#160;30, 2022 are not necessarily indicative of results that could be expected for the entire fiscal year. Certain amounts in the consolidated financial statements and associated notes may not add up due to rounding. All percentages have been calculated using unrounded amounts. </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">b.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant accounting policies </div></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2022To06_30_2022" escape="true"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recently adopted accounting pronouncements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In August 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> &#8220;Debt &#8211; Debt with Conversion and Other Options (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20)</div> and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211; 40).&#8221; This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. The amendments to this guidance are effective for fiscal years beginning after December&#160;15, 2021, and interim periods within those fiscal years. The adoption of this guidance did not have a significant impact on the Company&#8217;s consolidated financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In March 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-04</div> &#8220;Reference Rate Reform (Topic 848)&#8212;Facilitation of the Effects of Reference Rate Reform on Financial Reporting.&#8221; This guidance provides optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The guidance applies only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. This guidance is effective for all entities as of March&#160;12, 2020 through December&#160;31, 2022. There was no material impact to the Company&#8217;s consolidated financial statements for the period ended June&#160;30, 2022 as a result of adopting this standard update. The Company has completed negotiations to transform the facility base rate of its securitization program and evaluated the potential impact of the replacement of the LIBOR benchmark on its interest rate risk management activities. The adoption of this guidance did not have a material impact on the Company&#8217;s consolidated financial results of operations, financial position or cash flows. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_52308150"> <ix:nonNumeric name="teva:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" contextRef="P01_01_2022To06_30_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recently issued accounting pronouncements, not yet adopted </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In November 2021, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2021-10</div> &#8220;Government Assistance (Topic 832)&#8221;, which requires annual disclosures that increase the transparency of transactions involving government grants, including (1)&#160;the types of transactions, (2)&#160;the accounting for those transactions, and (3)&#160;the effect of those transactions on an entity&#8217;s financial statements. The amendments in this update are effective for financial statements issued for annual periods beginning after December&#160;15, 2021. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In October 2021, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2021-08</div> &#8220;Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#8221;, which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers. The guidance will result in the acquirer recognizing contract assets and contract liabilities at the same amounts recorded by the acquiree. The guidance should be applied prospectively to acquisitions occurring on or after the effective date. The guidance is effective for fiscal years beginning after December&#160;15, 2022, including interim periods within those fiscal years. Early adoption is permitted, including in interim periods, for any financial statements that have not yet been issued. Adoption in an interim period other than the first fiscal quarter requires an entity to apply the new guidance to all prior business combinations that have occurred since the beginning of the annual period in which the new guidance is adopted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements. </div><br/></div></ix:nonNumeric></ix:continuation> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div> </div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <ix:nonNumeric name="teva:CertainTransactionsDisclosureTextBlock" contextRef="P01_01_2022To06_30_2022" escape="true" continuedAt="TextSelection_52308183"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 2 &#8211; Certain transactions: </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has entered into alliances and other arrangements with third parties to acquire rights to products it does not have, to access markets it does not operate in and to otherwise share development costs or business risks. The Company&#8217;s most significant agreements of this nature are summarized below. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MODAG </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In October 2021, Teva announced a license agreement with MODAG GmbH (&#8220;Modag&#8221;) that will provide Teva an exclusive global license to develop, manufacture and commercialize Modag&#8217;s lead compound <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(TEV-56286)</div> and a related compound <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(TEV-56287).</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TEV-56286</div> was initially developed for the treatment of Multiple System Atrophy (&#8220;MSA&#8221;) and Parkinson&#8217;s disease, and has the potential to be applied to other treatments for neurodegenerative disorders, such as Alzheimer&#8217;s disease. A phase 1b clinical trial is currently being completed for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TEV-56286.</div> In the fourth quarter of 2021, Teva made an upfront payment of $<ix:nonFraction name="teva:MilestonePayment" contextRef="P10_01_2021To12_31_2021_ModagMemberusgaapBusinessAcquisitionAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction>&#160;million to Modag that was recorded as an R&amp;D expense. Modag may be eligible for future development milestone payments, totaling an aggregate amount of up to $<ix:nonFraction name="teva:LicenseAgreementPotentialAggregateMilestonePaymentsAmount" contextRef="P10_01_2021To10_31_2021_ModagMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">70</ix:nonFraction>&#160;million, as well as future commercial milestones and royalties. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Alvotech </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">In August 2020, Teva entered into an agreement with biopharmaceutical company Alvotech for the exclusive commercialization in the U.S. of five biosimilar product candidates. The initial pipeline for this collaboration contains biosimilar candidates addressing multiple therapeutic areas, including a proposed biosimilar to Humira<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>. Under this agreement, Alvotech is responsible for the development, registration and supply of the biosimilar product candidates and Teva will exclusively commercialize the products in the United States. Teva paid an upfront payment in the third quarter of 2020 and additional upfront and milestone payments in the second quarter of 2021 that were recorded as R&amp;D expenses. Additional development and commercial milestone payments of up to</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> $<ix:nonFraction name="teva:CollaborativeAgreementMilestonePayments" contextRef="P01_01_2022To06_30_2022_AlvotechMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">455</ix:nonFraction>&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million, as well as royalty payments, may be payable by Teva over the next few years. Teva and Alvotech will share profit from the commercialization of these biosimilars. Alvotech was previously involved in litigation involving certain IP and trade secrets claims filed by Abbvie in relation to Alvotech&#8217;s proposed biosimilar to Humira<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>, all of which were settled on March&#160;8, 2022.&#160;Pursuant to that settlement, Alvotech and Teva may sell Alvotech&#8217;s proposed biosimilar to Humira<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"> </div>in the United States beginning on July&#160;1, 2023, provided that U.S. regulatory approval is obtained by that date. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:continuation id="TextSelection_52308183" continuedAt="TextSelectionAppend_52308183_1"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Eli Lilly and Alder BioPharmaceuticals</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2018, Teva entered into an agreement with Eli Lilly&#160;&amp; Co. (&#8220;Lilly&#8221;) resolving the European Patent Office opposition they had filed against Teva&#8217;s AJOVY<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> patents. The settlement agreement with Lilly also resolved Lilly&#8217;s action to revoke the patent protecting AJOVY in the United&#160;Kingdom. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On January&#160;8, 2018, Teva signed a global license agreement with Alder BioPharmaceuticals (&#8220;Alder&#8221;). The agreement validates Teva&#8217;s intellectual property and resolves Alder&#8217;s opposition to Teva&#8217;s European patent with respect to anti-calcitonin gene-related peptide (CGRP) antibodies, including the withdrawal of Alder&#8217;s appeal before the European Patent Office. Under the terms of the agreement, Alder received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> license to Teva&#8217;s anti-CGRP antibodies patent portfolio to develop, manufacture and commercialize eptinezumab in the United States and worldwide, excluding Japan. Teva received a $<ix:nonFraction name="teva:UpfrontPayments" contextRef="P01_08_2018To01_08_2018_AlderMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">25</ix:nonFraction>&#160;million upfront payment that was recognized as revenue during the first quarter of 2018, and a $<ix:nonFraction name="teva:MilestonePayment" contextRef="P01_01_2020To03_31_2020_AlderMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">25</ix:nonFraction>&#160;million milestone payment in March 2020 that was recognized as revenue in the first quarter of 2020. The agreement stipulates additional development and commercial milestone payments to Teva of up to $<ix:nonFraction name="teva:CollaborativeAgreementMilestonePayments" contextRef="P01_08_2018To01_08_2018_AlderMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">150</ix:nonFraction>&#160;million, as well as future royalties. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Otsuka </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On May&#160;12, 2017, Teva entered into a license and collaboration agreement with Otsuka Pharmaceutical Co. Ltd. (&#8220;Otsuka&#8221;) providing Otsuka with an exclusive license to develop and commercialize AJOVY in Japan. Otsuka paid Teva an upfront payment of $<ix:nonFraction name="teva:UpfrontPayments" contextRef="P05_12_2017To05_12_2017_OtsukaMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">50</ix:nonFraction>&#160;million in consideration for the transaction. In the third quarter of 2020, Otsuka submitted an application to obtain manufacturing and marketing approval for AJOVY in Japan and, as a result, paid Teva a milestone payment of $<ix:nonFraction name="teva:MilestonePayment" contextRef="P01_01_2020To09_30_2020_OtsukaMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">15</ix:nonFraction>&#160;million, which was recognized as revenue in the third quarter of 2020. AJOVY was approved in Japan in June 2021 and launched on August&#160;30, 2021. As a result of the launch, Otsuka paid Teva a milestone payment of $<ix:nonFraction name="teva:MilestonePayment" contextRef="P01_01_2021To09_30_2021_OtsukaMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">35</ix:nonFraction>&#160;million, which was recognized as revenue in the third quarter of 2021. Teva may receive additional milestone payments upon achievement of certain revenue targets. Otsuka also pays Teva royalties on AJOVY sales in Japan. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Takeda </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2016, Teva entered into a license agreement with a subsidiary of Takeda Pharmaceutical Company Ltd. (&#8220;Takeda&#8221;), for the research, development, manufacture and commercialization of </div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Attenukine<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> technology.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Teva received a $<ix:nonFraction name="teva:UpfrontPayments" contextRef="P12_01_2016To12_31_2016_TakedaMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">30</ix:nonFraction>&#160;million upfront payment as well as a milestone payment of $<ix:nonFraction name="teva:MilestonePayment" contextRef="P12_01_2016To12_31_2016_TakedaMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">20</ix:nonFraction>&#160;million in 2017. During the second quarter of 2022, Takeda initiated Phase II study of modakafusp alfa (formerly TAK 573 or TEV 48573) and as a result paid Teva a milestone payment of $<ix:nonFraction name="teva:MilestonePayment" contextRef="P01_01_2022To06_30_2022_TakedaMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">25</ix:nonFraction>&#160;million, which was recognized as revenues in the second quarter of 2022. The license agreement stipulates additional milestone payments to Teva of up to $<ix:nonFraction name="teva:CollaborativeAgreementMilestonePayments" contextRef="P12_01_2016To12_31_2016_TakedaMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">519</ix:nonFraction>&#160;million in respect of this product, as well as future royalties. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Regeneron </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In September 2016, Teva and Regeneron Pharmaceuticals, Inc. (&#8220;Regeneron&#8221;) entered into a collaborative agreement to develop and commercialize Regeneron&#8217;s pain medication product, fasinumab. Teva and Regeneron share in the global commercial rights to this product (excluding Japan, Korea and nine other Asian countries), as well as ongoing associated R&amp;D costs of approximately $<ix:nonFraction name="teva:ResearchAndDevelopmentCosts" contextRef="P09_01_2016To09_30_2016_RegeneronMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-9" scale="9" format="ixt:num-dot-decimal">1</ix:nonFraction>&#160;billion. Teva made an upfront payment of $<ix:nonFraction name="teva:UpfrontPayments" contextRef="P07_01_2016To09_30_2016_RegeneronMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">250</ix:nonFraction>&#160;million to Regeneron in the third quarter of 2016 and additional payments for achievement of development milestones in an aggregate amount of $<ix:nonFraction name="teva:CollaborativeAgreementMilestonePayments" contextRef="P01_01_2018To12_31_2018_RegeneronMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="teva:CollaborativeAgreementMilestonePayments" contextRef="P01_01_2017To12_31_2017_RegeneronMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">120</ix:nonFraction></ix:nonFraction>&#160;million were paid during 2017 and 2018. The agreement stipulates additional development and commercial milestone payments of up to $<ix:nonFraction name="teva:CollaborativeAgreementMilestonePayments" contextRef="P09_01_2016To09_30_2016_RegeneronMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,230</ix:nonFraction>&#160;million, as well as future royalties. Currently, all <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-essential</div> activities and related expenditures for fasinumab have been put on hold. Next steps will be assessed together with Regeneron, with the intention of discussing data with the FDA. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MedinCell </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In November 2013, Teva entered into an agreement with MedinCell for the development and commercialization of multiple long-acting injectable products. The lead product candidate selected was risperidone LAI <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(TV-46000)</div> suspension for subcutaneous use for the treatment of schizophrenia. In August 2021, the FDA accepted the new drug application (&#8220;NDA&#8221;) for risperidone LAI, based on phase 3 data from two pivotal studies. Teva leads the clinical development and regulatory process and is responsible for commercialization of this product candidate. MedinCell may be eligible for development milestones, and future commercial milestones of up to $<ix:nonFraction name="teva:CollaborativeAgreementMilestonePayments" contextRef="P08_01_2021To08_31_2021_MedincellMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">112</ix:nonFraction>&#160;million in respect of risperidone LAI. Teva will also pay MedinCell royalties on net sales. In April 2022, the FDA issued a Complete Response Letter (&#8220;CRL&#8221;) regarding the NDA for risperidone LAI. Teva is working to address the issues raised in the CRL with a view to resubmission.</div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:continuation id="TextSelectionAppend_52308183_1"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets and Liabilities Held For Sale: </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets held for sale as of June&#160;30, 2022 included certain assets that are expected to be sold within the next year. Assets and liabilities held for sale as of December&#160;31, 2021 included certain manufacturing assets sold during the first and second quarters of 2022.<div style="display:inline;">&#160;</div><ix:nonNumeric name="teva:ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" contextRef="P01_01_2022To06_30_2022" escape="true" continuedAt="TextSelection_52308174">The table below summarizes all Teva assets and liabilities included as held for sale as of June&#160;30, 2022 and December&#160;31, 2021:</ix:nonNumeric></div></div> <ix:continuation id="TextSelection_52308174"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventories</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property, plant and equipment, net and others</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">46</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">86</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments of assets held for sale to fair value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AssetsFairValueAdjustment" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">30</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AssetsFairValueAdjustment" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">76</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets of the disposal group classified as held for sale in the consolidated balance sheets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">19</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities of the disposal group classified as held for sale in the consolidated balance sheets, recorded under accrued expenses and other long-term liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">43</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:continuation></ix:continuation></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <ix:nonNumeric name="us-gaap:RevenueFromContractWithCustomerTextBlock" contextRef="P01_01_2022To06_30_2022" escape="true" continuedAt="TextSelection_52308243"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 3 &#8211; Revenue from contracts with customers: </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disaggregation of revenue </div></div></div></div> <ix:nonNumeric name="us-gaap:DisaggregationOfRevenueTableTextBlock" contextRef="P01_01_2022To06_30_2022" escape="true" continuedAt="TextSelection_52308244"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table disaggregates Teva&#8217;s revenues by major revenue streams. For additional information on disaggregation of revenues, see note 15. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:nonNumeric></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13 </div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:continuation id="TextSelection_52308243" continuedAt="TextSelectionAppend_52308243_1"><ix:continuation id="TextSelection_52308244">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="18" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended June&#160;30, 2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North<br/>America</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International<br/>Markets</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other<br/>activities</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="18" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sale of goods</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_NorthAmericaMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,538</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_EuropeMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,127</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">448</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">176</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,289</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing arrangements</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_LicenseMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">54</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_EuropeMembersrtStatementGeographicalAxis_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">13</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_LicenseMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">72</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_DistributionServiceMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">308</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_DistributionServiceMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_DistributionServiceMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_DistributionServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">318</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_NorthAmericaMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_EuropeMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">31</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">81</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">106</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,904</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_EuropeMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,171</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">454</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">257</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,786</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#167; Represents an amount less t<div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">han $0.5&#160;</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">million.&#160; &#160;&#160;</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="18" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended June&#160;30, 2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North<br/>America</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International<br/>Markets</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other<br/>activities</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="18" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sale of goods</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_NorthAmericaMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,621</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_EuropeMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,185</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">462</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">198</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,465</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing arrangements</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_LicenseMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_EuropeMembersrtStatementGeographicalAxis_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_LicenseMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">19</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_DistributionServiceMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">316</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_DistributionServiceMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">15</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_DistributionServiceMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_DistributionServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">330</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_NorthAmericaMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction>)</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_EuropeMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">99</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">96</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,943</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_EuropeMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,184</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">485</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">298</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,910</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#167; Represents an amount less than $0.5&#160;million. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six months ended June&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North<br/> America</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International<br/> Markets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other<br/> activities</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sale of goods</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_NorthAmericaMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,915</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_EuropeMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,261</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">894</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">356</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,425</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing arrangements</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_LicenseMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">74</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_EuropeMembersrtStatementGeographicalAxis_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">26</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_LicenseMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">110</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_DistributionServiceMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">650</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_DistributionServiceMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">26</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_DistributionServiceMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_DistributionServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">677</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_NorthAmericaMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_EuropeMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">39</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">19</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">175</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">234</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,641</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_EuropeMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,327</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">946</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">532</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,447</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#167; Represents an amount less than $0.5&#160;million. </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="18" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six months ended June&#160;30, 2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North<br/>America</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International<br/>Markets</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other<br/>activities</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="18" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sale of goods</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_NorthAmericaMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,289</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_EuropeMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,363</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">902</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">374</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,928</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing arrangements</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_LicenseMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_EuropeMembersrtStatementGeographicalAxis_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_LicenseMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">68</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_DistributionServiceMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">605</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_DistributionServiceMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">34</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_DistributionServiceMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_DistributionServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">639</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_NorthAmericaMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction>)</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_EuropeMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">35</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">210</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">257</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,932</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_EuropeMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,398</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">975</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">587</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,892</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#167; Represents an amount less than $0.5&#160;million. </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </ix:continuation></ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:continuation id="TextSelectionAppend_52308243_1" continuedAt="TextSelectionAppend_52308243_2"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Variable consideration</div></div></div> <div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Variable consideration mainly includes sales reserves and allowances (&#8220;SR&amp;A&#8221;), comprised of rebates (including Medicaid and other governmental program discounts), chargebacks, returns and other promotional (including shelf stock adjustments) items. Provisions for prompt payment discounts are netted against accounts receivables. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes these provisions at the time of sale and adjusts them if the actual amounts differ from the estimated provisions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SR&amp;A to U.S. customers comprised approximately <div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="teva:SalesReservesAndAllowancesToCustomersPercentage" contextRef="P01_01_2022To06_30_2022_USsrtStatementGeographicalAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">74</ix:nonFraction></div>% of the Company&#8217;s total SR&amp;A as of June&#160;30, 2022, with the remaining balance primarily in Canada and Germany. <ix:nonNumeric name="teva:SalesReservesAndAllowancesCurrentTableTextBlock" contextRef="P01_01_2022To06_30_2022" escape="true" continuedAt="TextSelection_52308245">The changes in SR&amp;A for third-party sales for the six months ended June&#160;30, 2022 and 2021 were as follows:</ix:nonNumeric></div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited)</div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:continuation id="TextSelectionAppend_52308243_2"><ix:continuation id="TextSelection_52308245">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 37%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="26" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sales Reserves and Allowances</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reserves<br/>included in<br/>Accounts<br/>Receivable,&#160;net</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Rebates</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Medicaid and<br/>other<br/>governmental<br/>allowances</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Chargebacks</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Returns</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total&#160;reserves<br/>included&#160;in&#160;SR&amp;A</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="30" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2021_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">68</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2021_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,655</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2021_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">854</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2021_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,085</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2021_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">535</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2021_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">112</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2021_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,241</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,309</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions related to sales made in current year</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2022To06_30_2022_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">181</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2022To06_30_2022_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,889</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2022To06_30_2022_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">446</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2022To06_30_2022_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,836</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2022To06_30_2022_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">147</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2022To06_30_2022_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">152</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2022To06_30_2022_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,470</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,651</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions related to sales made in prior periods</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2022To06_30_2022_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">102</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2022To06_30_2022_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">20</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2022To06_30_2022_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">8</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2022To06_30_2022_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">16</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2022To06_30_2022_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2022To06_30_2022_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">108</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">108</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Credits and payments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2022To06_30_2022_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">185</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2022To06_30_2022_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,901</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2022To06_30_2022_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">497</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2022To06_30_2022_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,922</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2022To06_30_2022_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">211</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2022To06_30_2022_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">145</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2022To06_30_2022_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,676</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,861</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Translation differences</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2022To06_30_2022_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">33</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2022To06_30_2022_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">6</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2022To06_30_2022_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2022To06_30_2022_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2022To06_30_2022_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2022To06_30_2022_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">47</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">47</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at June&#160;30, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn06_30_2022_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">64</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn06_30_2022_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,508</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn06_30_2022_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">817</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn06_30_2022_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">984</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn06_30_2022_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">451</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn06_30_2022_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">120</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn06_30_2022_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,880</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,944</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 37%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reserves<br/> included in<br/> Accounts<br/> Receivable,&#160;net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Rebates</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Medicaid and<br/> other<br/> governmental<br/> allowances</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Chargebacks</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Returns</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total&#160;reserves<br/> included&#160;in&#160;SR&amp;A</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="30" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.$ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2020_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">80</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2020_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,054</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2020_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">828</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2020_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,108</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2020_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">686</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2020_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">148</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2020_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,824</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,904</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions related to sales made in current year</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2021To06_30_2021_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">192</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2021To06_30_2021_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,139</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2021To06_30_2021_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">391</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2021To06_30_2021_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,995</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2021To06_30_2021_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">143</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2021To06_30_2021_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">177</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2021To06_30_2021_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,845</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,037</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions related to sales made in prior periods</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2021To06_30_2021_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2021To06_30_2021_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">82</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2021To06_30_2021_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">35</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2021To06_30_2021_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">11</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2021To06_30_2021_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2021To06_30_2021_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">23</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2021To06_30_2021_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">191</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">196</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Credits and payments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2021To06_30_2021_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">196</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2021To06_30_2021_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,355</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2021To06_30_2021_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">362</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2021To06_30_2021_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,934</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2021To06_30_2021_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">186</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2021To06_30_2021_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">176</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2021To06_30_2021_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,013</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,209</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Translation differences</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2021To06_30_2021_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2021To06_30_2021_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2021To06_30_2021_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2021To06_30_2021_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2021To06_30_2021_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2021To06_30_2021_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at June&#160;30, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn06_30_2021_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">71</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn06_30_2021_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,748</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn06_30_2021_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">819</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn06_30_2021_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,157</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn06_30_2021_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">602</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn06_30_2021_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">127</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn06_30_2021_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,453</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,524</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:continuation></ix:continuation> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div> </div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <ix:nonNumeric name="us-gaap:InventoryDisclosureTextBlock" contextRef="P01_01_2022To06_30_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 4 &#8211; Inventories:</div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" contextRef="P01_01_2022To06_30_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventories, net of reserves, consisted of the following:</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finished products</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,875</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,932</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Raw and packaging materials</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,346</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,136</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Products in process</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">624</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">587</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Materials in transit and payments on account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherInventoryInTransit" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">204</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherInventoryInTransit" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">163</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,049</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,818</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:nonNumeric name="us-gaap:IntangibleAssetsDisclosureTextBlock" contextRef="P01_01_2022To06_30_2022" escape="true" continuedAt="TextSelection_52308242"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 5 &#8211; Identifiable intangible assets:</div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" contextRef="P01_01_2022To06_30_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Identifiable intangible assets consisted of the following:</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 54%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross&#160;carrying&#160;amount&#160;net</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">of impairment</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">amortization</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net carrying amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="22" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product rights</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn06_30_2022_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">17,987</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2021_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">18,815</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn06_30_2022_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">12,181</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2021_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">12,318</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn06_30_2022_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,806</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2021_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,497</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trade names</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn06_30_2022_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">570</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2021_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">590</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn06_30_2022_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">211</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2021_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">198</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn06_30_2022_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">359</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2021_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">392</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In process research and development</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn06_30_2022_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">535</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2021_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">577</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn06_30_2022_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">535</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2021_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">577</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">19,092</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">19,982</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">12,392</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">12,516</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,466</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product rights and trade names </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product rights and trade names are assets presented at amortized cost. Product rights and trade names represent a portfolio of pharmaceutical products from various therapeutic categories from various acquisitions with a weighted average life of approximately <ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="P01_01_2022To06_30_2022" format="ixt-sec:duryear">10</ix:nonNumeric> years. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization of intangible assets was $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">212</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">173</ix:nonFraction>&#160;million in the three months ended June&#160;30, 2022 and 2021, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization of intangible assets was $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">412</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">414</ix:nonFraction>&#160;million in the six months ended June&#160;30, 2022 and 2021, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">IPR&amp;D </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva&#8217;s IPR&amp;D are assets that have not yet been approved in major markets. Teva&#8217;s IPR&amp;D is comprised mainly of various generic products from the Actavis Generics acquisition of $<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" contextRef="PAsOn06_30_2022_ActavisMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">503</ix:nonFraction>&#160;million. IPR&amp;D carries intrinsic risks that the asset might not succeed in advanced phases and may be impaired in future periods. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Intangible assets impairments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairments of long-lived intangible assets for the three months ended June&#160;30, 2022 and 2021&#160;were $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">51</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">195</ix:nonFraction>&#160;million, respectively. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairments in the second quarter of 2022 consisted of: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Identifiable product rights of $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P04_01_2022To06_30_2022_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">32</ix:nonFraction>&#160;million related to updated market assumptions regarding price and volume of products acquired from Actavis Generics, and</div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(b)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D assets of $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P04_01_2022To06_30_2022_GenericPipelineProductsMembersrtProductOrServiceAxis_InprocessresearchandDevelopmenttoProductRightsMemberusgaapReclassificationTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">19</ix:nonFraction>&#160;million due to generic pipeline products acquired from Actavis Generics resulting from development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape, launch date). </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairments in the second quarter of 2021 consisted of: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Identifiable product rights of $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P04_01_2021To06_30_2021_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">168</ix:nonFraction>&#160;million due to: <div style="text-indent: 0px; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(i) $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P04_01_2021To06_30_2021_ActavisMemberusgaapBusinessAcquisitionAxis_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">138</ix:nonFraction> million, mainly related to updated market assumptions regarding price and </div></div><br/></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="text-indent: 0px; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">volume of products acquired from Actavis Generics that are primarily marketed in the United States, and (ii) </div>$<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P04_01_2021To06_30_2021_ActavisMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">30</ix:nonFraction>&#160;million related to </div><br/></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">lenalidomide (generic equivalent of Revlimid<div style="font-size: 75%; vertical-align: top; text-indent: 0px; white-space: nowrap;;display:inline;;font-size:8.3px">&#174;</div>), resulting from modified competition assumptions as a result of settlements between the </div><br/></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">innovator and other generic filers, and&#160;</div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(b)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D assets of $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P04_01_2021To06_30_2021_GenericPipelineProductsMembersrtProductOrServiceAxis_InprocessresearchandDevelopmenttoProductRightsMemberusgaapReclassificationTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">27</ix:nonFraction>&#160;million due to generic pipeline products acquired from Actavis Generics resulting from development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape, launch date) in the United States. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairments of long-lived intangible assets for the six months ended June&#160;30, 2022 and 2021&#160;were $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">199</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">274</ix:nonFraction>&#160;million, respectively.</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">17 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:continuation id="TextSelection_52308242"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairments in the first </div>six<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> months of </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> consisted mainly of:</div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Identifiable product rights of $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2022To06_30_2022_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">161</ix:nonFraction>&#160;million related to updated market assumptions regarding price and volume of products acquired from Actavis Generics, and</div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(b)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D assets of $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2022To06_30_2022_GenericPipelineProductsMembersrtProductOrServiceAxis_InprocessresearchandDevelopmenttoProductRightsMemberusgaapReclassificationTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">21</ix:nonFraction>&#160;million due to generic pipeline products acquired from Actavis Generics resulting from development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape, launch date) in the United States. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairments in the first six months of 2021 consisted of: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Identifiable product rights of $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2021To06_30_2021_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">196</ix:nonFraction>&#160;million <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">due to: (i) $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2021To06_30_2021_ActavisMemberusgaapBusinessAcquisitionAxis_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">166</ix:nonFraction> million</div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">, mainly related to updated market assumptions regarding price and </div></div><br/></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">volume of products acquired from Actavis Generics that are primarily marketed in the United States<div style="display:inline;">,</div>&#160;and (ii) </div>$<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2021To06_30_2021_ActavisMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">30</ix:nonFraction>&#160;million related to lenalidomide (generic equivalent of Revlimid<div style="font-size: 75%; vertical-align: top;;text-indent: 0px;;display:inline;;font-size:8.3px">&#174;</div>), resulting from modified competition assumptions as a result of settlements between the innovator and other generic filers<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(b)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D assets of $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2021To06_30_2021_GenericPipelineProductsMembersrtProductOrServiceAxis_InprocessresearchandDevelopmenttoProductRightsMemberusgaapReclassificationTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">78</ix:nonFraction>&#160;million, due to generic pipeline products acquired from Actavis Generics resulting from development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape, launch date) in the United States. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value measurement of the impaired intangible assets in the first six months of 2022 is based on significant unobservable inputs in the market and thus represents a Level&#160;3 measurement within the fair value hierarchy. The discount rate applied ranged from <ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" contextRef="PAsOn06_30_2022_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal">7.25</ix:nonFraction>% to <ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" contextRef="PAsOn06_30_2022_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal">8.25</ix:nonFraction>%. A probability of success factor ranging from <ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" contextRef="PAsOn06_30_2022_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">20</ix:nonFraction>% to <ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" contextRef="PAsOn06_30_2022_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">90</ix:nonFraction>% was used in the fair value calculation to reflect inherent regulatory and commercial risk of IPR&amp;D. </div><br/></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div> </div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <ix:nonNumeric name="us-gaap:GoodwillDisclosureTextBlock" contextRef="P01_01_2022To06_30_2022" escape="true" continuedAt="TextSelection_52308259"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 6 &#8211; Goodwill:</div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfGoodwillTextBlock" contextRef="P01_01_2022To06_30_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The changes in the carrying amount of goodwill for the period ended June&#160;30, 2022 were as follows:</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North&#160;America</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International<br/>Markets</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2021 (1)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2021_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52307391">6,474</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2021_EuropeMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52307392">8,544</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2021_InternationalMarketsMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52307393">2,328</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2021_OtherCountriesMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52307394">2,694</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52307395">20,040</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes during the period:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill impairment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="P01_01_2022To06_30_2022_InternationalMarketsMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">479</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="P01_01_2022To06_30_2022_OtherCountriesMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">266</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">745</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill acquired</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GoodwillAcquiredDuringPeriod" contextRef="P01_01_2022To06_30_2022_OtherCountriesMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GoodwillAcquiredDuringPeriod" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Translation differences</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" contextRef="P01_01_2022To06_30_2022_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" contextRef="P01_01_2022To06_30_2022_EuropeMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">320</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" contextRef="P01_01_2022To06_30_2022_InternationalMarketsMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" contextRef="P01_01_2022To06_30_2022_OtherCountriesMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">130</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">470</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of June&#160;30, 2022 (1)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn06_30_2022_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52307401">6,470</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn06_30_2022_EuropeMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52307402">8,224</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn06_30_2022_InternationalMarketsMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52307403">1,833</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn06_30_2022_OtherCountriesMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52307404">2,310</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52307405">18,837</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated goodwill impairment as of June&#160;30, 2022 and December&#160;31, 2021 was approximately $<ix:nonFraction name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">26.3</ix:nonFraction>&#160;billion and $<ix:nonFraction name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">25.6</ix:nonFraction>&#160;billion, respectively. </div><br/></div> </td> </tr> </table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Teva determines the fair value of its reporting units using the income approach. The income approach is a forward-looking approach for estimating fair value. Within the income approach, the method used is the discounted cash flow method. Teva starts with a forecast of all the expected net cash flows associated with the reporting unit, which includes the application of a terminal value, and then applies a discount rate to arrive at a net present value amount. Cash flow projections are based on Teva&#8217;s estimates of revenue growth rates and operating margins, taking into consideration industry and market conditions. The discount rate used is based on the weighted average cost of capital (&#8220;WACC&#8221;), adjusted for the relevant risk associated with country-specific and business-specific characteristics. If any of these expectations were to vary materially from Teva&#8217;s assumptions, Teva may record an impairment of goodwill allocated to these reporting units in the future.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">18 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> <ix:continuation id="TextSelection_52308259"> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">During</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="font-size: 10pt; letter-spacing: 0px; text-align: center; text-indent: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">the second qu</div>arter of </div>2022<div style="font-size: 10pt; letter-spacing: 0px; text-align: center; text-indent: 0px; top: 0px;;display:inline;">, Teva completed its long-range planning (&#8220;LRP&#8221;) process. The LRP is part of Teva&#8217;s internal financial planning and budgeting processes and is discussed and reviewed by Teva&#8217;s management and its board of directors.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, Teva conducted a quantitative analysis of all reporting units as part of its annual goodwill impairment test with the assistance of an independent valuation expert. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva identified an increase in certain components of the discount rate, mainly attributable to: (i)&#160;the risk-free interest rate, which resulted in an increase in the WACC; and (ii)&#160;the risk associated with country-specific characteristics of several countries. </div></div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on this quantitative analysis, in the second quarter of 2022, Teva recorded a goodwill impairment charge of</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>$<ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">745</ix:nonFraction>&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million as follows: (i) </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> $<ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn06_30_2022_InternationalMarketsReportingUnitMemberusgaapReportingUnitAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">479</ix:nonFraction>&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">million related to its International Markets reporting unit, mainly due to the increase in the discount rate; and (ii)</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>$<ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn06_30_2022_TevasApiReportingUnitMemberusgaapReportingUnitAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">266</ix:nonFraction>&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million related to its Teva&#8217;s API reporting unit, mainly due to the increase in the discount rate, as well as updated assumptions supporting the cash flow projections, including certain revenue growth assumptions and the associated operating profit margins. Teva&#8217;s API reporting unit is included under &#8220;Other&#8221; in the table above. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following the goodwill impairment charges recorded in relation to Teva&#8217;s International Markets and Teva&#8217;s API reporting units, the carrying values of </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">those reporting units </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> equaled their fair value as of June&#160;30, 2022. Therefore, if business conditions or expectations were to change materially, it may be necessary to record further impairment charges to Teva&#8217;s International Markets or Teva&#8217;s API reporting units in the future. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The estimated fair value of Teva&#8217;s Europe reporting unit exceeds its estimated carrying amount by <ix:nonFraction name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" contextRef="PAsOn06_30_2022" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">9</ix:nonFraction>% based on a terminal growth rate of <ix:nonFraction name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" contextRef="PAsOn06_30_2022_MeasurementInputTerminalGrowthRateMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.41</ix:nonFraction>% and a discount rate of <ix:nonFraction name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" contextRef="PAsOn06_30_2022_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">10.04</ix:nonFraction>%. If Teva holds all other assumptions constant, a reduction in the terminal growth rate of <ix:nonFraction name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" contextRef="PAsOn06_30_2022_MeasurementInputTerminalGrowthRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.50</ix:nonFraction>% to <ix:nonFraction name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" contextRef="PAsOn06_30_2022_MaximumMembersrtRangeAxis_MeasurementInputTerminalGrowthRateMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.91</ix:nonFraction>% or an increase in the discount rate of <ix:nonFraction name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" contextRef="PAsOn06_30_2022_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.50</ix:nonFraction>% to <ix:nonFraction name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" contextRef="PAsOn06_30_2022_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">10.54</ix:nonFraction>% would result in a reduction of the excess of fair value over carrying amount with respect to Teva&#8217;s Europe reporting unit to <ix:nonFraction name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" contextRef="PAsOn06_30_2022_TevasEuropeReportingUnitMemberusgaapReportingUnitAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction>%. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Teva&#8217;s</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> North America and Medis reporting units have<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;a</div> fair value in excess of <ix:nonFraction name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" contextRef="PAsOn06_30_2022_NorthAmericaAndMedisReportingUnitsMemberusgaapReportingUnitAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction>% over their book values as of June&#160;30, 2022</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva noted its market capitalization has been below management&#8217;s assessment of the aggregated fair value of the Company&#8217;s reporting units. However, as of June 30, 2022, the Company&#8217;s market capitalization plus a reasonable control premium exceeded its book value. </div></div></div> </ix:continuation> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <ix:nonNumeric name="us-gaap:DebtDisclosureTextBlock" contextRef="P01_01_2022To06_30_2022" escape="true" continuedAt="TextSelection_52308176"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 7 &#8211; Debt obligations:&#160; &#160;&#160;</div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfShortTermDebtTextBlock" contextRef="P01_01_2022To06_30_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a. Short-term debt:</div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 89%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average&#160;interest<br/>rate as of June&#160;30, 2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Maturity</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Convertible senior debentures</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn06_30_2022_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.25</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2022To06_30_2022_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis">2026</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="PAsOn06_30_2022_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">23</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="PAsOn12_31_2021_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">23</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current maturities of long-term liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52307410">1,696</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52307411">1,403</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total short-term debt</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,719</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,426</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Convertible senior debentures</div></div></div></div></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The principal amount of Teva&#8217;s <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn06_30_2022_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.25</ix:nonFraction>% convertible senior debentures due 2026 was $<ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn06_30_2022_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn12_31_2021_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">23</ix:nonFraction></ix:nonFraction>&#160;million as of June&#160;30, 2022 and December&#160;31, 2021. These convertible senior debentures include a &#8220;net share settlement&#8221; feature according to which the principal amount will be paid in cash and in case of conversion, only the residual conversion value above the principal amount will be paid in Teva shares. Due to the &#8220;net share settlement&#8221; feature, exercisable at any time, these convertible senior debentures are classified in the Balance Sheet under short-term debt.</div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">19 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:continuation id="TextSelection_52308176" continuedAt="TextSelectionAppend_52308176_1"> <ix:nonNumeric name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" contextRef="P01_01_2022To06_30_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">b. Long-term debt:</div></div><br/></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 87%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average&#160;interest<br/>rate as of June&#160;30, 2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Maturity</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,500</ix:nonFraction>&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:LongtermDebtWeightedAverageInterestRate" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.13</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis">2024</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">653</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2021_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">708</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: pre-wrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: pre-wrap;;display:inline;">Sustainability-linked senior notes EUR <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2030MemberusgaapDebtInstrumentAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,500</ix:nonFraction>&#160;million&#160;(1)<div style="letter-spacing: 0px; top: 0px; white-space: pre-wrap;;display:inline;">&#160;</div>(*)</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:LongtermDebtWeightedAverageInterestRate" contextRef="PAsOn06_30_2022_SustainabilityLinkedSeniorNotesDue2030MemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="Fact_52308383">4.38</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2022To06_30_2022_SustainabilityLinkedSeniorNotesDue2030MemberusgaapDebtInstrumentAxis" id="Fact_52307419">2030</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn06_30_2022_SustainabilityLinkedSeniorNotesDue2030MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52307420">1,566</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2021_SustainabilityLinkedSeniorNotesDue2030MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52307421">1,699</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,300</ix:nonFraction>&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:LongtermDebtWeightedAverageInterestRate" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.25</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis">2023</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">616</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2021_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">670</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sustainability-linked senior notes EUR <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn06_30_2022_SustainabilityLinkedSeniorNotesDue2027MemberusgaapDebtInstrumentAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,100</ix:nonFraction>&#160;million&#160;(2)<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>(*)</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:LongtermDebtWeightedAverageInterestRate" contextRef="PAsOn06_30_2022_SustainabilityLinkedSeniorNotesDue2027MemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="Fact_52308385">3.75</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2022To06_30_2022_SustainabilityLinkedSeniorNotesDue2027MemberusgaapDebtInstrumentAxis" id="Fact_52307425">2027</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn06_30_2022_SustainabilityLinkedSeniorNotesDue2027MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52307426">1,150</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2021_SustainabilityLinkedSeniorNotesDue2027MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52307427">1,246</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,000</ix:nonFraction>&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:LongtermDebtWeightedAverageInterestRate" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">6.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis">2025</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,043</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2021_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,134</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">900</ix:nonFraction>&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:LongtermDebtWeightedAverageInterestRate" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.50</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis">2025</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">942</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2021_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,020</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">750</ix:nonFraction>&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:LongtermDebtWeightedAverageInterestRate" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.63</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis">2028</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">779</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2021_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">844</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">700</ix:nonFraction>&#160;million (3)</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:LongtermDebtWeightedAverageInterestRate" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="Fact_52308389">3.25</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis" id="Fact_52307617">2022</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero" id="Fact_52307618">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2021_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52307619">307</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2027MemberusgaapDebtInstrumentAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">700</ix:nonFraction>&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:LongtermDebtWeightedAverageInterestRate" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2027MemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.88</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2027MemberusgaapDebtInstrumentAxis">2027</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2027MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">729</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2021_SubsidiarySeniorNotesDue2027MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">792</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,500</ix:nonFraction>&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:LongtermDebtWeightedAverageInterestRate" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">3.15</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis">2026</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,496</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2021_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,496</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,000</ix:nonFraction>&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:LongtermDebtWeightedAverageInterestRate" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.80</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis">2023</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,453</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2021_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,453</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,000</ix:nonFraction>&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:LongtermDebtWeightedAverageInterestRate" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis">2046</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,986</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2021_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,986</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,250</ix:nonFraction>&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:LongtermDebtWeightedAverageInterestRate" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">6.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis">2024</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,250</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2021_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,250</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,250</ix:nonFraction>&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:LongtermDebtWeightedAverageInterestRate" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">6.75</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis">2028</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,250</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2021_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,250</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,000</ix:nonFraction>&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:LongtermDebtWeightedAverageInterestRate" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">7.13</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis">2025</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2021_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sustainability-linked senior notes USD <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn06_30_2022_SustainabilityLinkedSeniorNotesDue2027TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,000</ix:nonFraction>&#160;million&#160;(2)<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>(*)</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:LongtermDebtWeightedAverageInterestRate" contextRef="PAsOn06_30_2022_SustainabilityLinkedSeniorNotesDue2027TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="Fact_52308397">4.75</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2022To06_30_2022_SustainabilityLinkedSeniorNotesDue2027TwoMemberusgaapDebtInstrumentAxis" id="Fact_52307452">2027</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn06_30_2022_SustainabilityLinkedSeniorNotesDue2027TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52307453">1,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2021_SustainabilityLinkedSeniorNotesDue2027TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52307454">1,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sustainability-linked senior notes USD <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn06_30_2022_SustainabilityLinkedSeniorNotesDue2029MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,000</ix:nonFraction>&#160;million&#160;(1)<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>(*)</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:LongtermDebtWeightedAverageInterestRate" contextRef="PAsOn06_30_2022_SustainabilityLinkedSeniorNotesDue2029MemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="Fact_52308398">5.13</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2022To06_30_2022_SustainabilityLinkedSeniorNotesDue2029MemberusgaapDebtInstrumentAxis" id="Fact_52307455">2029</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn06_30_2022_SustainabilityLinkedSeniorNotesDue2029MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52307456">1,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2021_SustainabilityLinkedSeniorNotesDue2029MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52307457">1,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2022TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">844</ix:nonFraction>&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:LongtermDebtWeightedAverageInterestRate" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2022TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.95</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2022TwoMemberusgaapDebtInstrumentAxis">2022</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2022TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">715</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2021_SubsidiarySeniorNotesDue2022TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">715</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">789</ix:nonFraction>&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:LongtermDebtWeightedAverageInterestRate" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">6.15</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis">2036</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">783</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2021_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">783</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes CHF <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_CHF" decimals="-6" scale="6" format="ixt:num-dot-decimal">350</ix:nonFraction>&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:LongtermDebtWeightedAverageInterestRate" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.50</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis">2022</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">366</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2021_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">382</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes CHF <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2025ThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_CHF" decimals="-6" scale="6" format="ixt:num-dot-decimal">350</ix:nonFraction>&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:LongtermDebtWeightedAverageInterestRate" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2025ThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2025ThreeMemberusgaapDebtInstrumentAxis">2025</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2025ThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">367</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2021_SubsidiarySeniorNotesDue2025ThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">383</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total senior notes</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">22,144</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">23,118</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long-term debt</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:LongTermNotesAndLoans" contextRef="PAsOn06_30_2022_OtherDebentures2026MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:LongTermNotesAndLoans" contextRef="PAsOn12_31_2021_OtherDebentures2026MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less current maturities</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(<ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,696</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(<ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,403</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less debt issuance costs</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredFinanceCostsNoncurrentNet" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">87</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredFinanceCostsNoncurrentNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total senior notes and loa<div style="letter-spacing: 0px; top: 0px;;display:inline;">n</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermNotesAndLoans" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">20,363</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermNotesAndLoans" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">21,617</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> </ix:nonNumeric> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="P01_01_2022To06_30_2022_InterestRateIncreaseMemberusgaapDebtInstrumentAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="5" scale="-2" format="ixt:num-dot-decimal">0.125</ix:nonFraction>%-<ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="P01_01_2022To06_30_2022_InterestRateIncreaseMemberusgaapDebtInstrumentAxis_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="5" scale="-2" format="ixt:num-dot-decimal">0.375</ix:nonFraction>%</div> per annum, from and including <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P01_01_2022To06_30_2022_InterestRateIncreaseMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-day-year-en">May 9, 2026</ix:nonNumeric>.&#160;</div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">If Teva fails to achieve certain sustainability performance targets, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> premium payment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="P01_01_2022To06_30_2022_MinimumMembersrtRangeAxis_OneTimePremiumPaymentMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.15</ix:nonFraction>%-<ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="P01_01_2022To06_30_2022_MaximumMembersrtRangeAxis_OneTimePremiumPaymentMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.45</ix:nonFraction>%</div> out of the principal amount will be paid at maturity or upon earlier redemption, if such redemption is on or after <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P01_01_2022To06_30_2022_OneTimePremiumPaymentMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-day-year-en">May 9, 2026</ix:nonNumeric>. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In April 2022, Teva repaid $<ix:nonFraction name="teva:SeniorNotesRepaidAmount" contextRef="PAsOn04_30_2022_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">296</ix:nonFraction>&#160;million of its <ix:nonFraction name="teva:SeniorNotesMaturityPercentage" contextRef="PAsOn04_30_2022_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">3.25</ix:nonFraction>% senior notes at maturity. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(*)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Interest rate adjustments and a potential <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> premium payment related to the sustainability-linked bonds are treated as bifurcated embedded derivatives. See note 8<div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>. </div> </td> </tr> </table> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term debt was issued by several indirect wholly-owned subsidiaries of the Company and is fully and unconditionally guaranteed by the Company as to payment of all principal, interest, discount and additional amounts, if any. The long-term debt outlined in the above table is generally redeemable at any time at varying redemption prices plus accrued and unpaid interest. </div><br/></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div> </div> </div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_52308176_1" continuedAt="TextSelectionAppend_52308176_2"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva&#8217;s </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">debt as of June&#160;30, 2022 <div style="letter-spacing: 0px; top: 0px;;display:inline;">was</div> effectively denominated in the following currencies: <ix:nonFraction name="teva:LongTermDebtCurrencyPortionUSD" contextRef="PAsOn06_30_2022" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">63</ix:nonFraction>% in U.S. dollar, <ix:nonFraction name="teva:LongTermDebtCurrencyPortionEUR" contextRef="PAsOn06_30_2022" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">34</ix:nonFraction>% in euro and <ix:nonFraction name="teva:LongTermDebtCurrencyPortionCHF" contextRef="PAsOn06_30_2022" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">3</ix:nonFraction>% in Swiss franc. </div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva&#8217;s principal sources of short-term liquidity are its cash on hand, existing cash investments, liquid securities and available credit facilities, primarily, as of June&#160;30, 2022, its $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="PAsOn06_30_2022_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">1.8</ix:nonFraction>&#160;billion unsecured syndicated sustainability-linked revolving credit facility&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">entered into in April 2022 (&#8220;RCF&#8221;). </div></div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;">In April 2022, Teva entered into an unsecured syndicated sustainability-linked revolving credit facility of $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="PAsOn04_30_2022_UnsecuredSyndicatedRevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.8</ix:nonFraction>&#160;billion with a maturity date of <span style="-sec-ix-hidden:hidden52308335">April</span> 2026, with two <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="teva:LineOfCreditExtentionPeriod" contextRef="P01_01_2022To06_30_2022_UnsecuredSyndicatedRevolvingCreditFacilityMemberusgaapCreditFacilityAxis">one-year</ix:nonNumeric></div> extension options. The RCF contains certain covenants, including certain limitations on incurring liens and indebtedness and maintenance of certain financial ratios, including a maximum leverage ratio, which becomes more restrictive over time. In addition, the RCF is linked to two sustainability performance targets, (i)&#160;the company&#8217;s S&amp;P ESG Score and (ii)&#160;number of new regulatory submissions in low and middle-income countries. The RCF margin may increase or decrease depending on the Company&#8217;s sustainability performance.</div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">20 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><ix:continuation id="TextSelectionAppend_52308176_2"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the terms of the RCF, the leverage ratio shall not exceed <ix:nonNumeric name="teva:LeverageRatio" contextRef="P07_01_2022To09_30_2022_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"><ix:nonNumeric name="teva:LeverageRatio" contextRef="P04_01_2022To06_30_2022_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis">4.50</ix:nonNumeric></ix:nonNumeric>x in the second and third quarters of 2022, <ix:nonNumeric name="teva:LeverageRatio" contextRef="P10_01_2022To12_31_2022_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">4.25</ix:nonNumeric>x in the fourth quarter of 2022, <ix:nonNumeric name="teva:LeverageRatio" contextRef="P01_01_2023To03_31_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"><ix:nonNumeric name="teva:LeverageRatio" contextRef="P07_01_2023To09_30_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"><ix:nonNumeric name="teva:LeverageRatio" contextRef="P04_01_2023To06_30_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">4.00</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric>x in the first, second and third quarters of 2023, <ix:nonNumeric name="teva:LeverageRatio" contextRef="P10_01_2023To12_31_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">3.75</ix:nonNumeric>x in the fourth quarter of 2023 and <ix:nonNumeric name="teva:LeverageRatio" contextRef="P01_01_2024To12_31_2024_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">3.50</ix:nonNumeric>x in 2024 and onwards. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><ix:nonNumeric name="us-gaap:DebtInstrumentCovenantDescription" contextRef="P01_01_2022To06_30_2022_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis">The RCF can be used for general corporate purposes, including repaying existing debt. As of June 30, 2022 and as of the date of this Quarterly Report on Form 10-Q, no amounts were outstanding under the RCF. Based on current and forecasted results, the Company expects that it will not exceed the financial covenant thresholds set forth in the RCF within one year from the date the financial statements are issued</ix:nonNumeric>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under specified circumstances, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with any of the covenants described above and the unavailability of any waiver, amendment or other modification thereto, the Company will not be able to borrow under the RCF. Additionally, violations of the covenants, under the above-mentioned circumstances, would result in an event of default in all borrowings under the RCF and, when greater than a specified threshold amount as set forth in each series of senior notes and sustainability-linked senior notes is outstanding, could lead to an event of default under the Company&#8217;s senior notes and sustainability-linked senior notes due to cross acceleration provisions.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva expects that it will continue to have sufficient cash resources to support its debt service payments and all other financial obligations within one year from the date that the financial statements are issued.</div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" contextRef="P01_01_2022To06_30_2022" escape="true" continuedAt="TextSelection_52308186"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 8 &#8211; Derivative instruments and hedging activities: </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">a. Foreign exchange risk management:</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-style: normal; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the first six months of 2022, approximately <ix:nonFraction name="teva:RevenuesOtherThanUsd" contextRef="PAsOn06_30_2022" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">48</ix:nonFraction>% of Teva&#8217;s revenues were denominated in currencies other than the U.S. dollar. As a result, Teva is subject to significant foreign currency risks. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company enters into forward exchange contracts, purchases and writes options in order to hedge the currency exposure on balance sheet items, revenues and expenses. In addition, the Company takes measures to reduce exposure by using natural hedging. The Company also acts to offset risks in opposite directions among the subsidiaries within Teva. The currency hedged items are usually denominated in the following main currencies: the euro, the Swiss franc, the Japanese yen, the British pound, the Russian ruble, the Canadian dollar, the Polish zloty, new Israeli shekel, the Indian rupee and other European and Latin American currencies. Depending on market conditions, foreign currency risk is also managed through the use of foreign currency debt. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may choose to hedge against possible fluctuations in foreign subsidiaries net assets (&#8220;net investment hedge&#8221;) and entered into cross currency swaps and forward contracts in the past in order to hedge such an exposure. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Most of the counterparties to the derivatives are major banks and the Company is monitoring the associated inherent credit risks. The Company does not enter into derivative transactions for trading purposes. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">b. Interest risk management: </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company raises capital through various debt instruments, including senior notes, sustainability-linked senior notes, bank loans, convertible debentures and syndicated revolving credit facility that bear a fixed or variable interest rate. In some cases, the Company has swapped from a fixed to a variable interest rate (&#8220;fair value hedge&#8221;) and from a fixed to a fixed interest rate with an exchange from a currency other than the functional currency (&#8220;cash flow hedge&#8221;), thereby reducing overall interest expenses or hedging risks associated with interest rate fluctuations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">c. Bifurcated embedded derivatives: </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Upon issuance of sustainability-linked senior notes, Teva recognized embedded derivatives related to interest rate adjustments and a potential <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> premium payment upon failure to achieve certain sustainability performance targets, such as access to medicines in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-to-middle-income</div></div> countries and absolute greenhouse gas emissions reduction, which were bifurcated and are accounted for separately as derivative financial instruments. As of June&#160;30, 2022<div style="letter-spacing: 0px; top: 0px;;display:inline;">,</div> the fair value of these derivative instruments is negligible.</div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">21 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></div><ix:continuation id="TextSelection_52308186" continuedAt="TextSelectionAppend_52308186_1"> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">d. Derivative instruments outstanding: </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" contextRef="P01_01_2022To06_30_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the classification and fair values of derivative instruments:</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Not designated as hedging</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">instruments</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">June&#160;30,</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31,</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td colspan="5" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Reported under</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asset derivatives:</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets:</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Option and forward contracts</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="PAsOn06_30_2022_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherCurrentAssetsMemberusgaapBalanceSheetLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">69</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="PAsOn12_31_2021_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherCurrentAssetsMemberusgaapBalanceSheetLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">30</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liability derivatives:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Option and forward contracts</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="PAsOn06_30_2022_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_SeniorNotesAndLoansMemberusgaapBalanceSheetLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">37</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="PAsOn12_31_2021_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_SeniorNotesAndLoansMemberusgaapBalanceSheetLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">23</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" contextRef="P01_01_2022To06_30_2022" escape="true" continuedAt="TextSelection_52308180"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The table below provides information regarding the location and amount of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> (gains) losses from derivatives not designated as hedging instruments:</div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial&#160;expenses,&#160;net</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net revenues</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months&#160;ended,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Reported under</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Line items in which effects of hedges are recorded</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P04_01_2022To06_30_2022_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">211</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P04_01_2021To06_30_2021_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">274</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P04_01_2022To06_30_2022_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3,786</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P04_01_2021To06_30_2021_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3,910</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Option and forward contracts (1)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P04_01_2022To06_30_2022_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal" id="Fact_52307503">38</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P04_01_2021To06_30_2021_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52307504">27</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P04_01_2022To06_30_2022_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero" id="Fact_52307505">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P04_01_2021To06_30_2021_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero" id="Fact_52307506">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Option and forward contracts economic hedge (2)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P04_01_2022To06_30_2022_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero" id="Fact_52307507">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P04_01_2021To06_30_2021_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero" id="Fact_52307508">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P04_01_2022To06_30_2022_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal" id="Fact_52307509">16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P04_01_2021To06_30_2021_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52307510">15</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr></table> </ix:nonNumeric> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_52308186_1" continuedAt="TextSelectionAppend_52308186_2"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><ix:continuation id="TextSelection_52308180" continuedAt="TextSelectionAppend_52308180_1">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial&#160;expenses,&#160;net</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net revenues</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six months ended,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six months ended,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Reported under</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 11pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Line items in which effects of hedges are recorded</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2022To06_30_2022_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">468</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2021To06_30_2021_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">564</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2022To06_30_2022_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">7,447</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2021To06_30_2021_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">7,892</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Option and forward contracts (1)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2022To06_30_2022_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal" id="Fact_52307515">43</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2021To06_30_2021_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal" id="Fact_52307516">43</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2022To06_30_2022_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero" id="Fact_52307517">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2021To06_30_2021_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero" id="Fact_52307518">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Option and forward contracts economic hedge (2)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2022To06_30_2022_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero" id="Fact_52307519">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2021To06_30_2021_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero" id="Fact_52307520">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2022To06_30_2022_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal" id="Fact_52307521">35</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2021To06_30_2021_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal" id="Fact_52307522">13</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Teva uses foreign exchange contracts (mainly option and forward contracts) to hedge balance sheet items from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, Teva recognizes gains or losses that offset the revaluation of the balance sheet items also recorded under financial expenses, net.</div></td></tr></table><div style="clear: both; max-height: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on projected revenues and expenses recorded in euro, the Swiss franc, the Japanese yen, the British pound, the Russian ruble, the Canadian dollar and some other currencies to protect its projected operating results for 2022 and 2021. These derivative instruments do not meet the criteria for hedge accounting, however, they are accounted for as an economic hedge. These derivative instruments, which may include hedging transactions against future projected revenues and expenses, are<br/></div> </div></div></td></tr></table></ix:continuation><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">22 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></div><ix:continuation id="TextSelectionAppend_52308186_2" continuedAt="TextSelectionAppend_52308186_3"><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><ix:continuation id="TextSelectionAppend_52308180_1">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. In the first six months of 2022, the positive impact from these derivatives recognized under revenues was $<ix:nonFraction name="us-gaap:DerivativeGainOnDerivative" contextRef="P01_01_2022To06_30_2022_CostOfSalesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">35</ix:nonFraction>&#160;million. In the first six months of 2021, the positive impact from these derivatives recognized under revenues was $<ix:nonFraction name="us-gaap:DerivativeGainOnDerivative" contextRef="P01_01_2021To06_30_2021_CostOfSalesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">13</ix:nonFraction>&#160;million. Changes in the fair value of the derivative instruments are recognized in the same line item in the statements of income as the underlying exposure being hedged. The cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows. </div></td></tr></table></ix:continuation></ix:continuation><ix:continuation id="TextSelectionAppend_52308186_3"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">e. Amortizations due to terminated derivative instruments: </div></div></div><div style="clear: both; max-height: 0px;"></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forward starting interest rate swaps and treasury lock agreements </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2015, Teva entered into forward starting interest rate swaps and treasury lock agreements to protect the Company from interest rate fluctuations in connection with a future debt issuance the Company was planning. These forward starting interest rate swaps and treasury lock agreements were terminated in July 2016 upon the debt issuance. The termination of these transactions resulted in a loss position of $<ix:nonFraction name="us-gaap:DerivativeLossOnDerivative" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">493</ix:nonFraction>&#160;million, which was recorded in other comprehensive income (loss) and is amortized under financial expenses, net over the life of the debt. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">With respect to these forward starting interest rate swaps and treasury lock agreements, losses of $<ix:nonFraction name="teva:ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction>&#160;million and $<ix:nonFraction name="teva:ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">8</ix:nonFraction>&#160;million were recognized under financial expenses, net for each of the three months ended June&#160;30, 2022 and 2021, respectively, and losses of $<ix:nonFraction name="teva:ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">15</ix:nonFraction>&#160;million and $<ix:nonFraction name="teva:ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">16</ix:nonFraction>&#160;million were recognized under financial expenses, net for each of the six months ended June&#160;30, 2022 and 2021, respectively. </div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value hedge </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the third quarter of 2016, Teva terminated interest rate swap agreements designated as a fair value hedge relating to its <ix:nonFraction name="teva:PreviouslyHedgeDebtRate" contextRef="PAsOn09_30_2016_SeniorNotesDue2022MemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.95</ix:nonFraction>% senior notes due 2022 with respect to $<ix:nonFraction name="teva:NotionalAmountHedgeDebt" contextRef="PAsOn09_30_2016_SeniorNotesDue2022MemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">844</ix:nonFraction>&#160;million notional amount and its <ix:nonFraction name="teva:PreviouslyHedgeDebtRate" contextRef="PAsOn09_30_2016_SeniorNotesDue2021MemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">3.65</ix:nonFraction>% senior notes due 2021 with respect to $<ix:nonFraction name="teva:NotionalAmountHedgeDebt" contextRef="PAsOn09_30_2016_SeniorNotesDue2021MemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">450</ix:nonFraction>&#160;million notional amount. Settlement of these transactions resulted in a gain position of $<ix:nonFraction name="us-gaap:DerivativeFairValueHedgeIncludedInEffectivenessGainLoss" contextRef="P07_01_2016To09_30_2016_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">41</ix:nonFraction>&#160;million. The fair value hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt as additional interest expense. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the third quarter of 2019, Teva terminated $<ix:nonFraction name="teva:NotionalAmountHedgeDebt" contextRef="PAsOn09_30_2019_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">500</ix:nonFraction>&#160;million interest rate swap agreements designated as a fair value hedge relating to its <ix:nonFraction name="teva:PreviouslyHedgeDebtRate" contextRef="PAsOn09_30_2019_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">2.8</ix:nonFraction>% senior notes due 2023 with respect to $<ix:nonFraction name="teva:NotionalAmountHedgeDebt" contextRef="PAsOn09_30_2016_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,000</ix:nonFraction>&#160;million notional amount. Settlement of these transactions resulted in cash proceeds of $<ix:nonFraction name="teva:CashReceivedOnSettlementOfPosition" contextRef="PAsOn09_30_2019_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction>&#160;million. The fair value hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">With respect to the interest rate swap and cross-currency swap agreements, gains of $</div><ix:nonFraction name="teva:InterestRateSwapLoss" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="teva:InterestRateSwapLoss" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million were recognized under financial expenses, net for each of the three months ended June&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively, and gains of $</div><ix:nonFraction name="teva:InterestRateSwapLoss" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="teva:InterestRateSwapLoss" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million were recognized under financial expenses, net for the six months ended June&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>202<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>202<div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively.</div><br/></div></ix:continuation><ix:nonNumeric name="us-gaap:LegalMattersAndContingenciesTextBlock" contextRef="P01_01_2022To06_30_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 9 &#8211; Legal settlements and loss contingencies: </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the second quarter of 2022, Teva recorded expenses of $<ix:nonFraction name="us-gaap:LitigationSettlementExpense" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">729</ix:nonFraction>&#160;million in legal settlements and loss contingencies, compared to $<ix:nonFraction name="us-gaap:LitigationSettlementExpense" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">6</ix:nonFraction>&#160;million in the second quarter of 2021. <ix:nonNumeric name="teva:RestructuringExpenseAndIncome" contextRef="P04_01_2022To06_30_2022_SettlementOnAccountOfProductLiabilityMembersrtLitigationCaseAxis">The expenses in the second quarter of 2022 were mainly related to an update of the estimated settlement provision recorded in connection with the remaining opioid cases.</ix:nonNumeric></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;See note 10. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the first six months of 2022, Teva recorded an expense of $<ix:nonFraction name="us-gaap:LitigationSettlementExpense" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,854</ix:nonFraction>&#160;million in legal settlements and loss contingencies, compared <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">to an&#160;</div></div>expense of $<ix:nonFraction name="us-gaap:LitigationSettlementExpense" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">110</ix:nonFraction>&#160;million in the first six months of 2021. The expense in the first six months of 2022 was mainly related to an update of the estimated settlement provision recorded in connection with the remaining opioid cases. <ix:nonNumeric name="teva:RestructuringExpenseAndIncome" contextRef="P01_01_2021To06_30_2021">The expense in the first six months of 2021 was mainly due to the provision for the carvedilol patent litigation.</ix:nonNumeric> </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2022 and December&#160;31, 2021, Teva&#8217;s provision for legal settlements and loss contingencies recorded under accrued expenses and other taxes and long-term liabilities was $<ix:nonFraction name="us-gaap:LossContingencyAccrualAtCarryingValue" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,928</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:LossContingencyAccrualAtCarryingValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,710</ix:nonFraction>&#160;million, respectively. In connection with Teva&#8217;s provision for legal settlements and loss contingencies as of December&#160;31, 2021, related to the Ontario Teachers Securities Litigation, Teva also recognized an insurance receivable.</div></div></ix:nonNumeric></div></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">23 </div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2022To06_30_2022" escape="true" continuedAt="TextSelection_52308185"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 10 &#8211; Commitments and contingencies: </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time, Teva and/or its subsidiaries are subject to claims for damages and/or equitable relief arising in the ordinary course of business. In addition, as described below, in large part as a result of the nature of its business, Teva is frequently subject to litigation. Teva generally believes that it has meritorious defenses to the actions brought against it and vigorously pursues the defense or settlement of each such action. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva records a provision in its financial statements to the extent that it concludes that a contingent liability is probable and the amount thereof is estimable. Based upon the status of the cases described below, management&#8217;s assessments of the likelihood of damages, and the advice of counsel, no provisions have been made regarding the matters disclosed in this note, except as noted below. Litigation outcomes and contingencies are unpredictable, and excessive verdicts can occur. Accordingly, management&#8217;s assessments involve complex judgments about future events and often rely heavily on estimates and assumptions. Teva continuously reviews the matters described below and may, from time to time, remove previously disclosed matters where the exposures were fully resolved in the prior year, or determined to no longer meet the materiality threshold for disclosure, or were substantially resolved. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If one or more of such proceedings described below were to result in final judgments against Teva, such judgments could be material to its results of operations and cash flows in a given period. In addition, Teva incurs significant legal fees and related expenses in the course of defending its positions even if the facts and circumstances of a particular litigation do not give rise to a provision in the financial statements. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with third-party agreements, Teva may under certain circumstances be required to indemnify, and may be indemnified by, in unspecified amounts, the parties to such agreements against third-party claims. Among other things, Teva&#8217;s agreements with third parties may require Teva to indemnify them, or require them to indemnify Teva, for the costs and damages incurred in connection with product liability claims, in specified or unspecified amounts. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Except as otherwise noted, all of the litigation matters disclosed below involve claims arising in the United States. Except as otherwise noted, all third party sales figures given below are based on IQVIA data. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intellectual Property Litigation </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time, Teva seeks to develop generic and biosimilar versions of patent-protected pharmaceuticals and biopharmaceuticals for sale prior to patent expiration in various markets. In the United States, to obtain approval for most generics prior to the expiration of the originator&#8217;s patents, Teva must challenge the patents under the procedures set forth in the Hatch-Waxman Act of 1984, as amended. For many biosimilar products that are covered by patents, Teva participates in the &#8220;patent dance&#8221; procedures of the Biologics Price Competition and Innovation Act (BPCIA), which allow for the challenge to originator patents prior to obtaining biosimilar product approval. To the extent that Teva seeks to utilize such patent challenge procedures, Teva is and expects to be involved in patent litigation regarding the validity, enforceability or infringement of the originator&#8217;s patents. Teva may also be involved in patent litigation involving the extent to which its product or manufacturing process techniques may infringe other originator or third-party patents. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, depending upon a complex analysis of a variety of legal and commercial factors, Teva may, in certain circumstances, elect to market a generic or biosimilar version of the product even though litigation is still pending. To the extent Teva elects to proceed in this manner, it could face substantial liability for patent infringement if the final court decision is adverse to Teva, which could be material to its results of operations and cash flows in a given period. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva could also be sued for patent infringement outside of the context of the Hatch-Waxman Act or BPCIA. For example, Teva could be sued for patent infringement after commencing sales of a product. This type of litigation can involve any of Teva&#8217;s pharmaceutical products, not just its generic and biosimilar products. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The general rule for damages in patent infringement cases in the United States is that the patentee should be compensated by no less than a reasonable royalty and it may also be able, in certain circumstances, to be compensated for its lost profits. The amount of a reasonable royalty award would generally be calculated based on the sales of Teva&#8217;s product. The amount of lost profits would generally be based on the lost sales of the patentee&#8217;s product. In addition, the patentee may seek consequential damages as well as enhanced damages of up to three times the profits lost by the patent holder for willful infringement, although courts have typically awarded much lower multiples. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">24 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_52308185" continuedAt="TextSelectionAppend_52308185_1"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva is also involved in litigation regarding patents in other countries where it does business, particularly in Europe. The laws concerning generic pharmaceuticals and patents differ from country to country. Damages for patent infringement in Europe may include lost profits or a reasonable royalty, but enhanced damages for willful infringement are generally not available. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In July 2014, GlaxoSmithKline (&#8220;GSK&#8221;) sued Teva in the District Court for the District of Delaware for infringement of a patent directed to using carvedilol in a specified manner to decrease the risk of mortality in patients with congestive heart failure. Teva and eight other generic producers began selling their carvedilol tablets (the generic version of GSK&#8217;s Coreg<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>) in September 2007. A jury trial was held and the jury returned a verdict in GSK&#8217;s favor finding Teva liable for induced infringement, including willful infringement, and assessing damages of $<ix:nonFraction name="teva:DamagesAssessment" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">235.5</ix:nonFraction>&#160;million, not including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-</div> or post-judgment interest or a multiplier for willfulness. Thereafter, the judge overturned the jury verdict, finding no induced infringement by Teva and that Teva did not owe any damages. On August&#160;5, 2021, the Court of Appeals for the Federal Circuit issued a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-to-one</div></div> decision reinstating the $<ix:nonFraction name="us-gaap:LossContingencyAccrualProvision" contextRef="P08_05_2021To08_05_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">235.5</ix:nonFraction>&#160;million verdict and finding Teva liable for patent infringement. On February&#160;11, 2022, the Court of Appeals for the Federal Circuit denied rehearing. Teva appealed this decision to the U.S. Supreme Court on July&#160;11, 2022. While that appeal is pending, the case is remanded to the district court for proceedings on Teva&#8217;s other legal and equitable defenses that have not yet been considered by the district court. In the first quarter of 2021, Teva recognized a provision based on its offer to settle such matter. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October 2016, Adapt and Emergent Biosciences Inc. (&#8220;EBSI&#8221;) sued Teva in the District Court for the District of New Jersey, asserting infringement of its patents expiring in 2035, as a result of Teva&#8217;s filing of its Abbreviated New Drug Application (&#8220;ANDA&#8221;) seeking to market a generic version of Narcan<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> nasal spray. In June 2020, the court issued a decision finding all of EBSI&#8217;s patents expiring in 2035, to be invalid. On December&#160;22, 2021, Teva launched its generic version of Narcan<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> nasal spray. On February&#160;10, 2022, the Court of Appeals for the Federal Circuit affirmed the lower court decision finding that EBSI&#8217;s patents are invalid. On May&#160;5, 2022, the Court of Appeals for the Federal Circuit denied EBSI&#8217;s petition for rehearing. EBSI still has the opportunity to seek further review from the U.S. Supreme Court. If Teva ultimately loses the case, Teva may be ordered to cease commercial sales or donations of its generic product and/or pay damages to EBSI. Annual sales of Narcan<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> in the U.S. were approximately $<ix:nonFraction name="teva:AnnualSalesOfNarcan" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">434</ix:nonFraction>&#160;million at the time Teva launched its generic version in December 2021. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product Liability Litigation </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva&#8217;s business inherently exposes it to potential product liability claims. Teva maintains a program of insurance, which may include commercial insurance, self-insurance (including direct risk retention), or a combination of both types of insurance, in amounts and on terms that it believes are reasonable and prudent in light of its business and related risks. However, Teva sells, and will continue to sell, pharmaceuticals that are not covered by its product liability insurance; in addition, it may be subject to claims for which insurance coverage is denied as well as claims that exceed its policy limits. Product liability coverage for pharmaceutical companies is becoming more expensive and increasingly difficult to obtain. As a result, Teva may not be able to obtain the type and amount of insurance it desires, or any insurance on reasonable terms, in all of its markets. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva and its subsidiaries are parties to litigation relating to previously unknown nitrosamine impurities discovered in certain products. The discovery led to a global recall of single and combination valsartan medicines around the world starting in July 2018 and to subsequent recalls on other products. The nitrosamine impurities in valsartan are allegedly found in the active pharmaceutical ingredient (&#8220;API&#8221;) supplied by multiple API manufacturers. Teva&#8217;s products allegedly at issue in the various nitrosamine-related litigations pending in the United States include valsartan, losartan, metformin and ranitidine. There are currently two Multi-District Litigations (&#8220;MDL&#8221;) pending in the United States District Courts against Teva and numerous other manufacturers. One MDL is pending in the United States District Court for the District of New Jersey for valsartan, losartan and irbesartan. Teva is not named in complaints with respect to irbesartan. The second MDL is pending in the United States District Court for the Southern District of Florida for ranitidine. The lawsuits against Teva in the MDLs consist of individual personal injury and/or product liability claims and economic damages claims brought by consumers and end payors on behalf of purported classes of other consumers and end payors as well as medical monitoring class claims. Defendants&#8217; motions to dismiss in the valsartan, losartan and irbesartan MDL were denied in part and granted in part and plaintiffs have filed amended complaints.&#160;In the ranitidine MDL, the generics manufacturers&#8217; motions to dismiss have been granted, although certain plaintiffs have appeals pending. Teva, as well as </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">25 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div></div></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_52308185_1" continuedAt="TextSelectionAppend_52308185_2"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">other generic manufacturers, is also named in several state court actions asserting allegations similar to those in the ranitidine MDL and the valsartan and losartan MDL. The state court valsartan and losartan actions are pending in New Jersey and Delaware and are currently stayed. The state court ranitidine cases naming Teva are pending in California, Illinois, Pennsylvania and New York. In addition to these MDLs, Teva has also been named in a consolidated proceeding pending in the United States District Court for the District of New Jersey brought by individuals and end payors seeking economic damages on behalf of purported classes of consumers and end payors who purchased Teva&#8217;s, as well as other generic manufacturers&#8217; metformin products. Defendants&#8217; motion to dismiss the plaintiffs&#8217; amended metformin complaint from June 2021, was granted without prejudice with respect to the consumer economic loss plaintiffs and granted in part and denied in part with respect to the end payor plaintiffs. Plaintiffs were granted leave to file a second amended complaint. Similar lawsuits are pending in Canada and Germany.</div></div></ix:continuation> <div style="margin-top: 1em; margin-bottom: 1em"></div><ix:continuation id="TextSelectionAppend_52308185_2" continuedAt="TextSelectionAppend_52308185_3"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Competition Matters </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of its generic pharmaceuticals business, Teva has challenged a number of patents covering branded pharmaceuticals, some of which are among the most widely-prescribed and well-known drugs on the market. Many of Teva&#8217;s patent challenges have resulted in litigation relating to Teva&#8217;s attempts to market generic versions of such pharmaceuticals under the federal Hatch-Waxman Act. Some of this litigation has been resolved through settlement agreements in which Teva obtained a license to market a generic version of the drug, often years before the patents expire. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva and its subsidiaries have been named as defendants in cases that allege antitrust violations arising from such settlement agreements. The plaintiffs in these cases are usually direct and indirect purchasers of pharmaceutical products, some of whom assert claims on behalf of classes of all direct and indirect purchasers, and they typically allege that (i)&#160;Teva received something of value from the innovator in exchange for an agreement to delay generic entry, and (ii)&#160;significant savings could have been realized if there had been no settlement agreement and generic competition had commenced earlier. These plaintiffs seek various forms of injunctive and monetary relief, including damages based on the difference between the brand price and what the generic price allegedly would have been and disgorgement of profits, which are often automatically tripled under the relevant statutes, plus attorneys&#8217; fees and costs. The alleged damages generally depend on the size of the branded market and the length of the alleged delay, and can be substantial&#8212;potentially measured in multiples of the annual brand sales&#8212;particularly where the alleged delays are lengthy or branded drugs with annual sales in the billions of dollars are involved. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva believes that its settlement agreements are lawful and serve to increase competition, and has defended them vigorously. In Teva&#8217;s experience to date, these cases have typically settled for a fraction of the high end of the damages sought, although there can be no assurance that such outcomes will continue. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2013, the U.S. Supreme Court held, in Federal Trade Commission (&#8220;FTC&#8221;) v. Actavis, Inc., that a rule of reason test should be applied in analyzing whether such settlements potentially violate the federal antitrust laws. The Supreme Court held that a trial court must analyze each agreement in its entirety in order to determine whether it violates the antitrust laws. This new test has resulted in increased scrutiny of Teva&#8217;s patent settlements, additional action by the FTC and state and local authorities, and an increased risk of liability in Teva&#8217;s currently pending antitrust litigations. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2015, Cephalon Inc., a Teva subsidiary (&#8220;Cephalon&#8221;), entered into a consent decree with the FTC (the &#8220;Modafinil Consent Decree&#8221;) under which the FTC dismissed antitrust claims against Cephalon related to certain finished modafinil products (marketed as PROVIGIL<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>) in exchange for Cephalon and Teva agreeing to, among other things, abide by certain restrictions and limitations, for a period of ten years, when entering into settlement agreements to resolve patent litigation in the United States. Those restrictions and limitations were further refined in connection with the settlement of other unrelated FTC antitrust lawsuits and the term of the Modafinil Consent Decree was extended until 2029. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In November 2020, the European Commission issued a final decision in its proceedings against both Cephalon and Teva, finding that the 2005 settlement agreement between the parties had the object and effect of hindering the entry of generic modafinil, and imposed fines totaling euro <ix:nonFraction name="us-gaap:LossContingencyAccrualAtCarryingValue" contextRef="PAsOn06_30_2022" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">60.5</ix:nonFraction>&#160;million on Teva and Cephalon. Teva and Cephalon filed an appeal against the decision in February 2021. A provision for this matter was included in the financial statements. Teva has provided the European Commission with a bank guarantee in the amount of the imposed fines. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2011, three groups of plaintiffs sued Wyeth and Teva for alleged violations of the antitrust laws in connection with their November 2005 settlement of patent litigation involving extended release venlafaxine (generic Effexor XR<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>). The cases were filed by a purported class of direct purchasers, by a purported class of indirect purchasers and by certain chain pharmacies in the U.S. District Court for the District of New Jersey. The plaintiffs claim that the settlement agreement between Wyeth and Teva unlawfully delayed generic entry. In March 2020, the district court temporarily stayed discovery and referred the case to mediation, and discovery remains stayed. Annual sales of Effexor XR<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> were approximately $<ix:nonFraction name="teva:AnnualSalesOfEffexor" contextRef="P08_21_2017To08_21_2021" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">2.6</ix:nonFraction>&#160;billion at the time of settlement and at the time Teva launched its generic version of Effexor XR<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> in July 2010. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">26 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_52308185_3" continuedAt="TextSelectionAppend_52308185_4"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In February 2012, two purported classes of direct-purchaser plaintiffs sued GSK and Teva in New Jersey federal court for alleged violations of the antitrust laws in connection with their settlement of patent litigation involving lamotrigine (generic Lamictal<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>) entered into in February 2005. The plaintiffs claim that the settlement agreement unlawfully delayed generic entry and seek unspecified damages. On April&#160;9, 2021, the district court, which had previously granted an initial motion for class certification by the direct purchaser plaintiffs but was reversed on that ruling by the Third Circuit in April 2020, denied the direct purchaser plaintiffs&#8217; renewed motion for class certification. Plaintiffs thereafter sought leave to file a supplemental expert report in an effort to show that they could still meet the class certification standard on certain of their claims, but on January&#160;21, 2022, the district court denied that request in full, and on April&#160;21, 2022, the court entered a schedule for additional briefing on the remaining class certification issues. Annual sales of Lamictal<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> were approximately $<ix:nonFraction name="teva:AnnualSalesOfLamictal" contextRef="PAsOn02_28_2005" unitRef="Unit_USD" decimals="-9" scale="9" format="ixt:num-dot-decimal">950</ix:nonFraction>&#160;million at the time of the settlement and approximately $<ix:nonFraction name="teva:AnnualSalesOfLamictal" contextRef="PAsOn07_31_2008" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">2.3</ix:nonFraction>&#160;billion at the time Teva launched its generic version of Lamictal<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> in July 2008. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In April 2013, purported classes of direct purchasers of, and end payers for, Niaspan<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> (extended release niacin) sued Teva and Abbott for violating the antitrust laws by entering into a settlement agreement in April 2005, to resolve patent litigation over the product. A multidistrict litigation has been established in the U.S. District Court for the Eastern District of Pennsylvania. Throughout 2015 and in January 2016, several individual direct-purchaser <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">opt-out</div> plaintiffs filed complaints with allegations nearly identical to those of the direct purchasers&#8217; class. In August 2019, the district court certified the direct-purchaser class, but in June 2020, the court denied the indirect purchasers&#8217; motion for class certification without prejudice. On September&#160;4, 2020, the indirect purchasers filed a renewed motion for class certification, which was subsequently denied with prejudice by the district court and is now on appeal before the Court of Appeals for the Third Circuit. In October 2016, the District Attorney for Orange County, California, filed a similar complaint in California state court, alleging violations of state law and seeking restitution and civil penalties. Annual sales of Niaspan<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> were approximately $<ix:nonFraction name="teva:AnnualSalesOfNiaspan" contextRef="P04_01_2013To04_30_2013" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">416</ix:nonFraction>&#160;million at the time of the settlement and approximately $<ix:nonFraction name="teva:AnnualSalesOfNiaspan" contextRef="P09_01_2013To09_30_2013" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">1.1</ix:nonFraction>&#160;billion at the time Teva launched its generic version of Niaspan<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> in September 2013. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Since January 2014, numerous lawsuits have been filed in the U.S. District Court for the Southern District of New York by purported classes of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">end-payers</div> for, and direct-purchasers of, Actos<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> and Actoplus Met (pioglitazone and pioglitazone plus metformin) against Takeda, the innovator, and several generic manufacturers, including Teva, Actavis and Watson. The lawsuits allege, among other things, that the settlement agreements between Takeda and the generic manufacturers violated the antitrust laws. The court dismissed the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">end-payers&#8217;</div> lawsuits against all defendants in September 2015. On February&#160;8, 2017, the Court of Appeals for the Second Circuit affirmed the dismissal in part and vacated and remanded the dismissal in part with respect to the claims against Takeda. The direct purchasers&#8217; case had been stayed pending resolution of the appeal in the end payer matter and the direct purchasers amended their complaint for a second time following the Second Circuit&#8217;s decision, but on October&#160;8, 2019, the district court dismissed, with prejudice, the direct purchasers&#8217; claims against the generic manufacturers (including Teva, Actavis, and Watson). At the time of Teva&#8217;s settlement, annual sales of Actos<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> and Actoplus Met were approximately $<ix:nonFraction name="teva:AnnualSalesOfActos" contextRef="P12_01_2010To12_31_2010" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">3.7</ix:nonFraction>&#160;billion and approximately $<ix:nonFraction name="teva:AnnualSalesOfActoplus" contextRef="P12_01_2010To12_31_2010" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">500</ix:nonFraction>&#160;million, respectively. At the time Teva launched its authorized generic version of Actos<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> and Actoplus Met in August 2012, annual sales of Actos<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> and Actoplus Met were approximately $<ix:nonFraction name="teva:AnnualSalesOfActos" contextRef="P08_01_2012To08_31_2012" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">2.8</ix:nonFraction>&#160;billion and approximately $<ix:nonFraction name="teva:AnnualSalesOfActoplus" contextRef="P08_01_2012To08_31_2012" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">430</ix:nonFraction>&#160;million, respectively. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Putative classes of direct-purchaser and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">end-payer</div> plaintiffs have filed antitrust lawsuits (which have since been coordinated in federal court in Delaware) against Amgen and Teva alleging that the January&#160;2, 2019 settlement agreement between Amgen and Teva, resolving patent litigation over cinacalcet (generic Sensipar<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>), violated the antitrust laws. On November&#160;30, 2020, the district court denied Teva&#8217;s motion to dismiss in part, and on February&#160;16, 2021, plaintiffs filed amended complaints. On March&#160;30, 2021, Teva again moved to dismiss those claims based on plaintiffs&#8217; failure to allege both&#160;that the settlement violated the antitrust laws and&#160;that the settlement caused any actual injury to plaintiffs. On March&#160;11, 2022, the district court denied Teva&#8217;s motion to dismiss in part. Teva has requested that the district court certify its rulings for review by the United States Court of Appeals for the Third Circuit, and is awaiting the court&#8217;s decision. Annual sales of Sensipar<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> in the United States were approximately $<ix:nonFraction name="teva:AnnualSalesOfSensipar" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">1.4</ix:nonFraction>&#160;billion at the time Teva launched its generic version of Sensipar<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> in December 2018, and at the time of the January&#160;2, 2019 settlement. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">27 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div></div></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_52308185_4" continuedAt="TextSelectionAppend_52308185_5"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2019, certain direct-purchaser plaintiffs filed claims in federal court in Philadelphia naming Teva and its affiliates as defendants alleging that certain patent litigation settlement agreements relating to AndroGel<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> 1% (testosterone gel) violate the antitrust laws, specifically the September 2006 patent litigation settlement between Watson Pharmaceuticals, Inc. (&#8220;Watson&#8221;), from which Teva later acquired certain assets and liabilities, and Solvay Pharmaceuticals, Inc. (&#8220;Solvay&#8221;), and a December 2011 settlement between Teva and AbbVie. Those claims remain pending. Annual sales of AndroGel<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> 1% were approximately $<ix:nonFraction name="teva:AnnualSalesAtTimeOfSettlement" contextRef="PAsOn08_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">350</ix:nonFraction>&#160;million at the time of the earlier Watson/Solvay settlement and approximately $<ix:nonFraction name="teva:AnnualSalesAtTimeOfSettlement" contextRef="PAsOn08_31_2019_AndroGelRateAtOnePercentageMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">140</ix:nonFraction>&#160;million at the time Actavis launched its generic version of AndroGel<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> 1% in November 2015. A provision for these matters and related litigations in Georgia that have since been settled was included in the financial statements. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Between September&#160;1, 2020 and December&#160;20, 2020, separate plaintiffs purporting to represent putative classes of direct and indirect purchasers and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">opt-out</div> retailer purchasers of Bystolic<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> (nebivolol hydrochloride) filed separate complaints in the U.S. District Court for the Southern District of New York against several generic manufacturers, including Teva, Actavis, and Watson, alleging, among other things, that the settlement agreements these generic manufacturers entered into with Forest Laboratories, Inc., the innovator, to resolve patent litigation over Bystolic<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> violated the antitrust laws. The cases were coordinated and on March&#160;15, 2021, plaintiffs filed amended complaints, which Teva, Actavis, and Watson moved to dismiss. On January&#160;24, 2022, the court dismissed plaintiffs&#8217; amended complaints without prejudice. The plaintiffs filed amended complaints on February&#160;22, 2022, which defendants (including Teva, Actavis and Watson) moved to dismiss on April&#160;19, 2022, and those motions remain pending. Annual sales of Bystolic<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> in the United States were approximately $<ix:nonFraction name="teva:AnnualSalesAtTimeOfSettlement" contextRef="PAsOn09_01_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">700</ix:nonFraction>&#160;million at the time of Watson&#8217;s 2013 settlement with Forest. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In February 2021, the State of New Mexico filed a lawsuit against Teva and certain other defendants related to various medicines used to treat HIV. Between September and December 2021, several private plaintiffs including retailers and health insurance providers filed similar claims in federal court in the Northern District of California and in the District of Minnesota. As they relate to Teva, the lawsuits challenge settlement agreements Teva entered into with Gilead in 2013 and 2014 to resolve patent litigation relating to Teva&#8217;s generic versions of Viread<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>, Truvada<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>, and Atripla<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>. Plaintiffs allege that the settlements contain improper reverse payments that delayed the availability of Teva&#8217;s generic products, in violation of the federal antitrust laws and state law. Several recently filed cases are in the process of being coordinated with the existing litigation in the Northern District of California, and any effect those cases may have on the overall case schedule remains unclear. On February&#160;16, 2022, Teva moved to dismiss the claims by certain private plaintiffs but that motion was denied. However, Teva has successfully moved to limit the potential damages period as to certain private plaintiffs. On August&#160;5, 2021, Teva moved to dismiss the complaint brought by the State of New Mexico, and on December&#160;20, 2021, the trial court denied Teva&#8217;s motion. The trial court certified the decision as appropriate for interlocutory appeal, but on April&#160;8, 2022, the appellate court in New Mexico declined to accept the appeal. Teva has appealed the decision to the New Mexico Supreme Court, and that appeal remains pending. Annual sales in the United States at the time of the settlement of Viread<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>, Truvada<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> and Atripla<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> were approximately $<ix:nonFraction name="teva:AnnualSalesAtTimeOfSettlement" contextRef="PAsOn02_01_2021_CAsrtStatementGeographicalAxis_VireadMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">582</ix:nonFraction>&#160;million, $<ix:nonFraction name="teva:AnnualSalesAtTimeOfSettlement" contextRef="PAsOn02_01_2021_CAsrtStatementGeographicalAxis_TiruvadaMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">2.4</ix:nonFraction>&#160;billion, and $<ix:nonFraction name="teva:AnnualSalesAtTimeOfSettlement" contextRef="PAsOn02_01_2021_AtripalaMembersrtProductOrServiceAxis_CAsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">2.9</ix:nonFraction>&#160;billion, respectively. Annual sales in the United States at the time Teva launched its generic version of Viread<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> in 2017, Truvada<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> in 2020 and Atripla<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> in 2020 were approximately $<ix:nonFraction name="teva:AnnualSalesAtTheTimeOfLaunchOfProduct" contextRef="P01_01_2017To12_31_2017_CAsrtStatementGeographicalAxis_VireadMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">728</ix:nonFraction>&#160;million, $<ix:nonFraction name="teva:AnnualSalesAtTheTimeOfLaunchOfProduct" contextRef="P01_01_2020To12_31_2020_CAsrtStatementGeographicalAxis_TiruvadaMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">2.1</ix:nonFraction>&#160;billion and $<ix:nonFraction name="teva:AnnualSalesAtTheTimeOfLaunchOfProduct" contextRef="P01_01_2020To12_31_2020_AtripalaMembersrtProductOrServiceAxis_CAsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">444</ix:nonFraction>&#160;million, respectively. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In March 2021, following the 2019 European Commission&#8217;s inspection of Teva and subsequent request for information, the European Commission opened a formal antitrust investigation to assess whether Teva may have abused a dominant position by delaying the market entry and uptake of medicines that compete with COPAXONE. Annual sales of COPAXONE in the European Economic Area for 2021 were approximately $<ix:nonFraction name="teva:AnnualSalesOfCopaxone" contextRef="P01_01_2014To12_31_2014" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">373</ix:nonFraction>&#160;million. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On July&#160;15, 2021, the U.K. Competition and Markets Authority (&#8220;CMA&#8221;) issued a decision imposing fines for breaches of U.K. competition law by Allergan, Actavis UK and Auden Mckenzie and a number of other companies in connection with the supply of 10mg and 20mg hydrocortisone tablets in the U.K. The decision combines the CMA&#8217;s three prior investigations into the supply of hydrocortisone tablets in the U.K. and encompasses those allegations which were subject to prior statements of objections (a provisional finding of breach of the Competition Act), in particular those under case <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">50277-1</div> (unfair pricing, originally subject to a statement of objections on December&#160;16, 2016), case <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">50277-2</div> (anti-competitive agreement with AMCo, originally subject to a statement of objections on March&#160;3, 2017) as well as the CMA&#8217;s subsequent investigation relating to an anti-competitive agreement with Waymade. On January&#160;9, 2017, Teva completed the sale of Actavis UK to Accord Healthcare Limited, in connection with which Teva will indemnify Accord Healthcare for potential fines imposed by the CMA and/or damages awarded by a court against Actavis UK in relation to the December&#160;16, 2016 and March&#160;3, 2017 statements of objections, and resulting from conduct prior to the closing date of the sale. In addition, Teva agreed to indemnify Allergan against losses arising from this matter in the event of any such fines or damages. On October&#160;6, 2021, Accord UK and Auden Mckenzie appealed the CMA&#8217;s decision. A provision for the estimated exposure for Teva related to the fines and/or damages has been recorded in the financial statements. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">28 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_52308185_5" continuedAt="TextSelectionAppend_52308185_6"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In August 2021, a plaintiff filed a putative class action suit in the United States District Court for the Eastern District of Pennsylvania against Takeda and several generic manufacturers, including Watson and Teva, alleging violations of the antitrust laws in connection with their settlement of patent litigation involving colchicine tablets (generic Colcrys<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>), entered into in January 2016. Plaintiff claims that the settlement was part of a horizontal conspiracy among Takeda and the generic manufacturers to unlawfully restrict output of colchicine by delaying generic entry. Defendants moved to dismiss the complaint for failure to state a claim. On December&#160;28, 2021, the Court granted the defendants&#8217; motion to dismiss, finding that plaintiff&#8217;s allegations were implausible, but granted plaintiff leave to amend, and on January&#160;18, 2022, plaintiff filed its amended complaint, making substantively the same antitrust allegations as before, but with certain new allegations regarding the nature of the alleged conspiracy. On March&#160;30, 2022, the Court granted in part and denied in part defendants&#8217; motion to dismiss, dismissing the newly pled bilateral conspiracy claims but allowing the revised overarching conspiracy claim to proceed against all defendants. On April&#160;8, 2022, Teva and Watson, along with their codefendant Amneal, moved the court to reconsider its partial <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">motion-to-dismiss</div></div> denial or, in the alternative, to certify that denial for immediate appellate review. However, that motion was denied on April&#160;25, 2022. Annual sales of Colcrys<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> in the United States were approximately $<ix:nonFraction name="teva:AnnualSalesAtTimeOfSettlement" contextRef="PAsOn02_01_2021_CAsrtStatementGeographicalAxis_ColcysMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">187</ix:nonFraction>&#160;million at the time of the settlement. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government Investigations and Litigation Relating to Pricing and Marketing </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva is involved in government investigations and litigation arising from the marketing and promotion of its pharmaceutical products in the United States. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In 2015 and 2016, Actavis and Teva USA each respectively received subpoenas from the U.S. Department of Justice (&#8220;DOJ&#8221;) Antitrust Division seeking documents and other information relating to the marketing and pricing of certain Teva USA generic products and communications with competitors about such products. On August&#160;25, 2020, a federal grand jury in the Eastern District of Pennsylvania returned a three count indictment charging Teva USA with criminal felony Sherman Act violations. See <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;20-cr-200</div></div> (E.D. Pa.). The indictment alleges Teva USA participated in three separate conspiracies with certain other generic drug manufacturers to maintain and fix prices, allocate customers, and other alleged antitrust offenses concerning the sale of generic drugs. The indictment identified the following generic drugs: Pravastatin, Carbamazepine, Clotrimazole, Etodolac (IR and ER), Fluocinonide (Cream <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">E-Cream,</div> Gel, and Ointment), Warfarin, Nadolol, Temozolomide, and Tobramycin. On September&#160;8, 2020, Teva USA pled not guilty to all counts. A tentative trial date is yet to be scheduled. While the Company is unable to estimate a range of loss at this time, a conviction on these criminal charges could have a material adverse impact on the Company&#8217;s business, including monetary penalties and debarment from federally funded health care programs. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2018, Teva received a civil investigative demand from the DOJ Civil Division, pursuant to the federal False Claims Act, seeking documents and information produced since January&#160;1, 2009 relevant to the Civil Division&#8217;s investigation concerning allegations that generic pharmaceutical manufacturers, including Teva, engaged in market allocation and price-fixing agreements, paid illegal remuneration, and caused false claims to be submitted in violation of the False Claims Act. An adverse resolution of this matter may include fines, penalties, financial forfeiture and compliance conditions. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2015 and 2016, Actavis and Teva USA each respectively received a subpoena from the Connecticut Attorney General seeking documents and other information relating to potential state antitrust law violations. Subsequently, on December&#160;15, 2016, a civil action was brought by the attorneys general of twenty states against Teva USA and several other companies asserting claims under federal antitrust law alleging price fixing of generic products in the United States. That complaint was later amended to add new states as named plaintiffs, as well as new allegations and new state law claims, and on June&#160;18, 2018, the attorneys general of 49 states plus Puerto Rico and the District of Columbia filed a consolidated amended complaint against Actavis and Teva, as well as other companies and individuals. On May&#160;10, 2019, most (though not all) of these attorneys general filed another antitrust complaint against Actavis, Teva and other companies and individuals, alleging price-fixing and market allocation with respect to additional generic products. On November&#160;1, 2019, the state attorneys general filed an amended complaint, bringing the total number of plaintiff states and territories to 54. The amended complaint alleges that Teva was at the center of a conspiracy in the generic pharmaceutical industry, and asserts that Teva and others fixed prices, rigged bids, and allocated customers and market share with respect to certain additional products. On June&#160;10, 2020, most, but not all, of the same states, with the addition </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">29 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div></div></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_52308185_6" continuedAt="TextSelectionAppend_52308185_7"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of the U.S. Virgin Islands, filed a third complaint in the District of Connecticut naming, among other defendants, Actavis, but not Teva USA, in a similar complaint relating to dermatological generics products. On September&#160;9, 2021, the states&#8217; attorneys general amended their third complaint to, among other things, add California as a plaintiff. In the various complaints described above, the states seek a finding that the defendants&#8217; actions violated federal antitrust law and state antitrust and consumer protection laws, as well as injunctive relief, disgorgement, damages on behalf of various state and governmental entities and consumers, civil penalties and costs. All such complaints have been transferred to the generic drug multidistrict litigation in the Eastern District of Pennsylvania (&#8220;Pennsylvania MDL&#8221;). On July&#160;13, 2020, the court overseeing the Pennsylvania MDL chose the attorneys&#8217; general November&#160;1, 2019 amended complaint, referenced above, along with certain complaints filed by private plaintiffs, to proceed first in the litigation as bellwether complaints. On February&#160;9, 2021, Teva&#8217;s motion to reconsider that ruling was granted, and on May&#160;7, 2021, the Court chose the attorneys&#8217; general third complaint filed on June&#160;10, 2020 and subsequently amended to serve as a bellwether complaint in the Pennsylvania MDL, along with certain complaints filed by private plaintiffs. Teva settled with the State of Mississippi for $<ix:nonFraction name="teva:LossContingencyClaimsDismissedValue" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">925,000</ix:nonFraction> in June 2021 and with the State of Louisiana for $<ix:nonFraction name="teva:LossContingencyClaimsDismissedValue" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,450,000</ix:nonFraction> in March 2022. Pursuant to these settlements, both states have dismissed their claims against Actavis and Teva USA, as well as certain former employees of Actavis and Teva USA. On December&#160;9, 2021, the Court entered an order setting the schedule for the proceedings in the bellwether cases. The order did not include trial dates, but provides for the parties to complete briefing on motions for summary judgement in early 2024. On March&#160;30, 2022, the State of Alabama voluntarily dismissed all of its claims in the litigation, including its claims against Actavis and Teva USA, without prejudice. On June&#160;7, 2022, the Court dismissed the attorneys&#8217; general claims for monetary relief under federal law, concluding that the federal statute under which the attorneys general brought suit authorizes injunctive relief only. However, the attorneys general have pending claims for monetary relief under state law.&#160;&#160;&#160;&#160; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Beginning on March&#160;2, 2016, and continuing through December 2020, numerous complaints have been filed in the United States on behalf of putative classes of direct and indirect purchasers of several generic drug products, as well as several individual direct and indirect purchaser <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">opt-out</div> plaintiffs. These complaints, which allege that the defendants engaged in conspiracies to fix prices and/or allocate market share of generic products have been brought against various manufacturer defendants, including Teva USA and Actavis. The plaintiffs generally seek injunctive relief and damages under federal antitrust law, and damages under various state laws. On October&#160;16, 2018, the court denied certain of the defendants&#8217; motions to dismiss as to certain federal claims, pending as of that date, and on February&#160;15, 2019, the court granted in part and denied in part defendants&#8217; motions to dismiss as to certain state law claims. On July&#160;18, 2019, May&#160;6, 2020 and October&#160;8, 2021, certain individual plaintiffs commenced civil actions in the Pennsylvania Court of Common Pleas of Philadelphia County against many of the defendants in the Pennsylvania MDL, including Teva and Actavis, but no complaints have been filed in the actions and each of the three of the cases have been placed in deferred status. Certain counties in New&#160;York and Texas have also commenced civil actions against many of the defendants in the Pennsylvania MDL, including Teva and Actavis, and the complaints have been transferred to the Pennsylvania MDL. There is also one similar complaint brought in Canada, which alleges that the defendants engaged in conspiracies to fix prices and/or allocate market share of generic drug products to the detriment of a class of private payors. The action is in its early stages. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In March 2017, Teva received a subpoena from the U.S. Attorney&#8217;s office in Boston, Massachusetts requesting documents related to Teva&#8217;s donations to patient assistance programs. Subsequently, in August 2020, the U.S. Attorney&#8217;s office in Boston, Massachusetts brought a civil action in the U.S. District Court for the District of Massachusetts alleging violations of the federal Anti-Kickback Statute, and asserting causes of action under the federal False Claims Act and state law. It is alleged that Teva caused the submission of false claims to Medicare through Teva&#8217;s donations to bona fide independent charities that provide financial assistance to patients. An adverse judgment may involve damages, civil penalties and injunctive remedies. On September&#160;10, 2021, the Court granted Teva&#8217;s motion to dismiss the unjust enrichment claim and denied the remainder of the motion. On October&#160;15, 2021, Teva filed an answer to the complaint. The proceeding is in early stages. Additionally, on January&#160;8, 2021, Humana, Inc. filed an action against Teva in the United States District Court for the Middle District of Florida based on the allegations raised in the August 2020 complaint filed by the U.S. Attorney&#8217;s Office in Boston. On April&#160;2, 2021, Teva filed a motion to dismiss the claims on the grounds that the claims are time-barred and/or insufficiently pled, and that motion remains pending. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In April 2021, a city and county in Washington sued Teva in the United States District Court for the Western District of Washington for alleged violations of the Racketeer Influenced and Corrupt Organizations Act, Washington&#8217;s Consumer Protection Act, and unjust enrichment concerning Teva&#8217;s sale of COPAXONE. Plaintiffs purport to represent a nationwide class of health plans and a subclass of Washington-based health plans that purchased and/or reimbursed health plan members for COPAXONE. Plaintiffs allege that Teva engaged in several fraudulent schemes that resulted in </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><br/></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">30 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_52308185_7" continuedAt="TextSelectionAppend_52308185_8"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">plaintiffs and the putative class members purchasing and/or reimbursing plan members for additional prescriptions of COPAXONE and/or at inflated COPAXONE prices. Plaintiffs seek treble damages for the excess reimbursements and inflated costs, as well as injunctive relief. On September&#160;28, 2021, plaintiffs filed an amended complaint. On November&#160;17, 2021, Teva moved to dismiss the suit, on the grounds that plaintiffs&#8217; claims are barred by the applicable statutes of limitations and the direct purchaser rule, suffer from jurisdictional defects, and fail to plausibly allege fraud or other elements of their claims. That motion is fully briefed and a decision remains pending. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;29, 2021, Mylan Pharmaceuticals (&#8220;Mylan&#8221;) sued Teva in the District Court for the District of New Jersey. On March&#160;11, 2022 and March&#160;15, 2022, FWK Holdings, LLC, KPH Healthcare Servs., Inc. d/b/a Kinney Drugs, Inc., Meijer Inc., Meijer Distribution, Inc., Labor-Management Healthcare Fund, the Mayor and City Council of Baltimore, and the New York State Teamsters Council Health and Hospital Fund sued Teva in the District Court for the District of New Jersey on behalf of themselves and others similarly situated direct and indirect purchasers of COPAXONE. The complaints assert claims for alleged violations of the Lanham Act, state and federal unfair competition and monopolization laws, tortious interference, trade libel, and a violation of the Racketeer Influenced and Corrupt Organizations Act. Plaintiffs claim Teva was involved in an unlawful scheme to delay and hinder generic competition concerning COPAXONE sales. Plaintiffs seek damages for lost profits and expenses, disgorgement, restitution, treble damages, attorneys&#8217; fees and costs, and injunctive relief. Teva has moved to dismiss the complaint filed by Mylan on the grounds, among others, that none of its challenged conduct violates the law. That motion is fully briefed and a decision remains pending. Teva has also moved to dismiss the remaining complaints on similar grounds and the briefing on that motion is ongoing. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opioids Litigation</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Since May 2014, more than 3,500 complaints have been filed with respect to opioid sales and distribution against various Teva affiliates, along with several other pharmaceutical companies, by a number of cities, counties, states, other governmental agencies, tribes and private plaintiffs (including various putative class actions of individuals) in both state and federal courts. Most of the federal cases have been consolidated into a multidistrict litigation in the Northern District of Ohio (&#8220;MDL Opioid Proceeding&#8221;) and many of the cases filed in state court have been removed to federal court and consolidated into the MDL Opioid Proceeding. Two cases that were included in the MDL Opioid Proceeding were transferred back to federal district court for additional discovery, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-trial</div> proceedings and trial. Those cases are: City of Chicago v. Purdue Pharma L.P. et al., <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;14-cv-04361</div></div> (N.D. Ill.) and City and County of San Francisco v. Purdue Pharma L.P. et al., <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;18-cv-07591-CRB</div></div></div> (N.D. Cal.). Other cases remain pending in various states. In some jurisdictions, such as Illinois, New York, Pennsylvania, South Carolina, Texas, Utah and West Virginia, certain state court cases have been transferred to a single court within their respective state court systems for coordinated pretrial proceedings. Complaints asserting claims under similar provisions of different state law generally contend that the defendants allegedly engaged in improper marketing and distribution of opioids, including ACTIQ<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> and FENTORA<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>. The complaints also assert claims related to Teva&#8217;s generic opioid products. In addition, over 950 personal injury plaintiffs, including various putative class actions of individuals, have asserted personal injury and wrongful death claims in over 600 complaints, nearly all of which are consolidated in the MDL Opioid Proceeding.&#160;Furthermore, approximately 700 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-personal</div> injury complaints and approximately 100 personal injury complaints have named Anda, Inc. (and other distributors and manufacturers) alleging that Anda failed to develop and implement systems sufficient to identify suspicious orders of opioid products and prevent the abuse and diversion of such products to individuals who used them for other than legitimate medical purposes. Plaintiffs seek a variety of remedies, including restitution, civil penalties, disgorgement of profits, treble damages,&#160;attorneys&#8217; fees and injunctive relief. Certain plaintiffs assert that the measure of damages is the entirety of the costs associated with addressing the abuse of opioids and opioid addiction and certain plaintiffs specify multiple billions of dollars in the aggregate as alleged damages. The individual personal injury plaintiffs further seek <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-economic</div> damages. In many of these cases, plaintiffs are seeking joint and several damages among all defendants. </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">On April&#160;19, 2021, a bench trial in California (The People of the State of California, acting by and through Santa Clara County Counsel James R. Williams, et. al. v. Purdue Pharma L.P., et. al.) commenced against Teva and other defendants focused on the marketing of branded opioids. On December&#160;14, 2021, the court issued its final judgment in favor of the defendants on all claims. Plaintiffs filed a notice of appeal of this judgment in February 2022. On June&#160;29, 2021, a jury trial in New York (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">In re Opioid Litigation</div></div>, Index No.&#160;400000/2017) commenced against Teva and other defendants, focused on the marketing and distribution of opioids. The case was bifurcated between liability and damages. On December&#160;30, 2021, the jury returned a liability verdict in favor of plaintiffs (the County of Suffolk, the County of Nassau and the State of New York) on the plaintiffs&#8217; public nuisance claim. Teva and the plaintiffs filed post-trial motions with respect to the liability portion of the case, and Teva intends to appeal if its post-trial motions are denied. The court has not yet set a schedule for damages discovery or a date for the relief phase of the trial. Teva, the State of New York and its subdivisions remain actively engaged in settlement negotiations. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">31 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_52308185_8" continuedAt="TextSelectionAppend_52308185_9"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2019, Teva settled the Oklahoma litigation brought by the Oklahoma Attorney General (State of Oklahoma, ex. rel. Mike Hunter, Attorney General of Oklahoma vs. Purdue Pharma L.P., et. al.) for $<ix:nonFraction name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" contextRef="P05_01_2019To05_31_2019_OpioidLitigationMembersrtLitigationCaseAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">85</ix:nonFraction>&#160;million. The settlement did not include any admission of violation of law for any of the claims or allegations made. As the Company demonstrated a willingness to settle part of the litigation, for accounting purposes, management considered a portion of opioid-related cases as probable and, as such, recorded an estimated provision in the second quarter of 2019. Given the relatively early stage of the cases, management viewed no amount within the range to be the most likely outcome. Therefore, management recorded a provision for the reasonably estimable minimum amount in the assessed range for such opioid-related cases in accordance with Accounting Standards Codification 450 &#8220;Accounting for Contingencies.&#8221; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, on October&#160;21, 2019, Teva reached a settlement with the two plaintiffs in the MDL Opioid Proceeding that was scheduled for trial for the Track One case, Cuyahoga and Summit Counties of Ohio. Under the terms of the settlement, Teva agreed to provide the two counties with opioid treatment medication, buprenorphine naloxone (sublingual tablets), known by the brand name Suboxone<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>, with a value of $<ix:nonFraction name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" contextRef="P10_21_2019To10_21_2019_OpioidLitigationMembersrtLitigationCaseAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">25</ix:nonFraction>&#160;million at wholesale acquisition cost and distributed over three years to help in the care and treatment of people suffering from addiction, and a cash payment in the amount of $<ix:nonFraction name="teva:LitigationSettlementAmountAwardedCashAmount" contextRef="P10_21_2019To10_21_2019_OpioidLitigationMembersrtLitigationCaseAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">20</ix:nonFraction>&#160;million, which has been paid. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;21, 2021, it was announced that four other defendants (not including Teva) reached nationwide settlements, subject to certain conditions, which include payment of up to approximately $<ix:nonFraction name="us-gaap:LossContingencyDamagesPaidValue" contextRef="P07_21_2021To07_21_2021_FourOtherDefendantsOtherThanTevaMemberTEVADefendantsAxis_NationwideSettlementMembersrtLitigationCaseAxis" unitRef="Unit_USD" decimals="-9" scale="9" format="ixt:num-dot-decimal">26</ix:nonFraction>&#160;billion spread over up to </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"> <ix:nonNumeric name="teva:LitigationSettlementAmountAwardedDistributionPeriod" contextRef="P07_21_2021To07_21_2021_FourOtherDefendantsOtherThanTevaMemberTEVADefendantsAxis_NationwideSettlementMembersrtLitigationCaseAxis" format="ixt-sec:duryear">18</ix:nonNumeric> years. Teva has continued to work toward a nationwide settlement with the working group of States&#8217; Attorneys General, the Multi-District Litigation Plaintiffs&#8217; Executive Committee and counsel for Native American tribes (&#8220;Tribes&#8221;). In July 2022, the parties reached an agreement in principle on the financial terms of a final nationwide settlement similar in structure to the nationwide settlements of other defendants. The parties continue to work on memorializing the non-financial terms of the proposed nationwide settlement agreement. Under the financial terms of the proposed nationwide settlement agreement, Teva will pay <div style="letter-spacing: 0px; top: 0px;;display:inline;">up to</div>&#160;$<ix:nonFraction name="teva:LitigationAmountIncludingAlreadyPaid" contextRef="PAsOn07_01_2022_CompaniesShareMemberTEVADefendantsAxis_StatesPoliticalSubdivisionsAndTribesMembersrtLitigationCaseAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-7" scale="9" format="ixt:num-dot-decimal">4.25</ix:nonFraction> </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">billion (including the already settled cases) plus approximately $<ix:nonFraction name="teva:LitigationAmountToBePaidToTribes" contextRef="PAsOn07_01_2022_CompaniesShareMemberTEVADefendantsAxis_StatesPoliticalSubdivisionsAndTribesMembersrtLitigationCaseAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">100</ix:nonFraction> million for the Tribes, spread over</div> </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"> <ix:nonNumeric name="teva:LitigationSettlementTerm" contextRef="P07_01_2022To07_31_2022_CompaniesShareMemberTEVADefendantsAxis_StatesPoliticalSubdivisionsAndTribesMembersrtLitigationCaseAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" format="ixt-sec:duryear">13</ix:nonNumeric> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">years. This total includes the supply of up to</div>&#160;</div>$<ix:nonFraction name="teva:ProductOfferingSettlementAtWholesaleAcquisitionCosts" contextRef="P07_01_2022To07_31_2022_CompaniesShareMemberTEVADefendantsAxis_StatesPoliticalSubdivisionsAndTribesMembersrtLitigationCaseAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">1.2</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">billion of Teva&#8217;s generic version of Narcan&#174; (naloxone hydrochloride nasal spray)<div style="letter-spacing: 0px; top: 0px;;display:inline;">,</div> valued at wholesale acquisition cost<div style="letter-spacing: 0px; top: 0px;;display:inline;">,</div> over&#160;</div><ix:nonNumeric name="teva:ProductToBeSettledValuationTerm" contextRef="P07_01_2022To07_31_2022_CompaniesShareMemberTEVADefendantsAxis_StatesPoliticalSubdivisionsAndTribesMembersrtLitigationCaseAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" format="ixt-sec:duryear">10</ix:nonNumeric> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">years or <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">cash at&#160;</div><ix:nonFraction name="teva:PercentageOfWholesaleAcquisitionCostValueInCashInLieuOfProductToBePaidUnderSettlementAgreement" contextRef="PAsOn07_31_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">20</ix:nonFraction>% of the wholesale acquisition cost <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">($<ix:nonFraction name="teva:WholesaleAcquisitionCostValueInCashAmountInLieuOfProductToBePaidUnderSettlementAgreement" contextRef="PAsOn07_31_2022_CompaniesShareMemberTEVADefendantsAxis_StatesPoliticalSubdivisionsAndTribesMembersrtLitigationCaseAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">240</ix:nonFraction> million) in lieu of product. The nationwide settlement agreement is contingent upon (i) final documentation among the working group and Teva, and reaching the thresholds for participation that will be set forth in the final agreement; and (ii) Teva reaching an agreement with Allergan with respect to any indemnification obligations, and Allergan reaching a nationwide opioids settlement. No other trials currently are scheduled against Teva in 2022 in any opioids matter, with the possible exception of the relief phase of the trial in the New York opioids litigation. If the nationwide settlement agreement is not finalized, additional trials are expected to proceed in several states in 2023.</div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On September&#160;28, 2021, Teva reached an agreement with the Attorney General of Louisiana that settles the state&#8217;s opioid-related claims. The agreement was contingent that all political subdivisions of Louisiana will formally release Teva as part of the settlement, which Teva was advised has occurred by the Attorney General of Louisiana. Under the terms of the settlement, Teva will pay Louisiana $<ix:nonFraction name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" contextRef="P09_28_2021To09_28_2021_AttorneyGeneralOfLouisanaMemberTEVAAgreementAxis_LAsrtStatementGeographicalAxis_OpioidLitigationMembersrtLitigationCaseAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">15</ix:nonFraction>&#160;million over an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="teva:LitigationSettlementAmountAwardedCashAmountDistributionPeriod" contextRef="P09_28_2021To09_28_2021_AttorneyGeneralOfLouisanaMemberTEVAAgreementAxis_LAsrtStatementGeographicalAxis_OpioidLitigationMembersrtLitigationCaseAxis" format="ixt-sec:duryear">18</ix:nonNumeric>-year</div> period and will provide buprenorphine naloxone (sublingual tablets) valued at $<ix:nonFraction name="teva:LitigationSettlementAmountDistributableinKind" contextRef="PAsOn09_28_2021_AttorneyGeneralOfLouisanaMemberTEVAAgreementAxis_LAsrtStatementGeographicalAxis_OpioidLitigationMembersrtLitigationCaseAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction>&#160;million (wholesale acquisition cost). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On February&#160;4, 2022, the Company reached an agreement with the Attorney General of the State of Texas that settles Texas&#8217; and its subdivisions&#8217; opioid-related claims. On March&#160;10, 2022, Texas confirmed that at least <ix:nonFraction name="teva:PercentageOfPopulationOfSubdivisionsWillFormallyReleaseAsAPartOfSettlement" contextRef="P02_04_2022To02_04_2022" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">96</ix:nonFraction>% of the population of subdivisions formally released Teva as part of the settlement. Under the terms of the settlement, Teva will pay Texas $<ix:nonFraction name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" contextRef="P02_04_2022To02_04_2022_OpioidLitigationMembersrtLitigationCaseAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">150</ix:nonFraction>&#160;million over a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="teva:LitigationSettlementAmountAwardedCashAmountDistributionPeriod" contextRef="P02_04_2022To02_04_2022_OpioidLitigationMembersrtLitigationCaseAxis" format="ixt-sec:duryear">15</ix:nonNumeric>-year</div> period and will provide its generic version of Narcan<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> (naloxone hydrochloride nasal spray), valued at $<ix:nonFraction name="teva:LitigationSettlementAmountDistributableinKind" contextRef="PAsOn02_04_2022_AttorneyGeneralOfLouisanaMemberTEVAAgreementAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">75</ix:nonFraction>&#160;million (wholesale acquisition cost) over 10 years. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;21, 2022, Teva reached an agreement with the Attorney General of Rhode Island that settles Rhode Island&#8217;s and its subdivisions&#8217; opioid-related claims. Under the terms of the settlement, Teva will pay Rhode Island $<ix:nonFraction name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" contextRef="P03_21_2022To03_21_2022_OpioidLitigationMembersrtLitigationCaseAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">21</ix:nonFraction>&#160;million over <ix:nonNumeric name="teva:LitigationSettlementAmountAwardedCashAmountDistributionPeriod" contextRef="P03_21_2022To03_21_2022_OpioidLitigationMembersrtLitigationCaseAxis" format="ixt-sec:duryear">13</ix:nonNumeric> years, in addition to attorneys&#8217; fees and costs, and will provide its generic version of Narcan<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> (naloxone hydrochloride nasal spray) and a significant amount of buprenorphine naloxone sublingual tablets known by the brand name Suboxone<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>, together valued at $<ix:nonFraction name="teva:LitigationSettlementAmountDistributableinKind" contextRef="PAsOn03_21_2022_AttorneyGeneralOfRhodeIslandMemberTEVAAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">78.5</ix:nonFraction>&#160;million (wholesale acquisition cost) over 10 years. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">32 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_52308185_9" continuedAt="TextSelectionAppend_52308185_10"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">On March&#160;30, 2022, Teva reached an agreement with the Attorney General of Florida that settles Florida&#8217;s and its subdivisions&#8217; opioid-related claims. Under the terms of the settlement, Teva will pay Florida $<ix:nonFraction name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" contextRef="P03_30_2022To03_30_2022_OpioidLitigationMembersrtLitigationCaseAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">177</ix:nonFraction>&#160;million over <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="teva:LitigationSettlementAmountAwardedCashAmountDistributionPeriod" contextRef="P03_30_2022To03_30_2022_OpioidLitigationMembersrtLitigationCaseAxis" format="ixt-sec:duryear">15</ix:nonNumeric>-years,</div> in addition to attorneys&#8217; fees and costs, and will provide its generic version of Narcan<div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:7.1px">&#174;</div></div> (naloxone hydrochloride nasal spray) valued at $<ix:nonFraction name="teva:LitigationSettlementAmountDistributableinKind" contextRef="PAsOn03_30_2022_AttorneyGeneralOfFloridaMemberTEVAAgreementAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">84</ix:nonFraction>&#160;million (wholesale acquisition cost) over 10 years. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On May&#160;24, 2022, Teva reached an agreement in principle with the Attorney General of West Virginia that settles West Virginia&#8217;s and its subdivisions&#8217; opioid-related claims. Under the terms of the settlement, Teva will pay West Virginia $<ix:nonFraction name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" contextRef="P05_24_2022To05_24_2022_OpioidLitigationMembersrtLitigationCaseAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">75</ix:nonFraction>&#160;million over <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="teva:LitigationSettlementAmountAwardedCashAmountDistributionPeriod" contextRef="P05_24_2022To05_24_2022_OpioidLitigationMembersrtLitigationCaseAxis" format="ixt-sec:duryear">15</ix:nonNumeric>-years,</div> in addition to attorneys&#8217; fees and costs, and will provide its generic version of Narcan<div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:7.1px">&#174;</div></div> (naloxone hydrochloride nasal spray) valued at $<ix:nonFraction name="teva:LitigationSettlementAmountDistributableinKind" contextRef="PAsOn05_24_2022_AttorneyGeneralOfWestVirginiaMemberTEVAAgreementAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">27</ix:nonFraction>&#160;million (wholesale acquisition cost) over 10 years. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;12, 2022, Teva reached an agreement in principle with the City and County of San Francisco and the People of the State of California that settles opioid-related claims asserted on behalf of the City and County of San Francisco. Teva will provide San Francisco $<ix:nonFraction name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" contextRef="P07_12_2022To07_12_2022_OpioidLitigationMembersrtLitigationCaseAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.3</ix:nonFraction>&#160;million over <ix:nonNumeric name="teva:LitigationSettlementAmountAwardedCashAmountDistributionPeriod" contextRef="P07_12_2022To07_12_2022_OpioidLitigationMembersrtLitigationCaseAxis" format="ixt-sec:duryear">13</ix:nonNumeric> years, in addition to attorneys&#8217; fees and costs, and will provide its generic version of Narcan</div><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:7.1px">&#174;</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (naloxone hydrochloride nasal spray), valued at $<ix:nonFraction name="teva:LitigationSettlementAmountDistributableinKind" contextRef="PAsOn07_12_2022_OpioidLitigationMembersrtLitigationCaseAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">20</ix:nonFraction>&#160;million (wholesale acquisition cost), over 10 years. </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In light of the agreement in principle on the nationwide settlement between Teva, and the States&#8217; Attorneys General, their subdivisions and the Tribes, Teva&#8217;s potential indemnification obligations arising from Teva&#8217;s acquisition of the Actavis Generics business for opioid-related claims, prior settlements with Texas, Florida, Louisiana, Rhode Island, West Virginia and San Francisco, the verdict in New York, decisions in California and Oklahoma, as well as an estimate for a number of items including, but not limited to, costs associated with administering injunctive terms, and most favored nations clauses associated with prior settlements, the Company has reconsidered the potential settlement outcome and revised its provision. The revised provision is a reasonable estimate of the ultimate costs in the likely event that the nationwide settlement is finalized under its current proposed terms and conditions, after discounting payments to states to their net present value. However, if the nationwide settlement is not finalized for the entirety of the remaining cases, a reasonable upper end of a range of loss cannot be determined. An adverse resolution of any of these lawsuits or investigations may involve large monetary penalties, damages, and/or other forms of monetary and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-monetary</div> relief and could have a material and adverse effect on Teva&#8217;s reputation, business, results of operations and cash flows. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2019, Teva received a grand jury subpoena from the United States Attorney&#8217;s Office for the Eastern District of New York for documents related to the Company&#8217;s anti-diversion policies and procedures and distribution of its opioid medications, in what the Company understands to be part of a broader investigation into manufacturers&#8217; and distributors&#8217; monitoring programs and reporting under the Controlled Substances Act. In September 2019, Teva received subpoenas from the New York State Department of Financial Services (NYDFS) as part of an industry-wide inquiry into the effect of opioid prescriptions on New York health insurance premiums. This was followed by a Statement of Charges and Notice of Hearing filed by the NYDFS, although no merits hearing date is currently set. Currently, Teva cannot predict how <div style="letter-spacing: 0px; top: 0px;;display:inline;">the</div> nationwide settlement (if finalized) will affect these investigations and administrative actions. In addition, a number of State Attorneys General, including a coordinated multistate effort, have initiated investigations into sales and marketing practices of Teva and its affiliates with respect to opioids. Other states are conducting their own investigations outside of the multistate group. Teva is cooperating with these ongoing investigations and cannot predict their outcome at this time. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, several jurisdictions and consumers in Canada have initiated litigation regarding opioids alleging similar claims as those in the United States. The cases in Canada are in their early stages. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shareholder Litigation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On November&#160;6, 2016 and December&#160;27, 2016, two putative securities class actions were filed in the U.S. District Court for the Central District of California against Teva and certain of its current and former officers and directors. Those lawsuits were consolidated and transferred to the U.S. District Court for the District of Connecticut (the &#8220;Ontario Teachers Securities Litigation&#8221;). On December&#160;13, 2019, the lead plaintiff in that action filed an amended complaint, purportedly on behalf of purchasers of Teva&#8217;s securities between February&#160;6, 2014 and May&#160;10, 2019. The amended complaint asserts that Teva and certain of its current and former officers and directors violated federal securities and common laws in connection with Teva&#8217;s alleged failure to disclose pricing strategies for various drugs in its generic drug portfolio and by making allegedly false or misleading statements in certain offering materials. The amended complaint seeks unspecified damages, legal fees, interest, and costs. In July 2017,&#160;August 2017, and June 2019, other putative securities class actions were filed in other federal courts based on similar allegations, and those cases have been transferred to the U.S. District Court for the District of Connecticut. Between August 2017 and January 2022, twenty-three complaints were filed against Teva and certain of its current and former officers and directors seeking unspecified compensatory damages, legal fees, costs and expenses. The similar claims in these complaints have been brought on behalf of plaintiffs, in various forums across the country, who have indicated that they intend to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;opt-out&#8221;</div> of the Ontario Teachers Securities Litigation. On March&#160;10, 2020, the Court consolidated the Ontario Teachers Securities Litigation with all of the above-referenced putative class actions for all purposes and the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;opt-out&#8221;</div> cases for pretrial purposes. Pursuant to that consolidation order, plaintiffs in several of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;opt-out&#8221;</div> cases filed amended complaints on May&#160;28, 2020. On January&#160;22, 2021, the Court </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">33 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_52308185_10" continuedAt="TextSelectionAppend_52308185_11"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">dismissed the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;opt-out&#8221;</div> plaintiffs&#8217; claims arising from statements made prior to the five year statute of repose, but denied Teva&#8217;s motion to dismiss their claims under Israeli laws. Those <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;opt-out&#8221;</div> plaintiffs moved for reconsideration, which was denied on March&#160;30, 2021. On May&#160;24, 2021, Teva moved to dismiss a majority of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;opt-out&#8221;</div> complaints on various other grounds. Those motions are still pending. The Ontario Teachers Securities Litigation plaintiffs&#8217; Motion for Class&#160;Certification and Appointment of Class&#160;Representatives and Class&#160;Counsel was granted on March&#160;9, 2021, to which Teva&#8217;s appeal was denied. On January&#160;18, 2022, Teva entered into a settlement in the Ontario Teachers Securities Litigation for $<ix:nonFraction name="us-gaap:LitigationSettlementExpense" contextRef="P06_02_2022To06_02_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">420</ix:nonFraction>&#160;million, which received final approval from the court on June&#160;2, 2022. Pursuant to an agreement between the Company and its insurance carriers, the insurance carriers provided the vast majority of the total settlement amount, with a small portion contributed by Teva. Additionally, as part of the settlement, Teva admitted no liability and denied all allegations of wrongdoing. A number of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;opt-out&#8221;</div> complaints still remain outstanding, and motions to approve securities class actions were also filed in the Tel Aviv District Court in Israel with similar allegations to those made in the Ontario Teachers Securities Litigation. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;23, 2020, a putative securities class action was filed in the U.S. District Court for the Eastern District of Pennsylvania against Teva and certain of its former officers. On August&#160;10, 2021, the lead plaintiff filed a corrected amended class action complaint, purportedly on behalf of persons who purchased or otherwise acquired Teva securities between October&#160;29, 2015 and August&#160;18, 2020. The corrected amended complaint alleges that Teva and certain of its current and former officers violated federal securities laws by allegedly making false and misleading statements regarding the commercial performance of COPAXONE, namely, by failing to disclose that Teva had allegedly caused the submission of false claims to Medicare through Teva&#8217;s donations to bona fide independent charities that provide financial assistance to patients, which allegedly impacted COPAXONE&#8217;s commercial success and the sustainability of its revenues and resulted in the above referenced August 2020 False Claims Act complaint filed by the DOJ. The corrected amended complaint seeks unspecified damages and legal fees. On March&#160;25, 2022, the court granted in part and denied in part Teva&#8217;s and the individual defendants&#8217; motion to dismiss the corrected amended complaint, (i)&#160;holding that the plaintiffs&#8217; complaint failed to plead that certain public statements regarding Teva&#8217;s compliance with the law were misleading, (ii)&#160;holding that two alleged partial corrective disclosures did not establish loss causation and cannot serve as the basis for plaintiff&#8217;s claimed loss, (iii)&#160;dismissing all claims against one of the individual defendants, and (iv)&#160;otherwise denying the motion to dismiss. A motion to approve a securities class action was also filed in the Central District Court in Israel, which has been stayed pending the U.S. litigation, with similar allegations to those made in the above complaint filed in the U.S. District Court for the Eastern District of Pennsylvania. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Motions to approve derivative actions seeking monetary damages against certain past and present directors and officers have been filed in Israeli Courts alleging negligence and recklessness. Motions for document disclosure prior to initiating derivative actions were filed with respect to several U.S. and EU settlement agreements, opioids, the U.S. price-fixing investigations and allegations related to the DOJ&#8217;s complaint regarding Copaxone patient assistance program in the U.S. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Environmental Matters </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva or its subsidiaries are party to a number of environmental proceedings, or have received claims, including under the federal Superfund law or other federal, provincial or state and local laws, imposing liability for alleged noncompliance, or for the investigation and remediation of releases of hazardous substances and for natural resource damages. Many of these proceedings and claims seek to require the generators of hazardous wastes disposed of at a third party-owned site, or the party responsible for a release of hazardous substances that impacted a site, to investigate and clean the site or to pay or reimburse others for such activities, including for oversight by governmental authorities and any related damages to natural resources. Teva or its subsidiaries have received claims, or been made a party to these proceedings, along with others, as an alleged generator of wastes that were disposed of or treated at third-party waste disposal sites, or as a result of an alleged release from one of Teva&#8217;s facilities or former facilities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Although liability among the responsible parties, under certain circumstances, may be joint and several, these proceedings are frequently resolved so that the allocation of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">clean-up</div> and other costs among the parties reflects the relative contributions of the parties to the site conditions and takes into account other pertinent factors. Teva&#8217;s potential liability varies greatly at each of the sites; for some sites the costs of the investigation, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">clean-up</div> and natural resource damages have not yet been determined, and for others Teva&#8217;s allocable share of liability has not been determined. At other sites, Teva has taken an active role in identifying those costs, to the extent they are identifiable and estimable, which do not include reductions for potential recoveries of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">clean-up</div> costs from insurers, indemnitors, former site owners or </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">34 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:continuation id="TextSelectionAppend_52308185_11"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">operators or other potentially responsible parties. In addition, enforcement proceedings relating to alleged violations of federal, state, commonwealth or local requirements at some of Teva&#8217;s facilities may result in the imposition of significant penalties (in amounts not expected to materially adversely affect Teva&#8217;s results of operations) and the recovery of certain costs and natural resource damages, and may require that corrective actions and enhanced compliance measures be implemented. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;103 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-K</div> promulgated by the SEC requires disclosure of certain environmental matters when a governmental authority is a party to the proceedings and such proceedings involve potential monetary sanctions, unless the Company reasonably believes that the matter will result in no monetary sanctions, or in monetary sanctions, exclusive of interest and costs, of less than $<ix:nonFraction name="us-gaap:AccrualForEnvironmentalLossContingencies" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">300,000</ix:nonFraction>. The following matter is disclosed in accordance with that requirement. On July&#160;8, 2021, the National Green Tribunal Principal Bench, New Delhi, issued an order against Teva&#8217;s subsidiary in India, Teva API India Private Limited, finding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with environmental laws and assessed a penalty of $<ix:nonFraction name="teva:LossContingenciesOnEnvironmentalLawsPenalty" contextRef="PAsOn07_08_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.4</ix:nonFraction>&#160;million. The Company disputed certain of the findings and the amount of the penalty and filed an appeal before the Supreme Court of India. On August&#160;5, 2021, the Supreme Court of India admitted the appeal for hearing and granted an interim unconditional stay on the National Green Tribunal&#8217;s order. The Company does not believe that the eventual outcome of such matter will have a material effect on its business. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Matters </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;1, 2018, former shareholders of Ception Therapeutics, Inc., a company that was acquired by and merged into Cephalon in 2010, prior to Cephalon&#8217;s acquisition by Teva, filed breach of contract and other related claims against the Company, Teva USA and Cephalon in the Delaware Court of Chancery.&#160;Among other things, the plaintiffs allege that Cephalon breached the terms of the 2010 Ception-Cephalon merger agreement by failing to exercise commercially reasonable efforts to develop and commercialize CINQAIR<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> (reslizumab) for the treatment of eosinophilic esophagitis (&#8220;EE&#8221;). The plaintiffs claim damages of at least $<ix:nonFraction name="us-gaap:LossContingencyDamagesSoughtValue" contextRef="P01_01_2022To06_30_2022_EosinophilicEsophagitisMemberusgaapLossContingenciesByNatureOfContingencyAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">200</ix:nonFraction>&#160;million, an amount they allege is equivalent to the milestones payable to the former shareholders of Ception in the event Cephalon were to obtain regulatory approval for EE in the United States ($<ix:nonFraction name="us-gaap:LossContingencyDamagesSoughtValue" contextRef="P01_01_2022To06_30_2022_EosinophilicEsophagitisMemberusgaapLossContingenciesByNatureOfContingencyAxis_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">150</ix:nonFraction> million) and Europe ($<ix:nonFraction name="us-gaap:LossContingencyDamagesSoughtValue" contextRef="P01_01_2022To06_30_2022_EuropeMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">50</ix:nonFraction> million). Defendants moved to dismiss the complaint and on December&#160;28, 2018, the court granted the motion in part and dismissed all of plaintiffs&#8217; claims, except for their claim against Cephalon for breach of contract. In November 2021, plaintiffs moved to amend their complaint to, among other things, reassert claims against the Company and Teva USA, but the plaintiffs </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">later stipulated to filing a new amended complaint that includes claims against Teva USA but not the Company, in exchange for Teva USA&#8217;s agreement to guarantee any judgment entered against Cephalon in the litigation. Plaintiffs filed that amended complaint on July 12, 2022. Trial in this matter is currently scheduled for September 2022.</div></div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></ix:continuation> <ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P01_01_2022To06_30_2022" escape="true" continuedAt="TextSelection_52307933"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 11 &#8211; Income taxes: </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In the second quarter of 2022, Teva recognized a tax benefit of $<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">900</ix:nonFraction>&#160;million, on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> loss of $<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,160</ix:nonFraction>&#160;million. In the second quarter of 2021, Teva recognized a tax expense of $<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">98</ix:nonFraction>&#160;million, on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> income of $<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">308</ix:nonFraction>&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the second quarter of 2022, one of Teva&#8217;s U.S. subsidiaries was determined to be insolvent for tax purposes (i.e., its liabilities exceeded the fair market value of its assets), mainly in light of its accumulated operational losses. Consequently, Teva will recognize on its 2022 tax return, a worthless stock deduction of approximately $<ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">4.2</ix:nonFraction> billion, with related tax benefit of approximately $<ix:nonFraction name="teva:EffectiveIncomeTaxReconciliationAmountInventoryWrittenOff" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">850</ix:nonFraction> million. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva&#8217;s tax rate for the second quarter of 2022 was mainly affected by the realization of losses related to its investment in one of its U.S. subsidiaries mentioned above, as well as impairments, legal settlements, adjustments to valuation allowances on deferred tax assets and interest expense disallowances. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In the first six months of 2022, Teva recognized a tax benefit of $<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">899</ix:nonFraction>&#160;million, on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> loss of $<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,131</ix:nonFraction>&#160;million. In the first six months of 2021, Teva recognized a tax expense of $<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">159</ix:nonFraction>&#160;million, on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> income of $<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">451</ix:nonFraction>&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva&#8217;s tax rate for the first six months of 2022 was mainly affected by the realization of losses related to its investment in one of its U.S. subsidiaries mentioned above, as well as impairments, legal settlements, adjustments to valuation allowances on deferred tax assets and interest expense disallowances. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The statutory Israeli corporate tax rate is <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2022To06_30_2022_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">23</ix:nonFraction>% in 2022. Teva&#8217;s tax rate differs from the Israeli statutory tax rate, mainly due to generation of profits in various jurisdictions in which tax rates are different than the Israeli tax rate, interest expense disallowances, tax benefits in Israel and other countries, as well as infrequent or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-recurring</div> items. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Teva filed a claim seeking the refund of withholding taxes paid to the Indian tax authorities in 2012. Trial in this case is scheduled to begin in November 2022. A final and binding decision against Teva in this case may lead to an impairment of</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> $<ix:nonFraction name="teva:ExpectedImpairmentOfIncomeTaxBenefit" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">133</ix:nonFraction>&#160;million.</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">35 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:continuation id="TextSelection_52307933"> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Israeli tax authorities issued tax assessment decrees for 2008-2012 and 2013-2016, challenging the Company&#8217;s positions on several issues. Teva has protested the 2008-2012 and 2013-2016 decrees before the Central District Court in Israel. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">In October 2021, the Central District Court in Israel held in favor of the Israeli tax authorities with respect to 2008-2011 decrees. The case with respect to 2012-2016 remains pending with similar legal claims. The October 2021 Central District Court decision found that Teva has a tax liability to the Israeli government for 2008-2011 of approximately $<ix:nonFraction name="us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss" contextRef="P10_01_2021To10_31_2021_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis_TaxYear2008To2011MemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">350</ix:nonFraction>&#160;million,<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;of which a portion is being paid in cash during 2022 and 2023, and the remaining portion is being offset by carried forward losses that Teva would otherwise be entitled to. Teva appealed the decision to the Israeli Supreme Court and expects the appeal hearings to begin in early 2023.&#160;</div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company believes it has adequately provided for all of its uncertain tax positions, including those items currently under dispute, however, adverse results could be material. </div><br/></div> </ix:continuation></div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <ix:nonNumeric name="teva:OtherExpensesTextBlock" contextRef="P01_01_2022To06_30_2022" escape="true" continuedAt="TextSelection_52308169"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 12 &#8211; Other assets impairments, restructuring and other </div></div><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">items: </div></div></div><br/></div> <ix:nonNumeric name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" contextRef="P01_01_2022To06_30_2022" escape="true"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months&#160;ended<br/>June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six&#160;months&#160;ended<br/>June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairments of long-lived tangible assets (1)</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52307555">14</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52307556">32</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52307557">30</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52307558">80</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">61</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">19</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">94</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restructuring</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">35</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">13</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">92</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">69</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:LegalSettlementsLossContingenciesImpairmentsOtherExpenses" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:LegalSettlementsLossContingenciesImpairmentsOtherExpenses" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">28</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:LegalSettlementsLossContingenciesImpairmentsOtherExpenses" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">30</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:LegalSettlementsLossContingenciesImpairmentsOtherExpenses" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">33</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%; line-height: 11pt; font-size: 11pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size:11pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 11pt;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom; width: 5%; line-height: 11pt; font-size: 11pt;"><div style="font-size:11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size:11pt;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;"><ix:nonFraction name="teva:ImpairmentAndRestructuring" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">118</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size:11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 5%; line-height: 11pt; font-size: 11pt;"><div style="font-size:11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size:11pt;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;"><ix:nonFraction name="teva:ImpairmentAndRestructuring" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">28</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size:11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%; line-height: 11pt; font-size: 11pt;"><div style="font-size:11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size:11pt;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;"><ix:nonFraction name="teva:ImpairmentAndRestructuring" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">246</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size:11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 5%; line-height: 11pt; font-size: 11pt;"><div style="font-size:11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size:11pt;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;"><ix:nonFraction name="teva:ImpairmentAndRestructuring" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">165</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size:11pt;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="width: 26%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Including impairments related to exit and disposal activities. </div></div> </td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impairments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairments of tangible assets for the three months ended June&#160;30, 2022 and 2021 were $<ix:nonFraction name="us-gaap:TangibleAssetImpairmentCharges" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">14</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:TangibleAssetImpairmentCharges" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">32</ix:nonFraction>&#160;million, respectively.&#160;The impairment for the three months ended June&#160;30, 2021 was mainly related to certain assets in Europe. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Impairments of tangible assets for the six months ended June&#160;30, 2022 and 2021 were $<ix:nonFraction name="us-gaap:TangibleAssetImpairmentCharges" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">30</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:TangibleAssetImpairmentCharges" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">80</ix:nonFraction>&#160;million, respectively.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;The impairment for the six months ended June 30, 2022 was mainly related to certain assets in North America. The impairment for the six months ended June 30, 2021 was mainly related to certain assets in Europe.&#160;</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva may record additional impairments in the future, to the extent it changes its plans on any given asset and/or the assumptions underlying such plans, as a result of its network consolidation activities. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contingent consideration </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the three months ended June&#160;30, 2022, Teva recorded an expense of $<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">61</ix:nonFraction>&#160;million for contingent consideration, compared to an income of $<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">19</ix:nonFraction>&#160;</div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million in the three months ended June&#160;30, 2021. The expense in the second quarter of 2022 and the income in the second quarter of 2021 were mainly related to changes in the estimated future royalty payments to Allergan in connection with lenalidomide (generic equivalent of Revlimid<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>), which was part of the Actavis Generics acquisition. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the six months ended June&#160;30, 2022, Teva recorded an expense of $<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">94</ix:nonFraction>&#160;million for contingent consideration, compared to an income of $<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">16</ix:nonFraction>&#160;million in the six months ended June&#160;30, 2021. The expense in the first six months of 2022</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, and the income in the first six months of 2021 were </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> mainly related to change<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div> in the estimated future royalty payments to Allergan in connection with lenalidomide (generic equivalent of Revlimid<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>), which was part of the Actavis Generics acquisition.</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">36 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;;text-indent: 0px;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);;text-indent: 0px;"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:continuation id="TextSelection_52308169" continuedAt="TextSelectionAppend_52308169_1"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restructuring </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the three months ended June&#160;30, 2022, Teva recorded $<ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">35</ix:nonFraction>&#160;million of restructuring expenses, compared to $<ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">13</ix:nonFraction>&#160;million of restructuring <div style="letter-spacing: 0px; top: 0px;;display:inline;">income</div>&#160;in the three months ended June&#160;30, 2021. </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">The expenses for the three months </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ended June&#160;30, 2022 were primarily related to network consolidation activities and residual expenses of the restructuring plan announced in 2017. The income for the three months ended June&#160;30, 2021 was primarily related to reassessment of the estimate of a prior employee termination provision. </div></div><br/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the six months ended June&#160;30, 2022, Teva recorded $</div><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">92</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of restructuring expenses, compared to $</div><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">69</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in the six months ended June&#160;30, 2021. The expenses for the six months ended June&#160;30, 2022 and June&#160;30, 2021 were primarily related to network consolidation activities and residual expenses of the restructuring plan announced in 2017.</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">37</div><br/></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div> </div> </div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_52308169_1" continuedAt="TextSelectionAppend_52308169_2"> <ix:nonNumeric name="teva:ScheduleOfRestructuringChargesTableTextBlock" contextRef="P01_01_2022To06_30_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables provide the components of restructuring costs: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months&#160;ended&#160;June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restructuring</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee termination</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P04_01_2022To06_30_2022_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">11</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P04_01_2021To06_30_2021_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">19</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P04_01_2022To06_30_2022_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">24</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P04_01_2021To06_30_2021_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">35</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">13</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six&#160;months&#160;ended&#160;June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restructuring</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee termination</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2022To06_30_2022_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">63</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2021To06_30_2021_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">61</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2022To06_30_2022_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">29</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2021To06_30_2021_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">92</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">69</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" contextRef="P01_01_2022To06_30_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides the components of and changes in the Company&#8217;s restructuring accruals: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employee&#160;termination<br/> costs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of January&#160;1, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn12_31_2021_EmployeeTerminationMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">131</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn12_31_2021_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">138</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provision</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:RestructuringAccrualProvision" contextRef="P01_01_2022To06_30_2022_EmployeeTerminationMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">63</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:RestructuringAccrualProvision" contextRef="P01_01_2022To06_30_2022_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">29</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:RestructuringAccrualProvision" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">92</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Utilization and other*</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:UtilizationAndOther" contextRef="P01_01_2022To06_30_2022_EmployeeTerminationMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52308226">74</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:UtilizationAndOther" contextRef="P01_01_2022To06_30_2022_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52308225">29</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:UtilizationAndOther" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52307908">103</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of June&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn06_30_2022_EmployeeTerminationMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">120</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn06_30_2022_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">127</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"></td>
<td colspan="4" style="height: 12pt;"></td>
<td colspan="4" style="height: 12pt;"></td>
<td colspan="4" style="height: 12pt;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employee&#160;termination<br/> costs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of January&#160;1, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn12_31_2020_EmployeeTerminationMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">115</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn12_31_2020_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">122</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provision</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:RestructuringAccrualProvision" contextRef="P01_01_2021To06_30_2021_EmployeeTerminationMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">61</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:RestructuringAccrualProvision" contextRef="P01_01_2021To06_30_2021_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:RestructuringAccrualProvision" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">69</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Utilization and other*</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:UtilizationAndOther" contextRef="P01_01_2021To06_30_2021_EmployeeTerminationMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52307612">56</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:UtilizationAndOther" contextRef="P01_01_2021To06_30_2021_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52307613">8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:UtilizationAndOther" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52307614">64</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of June&#160;30, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn06_30_2021_EmployeeTerminationMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">120</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn06_30_2021_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">127</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="width: 26%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">*</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Includes adjustments for foreign currency translation. </div></div></div></td></tr></table></ix:nonNumeric> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Significant regulatory and other events </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In July 2018, Teva announced the voluntary recall of valsartan and certain combination valsartan medicines in various countries due to the detection of trace amounts of a previously unknown nitrosamine impurity called NDMA found in valsartan API supplied by Zhejiang Huahai Pharmaceuticals Co. Ltd. (&#8220;Huahai&#8221;). Since July 2018, Teva has been actively engaged with global regulatory authorities in reviewing its sartan and other products to determine whether NDMA and/or other related nitrosamine impurities are present in specific products. Where necessary, Teva has initiated additional voluntary recalls. In December 2019, Teva reached a settlement with Huahai resolving Teva&#8217;s claims related to certain sartan API supplied by Huahai. Under the settlement agreement, Huahai agreed to compensate Teva for some of </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">38 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><ix:continuation id="TextSelectionAppend_52308169_2" continuedAt="TextSelectionAppend_52308169_3"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">its direct losses and provide it with prospective cost reductions for API. The settlement does not release Huahai from liability for any losses Teva may incur as a result of third party personal injury or product liability claims relating to the sartan API at issue. In addition, multiple lawsuits have been filed in connection with this matter, which may lead to additional customer penalties, impairments and litigation costs. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the second quarter of 2020, Teva&#8217;s operations in its manufacturing facilities in Goa, India were temporarily suspended due to a water supply issue. During the second half of 2020, Teva completed partial remediation of this issue and restarted limited supply from its Goa facilities. The site experienced some additional delays in the first quarter of 2021 due to labor related issues, but the situation stabilized during the second quarter of 2021. The water supply remediation is expected to be completed during the third quarter of 2022, and in the meantime the site is operating under an interim water solution without any material impact expected on compliance and supply capacity. The impact to Teva&#8217;s financial results for the three and six months ended June&#160;30, 2022 was immaterial. </div></div></div></ix:continuation></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_52308169_3"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In June 2021, the Company temporarily paused manufacturing at its Irvine, California facility in the United States, and suspended release of product from the facility pending completion of an open manufacturing investigation. In July 2021, the FDA initiated an establishment inspection at the facility. On August&#160;18, 2021, the Company issued field alert reports to the FDA for products manufactured at the Irvine facility and put Irvine manufactured products in Teva&#8217;s distribution center on hold. On August&#160;20, 2021, the FDA completed its inspection and issued a Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-483</div> to the Irvine facility with ten observations and, on December&#160;17, 2021, the FDA notified the Company that the inspection classification of this site is &#8220;official action indicated&#8221; (&#8220;OAI&#8221;). Teva began working diligently to address the FDA&#8217;s concerns in a manner consistent with current good manufacturing practice (&#8220;CGMP&#8221;) requirements, and was in discussions with the FDA Drug Shortage Staff (DSS) and FDA Office of Manufacturing Quality (OMQ) to recommence distribution, release and manufacture of certain medically necessary products from the site under defined controls and protocols. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;22, 2022, the Company announced its decision to permanently cease all manufacturing activities and to close the site, and to transfer certain products to other facilities. Teva will remain in contact with FDA regarding the status of the Irvine, California site to ensure that the Company continues to comply with all relevant CGMP requirements, particularly those involved with product transfers to other sites within the Teva network. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If Teva is unable to address FDA inspection issues satisfactorily, it could be subject to additional regulatory actions. Teva has considered these developments and, during the six months ended June&#160;30, 2022, recorded $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">73</ix:nonFraction>&#160;million costs in its financial statements related to this matter. Teva will continue to assess potential financial implications, including loss of revenues, impairments, inventory write offs, customer penalties, costs of additional remediation and/or FDA enforcement actions. </div><br/></div></ix:continuation><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div></div></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="P01_01_2022To06_30_2022" escape="true" continuedAt="TextSelection_52308171"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 13 &#8211; Earnings (Loss) per share: </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic earnings and loss per share are computed by dividing net income (loss) attributable to Teva&#8217;s ordinary shareholders by the weighted average number of ordinary shares outstanding, including fully vested restricted share units (&#8220;RSUs&#8221;) and performance share units (&#8220;PSUs&#8221;) during the period, net of treasury shares. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In computing diluted loss per share for the three months ended June&#160;30, 2022, <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P04_01_2022To06_30_2022_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> account was taken of the potential dilution that could occur upon the exercise of options and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> RSUs and PSUs granted under employee stock compensation plans, and convertible senior debentures, since they had an anti-dilutive effect on loss per share. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In computing diluted earnings per share for the three months ended June&#160;30, 2021, basic earnings per share were adjusted to take into account the potential dilution that could occur upon the exercise of options and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> RSUs granted under employee stock compensation plans. <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P04_01_2021To06_30_2021_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction> account was taken of the potential dilution by the convertible senior debentures, since they had an anti-dilutive effect on earnings per share. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In computing diluted loss per share for the six months ended June&#160;30, 2022, <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To06_30_2022_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> account was taken of the potential dilution that could occur upon the exercise of options and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> RSUs and PSUs granted under employee stock compensation plans, and convertible senior debentures, since they had an anti-dilutive effect on loss per share. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In computing diluted earnings per share for the six months ended June&#160;30, 2021, basic earnings per share were adjusted to take into account the potential dilution that could occur upon the exercise of options and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> RSUs granted under employee stock compensation plans. <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To06_30_2021_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction> account was taken of the potential dilution by the convertible senior debentures, since they had an anti-dilutive effect on earnings per share.</div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">39 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></div> <ix:continuation id="TextSelection_52308171"> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The weighted average diluted shares outstanding used for the fully diluted share calculations for the three months ended June&#160;30, 2022, and 2021, were <ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,110</ix:nonFraction> and <ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,109</ix:nonFraction> shares, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The weighted average diluted shares outstanding used for the fully diluted share calculations for the six months ended June&#160;30, 2022, and 2021, were <ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,109</ix:nonFraction> and <ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,108</ix:nonFraction> shares, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted loss per share was $<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal">0.21</ix:nonFraction></ix:nonFraction> for the three months ended June&#160;30, 2022, compared to basic and diluted earnings per share of $<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.19</ix:nonFraction></ix:nonFraction> for the three months ended June&#160;30, 2021. Basic and diluted loss per share was $<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal">1.07</ix:nonFraction></ix:nonFraction> for the six months ended June&#160;30, 2022, compared to basic and diluted earnings per share of $<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.26</ix:nonFraction></ix:nonFraction> for the six months ended June&#160;30, 2021. </div><br/></div> </ix:continuation></div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P01_01_2022To06_30_2022" escape="true" continuedAt="TextSelection_52308170"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 14 &#8211; Accumulated other comprehensive income (loss): </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" contextRef="P01_01_2022To06_30_2022" escape="true" continuedAt="TextSelection_52307929">The components of, and changes within, accumulated other comprehensive income (loss) attributable to Teva are presented in the table below:</ix:nonNumeric> </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">40 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></div> <ix:continuation id="TextSelection_52307929"><ix:continuation id="TextSelection_52308170"> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net&#160;Unrealized&#160;Gains&#160;(Losses)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Benefit&#160;Plans</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign<br/> currency<br/> translation<br/> adjustments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Derivative<br/> financial<br/> instruments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Actuarial&#160;gains<br/> (losses)&#160;and<br/> prior&#160;service<br/> (costs)&#160;credits</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2021, net of taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2021_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,274</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2021_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">324</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2021_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">85</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,683</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income (loss) before reclassifications</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" contextRef="P01_01_2022To06_30_2022_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">127</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" contextRef="P01_01_2022To06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">127</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts reclassified to the statements of income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" contextRef="P01_01_2022To06_30_2022_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" contextRef="P01_01_2022To06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Net other comprehensive income (loss) before tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" contextRef="P01_01_2022To06_30_2022_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">127</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" contextRef="P01_01_2022To06_30_2022_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" contextRef="P01_01_2022To06_30_2022_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" contextRef="P01_01_2022To06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">113</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Corresponding income tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" contextRef="P01_01_2022To06_30_2022_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" contextRef="P01_01_2022To06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Net other comprehensive income (loss) after tax*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2022To06_30_2022_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal" id="Fact_52307826">132</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2022To06_30_2022_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52307827">14</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2022To06_30_2022_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero" id="Fact_52307828">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2022To06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal" id="Fact_52307829">118</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of June&#160;30, 2022, net of taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn06_30_2022_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,406</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn06_30_2022_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">310</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn06_30_2022_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">85</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,801</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="width: 26%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family:Times New Roman,Times,serif;;display:inline;">Amounts do not include a $<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2022To06_30_2022_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">150</ix:nonFraction>&#160;million loss from foreign currency translation adjustments attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests.&#160;</div></div> </td> </tr> </table> <div style="font-family:Times New Roman,Times,serif;;display:inline;"> </div> <div style="font-family:Times New Roman,Times,serif;;display:inline;"> </div> <div style="font-family:Times New Roman,Times,serif;;display:inline;"> </div> <div style="font-family:Times New Roman,Times,serif;;display:inline;"> </div> <div style="font-family:Times New Roman,Times,serif;;display:inline;"> </div> <div style="font-family:Times New Roman,Times,serif;;display:inline;"> </div> <div style="font-family:Times New Roman,Times,serif;;display:inline;"> </div> <div style="font-family:Times New Roman,Times,serif;;display:inline;"> </div> <div style="clear: both; max-height: 0px;"></div> <div style="font-family:Times New Roman,Times,serif;;display:inline;"> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net&#160;Unrealized&#160;Gains&#160;(Losses)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Benefit&#160;Plans</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign<br/> currency<br/> translation<br/> adjustments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Derivative<br/> financial<br/> instruments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Actuarial&#160;gains<br/> (losses)&#160;and<br/> prior&#160;service<br/> (costs)&#160;credits</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2020, net of taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2020_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,919</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2020_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">363</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2020_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">117</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,399</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income (loss) before reclassifications</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" contextRef="P01_01_2021To06_30_2021_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">77</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" contextRef="P01_01_2021To06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">77</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts reclassified to the statements of income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" contextRef="P01_01_2021To06_30_2021_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">18</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" contextRef="P01_01_2021To06_30_2021_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" contextRef="P01_01_2021To06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">19</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Net other comprehensive income (loss) before tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" contextRef="P01_01_2021To06_30_2021_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">77</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" contextRef="P01_01_2021To06_30_2021_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">18</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" contextRef="P01_01_2021To06_30_2021_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" contextRef="P01_01_2021To06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">58</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Corresponding income tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" contextRef="P01_01_2021To06_30_2021_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">15</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" contextRef="P01_01_2021To06_30_2021_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" contextRef="P01_01_2021To06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">11</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Net other comprehensive income (loss) after tax*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2021To06_30_2021_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal" id="Fact_52307781">62</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2021To06_30_2021_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52307780">14</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2021To06_30_2021_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52307958">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2021To06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal" id="Fact_52307779">47</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of June&#160;30, 2021, net of taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn06_30_2021_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,981</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn06_30_2021_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">349</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn06_30_2021_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">116</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,446</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="width: 26%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Amounts do not include a $<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2021To06_30_2021_AccountingStandardsUpdate201601MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">68</ix:nonFraction>&#160;million loss from foreign currency translation adjustments attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests. </div> </td> </tr> </table> </ix:continuation></ix:continuation> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div> </div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <ix:nonNumeric name="us-gaap:SegmentReportingDisclosureTextBlock" contextRef="P01_01_2022To06_30_2022" escape="true" continuedAt="TextSelection_52308177"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 15 &#8211; Segments: </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva operates its business and reports its financial results in three segments: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">North America segment, which includes the United States and Canada. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(b)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Europe segment, which includes the European Union, the United Kingdom and certain other European countries. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(c)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International Markets segment, which includes all countries other than those in the North America and Europe segments. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In addition to these <ix:nonFraction name="us-gaap:NumberOfReportableSegments" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_Segment" decimals="0" scale="0" format="ixt-sec:numwordsen">three </ix:nonFraction>segments, Teva has other sources of revenues, primarily the sale of APIs to third parties, certain contract manufacturing services and an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licensing</div> platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva&#8217;s<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chief Executive Officer (&#8220;CEO&#8221;), who is the chief operating decision maker (&#8220;CODM&#8221;), reviews financial information prepared on a consolidated basis, accompanied by disaggregated information about revenues and contributed profit by the </div>three<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> identified reportable segments, namely North America, Europe and International Markets, to make decisions about resources to be allocated to the segments and assess their performance.</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">41 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:continuation id="TextSelection_52308177" continuedAt="TextSelectionAppend_52308177_1"> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit is comprised of gross profit for the segment less R&amp;D expenses, S&amp;M expenses, G&amp;A expenses and other income related to the segment. Segment profit does not include amortization and certain other items. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva manages its assets on a company basis, not by segments, as many of its assets are shared or commingled. Teva&#8217;s CODM does not regularly review asset information by reportable segment and, therefore, Teva does not report asset information by reportable segment. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Teva&#8217;s</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;CEO may review its strategy and organizational structure from time to time. Any changes in strategy may lead to a reevaluation of the Company&#8217;s segments and goodwill allocation to reporting units, as well as fair value attributable to its reporting units. See note 3 and note 6. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">42 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>&#160;</div> <ix:continuation id="TextSelectionAppend_52308177_1" continuedAt="TextSelectionAppend_52308177_2"> <ix:nonNumeric name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" contextRef="P01_01_2022To06_30_2022" escape="true" continuedAt="TextSelection_52308173"><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div></div></div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 10pt; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>Seg<div style="font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 10pt; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ment </div></div></div></div></div><div style="font-size: 8pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">information:</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North&#160;America</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International&#160;Markets</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,904</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,171</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">454</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P04_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,010</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P04_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">703</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P04_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">242</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P04_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">147</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P04_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">56</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P04_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">19</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P04_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">256</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P04_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">196</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P04_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">99</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P04_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">127</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P04_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">63</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P04_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">30</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:OtherOperatingIncomeExpense" contextRef="P04_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:OtherOperatingIncomeExpense" contextRef="P04_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:OtherOperatingIncomeExpense" contextRef="P04_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P04_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">481</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P04_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">389</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P04_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">95</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North&#160;America</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International&#160;Markets</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,943</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,184</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">485</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P04_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,040</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P04_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">661</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P04_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">270</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P04_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">162</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P04_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">63</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P04_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">18</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P04_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">255</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P04_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">209</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P04_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">105</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P04_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">106</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P04_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">47</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P04_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">25</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:OtherOperatingIncomeExpense" contextRef="P04_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:OtherOperatingIncomeExpense" contextRef="P04_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P04_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">521</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P04_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">343</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P04_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">123</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#167; Represents an amount less than $0.5&#160;million. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">43</div><br/></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><br/></div> <ix:continuation id="TextSelectionAppend_52308177_2" continuedAt="TextSelectionAppend_52308177_3"> <ix:continuation id="TextSelection_52308173">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six months ended June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North&#160;America</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International&#160;Markets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,641</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,327</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">946</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,899</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,397</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">528</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">289</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">114</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">39</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P01_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">501</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P01_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">393</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P01_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">196</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">239</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">122</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">60</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:OtherOperatingIncomeExpense" contextRef="P01_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:OtherOperatingIncomeExpense" contextRef="P01_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:OtherOperatingIncomeExpense" contextRef="P01_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">41</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">883</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">769</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">274</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six months ended June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North&#160;America</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International&#160;Markets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,932</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,398</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">975</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,114</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,349</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">530</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">322</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">129</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">35</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P01_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">483</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P01_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">424</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P01_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">201</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">218</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">117</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">51</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:OtherOperatingIncomeExpense" contextRef="P01_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:OtherOperatingIncomeExpense" contextRef="P01_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:OtherOperatingIncomeExpense" contextRef="P01_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,098</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">680</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">245</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:continuation> <ix:nonNumeric name="teva:ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock" contextRef="P01_01_2022To06_30_2022" escape="true" continuedAt="TextSelection_52308172"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents a reconciliation of Teva&#8217;s segment profits to its consolidated operating income (loss) and to consolidated income (loss) before income taxes for the three and six months ended June&#160;30, 2022 and 2021: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:nonNumeric> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">44 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div> </div> </div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><ix:continuation id="TextSelection_52308172"><ix:continuation id="TextSelectionAppend_52308177_3" continuedAt="TextSelectionAppend_52308177_4"> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended </div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six months ended </div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $&#160;in millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $&#160;in millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 69%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-size: 0px;">
<td style="width: 69%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-size: 0px;">
<td style="width: 82%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 0.5%; vertical-align: bottom;"></td>
<td style="width: 0.25%; vertical-align: bottom;"></td>
<td style="width: 0.125%; vertical-align: bottom;"></td>
<td style="width: 0.0625%; vertical-align: bottom;"></td>
<td style="width: 0.03125%; vertical-align: bottom;"></td>
<td style="width: 0.015625%; vertical-align: bottom;"></td>
<td style="width: 0.015625%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">North America profit</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div>&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P04_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">481</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P04_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">521</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">883</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,098</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Europe profit</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P04_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">389</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P04_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">343</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">769</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">680</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International Markets profit</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P04_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">95</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P04_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">123</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">274</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">245</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr>
<td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total reportable segments profit</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P04_01_2022To06_30_2022_CorporateMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">964</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P04_01_2021To06_30_2021_CorporateMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">987</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To06_30_2022_CorporateMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,926</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2021To06_30_2021_CorporateMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,023</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Profit of other activities</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P04_01_2022To06_30_2022_AllOtherSegmentsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">55</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P04_01_2021To06_30_2021_AllOtherSegmentsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">47</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To06_30_2022_AllOtherSegmentsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">107</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2021To06_30_2021_AllOtherSegmentsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">87</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr>
<td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total segments profit</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P04_01_2022To06_30_2022_SegmentsAndOtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,019</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P04_01_2021To06_30_2021_SegmentsAndOtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,034</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To06_30_2022_SegmentsAndOtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,032</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2021To06_30_2021_SegmentsAndOtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,111</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts not allocated to segments:</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; padding: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; padding: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; padding: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; padding: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; padding: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; padding: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; padding: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; padding: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">212</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">173</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">412</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">414</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets impairments, restructuring and other items</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="teva:ImpairmentsRestructuringAndOthers" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">118</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="teva:ImpairmentsRestructuringAndOthers" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">28</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ImpairmentsRestructuringAndOthers" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">246</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ImpairmentsRestructuringAndOthers" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">165</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill impairment</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">745</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; width: 4%;;text-align:right;"><div style="line-height: normal;"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">745</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets impairments</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">51</ix:nonFraction></div><br/></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">195</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">199</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">274</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legal settlements and loss contingencies</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="teva:LegalSettlementsAndLossContingencies" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">729</ix:nonFraction></div><br/></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="teva:LegalSettlementsAndLossContingencies" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">6</ix:nonFraction></div><br/></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:LegalSettlementsAndLossContingencies" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,854</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:LegalSettlementsAndLossContingencies" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">110</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other unallocated amounts</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="teva:OtherUnallocatedAmounts" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">113</ix:nonFraction></div><br/></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="teva:OtherUnallocatedAmounts" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">50</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:OtherUnallocatedAmounts" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">240</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:OtherUnallocatedAmounts" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">132</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr>
<td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated operating income (loss)</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">949</ix:nonFraction></div><br/></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div><br/></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">582</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,662</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,015</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr>
<td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial expenses, net</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">211</ix:nonFraction></div><br/></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">274</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">468</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">564</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr>
<td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated income (loss) before income taxes</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,160</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div>&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">308</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,131</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">451</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr>
<td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 1.25pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 1.25pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 1.25pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 1.25pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 1.25pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table> </ix:continuation></ix:continuation> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <ix:continuation id="TextSelectionAppend_52308177_4" continuedAt="TextSelectionAppend_52308177_5"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">b. Segment revenues by major products and activities: </div></div></div></div> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables present revenues by major products and activities for the three and six months ended June&#160;30, 2022 and 2021: </div></div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">45 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(</div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unaudited) </div></div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" contextRef="P01_01_2022To06_30_2022" escape="true" continuedAt="TextSelection_52308319"><ix:continuation id="TextSelectionAppend_52308177_5" continuedAt="TextSelectionAppend_52308177_6"> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 81%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North America</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months&#160;ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 81%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic products</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_GenericsMediciansMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,026</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_GenericsMediciansMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">951</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AJOVY</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_AjovyMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">49</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_AjovyMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">46</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AUSTEDO</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_AustedoMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">204</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_AustedoMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">174</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">BENDEKA&#174;/TREANDA&#174;<br/></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_BendekaAndTreandaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">83</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_BendekaAndTreandaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">106</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_COPAXONEMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">94</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_COPAXONEMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">152</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Anda</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_AndaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">308</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_AndaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">316</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">139</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">199</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,904</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,943</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North America</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six&#160;months&#160;ended<br/>June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic products</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_GenericsMediciansMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,925</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_GenericsMediciansMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,004</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AJOVY</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_AjovyMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">86</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_AjovyMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">77</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AUSTEDO</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_AustedoMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">358</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_AustedoMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">320</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BENDEKA/TREANDA</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_BendekaAndTreandaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">165</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_BendekaAndTreandaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">197</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_COPAXONEMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">180</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_COPAXONEMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">315</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Anda</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_AndaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">650</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_AndaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">605</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">278</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">414</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,641</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,932</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 1px;">
<td></td></tr></table>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 82%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months&#160;ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 82%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic products</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_GenericsMediciansMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">873</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_GenericsMediciansMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">878</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AJOVY</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_AjovyMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">29</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_AjovyMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">19</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_COPAXONEMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">72</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_COPAXONEMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Respiratory products</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_RespiratoryProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">65</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_RespiratoryProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">85</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">131</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">102</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,171</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,184</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </ix:continuation></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">46 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><ix:continuation id="TextSelectionAppend_52308177_6"> <ix:continuation id="TextSelection_52308319">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six&#160;months&#160;ended<br/> June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 80%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic products</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_GenericsMediciansMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,749</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_GenericsMediciansMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,742</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 80%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AJOVY</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_AjovyMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">60</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_AjovyMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">35</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 80%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_COPAXONEMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">144</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_COPAXONEMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">201</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 80%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Respiratory products</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_RespiratoryProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">137</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_RespiratoryProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">179</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 80%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">238</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">242</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 80%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; width: 80%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,327</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,398</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 80%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 84%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International markets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months&#160;ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic products</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_GenericsMediciansMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">394</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_GenericsMediciansMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">407</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AJOVY</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_AjovyMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_AjovyMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_COPAXONEMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_COPAXONEMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">65</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">454</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">485</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 84%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International markets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six&#160;months&#160;ended<br/> June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic products</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_GenericsMediciansMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">782</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_GenericsMediciansMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">799</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AJOVY</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_AjovyMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_AjovyMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_COPAXONEMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_COPAXONEMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">19</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">128</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">150</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">946</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">975</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:continuation> </ix:continuation> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2022To06_30_2022" escape="true" continuedAt="TextSelection_52308187"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 16 &#8211; Fair value measurement: </div></div></div></div> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <ix:nonNumeric name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="P01_01_2022To06_30_2022" escape="true" continuedAt="TextSelection_52308184"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial items carried at fair value on a recurring basis as of June&#160;30, 2022 and December&#160;31, 2021 are classified in the tables below in one of the three categories of fair value levels: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:nonNumeric></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">47 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></div> <div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <ix:continuation id="TextSelection_52308187" continuedAt="TextSelectionAppend_52308187_1"><ix:continuation id="TextSelection_52308184">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money markets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn06_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">451</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn06_30_2022_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">451</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, deposits and other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn06_30_2022_DemandDepositsMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,607</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn06_30_2022_DemandDepositsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,607</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in securities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity securities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn06_30_2022_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn06_30_2022_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn06_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn06_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn06_30_2022_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="PAsOn06_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">33</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">33</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivatives:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asset derivatives&#8212;options and forward contracts</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeAssets" contextRef="PAsOn06_30_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_InterestRateSwapMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">69</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeAssets" contextRef="PAsOn06_30_2022_InterestRateSwapMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">69</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liability derivatives:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options and forward contracts</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn06_30_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">37</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn06_30_2022_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">37</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bifurcated embedded derivatives</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn06_30_2022_CrossCurrencyInterestRateContractMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn06_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52307481">205</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52307482">205</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="PAsOn06_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,106</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="PAsOn06_30_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">32</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="PAsOn06_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">204</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,934</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money markets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">220</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2021_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">220</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, deposits and other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2021_DemandDepositsMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,945</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2021_DemandDepositsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,945</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in securities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity securities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn12_31_2021_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">18</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn12_31_2021_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">18</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn12_31_2021_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">33</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">33</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivatives:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asset derivatives&#8212;options and forward contracts</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeAssets" contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_InterestRateSwapMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">30</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeAssets" contextRef="PAsOn12_31_2021_InterestRateSwapMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">30</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liability derivatives:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options and forward contracts</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">23</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2021_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">23</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bifurcated embedded derivatives</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2021_CrossCurrencyInterestRateContractMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52308001">176</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_52308002">176</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,222</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">175</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,054</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="width: 26%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#167;</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than $0.5&#160;million. </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">*</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration represents liabilities recorded at fair value in connection with acquisitions. </div></div></div> </td> </tr> </table> </ix:continuation></ix:continuation> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_52308187_1" continuedAt="TextSelectionAppend_52308187_2"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva determined the fair value of the liabilities for the contingent consideration based on a probability-weighted discounted cash flow analysis. This fair value measurement is based on significant unobservable inputs in the market and thus represents a Level&#160;3 measurement within the fair value hierarchy. The fair value of the contingent consideration is based on several factors, such as: the cash flows projected from the success of unapproved product candidates; the probability of success of product candidates, including risks associated with uncertainty regarding achievement and payment of milestone events; the time and resources needed to complete the development and approval of product candidates; the life of the potential commercialized products and associated risks of obtaining regulatory approvals in the United States and Europe, and the risk adjusted discount rate for fair value measurement. A probability of success factor of <ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" contextRef="PAsOn06_30_2022_MeasurementInputProbabilityOfSuccessMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">100</ix:nonFraction>% was used in the fair value calculation to reflect inherent regulatory and commercial risk of the contingent payments and IPR&amp;D. The discount rate applied ranged from <ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" contextRef="PAsOn06_30_2022_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="1" scale="0" format="ixt:num-dot-decimal">8.3</ix:nonFraction>% to <ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" contextRef="PAsOn06_30_2022_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="1" scale="0" format="ixt:num-dot-decimal">11.2</ix:nonFraction>%. The weighted average discount rate, calculated based on the relative fair value of Teva&#8217;s contingent consideration liabilities, was <ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" contextRef="PAsOn06_30_2022_WeightedAverageMembersrtRangeAxis" unitRef="Unit_pure" decimals="1" scale="0" format="ixt:num-dot-decimal">8.8</ix:nonFraction>%. The contingent</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">48 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:continuation id="TextSelectionAppend_52308187_2"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">consideration is evaluated quarterly, or more frequently, if circumstances dictate. Changes in the fair value of contingent consideration are recorded in consolidated statements of income. Significant changes in unobservable inputs, mainly the probability of success and cash flows projected, could result in material changes to the contingent consideration liabilities. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"> <div style="top: 0px; letter-spacing: 0px; font-family: 'Times New Roman'; font-size: 10pt; display: inline;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="P01_01_2022To06_30_2022" escape="true" continuedAt="TextSelection_52308181">The following table summarizes the activity for those financial assets and liabilities where fair value measurements are estimated utilizing Level&#160;3 inputs:</ix:nonNumeric> </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:continuation id="TextSelection_52308181" continuedAt="TextSelectionAppend_52308181_1">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six&#160;months<br/>ended&#160;June&#160;30,<br/>2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six&#160;months<br/>ended<br/>June&#160;30,<br/>2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value at the beginning of the period</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">175</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">258</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Redemption of debt securities</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" contextRef="P01_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bifurcated embedded derivatives</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:BifurcatedEmbeddedDerivatives" contextRef="P01_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to provisions for contingent consideration:</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Actavis Generics transaction</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod" contextRef="P01_01_2022To06_30_2022_ActavisGenericsMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">92</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod" contextRef="P01_01_2021To06_30_2021_ActavisGenericsMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">22</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Eagle transaction</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" contextRef="P01_01_2022To06_30_2022_EagleTransactionMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" contextRef="P01_01_2021To06_30_2021_EagleTransactionMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Settlement of contingent consideration:</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Actavis Generics transaction</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="P01_01_2022To06_30_2022_ActavisGenericsMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">30</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="P01_01_2021To06_30_2021_ActavisGenericsMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Eagle transaction</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="P01_01_2022To06_30_2022_EagleTransactionMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">46</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="P01_01_2021To06_30_2021_EagleTransactionMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">48</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Additional contingent consideration resulting from Novetide acquisition*</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" contextRef="P01_01_2022To06_30_2022_NoveTideAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">11</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" contextRef="P01_01_2021To06_30_2021_NoveTideAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 75%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value at the end of the period</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">204</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">204</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 75%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:continuation></div> </div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> </div> <div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="width: 26%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:continuation id="TextSelectionAppend_52308181_1">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#167;</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than $0.5&#160;million. </div></div></div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">In January 2022, Teva acquired <ix:nonFraction name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" contextRef="PAsOn01_01_2022_NoveTideAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>% ownership of Novetide Ltd. (&#8220;Novetide&#8221;), which was previously accounted for as &#8220;investment in associated <div style="display:inline;">companies.&#8221; This</div>&#160;transaction was accounted for as a business combination. Total consideration for the transaction included cash and certain contingent royalty payments through 2034. As part of the transaction, Teva recognized a gain under &#8220;Share in (profits) losses of associated companies, net&#8221;, reflecting the difference between the book value of its investment in Novetide and its fair value as of the date Teva completed its acquisition. </div></div> </td> </tr> </table> </ix:continuation> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments not measured at fair value </div></div></div> <ix:nonNumeric name="us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" contextRef="P01_01_2022To06_30_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments measured on a basis other than fair value mostly consist of senior notes and convertible senior debentures (see note 7) and are presented in the table below in terms of fair value (level 1 inputs): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated fair value*</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes and sustainability-linked senior notes included under senior notes and loans</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn06_30_2022_SeniorNotesAndSustainabilityLinkedSeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">17,481</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn12_31_2021_SeniorNotesAndSustainabilityLinkedSeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">21,477</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes and convertible senior debentures included under short-term debt</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn06_30_2022_SeniornotesandconvertibleseniordebenturesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,702</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn12_31_2021_SeniornotesandconvertibleseniordebenturesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,426</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">19,183</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">22,903</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="width: 26%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value was estimated based on quoted market prices. </div></div> </td> </tr> </table> </ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">49</div></div> </div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx360666_9" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ITEM&#160;2.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Business Overview </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are a global pharmaceutical company, committed to helping patients around the world to access affordable medicines and benefit from innovations to improve their health. Our mission is to be a global leader in generics, specialty medicines and biopharmaceuticals, improving the lives of patients. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We operate worldwide, with headquarters in Israel and a significant presence in the United States, Europe and many other markets around the world. Our key strengths include our world-leading generic medicines expertise and portfolio, focused specialty medicines portfolio and global infrastructure and scale. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva was incorporated in Israel on February&#160;13, 1944 and is the successor to a number of Israeli corporations, the oldest of which was established in 1901. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Business Segments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We operate our business through three segments: North America, Europe and International Markets. Each business segment manages our entire product portfolio in its region, including generics, specialty and OTC products. This structure enables strong alignment and integration between operations, commercial regions, R&amp;D and our global marketing and portfolio function, optimizing our product lifecycle across therapeutic areas. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition to these three segments, we have other activities, primarily the sale of API to third parties, certain contract manufacturing services and an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licensing</div> platform offering a portfolio of products to other pharmaceutical companies through our affiliate Medis. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> Pandemic </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a leading global pharmaceutical company, Teva provides essential medicines to millions of patients around the world every day. Our priorities remain focused on the health and well-being of our employees and on our responsibility to continue to provide our medicines to the nearly 200&#160;million patients who depend on us every day. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">During the second quarter of 2022, we have not experienced material delays in the production and distribution of medicines. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has had an effect on our suppliers, which led to minimal delays or disruptions in our materials supply. However, the supply chain supporting our key products &#8211; specialty, generics and API &#8211; remains largely uninterrupted, with adequate product inventory across our network and redundancy plans in place to address potential shortfalls, if any. Our facilities that research, manufacture, order, pack, distribute and provide critical customer and patient services remain largely uninterrupted as well, and are currently functioning to meet demand for essential medicines for patients throughout the world. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">During the second quarter of 2022, we have experienced delays in some clinical trials due to slow-downs of recruitment for studies and suspended regulatory inspections, delays in regulatory approvals of new products due to reduced capacity or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-prioritization</div> of regulatory agencies and delays in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-commercial</div> launch activities. We may experience further delays if the pandemic continues for an extended period of time, including as a result of the emergence of new <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> variants. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The long-term effects of the pandemic cannot be predicted at this time and would depend on the duration and severity of the pandemic and the restrictive measures put in place to control its impact. Although no one can predict future demand for pharmaceutical products, market dynamics or the scope or duration of the financial and other challenges arising from the pandemic, it is possible that we will continue to see variable demand in future periods. We do not currently anticipate that the ongoing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic will have a material impact on our 2022 financial results. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Highlights </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant highlights in the second quarter of 2022 included: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues in the second quarter of 2022 were $3,786&#160;million, a decrease of 3% compared to the second quarter of 2021, or an increase of 1% in local currency terms. This increase in local currency terms was mainly due to higher revenues from generic products in our Europe and North America segments, partially offset by lower revenues from COPAXONE and BENDEKA/TREANDA in our North America segment. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">50 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our North America segment generated revenues of $1,904&#160;million and profit of $481&#160;million in the second quarter of 2022. Revenues decreased by 2% compared to the second quarter of 2021. Profit decreased by 8% compared to the second quarter of 2021. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Europe segment generated revenues of $1,171&#160;million and profit of $389&#160;million in the second quarter of 2022. Revenues decreased by 1% in U.S. dollars, but increased by 8% in local currency terms compared to the second quarter of 2021. Profit increased by 13% compared to the second quarter of 2021. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our International Markets segment generated revenues of $454&#160;million and profit of $95&#160;million in the second quarter of 2022. Revenues decreased by 6% in U.S. dollars, but increased by 3% in local currency terms, compared to the second quarter of 2021. Profit decreased by 23% compared to the second quarter of 2021. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our revenues from other activities in the second quarter of 2022 were $257&#160;million, a decrease of 14% compared to the second quarter of 2021. In local currency terms, revenues decreased by 10% compared to the second quarter of 2021. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exchange rate movements during the second quarter of 2022, net of hedging effects, negatively impacted revenues by $162&#160;million, compared to the second quarter of 2021. See note 8d to our consolidated financial statements. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairments of identifiable intangible assets were $51&#160;million in the second quarter of 2022, compared to $195&#160;million in the second quarter of 2021. See note 5 to our consolidated financial statements. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recorded a goodwill impairment charge of $745&#160;million in the second quarter of 2022, of which $479&#160;million is related to our International Markets reporting unit and $266&#160;million is related to Teva&#8217;s API reporting unit. See note 6 to our consolidated financial statements. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recorded expenses of $118&#160;million for other asset impairments, restructuring and other items in the second quarter of 2022, compared to expenses of $28&#160;million in the second quarter of 2021. See note 12 to our consolidated financial statements. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legal settlements and loss contingencies expenses were $729&#160;million in the second quarter of 2022, compared to $6&#160;million in the second quarter of 2021. See note 9 to our consolidated financial statements. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating loss was $949&#160;million in the second quarter of 2022, compared to an operating income of $582&#160;million in the second quarter of 2021. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial expenses were $211&#160;million in the second quarter of 2022, compared to $274&#160;million in the second quarter of 2021. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">In the second quarter of 2022, we recognized a tax benefit of $900&#160;million, on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> loss of $1,160&#160;million. In the second quarter of 2021, we recognized a tax expense of $98&#160;million, on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> income of $308&#160;million. See note&#160;11 to our consolidated financial statements. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2022, our debt was $22,082&#160;million, compared to $23,043&#160;million as of December&#160;31, 2021. This decrease was mainly due to $680&#160;million from exchange rate fluctuations and $296&#160;million of senior notes repaid at maturity. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flow generated from operating activities during the second quarter of 2022 was $123&#160;million, compared to $218&#160;million in the second quarter of 2021. This decrease was mainly due to payments related to legal settlements in the second quarter of 2022, partially offset by an increase in accounts payables. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the second quarter of 2022, we generated free cash flow of $301&#160;million, which we define as comprising: $123&#160;million in cash flow generated from operating activities, $287&#160;million in beneficial interest collected in exchange for securitized accounts receivables and $18&#160;million in proceeds from divestitures of businesses and other assets, partially offset by $127&#160;million in cash used for capital investment. During the second quarter of 2021, we generated free cash flow of $625&#160;million. The decrease in the second quarter of 2022 resulted mainly from lower cash flow from operating activities as well as lower proceeds from sales of assets. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">51 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Results of Operations </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comparison of Three Months Ended June&#160;30, 2022 to Three Months Ended June&#160;30, 2021 </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment Information </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">North America Segment </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents revenues, expenses and profit for our North America segment for the three months ended June&#160;30, 2022 and 2021: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions&#160;/&#160;%&#160;of&#160;Segment<br/>Revenues)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,904</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,943</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,010</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,040</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">147</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">162</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">256</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">255</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">127</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">106</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">481</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">521</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit does not include amortization and certain other items. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">&#167;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than 0.5%. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">North America Revenues </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our North America segment includes the United States and Canada. Revenues from our North America segment in the second quarter of 2022 were $1,904&#160;million, a decrease of $39&#160;million, or 2%, compared to the second quarter of 2021, mainly due to a decrease in revenues from COPAXONE and BENDEKA/TREANDA, partially offset by higher revenues from generic products. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenues by Major Products and Activities </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents revenues for our North America segment by major products and activities for the three months ended June&#160;30, 2022 and 2021: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months&#160;ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Percentage</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022-2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic products</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,026</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">951</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AJOVY</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">49</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AUSTEDO</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">204</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">174</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BENDEKA/TREANDA</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">83</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">106</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(22</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">152</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(38</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Anda</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">308</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">316</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">139</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(30</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,904</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,943</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">52 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Generic products</div></div> revenues in our North America segment (including biosimilars) in the second quarter of 2022 were $1,026&#160;million, an increase of 8% compared to the second quarter of 2021, mainly due to revenues from lenalidomide capsules (the generic version of Revlimid<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>), partially offset by increased competition and loss of revenues due to the closure of the Irvine, CA site. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Among the most significant generic products we sold in North America in the second quarter of 2022 were lenalidomide capsules (the generic version of Revlimid<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>), Truxima<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> (the biosimilar to Rituxan<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>), epinephrine injectable solution (the generic equivalent of EpiPen<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> and EpiPen Jr.<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>) and albuterol sulfate inhalation aerosol (our ProAir<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> authorized generic). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the second quarter of 2022, our total prescriptions were approximately 302&#160;million (based on trailing twelve months), representing 8.2% of total U.S. generic prescriptions according to IQVIA data. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;7, 2022, we announced the launch of the first generic version of Revlimid<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>&#160;(lenalidomide capsules), in 5mg, 10mg, 15mg, and 25mg strengths, in the United States. These lenalidomide capsules are a prescription medicine used in adults for the treatment of (i)&#160;multiple myeloma in combination with the medicine dexamethasone, (ii)&#160;certain myelodysplastic syndromes, and (iii)&#160;mantle cell lymphoma following specific prior treatment. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AJOVY</div></div> revenues in our North America segment in the second quarter of 2022 increased by 9% to $49&#160;million, compared to the second quarter of 2021, mainly due to growth in volume. In the second quarter of 2022, AJOVY&#8217;s exit market share in the United States in terms of total number of prescriptions was 24.4% compared to 20.7% in the second quarter of 2021. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AJOVY is indicated for the preventive treatment of migraine in adults. AJOVY was launched in the U.S. in 2018, and was approved in Canada in April 2020. Our auto-injector device for AJOVY became commercially available in the U.S. in April 2020 and in Canada in April 2021. AJOVY is the only anti-CGRP product indicated for quarterly treatment and in January 2021, we launched a new product offering, providing a quarterly dose. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AJOVY is protected by patents expiring in 2026 in Europe and in 2027 in the United States. Applications for patent term extensions have been submitted in various markets around the world, and certain extensions in Europe and other countries have already been granted until 2031. Additional patents relating to the use of AJOVY in the treatment of migraine have also been issued in the United States and will expire between 2035 and 2039. Such patents are also pending in other countries. AJOVY will also be protected by regulatory exclusivity for 12 years from marketing approval in the United States and 10 years from marketing approval in Europe. We filed a lawsuit in the U.S. District Court for the District of Massachusetts alleging that Eli Lilly&#160;&amp; Co.&#8217;s (&#8220;Lilly&#8221;) marketing and sale of its galcanezumab product for the treatment of migraine infringes nine Teva patents. Lilly then submitted inter partes review (&#8220;IPR&#8221;) petitions to the Patent Trial and Appeal Board (&#8220;PTAB&#8221;), challenging the validity of the nine patents asserted against it in the litigation. The litigation in the district court was stayed pending resolution of the IPR petitions. On February&#160;18, 2020, the PTAB issued decisions on the first six IPRs, finding the six composition of matter patents invalid as being obvious. On March&#160;31, 2020, the PTAB issued a decision upholding the three method of treatment patents. On August&#160;16, 2021 the Court of Appeals for the Federal Circuit affirmed all of the PTAB&#8217;s decisions. The litigation is proceeding as to the three method of treatment patents and trial is expected in October 2022. We also filed another suit against Lilly on June&#160;8, 2021, asserting two patents recently granted to Teva, related to the treatment of refractory migraine. Lilly responded to the complaint with a motion to dismiss, which Teva opposed. On March&#160;15, 2022, the U.S. District Court for the District of Massachusetts denied Lilly&#8217;s motion to dismiss and on March&#160;23, 2022, Lilly submitted IPR petitions challenging the patentability of the two refractory migraine patents. On April&#160;11, 2022, Lilly submitted another IPR petition challenging the patentability of a patent related to the two refractory migraine patents. In addition, in 2018 we entered into separate agreements with Alder Biopharmaceuticals, Inc. and Lilly, resolving the European Patent Office oppositions that they filed against our AJOVY patents. The settlement agreement with Lilly also resolved Lilly&#8217;s action to revoke the patent protecting AJOVY in the United Kingdom. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AUSTEDO </div></div>revenues in our North America segment in the second quarter of 2022 increased by 17%, to $204&#160;million, compared to $174&#160;million in the second quarter of 2021, mainly due to growth in volume. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AUSTEDO was launched in the U.S. in 2017. It is indicated for the treatment of chorea associated with Huntington disease and for the treatment of tardive dyskinesia in adults. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AUSTEDO is protected in the United States by eight Orange Book patents expiring between 2031 and 2038 and in Europe by two patents expiring in 2029. We received notice letters from two ANDA filers regarding the filing of their ANDAs with paragraph (IV)&#160;certifications for certain of the patents listed in the Orange Book for AUSTEDO. On July&#160;1, </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">53 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2021, we filed a complaint against Aurobindo, asserting six of the Orange Book patents, and a separate complaint against Lupin, asserting four of the Orange Book patents. The suits were filed in the U.S. District Court for the District of New Jersey. The seventh patent was issued in November 2021, and listed in the Orange Book in December 2021. In addition, Apotex filed a petition for IPR by the PTAB of the patent covering the deutetrabenazine compound that expires in 2031. On March&#160;9, 2022, the U.S. Patent and Trademark Office denied Apotex&#8217;s petition and declined to institute a review of the deutetrabenazine patent. On April&#160;29, 2022, we reached an agreement with Lupin to resolve the abovementioned dispute over Lupin&#8217;s ANDA for a generic deutetrabenazine product. On June&#160;8, 2022 we reached an agreement with Aurobindo regarding the dispute over Aurobindo&#8217;s ANDA for a generic deutetrabenazine product. Under the terms of the settlement agreements, the litigation between the parties in the U.S. District Court for the District of New Jersey have been ended, and Lupin and Aurobindo will have a license to sell its generic product beginning April 2033, or earlier under certain circumstances. There are no further patent litigations pending regarding AUSTEDO. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">BENDEKA </div></div>and<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> TREANDA</div></div> combined revenues in our North America segment in the second quarter of 2022 decreased by 22% to $83&#160;million, compared to the second quarter of 2021, mainly due to the availability of alternative therapies and continued competition from Belrapzo<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"> </div>(a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ready-to-dilute</div></div> bendamustine hydrochloride product from Eagle). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In July 2018, Eagle prevailed in its suit against the FDA to obtain seven years of orphan drug exclusivity in the United States for BENDEKA. On March&#160;13, 2020, this decision was upheld in the appellate court. As things currently stand, drug applications referencing BENDEKA, TREANDA or any other bendamustine product will not be approved by the FDA until the orphan drug exclusivity expires in December 2022. In April 2019, we signed an amendment to the license agreement with Eagle extending the royalty term applicable to the United States to the full period for which we sell BENDEKA and increased the royalty rate. In consideration, Eagle agreed to assume a portion of BENDEKA-related patent litigation expenses. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are 16 patents listed in the U.S. Orange Book for BENDEKA with expiry dates in 2026 and 2031. In September 2019, a patent infringement action against four of six ANDA filers for generic versions of BENDEKA was tried in the U.S. District Court for the District of Delaware. On April&#160;27, 2020, the district court upheld the validity of all of the asserted patents and found that all four ANDA filers infringe at least one of the patents. Three of the four ANDA filers appealed the district court decision. Teva settled with one of the three ANDA filers, and on August&#160;13, 2021, the Federal Circuit issued a Rule 36 affirmance of the district court decision with respect to the other two filers. On December&#160;14, 2021, Apotex filed a Petition for a Writ of Certiorari with the U.S. Supreme Court, which was denied. Litigation against the fifth ANDA filer was dismissed after the withdrawal of its patent challenge, and the case against a sixth ANDA filer was also settled. Suits against two filers of 505(b)(2) NDAs referencing BENDEKA are pending. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, in July 2018, Teva and Eagle filed suit against Hospira, Inc. (&#8220;Hospira&#8221;) related to its 505(b)(2) NDA referencing BENDEKA in the U.S. District Court for the District of Delaware. On December&#160;16, 2019, the district court dismissed the case against Hospira on all but one of the asserted patents, which expires in 2031. On April&#160;18, 2022, Teva and Eagle settled this matter, allowing Hospira to launch its product on January&#160;17, 2028 or earlier under certain circumstances. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to the settlement with Eagle regarding its bendamustine 505(b)(2) NDA, between 2015 and 2020, we reached final settlements with 22 ANDA filers for generic versions of the lyophilized form of TREANDA and one 505(b)(2) NDA filer for a generic version of the liquid form of TREANDA, providing for the launch of generic versions of TREANDA prior to patent expiration. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">COPAXONE</div></div> revenues in our North America segment in the second quarter of 2022 decreased by 38% to $94&#160;million, compared to the second quarter of 2021, mainly due to generic competition in the United States and a decrease in glatiramer acetate market share due to availability of alternative therapies. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The market for MS treatments continues to develop, particularly with the approval of generic versions of COPAXONE. Oral treatments for MS, such as Tecfidera<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>, Gilenya<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> and Aubagio<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>, continue to present significant and increasing competition. COPAXONE also continues to face competition from existing injectable products, as well as from monoclonal antibodies, such as Ocrevus<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> and Kesimpta<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Anda</div></div> revenues in our North America segment in the second quarter of 2022 decreased by 2% to $308&#160;million, compared to $316&#160;million in the second quarter of 2021, mainly due to lower market demand. Anda, our distribution business in the United States, distributes generic, specialty and OTC pharmaceutical products from various third party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals and physician offices in the United States. Anda is able to compete in the secondary distribution market by maintaining high inventory levels for a broad offering of products, competitive pricing and offering next day delivery throughout the United States. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">54 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;;text-indent: 0px;"></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Launches and Pipeline </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the second quarter of 2022, we launched the generic version of the following branded products in North America: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 49%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 14%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 13%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 14%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Product Name</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Brand&#160;Name</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Launch<br/>Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total&#160;Annual&#160;U.S. <br/>Branded&#160;Sales&#160;at&#160;Time<br/>of Launch <br/>(U.S. $ in millions<br/>(IQVIA))<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:7.5px">*</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pirfenidone Tablets 267mg&#160;&amp; 801mg</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Esbriet<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>&#160;tablets</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">May</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">569.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vilazodone Hydrochloride Tablets 10mg, 20mg, 40mg</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Viibryd<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>&#160;tablets</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">569.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Scopolamine Transdermal System 1mg/3 days</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Transderm&#160;Scop<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div><br/>Transdermal&#160;System</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">May</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">87.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dalfampridine Extended-release Tablets 10mg</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Ampyra<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>&#160;Extended<br/>Release Tablets</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">May</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">81.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mycophenolate Mofetil for Oral Suspension, USP, 200mg/mL</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">CellCept<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> Oral<br/>Suspension</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">June</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lanthanum Carbonate Chewable Tablets 500mg, 750mg, 1000mg</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Fosrenol<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>&#160;chewable<br/>tablets</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">May</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pemetrexed Injection 100mg/4mL, 500mg/20mL, 1g/40mL**</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">N/A</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">May</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">N/A</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The figures presented are for the twelve months ended in the calendar quarter immediately prior to our launch or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-launch.</div> </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">**</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva&#8217;s Pemetrexed is a 505(b)(2) product, was filed as an NDA and is not bioequivalent to a brand product. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our generic products pipeline in the United States includes, as of June&#160;30, 2022, 178 product applications awaiting FDA approval, including 68 tentative approvals. This total reflects all pending ANDAs, supplements for product line extensions and tentatively approved applications and includes some instances where more than one application was submitted for the same reference product. Excluding overlaps, the branded products underlying these pending applications had U.S. sales for the twelve months ended March&#160;31, 2022 of approximately $109&#160;billion, according to IQVIA. Approximately 73% of pending applications include a paragraph IV patent challenge, and we believe we are first to file with respect to 69 of these products, or 97 products including final approvals where launch is pending a settlement agreement or court decision. Collectively, these first to file opportunities represent over $82&#160;billion in U.S. brand sales for the twelve months ended March&#160;31, 2022, according to IQVIA. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">IQVIA reported brand sales are one of the many indicators of future potential value of a launch, but equally important are the mix and timing of competition, as well as cost effectiveness. The potential advantages of being the first filer with respect to some of these products may be subject to forfeiture, shared exclusivity or competition from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">so-called</div> &#8220;authorized generics,&#8221; which may ultimately affect the value derived. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In the second quarter of 2022, we received tentative approvals for generic equivalents of the products listed in the table below, excluding overlapping applications. A &#8220;tentative approval&#8221; indicates that the FDA has substantially completed its review of an application and final approval is expected once the relevant patent expires, a court decision is reached, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-month</div> regulatory stay lapses or a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">180-day</div> exclusivity period awarded to another manufacturer either expires or is forfeited. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">55 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 12%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 11%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic Name</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Brand&#160;Name</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total&#160;Annual&#160;U.S. <br/>Branded&#160;Sales&#160;at&#160;Time<br/>of Launch <br/>(U.S. $ in millions<br/>(IQVIA))<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:7.5px">*</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Canagliflozin Tabs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Invokana<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">900</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Linaclotide Capsules, 72 mcg</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Linzess<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">457</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plerixafor Injection, 24 mg/1.2 mL (20 mg/mL)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Mozobil<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">192</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Methylnaltrexone Bromide Tablets, 150 mg</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Relistor<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">131</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Methylphenidate Hydrochloride Extended-Release Chewable Tablets, 20 mg, 30 mg and 40 mg</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Quillichew&#160;ER<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">118</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The figures presented are for the twelve months ended in the calendar quarter immediately prior to our launch or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-launch.</div> </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For information regarding our specialty and biosimilar products pipeline, see &#8220;&#8212;Teva Consolidated Results&#8212;Research and Development (R&amp;D) Expenses&#8221; below. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">North America Gross Profit </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit from our North America segment in the second quarter of 2022 was $1,010&#160;million, a decrease of 3%, compared to $1,040&#160;million in the second quarter of 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit margin for our North America segment in the second quarter of 2022 decreased to 53.0%, compared to 53.5% in the second quarter of 2021. This decrease was mainly due to a change in mix of products. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">North America R&amp;D Expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses relating to our North America segment in the second quarter of 2022 were $147&#160;million, a decrease of 10%, compared to $162&#160;million in the second quarter of 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For a description of our R&amp;D expenses in the second quarter of 2022, see &#8220;&#8212;Teva Consolidated Results&#8212;Research and Development (R&amp;D) Expenses&#8221; below. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">North America S&amp;M Expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses relating to our North America segment in the second quarter of 2022 were $256&#160;million, flat compared to the second quarter of 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">North America G&amp;A Expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses relating to our North America segment in the second quarter of 2022 were $127&#160;million, an increase of 19% compared to the second quarter of 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">North America Profit </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Profit from our North America segment consists of gross profit less R&amp;D expenses, S&amp;M expenses, G&amp;A expenses and any other income related to this segment. Segment profit does not include amortization and certain other items. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Profit from our North America segment in the second quarter of 2022 was $481&#160;million, a decrease of 8% compared to $521&#160;million in the second quarter of 2021, mainly due to lower revenues, as discussed above. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Europe Segment </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents revenues, expenses and profit for our Europe segment for the three months ended June&#160;30, 2022 and 2021: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">56 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions / % of Segment</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenues)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,171</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,184</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">703</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">661</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">56</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">63</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">196</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">209</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">63</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">47</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">389</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">343</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit does not include amortization and certain other items. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">&#167;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than $0.5&#160;million or 0.5%, as applicable. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Europe Revenues </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Europe segment includes the European Union, the United Kingdom and certain other European countries. Revenues from our Europe segment in the second quarter of 2022 were $1,171&#160;million, a decrease of 1%, or $13&#160;million, compared to the second quarter of 2021. In local currency terms, revenues increased by 8%. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In the second quarter of 2021, our revenues were impacted by the implications of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. In the second quarter of 2022, the increase in our revenues in local currency terms was attributed to higher demand for generic and OTC products resulting mainly from the removal of restrictions related to doctor and hospital visits by patients that were previously implemented in response to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, together with higher revenues from generic product launches. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the second quarter of 2022, revenues were negatively impacted by exchange rate fluctuations of $106&#160;million, net of hedging effects, compared to the second quarter of 2021. Revenues in the second quarter of 2022 included $31&#160;million from a positive hedging impact, which is included in &#8220;Other&#8221; in the table below. See note 8d to our consolidated financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenues by Major Products and Activities </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents revenues for our Europe segment by major products and activities for the three months ended June&#160;30, 2022 and 2021: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months&#160;ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Percentage</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Change</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022-2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic products</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">873</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">878</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AJOVY</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">52</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(28</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Respiratory products</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">65</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">85</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(23</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">131</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">102</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,171</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,184</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Generic products</div></div> revenues in our Europe segment in the second quarter of 2022, including OTC products, decreased by 1% to $873&#160;million, compared to the second quarter of 2021. In local currency terms, revenues increased by 12%, mainly due to higher demand for generic and OTC products, resulting mainly from the removal of restrictions related to doctor and hospital visits by patients that were previously implemented in response to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, together with higher revenues from generic product launches. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AJOVY</div></div> revenues in our Europe segment in the second quarter of 2022 increased to $29&#160;million, compared to $19&#160;million in the second quarter of 2021, mainly due to growth in European countries in which AJOVY had previously been launched, as well as launches and reimbursements in additional European countries. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">57 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For information about AJOVY patent protection, see &#8220;&#8212;North America Revenues&#8212;Revenues by Major Product&#8221; above. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">COPAXONE</div></div> revenues in our Europe segment in the second quarter of 2022 decreased by 28% to $72&#160;million, compared to the second quarter of 2021. In local currency terms, revenues decreased by 18%, due to price reductions and a decline in volume resulting from competing glatiramer acetate products. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">One European patent protecting COPAXONE 40 mg/mL was found invalid by the Board of Appeal of the European Patent Office in September 2020. Two additional patents expiring in 2030 were found invalid at the European Patent Office in December 2021. In certain countries, Teva remains in litigation against generic companies on an additional COPAXONE 40 mg/mL patent that expires in 2030. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Respiratory products</div></div> revenues in our Europe segment in the second quarter of 2022 decreased by 23% to $65&#160;million compared to the second quarter of 2021. In local currency terms, revenues decreased by 14%, mainly due to net price reductions and lower volumes. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Launches and Pipeline </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2022, our generic products pipeline in Europe included 434 generic approvals relating to 54 compounds in 118 formulations, with no European Medicines Agency (&#8220;EMA&#8221;) approvals received. In addition, approximately 1,144 marketing authorization applications are pending approval in 37 European countries, relating to 125 compounds in 252 formulations. Two applications are pending with the EMA with one application relating to two strengths in 30 markets and one application relating to three strengths in 30 markets. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For information regarding our specialty and biosimilar products pipeline, see &#8220;&#8212;Teva Consolidated Results&#8212;Research and Development (R&amp;D) Expenses&#8221; below. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Europe Gross Profit </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit from our Europe segment in the second quarter of 2022 was $703&#160;million, an increase of 6% compared to $661&#160;million in the second quarter of 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit margin for our Europe segment in the second quarter of 2022 increased to 60.0%, compared to 55.8% in the second quarter of 2021. This increase was mainly due to higher revenues from the positive impact of hedging activities discussed above as well as lower cost of goods sold, mainly due to better mix of products and decrease in write-offs. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Europe R&amp;D Expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses relating to our Europe segment in the second quarter of 2022 were $56&#160;million, a decrease of 11% compared to $63&#160;million in the second quarter of 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For a description of our R&amp;D expenses in the second quarter of 2022, see &#8220;&#8212;Teva Consolidated Results&#8212;Research and Development (R&amp;D) Expenses&#8221; below. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Europe S&amp;M Expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses relating to our Europe segment in the second quarter of 2022 were $196&#160;million, a decrease of 6% compared to $209&#160;million in the second quarter of 2021. This decrease was mainly due to exchange rate fluctuations in the second quarter of 2022. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Europe G&amp;A Expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses relating to our Europe segment in the second quarter of 2022 were $63&#160;million, an increase of 34% compared to $47&#160;million in the second quarter of 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Europe Profit </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Profit from our Europe segment consists of gross profit less R&amp;D expenses, S&amp;M expenses, G&amp;A expenses and any other income related to this segment. Segment profit does not include amortization and certain other items. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Profit from our Europe segment in the second quarter of 2022 was $389&#160;million, an increase of 13%, compared to $343&#160;million in the second quarter of 2021. This increase was mainly due to higher gross profit as discussed above. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">58 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International Markets Segment </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents revenues, expenses and profit for our International Markets segment for the three months ended June&#160;30, 2022 and 2021: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 79%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions&#160;/%&#160;of&#160;Segment&#160;Revenues)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">454</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">485</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">242</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">270</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">99</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">105</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">95</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">123</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit does not include amortization and certain other items. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">&#167;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than 0.5%. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">International Markets Revenues </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our International Markets segment includes all countries in which we operate other than those in our North America and Europe segments. The International Markets segment includes more than 35 countries, covering a substantial portion of the global pharmaceutical market. Our key international markets are Japan, Russia and Israel. The countries in our International Markets segment include highly regulated, pure generic markets, such as Israel, branded generics oriented markets, such as Russia and certain Latin America markets and hybrid markets, such as Japan. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In February 2022, Russia launched an invasion of Ukraine. As of the date of this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q,</div> sustained conflict and disruption in the region is ongoing. Russia and Ukraine markets are included in our International Markets segment results. We have no manufacturing or R&amp;D facilities in these markets. During the three and six months ended June&#160;30, 2022, the impact of this conflict on our International Markets segment&#8217;s results of operations and financial condition was immaterial. Consistent with our foreign exchange risk management hedging programs, we entered into hedges to hedge our exposure to currency exchange rate fluctuations with respect to our balance sheet assets, revenues and expenses. However, as of the end of the second quarter of 2022, we were unable to renew certain of our expiring hedging positions due to the liquidity situation in the market for Rubles. Prior to and since the escalation of the conflict, we have been taking measures to reduce our operational cash balances in Russia and Ukraine. We have been monitoring the solvency of our customers in Russia and Ukraine and have taken measures, where practicable, to mitigate our exposure to risks related to the conflict in the region. However, the duration, severity and global implications (including potential inflation and devaluation consequences) of the conflict cannot be predicted at this time and could have an effect on our business, including on our exchange rate exposure, supply chain, operational costs and commercial presence in these markets. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Revenues from our International Markets segment in the second quarter of 2022 were $454&#160;million, a decrease of 6% compared to the second quarter of 2021. In local currency terms, revenues increased by 3% compared to the second quarter of 2021, mainly due to higher revenues in certain markets, partially offset by lower revenues in Japan due to regulatory price reductions and generic competition to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-patented</div> products. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the second quarter of 2022, revenues were negatively impacted by exchange rate fluctuations of $45&#160;million, including hedging effects, compared to the second quarter of 2021. Revenues in the second quarter of 2022 included $17&#160;million from a negative hedging impact, which is included in &#8220;Other&#8221; in the table below. See note 8d to our consolidated financial statements. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">59 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;;text-indent: 0px;"></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenues by Major Products and Activities </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents revenues for our International Markets segment by major products and activities for the three months ended June&#160;30, 2022 and 2021: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months&#160;ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Percentage</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Change</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022-2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic products</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">394</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">407</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AJOVY</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">96</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">65</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(39</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">454</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">485</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Generic products</div></div> revenues in our International Markets segment in the second quarter of 2022, which include OTC products, decreased by 3% in U.S. dollars. In local currency terms, revenues increased by 4% to $394&#160;million, compared to the second quarter of 2021. This increase was mainly due to higher revenues in certain markets, partially offset by lower sales in Japan due to regulatory price reductions and generic competition to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-patented</div> products in Japan. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AJOVY</div></div> was launched in certain markets in our International Markets segment, including in Japan in August 2021. We are moving forward with plans to launch AJOVY in other markets. AJOVY revenues in our International Markets segment in the second quarter of 2022 were $10&#160;million, compared to $5&#160;million in the second quarter of 2021. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">COPAXONE</div></div> revenues in our International Markets segment in the second quarter of 2022 were $9&#160;million compared to $7&#160;million in the second quarter of 2021. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AUSTEDO</div></div> was launched in early 2021 in China for the treatment of chorea associated with Huntington&#8217;s disease and for the treatment of tardive dyskinesia, and was also launched in Israel during 2021. In October 2021, we received marketing approval for both indications in Brazil. We continue with additional submissions in various other markets. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">International Markets Gross Profit </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit from our International Markets segment in the second quarter of 2022 was $242&#160;million, a decrease of 10% compared to $270&#160;million in the second quarter of 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Gross profit margin for our International Markets segment in the second quarter of 2022 decreased to 53.3%, compared to 55.7% in the second quarter of 2021. This decrease was mainly due to regulatory price reductions and generic competition to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-patented</div> products in Japan, as well as a negative impact from hedging activity. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">International Markets R&amp;D Expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses relating to our International Markets segment in the second quarter of 2022 were $19&#160;million, an increase of 10% compared to $18&#160;million in the second quarter of 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For a description of our R&amp;D expenses in the second quarter of 2022, see &#8220;&#8212;Teva Consolidated Results&#8212;Research and Development (R&amp;D) Expenses&#8221; below. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">International Markets S&amp;M Expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses relating to our International Markets segment in the second quarter of 2022 were $99&#160;million, a decrease of 6% compared to $105&#160;million the second quarter of 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">International Markets G&amp;A Expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses relating to our International Markets segment in the second quarter of 2022 were $30&#160;million, an increase of 22% compared to $25&#160;million in the second quarter of 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">International Markets Profit </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Profit from our International Markets segment consists of gross profit less R&amp;D expenses, S&amp;M expenses, G&amp;A expenses and any other income related to this segment. Segment profit does not include amortization and certain other items. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">60 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Profit from our International Markets segment in the second quarter of 2022 was $95&#160;million, a decrease of 23%, compared to $123&#160;million in the second quarter of 2021. This decrease was mainly due to lower gross profit, as discussed above. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Activities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We have other sources of revenues, primarily the sale of APIs to third parties, certain contract manufacturing services and an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licensing</div> platform offering a portfolio of products to other pharmaceutical companies through our affiliate Medis. Our other activities are not included in our North America, Europe or International Markets segments described above. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our revenues from other activities in the second quarter of 2022 were $257&#160;million, a decrease of 14% compared to the second quarter of 2021. In local currency terms, revenues decreased by 10%. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">API sales to third parties in the second quarter of 2022 were $177&#160;million, a decrease of 11% in both U.S. dollars and local currency terms compared to the second quarter of 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva Consolidated Results </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues in the second quarter of 2022 were $3,786&#160;million, a decrease of 3% compared to the second quarter of 2021. In local currency terms, revenues increased by 1%, mainly due to higher revenues from generic products in our Europe and North America segments, partially offset by lower revenues from COPAXONE and BENDEKA/TREANDA in our North America segment. See &#8220;&#8212;North America Revenues,&#8221; &#8220;&#8212;Europe Revenues,&#8221; &#8220;&#8212;International Markets Revenues&#8221; and &#8220;&#8212;Other Activities&#8221; above. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exchange rate movements during the second quarter of 2022, net of hedging effects, negatively impacted revenues by $162&#160;million, compared to the second quarter of 2021. See note 8d to our consolidated financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross Profit </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit in the second quarter of 2022 was $1,794&#160;million, a decrease of 4% compared to the second quarter of 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit margin was 47.4% in the second quarter of 2022, compared to 47.9% in the second quarter of 2021. This decrease was mainly driven by lower revenues from COPAXONE and a change in the mix of products in our North America segment, partially offset by a favorable mix of products in our Europe segment. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and Development (R&amp;D) Expenses </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our R&amp;D activities for generic products in each of our segments include both (i)&#160;direct expenses relating to product formulation, analytical method development, stability testing, management of bioequivalence and other clinical studies and regulatory filings; and (ii)&#160;indirect expenses, such as costs of internal administration, infrastructure and personnel. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our R&amp;D activities for specialty and biosimilar products in each of our segments include costs of discovery research, preclinical development, early- and late-clinical development and drug formulation, clinical trials and product registration costs. These expenditures are reported net of contributions received from collaboration partners. Our spending takes place throughout the development process, including (i)&#160;early-stage projects in both discovery and preclinical phases; (ii)&#160;middle-stage projects in clinical programs up to phase 3; (iii) late-stage projects in phase 3 programs, including where a new drug application is currently pending approval; (iv)&#160;post-approval studies for marketed products; and (v)&#160;indirect expenses, such as costs of internal administration, infrastructure and personnel. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses in the second quarter of 2022 were $228&#160;million, a decrease of 8% compared to the second quarter of 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the second quarter of 2022, our R&amp;D expenses related primarily to specialty product candidates in neuroscience (such as migraine, movement disorders/&#160;neurodegeneration and neuropsychiatry, including post-approval commitments), immunology (such as respiratory medicines) and selected other areas, as well as generic products and biosimilars. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">61 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our lower R&amp;D expenses in the second quarter of 2022, compared to the second quarter of 2021, were mainly due to a decrease in neuroscience (in the pain and migraine and headache therapeutic areas) and immunology (in the respiratory therapeutic area) as well as various generics projects, partially offset by higher R&amp;D expenses related to our biosimilar products pipeline. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses as a percentage of revenues were 6.0% in the second quarter of 2022, compared to 6.3% in the second quarter of 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Specialty Products Pipeline </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Below is a description of key products in our specialty pipeline as of July&#160;15, 2022: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 23%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 19%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 19%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 17%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 16%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Phase 2</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Phase 3</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Submission</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Under&#160;Regulatory&#160;Review</div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Novel Biologics</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TEV-48574</div></div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inflammatory Bowel Disease</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fasinumab </div></div></div></div>Osteoarthritic&#160;Pain</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(March&#160;2016)<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#160;(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Small Molecules</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Deutetrabenazine</div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dyskinesia in&#160;Cerebral Palsy</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(September&#160;2019)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risperidone&#160;LAI</div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Schizophrenia <div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">(2)</div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Digital Respiratory</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Digihaler<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div></div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(budesonide and formoterol fumarate dihydrate)</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(EU)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">QVAR</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div></div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;Digihaler</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div></div></div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(beclomethasone dipropionate HFA)(U.S.)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Developed in collaboration with Regeneron Pharmaceuticals, Inc. (&#8220;Regeneron&#8221;). Results for two phase 3 clinical trials, FACT OA1 and FACT OA2, were released on August&#160;5, 2020, indicating that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-primary</div> endpoints for fasinumab 1 mg monthly were achieved. Fasinumab 1 mg monthly demonstrated significant improvements in pain and physical function over placebo at week 16 and week 24, respectively. Fasinumab 1 mg monthly also showed nominally significant benefits in physical function in two trials and pain in one trial, when compared to the maximum <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> prescription doses of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-steroidal</div> anti-inflammatory drugs for osteoarthritis. The FACT OA1 trial included an additional treatment arm, fasinumab 1 mg every two months, which showed numerical benefit over placebo, but did not reach statistical significance. In initial safety analyses from the phase 3 trials, there was an increase in arthropathies reported with fasinumab. In a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-group</div> of patients from one phase 3 long-term safety trial, there was an increase in joint replacement with fasinumab 1 mg monthly treatment during the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-drug</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> period, although this increase was not seen in the other trials to date. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Active treatment of patients with fasinumab, which only involved dosing in an optional second-year extension phase of one trial, has been discontinued following a recommendation from the fasinumab program&#8217;s Independent Data Monitoring Committee that the program should be terminated, based on available evidence obtained to date. The core efficacy data has already been obtained to support potential fasinumab regulatory filings. Long-term safety data is expected to be discussed with the FDA in 2022. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">Currently, all <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-essential</div> activities and related expenditures for fasinumab have been put on hold. Next steps will be assessed together with Regeneron, with the intention of discussing data with the FDA. </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Developed under a license agreement with MedinCell. In August 2021, the FDA accepted the NDA for risperidone LAI, based on phase 3 data from two pivotal studies. In April 2022, the FDA issued a Complete Response Letter (&#8220;CRL&#8221;) regarding the NDA for risperidone LAI. We are working to address the issues raised in the CRL with a view to resubmission. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Biosimilar Products Pipeline </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We have additional biosimilar products in development internally and with our partners that are in various stages of clinical trials and regulatory review worldwide, including phase 3 clinical trials for biosimilars to Prolia<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> (denosumab), Stelara<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> (ustekinumab), Xolair<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> (omalizumab) and Eylea<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> (afilbercept), a biosimilar to Lucentis<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> (ranibizumab) that is currently under regulatory review in Europe and is in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-submission</div> in Canada, as well as a biosimilar to Humira<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> (adalimumab) that is currently under U.S. regulatory review. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">62 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selling and Marketing (S&amp;M) Expenses </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses in the second quarter of 2022 were $594&#160;million, a decrease of 3% compared to the second quarter of 2021. This decrease was mainly a result of the factors discussed above under &#8220;&#8212;Europe Segment&#8212;S&amp;M Expenses.&#8221; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses as a percentage of revenues were 15.7% in the second quarter of both 2022 and 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and Administrative (G&amp;A) Expenses </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses in the second quarter of 2022 were $313&#160;million, an increase of 29% compared to the second quarter of 2021. The increase in G&amp;A expenses in the second quarter of 2022 was related to proceeds received from Teva&#8217;s insurance carriers pursuant to a settlement reached on a derivative proceeding related to the acquisition of Actavis Generics in the second quarter of 2021, as well as higher litigation fees in the second quarter of 2022. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses as a percentage of revenues were 8.3% in the second quarter of 2022, compared to 6.2% in the second quarter of 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible Asset Impairments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recorded expenses of $51&#160;million for identifiable intangible asset impairments in the second quarter of 2022, compared to expenses of $195&#160;million in the second quarter of 2021. See note 5 to our consolidated financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill Impairment </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recorded a goodwill impairment charge of $745&#160;million in the second quarter of 2022, of which $479&#160;million is related to our International Markets reporting unit and $266&#160;million is related to Teva&#8217;s API reporting unit. See note 6 to our consolidated financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Asset Impairments, Restructuring and Other Items </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recorded expenses of $118&#160;million for other asset impairments, restructuring and other items in the second quarter of 2022, compared to expenses of $28&#160;million in the second quarter of 2021. For further details, as well as a description of significant regulatory and other events, see note 12 to our consolidated financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legal Settlements and Loss Contingencies </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the second quarter of 2022, we recorded expenses of $729&#160;million in legal settlements and loss contingencies, compared to an expense of $6&#160;million in the second quarter of 2021. See note 9 to our consolidated financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Income </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income in the second quarter of 2022 was $34&#160;million, compared to $43&#160;million in the second quarter of 2021. Other income in the second quarter of 2022 was mainly related to a capital gain related to the sale of an R&amp;D site. Other income in the second quarter of 2021 was mainly due to capital gains related to the sale of certain OTC assets. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating Income (Loss) </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating loss was $949&#160;million in the second quarter of 2022, compared to an operating income of $582&#160;million in the second quarter of 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating loss as a percentage of revenues was 25.1% in the second quarter of 2022, compared to operating income as a percentage of revenues of 14.9% in the second quarter of 2021. Operating loss in the second quarter of 2022 was mainly affected by goodwill impairment charges and legal settlements and loss contingencies, as discussed above. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial Expenses, Net </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial expenses were $211&#160;million in the second quarter of 2022, compared to $274&#160;million in the second quarter of 2021. Financial expenses in the second quarter of 2022 were mainly comprised of interest expenses of $225&#160;million, partially offset by a positive exchange rate impact driven mainly from currencies which we were unable to hedge, such as the Russian ruble. Financial expenses in the second quarter of 2021 were mainly comprised of interest expenses of $240&#160;million and loss on revaluations of marketable securities of $34&#160;million. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">63 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents a reconciliation of our segment profits to our consolidated operating income (loss) and to consolidated income (loss) before income taxes for the three months ended June&#160;30, 2022 and 2021: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months&#160;ended&#160;June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">North America profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">481</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">521</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Europe profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">389</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">343</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International Markets profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">95</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">123</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total reportable segments profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">964</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">987</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Profit of other activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">47</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total segments profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,019</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,034</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts not allocated to segments:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">212</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">173</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets impairments, restructuring and other items</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">118</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill impairment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">745</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets impairments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">51</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">195</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legal settlements and loss contingencies</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">729</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other unallocated amounts</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">113</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated operating income (loss)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(949</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">582</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial expenses, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">211</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">274</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated income (loss) before income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,160</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">308</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax Rate </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In the second quarter of 2022, we recognized a tax benefit of $900&#160;million, on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> loss of $1,160&#160;million. In the second quarter of 2021, we recognized a tax expense of $98&#160;million, on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> income of $308&#160;million. See note 11 to our consolidated financial statements. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share In (Profits) Losses of Associated Companies, Net </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We did not have any share in (profits) losses of associated companies, net in the second quarter of 2022. Share in profits of associated companies, net in the second quarter of 2021 was $11&#160;million. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Income (Loss) Attributable to Teva </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss was $232&#160;million in the second quarter of 2022, compared to net income of $207&#160;million in the second quarter of 2021. Net loss in the second quarter of 2022 was mainly affected by goodwill impairment charges and legal settlements and loss contingencies, partially offset by a tax benefit, all as discussed above. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted Shares Outstanding and Earnings (Loss) per Share </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The weighted average diluted shares outstanding used for the fully diluted share calculations for the three months ended June&#160;30, 2022 and 2021 were 1,110&#160;million and 1,109&#160;million shares, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted loss per share was $0.21 in the second quarter of 2022, compared to diluted earnings per share of $0.19 in the second quarter of 2021. See note 13 to our consolidated financial statements. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">64 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share Count for Market Capitalization </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We calculate share amounts using the outstanding number of shares (i.e., excluding treasury shares) plus shares that would be outstanding upon the exercise of options and vesting of RSUs and PSUs and the conversion of our convertible senior debentures, in each case, at period end. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2022 and 2021, the fully diluted share count for purposes of calculating our market capitalization was approximately 1,144&#160;million and 1,129&#160;million, respectively. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impact of Currency Fluctuations on Results of Operations </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the second quarter of 2022, approximately 47% of our revenues were denominated in currencies other than the U.S. dollar. Because our results are reported in U.S. dollars, we are subject to significant foreign currency risks. Accordingly, changes in the rate of exchange between the U.S. dollar and the local currencies in the markets in which we operate (primarily the euro, British pound, Canadian dollar, Russian ruble, Japanese yen, Swiss franc and new Israeli shekel) impact our results. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the second quarter of 2022, the following main currencies relevant to our operations decreased in value against the U.S. dollar (each on a quarterly average compared to quarterly average basis): Turkish lira by 46%, Argentinian peso by 20%, Hungarian forint by 18%, Japanese yen by 15%, Chilean peso by 15%, Swedish krona by 14%, Polish zloty by 14% and euro by 12%. The following main currencies relevant to our operations increased in value against the U.S. dollar: Russian ruble by 11% and Brazilian real by 8%. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a result, exchange rate movements during the second quarter of 2022, net of hedging effects, negatively impacted overall revenues by $162&#160;million and operating income by $6&#160;million, compared to the second quarter of 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the second quarter of 2022, a positive hedging impact of $17&#160;million was recognized under revenues, and a positive impact of $3&#160;million was recognized under cost of sales. In the second quarter of 2021, a negative hedging impact of $15&#160;million was recognized under revenues and a minimal negative impact was recognized under cost of sales. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hedging transactions against future projected revenues and expenses are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. See note 8d to our consolidated financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commencing in the third quarter of 2018, the cumulative inflation in Argentina exceeded 100% or more over a three-year period. Although this triggered highly inflationary accounting treatment, it did not have a material impact on our results of operations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commencing in the second quarter of 2022, the cumulative inflation in Turkey exceeded 100% or more over a three-year period. Although this triggered highly inflationary accounting treatment, it did not have a material impact on our results of operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comparison of Six Months Ended June&#160;30, 2022 to Six Months Ended June&#160;30, 2021 </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unless specified otherwise, the factors used to explain quarterly changes on a year-over-year basis are also relevant for the comparison of the results for the six months ended June&#160;30, 2022 and 2021. Where there are different factors affecting the six months comparison, we have described them below. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment Information </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">North America Segment </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents revenues, expenses and profit for our North America segment for the six months ended June&#160;30, 2022 and 2021: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six months ended June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions /&#160;% of Segment<br/>Revenues)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,641</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,932</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,899</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">52.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,114</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">289</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">322</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">501</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">483</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">239</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">218</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;;text-align:right;"></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;;text-align:right;"></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">883</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,098</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit does not include amortization and certain other items. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">&#167;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than 0.5%. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">65 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">North America Revenues </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our North America segment includes the United States and Canada. Revenues from our North America segment in the first six months of 2022 were $3,641&#160;million, a decrease of 7% compared to $3,932&#160;million in the first six months of 2021. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenues by Major Products and Activities </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents revenues for our North America segment by major products and activities for the six months ended June&#160;30, 2022 and 2021: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six months ended<br/>June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Percentage</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022-2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic products</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,925</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,004</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AJOVY</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">86</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">77</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AUSTEDO</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">358</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">320</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BENDEKA/TREANDA</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">165</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">180</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">315</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(43</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Anda</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">650</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">605</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">278</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">414</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(33</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,641</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,932</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Generic products</div></div> revenues in our North America segment (including biosimilars) in the first six months of 2022 were $1,925&#160;million, a decrease of 4% compared to the first six months of 2021, mainly due to increased competition and loss of revenues due to the closure of the Irvine, CA site, partially offset by revenues from lenalidomide capsules (the generic version of Revlimid<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Anda</div></div> revenues in our North America segment in the first six months of 2022 increased by 7% to $650&#160;million, compared to $605&#160;million in the first six months of 2021, mainly due to higher demand for COVID-related products. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">North America Gross Profit </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit from our North America segment in the first six months of 2022 was $1,899&#160;million, a decrease of 10%, compared to $2,114&#160;million in the first six months of 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit margin for our North America segment in the first six months of 2022 decreased to 52.2% compared to 53.8% in the first six months of 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">North America R&amp;D Expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses relating to our North America segment in the first six months of 2022 were $289&#160;million, a decrease of 10%, compared to $322&#160;million in the first six months of 2021. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">66 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">North America S&amp;M Expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses relating to our North America segment in the first six months of 2022 were $501&#160;million, an increase of 3.5% compared to $483&#160;million in the first six months of 2021. This increase was mainly due to promotional activities related to AUSTEDO. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">North America G&amp;A Expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses relating to our North America segment in the first six months of 2022 were $239&#160;million, an increase of 10%, compared to $218&#160;million in the first six months of 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">North America Profit </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Profit from our North America segment in the first six months of 2022 was $883&#160;million, a decrease of 20%, compared to $1,098&#160;million in the first six months of 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Europe Segment </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents revenues, expenses and profit for our Europe segment for the six months ended June&#160;30, 2022 and 2021: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six months ended June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions / % of Segment<br/>Revenues)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,327</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,398</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,397</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,349</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">56.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">114</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">129</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">393</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">424</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">122</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">117</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other (income) expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;;text-align:right;"></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;;text-align:right;"></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">769</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">680</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit does not include amortization and certain other items. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">&#167;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than 0.5%. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Europe Revenues </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our Europe segment includes the European Union and certain other European countries. Revenues from our Europe segment in the first six months of 2022 were $2,327&#160;million, a decrease of 3% or $71&#160;million, compared to the first six months of 2021. In local currency terms, revenues increased by 3%, compared to the first six months of 2021, which increase was attributed to higher demand for generic and OTC products resulting mainly from the removal of restrictions related to doctor and hospital visits by patients that were previously implemented in response to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, together with higher revenues from generic product launches. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the first six months of 2022, revenues were negatively impacted by exchange rate fluctuations of $196&#160;million, net of hedging effects, compared to the first six months of 2021. Revenues in the first six months of 2022 included $39&#160;million from a positive hedging impact, which are included in &#8220;Other&#8221; in the table below. See note 8d to our consolidated financial statements. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">67 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenues by Major Products and Activities </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents revenues for our Europe segment by major products and activities for the six months ended June&#160;30, 2022 and 2021: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six&#160;months&#160;ended<br/>June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Percentage</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022-2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic products</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,749</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,742</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;;text-align:right;"></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AJOVY</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">71</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">144</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">201</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(28</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Respiratory products</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">137</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">179</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(24</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">238</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">242</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,327</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,398</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">&#167;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than 0.5%. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Europe Gross Profit </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit from our Europe segment in the first six months of 2022 was $1,397&#160;million, an increase of 4% compared to $1,349&#160;million in the first six months of 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit margin for our Europe segment in the first six months of 2022 increased to 60.0% compared to 56.2% in the first six months of 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Europe R&amp;D Expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses relating to our Europe segment in the first six months of 2022 were $114&#160;million, a decrease of 12% compared to $129&#160;million in the first six months of 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Europe S&amp;M Expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses relating to our Europe segment in the first six months of 2022 were $393&#160;million, a decrease of 7% compared to $424&#160;million in the first six months of 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Europe G&amp;A Expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses relating to our Europe segment in the first six months of 2022 were $122&#160;million, an increase of 4% compared to $117&#160;million in the first six months of 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Europe Profit </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Profit from our Europe segment in the first six months of 2022 was $769&#160;million, an increase of 13% compared to the first six months of 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International Markets Segment </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents revenues, expenses and profit for our International Markets segment for the six months ended June&#160;30, 2022 and 2021: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions&#160;/%&#160;of&#160;Segment&#160;Revenues)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">946</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">975</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">528</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">530</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">54.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">39</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">196</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">201</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">51</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other (income) expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(41</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;;text-align:right;"></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">274</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">245</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit does not include amortization and certain other items. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">&#167;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than 0.5%. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">68 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">International Markets Revenues </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our International Markets segment includes all countries other than those in our North America and Europe segments. Revenues from our International Markets segment in the first six months of 2022 were $946&#160;million, a decrease of $29&#160;million, or 3%, compared to the first six months of 2021. In local currency terms, revenues increased by 5%. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the first six months of 2022, revenues were negatively impacted by exchange rate fluctuations of $81&#160;million, including hedging effects, compared to the first six months of 2021. Revenues in the first six months of 2022 included $5&#160;million from a negative hedging impact, which is included in &#8220;Other&#8221; in the table below. See note 8d to our consolidated financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;1, 2021, we completed the sale of the majority of the generic and operational assets of our business venture in Japan. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenues by Major Products and Activities </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents revenues for our International Markets segment by major products and activities for the six months ended June&#160;30, 2022 and 2021: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six&#160;months&#160;ended<br/>June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Percentage</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Change</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022-2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic products</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">782</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">799</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AJOVY</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">143</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">128</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">150</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">946</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">975</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">International Markets Gross Profit </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit from our International Markets segment in the first six months of 2022 was $528&#160;million, compared to $530&#160;million in the first six months of 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit margin for our International Markets segment in the first six months of 2022 increased to 55.8%, compared to 54.4% in the first six months of 2021. This increase was mainly due to price increases largely as a result of rising costs due to inflationary pressure. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">International Markets R&amp;D Expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses relating to our International Markets segment in the first six months of 2022 were $39&#160;million, an increase of 11% compared to $35&#160;million in the first six months of 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">International Markets S&amp;M Expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses relating to our International Markets segment in the first six months of 2022 were $196&#160;million, a decrease of 3% compared to $201&#160;million in the first six months of 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">International Markets G&amp;A Expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses relating to our International Markets segment in the first six months of 2022 were $60&#160;million, an increase of 17% compared to $51&#160;million in the first six months of 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">International Markets Other Income </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income in the first six months of 2022 was $41&#160;million, compared to $3&#160;million in the first six months of 2021. Other income in the first six months of 2022 was mainly the result of settlement proceeds. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">International Markets Profit </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Profit from our International Markets segment in the first six months of 2022 was $274&#160;million, an increase of 12%, compared to $245&#160;million in the first six months of 2021. This increase was mainly due to the higher other income discussed above. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">69 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Activities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our revenues from other activities in the first six months of 2022 decreased by 9% to $532&#160;million, compared to the first six months of 2021. In local currency terms, revenues decreased by 7%. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">API sales to third parties in the first six months of 2022 were $357&#160;million, a decrease of 5% in both U.S. dollars and local currency terms, compared to the first six months of 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva Consolidated Results </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues in the first six months of 2022 were $7,447&#160;million, a decrease of 6%, or 2% in local currency terms, compared to the first six months of 2021. The decrease in the first six months of 2022 was mainly due to lower revenues from COPAXONE in our North America and Europe segments, and from generic products and BENDEKA/TREANDA in our North America segment, partially offset by higher revenues from generic products in our Europe segment. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exchange rate movements during the first six months of 2022, net of hedging effects, negatively impacted revenues by $295&#160;million, compared to the first six months of 2021. See note 8d to our consolidated financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross Profit </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit in the first six months of 2022 was $3,534&#160;million, a decrease of 6% compared to the first six months of 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit margin was 47.5% in the first six months of 2022, flat compared to the first six months of 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and Development (R&amp;D) Expenses </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses in the first six months of 2022 were $453&#160;million, a decrease of 10% compared to the first six months of 2021.&#160;&#160;&#160;&#160; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses as a percentage of revenues were 6.1% in the first six months of 2022, compared to 6.4% in the first six months of 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selling and Marketing (S&amp;M) Expenses </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses in the first six months of 2022 were $1,178&#160;million, a decrease of 2% compared to the first six months of 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses as a percentage of revenues were 15.8% in the first six months of 2022, compared to 15.2% in the first six months of 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and Administrative (G&amp;A) Expenses </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses in the first six months of 2022 were $609&#160;million, an increase of 15% compared to the first six months of 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses as a percentage of revenues were 8.2% in the first six months of 2022, compared to 6.7% in the first six months of 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible Asset Impairments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recorded expenses of $199&#160;million for identifiable intangible asset impairments, in the first six months of 2022, compared to expenses of $274&#160;million in the first six months of 2021. See note 5 to our consolidated financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill Impairment </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recorded a goodwill impairment charge of $745&#160;million in the first six months of 2022, of which $479&#160;million is related to our International Markets reporting unit and $266&#160;million is related to Teva&#8217;s API reporting unit. See note 6 to our consolidated financial statements. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">70 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Asset Impairments, Restructuring and Other Items </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recorded expenses of $246&#160;million for other asset impairments, restructuring and other items in the first six months of 2022, compared to expenses of $165&#160;million in the first six months of 2021. See note 12 to our consolidated financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legal Settlements and Loss Contingencies </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the first six months of 2022, we recorded expenses of $1,854&#160;million in legal settlements and loss contingencies, compared to an expense of $110&#160;million in the first six months of 2021. See note 9 to our consolidated financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Income </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income in the first six months of 2022 was $87&#160;million, compared to $48&#160;million in the first six months of 2021. Other income in the first six months of 2022 was mainly the result of settlement proceeds in our International Markets segment as well as a capital gain related to the sale of an R&amp;D site. Other income in the first six months of 2021 was mainly due to capital gains related to the sale of certain OTC assets. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating Income (Loss) </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating loss was $1,662&#160;million in the first six months of 2022, compared to operating income of $1,015&#160;million in the first six months of 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating loss as a percentage of revenues was 22.3% in the first six months of 2022, compared to operating income as a percentage of revenues of 12.9% in the first six months of 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial Expenses, Net </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial expenses were $468&#160;million in the first six months of 2022, compared to $564 million&#160;in the first six months of 2021. Financial expenses in the first six months of 2022 were mainly comprised of interest expenses of $463&#160;million. Financial expenses in the first six months of 2021 were mainly comprised of interest expenses of $479&#160;million and loss on revaluations of marketable securities of $98&#160;million. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents a reconciliation of our segment profits to our consolidated operating income (loss) and to consolidated income (loss) before income taxes for the six months ended June&#160;30, 2022 and 2021: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six months ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">North America profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">883</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,098</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Europe profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">769</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">680</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International Markets profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">274</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">245</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total reportable segments profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,926</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,023</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Profit of other activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">107</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">87</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total segments profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,033</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,111</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts not allocated to segments:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">412</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">414</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets impairments, restructuring and other items</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">246</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">165</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill impairment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">745</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible asset impairments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">274</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legal settlements and loss contingencies</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,854</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">110</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other unallocated amounts</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">240</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">132</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated operating income (loss)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,662</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,015</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial expenses, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">468</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">564</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated income (loss) before income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,131</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">451</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">71 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax Rate </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In the first six months of 2022, we recognized a tax benefit of $899&#160;million, on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> loss of $2,131&#160;million. In the first six months of 2021, we recognized a tax expense of $159&#160;million, on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> income of $451&#160;million. See note 11 to our consolidated financial statements. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share in (Profits) Losses of Associated Companies, Net </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share in profits of associated companies, net in the first six months of 2022 was $21&#160;million, compared to share in profits of $14&#160;million in the first six months of 2021. The share in profits of associated companies, net in the first six months of 2022 was mainly related to the difference between the book value of our investment in Novetide and its fair value as of the date we completed its acquisition in January 2022. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Income (Loss) Attributable to Teva </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss was $1,187&#160;million in the first six months of 2022, compared to net income of $284&#160;million in the first six months of 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted Shares Outstanding and Earnings (Loss) per Share </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The weighted average diluted shares outstanding used for the fully diluted share calculation for the six months ended June&#160;30, 2022 and 2021 were 1,109&#160;million and 1,108&#160;million shares. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted loss per share was $1.07 in the first six months of 2022, compared to diluted earnings per share of $0.26 in the first six months of 2021. See note 13 to our consolidated financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impact of Currency Fluctuations on Results of Operations </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the first six months of 2022, approximately 48% of our revenues were denominated in currencies other than the U.S. dollar. Because our results are reported in U.S. dollars, we are subject to significant foreign currency risks and, accordingly, changes in the exchange rate between the U.S. dollar and local currencies in markets in which we operate (primarily the euro, British pound, Canadian dollar, Russian ruble, Japanese yen, Swiss franc and new Israeli shekel) impact our results. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">During the first six months of 2022, the following main currencies relevant to our operations decreased in value against the U.S. dollar: Turkish lira by 47%, Argentinian peso by 18%, Hungarian forint by 13%, Chilean peso by 13%, Japanese yen by 12%, Swedish krona by 12%, Polish zloty by 11% and euro by 9% (all compared on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-month</div> average basis). The following main currency relevant to our operations increased in value against the U.S. dollar: Brazilian real by 6%. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a result, exchange rate movements during the first six months of 2022 negatively impacted overall revenues by $295&#160;million and our operating income by $63&#160;million, in comparison to the first six months of 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the first six months of 2022, a positive hedging impact of $35&#160;million was recognized under revenues, and a positive hedging impact of $4&#160;million was recognized under cost of sales. In the first six months of 2021, a positive hedging impact of $13&#160;million was recognized under revenues and a minimal impact was recognized under cost of sales. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hedging transactions against future projected revenues and expenses are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. See note 8d to our consolidated financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity and Capital Resources </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total balance sheet assets were $45,932&#160;million as of June&#160;30, 2022, compared to $47,666&#160;million as of December&#160;31, 2021. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">72 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our working capital balance, which includes accounts receivables net of SR&amp;A, inventories, prepaid expenses and other current assets, accounts payables, employee-related obligations, accrued expenses and other current liabilities, was $814&#160;million as of June&#160;30, 2022, compared to $787&#160;million as of December&#160;31, 2021. This increase was mainly due to an increase in inventory levels and accounts receivables, net of SR&amp;A, partially offset by an update to the estimated settlement provision recorded in connection with the remaining opioid cases and an increase in accounts payables. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee-related obligations, as of June&#160;30, 2022 were $467&#160;million, compared to $563&#160;million as of December&#160;31, 2021. The decrease in the first six months of 2022 was mainly due to performance incentive payments to employees for 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash investment in property, plant and equipment in the second quarter of 2022 was $127&#160;million, compared to $113&#160;million in the second quarter of 2021. Depreciation in the second quarter of 2022 was $146&#160;million, compared to $134&#160;million in the second quarter of 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents and short-term and long-term investments as of June&#160;30, 2022 were $2,108&#160;million, compared to $2,191&#160;million as of December&#160;31, 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our cash on hand that is not used for ongoing operations is generally invested in bank deposits as well as liquid securities that bear fixed and floating rates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva&#8217;s principal sources of short-term liquidity are its cash on hand, existing cash investments, liquid securities and available credit facilities, primarily, as of June&#160;30, 2022, its $1.8&#160;billion unsecured syndicated sustainability-linked revolving credit facility, entered into in April 2022 (&#8220;RCF&#8221;). See note 7 to our consolidated financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt Balance and Movements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2022, our debt was $22,082&#160;million, compared to $23,043&#160;million as of December&#160;31, 2021. This decrease was mainly due to $680&#160;million from exchange rate fluctuations and $296&#160;million senior notes repaid at maturity. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our debt as of June&#160;30, 2022 was effectively denominated in the following currencies: 63% in U.S. dollars, 34% in euros and 3% in Swiss francs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The portion of total debt classified as short-term as of June&#160;30, 2022 was 8%, compared to 6% as of December&#160;31, 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our financial leverage was 69% as of June&#160;30, 2022, compared to 67% as of December&#160;31, 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our average debt maturity was approximately 6.1 years as of June&#160;30, 2022, compared to 6.4 years as of December&#160;31, 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Equity </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total equity was $9,828&#160;million as of June&#160;30, 2022, compared to $11,244&#160;million as of December&#160;31, 2021. This decrease was mainly due to a net loss of $1,211&#160;million and a negative impact of $282&#160;million from exchange rate fluctuations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Exchange rate fluctuations affected our balance sheet, as approximately 58% of our net assets as of June&#160;30, 2022 (including both <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-monetary</div> and monetary assets) were in currencies other than the U.S. dollar. When compared to December&#160;31, 2021, changes in currency rates had a negative impact of $282&#160;million on our equity as of June&#160;30, 2022. The following main currencies decreased in value against the U.S. dollar: the Turkish lira by 27%, the Japanese yen by 19%, the British pound by 11%, the Polish zloty by 10%, the Chilean peso by 9%, the Croatian kuna by 9%, the Bulgarian lev by 8%, the euro by 8% and the Indian rupee by 6&#160;%. The following main currency increased in value against the U.S. dollar: the Russian ruble by 30%. All comparisons are on a year to date basis. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash Flow </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We seek to continually improve the efficiency of our working capital management. From time to time, as part of our cash and commercial relationship management activities, we may make decisions in our commercial and supply chain activities which may drive an acceleration of receivable payments from customers or deceleration of payments to vendors, having the effect of increasing or decreasing cash from operations in an individual period. Such decisions may have an impact on our annual operating cash flow measurement, as well as on our quarterly results. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">73 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flow generated from operating activities during the second quarter of 2022 was $123&#160;million, compared to $218&#160;million in the second quarter of 2021. This decrease was mainly due to payments related to legal settlements in the second quarter of 2022, partially offset by an increase in accounts payables. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the second quarter of 2022, we generated free cash flow of $301&#160;million, which we define as comprising $123&#160;million in cash flow generated from operating activities, $287&#160;million in beneficial interest collected in exchange for securitized accounts receivables and $18&#160;million in proceeds from divestitures of businesses and other assets, partially offset by $127&#160;million in cash used for capital investment. During the second quarter of 2021, we generated free cash flow of $625&#160;million, comprising $218&#160;million in cash flow generated from operating activities, $405&#160;million in beneficial interest collected in exchange for securitized accounts receivables and $115&#160;million in proceeds from divestitures of businesses and other assets, partially offset by $113&#160;million in cash used for capital investment. The decrease in the second quarter of 2022 resulted mainly from lower cash flow from operating activities as well as lower proceeds from sales of assets. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividends </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have not paid dividends on our ordinary shares or ADSs since December 2017. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to financing obligations under short-term debt and long-term senior notes and loans, debentures and convertible debentures, our major contractual obligations and commercial commitments include leases, royalty payments, contingent payments pursuant to acquisition agreements and participation in joint ventures associated with R&amp;D activities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In October 2021, Teva announced a license agreement with MODAG GmbH (&#8220;Modag&#8221;) that will provide Teva an exclusive global license to develop, manufacture and commercialize Modag&#8217;s lead compound <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(TEV-56286)</div> and a related compound <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(TEV-56287).</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TEV-56286</div> was initially developed for the treatment of Multiple System Atrophy (&#8220;MSA&#8221;) and Parkinson&#8217;s disease, and has the potential to be applied to other treatments for neurodegenerative disorders, such as Alzheimer&#8217;s disease. A phase 1b clinical trial is currently being completed for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TEV-56286.</div> In the fourth quarter of 2021, Teva made an upfront payment of $10&#160;million to Modag that was recorded as an R&amp;D expense. Modag may be eligible for future development milestone payments, totaling an aggregate amount of up to $70&#160;million, as well as future commercial milestones and royalties. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2020, Teva entered into an agreement with biopharmaceutical company Alvotech for the exclusive commercialization in the U.S. of five biosimilar product candidates. The initial pipeline for this collaboration contains biosimilar candidates addressing multiple therapeutic areas, including a proposed biosimilar to Humira<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>. Under this agreement, Alvotech is responsible for the development, registration and supply of the biosimilar product candidates and Teva will exclusively commercialize the products in the United States. Teva paid an upfront payment in the third quarter of 2020 and additional upfront and milestone payments in the second quarter of 2021 that were recorded as R&amp;D expenses. Additional development and commercial milestone payments of up to $455&#160;million, as well as royalty payments, may be payable by Teva over the next few years. Teva and Alvotech will share profit from the commercialization of these biosimilars. Alvotech was previously involved in litigation involving certain IP and trade secrets claims filed by Abbvie in relation to Alvotech&#8217;s proposed biosimilar to Humira<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>, all of which were settled on March&#160;8, 2022.&#160;Pursuant to that settlement, Alvotech and Teva may sell Alvotech&#8217;s proposed biosimilar to Humira<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"> </div>in the United States beginning on July&#160;1, 2023, provided that U.S. regulatory approval is obtained by that date. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In September 2016, Teva and Regeneron entered into a collaborative agreement to develop and commercialize Regeneron&#8217;s pain medication product, fasinumab. Teva and Regeneron share in the global commercial rights to this product (excluding Japan, Korea and nine other Asian countries), as well as ongoing associated R&amp;D costs of approximately $1&#160;billion. Teva made an upfront payment of $250&#160;million to Regeneron in the third quarter of 2016 and additional payments for achievement of development milestones in an aggregate amount of $120&#160;million were paid during 2017 and 2018. The agreement stipulates additional development and commercial milestone payments of up to $2,230&#160;million, as well as future royalties. Currently, all <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-essential</div> activities and related expenditures for fasinumab have been put on hold. Next steps will be assessed together with Regeneron, with the intention of discussing data with the FDA. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">74 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In November 2013, Teva entered into an agreement with MedinCell for the development and commercialization of multiple long-acting injectable products. The lead product candidate selected was risperidone LAI <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(TV-46000)</div> suspension for subcutaneous use for the treatment of schizophrenia. In August 2021, the FDA accepted the new drug application (&#8220;NDA&#8221;) for risperidone LAI, based on phase 3 data from two pivotal studies. Teva leads the clinical development and regulatory process and is responsible for commercialization of this product candidate. MedinCell may be eligible for development milestones, and future commercial milestones of up to $112&#160;million in respect of risperidone LAI. Teva will also pay MedinCell royalties on net sales. In April 2022, the FDA issued a Complete Response Letter (&#8220;CRL&#8221;) regarding the NDA for risperidone LAI. Teva is working to address the issues raised in the CRL with a view to resubmission. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We are committed to paying royalties to owners of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> partners in alliances and certain other arrangements, and to parties that financed R&amp;D at a wide range of rates as a percentage of sales of certain products, as defined in the agreements. In some cases, the royalty period is not defined; in other cases, royalties will be paid over various periods not exceeding 20 years. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with certain development, supply and marketing, and research and collaboration or services agreements, we are required to indemnify, in unspecified amounts, the parties to such agreements against third-party claims relating to (i)&#160;infringement or violation of intellectual property or other rights of such third party; or (ii)&#160;damages to users of the related products. Except as described in our financial statements, we are not aware of any material pending action that may result in the counterparties to these agreements claiming such indemnification. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022 Aggregated Contractual Obligations </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">There have not been any material changes in our assessment of material contractual obligations and commitments as set forth in Item 7 of our Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the year ended December&#160;31, 2021. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Supplemental <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-GAAP</div> Income Data </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We utilize certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measures to evaluate performance, in conjunction with other performance metrics. The following are examples of how we utilize the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> measures: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">our management and Board of Directors use the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> measures to evaluate our operational performance, to compare against work plans and budgets, and ultimately to evaluate the performance of management; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">our annual budgets are prepared on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> basis; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">senior management&#8217;s annual compensation is derived, in part, using these <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> measures. While qualitative factors and judgment also affect annual bonuses, the principal quantitative element in the determination of such bonuses is performance targets tied to the work plan, which is based on the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> presentation set forth below. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-GAAP</div> financial measures have no standardized meaning and accordingly have limitations in their usefulness to investors. We provide such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> data because management believes that such data provide useful information to investors. However, investors are cautioned that, unlike financial measures prepared in accordance with U.S. GAAP, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> measures may not be comparable with the calculation of similar measures for other companies. These <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measures are presented solely to permit investors to more fully understand how management assesses our performance. The limitations of using <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measures as performance measures are that they provide a view of our results of operations without including all events during a period and may not provide a comparable view of our performance to other companies in the pharmaceutical industry. </div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Investors should consider <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In arriving at our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> presentation, we exclude items that either have a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-recurring</div> impact on the income statement or which, in the judgment of our management, are items that, either as a result of their nature or size, could, were they not singled out, potentially cause investors to extrapolate future performance from an improper base. In addition, we also exclude equity compensation expenses to facilitate a better understanding of our financial results, since we believe that such exclusion is important for understanding the trends in our financial results and that these expenses do not affect our business operations. While not all inclusive, examples of these items include: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">amortization of purchased intangible assets; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">legal settlements and material litigation fees and/or loss contingencies, due to the difficulty in predicting their timing and scope; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">impairments of long-lived assets, including intangibles, property, plant and equipment and goodwill; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">75 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">restructuring expenses, including severance, retention costs, contract cancellation costs and certain accelerated depreciation expenses primarily related to the rationalization of our plants or to certain other strategic activities, such as the realignment of R&amp;D focus or other similar activities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">acquisition- or divestment- related items, including changes in contingent consideration, integration costs, banker and other professional fees and inventory <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">step-up;</div> </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">expenses related to our equity compensation; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">significant <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> financing costs, amortization of issuance costs and terminated derivative instruments, and marketable securities investment valuation gains/losses; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">unusual tax items; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">other awards or settlement amounts, either paid or received; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">other exceptional items that we believe are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial results, such as impacts due to changes in accounting, significant costs for remediation of plants, such as inventory write-offs or related consulting costs, or other unusual events; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">corresponding tax effects of the foregoing items. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Commencing the first quarter of 2022, we no longer exclude IPR&amp;D acquired in development arrangements from our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measures. No IPR&amp;D acquired in development arrangements was recorded in our comparable non-GAAP financial measures for the second quarter of 2021. In our comparable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measures for the six months ended June&#160;30, 2021, we excluded $5&#160;million IPR&amp;D acquired in development. We are not recasting the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> presentation for the six months ended June&#160;30, 2021 since the adjustment is not significant. We are making this change to our presentation of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measures to improve the comparability of our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> presentation to those of other companies in the pharmaceutical industry that are making a similar change to their presentations beginning in the first quarter of 2022. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The following tables present supplemental <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> data, in U.S. dollars, which we believe facilitates an understanding of the factors affecting our business. In these tables, we exclude the following amounts: </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">76 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">The following table presents the GAAP measures, related <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> adjustments and the corresponding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> amounts for the applicable periods: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 23%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="50" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended June&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="50" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">U.S. $ and shares in millions (except per share amounts)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">GAAP</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="42" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Excluded for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> measurement</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-GAAP</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Amortization<br/>of purchased<br/>intangible<br/>assets</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Legal<br/>settlements<br/>and loss<br/>contingencies</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Goodwill<br/>impairment</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairment<br/>of long<br/>lived</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Restructuring<br/>costs</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Costs<br/>related to<br/>regulatory<br/>actions<br/>taken in<br/>facilities</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Equity<br/>compensation</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Contingent<br/>consideration</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Other<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div><br/>items*</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Accelerated<br/>Depreciation</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Other<br/>items</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,786</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,786</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of sales</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,992</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">191</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,726</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,794</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">191</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,059</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit margin</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">47.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">54.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">228</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">222</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">594</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">563</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">313</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">258</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(34</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(31</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Legal settlements and loss contingencies</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">729</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">729</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets impairments, restructuring and other items</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">118</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">61</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets impairments</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">51</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">51</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill Impairment</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">745</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">745</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating income (loss)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(949</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">212</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">729</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">745</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">65</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">39</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">61</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,019</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial expenses, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">211</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">188</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Income (loss) before income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,160</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">212</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">729</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">745</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">65</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">39</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">61</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">831</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(900</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">**(965</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">64</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(259</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">212</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">729</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">745</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">65</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">39</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">61</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(942</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">767</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Net income (loss) attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests</div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(27</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(39</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to Teva</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(232</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">212</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">729</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">745</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">65</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">39</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">61</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(981</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">754</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">EPS - Basic</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.21</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.89</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.68</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">EPS - Diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.21</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.89</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.68</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> diluted weighted average number of shares was 1,114&#160;million for the three months ended June&#160;30, 2022. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-GAAP</div> income taxes for the three months ended June&#160;30, 2022 were 8% on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> income. </div> <div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> items include other exceptional items that we believe are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial results, such as certain accelerated depreciation expenses and inventory write offs, primarily related to the rationalization of our plants and other unusual events. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">**</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Includes a portion of the realization of losses related to an investment in one of our U.S. subsidiaries as well as corresponding tax effects on non-GAAP items. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">77 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 44%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="42" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended June&#160;30, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="42" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">U.S. $ and shares in millions (except per share amounts)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">GAAP</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="34" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Excluded for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> measurement</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-GAAP</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Amortization<br/>of purchased<br/>intangible<br/>assets</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Legal<br/>settlements<br/>and loss<br/>contingencies</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairment<br/>of long<br/>lived</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Restructuring<br/>costs</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Costs<br/>related to<br/>regulatory<br/>actions<br/>taken in<br/>facilities</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Equity<br/>compensation</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Contingent<br/>consideration</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Other<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div><br/>items*</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Other<br/>items</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,910</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,910</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of sales</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,037</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">148</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,826</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,873</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">148</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,084</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit margin</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">47.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">248</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">243</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">615</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">582</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">242</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">231</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(43</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(37</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Legal settlements and loss contingencies</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets impairments, restructuring and other items</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(19</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets impairments</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">195</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">195</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating income (loss)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">582</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">173</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">226</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(19</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">42</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,034</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial expenses, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">274</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">240</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Income (loss) before income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">308</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">173</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">226</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(19</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">42</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">794</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">98</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(36</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">133</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Share in (profit) losses of associated companies &#8211; net</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">221</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">173</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">226</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(19</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">42</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">669</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Net income (loss) attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests</div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to Teva</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">207</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">173</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">226</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(19</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">42</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">651</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">EPS - Basic</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.19</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.59</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">EPS - Diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.19</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.59</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> diluted weighted average number of shares was 1,109&#160;million for the three months ended June&#160;30, 2021. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-GAAP</div> income taxes for the three months ended June&#160;30, 2021 were 17% on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> income. </div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> items include other exceptional items that we believe are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial results, such as certain accelerated depreciation expenses and inventory write offs, primarily related to the rationalization of our plants and other unusual events. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">78 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 31%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="50" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended June&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="50" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">U.S. $ and shares in millions (except per share amounts)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">GAAP</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="42" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Excluded for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> measurement</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-GAAP</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Amortization<br/>of purchased<br/>intangible<br/>assets</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Legal<br/>settlements<br/>and loss<br/>contingencies</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Goodwill<br/>impairment</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairment<br/>of long-<br/>lived</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Restructuring<br/>costs</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Costs<br/>related to<br/>regulatory<br/>actions<br/>taken in<br/>facilities</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Equity<br/>compensation</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Contingent<br/>consideration</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Accelerated<br/>depreciation</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Other<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div><br/>items*</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Other<br/>items</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,447</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,447</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of sales</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,913</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">368</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">95</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,401</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,534</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">368</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">95</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,045</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit margin</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">47.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">54.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">453</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">443</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,178</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">43</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,115</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">609</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">73</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">510</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Other (income) expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(87</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(31</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(55</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Legal settlements and loss contingencies</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,854</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,854</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets impairments, restructuring and other items</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">246</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">92</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets impairment</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill impairment</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">745</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">745</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating income (loss)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,662</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">412</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,854</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">745</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">230</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">92</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">63</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">170</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,033</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial expenses, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">468</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">435</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Income (loss) before income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,131</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">412</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,854</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">745</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">230</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">92</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">63</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">170</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,597</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(899</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">**(1,105</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">206</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Share in (profits) losses of associated companies &#8211; net</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(21</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(22</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,211</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">412</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,854</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">745</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">230</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">92</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">63</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">170</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,094</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,390</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Net income (loss) attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests</div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(24</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(50</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to Teva</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,187</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">412</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,854</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">745</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">230</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">92</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">63</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">170</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,144</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,363</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">EPS - Basic</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1.07</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.23</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">EPS - Diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1.07</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.29</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.22</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> diluted weighted average number of shares was 1,116&#160;million for the six months ended June&#160;30, 2022. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-GAAP</div> income taxes for the six months ended June&#160;30, 2022 were 13% on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> income. </div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> items include other exceptional items that we believe are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial results, such as certain accelerated depreciation expenses and inventory write offs, primarily related to the rationalization of our plants and other unusual events. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">**</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Includes a portion of the realization of losses related to an investment in one of our U.S. subsidiaries as well as corresponding tax effects on non-GAAP items. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">79 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 33%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"></td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 33%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-size: 8pt; break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="42" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six months ended June&#160;30, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 8pt; break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="42" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">U.S. $ and shares in millions (except per share amounts)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-size: 8pt; break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">GAAP</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="34" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Excluded for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> measurement</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-GAAP</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-size: 8pt; break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Amortization<br/>of purchased<br/>intangible<br/>assets</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Legal<br/>settlements<br/>and loss<br/>contingencies</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairment<br/>of long-<br/>lived</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Restructuring<br/>costs</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Costs<br/>related to<br/>regulatory<br/>actions<br/>taken in<br/>facilities</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Equity<br/>compensation</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Contingent<br/>consideration</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Other<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div><br/>items*</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Other<br/>items</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 8pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,892</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,892</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 8pt; break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of sales</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,141</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">363</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">91</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,663</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 8pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,750</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">363</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">91</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,228</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 8pt; break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit margin</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">47.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 8pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">501</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">487</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 8pt; break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">52</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,131</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 8pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">532</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">510</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 8pt; break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Other (income) expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(48</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(37</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 8pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Legal settlements and loss contingencies</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">110</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">110</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 8pt; break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets impairments, restructuring and other items</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">165</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 8pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets impairment</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">274</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">274</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 8pt; break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating income (loss)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,015</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">414</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">110</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">354</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">92</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,111</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 8pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial expenses, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">564</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">98</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">467</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 8pt; break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Income (loss) before income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">451</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">414</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">110</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">354</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">92</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">98</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,644</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 8pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">159</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(120</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">280</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 8pt; break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Share in losses of associated companies &#8211; net</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(14</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 8pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to Teva</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">306</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">414</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">110</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">354</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">92</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(24</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,377</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 8pt; break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Net income (loss) attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests</div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 8pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">284</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">414</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">110</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">354</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">92</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(30</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,350</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 8pt; break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">EPS - Basic</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.26</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.97</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.23</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 8pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">EPS - Diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.26</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.96</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.22</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> diluted weighted average number of shares was 1,108&#160;million for the six months ended June&#160;30, 2021. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-GAAP</div> income taxes for the six months ended June&#160;30, 2021 were 17% on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> income. </div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> items include other exceptional items that we believe are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial results, such as certain accelerated depreciation expenses and inventory write offs, primarily related to the rationalization of our plants and other unusual events. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">80 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-GAAP</div> Tax Rate </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-GAAP</div> income taxes in the second quarter of 2022 were $64&#160;million, or 7.7%, on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> income of $831&#160;million. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-GAAP</div> income taxes in the second quarter of 2021 were $133&#160;million, or 17%, on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> income of $794&#160;million. Our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> tax rate in the second quarter of 2022 was mainly affected by a portion of the realization of losses related to an investment in one of our U.S. subsidiaries, as mentioned in note 11 to our consolidated financial statements, as well as the mix of products we sold and interest expense disallowances. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-GAAP</div> income taxes in the first six months of 2022 were $206&#160;million, or 12.9%, on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> income of $1,597&#160;million. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-GAAP</div> income taxes in the first six months of 2021 were $280&#160;million, or 17%, on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> income of $1,644&#160;million. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We expect our annual <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> tax rate for 2022 to be between 13% to 14%, lower than our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> tax rate for 2021, which was 16.4%, mainly due to the effect of a portion of the realization of losses related to an investment in one of our U.S. subsidiaries, as mentioned in note 11 to our consolidated financial statements. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Off-Balance</div> Sheet Arrangements </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Except for securitization transactions, which are disclosed in note 10(f) to our consolidated financial statements included in our Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the year ended December&#160;31, 2021, we do not have any material <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-balance</div> sheet arrangements. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Critical Accounting Policies </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">For a summary of our significant accounting policies, see note 1 to our consolidated financial statements and &#8220;Critical Accounting Policies&#8221; included in our Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the year ended December&#160;31, 2021. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recently Issued Accounting Pronouncements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See note 1 to our consolidated financial statements. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx360666_10" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ITEM&#160;3.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">There has not been any material change in our assessment of market risk as set forth in Item 7A to our Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the year ended December&#160;31, 2021. </div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx360666_11" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ITEM&#160;4.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONTROLS AND PROCEDURES </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disclosure Controls and Procedures</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Teva maintains &#8220;disclosure controls and procedures&#8221; (as defined in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Rules&#160;13a-15(e)&#160;and&#160;15d-15(e)&#160;under</div></div> the Securities Exchange Act of 1934, as amended) that are designed to provide reasonable assurance that information required to be disclosed in Teva&#8217;s reports filed or submitted under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to Teva&#8217;s management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">After evaluating the effectiveness of our disclosure controls and procedures as of June&#160;30, 2022, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, Teva&#8217;s disclosure controls and procedures were effective at the reasonable assurance level. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in Internal Control over Financial Reporting </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the quarter ended June&#160;30, 2022, there were no changes in internal control over financial reporting that materially affected or are reasonably likely to materially affect Teva&#8217;s internal control over financial reporting. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">81 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="tx360666_12" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 14pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 14pt; letter-spacing: 0px; top: 0px;;display:inline;">PART II &#8212; OTHER INFORMATION </div></div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx360666_13" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ITEM&#160;1.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LEGAL PROCEEDINGS </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We are subject to various litigation and other legal proceedings. For a discussion of these matters, see &#8220;Commitments and Contingencies&#8221; included in note 10 to the consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q.</div> </div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx360666_14" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ITEM&#160;1A.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RISK FACTORS </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">There are no material changes to the risk factors previously disclosed in our Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the year ended December&#160;31, 2021. </div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx360666_15" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ITEM&#160;2.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unregistered Sales of Equity Securities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no sales of unregistered equity securities during the three months ended June&#160;30, 2022. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repurchase of Shares </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We did not repurchase any of our shares during the three months ended June&#160;30, 2022 and currently cannot conduct share repurchases or pay dividends due to our accumulated deficit. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx360666_16" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ITEM&#160;3.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DEFAULTS UPON SENIOR SECURITIES </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx360666_17" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ITEM&#160;4.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MINE SAFETY DISCLOSURES </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx360666_18" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ITEM&#160;5.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OTHER INFORMATION </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">82 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx360666_19" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ITEM&#160;6.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">EXHIBITS </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td style="width: 90%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">3.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312522180042/d730888dex31.htm">Articles of Association (1) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">31.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d360666dex311.htm">Certification of the Chief Executive Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002&#160;* </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">31.2</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d360666dex312.htm">Certification of the Chief Financial Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002&#160;* </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">32</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d360666dex32.htm">Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 * </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.INS</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Instance Document</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.SCH</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Schema Document</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.CAL</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.DEF</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Definition Linkbase Document</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.LAB</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Labels Linkbase Document</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.PRE</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">104</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="width: 26%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Filed herewith. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">1.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 3.1 to Current Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div> filed on June&#160;23, 2022. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">83 </div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="tx360666_20" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SIGNATURES </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 44%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 4%;"></td>
<td style="vertical-align: bottom;"></td>
<td style="width: 5%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 44%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="3" style="vertical-align: top;">TEVA&#160;PHARMACEUTICAL&#160;INDUSTRIES&#160;LIMITED</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Date: July&#160;27, 2022</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">By:</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/&#160;Eli Kalif</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Name:</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Eli Kalif</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Title:</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Executive Vice President,</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chief Financial Officer</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Duly Authorized Officer)</div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">84 </div></div> </div> </div>
</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>d360666dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION OF CHIEF EXECUTIVE OFFICER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, K&aring;re Schultz, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of Teva
Pharmaceutical Industries Limited; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The company&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act Rules <FONT
STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the company and have: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being
prepared; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">evaluated the effectiveness of the company&#146;s disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">disclosed in this report any change in the company&#146;s internal control over financial reporting that
occurred during the company&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the company&#146;s internal
control over financial reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The company&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the company&#146;s auditors and the audit committee of the company&#146;s board of directors (or persons performing the equivalent functions): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the company&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any fraud, whether or not material, that involves management or other employees who have a significant role in
the company&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: July&nbsp;27, 2022 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ K&aring;re Schultz</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">K&aring;re Schultz</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>d360666dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.2 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION OF CHIEF FINANCIAL OFFICER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Eli Kalif, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of Teva
Pharmaceutical Industries Limited; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The company&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act Rules <FONT
STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the company and have: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being
prepared; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">evaluated the effectiveness of the company&#146;s disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">disclosed in this report any change in the company&#146;s internal control over financial reporting that
occurred during the company&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the company&#146;s internal
control over financial reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The company&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the company&#146;s auditors and the audit committee of the company&#146;s board of directors (or persons performing the equivalent functions): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the company&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any fraud, whether or not material, that involves management or other employees who have a significant role in
the company&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: July&nbsp;27, 2022 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Eli Kalif</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Eli Kalif</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Executive Vice President, Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>4
<FILENAME>d360666dex32.htm
<DESCRIPTION>EX-32
<TEXT>
<HTML><HEAD>
<TITLE>EX-32</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO 18 U.S.C. SECTION 1350, </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Quarterly Report of Teva Pharmaceutical Industries Limited (the &#147;Company&#148;) on Form
<FONT STYLE="white-space:nowrap">10-Q</FONT> for the period ended June&nbsp;30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), we, K&aring;re Schultz, President and Chief Executive Officer of
the Company, and Eli Kalif, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of
1934; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The information contained in the Report fairly presents, in all material respects, the financial condition and
results of operations of the Company. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: July&nbsp;27, 2022 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ K&aring;re Schultz</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">K&aring;re Schultz</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Eli Kalif</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Eli Kalif</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Executive Vice President, Chief Financial Officer</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>teva-20220630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 27-July-2022 [08:44:53] {AM}-->
<schema targetNamespace="http://www.tevapharm.com/20220630" elementFormDefault="qualified" xmlns:teva="http://www.tevapharm.com/20220630" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
<annotation>
<appinfo>
<link:roleType roleURI="http://www.tevapharm.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
<link:definition>1002 - Statement - Consolidated Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
<link:definition>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss" id="ConsolidatedStatementsOfIncomeLoss">
<link:definition>1004 - Statement - Consolidated Statements of Income (Loss)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" id="ConsolidatedStatementsOfComprehensiveIncomeLoss">
<link:definition>1005 - Statement - Consolidated Statements of Comprehensive Income (Loss)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity" id="ConsolidatedStatementsOfChangesInEquity">
<link:definition>1006 - Statement - Consolidated Statements of Changes in Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical" id="ConsolidatedStatementsOfChangesInEquityParenthetical">
<link:definition>1007 - Statement - Consolidated Statements of Changes in Equity (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
<link:definition>1008 - Statement - Consolidated Statements of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/BasisOfPresentation" id="BasisOfPresentation">
<link:definition>1009 - Disclosure - Basis of presentation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/CertainTransactions" id="CertainTransactions">
<link:definition>1010 - Disclosure - Certain transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomers" id="RevenueFromContractsWithCustomers">
<link:definition>1011 - Disclosure - Revenue from contracts with customers</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/Inventories" id="Inventories">
<link:definition>1012 - Disclosure - Inventories</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/IdentifiableIntangibleAssets" id="IdentifiableIntangibleAssets">
<link:definition>1013 - Disclosure - Identifiable Intangible Assets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/Goodwill" id="Goodwill">
<link:definition>1014 - Disclosure - Goodwill</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DebtObligations" id="DebtObligations">
<link:definition>1015 - Disclosure - Debt obligations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities" id="DerivativeInstrumentsAndHedgingActivities">
<link:definition>1016 - Disclosure - Derivative instruments and hedging activities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies" id="LegalSettlementsAndLossContingencies">
<link:definition>1017 - Disclosure - Legal Settlements and Loss Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>1018 - Disclosure - Commitments and contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>1019 - Disclosure - Income taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems" id="OtherAssetsImpairmentsRestructuringAndOtherItems">
<link:definition>1020 - Disclosure - Other assets impairments, restructuring and other items</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/EarningsLossPerShare" id="EarningsLossPerShare">
<link:definition>1021 - Disclosure - Earnings (Loss) per Share</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLoss" id="AccumulatedOtherComprehensiveIncomeLoss">
<link:definition>1022 - Disclosure - Accumulated other comprehensive income (loss)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/Segments" id="Segments">
<link:definition>1023 - Disclosure - Segments</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/FairValueMeasurement" id="FairValueMeasurement">
<link:definition>1024 - Disclosure - Fair value measurement</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/BasisOfPresentationPolicies" id="BasisOfPresentationPolicies">
<link:definition>1025 - Disclosure - Basis of presentation (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/CertainTransactionsTables" id="CertainTransactionsTables">
<link:definition>1026 - Disclosure - Certain transactions (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables" id="RevenueFromContractsWithCustomersTables">
<link:definition>1027 - Disclosure - Revenue from contracts with customers (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/InventoriesTables" id="InventoriesTables">
<link:definition>1028 - Disclosure - Inventories (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables" id="IdentifiableIntangibleAssetsTables">
<link:definition>1029 - Disclosure - Identifiable Intangible Assets (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/GoodwillTables" id="GoodwillTables">
<link:definition>1030 - Disclosure - Goodwill (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DebtObligationsTables" id="DebtObligationsTables">
<link:definition>1031 - Disclosure - Debt obligations (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables" id="DerivativeInstrumentsAndHedgingActivitiesTables">
<link:definition>1032 - Disclosure - Derivative instruments and hedging activities (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables" id="OtherAssetsImpairmentsRestructuringAndOtherItemsTables">
<link:definition>1033 - Disclosure - Other assets impairments, restructuring and other items (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossTables" id="AccumulatedOtherComprehensiveIncomeLossTables">
<link:definition>1034 - Disclosure - Accumulated other comprehensive income (loss) (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/SegmentsTables" id="SegmentsTables">
<link:definition>1035 - Disclosure - Segments (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/FairValueMeasurementTables" id="FairValueMeasurementTables">
<link:definition>1036 - Disclosure - Fair Value Measurement (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" id="CertainTransactionsOtherTransactionsAdditionalInformationDetail">
<link:definition>1037 - Disclosure - Certain Transactions - Other Transactions - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail" id="CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail">
<link:definition>1038 - Disclosure - Certain Transactions - Business Acquisitions - Summary of Major Classes of Assets and Liabilities Included as Held for Sale (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail" id="RevenueFromContractsWithCustomersAdditionalInformationDetail">
<link:definition>1039 - Disclosure - Revenue from Contracts with Customers - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail" id="RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail">
<link:definition>1040 - Disclosure - Revenue from Contracts with Customers - Summary of Disaggregation of Revenues by Major Revenue Streams (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" id="RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail">
<link:definition>1041 - Disclosure - Revenue from Contracts with Customers - Schedule of Sales Reserves and Allowances (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail" id="InventoriesSummaryOfInventoriesDetail">
<link:definition>1042 - Disclosure - Inventories - Summary of Inventories (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail" id="IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail">
<link:definition>1043 - Disclosure - Identifiable Intangible Assets - Summary of Identifiable Intangible Assets (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" id="IdentifiableIntangibleAssetsAdditionalInformationDetail">
<link:definition>1044 - Disclosure - Identifiable Intangible Assets - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail" id="GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail">
<link:definition>1045 - Disclosure - Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail" id="GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail">
<link:definition>1046 - Disclosure - Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Parenthetical) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail" id="GoodwillAdditionalInformationDetail">
<link:definition>1047 - Disclosure - Goodwill - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail" id="DebtObligationsScheduleOfShortTermDebtDetail">
<link:definition>1048 - Disclosure - Debt Obligations - Schedule of Short-term Debt (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail" id="DebtObligationsScheduleOfSeniorNotesAndLoansDetail">
<link:definition>1049 - Disclosure - Debt Obligations - Schedule of Senior Notes and Loans (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" id="DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail">
<link:definition>1050 - Disclosure - Debt Obligations - Schedule of Senior Notes and Loans (Parenthetical) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail" id="DebtObligationsAdditionalInformationDetail">
<link:definition>1051 - Disclosure - Debt Obligations - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail" id="DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail">
<link:definition>1052 - Disclosure - Derivative Instruments and Hedging Activities - Summary of Classification and Fair Values of Derivative Instruments (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails" id="DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails">
<link:definition>1053 - Disclosure - Derivative Instruments and Hedging Activities - Schedule Of Other Derivatives Not Designated As Hedging Instruments Statements OfFinancial Performance And Financial Position Location (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" id="DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail">
<link:definition>1054 - Disclosure - Derivative Instruments and Hedging Activities - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail" id="LegalSettlementsAndLossContingenciesAdditionalInformationDetail">
<link:definition>1055 - Disclosure - Legal Settlements and Loss Contingencies - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" id="CommitmentsAndContingenciesAdditionalInformationDetail">
<link:definition>1056 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" id="IncomeTaxesAdditionalInformationDetail">
<link:definition>1057 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail" id="OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail">
<link:definition>1058 - Disclosure - Other assets impairments, restructuring and other items - Schedule of Other Assets Impairments, Restructuring and Other Items (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail" id="OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail">
<link:definition>1059 - Disclosure - Other assets impairments, restructuring and other items - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail" id="OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail">
<link:definition>1060 - Disclosure - Other assets impairments, restructuring and other items - Components of costs associated with restructuring plan including costs related to exit and disposal activities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail" id="OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail">
<link:definition>1061 - Disclosure - Other assets impairments, restructuring and other items - Summary of Restructuring Accruals (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail" id="EarningsLossPerShareAdditionalInformationDetail">
<link:definition>1062 - Disclosure - Earnings (Loss) per Share - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail" id="AccumulatedOtherComprehensiveIncomeLossDetail">
<link:definition>1063 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail" id="AccumulatedOtherComprehensiveIncomeLossParentheticalDetail">
<link:definition>1064 - Disclosure - Accumulated Other Comprehensive Income (Loss)  (Parenthetical) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" id="SegmentsSummaryOfSegmentProfitDetail">
<link:definition>1065 - Disclosure - Segments - Summary of Segment Profit (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail" id="SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail">
<link:definition>1066 - Disclosure - Segments - Summary of Profit by Segments and Reconciliation of Segments Profit to Consolidated Income Before Income Taxes (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail" id="SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail">
<link:definition>1067 - Disclosure - Segments - Schedule of Revenues by Major Products and Activities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail" id="SegmentsAdditionalInformationDetail">
<link:definition>1068 - Disclosure - Segments - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" id="FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail">
<link:definition>1069 - Disclosure - Fair Value Measurement - Summary of Financial Items Carried at Fair Value (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail" id="FairValueMeasurementAdditionalInformationDetail">
<link:definition>1070 - Disclosure - Fair value measurement - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail" id="FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail">
<link:definition>1071 - Disclosure - Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail" id="FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail">
<link:definition>1072 - Disclosure - Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Parenthetical) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail" id="FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail">
<link:definition>1073 - Disclosure - Fair Value Measurement - Summary of Financial Instrument Measured on a Basis Other Than Fair Value (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="teva-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="teva-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="teva-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="teva-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
<import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
<import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
<import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
<import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
<element name="AccruedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_AccruedExpenses" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SalesReservesAndAllowances" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_SalesReservesAndAllowances" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ImpairmentsRestructuringAndOthers" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ImpairmentsRestructuringAndOthers" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IntangibleAssetsImpairments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_IntangibleAssetsImpairments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LegalSettlementsAndLossContingencies" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_LegalSettlementsAndLossContingencies" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="UnrealizedGainLossOnDerivativeNetOfTax" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_UnrealizedGainLossOnDerivativeNetOfTax" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeferredIncomeTaxesNetAndUncertainTaxPositions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_DeferredIncomeTaxesNetAndUncertainTaxPositions" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProfitFromSaleOfLongLivedAssetsAndInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ProfitFromSaleOfLongLivedAssetsAndInvestment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PaymentToAcquireMarketableSecuritiesAndOtherAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="BasisOfPresentationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_BasisOfPresentationAbstract" substitutionGroup="xbrli:item" />
<element name="CertainTransactionsDisclosureTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_CertainTransactionsDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="OtherExpensesTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_OtherExpensesTextBlock" substitutionGroup="xbrli:item" />
<element name="RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" substitutionGroup="xbrli:item" />
<element name="SalesReservesAndAllowancesCurrentTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_SalesReservesAndAllowancesCurrentTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfRestructuringChargesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ScheduleOfRestructuringChargesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock" substitutionGroup="xbrli:item" />
<element name="AlderMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_AlderMember" substitutionGroup="xbrli:item" />
<element name="AlvotechMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_AlvotechMember" substitutionGroup="xbrli:item" />
<element name="OtsukaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_OtsukaMember" substitutionGroup="xbrli:item" />
<element name="RegeneronMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_RegeneronMember" substitutionGroup="xbrli:item" />
<element name="ModagMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ModagMember" substitutionGroup="xbrli:item" />
<element name="MedincellMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_MedincellMember" substitutionGroup="xbrli:item" />
<element name="TakedaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_TakedaMember" substitutionGroup="xbrli:item" />
<element name="ResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ResearchAndDevelopmentCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CollaborativeAgreementMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_CollaborativeAgreementMilestonePayments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="UpfrontPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_UpfrontPayments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LicenseAgreementPotentialAggregateMilestonePaymentsAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="MilestonePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_MilestonePayment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RevenueRecognitionTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_RevenueRecognitionTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="RevenueRecognitionLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_RevenueRecognitionLineItems" substitutionGroup="xbrli:item" />
<element name="SalesReservesAndAllowancesToCustomersPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_SalesReservesAndAllowancesToCustomersPercentage" substitutionGroup="xbrli:item" />
<element name="InternationalMarketsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_InternationalMarketsMember" substitutionGroup="xbrli:item" />
<element name="OtherActivitiesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_OtherActivitiesMember" substitutionGroup="xbrli:item" />
<element name="TotalReservesIncludedInSalesReservesAndAllowancesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_TotalReservesIncludedInSalesReservesAndAllowancesMember" substitutionGroup="xbrli:item" />
<element name="ChargebacksMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ChargebacksMember" substitutionGroup="xbrli:item" />
<element name="OtherSalesReservesAndAllowancesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_OtherSalesReservesAndAllowancesMember" substitutionGroup="xbrli:item" />
<element name="ReservesIncludedInAccountsReceivableNetMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ReservesIncludedInAccountsReceivableNetMember" substitutionGroup="xbrli:item" />
<element name="ReturnsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ReturnsMember" substitutionGroup="xbrli:item" />
<element name="MedicaidAndOtherGovernmentalAllowancesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_MedicaidAndOtherGovernmentalAllowancesMember" substitutionGroup="xbrli:item" />
<element name="RebatesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_RebatesMember" substitutionGroup="xbrli:item" />
<element name="ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ValuationAllowancesAndReservesForeignCurrencyTranslation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ValuationAllowancesAndReservesForeignCurrencyTranslation" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ValuationAllowancesAndReservesRelatedToPriorPeriodSales" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="InventoriesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_InventoriesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="InventoriesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_InventoriesLineItems" substitutionGroup="xbrli:item" />
<element name="ProductRightsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ProductRightsMember" substitutionGroup="xbrli:item" />
<element name="GenericPipelineProductsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_GenericPipelineProductsMember" substitutionGroup="xbrli:item" />
<element name="DiscontinuationOfBusinessAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_DiscontinuationOfBusinessAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="DiscontinuationOfBusinessDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_DiscontinuationOfBusinessDomain" substitutionGroup="xbrli:item" />
<element name="InprocessresearchandDevelopmenttoProductRightsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_InprocessresearchandDevelopmenttoProductRightsMember" substitutionGroup="xbrli:item" />
<element name="ActavisMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ActavisMember" substitutionGroup="xbrli:item" />
<element name="ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain" substitutionGroup="xbrli:item" />
<element name="OtherCountriesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_OtherCountriesMember" substitutionGroup="xbrli:item" />
<element name="MeasurementInputTerminalGrowthRateMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_MeasurementInputTerminalGrowthRateMember" substitutionGroup="xbrli:item" />
<element name="NorthAmericaAndMedisReportingUnitsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_NorthAmericaAndMedisReportingUnitsMember" substitutionGroup="xbrli:item" />
<element name="InternationalMarketsReportingUnitMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_InternationalMarketsReportingUnitMember" substitutionGroup="xbrli:item" />
<element name="TevasEuropeReportingUnitMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_TevasEuropeReportingUnitMember" substitutionGroup="xbrli:item" />
<element name="TevasApiReportingUnitMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_TevasApiReportingUnitMember" substitutionGroup="xbrli:item" />
<element name="ShortCreditAgreement2026Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ShortCreditAgreement2026Member" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentMaturityYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_DebtInstrumentMaturityYear" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2046Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2046Member" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2028OneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2028OneMember" substitutionGroup="xbrli:item" />
<element name="OtherDebentures2026Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_OtherDebentures2026Member" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2026OneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2026OneMember" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2025ThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2025ThreeMember" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2023OneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2023OneMember" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2036Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2036Member" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2025TwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2025TwoMember" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2024OneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2024OneMember" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2024Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2024Member" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2027Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2027Member" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2022OneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2022OneMember" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2023TwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2023TwoMember" substitutionGroup="xbrli:item" />
<element name="SustainabilityLinkedSeniorNotesDue2030Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SustainabilityLinkedSeniorNotesDue2030Member" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2028Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2028Member" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2022TwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2022TwoMember" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2022ThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2022ThreeMember" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2025Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2025Member" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2025OneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2025OneMember" substitutionGroup="xbrli:item" />
<element name="SustainabilityLinkedSeniorNotesDue2027Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SustainabilityLinkedSeniorNotesDue2027Member" substitutionGroup="xbrli:item" />
<element name="SustainabilityLinkedSeniorNotesDue2027TwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SustainabilityLinkedSeniorNotesDue2027TwoMember" substitutionGroup="xbrli:item" />
<element name="SustainabilityLinkedSeniorNotesDue2029Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SustainabilityLinkedSeniorNotesDue2029Member" substitutionGroup="xbrli:item" />
<element name="SeniorNotesRepaidAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_SeniorNotesRepaidAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SeniorNotesMaturityPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_SeniorNotesMaturityPercentage" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2030Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2030Member" substitutionGroup="xbrli:item" />
<element name="InterestRateIncreaseMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_InterestRateIncreaseMember" substitutionGroup="xbrli:item" />
<element name="OneTimePremiumPaymentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_OneTimePremiumPaymentMember" substitutionGroup="xbrli:item" />
<element name="LongTermDebtCurrencyPortionCHF" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_LongTermDebtCurrencyPortionCHF" substitutionGroup="xbrli:item" />
<element name="LongTermDebtCurrencyPortionEUR" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_LongTermDebtCurrencyPortionEUR" substitutionGroup="xbrli:item" />
<element name="LongTermDebtCurrencyPortionUSD" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_LongTermDebtCurrencyPortionUSD" substitutionGroup="xbrli:item" />
<element name="LineOfCreditExtentionPeriod" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_LineOfCreditExtentionPeriod" substitutionGroup="xbrli:item" />
<element name="LeverageRatio" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_LeverageRatio" substitutionGroup="xbrli:item" />
<element name="UnsecuredSyndicatedRevolvingCreditFacilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_UnsecuredSyndicatedRevolvingCreditFacilityMember" substitutionGroup="xbrli:item" />
<element name="AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_AgreementAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="AgreementDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_AgreementDomain" substitutionGroup="xbrli:item" />
<element name="TrancheAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_TrancheAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="TrancheDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_TrancheDomain" substitutionGroup="xbrli:item" />
<element name="SeniorNotesAndLoansMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SeniorNotesAndLoansMember" substitutionGroup="xbrli:item" />
<element name="NetRevenuesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_NetRevenuesMember" substitutionGroup="xbrli:item" />
<element name="FinancialExpensesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_FinancialExpensesMember" substitutionGroup="xbrli:item" />
<element name="SeniorNotesDue2023TwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SeniorNotesDue2023TwoMember" substitutionGroup="xbrli:item" />
<element name="SeniorNotesDue2022Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SeniorNotesDue2022Member" substitutionGroup="xbrli:item" />
<element name="SeniorNotesDue2021Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SeniorNotesDue2021Member" substitutionGroup="xbrli:item" />
<element name="RevenuesOtherThanUsd" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_RevenuesOtherThanUsd" substitutionGroup="xbrli:item" />
<element name="PreviouslyHedgeDebtRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_PreviouslyHedgeDebtRate" substitutionGroup="xbrli:item" />
<element name="NotionalAmountHedgeDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_NotionalAmountHedgeDebt" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CashReceivedOnSettlementOfPosition" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_CashReceivedOnSettlementOfPosition" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="InterestRateSwapLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_InterestRateSwapLoss" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RestructuringExpenseAndIncome" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_RestructuringExpenseAndIncome" substitutionGroup="xbrli:item" />
<element name="SettlementOnAccountOfProductLiabilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SettlementOnAccountOfProductLiabilityMember" substitutionGroup="xbrli:item" />
<element name="CommitmentAndContingenciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_CommitmentAndContingenciesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="CommitmentAndContingenciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_CommitmentAndContingenciesLineItems" substitutionGroup="xbrli:item" />
<element name="AnnualSalesOfCopaxone" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_AnnualSalesOfCopaxone" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AnnualSalesOfSensipar" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_AnnualSalesOfSensipar" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DamagesAssessment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_DamagesAssessment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LitigationSettlementAmountAwardedDistributionPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_LitigationSettlementAmountAwardedDistributionPeriod" substitutionGroup="xbrli:item" />
<element name="AnnualSalesOfNiaspan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_AnnualSalesOfNiaspan" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AnnualSalesOfActoplus" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_AnnualSalesOfActoplus" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LitigationSettlementAmountAwardedCashAmountDistributionPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_LitigationSettlementAmountAwardedCashAmountDistributionPeriod" substitutionGroup="xbrli:item" />
<element name="AnnualSalesAtTimeOfSettlement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_AnnualSalesAtTimeOfSettlement" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AnnualSalesOfActos" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_AnnualSalesOfActos" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LitigationSettlementAmountAwardedCashAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_LitigationSettlementAmountAwardedCashAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LitigationSettlementAmountDistributableinKind" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_LitigationSettlementAmountDistributableinKind" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AnnualSalesOfLamictal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_AnnualSalesOfLamictal" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AnnualSalesOfNarcan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_AnnualSalesOfNarcan" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LossContingenciesOnEnvironmentalLawsPenalty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_LossContingenciesOnEnvironmentalLawsPenalty" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AnnualSalesOfEffexor" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_AnnualSalesOfEffexor" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LossContingencyClaimsDismissedValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_LossContingencyClaimsDismissedValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PercentageOfPopulationOfSubdivisionsWillFormallyReleaseAsAPartOfSettlement" type="xbrli:pureItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_PercentageOfPopulationOfSubdivisionsWillFormallyReleaseAsAPartOfSettlement" substitutionGroup="xbrli:item" />
<element name="AnnualSalesAtTheTimeOfLaunchOfProduct" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_AnnualSalesAtTheTimeOfLaunchOfProduct" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LitigationAmountIncludingAlreadyPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_LitigationAmountIncludingAlreadyPaid" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LitigationSettlementTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_LitigationSettlementTerm" substitutionGroup="xbrli:item" />
<element name="ProductOfferingSettlementAtWholesaleAcquisitionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ProductOfferingSettlementAtWholesaleAcquisitionCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProductToBeSettledValuationTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ProductToBeSettledValuationTerm" substitutionGroup="xbrli:item" />
<element name="PercentageOfWholesaleAcquisitionCostValueInCashInLieuOfProductToBePaidUnderSettlementAgreement" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_PercentageOfWholesaleAcquisitionCostValueInCashInLieuOfProductToBePaidUnderSettlementAgreement" substitutionGroup="xbrli:item" />
<element name="LitigationAmountToBePaidToTribes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_LitigationAmountToBePaidToTribes" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="WholesaleAcquisitionCostValueInCashAmountInLieuOfProductToBePaidUnderSettlementAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_WholesaleAcquisitionCostValueInCashAmountInLieuOfProductToBePaidUnderSettlementAgreement" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="EosinophilicEsophagitisMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_EosinophilicEsophagitisMember" substitutionGroup="xbrli:item" />
<element name="AttorneyGeneralOfLouisanaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_AttorneyGeneralOfLouisanaMember" substitutionGroup="xbrli:item" />
<element name="AttorneyGeneralOfRhodeIslandMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_AttorneyGeneralOfRhodeIslandMember" substitutionGroup="xbrli:item" />
<element name="AttorneyGeneralOfFloridaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_AttorneyGeneralOfFloridaMember" substitutionGroup="xbrli:item" />
<element name="AttorneyGeneralOfWestVirginiaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_AttorneyGeneralOfWestVirginiaMember" substitutionGroup="xbrli:item" />
<element name="AndroGelRateAtOnePercentageMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_AndroGelRateAtOnePercentageMember" substitutionGroup="xbrli:item" />
<element name="AtripalaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_AtripalaMember" substitutionGroup="xbrli:item" />
<element name="TiruvadaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_TiruvadaMember" substitutionGroup="xbrli:item" />
<element name="VireadMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_VireadMember" substitutionGroup="xbrli:item" />
<element name="ColcysMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ColcysMember" substitutionGroup="xbrli:item" />
<element name="DefendantsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_DefendantsAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="DefendantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_DefendantsMember" substitutionGroup="xbrli:item" />
<element name="FourOtherDefendantsOtherThanTevaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_FourOtherDefendantsOtherThanTevaMember" substitutionGroup="xbrli:item" />
<element name="CompaniesShareMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_CompaniesShareMember" substitutionGroup="xbrli:item" />
<element name="OpioidLitigationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_OpioidLitigationMember" substitutionGroup="xbrli:item" />
<element name="NationwideSettlementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_NationwideSettlementMember" substitutionGroup="xbrli:item" />
<element name="StatesPoliticalSubdivisionsAndTribesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_StatesPoliticalSubdivisionsAndTribesMember" substitutionGroup="xbrli:item" />
<element name="IncomeTaxTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_IncomeTaxTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="TaxYear2008To2011Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_TaxYear2008To2011Member" substitutionGroup="xbrli:item" />
<element name="IncomeTaxLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_IncomeTaxLineItems" substitutionGroup="xbrli:item" />
<element name="ExpectedImpairmentOfIncomeTaxBenefit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ExpectedImpairmentOfIncomeTaxBenefit" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="EffectiveIncomeTaxReconciliationAmountInventoryWrittenOff" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_EffectiveIncomeTaxReconciliationAmountInventoryWrittenOff" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RestructuringAndImpairmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_RestructuringAndImpairmentAbstract" substitutionGroup="xbrli:item" />
<element name="RestructuringAndImpairmentCostsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_RestructuringAndImpairmentCostsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="RestructuringAndImpairmentCostsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_RestructuringAndImpairmentCostsLineItems" substitutionGroup="xbrli:item" />
<element name="LegalSettlementsLossContingenciesImpairmentsOtherExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ImpairmentAndRestructuring" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ImpairmentAndRestructuring" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ExitAndDisposalAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ExitAndDisposalAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="ExitAndDisposalDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ExitAndDisposalDomain" substitutionGroup="xbrli:item" />
<element name="OtherExitAndDisposalMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_OtherExitAndDisposalMember" substitutionGroup="xbrli:item" />
<element name="EmployeeTerminationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_EmployeeTerminationMember" substitutionGroup="xbrli:item" />
<element name="UtilizationAndOther" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_UtilizationAndOther" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RestructuringAccrualProvision" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_RestructuringAccrualProvision" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OtherOperatingIncomeExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_OtherOperatingIncomeExpense" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="EuropeSegmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_EuropeSegmentMember" substitutionGroup="xbrli:item" />
<element name="NorthAmericaSegmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_NorthAmericaSegmentMember" substitutionGroup="xbrli:item" />
<element name="AmountsAllocatedToSegmentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_AmountsAllocatedToSegmentsAbstract" substitutionGroup="xbrli:item" />
<element name="AmountsNotAllocatedToSegmentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_AmountsNotAllocatedToSegmentsAbstract" substitutionGroup="xbrli:item" />
<element name="OtherUnallocatedAmounts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_OtherUnallocatedAmounts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="SegmentsAndOtherActivitiesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SegmentsAndOtherActivitiesMember" substitutionGroup="xbrli:item" />
<element name="RevenueTypeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_RevenueTypeAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="RevenueTypeDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_RevenueTypeDomain" substitutionGroup="xbrli:item" />
<element name="BendekaAndTreandaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_BendekaAndTreandaMember" substitutionGroup="xbrli:item" />
<element name="COPAXONEMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_COPAXONEMember" substitutionGroup="xbrli:item" />
<element name="AndaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_AndaMember" substitutionGroup="xbrli:item" />
<element name="OtherProductsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_OtherProductsMember" substitutionGroup="xbrli:item" />
<element name="RespiratoryProductMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_RespiratoryProductMember" substitutionGroup="xbrli:item" />
<element name="AustedoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_AustedoMember" substitutionGroup="xbrli:item" />
<element name="GenericsMediciansMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_GenericsMediciansMember" substitutionGroup="xbrli:item" />
<element name="AjovyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_AjovyMember" substitutionGroup="xbrli:item" />
<element name="OtherRestrictedCashMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_OtherRestrictedCashMember" substitutionGroup="xbrli:item" />
<element name="OptionsAndForwardContractsDerivativeLiabilitiesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_OptionsAndForwardContractsDerivativeLiabilitiesMember" substitutionGroup="xbrli:item" />
<element name="MeasurementInputProbabilityOfSuccessMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_MeasurementInputProbabilityOfSuccessMember" substitutionGroup="xbrli:item" />
<element name="NoveTideAcquisitionMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_NoveTideAcquisitionMember" substitutionGroup="xbrli:item" />
<element name="BifurcatedEmbeddedDerivatives" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_BifurcatedEmbeddedDerivatives" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ActavisGenericsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ActavisGenericsMember" substitutionGroup="xbrli:item" />
<element name="EagleTransactionMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_EagleTransactionMember" substitutionGroup="xbrli:item" />
<element name="SeniornotesandconvertibleseniordebenturesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SeniornotesandconvertibleseniordebenturesMember" substitutionGroup="xbrli:item" />
<element name="SeniorNotesAndSustainabilityLinkedSeniorNotesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SeniorNotesAndSustainabilityLinkedSeniorNotesMember" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>teva-20220630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 27-July-2022 [08:44:53] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#ConsolidatedBalanceSheets" roleURI="http://www.tevapharm.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#ConsolidatedStatementsOfIncomeLoss" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#ConsolidatedStatementsOfComprehensiveIncomeLoss" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#InventoriesSummaryOfInventoriesDetail" roleURI="http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail" roleURI="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail" roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail" />
<calculationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSeniorDebt" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AssetImpairmentCharges" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DepreciationAndAmortization" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapital" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapital" use="optional" order="9" weight="-1" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_DeferredIncomeTaxesNetAndUncertainTaxPositions" xlink:label="loc_TEVA_DeferredIncomeTaxesNetAndUncertainTaxPositions" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_TEVA_DeferredIncomeTaxesNetAndUncertainTaxPositions" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ProfitFromSaleOfLongLivedAssetsAndInvestment" xlink:label="loc_TEVA_ProfitFromSaleOfLongLivedAssetsAndInvestment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_TEVA_ProfitFromSaleOfLongLivedAssetsAndInvestment" use="optional" order="11" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" xlink:label="loc_TEVA_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_TEVA_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="18" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets" xlink:label="loc_TEVA_PaymentToAcquireMarketableSecuritiesAndOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_TEVA_PaymentToAcquireMarketableSecuritiesAndOtherAssets" use="optional" order="20" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" use="optional" order="21" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" use="optional" order="22" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" use="optional" order="24" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_SellingAndMarketingExpense" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="6" weight="-1" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_IntangibleAssetsImpairments" xlink:label="loc_TEVA_IntangibleAssetsImpairments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_TEVA_IntangibleAssetsImpairments" use="optional" order="7" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_GoodwillImpairmentLoss" use="optional" order="8" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ImpairmentsRestructuringAndOthers" xlink:label="loc_TEVA_ImpairmentsRestructuringAndOthers" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_TEVA_ImpairmentsRestructuringAndOthers" use="optional" order="10" weight="-1" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LegalSettlementsAndLossContingencies" xlink:label="loc_TEVA_LegalSettlementsAndLossContingencies" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_TEVA_LegalSettlementsAndLossContingencies" use="optional" order="11" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_GrossProfit" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold" use="optional" order="14" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" use="optional" order="16" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" use="optional" order="18" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DebtCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SalesReservesAndAllowances" xlink:label="loc_TEVA_SalesReservesAndAllowances" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_TEVA_SalesReservesAndAllowances" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AccruedExpenses" xlink:label="loc_TEVA_AccruedExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_TEVA_AccruedExpenses" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesNoncurrent" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesAndLoans" xlink:label="loc_us-gaap_LongTermNotesAndLoans" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="loc_us-gaap_LongTermNotesAndLoans" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_TreasuryStockValue" use="optional" order="20" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_MinorityInterest" use="optional" order="21" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_InventoryNet" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" use="optional" order="26" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_OtherAssetsCurrent" use="optional" order="27" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" use="optional" order="28" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet" use="optional" order="29" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="31" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet" use="optional" order="32" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_Goodwill" use="optional" order="33" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" order="34" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventoryInTransit" xlink:label="loc_us-gaap_OtherInventoryInTransit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_OtherInventoryInTransit" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" use="optional" order="2" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail">
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ImpairmentAndRestructuring" xlink:label="loc_TEVA_ImpairmentAndRestructuring" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TEVA_ImpairmentAndRestructuring" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TEVA_ImpairmentAndRestructuring" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TEVA_ImpairmentAndRestructuring" xlink:to="loc_us-gaap_RestructuringCharges" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses" xlink:label="loc_TEVA_LegalSettlementsLossContingenciesImpairmentsOtherExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TEVA_ImpairmentAndRestructuring" xlink:to="loc_TEVA_LegalSettlementsLossContingenciesImpairmentsOtherExpenses" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_UnrealizedGainLossOnDerivativeNetOfTax" xlink:label="loc_TEVA_UnrealizedGainLossOnDerivativeNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="loc_TEVA_UnrealizedGainLossOnDerivativeNetOfTax" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" use="optional" order="7" weight="-1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>teva-20220630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 27-July-2022 [08:44:53] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#ConsolidatedBalanceSheets" roleURI="http://www.tevapharm.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#ConsolidatedStatementsOfIncomeLoss" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#ConsolidatedStatementsOfComprehensiveIncomeLoss" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#ConsolidatedStatementsOfChangesInEquity" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#ConsolidatedStatementsOfChangesInEquityParenthetical" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#CertainTransactions" roleURI="http://www.tevapharm.com/role/CertainTransactions" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#RevenueFromContractsWithCustomers" roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomers" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#Inventories" roleURI="http://www.tevapharm.com/role/Inventories" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#IdentifiableIntangibleAssets" roleURI="http://www.tevapharm.com/role/IdentifiableIntangibleAssets" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#Goodwill" roleURI="http://www.tevapharm.com/role/Goodwill" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#DebtObligations" roleURI="http://www.tevapharm.com/role/DebtObligations" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#DerivativeInstrumentsAndHedgingActivities" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#LegalSettlementsAndLossContingencies" roleURI="http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#CommitmentsAndContingencies" roleURI="http://www.tevapharm.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#IncomeTaxes" roleURI="http://www.tevapharm.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#OtherAssetsImpairmentsRestructuringAndOtherItems" roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#EarningsLossPerShare" roleURI="http://www.tevapharm.com/role/EarningsLossPerShare" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#AccumulatedOtherComprehensiveIncomeLoss" roleURI="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLoss" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#Segments" roleURI="http://www.tevapharm.com/role/Segments" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#FairValueMeasurement" roleURI="http://www.tevapharm.com/role/FairValueMeasurement" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#BasisOfPresentationPolicies" roleURI="http://www.tevapharm.com/role/BasisOfPresentationPolicies" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#CertainTransactionsTables" roleURI="http://www.tevapharm.com/role/CertainTransactionsTables" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#RevenueFromContractsWithCustomersTables" roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#InventoriesTables" roleURI="http://www.tevapharm.com/role/InventoriesTables" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#IdentifiableIntangibleAssetsTables" roleURI="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#GoodwillTables" roleURI="http://www.tevapharm.com/role/GoodwillTables" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#DebtObligationsTables" roleURI="http://www.tevapharm.com/role/DebtObligationsTables" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#DerivativeInstrumentsAndHedgingActivitiesTables" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#OtherAssetsImpairmentsRestructuringAndOtherItemsTables" roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#AccumulatedOtherComprehensiveIncomeLossTables" roleURI="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossTables" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#SegmentsTables" roleURI="http://www.tevapharm.com/role/SegmentsTables" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#FairValueMeasurementTables" roleURI="http://www.tevapharm.com/role/FairValueMeasurementTables" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#CertainTransactionsOtherTransactionsAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#RevenueFromContractsWithCustomersAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail" roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#InventoriesSummaryOfInventoriesDetail" roleURI="http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail" roleURI="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#IdentifiableIntangibleAssetsAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail" roleURI="http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail" roleURI="http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#GoodwillAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#DebtObligationsScheduleOfShortTermDebtDetail" roleURI="http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#DebtObligationsScheduleOfSeniorNotesAndLoansDetail" roleURI="http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" roleURI="http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#DebtObligationsAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#LegalSettlementsAndLossContingenciesAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#IncomeTaxesAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail" roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail" roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail" roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#EarningsLossPerShareAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#AccumulatedOtherComprehensiveIncomeLossDetail" roleURI="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#AccumulatedOtherComprehensiveIncomeLossParentheticalDetail" roleURI="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#SegmentsSummaryOfSegmentProfitDetail" roleURI="http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail" roleURI="http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail" roleURI="http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#SegmentsAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" roleURI="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#FairValueMeasurementAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail" roleURI="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail" roleURI="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail" roleURI="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#CoverPage" roleURI="http://www.tevapharm.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail" roleURI="http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#BasisOfPresentation" roleURI="http://www.tevapharm.com/role/BasisOfPresentation" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_33" xlink:to="loc_us-gaap_AssetsAbstract_27" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_AssetsCurrentAbstract_28" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_47" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_47" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_46" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_OtherAssetsCurrent_46" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_45" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_45" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_43" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_43" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_44" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_InventoryNet_44" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_48" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_AssetsCurrent_48" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_42" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_42" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_39" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_39" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_38" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_38" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_37" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_37" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_36" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_36" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_41" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_Assets_41" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_40" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_Goodwill_40" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_389976" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_389976" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_33" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_50" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_CommitmentsAndContingencies_50" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_52" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_MinorityInterest_52" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_31" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_57" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_57" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_60" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_60" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_62" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_us-gaap_LiabilitiesCurrent_62" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_58" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_58" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_55" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_us-gaap_DebtCurrent_55" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AccruedExpenses" xlink:label="loc_teva_AccruedExpenses_59" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_teva_AccruedExpenses_59" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SalesReservesAndAllowances" xlink:label="loc_teva_SalesReservesAndAllowances_56" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_teva_SalesReservesAndAllowances_56" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_51" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_Liabilities_51" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_35" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_StockholdersEquityAbstract_35" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_68" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_CommonStockValue_68" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_71" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_71" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_70" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_70" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_69" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_AdditionalPaidInCapital_69" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_73" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_StockholdersEquity_73" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_72" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_TreasuryStockValue_72" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_63" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_63" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_66" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_66" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_389981" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_389981" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesAndLoans" xlink:label="loc_us-gaap_LongTermNotesAndLoans_65" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" xlink:to="loc_us-gaap_LongTermNotesAndLoans_65" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_64" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_64" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_53" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_53" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_54" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_54" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_33" xlink:to="loc_us-gaap_StatementTable_34" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_34" xlink:to="loc_dei_LegalEntityAxis_29" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_49" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_29" xlink:to="loc_dei_EntityDomain_49" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_49_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_29" xlink:to="loc_dei_EntityDomain_49_default" use="optional" order="47" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_77" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_688255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_688255" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_86" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77" xlink:to="loc_us-gaap_TreasuryStockShares_86" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_78" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_77" xlink:to="loc_us-gaap_StatementTable_78" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_76" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_78" xlink:to="loc_dei_LegalEntityAxis_76" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_79" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_76" xlink:to="loc_dei_EntityDomain_79" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_79_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_76" xlink:to="loc_dei_EntityDomain_79_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_85" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77" xlink:to="loc_us-gaap_CommonStockSharesIssued_85" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_84" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_84" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_83" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_83" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_91" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_89" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_EarningsPerShareAbstract_89" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_94" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_89" xlink:to="loc_us-gaap_EarningsPerShareBasic_94" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_95" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_89" xlink:to="loc_us-gaap_EarningsPerShareDiluted_95" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_98" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_98" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_93" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_93" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_93" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_118" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_93" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_119" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ImpairmentsRestructuringAndOthers" xlink:label="loc_teva_ImpairmentsRestructuringAndOthers_408527" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_teva_ImpairmentsRestructuringAndOthers_408527" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_99" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_GrossProfit_99" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_OperatingIncomeLoss_108" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_102" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_100" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_111" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_IntangibleAssetsImpairments" xlink:label="loc_teva_IntangibleAssetsImpairments_103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_teva_IntangibleAssetsImpairments_103" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_112" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_NetIncomeLoss_115" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_107" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_114" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_109" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_104" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_92" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_StatementTable_92" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_90" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_92" xlink:to="loc_dei_LegalEntityAxis_90" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_96" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_90" xlink:to="loc_dei_EntityDomain_96" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_96_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_90" xlink:to="loc_dei_EntityDomain_96_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_ProfitLoss_113" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LegalSettlementsAndLossContingencies" xlink:label="loc_teva_LegalSettlementsAndLossContingencies_412170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_teva_LegalSettlementsAndLossContingencies_412170" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_97" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_97" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_SellingAndMarketingExpense_101" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_110" use="optional" order="29" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_124" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_125" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_StatementTable_125" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_125" xlink:to="loc_dei_LegalEntityAxis_122" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_122" xlink:to="loc_dei_EntityDomain_126" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_126_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_122" xlink:to="loc_dei_EntityDomain_126_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_135" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_131" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_133" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_123" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_123" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_UnrealizedGainLossOnDerivativeNetOfTax" xlink:label="loc_teva_UnrealizedGainLossOnDerivativeNetOfTax_128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_123" xlink:to="loc_teva_UnrealizedGainLossOnDerivativeNetOfTax_128" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_123" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_127" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax_720057" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_123" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax_720057" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_ProfitLoss_132" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_134" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_141" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_152" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_152" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_155" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_SharesIssued_154" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_162" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_162" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_StatementTable_142" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_142" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_140" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_140" xlink:to="loc_us-gaap_EquityComponentDomain_138" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_138_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_140" xlink:to="loc_us-gaap_EquityComponentDomain_138_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_147" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_150" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_NoncontrollingInterestMember_150" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_145" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_143" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_CommonStockMember_143" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_RetainedEarningsMember_146" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_ParentMember_149" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_TreasuryStockMember_148" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_158" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_720066" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_ProfitLoss_720066" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_760310" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_760310" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_176" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_177" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_176" xlink:to="loc_us-gaap_StatementTable_177" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_177" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_175" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_171" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_175" xlink:to="loc_us-gaap_EquityComponentDomain_171" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_171_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_175" xlink:to="loc_us-gaap_EquityComponentDomain_171_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_178" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_171" xlink:to="loc_us-gaap_CommonStockMember_178" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_472726" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_177" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_472726" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_472727" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_472726" xlink:to="loc_us-gaap_TypeOfAdoptionMember_472727" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_472727_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_472726" xlink:to="loc_us-gaap_TypeOfAdoptionMember_472727_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_173" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_177" xlink:to="loc_srt_RangeAxis_173" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_173" xlink:to="loc_srt_RangeMember_174" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_174_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_173" xlink:to="loc_srt_RangeMember_174_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_180" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_174" xlink:to="loc_srt_MaximumMember_180" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_176" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_181" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_190" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_231" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_231" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_191" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_StatementTable_191" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_186" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_191" xlink:to="loc_dei_LegalEntityAxis_186" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_186" xlink:to="loc_dei_EntityDomain_210" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_210_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_186" xlink:to="loc_dei_EntityDomain_210_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_189" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_189" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_DeferredIncomeTaxesNetAndUncertainTaxPositions" xlink:label="loc_teva_DeferredIncomeTaxesNetAndUncertainTaxPositions_196" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_teva_DeferredIncomeTaxesNetAndUncertainTaxPositions_196" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ProfitFromSaleOfLongLivedAssetsAndInvestment" xlink:label="loc_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment_200" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment_200" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_194" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_us-gaap_DepreciationAndAmortization_194" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_us-gaap_AssetImpairmentCharges_193" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapital" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital_195" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapital_195" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_515089" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_515089" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_412174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_us-gaap_ShareBasedCompensation_412174" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_189" xlink:to="loc_us-gaap_ProfitLoss_229" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_189" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_230" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_226" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_555980" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_555980" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_224" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_1260619" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_1260619" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets" xlink:label="loc_teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets_225" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets_225" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_228" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_228" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" xlink:label="loc_teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables_222" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables_222" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_1260620" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_1260620" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_233" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_232" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_232" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1260697" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1260697" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1260699" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1260697" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1260699" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1260700" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1260697" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1260700" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_221" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_221" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_214" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_1260621" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_1260621" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSeniorDebt" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_1559573" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_1559573" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_192" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" xlink:label="loc_teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables_235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_192" xlink:to="loc_teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables_235" use="optional" order="37" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CertainTransactions">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1696" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1697" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1696" xlink:to="loc_us-gaap_StatementTable_1697" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1695" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1697" xlink:to="loc_dei_LegalEntityAxis_1695" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1698" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1695" xlink:to="loc_dei_EntityDomain_1698" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1698_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1695" xlink:to="loc_dei_EntityDomain_1698_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_CertainTransactionsDisclosureTextBlock" xlink:label="loc_teva_CertainTransactionsDisclosureTextBlock_1699" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1696" xlink:to="loc_teva_CertainTransactionsDisclosureTextBlock_1699" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/RevenueFromContractsWithCustomers">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1797" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_1800" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1797" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_1800" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1798" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1797" xlink:to="loc_us-gaap_StatementTable_1798" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1798" xlink:to="loc_dei_LegalEntityAxis_1796" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1799" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1796" xlink:to="loc_dei_EntityDomain_1799" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1799_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1796" xlink:to="loc_dei_EntityDomain_1799_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/Inventories">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1741" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1742" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1741" xlink:to="loc_us-gaap_StatementTable_1742" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1740" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1742" xlink:to="loc_dei_LegalEntityAxis_1740" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1743" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1740" xlink:to="loc_dei_EntityDomain_1743" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1743_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1740" xlink:to="loc_dei_EntityDomain_1743_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_1744" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1741" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_1744" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IdentifiableIntangibleAssets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1783" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_1786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1783" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_1786" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1783" xlink:to="loc_us-gaap_StatementTable_1784" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1782" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1784" xlink:to="loc_dei_LegalEntityAxis_1782" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1785" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1782" xlink:to="loc_dei_EntityDomain_1785" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1785_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1782" xlink:to="loc_dei_EntityDomain_1785_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/Goodwill">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1769" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1770" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1769" xlink:to="loc_us-gaap_StatementTable_1770" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1768" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1770" xlink:to="loc_dei_LegalEntityAxis_1768" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1771" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1768" xlink:to="loc_dei_EntityDomain_1771" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1771_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1768" xlink:to="loc_dei_EntityDomain_1771_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillDisclosureTextBlock_1772" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1769" xlink:to="loc_us-gaap_GoodwillDisclosureTextBlock_1772" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1826" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1826" xlink:to="loc_us-gaap_StatementTable_1827" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1825" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1827" xlink:to="loc_dei_LegalEntityAxis_1825" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1828" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1825" xlink:to="loc_dei_EntityDomain_1828" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1828_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1825" xlink:to="loc_dei_EntityDomain_1828_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_1829" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1826" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_1829" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1903" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1904" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1903" xlink:to="loc_us-gaap_StatementTable_1904" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1902" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1904" xlink:to="loc_dei_LegalEntityAxis_1902" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1905" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1902" xlink:to="loc_dei_EntityDomain_1905" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1905_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1902" xlink:to="loc_dei_EntityDomain_1905_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1906" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1903" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1906" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1949" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1950" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1949" xlink:to="loc_us-gaap_StatementTable_1950" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1948" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1950" xlink:to="loc_dei_LegalEntityAxis_1948" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1951" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1948" xlink:to="loc_dei_EntityDomain_1951" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1951_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1948" xlink:to="loc_dei_EntityDomain_1951_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_1952" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1949" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_1952" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1856" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1857" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1856" xlink:to="loc_us-gaap_StatementTable_1857" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1855" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1857" xlink:to="loc_dei_LegalEntityAxis_1855" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1858" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1855" xlink:to="loc_dei_EntityDomain_1858" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1858_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1855" xlink:to="loc_dei_EntityDomain_1858_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1859" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1856" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1859" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1884" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1885" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1884" xlink:to="loc_us-gaap_StatementTable_1885" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1883" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1885" xlink:to="loc_dei_LegalEntityAxis_1883" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1886" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1883" xlink:to="loc_dei_EntityDomain_1886" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1886_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1883" xlink:to="loc_dei_EntityDomain_1886_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1887" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1884" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1887" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1933" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1934" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1933" xlink:to="loc_us-gaap_StatementTable_1934" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1932" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1934" xlink:to="loc_dei_LegalEntityAxis_1932" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1935" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1932" xlink:to="loc_dei_EntityDomain_1935" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1935_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1932" xlink:to="loc_dei_EntityDomain_1935_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OtherExpensesTextBlock" xlink:label="loc_teva_OtherExpensesTextBlock_1936" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1933" xlink:to="loc_teva_OtherExpensesTextBlock_1936" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/EarningsLossPerShare">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1974" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1977" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1974" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_1977" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1975" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1974" xlink:to="loc_us-gaap_StatementTable_1975" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1973" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1975" xlink:to="loc_dei_LegalEntityAxis_1973" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1976" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1973" xlink:to="loc_dei_EntityDomain_1976" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1976_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1973" xlink:to="loc_dei_EntityDomain_1976_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_390015" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_390022" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_390015" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_390022" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_390014" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_390015" xlink:to="loc_us-gaap_StatementTable_390014" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_390018" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_390014" xlink:to="loc_dei_LegalEntityAxis_390018" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_390019" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_390018" xlink:to="loc_dei_EntityDomain_390019" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_390019_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_390018" xlink:to="loc_dei_EntityDomain_390019_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/Segments">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1956" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1957" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1956" xlink:to="loc_us-gaap_StatementTable_1957" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1955" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1957" xlink:to="loc_dei_LegalEntityAxis_1955" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1958" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1955" xlink:to="loc_dei_EntityDomain_1958" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1958_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1955" xlink:to="loc_dei_EntityDomain_1958_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_1959" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1956" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_1959" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurement">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1710" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1711" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1710" xlink:to="loc_us-gaap_StatementTable_1711" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1709" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1711" xlink:to="loc_dei_LegalEntityAxis_1709" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1712" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1709" xlink:to="loc_dei_EntityDomain_1712" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1712_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1709" xlink:to="loc_dei_EntityDomain_1712_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_1713" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1710" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_1713" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/BasisOfPresentationPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1661" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="loc_teva_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_514943" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_teva_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_514943" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1665" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1665" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1662" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_StatementTable_1662" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1660" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1662" xlink:to="loc_dei_LegalEntityAxis_1660" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1663" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1660" xlink:to="loc_dei_EntityDomain_1663" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1663_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1660" xlink:to="loc_dei_EntityDomain_1663_default" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CertainTransactionsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1703" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" xlink:label="loc_teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock_1706" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1703" xlink:to="loc_teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock_1706" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1704" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1703" xlink:to="loc_us-gaap_StatementTable_1704" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1702" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1704" xlink:to="loc_dei_LegalEntityAxis_1702" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1705" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1702" xlink:to="loc_dei_EntityDomain_1705" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1705_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1702" xlink:to="loc_dei_EntityDomain_1705_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1804" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SalesReservesAndAllowancesCurrentTableTextBlock" xlink:label="loc_teva_SalesReservesAndAllowancesCurrentTableTextBlock_1808" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1804" xlink:to="loc_teva_SalesReservesAndAllowancesCurrentTableTextBlock_1808" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_1807" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1804" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_1807" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1805" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1804" xlink:to="loc_us-gaap_StatementTable_1805" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1803" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1805" xlink:to="loc_dei_LegalEntityAxis_1803" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1806" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1803" xlink:to="loc_dei_EntityDomain_1806" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1806_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1803" xlink:to="loc_dei_EntityDomain_1806_default" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/InventoriesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1748" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1751" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1748" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1751" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1749" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1748" xlink:to="loc_us-gaap_StatementTable_1749" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1747" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1749" xlink:to="loc_dei_LegalEntityAxis_1747" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1750" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1747" xlink:to="loc_dei_EntityDomain_1750" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1750_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1747" xlink:to="loc_dei_EntityDomain_1750_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1790" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1793" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1790" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1793" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1791" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1790" xlink:to="loc_us-gaap_StatementTable_1791" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1789" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1791" xlink:to="loc_dei_LegalEntityAxis_1789" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1792" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1789" xlink:to="loc_dei_EntityDomain_1792" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1792_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1789" xlink:to="loc_dei_EntityDomain_1792_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/GoodwillTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1776" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_1779" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1776" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_1779" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1777" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1776" xlink:to="loc_us-gaap_StatementTable_1777" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1775" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1777" xlink:to="loc_dei_LegalEntityAxis_1775" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1778" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1775" xlink:to="loc_dei_EntityDomain_1778" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1778_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1775" xlink:to="loc_dei_EntityDomain_1778_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligationsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1833" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_556360" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1833" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_556360" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTextBlock_1836" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1833" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTextBlock_1836" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1833" xlink:to="loc_us-gaap_StatementTable_1834" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1832" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1834" xlink:to="loc_dei_LegalEntityAxis_1832" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1835" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1832" xlink:to="loc_dei_EntityDomain_1835" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1835_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1832" xlink:to="loc_dei_EntityDomain_1835_default" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1910" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1911" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1910" xlink:to="loc_us-gaap_StatementTable_1911" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1911" xlink:to="loc_dei_LegalEntityAxis_1909" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1912" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1909" xlink:to="loc_dei_EntityDomain_1912" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1912_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1909" xlink:to="loc_dei_EntityDomain_1912_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_1914" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1910" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_1914" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_390224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1910" xlink:to="loc_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_390224" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1940" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ScheduleOfRestructuringChargesTableTextBlock" xlink:label="loc_teva_ScheduleOfRestructuringChargesTableTextBlock_1944" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1940" xlink:to="loc_teva_ScheduleOfRestructuringChargesTableTextBlock_1944" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_1945" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1940" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_1945" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_1943" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1940" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_1943" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1941" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1940" xlink:to="loc_us-gaap_StatementTable_1941" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1939" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1941" xlink:to="loc_dei_LegalEntityAxis_1939" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1942" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1939" xlink:to="loc_dei_EntityDomain_1942" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1942_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1939" xlink:to="loc_dei_EntityDomain_1942_default" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_390179" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_390181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_390179" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_390181" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_390175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_390179" xlink:to="loc_us-gaap_StatementTable_390175" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_390177" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_390175" xlink:to="loc_dei_LegalEntityAxis_390177" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_390178" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_390177" xlink:to="loc_dei_EntityDomain_390178" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_390178_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_390177" xlink:to="loc_dei_EntityDomain_390178_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SegmentsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1963" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_1966" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1963" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_1966" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1964" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1963" xlink:to="loc_us-gaap_StatementTable_1964" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1962" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1964" xlink:to="loc_dei_LegalEntityAxis_1962" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1965" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1962" xlink:to="loc_dei_EntityDomain_1965" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1965_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1962" xlink:to="loc_dei_EntityDomain_1965_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock" xlink:label="loc_teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock_1967" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1963" xlink:to="loc_teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock_1967" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_1968" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1963" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_1968" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurementTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1717" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1721" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1717" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1721" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1718" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1717" xlink:to="loc_us-gaap_StatementTable_1718" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1716" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1718" xlink:to="loc_dei_LegalEntityAxis_1716" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1719" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1716" xlink:to="loc_dei_EntityDomain_1719" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1719_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1716" xlink:to="loc_dei_EntityDomain_1719_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1720" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1717" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1720" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1722" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1717" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1722" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionsLineItems" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ResearchAndDevelopmentCosts" xlink:label="loc_teva_ResearchAndDevelopmentCosts_335" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_teva_ResearchAndDevelopmentCosts_335" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_CollaborativeAgreementMilestonePayments" xlink:label="loc_teva_CollaborativeAgreementMilestonePayments_327" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_teva_CollaborativeAgreementMilestonePayments_327" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionsTable" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_303" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_srt_CounterpartyNameAxis_303" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_311" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_303" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_311" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_311_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_303" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_311_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_302" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_302" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_302" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_302" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AlderMember" xlink:label="loc_teva_AlderMember_313" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" xlink:to="loc_teva_AlderMember_313" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AlvotechMember" xlink:label="loc_teva_AlvotechMember_758265" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" xlink:to="loc_teva_AlvotechMember_758265" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OtsukaMember" xlink:label="loc_teva_OtsukaMember_314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" xlink:to="loc_teva_OtsukaMember_314" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RegeneronMember" xlink:label="loc_teva_RegeneronMember_318" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" xlink:to="loc_teva_RegeneronMember_318" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ModagMember" xlink:label="loc_teva_ModagMember_1241734" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" xlink:to="loc_teva_ModagMember_1241734" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_MedincellMember" xlink:label="loc_teva_MedincellMember_1241907" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" xlink:to="loc_teva_MedincellMember_1241907" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_TakedaMember" xlink:label="loc_teva_TakedaMember_1559574" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" xlink:to="loc_teva_TakedaMember_1559574" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_310" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_310" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_309" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_310" xlink:to="loc_us-gaap_RelatedPartyDomain_309" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_309_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_310" xlink:to="loc_us-gaap_RelatedPartyDomain_309_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_758266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_758266" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_758267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_758266" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_758267" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_758267_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_758266" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_758267_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_758268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_758267" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_758268" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_765341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_srt_RangeAxis_765341" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_765342" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_765341" xlink:to="loc_srt_RangeMember_765342" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_765342_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_765341" xlink:to="loc_srt_RangeMember_765342_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_304" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_dei_LegalEntityAxis_304" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_304" xlink:to="loc_dei_EntityDomain_319" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_319_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_304" xlink:to="loc_dei_EntityDomain_319_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1241737" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1241737" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1241738" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1241737" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1241738" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1241738_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1241737" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1241738_default" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_307" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_srt_ProductOrServiceAxis_307" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_308" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_307" xlink:to="loc_srt_ProductsAndServicesDomain_308" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_308_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_307" xlink:to="loc_srt_ProductsAndServicesDomain_308_default" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis_758271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_us-gaap_LeaseContractualTermAxis_758271" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_758272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_758271" xlink:to="loc_us-gaap_LeaseContractualTermDomain_758272" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_758272_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_758271" xlink:to="loc_us-gaap_LeaseContractualTermDomain_758272_default" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_UpfrontPayments" xlink:label="loc_teva_UpfrontPayments_326" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_teva_UpfrontPayments_326" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount" xlink:label="loc_teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount_1241741" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount_1241741" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_MilestonePayment" xlink:label="loc_teva_MilestonePayment_572506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_teva_MilestonePayment_572506" use="optional" order="41" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RevenueRecognitionLineItems" xlink:label="loc_teva_RevenueRecognitionLineItems_607" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SalesReservesAndAllowancesToCustomersPercentage" xlink:label="loc_teva_SalesReservesAndAllowancesToCustomersPercentage_616" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RevenueRecognitionLineItems_607" xlink:to="loc_teva_SalesReservesAndAllowancesToCustomersPercentage_616" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RevenueRecognitionTable" xlink:label="loc_teva_RevenueRecognitionTable_608" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_teva_RevenueRecognitionLineItems_607" xlink:to="loc_teva_RevenueRecognitionTable_608" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_604" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_RevenueRecognitionTable_608" xlink:to="loc_dei_LegalEntityAxis_604" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_611" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_604" xlink:to="loc_dei_EntityDomain_611" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_611_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_604" xlink:to="loc_dei_EntityDomain_611_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_610" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_RevenueRecognitionTable_608" xlink:to="loc_srt_StatementGeographicalAxis_610" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_609" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_610" xlink:to="loc_srt_SegmentGeographicalDomain_609" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_609_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_610" xlink:to="loc_srt_SegmentGeographicalDomain_609_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_617" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_609" xlink:to="loc_country_US_617" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_620" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_621" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_620" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_621" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_627" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_621" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_627" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_625" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_627" xlink:to="loc_us-gaap_SegmentDomain_625" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_625_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_627" xlink:to="loc_us-gaap_SegmentDomain_625_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_InternationalMarketsMember" xlink:label="loc_teva_InternationalMarketsMember_635" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_625" xlink:to="loc_teva_InternationalMarketsMember_635" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OtherActivitiesMember" xlink:label="loc_teva_OtherActivitiesMember_636" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_625" xlink:to="loc_teva_OtherActivitiesMember_636" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_623" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_621" xlink:to="loc_srt_ProductOrServiceAxis_623" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_624" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_623" xlink:to="loc_srt_ProductsAndServicesDomain_624" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_624_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_623" xlink:to="loc_srt_ProductsAndServicesDomain_624_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DistributionServiceMember" xlink:label="loc_us-gaap_DistributionServiceMember_633" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_624" xlink:to="loc_us-gaap_DistributionServiceMember_633" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_634" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_624" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_634" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_632" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_624" xlink:to="loc_us-gaap_LicenseMember_632" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_631" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_624" xlink:to="loc_us-gaap_ProductMember_631" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_622" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_621" xlink:to="loc_dei_LegalEntityAxis_622" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_630" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_622" xlink:to="loc_dei_EntityDomain_630" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_630_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_622" xlink:to="loc_dei_EntityDomain_630_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_628" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_621" xlink:to="loc_srt_StatementGeographicalAxis_628" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_626" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_628" xlink:to="loc_srt_SegmentGeographicalDomain_626" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_626_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_628" xlink:to="loc_srt_SegmentGeographicalDomain_626_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_638" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_626" xlink:to="loc_srt_EuropeMember_638" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NorthAmericaMember" xlink:label="loc_srt_NorthAmericaMember_637" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_626" xlink:to="loc_srt_NorthAmericaMember_637" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_629" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_620" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_629" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail">
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RevenueRecognitionLineItems" xlink:label="loc_teva_RevenueRecognitionLineItems_642" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_647" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RevenueRecognitionLineItems_642" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_647" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RevenueRecognitionTable" xlink:label="loc_teva_RevenueRecognitionTable_643" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_teva_RevenueRecognitionLineItems_642" xlink:to="loc_teva_RevenueRecognitionTable_643" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_645" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_RevenueRecognitionTable_643" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_645" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_645" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_644_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_645" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_644_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_TotalReservesIncludedInSalesReservesAndAllowancesMember" xlink:label="loc_teva_TotalReservesIncludedInSalesReservesAndAllowancesMember_659" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_TotalReservesIncludedInSalesReservesAndAllowancesMember_659" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ChargebacksMember" xlink:label="loc_teva_ChargebacksMember_656" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_ChargebacksMember_656" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OtherSalesReservesAndAllowancesMember" xlink:label="loc_teva_OtherSalesReservesAndAllowancesMember_658" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_OtherSalesReservesAndAllowancesMember_658" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ReservesIncludedInAccountsReceivableNetMember" xlink:label="loc_teva_ReservesIncludedInAccountsReceivableNetMember_653" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_ReservesIncludedInAccountsReceivableNetMember_653" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ReturnsMember" xlink:label="loc_teva_ReturnsMember_657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_ReturnsMember_657" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_MedicaidAndOtherGovernmentalAllowancesMember" xlink:label="loc_teva_MedicaidAndOtherGovernmentalAllowancesMember_655" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_MedicaidAndOtherGovernmentalAllowancesMember_655" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RebatesMember" xlink:label="loc_teva_RebatesMember_654" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_RebatesMember_654" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_641" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_RevenueRecognitionTable_643" xlink:to="loc_dei_LegalEntityAxis_641" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_646" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_641" xlink:to="loc_dei_EntityDomain_646" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_646_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_641" xlink:to="loc_dei_EntityDomain_646_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" xlink:label="loc_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales_648" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RevenueRecognitionLineItems_642" xlink:to="loc_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales_648" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_650" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RevenueRecognitionLineItems_642" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_650" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ValuationAllowancesAndReservesForeignCurrencyTranslation" xlink:label="loc_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation_651" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RevenueRecognitionLineItems_642" xlink:to="loc_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation_651" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales" xlink:label="loc_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales_649" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RevenueRecognitionLineItems_642" xlink:to="loc_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales_649" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail">
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_InventoriesLineItems" xlink:label="loc_teva_InventoriesLineItems_452" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_456" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_InventoriesLineItems_452" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_456" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_InventoriesTable" xlink:label="loc_teva_InventoriesTable_453" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_teva_InventoriesLineItems_452" xlink:to="loc_teva_InventoriesTable_453" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_454" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_InventoriesTable_453" xlink:to="loc_dei_LegalEntityAxis_454" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_460" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_454" xlink:to="loc_dei_EntityDomain_460" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_460_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_454" xlink:to="loc_dei_EntityDomain_460_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_457" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_InventoriesLineItems_452" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_457" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_455" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_InventoriesLineItems_452" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_455" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_459" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_InventoriesLineItems_452" xlink:to="loc_us-gaap_InventoryNet_459" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventoryInTransit" xlink:label="loc_us-gaap_OtherInventoryInTransit_458" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_InventoriesLineItems_452" xlink:to="loc_us-gaap_OtherInventoryInTransit_458" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_560" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_563" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_560" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_563" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_559" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_563" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_559" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_561" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_559" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_561" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_561_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_559" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_561_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember_568" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_561" xlink:to="loc_us-gaap_TradeNamesMember_568" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ProductRightsMember" xlink:label="loc_teva_ProductRightsMember_567" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_561" xlink:to="loc_teva_ProductRightsMember_567" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_569" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_561" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_569" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_565" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_560" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_565" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_566" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_560" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_566" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_564" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_560" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_564" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_594" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_594" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_578" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_dei_LegalEntityAxis_578" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_599" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_578" xlink:to="loc_dei_EntityDomain_599" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_599_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_578" xlink:to="loc_dei_EntityDomain_599_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_408202" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_srt_ProductOrServiceAxis_408202" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_408203" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_408202" xlink:to="loc_srt_ProductsAndServicesDomain_408203" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_408203_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_408202" xlink:to="loc_srt_ProductsAndServicesDomain_408203_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_GenericPipelineProductsMember" xlink:label="loc_teva_GenericPipelineProductsMember_473346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_408203" xlink:to="loc_teva_GenericPipelineProductsMember_473346" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_DiscontinuationOfBusinessAxis" xlink:label="loc_teva_DiscontinuationOfBusinessAxis_581599" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_teva_DiscontinuationOfBusinessAxis_581599" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_DiscontinuationOfBusinessDomain" xlink:label="loc_teva_DiscontinuationOfBusinessDomain_581600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_teva_DiscontinuationOfBusinessAxis_581599" xlink:to="loc_teva_DiscontinuationOfBusinessDomain_581600" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_DiscontinuationOfBusinessDomain" xlink:label="loc_teva_DiscontinuationOfBusinessDomain_581600_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_teva_DiscontinuationOfBusinessAxis_581599" xlink:to="loc_teva_DiscontinuationOfBusinessDomain_581600_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTypeAxis" xlink:label="loc_us-gaap_ReclassificationTypeAxis_1261963" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_us-gaap_ReclassificationTypeAxis_1261963" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTypeDomain" xlink:label="loc_us-gaap_ReclassificationTypeDomain_1261964" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationTypeAxis_1261963" xlink:to="loc_us-gaap_ReclassificationTypeDomain_1261964" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTypeDomain" xlink:label="loc_us-gaap_ReclassificationTypeDomain_1261964_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationTypeAxis_1261963" xlink:to="loc_us-gaap_ReclassificationTypeDomain_1261964_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_InprocessresearchandDevelopmenttoProductRightsMember" xlink:label="loc_teva_InprocessresearchandDevelopmenttoProductRightsMember_1261965" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationTypeDomain_1261964" xlink:to="loc_teva_InprocessresearchandDevelopmenttoProductRightsMember_1261965" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_574" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_574" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_573" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_574" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_573" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_573_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_574" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_573_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ActavisMember" xlink:label="loc_teva_ActavisMember_582" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_573" xlink:to="loc_teva_ActavisMember_582" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_764548" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_srt_RangeAxis_764548" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_764549" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_764548" xlink:to="loc_srt_RangeMember_764549" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_764549_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_764548" xlink:to="loc_srt_RangeMember_764549_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_764550" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_764549" xlink:to="loc_srt_MinimumMember_764550" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_764551" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_764549" xlink:to="loc_srt_MaximumMember_764551" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_575" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_577" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_575" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_577" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_577_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_575" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_577_default" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ProductRightsMember" xlink:label="loc_teva_ProductRightsMember_598" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_577" xlink:to="loc_teva_ProductRightsMember_598" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_597" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_577" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_597" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_581" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_srt_StatementGeographicalAxis_581" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_580" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_581" xlink:to="loc_srt_SegmentGeographicalDomain_580" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_580_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_581" xlink:to="loc_srt_SegmentGeographicalDomain_580_default" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_682394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_580" xlink:to="loc_country_US_682394" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis" xlink:label="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis_764580" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis_764580" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain" xlink:label="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain_764582" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis_764580" xlink:to="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain_764582" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain" xlink:label="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain_764582_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis_764580" xlink:to="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain_764582_default" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_764554" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_764554" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_764555" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_764554" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_764555" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_764555_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_764554" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_764555_default" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_764556" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_764555" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_764556" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_588" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_588" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_596" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_596" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_764546" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_764546" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_587" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_587" use="optional" order="45" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_499" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_511" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_499" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_511" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_501" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_499" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_501" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_500" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_501" xlink:to="loc_dei_LegalEntityAxis_500" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_514" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_500" xlink:to="loc_dei_EntityDomain_514" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_514_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_500" xlink:to="loc_dei_EntityDomain_514_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_391588" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_501" xlink:to="loc_srt_ConsolidationItemsAxis_391588" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_391589" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_391588" xlink:to="loc_srt_ConsolidationItemsDomain_391589" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_391589_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_391588" xlink:to="loc_srt_ConsolidationItemsDomain_391589_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_504" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_501" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_504" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_502" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_504" xlink:to="loc_us-gaap_SegmentDomain_502" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_502_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_504" xlink:to="loc_us-gaap_SegmentDomain_502_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_505" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_501" xlink:to="loc_srt_StatementGeographicalAxis_505" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_503" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_505" xlink:to="loc_srt_SegmentGeographicalDomain_503" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_503_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_505" xlink:to="loc_srt_SegmentGeographicalDomain_503_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OtherCountriesMember" xlink:label="loc_teva_OtherCountriesMember_521" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_503" xlink:to="loc_teva_OtherCountriesMember_521" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_503" xlink:to="loc_srt_EuropeMember_519" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_InternationalMarketsMember" xlink:label="loc_teva_InternationalMarketsMember_520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_503" xlink:to="loc_teva_InternationalMarketsMember_520" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NorthAmericaMember" xlink:label="loc_srt_NorthAmericaMember_518" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_503" xlink:to="loc_srt_NorthAmericaMember_518" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_1403742" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_499" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_1403742" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_499" xlink:to="loc_us-gaap_Goodwill_506" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_509" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_499" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_509" use="optional" order="21" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_524" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_527" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_524" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_527" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_526" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_524" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_526" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_526" xlink:to="loc_dei_LegalEntityAxis_525" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_528" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_525" xlink:to="loc_dei_EntityDomain_528" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_528_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_525" xlink:to="loc_dei_EntityDomain_528_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_531" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_718483" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_531" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_718483" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_536" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_531" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_536" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_540" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_srt_StatementGeographicalAxis_540" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_538" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_540" xlink:to="loc_srt_SegmentGeographicalDomain_538" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_538_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_540" xlink:to="loc_srt_SegmentGeographicalDomain_538_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_533" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_srt_RangeAxis_533" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_534" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_533" xlink:to="loc_srt_RangeMember_534" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_534_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_533" xlink:to="loc_srt_RangeMember_534_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_546" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_534" xlink:to="loc_srt_MaximumMember_546" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_547" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_534" xlink:to="loc_srt_MinimumMember_547" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_539" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_539" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_537" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_539" xlink:to="loc_us-gaap_SegmentDomain_537" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_537_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_539" xlink:to="loc_us-gaap_SegmentDomain_537_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_532" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_dei_LegalEntityAxis_532" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_545" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_532" xlink:to="loc_dei_EntityDomain_545" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_545_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_532" xlink:to="loc_dei_EntityDomain_545_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_556283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_srt_StatementScenarioAxis_556283" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_556284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_556283" xlink:to="loc_srt_ScenarioUnspecifiedDomain_556284" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_556284_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_556283" xlink:to="loc_srt_ScenarioUnspecifiedDomain_556284_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1562937" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1562937" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1562938" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1562937" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1562938" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1562938_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1562937" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1562938_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_MeasurementInputTerminalGrowthRateMember" xlink:label="loc_teva_MeasurementInputTerminalGrowthRateMember_1562939" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1562938" xlink:to="loc_teva_MeasurementInputTerminalGrowthRateMember_1562939" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_1562940" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1562938" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_1562940" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis" xlink:label="loc_us-gaap_ReportingUnitAxis_1562930" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_us-gaap_ReportingUnitAxis_1562930" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain" xlink:label="loc_us-gaap_ReportingUnitDomain_1562931" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_1562930" xlink:to="loc_us-gaap_ReportingUnitDomain_1562931" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain" xlink:label="loc_us-gaap_ReportingUnitDomain_1562931_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_1562930" xlink:to="loc_us-gaap_ReportingUnitDomain_1562931_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_NorthAmericaAndMedisReportingUnitsMember" xlink:label="loc_teva_NorthAmericaAndMedisReportingUnitsMember_1562936" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_1562931" xlink:to="loc_teva_NorthAmericaAndMedisReportingUnitsMember_1562936" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_InternationalMarketsReportingUnitMember" xlink:label="loc_teva_InternationalMarketsReportingUnitMember_1562933" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_1562931" xlink:to="loc_teva_InternationalMarketsReportingUnitMember_1562933" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_TevasEuropeReportingUnitMember" xlink:label="loc_teva_TevasEuropeReportingUnitMember_1562935" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_1562931" xlink:to="loc_teva_TevasEuropeReportingUnitMember_1562935" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_TevasApiReportingUnitMember" xlink:label="loc_teva_TevasApiReportingUnitMember_1562934" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_1562931" xlink:to="loc_teva_TevasApiReportingUnitMember_1562934" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_412047" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_531" xlink:to="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_412047" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_543" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_531" xlink:to="loc_us-gaap_Goodwill_543" use="optional" order="33" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_688" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_700" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_688" xlink:to="loc_us-gaap_LongTermDebtCurrent_700" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaap_ShortTermBorrowings_699" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_688" xlink:to="loc_us-gaap_ShortTermBorrowings_699" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_DebtInstrumentMaturityYear" xlink:label="loc_teva_DebtInstrumentMaturityYear_698" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_688" xlink:to="loc_teva_DebtInstrumentMaturityYear_698" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_695" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_688" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_695" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_701" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_688" xlink:to="loc_us-gaap_DebtCurrent_701" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_690" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_688" xlink:to="loc_us-gaap_DebtInstrumentTable_690" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_504448" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_690" xlink:to="loc_us-gaap_CreditFacilityAxis_504448" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_504449" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_504448" xlink:to="loc_us-gaap_CreditFacilityDomain_504449" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_504449_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_504448" xlink:to="loc_us-gaap_CreditFacilityDomain_504449_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_686" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_690" xlink:to="loc_srt_CurrencyAxis_686" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_685" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_686" xlink:to="loc_currency_AllCurrenciesDomain_685" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_685_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_686" xlink:to="loc_currency_AllCurrenciesDomain_685_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_691" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_690" xlink:to="loc_dei_LegalEntityAxis_691" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_705" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_691" xlink:to="loc_dei_EntityDomain_705" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_705_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_691" xlink:to="loc_dei_EntityDomain_705_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_687" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_690" xlink:to="loc_us-gaap_DebtInstrumentAxis_687" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_689" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_687" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_689" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_689_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_687" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_689_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ShortCreditAgreement2026Member" xlink:label="loc_teva_ShortCreditAgreement2026Member_704" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_689" xlink:to="loc_teva_ShortCreditAgreement2026Member_704" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_692" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_690" xlink:to="loc_us-gaap_VariableRateAxis_692" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_693" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_692" xlink:to="loc_us-gaap_VariableRateDomain_693" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_693_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_692" xlink:to="loc_us-gaap_VariableRateDomain_693_default" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_762" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_DebtInstrumentMaturityYear" xlink:label="loc_teva_DebtInstrumentMaturityYear_772" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_762" xlink:to="loc_teva_DebtInstrumentMaturityYear_772" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_764" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_762" xlink:to="loc_us-gaap_DebtInstrumentTable_764" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_766" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_764" xlink:to="loc_us-gaap_VariableRateAxis_766" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_767" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_766" xlink:to="loc_us-gaap_VariableRateDomain_767" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_767_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_766" xlink:to="loc_us-gaap_VariableRateDomain_767_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_760" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_764" xlink:to="loc_srt_CurrencyAxis_760" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_759" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_760" xlink:to="loc_currency_AllCurrenciesDomain_759" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_759_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_760" xlink:to="loc_currency_AllCurrenciesDomain_759_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_761" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_764" xlink:to="loc_us-gaap_DebtInstrumentAxis_761" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_763" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_761" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_763" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_763_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_761" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_763_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2046Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2046Member_794" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2046Member_794" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2028OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2028OneMember_797" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2028OneMember_797" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OtherDebentures2026Member" xlink:label="loc_teva_OtherDebentures2026Member_814" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_OtherDebentures2026Member_814" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2026OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2026OneMember_790" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2026OneMember_790" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2025ThreeMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025ThreeMember_572585" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025ThreeMember_572585" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2023OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2023OneMember_784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2023OneMember_784" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2036Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2036Member_799" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2036Member_799" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2025TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025TwoMember_572603" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025TwoMember_572603" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2024OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2024OneMember_796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2024OneMember_796" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2024Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2024Member_783" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2024Member_783" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2027Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2027Member_789" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2027Member_789" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2022OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022OneMember_788" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2022OneMember_788" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2023TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2023TwoMember_673253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2023TwoMember_673253" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SustainabilityLinkedSeniorNotesDue2030Member" xlink:label="loc_teva_SustainabilityLinkedSeniorNotesDue2030Member_1260375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SustainabilityLinkedSeniorNotesDue2030Member_1260375" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2028Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2028Member_787" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2028Member_787" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2022TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022TwoMember_798" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2022TwoMember_798" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2022ThreeMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022ThreeMember_804" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2022ThreeMember_804" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2025Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025Member_786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025Member_786" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2025OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025OneMember_572204" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025OneMember_572204" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SustainabilityLinkedSeniorNotesDue2027Member" xlink:label="loc_teva_SustainabilityLinkedSeniorNotesDue2027Member_1260377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SustainabilityLinkedSeniorNotesDue2027Member_1260377" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SustainabilityLinkedSeniorNotesDue2027TwoMember" xlink:label="loc_teva_SustainabilityLinkedSeniorNotesDue2027TwoMember_1260378" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SustainabilityLinkedSeniorNotesDue2027TwoMember_1260378" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SustainabilityLinkedSeniorNotesDue2029Member" xlink:label="loc_teva_SustainabilityLinkedSeniorNotesDue2029Member_1260379" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SustainabilityLinkedSeniorNotesDue2029Member_1260379" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_765" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_764" xlink:to="loc_dei_LegalEntityAxis_765" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_815" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_765" xlink:to="loc_dei_EntityDomain_815" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_815_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_765" xlink:to="loc_dei_EntityDomain_815_default" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotes" xlink:label="loc_us-gaap_SeniorNotes_775" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_762" xlink:to="loc_us-gaap_SeniorNotes_775" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_780" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_762" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_780" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_778" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_762" xlink:to="loc_us-gaap_LongTermDebtCurrent_778" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesAndLoans" xlink:label="loc_us-gaap_LongTermNotesAndLoans_781" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_762" xlink:to="loc_us-gaap_LongTermNotesAndLoans_781" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:label="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_1522385" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_762" xlink:to="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_1522385" use="optional" order="41" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_820" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_824" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_824" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_822" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820" xlink:to="loc_us-gaap_DebtInstrumentTable_822" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1413574" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_822" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1413574" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1413575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1413574" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1413575" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1413575_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1413574" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1413575_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1413601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_822" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1413601" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1413602" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1413601" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1413602" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1413602_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1413601" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1413602_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_1413603" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1413602" xlink:to="loc_us-gaap_SeniorNotesMember_1413603" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_819" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_822" xlink:to="loc_us-gaap_DebtInstrumentAxis_819" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_821" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_819" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_821" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_821_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_819" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_821_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2030Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2030Member_1241820" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2030Member_1241820" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2023TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2023TwoMember_835" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2023TwoMember_835" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2023OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2023OneMember_827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2023OneMember_827" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2025Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025Member_829" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025Member_829" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2024Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2024Member_826" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2024Member_826" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2022TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022TwoMember_841" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2022TwoMember_841" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2028OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2028OneMember_840" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2028OneMember_840" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2024OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2024OneMember_839" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2024OneMember_839" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2022OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022OneMember_831" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2022OneMember_831" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2022ThreeMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022ThreeMember_847" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2022ThreeMember_847" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2025TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025TwoMember_572210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025TwoMember_572210" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2028Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2028Member_830" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2028Member_830" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2036Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2036Member_842" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2036Member_842" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SustainabilityLinkedSeniorNotesDue2027TwoMember" xlink:label="loc_teva_SustainabilityLinkedSeniorNotesDue2027TwoMember_1260399" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SustainabilityLinkedSeniorNotesDue2027TwoMember_1260399" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2026OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2026OneMember_833" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2026OneMember_833" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SustainabilityLinkedSeniorNotesDue2027Member" xlink:label="loc_teva_SustainabilityLinkedSeniorNotesDue2027Member_1260398" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SustainabilityLinkedSeniorNotesDue2027Member_1260398" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2025ThreeMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025ThreeMember_848" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025ThreeMember_848" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SustainabilityLinkedSeniorNotesDue2029Member" xlink:label="loc_teva_SustainabilityLinkedSeniorNotesDue2029Member_1260400" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SustainabilityLinkedSeniorNotesDue2029Member_1260400" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2025OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025OneMember_572208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025OneMember_572208" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2046Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2046Member_837" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2046Member_837" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2027Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2027Member_832" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2027Member_832" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_InterestRateIncreaseMember" xlink:label="loc_teva_InterestRateIncreaseMember_1413582" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_InterestRateIncreaseMember_1413582" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OneTimePremiumPaymentMember" xlink:label="loc_teva_OneTimePremiumPaymentMember_1413597" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_OneTimePremiumPaymentMember_1413597" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1413583" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_822" xlink:to="loc_srt_RangeAxis_1413583" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1413584" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1413583" xlink:to="loc_srt_RangeMember_1413584" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1413584_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1413583" xlink:to="loc_srt_RangeMember_1413584_default" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1413585" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1413584" xlink:to="loc_srt_MinimumMember_1413585" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1413586" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1413584" xlink:to="loc_srt_MaximumMember_1413586" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_1413590" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820" xlink:to="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_1413590" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_1413592" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_1413592" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SeniorNotesRepaidAmount" xlink:label="loc_teva_SeniorNotesRepaidAmount_1413593" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820" xlink:to="loc_teva_SeniorNotesRepaidAmount_1413593" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SeniorNotesMaturityPercentage" xlink:label="loc_teva_SeniorNotesMaturityPercentage_1413595" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820" xlink:to="loc_teva_SeniorNotesMaturityPercentage_1413595" use="optional" order="44" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_722" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LongTermDebtCurrencyPortionCHF" xlink:label="loc_teva_LongTermDebtCurrencyPortionCHF_741" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_teva_LongTermDebtCurrencyPortionCHF_741" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_724" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_DebtInstrumentTable_724" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_408262" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_408262" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_408264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_408262" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_408264" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_408264_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_408262" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_408264_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_466637" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_466637" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_466638" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_466637" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_466638" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_466638_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_466637" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_466638_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_466640" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_466638" xlink:to="loc_us-gaap_SubsequentEventMember_466640" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_682892" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_682892" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_682893" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_682892" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_682893" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_682893_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_682892" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_682893_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_721" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_us-gaap_DebtInstrumentAxis_721" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_723" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_721" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_723" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_723_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_721" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_723_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_726" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_726" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_727" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_726" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_727" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_727_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_726" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_727_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_756" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_727" xlink:to="loc_us-gaap_ConvertibleDebtMember_756" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_765345" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_srt_RangeAxis_765345" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_765346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_765345" xlink:to="loc_srt_RangeMember_765346" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_765346_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_765345" xlink:to="loc_srt_RangeMember_765346_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_725" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_dei_LegalEntityAxis_725" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_755" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_725" xlink:to="loc_dei_EntityDomain_755" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_755_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_725" xlink:to="loc_dei_EntityDomain_755_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_719" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_us-gaap_CreditFacilityAxis_719" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_720" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_719" xlink:to="loc_us-gaap_CreditFacilityDomain_720" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_720_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_719" xlink:to="loc_us-gaap_CreditFacilityDomain_720_default" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_728" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_720" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_728" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_UnsecuredSyndicatedRevolvingCreditFacilityMember" xlink:label="loc_teva_UnsecuredSyndicatedRevolvingCreditFacilityMember_1388216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_720" xlink:to="loc_teva_UnsecuredSyndicatedRevolvingCreditFacilityMember_1388216" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AgreementAxis" xlink:label="loc_teva_AgreementAxis_1280331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_teva_AgreementAxis_1280331" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AgreementDomain" xlink:label="loc_teva_AgreementDomain_1280332" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_teva_AgreementAxis_1280331" xlink:to="loc_teva_AgreementDomain_1280332" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AgreementDomain" xlink:label="loc_teva_AgreementDomain_1280332_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_teva_AgreementAxis_1280331" xlink:to="loc_teva_AgreementDomain_1280332_default" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_TrancheAxis" xlink:label="loc_teva_TrancheAxis_682383" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_teva_TrancheAxis_682383" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_TrancheDomain" xlink:label="loc_teva_TrancheDomain_682384" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_teva_TrancheAxis_682383" xlink:to="loc_teva_TrancheDomain_682384" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_TrancheDomain" xlink:label="loc_teva_TrancheDomain_682384_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_teva_TrancheAxis_682383" xlink:to="loc_teva_TrancheDomain_682384_default" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LongTermDebtCurrencyPortionEUR" xlink:label="loc_teva_LongTermDebtCurrencyPortionEUR_740" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_teva_LongTermDebtCurrencyPortionEUR_740" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_735" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_735" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_732" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_732" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LongTermDebtCurrencyPortionUSD" xlink:label="loc_teva_LongTermDebtCurrencyPortionUSD_739" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_teva_LongTermDebtCurrencyPortionUSD_739" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCovenantDescription" xlink:label="loc_us-gaap_DebtInstrumentCovenantDescription_466634" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_DebtInstrumentCovenantDescription_466634" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_682881" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_682881" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_1241835" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_1241835" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LineOfCreditExtentionPeriod" xlink:label="loc_teva_LineOfCreditExtentionPeriod_1403836" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_teva_LineOfCreditExtentionPeriod_1403836" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LeverageRatio" xlink:label="loc_teva_LeverageRatio_1403837" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_teva_LeverageRatio_1403837" use="optional" order="45" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_1339" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_1352" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1339" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_1352" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_1340" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_1339" xlink:to="loc_us-gaap_DerivativeTable_1340" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1338" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1340" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1338" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_1343" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1338" xlink:to="loc_us-gaap_HedgingRelationshipDomain_1343" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_1343_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1338" xlink:to="loc_us-gaap_HedgingRelationshipDomain_1343_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_1337" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1340" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_1337" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1336" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1337" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1336" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1336_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1337" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1336_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_1348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1336" xlink:to="loc_us-gaap_ForeignExchangeContractMember_1348" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1344" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1340" xlink:to="loc_dei_LegalEntityAxis_1344" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1357" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1344" xlink:to="loc_dei_EntityDomain_1357" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1357_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1344" xlink:to="loc_dei_EntityDomain_1357_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_1341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1340" xlink:to="loc_us-gaap_HedgingDesignationAxis_1341" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_1342" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_1341" xlink:to="loc_us-gaap_HedgingDesignationDomain_1342" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_1342_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_1341" xlink:to="loc_us-gaap_HedgingDesignationDomain_1342_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_1354" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_1342" xlink:to="loc_us-gaap_NondesignatedMember_1354" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1340" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1334" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1335" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1334" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1335" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1335_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1334" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1335_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SeniorNotesAndLoansMember" xlink:label="loc_teva_SeniorNotesAndLoansMember_1346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1335" xlink:to="loc_teva_SeniorNotesAndLoansMember_1346" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_390198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1335" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_390198" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_1351" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1339" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_1351" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_390516" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_390515" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_390516" xlink:to="loc_us-gaap_DerivativeTable_390515" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_682286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_390515" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_682286" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_682287" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_682286" xlink:to="loc_us-gaap_HedgingRelationshipDomain_682287" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_682287_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_682286" xlink:to="loc_us-gaap_HedgingRelationshipDomain_682287_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_390519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_390515" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_390519" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_390520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_390519" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_390520" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_390520_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_390519" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_390520_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_NetRevenuesMember" xlink:label="loc_teva_NetRevenuesMember_406886" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_390520" xlink:to="loc_teva_NetRevenuesMember_406886" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_FinancialExpensesMember" xlink:label="loc_teva_FinancialExpensesMember_406916" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_390520" xlink:to="loc_teva_FinancialExpensesMember_406916" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_406887" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_390515" xlink:to="loc_us-gaap_HedgingDesignationAxis_406887" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_406888" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_406887" xlink:to="loc_us-gaap_HedgingDesignationDomain_406888" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_406888_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_406887" xlink:to="loc_us-gaap_HedgingDesignationDomain_406888_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_406890" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_406888" xlink:to="loc_us-gaap_NondesignatedMember_406890" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotDesignatedAsHedgingInstrumentTradingMember" xlink:label="loc_us-gaap_NotDesignatedAsHedgingInstrumentTradingMember_406891" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_406888" xlink:to="loc_us-gaap_NotDesignatedAsHedgingInstrumentTradingMember_406891" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember" xlink:label="loc_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember_466838" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_406888" xlink:to="loc_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember_466838" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_406900" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_390516" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_406900" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_1285" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RevenuesOtherThanUsd" xlink:label="loc_teva_RevenuesOtherThanUsd_1298" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_teva_RevenuesOtherThanUsd_1298" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_PreviouslyHedgeDebtRate" xlink:label="loc_teva_PreviouslyHedgeDebtRate_1304" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_teva_PreviouslyHedgeDebtRate_1304" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_1286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_us-gaap_DerivativeTable_1286" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1290" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_dei_LegalEntityAxis_1290" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1312" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1290" xlink:to="loc_dei_EntityDomain_1312" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1312_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1290" xlink:to="loc_dei_EntityDomain_1312_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1284" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_1287" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1284" xlink:to="loc_us-gaap_HedgingRelationshipDomain_1287" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_1287_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1284" xlink:to="loc_us-gaap_HedgingRelationshipDomain_1287_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1288" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1289" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1288" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1289" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1289_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1288" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1289_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_688628" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1289" xlink:to="loc_us-gaap_CostOfSalesMember_688628" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_1283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_1283" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1283" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1282" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1282_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1283" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1282_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SeniorNotesDue2023TwoMember" xlink:label="loc_teva_SeniorNotesDue2023TwoMember_1291" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1282" xlink:to="loc_teva_SeniorNotesDue2023TwoMember_1291" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SeniorNotesDue2022Member" xlink:label="loc_teva_SeniorNotesDue2022Member_1294" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1282" xlink:to="loc_teva_SeniorNotesDue2022Member_1294" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SeniorNotesDue2021Member" xlink:label="loc_teva_SeniorNotesDue2021Member_1297" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1282" xlink:to="loc_teva_SeniorNotesDue2021Member_1297" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_558657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_us-gaap_HedgingDesignationAxis_558657" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_558658" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_558657" xlink:to="loc_us-gaap_HedgingDesignationDomain_558658" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_558658_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_558657" xlink:to="loc_us-gaap_HedgingDesignationDomain_558658_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_817877" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_srt_RangeAxis_817877" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_817878" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_817877" xlink:to="loc_srt_RangeMember_817878" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_817878_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_817877" xlink:to="loc_srt_RangeMember_817878_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_NotionalAmountHedgeDebt" xlink:label="loc_teva_NotionalAmountHedgeDebt_1300" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_teva_NotionalAmountHedgeDebt_1300" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="loc_us-gaap_DerivativeGainOnDerivative_688630" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_us-gaap_DerivativeGainOnDerivative_688630" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" xlink:label="loc_teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses_1303" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses_1303" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="loc_us-gaap_DerivativeLossOnDerivative_1301" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_us-gaap_DerivativeLossOnDerivative_1301" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_CashReceivedOnSettlementOfPosition" xlink:label="loc_teva_CashReceivedOnSettlementOfPosition_581646" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_teva_CashReceivedOnSettlementOfPosition_581646" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_InterestRateSwapLoss" xlink:label="loc_teva_InterestRateSwapLoss_1403869" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_teva_InterestRateSwapLoss_1403869" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss" xlink:label="loc_us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss_718504" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss_718504" use="optional" order="32" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_1458" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1462" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1458" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1462" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_1461" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1458" xlink:to="loc_us-gaap_LitigationSettlementExpense_1461" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RestructuringExpenseAndIncome" xlink:label="loc_teva_RestructuringExpenseAndIncome_720065" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1458" xlink:to="loc_teva_RestructuringExpenseAndIncome_720065" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_1459" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_1458" xlink:to="loc_us-gaap_LossContingenciesTable_1459" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1457" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1459" xlink:to="loc_dei_LegalEntityAxis_1457" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1460" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1457" xlink:to="loc_dei_EntityDomain_1460" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1460_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1457" xlink:to="loc_dei_EntityDomain_1460_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_720032" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1459" xlink:to="loc_srt_StatementGeographicalAxis_720032" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_720033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_720032" xlink:to="loc_srt_SegmentGeographicalDomain_720033" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_720033_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_720032" xlink:to="loc_srt_SegmentGeographicalDomain_720033_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_471102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1459" xlink:to="loc_srt_LitigationCaseAxis_471102" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_471103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_471102" xlink:to="loc_srt_LitigationCaseTypeDomain_471103" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_471103_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_471102" xlink:to="loc_srt_LitigationCaseTypeDomain_471103_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SettlementOnAccountOfProductLiabilityMember" xlink:label="loc_teva_SettlementOnAccountOfProductLiabilityMember_720064" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_471103" xlink:to="loc_teva_SettlementOnAccountOfProductLiabilityMember_720064" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_CommitmentAndContingenciesLineItems" xlink:label="loc_teva_CommitmentAndContingenciesLineItems_900" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AnnualSalesOfCopaxone" xlink:label="loc_teva_AnnualSalesOfCopaxone_720069" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfCopaxone_720069" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AnnualSalesOfSensipar" xlink:label="loc_teva_AnnualSalesOfSensipar_471045" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfSensipar_471045" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_DamagesAssessment" xlink:label="loc_teva_DamagesAssessment_911" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_DamagesAssessment_911" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_932" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_932" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LitigationSettlementAmountAwardedDistributionPeriod" xlink:label="loc_teva_LitigationSettlementAmountAwardedDistributionPeriod_515103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_LitigationSettlementAmountAwardedDistributionPeriod_515103" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AnnualSalesOfNiaspan" xlink:label="loc_teva_AnnualSalesOfNiaspan_922" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfNiaspan_922" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AnnualSalesOfActoplus" xlink:label="loc_teva_AnnualSalesOfActoplus_926" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfActoplus_926" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LitigationSettlementAmountAwardedCashAmountDistributionPeriod" xlink:label="loc_teva_LitigationSettlementAmountAwardedCashAmountDistributionPeriod_515113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_LitigationSettlementAmountAwardedCashAmountDistributionPeriod_515113" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AnnualSalesAtTimeOfSettlement" xlink:label="loc_teva_AnnualSalesAtTimeOfSettlement_919" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesAtTimeOfSettlement_919" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_CommitmentAndContingenciesTable" xlink:label="loc_teva_CommitmentAndContingenciesTable_901" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_CommitmentAndContingenciesTable_901" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_515106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_515106" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_515107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_515106" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_515107" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_515107_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_515106" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_515107_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_515108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_515107" xlink:to="loc_us-gaap_SubsequentEventMember_515108" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_902" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_srt_CounterpartyNameAxis_902" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_908" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_902" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_908" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_908_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_902" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_908_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_904" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_904" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_905" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_904" xlink:to="loc_us-gaap_LossContingencyNatureDomain_905" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_905_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_904" xlink:to="loc_us-gaap_LossContingencyNatureDomain_905_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_EosinophilicEsophagitisMember" xlink:label="loc_teva_EosinophilicEsophagitisMember_936" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_905" xlink:to="loc_teva_EosinophilicEsophagitisMember_936" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AgreementAxis" xlink:label="loc_teva_AgreementAxis_1280188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_teva_AgreementAxis_1280188" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AgreementDomain" xlink:label="loc_teva_AgreementDomain_1281018" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_teva_AgreementAxis_1280188" xlink:to="loc_teva_AgreementDomain_1281018" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AgreementDomain" xlink:label="loc_teva_AgreementDomain_1281018_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_teva_AgreementAxis_1280188" xlink:to="loc_teva_AgreementDomain_1281018_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AttorneyGeneralOfLouisanaMember" xlink:label="loc_teva_AttorneyGeneralOfLouisanaMember_1280191" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_AgreementDomain_1281018" xlink:to="loc_teva_AttorneyGeneralOfLouisanaMember_1280191" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AttorneyGeneralOfRhodeIslandMember" xlink:label="loc_teva_AttorneyGeneralOfRhodeIslandMember_1411784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_AgreementDomain_1281018" xlink:to="loc_teva_AttorneyGeneralOfRhodeIslandMember_1411784" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AttorneyGeneralOfFloridaMember" xlink:label="loc_teva_AttorneyGeneralOfFloridaMember_1411785" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_AgreementDomain_1281018" xlink:to="loc_teva_AttorneyGeneralOfFloridaMember_1411785" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AttorneyGeneralOfWestVirginiaMember" xlink:label="loc_teva_AttorneyGeneralOfWestVirginiaMember_1562962" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_AgreementDomain_1281018" xlink:to="loc_teva_AttorneyGeneralOfWestVirginiaMember_1562962" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_906" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_srt_ProductOrServiceAxis_906" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_907" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_906" xlink:to="loc_srt_ProductsAndServicesDomain_907" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_907_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_906" xlink:to="loc_srt_ProductsAndServicesDomain_907_default" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AndroGelRateAtOnePercentageMember" xlink:label="loc_teva_AndroGelRateAtOnePercentageMember_937" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_907" xlink:to="loc_teva_AndroGelRateAtOnePercentageMember_937" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AtripalaMember" xlink:label="loc_teva_AtripalaMember_1562952" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_907" xlink:to="loc_teva_AtripalaMember_1562952" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_TiruvadaMember" xlink:label="loc_teva_TiruvadaMember_1562953" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_907" xlink:to="loc_teva_TiruvadaMember_1562953" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_VireadMember" xlink:label="loc_teva_VireadMember_1562955" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_907" xlink:to="loc_teva_VireadMember_1562955" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ColcysMember" xlink:label="loc_teva_ColcysMember_1562959" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_907" xlink:to="loc_teva_ColcysMember_1562959" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_910" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_srt_StatementGeographicalAxis_910" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_910" xlink:to="loc_srt_SegmentGeographicalDomain_909" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_909_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_910" xlink:to="loc_srt_SegmentGeographicalDomain_909_default" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_940" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_909" xlink:to="loc_country_US_940" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_941" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_909" xlink:to="loc_srt_EuropeMember_941" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_LA" xlink:label="loc_stpr_LA_1411614" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_909" xlink:to="loc_stpr_LA_1411614" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA" xlink:label="loc_country_CA_1562951" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_909" xlink:to="loc_country_CA_1562951" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_DefendantsAxis" xlink:label="loc_teva_DefendantsAxis_1280170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_teva_DefendantsAxis_1280170" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_DefendantsMember" xlink:label="loc_teva_DefendantsMember_1280172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_teva_DefendantsAxis_1280170" xlink:to="loc_teva_DefendantsMember_1280172" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_DefendantsMember" xlink:label="loc_teva_DefendantsMember_1280172_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_teva_DefendantsAxis_1280170" xlink:to="loc_teva_DefendantsMember_1280172_default" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_FourOtherDefendantsOtherThanTevaMember" xlink:label="loc_teva_FourOtherDefendantsOtherThanTevaMember_1280174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_DefendantsMember_1280172" xlink:to="loc_teva_FourOtherDefendantsOtherThanTevaMember_1280174" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_CompaniesShareMember" xlink:label="loc_teva_CompaniesShareMember_1566425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_DefendantsMember_1280172" xlink:to="loc_teva_CompaniesShareMember_1566425" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_471076" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_srt_LitigationCaseAxis_471076" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_471078" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_471076" xlink:to="loc_srt_LitigationCaseTypeDomain_471078" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_471078_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_471076" xlink:to="loc_srt_LitigationCaseTypeDomain_471078_default" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OpioidLitigationMember" xlink:label="loc_teva_OpioidLitigationMember_471080" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_471078" xlink:to="loc_teva_OpioidLitigationMember_471080" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_NationwideSettlementMember" xlink:label="loc_teva_NationwideSettlementMember_515110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_471078" xlink:to="loc_teva_NationwideSettlementMember_515110" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_StatesPoliticalSubdivisionsAndTribesMember" xlink:label="loc_teva_StatesPoliticalSubdivisionsAndTribesMember_1566427" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_471078" xlink:to="loc_teva_StatesPoliticalSubdivisionsAndTribesMember_1566427" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AnnualSalesOfActos" xlink:label="loc_teva_AnnualSalesOfActos_925" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfActos_925" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LitigationSettlementAmountAwardedCashAmount" xlink:label="loc_teva_LitigationSettlementAmountAwardedCashAmount_515111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_LitigationSettlementAmountAwardedCashAmount_515111" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualProvision" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_1279981" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_1279981" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LitigationSettlementAmountDistributableinKind" xlink:label="loc_teva_LitigationSettlementAmountDistributableinKind_1280198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_LitigationSettlementAmountDistributableinKind_1280198" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_818712" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_818712" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AnnualSalesOfLamictal" xlink:label="loc_teva_AnnualSalesOfLamictal_921" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfLamictal_921" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AnnualSalesOfNarcan" xlink:label="loc_teva_AnnualSalesOfNarcan_1279997" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfNarcan_1279997" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_934" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_934" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LossContingenciesOnEnvironmentalLawsPenalty" xlink:label="loc_teva_LossContingenciesOnEnvironmentalLawsPenalty_1280223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_LossContingenciesOnEnvironmentalLawsPenalty_1280223" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AnnualSalesOfEffexor" xlink:label="loc_teva_AnnualSalesOfEffexor_920" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfEffexor_920" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue_933" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_LossContingencyDamagesPaidValue_933" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_1280206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_LitigationSettlementExpense_1280206" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LossContingencyClaimsDismissedValue" xlink:label="loc_teva_LossContingencyClaimsDismissedValue_1280153" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_LossContingencyClaimsDismissedValue_1280153" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccrualForEnvironmentalLossContingencies" xlink:label="loc_us-gaap_AccrualForEnvironmentalLossContingencies_1280219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_AccrualForEnvironmentalLossContingencies_1280219" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_PercentageOfPopulationOfSubdivisionsWillFormallyReleaseAsAPartOfSettlement" xlink:label="loc_teva_PercentageOfPopulationOfSubdivisionsWillFormallyReleaseAsAPartOfSettlement_1284351" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_PercentageOfPopulationOfSubdivisionsWillFormallyReleaseAsAPartOfSettlement_1284351" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AnnualSalesAtTheTimeOfLaunchOfProduct" xlink:label="loc_teva_AnnualSalesAtTheTimeOfLaunchOfProduct_1562958" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesAtTheTimeOfLaunchOfProduct_1562958" use="optional" order="70" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LitigationAmountIncludingAlreadyPaid" xlink:label="loc_teva_LitigationAmountIncludingAlreadyPaid_1566438" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_LitigationAmountIncludingAlreadyPaid_1566438" use="optional" order="71" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LitigationSettlementTerm" xlink:label="loc_teva_LitigationSettlementTerm_1566420" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_LitigationSettlementTerm_1566420" use="optional" order="72" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ProductOfferingSettlementAtWholesaleAcquisitionCosts" xlink:label="loc_teva_ProductOfferingSettlementAtWholesaleAcquisitionCosts_1566421" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_ProductOfferingSettlementAtWholesaleAcquisitionCosts_1566421" use="optional" order="73" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ProductToBeSettledValuationTerm" xlink:label="loc_teva_ProductToBeSettledValuationTerm_1566422" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_ProductToBeSettledValuationTerm_1566422" use="optional" order="74" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_PercentageOfWholesaleAcquisitionCostValueInCashInLieuOfProductToBePaidUnderSettlementAgreement" xlink:label="loc_teva_PercentageOfWholesaleAcquisitionCostValueInCashInLieuOfProductToBePaidUnderSettlementAgreement_1568578" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_PercentageOfWholesaleAcquisitionCostValueInCashInLieuOfProductToBePaidUnderSettlementAgreement_1568578" use="optional" order="75" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LitigationAmountToBePaidToTribes" xlink:label="loc_teva_LitigationAmountToBePaidToTribes_1568814" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_LitigationAmountToBePaidToTribes_1568814" use="optional" order="76" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_WholesaleAcquisitionCostValueInCashAmountInLieuOfProductToBePaidUnderSettlementAgreement" xlink:label="loc_teva_WholesaleAcquisitionCostValueInCashAmountInLieuOfProductToBePaidUnderSettlementAgreement_1568816" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_WholesaleAcquisitionCostValueInCashAmountInLieuOfProductToBePaidUnderSettlementAgreement_1568816" use="optional" order="77" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_IncomeTaxLineItems" xlink:label="loc_teva_IncomeTaxLineItems_1209" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_IncomeTaxTable" xlink:label="loc_teva_IncomeTaxTable_1210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_teva_IncomeTaxTable_1210" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_1218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_us-gaap_TaxPeriodAxis_1218" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_1219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_1218" xlink:to="loc_us-gaap_TaxPeriodDomain_1219" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_1219_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_1218" xlink:to="loc_us-gaap_TaxPeriodDomain_1219_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_TaxYear2008To2011Member" xlink:label="loc_teva_TaxYear2008To2011Member_1280227" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_1219" xlink:to="loc_teva_TaxYear2008To2011Member_1280227" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_1207" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_1207" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_1208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_1207" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_1208" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_1208_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_1207" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_1208_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IsraelTaxAuthorityMember" xlink:label="loc_us-gaap_IsraelTaxAuthorityMember_1220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_1208" xlink:to="loc_us-gaap_IsraelTaxAuthorityMember_1220" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1211" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_dei_LegalEntityAxis_1211" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1242" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1211" xlink:to="loc_dei_EntityDomain_1242" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1242_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1211" xlink:to="loc_dei_EntityDomain_1242_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1212" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1212" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1213" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1213_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1212" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1213_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_581719" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_581719" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_581720" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_581719" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_581720" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_581720_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_581719" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_581720_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_1216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_1216" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_1217" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1216" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_1217" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_1217_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1216" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_1217_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_673833" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_srt_StatementScenarioAxis_673833" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_673834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_673833" xlink:to="loc_srt_ScenarioUnspecifiedDomain_673834" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_673834_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_673833" xlink:to="loc_srt_ScenarioUnspecifiedDomain_673834_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_srt_RangeAxis_1214" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1214" xlink:to="loc_srt_RangeMember_1215" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1215_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1214" xlink:to="loc_srt_RangeMember_1215_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1229" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:label="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_1280226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_1280226" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_672012" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_672012" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ExpectedImpairmentOfIncomeTaxBenefit" xlink:label="loc_teva_ExpectedImpairmentOfIncomeTaxBenefit_581718" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_teva_ExpectedImpairmentOfIncomeTaxBenefit_581718" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_1566443" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_InventoryWriteDown_1566443" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_EffectiveIncomeTaxReconciliationAmountInventoryWrittenOff" xlink:label="loc_teva_EffectiveIncomeTaxReconciliationAmountInventoryWrittenOff_1566444" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_teva_EffectiveIncomeTaxReconciliationAmountInventoryWrittenOff_1566444" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_671996" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_671996" use="optional" order="34" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail">
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RestructuringAndImpairmentCostsLineItems" xlink:label="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses" xlink:label="loc_teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses_1400" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" xlink:to="loc_teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses_1400" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_1398" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" xlink:to="loc_us-gaap_RestructuringCharges_1398" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_1395" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_1395" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RestructuringAndImpairmentCostsTable" xlink:label="loc_teva_RestructuringAndImpairmentCostsTable_1393" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" xlink:to="loc_teva_RestructuringAndImpairmentCostsTable_1393" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1393" xlink:to="loc_dei_LegalEntityAxis_1391" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1391" xlink:to="loc_dei_EntityDomain_1394" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1394_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1391" xlink:to="loc_dei_EntityDomain_1394_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ImpairmentAndRestructuring" xlink:label="loc_teva_ImpairmentAndRestructuring_1401" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" xlink:to="loc_teva_ImpairmentAndRestructuring_1401" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1396" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1396" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RestructuringAndImpairmentCostsLineItems" xlink:label="loc_teva_RestructuringAndImpairmentCostsLineItems_1411" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_1419" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1411" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_1419" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RestructuringAndImpairmentCostsTable" xlink:label="loc_teva_RestructuringAndImpairmentCostsTable_1412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1411" xlink:to="loc_teva_RestructuringAndImpairmentCostsTable_1412" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1412" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1404" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1405" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1404" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1405" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1405_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1404" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1405_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1406" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1412" xlink:to="loc_dei_LegalEntityAxis_1406" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1416" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1406" xlink:to="loc_dei_EntityDomain_1416" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1416_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1406" xlink:to="loc_dei_EntityDomain_1416_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1407" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1412" xlink:to="loc_srt_ProductOrServiceAxis_1407" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1408" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1407" xlink:to="loc_srt_ProductsAndServicesDomain_1408" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1408_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1407" xlink:to="loc_srt_ProductsAndServicesDomain_1408_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1414" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1412" xlink:to="loc_srt_StatementGeographicalAxis_1414" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1413" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1414" xlink:to="loc_srt_SegmentGeographicalDomain_1413" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1413_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1414" xlink:to="loc_srt_SegmentGeographicalDomain_1413_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_515346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1412" xlink:to="loc_srt_StatementScenarioAxis_515346" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_515347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_515346" xlink:to="loc_srt_ScenarioUnspecifiedDomain_515347" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_515347_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_515346" xlink:to="loc_srt_ScenarioUnspecifiedDomain_515347_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_1421" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1411" xlink:to="loc_us-gaap_RestructuringCharges_1421" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_758336" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1411" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_758336" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1403736" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1411" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1403736" use="optional" order="20" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_1434" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1435" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1434" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1435" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1432" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1435" xlink:to="loc_dei_LegalEntityAxis_1432" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1437" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1432" xlink:to="loc_dei_EntityDomain_1437" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1437_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1432" xlink:to="loc_dei_EntityDomain_1437_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_390248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1435" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_390248" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_390250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_390248" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_390250" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_390250_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_390248" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_390250_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_1433" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1435" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_1433" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1436" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1433" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_1436" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1436_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1433" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_1436_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember" xlink:label="loc_us-gaap_OtherRestructuringMember_1440" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1436" xlink:to="loc_us-gaap_OtherRestructuringMember_1440" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="loc_us-gaap_EmployeeSeveranceMember_1439" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1436" xlink:to="loc_us-gaap_EmployeeSeveranceMember_1439" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_1438" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1434" xlink:to="loc_us-gaap_RestructuringCharges_1438" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_1446" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_UtilizationAndOther" xlink:label="loc_teva_UtilizationAndOther_1453" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1446" xlink:to="loc_teva_UtilizationAndOther_1453" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_1451" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1446" xlink:to="loc_us-gaap_RestructuringReserve_1451" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RestructuringAccrualProvision" xlink:label="loc_teva_RestructuringAccrualProvision_1452" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1446" xlink:to="loc_teva_RestructuringAccrualProvision_1452" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1447" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1446" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1447" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1445" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1447" xlink:to="loc_dei_LegalEntityAxis_1445" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1450" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1445" xlink:to="loc_dei_EntityDomain_1450" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1450_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1445" xlink:to="loc_dei_EntityDomain_1450_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ExitAndDisposalAxis" xlink:label="loc_teva_ExitAndDisposalAxis_1443" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1447" xlink:to="loc_teva_ExitAndDisposalAxis_1443" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ExitAndDisposalDomain" xlink:label="loc_teva_ExitAndDisposalDomain_1444" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_teva_ExitAndDisposalAxis_1443" xlink:to="loc_teva_ExitAndDisposalDomain_1444" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ExitAndDisposalDomain" xlink:label="loc_teva_ExitAndDisposalDomain_1444_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_teva_ExitAndDisposalAxis_1443" xlink:to="loc_teva_ExitAndDisposalDomain_1444_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OtherExitAndDisposalMember" xlink:label="loc_teva_OtherExitAndDisposalMember_1449" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_ExitAndDisposalDomain_1444" xlink:to="loc_teva_OtherExitAndDisposalMember_1449" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_EmployeeTerminationMember" xlink:label="loc_teva_EmployeeTerminationMember_1448" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_ExitAndDisposalDomain_1444" xlink:to="loc_teva_EmployeeTerminationMember_1448" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1593" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_718513" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1593" xlink:to="loc_us-gaap_EarningsPerShareBasic_718513" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_718514" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1593" xlink:to="loc_us-gaap_EarningsPerShareDiluted_718514" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1596" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1593" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1596" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1595" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1596" xlink:to="loc_dei_LegalEntityAxis_1595" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1603" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1595" xlink:to="loc_dei_EntityDomain_1603" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1603_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1595" xlink:to="loc_dei_EntityDomain_1603_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1592" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1596" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1592" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1594" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1592" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1594" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1594_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1592" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1594_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_1601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1594" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_1601" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1411267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1593" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1411267" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1597" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1593" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1597" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390030" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_390033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390030" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_390033" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_390031" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390030" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_390031" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_466595" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390030" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_466595" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_390034" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390030" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_390034" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_390032" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390030" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_390032" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_390049" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390030" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_390049" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_390027" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390030" xlink:to="loc_us-gaap_StatementTable_390027" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_390055" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_390027" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_390055" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_390057" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_390055" xlink:to="loc_us-gaap_EquityComponentDomain_390057" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_390057_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_390055" xlink:to="loc_us-gaap_EquityComponentDomain_390057_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_390090" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_390057" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_390090" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_390089" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_390057" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_390089" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_390091" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_390057" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_390091" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_390087" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_390057" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_390087" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_390028" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_390027" xlink:to="loc_dei_LegalEntityAxis_390028" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_390029" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_390028" xlink:to="loc_dei_EntityDomain_390029" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_390029_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_390028" xlink:to="loc_dei_EntityDomain_390029_default" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390135" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_390130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390135" xlink:to="loc_us-gaap_StatementTable_390130" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_390133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_390130" xlink:to="loc_dei_LegalEntityAxis_390133" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_390134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_390133" xlink:to="loc_dei_EntityDomain_390134" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_390134_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_390133" xlink:to="loc_dei_EntityDomain_390134_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_390146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_390130" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_390146" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_390148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_390146" xlink:to="loc_us-gaap_TypeOfAdoptionMember_390148" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_390148_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_390146" xlink:to="loc_us-gaap_TypeOfAdoptionMember_390148_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_390149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_390148" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_390149" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_720088" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_390130" xlink:to="loc_srt_RangeAxis_720088" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_720089" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_720088" xlink:to="loc_srt_RangeMember_720089" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_720089_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_720088" xlink:to="loc_srt_RangeMember_720089_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_390142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_390130" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_390142" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_390143" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_390142" xlink:to="loc_us-gaap_EquityComponentDomain_390143" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_390143_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_390142" xlink:to="loc_us-gaap_EquityComponentDomain_390143_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember_390145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_390143" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember_390145" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_390137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390135" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_390137" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_1497" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_us-gaap_OperatingIncomeLoss_1497" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OtherOperatingIncomeExpense" xlink:label="loc_teva_OtherOperatingIncomeExpense_1496" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_teva_OtherOperatingIncomeExpense_1496" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1495" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1495" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1493" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1493" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_1494" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_us-gaap_SellingAndMarketingExpense_1494" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_1492" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_us-gaap_GrossProfit_1492" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1483" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1483" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1486" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1483" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1486" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1484" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1486" xlink:to="loc_us-gaap_SegmentDomain_1484" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1484_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1486" xlink:to="loc_us-gaap_SegmentDomain_1484_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_InternationalMarketsMember" xlink:label="loc_teva_InternationalMarketsMember_1490" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1484" xlink:to="loc_teva_InternationalMarketsMember_1490" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_EuropeSegmentMember" xlink:label="loc_teva_EuropeSegmentMember_1489" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1484" xlink:to="loc_teva_EuropeSegmentMember_1489" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_NorthAmericaSegmentMember" xlink:label="loc_teva_NorthAmericaSegmentMember_1488" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1484" xlink:to="loc_teva_NorthAmericaSegmentMember_1488" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1482" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1483" xlink:to="loc_dei_LegalEntityAxis_1482" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1487" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1482" xlink:to="loc_dei_EntityDomain_1487" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1487_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1482" xlink:to="loc_dei_EntityDomain_1487_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1491" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1505" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AmountsAllocatedToSegmentsAbstract" xlink:label="loc_teva_AmountsAllocatedToSegmentsAbstract_1500" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1505" xlink:to="loc_teva_AmountsAllocatedToSegmentsAbstract_1500" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_1507" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_AmountsAllocatedToSegmentsAbstract_1500" xlink:to="loc_us-gaap_OperatingIncomeLoss_1507" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1503" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1505" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1503" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1502" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1503" xlink:to="loc_dei_LegalEntityAxis_1502" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1518" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1502" xlink:to="loc_dei_EntityDomain_1518" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1518_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1502" xlink:to="loc_dei_EntityDomain_1518_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1503" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1506" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1504" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1506" xlink:to="loc_us-gaap_SegmentDomain_1504" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1504_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1506" xlink:to="loc_us-gaap_SegmentDomain_1504_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SegmentsAndOtherActivitiesMember" xlink:label="loc_teva_SegmentsAndOtherActivitiesMember_1524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1504" xlink:to="loc_teva_SegmentsAndOtherActivitiesMember_1524" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateMember" xlink:label="loc_us-gaap_CorporateMember_1522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1504" xlink:to="loc_us-gaap_CorporateMember_1522" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_EuropeSegmentMember" xlink:label="loc_teva_EuropeSegmentMember_1520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1504" xlink:to="loc_teva_EuropeSegmentMember_1520" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_NorthAmericaSegmentMember" xlink:label="loc_teva_NorthAmericaSegmentMember_1519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1504" xlink:to="loc_teva_NorthAmericaSegmentMember_1519" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_InternationalMarketsMember" xlink:label="loc_teva_InternationalMarketsMember_1521" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1504" xlink:to="loc_teva_InternationalMarketsMember_1521" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember" xlink:label="loc_us-gaap_AllOtherSegmentsMember_1523" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1504" xlink:to="loc_us-gaap_AllOtherSegmentsMember_1523" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_1525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1505" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_1525" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AmountsNotAllocatedToSegmentsAbstract" xlink:label="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1505" xlink:to="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_1510" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_1510" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OtherUnallocatedAmounts" xlink:label="loc_teva_OtherUnallocatedAmounts_1517" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_teva_OtherUnallocatedAmounts_1517" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ImpairmentsRestructuringAndOthers" xlink:label="loc_teva_ImpairmentsRestructuringAndOthers_1509" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_teva_ImpairmentsRestructuringAndOthers_1509" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1511" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1511" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_1508" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_us-gaap_AdjustmentForAmortization_1508" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LegalSettlementsAndLossContingencies" xlink:label="loc_teva_LegalSettlementsAndLossContingencies_1516" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_teva_LegalSettlementsAndLossContingencies_1516" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1526" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1505" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1526" use="optional" order="24" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaap_ProductInformationLineItems_1530" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable_1533" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ProductInformationLineItems_1530" xlink:to="loc_us-gaap_ScheduleOfProductInformationTable_1533" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1535" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_1533" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1535" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1534" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1535" xlink:to="loc_us-gaap_SegmentDomain_1534" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1534_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1535" xlink:to="loc_us-gaap_SegmentDomain_1534_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_NorthAmericaSegmentMember" xlink:label="loc_teva_NorthAmericaSegmentMember_1548" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1534" xlink:to="loc_teva_NorthAmericaSegmentMember_1548" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_EuropeSegmentMember" xlink:label="loc_teva_EuropeSegmentMember_1549" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1534" xlink:to="loc_teva_EuropeSegmentMember_1549" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_InternationalMarketsMember" xlink:label="loc_teva_InternationalMarketsMember_1550" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1534" xlink:to="loc_teva_InternationalMarketsMember_1550" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RevenueTypeAxis" xlink:label="loc_teva_RevenueTypeAxis_558204" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_1533" xlink:to="loc_teva_RevenueTypeAxis_558204" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RevenueTypeDomain" xlink:label="loc_teva_RevenueTypeDomain_558211" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_teva_RevenueTypeAxis_558204" xlink:to="loc_teva_RevenueTypeDomain_558211" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RevenueTypeDomain" xlink:label="loc_teva_RevenueTypeDomain_558211_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_teva_RevenueTypeAxis_558204" xlink:to="loc_teva_RevenueTypeDomain_558211_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1529" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_1533" xlink:to="loc_dei_LegalEntityAxis_1529" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1536" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1529" xlink:to="loc_dei_EntityDomain_1536" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1536_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1529" xlink:to="loc_dei_EntityDomain_1536_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1531" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_1533" xlink:to="loc_srt_ProductOrServiceAxis_1531" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1532" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1531" xlink:to="loc_srt_ProductsAndServicesDomain_1532" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1532_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1531" xlink:to="loc_srt_ProductsAndServicesDomain_1532_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_BendekaAndTreandaMember" xlink:label="loc_teva_BendekaAndTreandaMember_1540" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_BendekaAndTreandaMember_1540" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_COPAXONEMember" xlink:label="loc_teva_COPAXONEMember_1539" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_COPAXONEMember_1539" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AndaMember" xlink:label="loc_teva_AndaMember_1546" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_AndaMember_1546" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OtherProductsMember" xlink:label="loc_teva_OtherProductsMember_1547" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_OtherProductsMember_1547" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RespiratoryProductMember" xlink:label="loc_teva_RespiratoryProductMember_1545" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_RespiratoryProductMember_1545" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AustedoMember" xlink:label="loc_teva_AustedoMember_1543" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_AustedoMember_1543" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_GenericsMediciansMember" xlink:label="loc_teva_GenericsMediciansMember_1538" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_GenericsMediciansMember_1538" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AjovyMember" xlink:label="loc_teva_AjovyMember_408213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_AjovyMember_408213" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1537" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_1530" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1537" use="optional" order="25" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_1472" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1472" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1469" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" xlink:to="loc_dei_LegalEntityAxis_1469" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1476" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1469" xlink:to="loc_dei_EntityDomain_1476" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1476_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1469" xlink:to="loc_dei_EntityDomain_1476_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1473" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" xlink:to="loc_srt_StatementGeographicalAxis_1473" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1471" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1473" xlink:to="loc_srt_SegmentGeographicalDomain_1471" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1471_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1473" xlink:to="loc_srt_SegmentGeographicalDomain_1471_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1467" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_1467" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1468" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1467" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1468" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1468_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1467" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1468_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1260429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1260429" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1260430" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1260429" xlink:to="loc_us-gaap_SegmentDomain_1260430" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1260430_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1260429" xlink:to="loc_us-gaap_SegmentDomain_1260430_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1466" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1466" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1465" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1466" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1465" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1465_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1466" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1465_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_1478" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1472" xlink:to="loc_us-gaap_NumberOfReportableSegments_1478" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_369" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_369" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_368" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_368" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets" xlink:label="loc_us-gaap_DerivativeAssets_370" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_DerivativeAssets_370" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_372" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_372" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaap_FairValueNetAssetLiability_373" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_FairValueNetAssetLiability_373" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_371" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_DerivativeLiabilities_371" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_1280201" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_RestrictedCash_1280201" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_360" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_360" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_360" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_360" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_374" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359" xlink:to="loc_us-gaap_MoneyMarketFundsMember_374" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DemandDepositsMember" xlink:label="loc_us-gaap_DemandDepositsMember_375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359" xlink:to="loc_us-gaap_DemandDepositsMember_375" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359" xlink:to="loc_us-gaap_EquitySecuritiesMember_376" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OtherRestrictedCashMember" xlink:label="loc_teva_OtherRestrictedCashMember_1260419" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359" xlink:to="loc_teva_OtherRestrictedCashMember_1260419" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_362" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_362" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_363" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_362" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_363" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_363_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_362" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_363_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OptionsAndForwardContractsDerivativeLiabilitiesMember" xlink:label="loc_teva_OptionsAndForwardContractsDerivativeLiabilitiesMember_379" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_363" xlink:to="loc_teva_OptionsAndForwardContractsDerivativeLiabilitiesMember_379" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_365" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" xlink:to="loc_us-gaap_FinancialInstrumentAxis_365" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_367" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_365" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_367" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_367_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_365" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_367_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_384" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_367" xlink:to="loc_us-gaap_InterestRateSwapMember_384" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_385" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_367" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_385" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" xlink:to="loc_dei_LegalEntityAxis_366" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_383" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_366" xlink:to="loc_dei_EntityDomain_383" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_383_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_366" xlink:to="loc_dei_EntityDomain_383_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_361" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_361" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_364" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_361" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_364" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_364_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_361" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_364_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_382" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_364" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_382" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_381" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_364" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_381" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_380" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_364" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_380" use="optional" order="33" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_682371" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_682381" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_682371" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_682381" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_682370" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_682371" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_682370" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xlink:label="loc_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis_764533" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_682370" xlink:to="loc_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis_764533" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfFreshStartAdjustmentDomain" xlink:label="loc_us-gaap_TypeOfFreshStartAdjustmentDomain_764534" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis_764533" xlink:to="loc_us-gaap_TypeOfFreshStartAdjustmentDomain_764534" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfFreshStartAdjustmentDomain" xlink:label="loc_us-gaap_TypeOfFreshStartAdjustmentDomain_764534_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis_764533" xlink:to="loc_us-gaap_TypeOfFreshStartAdjustmentDomain_764534_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_682378" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_682370" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_682378" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_682379" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_682378" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_682379" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_682379_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_682378" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_682379_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_MeasurementInputProbabilityOfSuccessMember" xlink:label="loc_teva_MeasurementInputProbabilityOfSuccessMember_682380" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_682379" xlink:to="loc_teva_MeasurementInputProbabilityOfSuccessMember_682380" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_682382" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_682379" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_682382" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_682372" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_682370" xlink:to="loc_srt_RangeAxis_682372" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_682373" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_682372" xlink:to="loc_srt_RangeMember_682373" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_682373_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_682372" xlink:to="loc_srt_RangeMember_682373_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_682374" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_682373" xlink:to="loc_srt_MaximumMember_682374" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember_688250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_682373" xlink:to="loc_srt_WeightedAverageMember_688250" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_682375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_682373" xlink:to="loc_srt_MinimumMember_682375" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_1280210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_1280210" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_397" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_397" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_BifurcatedEmbeddedDerivatives" xlink:label="loc_teva_BifurcatedEmbeddedDerivatives_1280215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_teva_BifurcatedEmbeddedDerivatives_1280215" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_391" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_391" xlink:to="loc_dei_LegalEntityAxis_394" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_407" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_394" xlink:to="loc_dei_EntityDomain_407" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_407_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_394" xlink:to="loc_dei_EntityDomain_407_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_389" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_391" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_389" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_389" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_388" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_388_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_389" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_388_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_NoveTideAcquisitionMember" xlink:label="loc_teva_NoveTideAcquisitionMember_1411437" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_388" xlink:to="loc_teva_NoveTideAcquisitionMember_1411437" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_392" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_391" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_392" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_393" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_392" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_393" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_393_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_392" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_393_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ActavisGenericsMember" xlink:label="loc_teva_ActavisGenericsMember_404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_393" xlink:to="loc_teva_ActavisGenericsMember_404" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_EagleTransactionMember" xlink:label="loc_teva_EagleTransactionMember_406" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_393" xlink:to="loc_teva_EagleTransactionMember_406" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_402" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_402" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod" xlink:label="loc_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod_400" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod_400" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" xlink:label="loc_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease_401" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease_401" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1411496" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_1411497" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1411496" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_1411497" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1411484" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1411496" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1411484" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1411486" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1411484" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1411486" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1411490" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1411486" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1411490" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1411490_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1411486" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1411490_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_NoveTideAcquisitionMember" xlink:label="loc_teva_NoveTideAcquisitionMember_1411494" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1411490" xlink:to="loc_teva_NoveTideAcquisitionMember_1411494" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_410" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_410" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_411" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_413" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_411" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_413" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_414" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_413" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_414" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_414_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_413" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_414_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SeniornotesandconvertibleseniordebenturesMember" xlink:label="loc_teva_SeniornotesandconvertibleseniordebenturesMember_418" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_414" xlink:to="loc_teva_SeniornotesandconvertibleseniordebenturesMember_418" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SeniorNotesAndSustainabilityLinkedSeniorNotesMember" xlink:label="loc_teva_SeniorNotesAndSustainabilityLinkedSeniorNotesMember_1260415" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_414" xlink:to="loc_teva_SeniorNotesAndSustainabilityLinkedSeniorNotesMember_1260415" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_411" xlink:to="loc_dei_LegalEntityAxis_412" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_416" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_412" xlink:to="loc_dei_EntityDomain_416" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_416_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_412" xlink:to="loc_dei_EntityDomain_416_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_415" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_410" xlink:to="loc_us-gaap_DebtInstrumentFairValue_415" use="optional" order="10" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>teva-20220630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 27-July-2022 [08:44:53] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentTransitionReport" xml:lang="en-US">Document Transition Report</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentTransitionReport" xml:lang="en-US">Document Transition Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany" xml:lang="en-US">Entity Shell Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityShellCompany" xml:lang="en-US">Entity Shell Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Smaller Reporting Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent" xml:lang="en-US">Entity Interactive Data Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityInteractiveDataCurrent" xml:lang="en-US">Entity Interactive Data Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCountry" xml:lang="en-US">Entity Address, Country</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressCountry" xml:lang="en-US">Entity Address, Country</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_Security12bTitle" xml:lang="en-US">Title of 12(b) Security</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_Security12bTitle" xml:lang="en-US">Title of 12(b) Security</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber" xml:lang="en-US">Entity File Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityFileNumber" xml:lang="en-US">Entity File Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentQuarterlyReport" xml:lang="en-US">Document Quarterly Report</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentQuarterlyReport" xml:lang="en-US">Document Quarterly Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SecurityExchangeName" xml:lang="en-US">Security Exchange Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_SecurityExchangeName" xml:lang="en-US">Security Exchange Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xml:lang="en-US">Assets held for sale</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xml:lang="en-US">Total assets of the disposal group classified as held for sale in the consolidated balance sheets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, Net, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivables, net of allowance for credit losses of $95 million and $90 million as of June 30, 2022 and December 31, 2021</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventory, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventories</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Identifiable intangible assets, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Net carrying amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, plant and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other Assets, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other&#160;non-current&#160;assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xml:lang="en-US">Deferred Income Tax Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xml:lang="en-US">Deferred income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Ending balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Beginning balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating lease right-of-use assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES AND EQUITY</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies, see note 10</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinorityInterest" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MinorityInterest" xml:lang="en-US">Non-controlling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xml:lang="en-US">Accounts Payable, Trade, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xml:lang="en-US">Accounts payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrent" xlink:to="lab_us-gaap_AccountsPayableTradeCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xml:lang="en-US">Other Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xml:lang="en-US">Other current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Employee-related Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Employee-related obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtCurrent" xml:lang="en-US">Debt, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtCurrent" xml:lang="en-US">Short-term debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_DebtCurrent" xml:lang="en-US">Total short term debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AccruedExpenses" xlink:label="loc_teva_AccruedExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AccruedExpenses" xml:lang="en-US">Accrued Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AccruedExpenses" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AccruedExpenses" xlink:to="lab_teva_AccruedExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AccruedExpenses" xml:lang="en-US">Accrued expenses.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SalesReservesAndAllowances" xlink:label="loc_teva_SalesReservesAndAllowances" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SalesReservesAndAllowances" xml:lang="en-US">Sales Reserves And Allowances</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SalesReservesAndAllowances" xml:lang="en-US">Sales reserves and allowances</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SalesReservesAndAllowances" xlink:to="lab_teva_SalesReservesAndAllowances" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SalesReservesAndAllowances" xml:lang="en-US">The sum of the balance sheet amounts of the allowances for chargebacks, returns, rebates, other promotional items and price protection.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Teva shareholders' equity:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Ordinary shares of NIS 0.10 par value per share; June 30, 2022 and December 31, 2021: authorized 2,495 million shares; issued 1,216 million shares and 1,209 million shares, respectively.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated other comprehensive loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Ending Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Beginning Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid in Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional&#160;paid-in&#160;capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' equity attributable to Teva shareholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockValue" xml:lang="en-US">Treasury Stock, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_TreasuryStockValue" xml:lang="en-US">Treasury shares as of June 30, 2022 and December 31, 2021: 106 million ordinary shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xml:lang="en-US">Long-term liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xml:lang="en-US">Deferred Tax and Other Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xml:lang="en-US">Deferred income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xml:lang="en-US">Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xml:lang="en-US">Total long-term liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesAndLoans" xlink:label="loc_us-gaap_LongTermNotesAndLoans" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermNotesAndLoans" xml:lang="en-US">Notes and Loans, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermNotesAndLoans" xml:lang="en-US">Senior notes and loans</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LongTermNotesAndLoans" xml:lang="en-US">Total senior notes and loans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesAndLoans" xlink:to="lab_us-gaap_LongTermNotesAndLoans" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other taxes and long-term liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Total equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Ending balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Beginning balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xml:lang="en-US">Allowance for credit losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockShares" xml:lang="en-US">Treasury Stock, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TreasuryStockShares" xml:lang="en-US">Treasury shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Ordinary shares, issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Ordinary shares, authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par or stated value per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings (loss) per share attributable to ordinary shareholders:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings Per Share, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings per share, Basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings Per Share, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings per share, Diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xml:lang="en-US">Cost of Goods and Services Sold</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xml:lang="en-US">Cost of sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Weighted average number of shares (in millions):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ImpairmentsRestructuringAndOthers" xlink:label="loc_teva_ImpairmentsRestructuringAndOthers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ImpairmentsRestructuringAndOthers" xml:lang="en-US">Impairments Restructuring And Others</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_teva_ImpairmentsRestructuringAndOthers" xml:lang="en-US">Other asset impairments, restructuring and other items</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ImpairmentsRestructuringAndOthers" xlink:to="lab_teva_ImpairmentsRestructuringAndOthers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ImpairmentsRestructuringAndOthers" xml:lang="en-US">Impairments restructuring and others.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GrossProfit" xml:lang="en-US">Gross Profit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_GrossProfit" xml:lang="en-US">Gross profit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GrossProfit" xml:lang="en-US">Gross profit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating income (loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Segment profit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Segments profit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Consolidated operating income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">G&amp;A expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xml:lang="en-US">Research and development expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xml:lang="en-US">R&amp;D expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income taxes (benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax expense (benefit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_IntangibleAssetsImpairments" xlink:label="loc_teva_IntangibleAssetsImpairments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_IntangibleAssetsImpairments" xml:lang="en-US">Intangible Assets Impairments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_IntangibleAssetsImpairments" xml:lang="en-US">Intangible assets impairments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_IntangibleAssetsImpairments" xlink:to="lab_teva_IntangibleAssetsImpairments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_IntangibleAssetsImpairments" xml:lang="en-US">Intangible Assets Impairments</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xml:lang="en-US">Income (Loss) from Equity Method Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xml:lang="en-US">Share in (profits) losses of associated companies, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net income (loss) attributable to Teva</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xml:lang="en-US">Other Operating Income (Expense), Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xml:lang="en-US">Other income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xml:lang="en-US">Net income (loss) attributable to non-controlling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Financial expenses, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Financial expenses, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xml:lang="en-US">Goodwill, Impairment Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xml:lang="en-US">Goodwill impairment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xml:lang="en-US">Goodwill impairment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net income (loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net income (loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net Income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LegalSettlementsAndLossContingencies" xlink:label="loc_teva_LegalSettlementsAndLossContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LegalSettlementsAndLossContingencies" xml:lang="en-US">Legal Settlements And Loss Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LegalSettlementsAndLossContingencies" xml:lang="en-US">Legal settlements and loss contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LegalSettlementsAndLossContingencies" xlink:to="lab_teva_LegalSettlementsAndLossContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LegalSettlementsAndLossContingencies" xml:lang="en-US">The net proceeds or assets obtained in excess of (less than) the net carrying amount of assets recorded, or assets distributed and liabilities assumed less than (in excess of) litigation reserves extinguished, in settlement of a litigation matter. Represents (for other than an insurance entity in its normal claims settlement process), the amount of income (expense) recognized in the period to settle pending or threatened litigation and insurance claims and the aggregate amount provided for estimated restructuring charges, remediation costs, and asset impairment loss during an accounting period. Generally, these items are either unusual or infrequent, but not both (in which case they would be extraordinary items).</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Net revenues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Total revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Revenues</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xml:lang="en-US">Selling and Marketing Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xml:lang="en-US">Selling and marketing expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xml:lang="en-US">S&amp;M expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xml:lang="en-US">Income (loss) before income taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xml:lang="en-US">Pre-tax income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive income (loss) attributable to Teva</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Total other comprehensive income (loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Other comprehensive income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Total comprehensive income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xml:lang="en-US">Other comprehensive income (loss), net of tax:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_UnrealizedGainLossOnDerivativeNetOfTax" xlink:label="loc_teva_UnrealizedGainLossOnDerivativeNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_UnrealizedGainLossOnDerivativeNetOfTax" xml:lang="en-US">Unrealized gain (loss) on derivative net of tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_UnrealizedGainLossOnDerivativeNetOfTax" xml:lang="en-US">Unrealized gain (loss) from derivative financial instruments, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_UnrealizedGainLossOnDerivativeNetOfTax" xlink:to="lab_teva_UnrealizedGainLossOnDerivativeNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_UnrealizedGainLossOnDerivativeNetOfTax" xml:lang="en-US">Unrealized gain (loss) on derivative net of tax.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xml:lang="en-US">Currency translation adjustment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement and Curtailment Gain (Loss), after Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" xml:lang="en-US">Unrealized loss on defined benefit plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xml:lang="en-US">Comprehensive income (loss) attributable to non-controlling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Ending balance, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Beginning balance, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of Shares, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issuance of Shares, value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xml:lang="en-US">Noncontrolling Interest [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xml:lang="en-US">Non-controlling Interests [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Ordinary Shares [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ParentMember" xml:lang="en-US">Parent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ParentMember" xml:lang="en-US">Total Teva Shareholders' Equity [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockMember" xml:lang="en-US">Treasury Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TreasuryStockMember" xml:lang="en-US">Treasury Shares [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xml:lang="en-US">Type of Adoption [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Range [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Exercise of options by employees and vested RSUs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Translation adjustment on cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash provided by operations:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_DeferredIncomeTaxesNetAndUncertainTaxPositions" xlink:label="loc_teva_DeferredIncomeTaxesNetAndUncertainTaxPositions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DeferredIncomeTaxesNetAndUncertainTaxPositions" xml:lang="en-US">Deferred Income Taxes Net And Uncertain Tax Positions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_DeferredIncomeTaxesNetAndUncertainTaxPositions" xml:lang="en-US">Deferred income taxes &#8211; net and uncertain tax positions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DeferredIncomeTaxesNetAndUncertainTaxPositions" xlink:to="lab_teva_DeferredIncomeTaxesNetAndUncertainTaxPositions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_DeferredIncomeTaxesNetAndUncertainTaxPositions" xml:lang="en-US">Deferred income taxes net and uncertain tax positions.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ProfitFromSaleOfLongLivedAssetsAndInvestment" xlink:label="loc_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment" xml:lang="en-US">Profit From Sale Of Long Lived Assets And Investment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment" xml:lang="en-US">Net loss (gain) from investments and from sale of long lived assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment" xlink:to="lab_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment" xml:lang="en-US">Profit from sale of long lived assets and investment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DepreciationAndAmortization" xml:lang="en-US">Depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetImpairmentCharges" xml:lang="en-US">Asset Impairment Charges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetImpairmentCharges" xml:lang="en-US">Impairment of goodwill long-lived assets and assets held for sale</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapital" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapital" xml:lang="en-US">Increase (Decrease) in Operating Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapital" xml:lang="en-US">Net change in operating assets and liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapital" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xml:lang="en-US">Other items</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash provided by (used in) operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Investing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xml:lang="en-US">Other investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xml:lang="en-US">Acquisition of businesses, net of cash acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchases of property, plant and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xml:lang="en-US">Proceeds from Divestiture of Businesses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xml:lang="en-US">Proceeds from sale of business and long lived assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets" xlink:label="loc_teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets" xml:lang="en-US">Payment To Acquire Marketable Securities And Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets" xml:lang="en-US">Purchases of investments and other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets" xlink:to="lab_teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets" xml:lang="en-US">The cash outflow from purchase of available for sales securities and other assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" xlink:label="loc_teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" xml:lang="en-US">Proceeds from beneficial interest in exchange for securitized trade receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" xml:lang="en-US">Beneficial interest collected in exchange for securitized trade receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" xlink:to="lab_teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" xml:lang="en-US">Proceeds from beneficial interest in exchange for securitized trade receivables</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xml:lang="en-US">Proceeds from sale of investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Balance of cash, cash equivalents and restricted cash at beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Balance of cash, cash equivalents and restricted cash at end of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Total cash, cash equivalents and restricted cash shown in the statement of cash flows</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xml:lang="en-US">Reconciliation of cash, cash equivalents and restricted cash reported in the consolidated balance sheets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Restricted cash included in other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by (used in) financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xml:lang="en-US">Other financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xml:lang="en-US">Redemption of convertible senior notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSeniorDebt" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xml:lang="en-US">Repayments of Senior Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xml:lang="en-US">Repayment of senior notes and loans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:to="lab_us-gaap_RepaymentsOfSeniorDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Non-cash&#160;financing and investing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" xlink:label="loc_teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" xml:lang="en-US">Beneficial Interest Obtained in Exchange for Securitized Trade Receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" xml:lang="en-US">Beneficial interest obtained in exchange for securitized accounts receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" xlink:to="lab_teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" xml:lang="en-US">Beneficial Interest Obtained in Exchange for Securitized Trade Receivables</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_BasisOfPresentationAbstract" xlink:label="loc_teva_BasisOfPresentationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_BasisOfPresentationAbstract" xml:lang="en-US">Basis of Presentation [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_BasisOfPresentationAbstract" xlink:to="lab_teva_BasisOfPresentationAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Basis of presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TextBlockAbstract" xml:lang="en-US">Text Block [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TextBlockAbstract" xlink:to="lab_us-gaap_TextBlockAbstract" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_CertainTransactionsDisclosureTextBlock" xlink:label="loc_teva_CertainTransactionsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_CertainTransactionsDisclosureTextBlock" xml:lang="en-US">Certain Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_CertainTransactionsDisclosureTextBlock" xml:lang="en-US">Certain transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_CertainTransactionsDisclosureTextBlock" xlink:to="lab_teva_CertainTransactionsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_CertainTransactionsDisclosureTextBlock" xml:lang="en-US">This element may be used for the entire related party transactions disclosure as a single block of text. Disclosure may include: business acquisitions, agreements with related parties, significant cooperation agreements, the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xml:lang="en-US">Revenue from contracts with customers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xml:lang="en-US">Inventory Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xml:lang="en-US">Inventories</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xml:lang="en-US">Identifiable Intangible Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillDisclosureTextBlock" xml:lang="en-US">Goodwill Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GoodwillDisclosureTextBlock" xml:lang="en-US">Goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Debt Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xml:lang="en-US">Derivative Instruments and Hedging Activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xml:lang="en-US">Legal Settlements and Loss Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OtherExpensesTextBlock" xlink:label="loc_teva_OtherExpensesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OtherExpensesTextBlock" xml:lang="en-US">Other Expenses [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OtherExpensesTextBlock" xml:lang="en-US">Other assets impairments, restructuring and other items</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OtherExpensesTextBlock" xlink:to="lab_teva_OtherExpensesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OtherExpensesTextBlock" xml:lang="en-US">Other Expenses [Text Block]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings (Loss) per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Accumulated other comprehensive income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingAbstract" xml:lang="en-US">Segment Reporting [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xml:lang="en-US">Segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair value measurement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="loc_teva_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xml:lang="en-US">Recently Issued Accounting Pronouncements Not Yet Adopted [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xml:lang="en-US">Recently issued accounting pronouncements, not yet adopted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:to="lab_teva_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xml:lang="en-US">Recently issued accounting pronouncements not yet adopted.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recently adopted and issued accounting pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" xlink:label="loc_teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" xml:lang="en-US">Schedule Of Assets And Liabilities Held For Sale [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" xml:lang="en-US">Summary of Major Classes of Assets and Liabilities Included as Held for Sale</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" xlink:to="lab_teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" xml:lang="en-US">Schedule Of Assets And Liabilities Held For Sale [Table Text Block]</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SalesReservesAndAllowancesCurrentTableTextBlock" xlink:label="loc_teva_SalesReservesAndAllowancesCurrentTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SalesReservesAndAllowancesCurrentTableTextBlock" xml:lang="en-US">Sales Reserves And Allowances Current [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SalesReservesAndAllowancesCurrentTableTextBlock" xml:lang="en-US">Summary of Sales Reserves and Allowances</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SalesReservesAndAllowancesCurrentTableTextBlock" xlink:to="lab_teva_SalesReservesAndAllowancesCurrentTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SalesReservesAndAllowancesCurrentTableTextBlock" xml:lang="en-US">Tabular disclosure of sales reserves and allowances current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xml:lang="en-US">Summary of disaggregates revenues by major revenue streams</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xml:lang="en-US">Summary of Inventories</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xml:lang="en-US">Summary of Identifiable Intangible Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xml:lang="en-US">Summary of Changes in the Carrying Amount of Goodwill by Segment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xml:lang="en-US">Required Annual Principal Payments of Long-term Debt, Excluding Debt Issuance Cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTextBlock" xml:lang="en-US">Schedule of Short-term Debt [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTextBlock" xml:lang="en-US">Schedule of Short-term Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xml:lang="en-US">Summary of Classification and Fair Values of Derivative Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xml:lang="en-US">Schedule of Cash Flow Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xml:lang="en-US">Information Regarding The Location And Amount Of Pretax (Gains) Losses Of Derivatives Designated In Fair Value Or Cash Flow Hedging Relationships</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ScheduleOfRestructuringChargesTableTextBlock" xlink:label="loc_teva_ScheduleOfRestructuringChargesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ScheduleOfRestructuringChargesTableTextBlock" xml:lang="en-US">Schedule of Restructuring Charges [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ScheduleOfRestructuringChargesTableTextBlock" xml:lang="en-US">Summary of Restructuring Plan Including Costs Related to Exit and Disposal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ScheduleOfRestructuringChargesTableTextBlock" xlink:to="lab_teva_ScheduleOfRestructuringChargesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ScheduleOfRestructuringChargesTableTextBlock" xml:lang="en-US">Schedule of Restructuring Charges [Table Text Block]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xml:lang="en-US">Summary of Restructuring Accruals</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xml:lang="en-US">Schedule of Other Assets Impairments, Restructuring and Other Items</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xml:lang="en-US">Accumulated Other Comprehensive Income/(Loss) (Net of Tax)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xml:lang="en-US">Summary of Segment Profit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock" xlink:label="loc_teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock" xml:lang="en-US">Schedule Of Consolidated Income Before Income Tax [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock" xml:lang="en-US">Schedule Of Consolidated Income Before Income Tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock" xlink:to="lab_teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock" xml:lang="en-US">Schedule of consolidated income before income tax.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xml:lang="en-US">Schedule of Net Sales by Product Line</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US">Summary of Financial Items Carried at Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xml:lang="en-US">Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xml:lang="en-US">Summary of Financial Instrument Measured on a Basis Other Than Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xml:lang="en-US">Business Combination, Consideration Transferred [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionsTable" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionsTable" xml:lang="en-US">Noncash or Part Noncash Acquisitions [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionsTable" xml:lang="en-US">Noncash or Part Noncash Acquisitions [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_CounterpartyNameAxis" xml:lang="en-US">Counterparty Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_CounterpartyNameAxis" xml:lang="en-US">Counterparty Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xml:lang="en-US">Counterparty Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xml:lang="en-US">Counterparty Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xml:lang="en-US">Business Acquisition [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xml:lang="en-US">Business Acquisition [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AlderMember" xlink:label="loc_teva_AlderMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AlderMember" xml:lang="en-US">Alder [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AlderMember" xml:lang="en-US">Alder [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AlderMember" xlink:to="lab_teva_AlderMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AlderMember" xml:lang="en-US">Alder [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AlvotechMember" xlink:label="loc_teva_AlvotechMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AlvotechMember" xml:lang="en-US">Alvotech [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AlvotechMember" xml:lang="en-US">Alvotech [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AlvotechMember" xlink:to="lab_teva_AlvotechMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AlvotechMember" xml:lang="en-US">Alvotech.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OtsukaMember" xlink:label="loc_teva_OtsukaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OtsukaMember" xml:lang="en-US">Otsuka [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OtsukaMember" xml:lang="en-US">Otsuka [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OtsukaMember" xlink:to="lab_teva_OtsukaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OtsukaMember" xml:lang="en-US">Otsuka [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RegeneronMember" xlink:label="loc_teva_RegeneronMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RegeneronMember" xml:lang="en-US">Regeneron [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_RegeneronMember" xml:lang="en-US">Regeneron [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RegeneronMember" xlink:to="lab_teva_RegeneronMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_RegeneronMember" xml:lang="en-US">Regeneron [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ModagMember" xlink:label="loc_teva_ModagMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ModagMember" xml:lang="en-US">Modag [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ModagMember" xml:lang="en-US">MODAG [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ModagMember" xlink:to="lab_teva_ModagMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ModagMember" xml:lang="en-US">Modag .</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_MedincellMember" xlink:label="loc_teva_MedincellMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_MedincellMember" xml:lang="en-US">MedinCell [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_MedincellMember" xlink:to="lab_teva_MedincellMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_MedincellMember" xml:lang="en-US">MedinCell [ Member].</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_TakedaMember" xlink:label="loc_teva_TakedaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_TakedaMember" xml:lang="en-US">Takeda [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_TakedaMember" xml:lang="en-US">Takeda [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_TakedaMember" xlink:to="lab_teva_TakedaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_TakedaMember" xml:lang="en-US">Takeda.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionsLineItems" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems" xml:lang="en-US">Noncash or Part Noncash Acquisitions [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems" xml:lang="en-US">Noncash or Part Noncash Acquisitions [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ResearchAndDevelopmentCosts" xlink:label="loc_teva_ResearchAndDevelopmentCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ResearchAndDevelopmentCosts" xml:lang="en-US">Research And Development Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ResearchAndDevelopmentCosts" xml:lang="en-US">Research and development costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ResearchAndDevelopmentCosts" xlink:to="lab_teva_ResearchAndDevelopmentCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ResearchAndDevelopmentCosts" xml:lang="en-US">Research And Development Costs</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_CollaborativeAgreementMilestonePayments" xlink:label="loc_teva_CollaborativeAgreementMilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_CollaborativeAgreementMilestonePayments" xml:lang="en-US">Collaborative Agreement Milestone Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_CollaborativeAgreementMilestonePayments" xml:lang="en-US">Collaborative agreement milestone payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_CollaborativeAgreementMilestonePayments" xlink:to="lab_teva_CollaborativeAgreementMilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_CollaborativeAgreementMilestonePayments" xml:lang="en-US">Collaborative Agreement Milestone Payments</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_UpfrontPayments" xlink:label="loc_teva_UpfrontPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_UpfrontPayments" xml:lang="en-US">Upfront Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_UpfrontPayments" xml:lang="en-US">Upfront payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_UpfrontPayments" xlink:to="lab_teva_UpfrontPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_UpfrontPayments" xml:lang="en-US">Upfront payments</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount" xlink:label="loc_teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount" xml:lang="en-US">License Agreement Potential Aggregate Milestone Payments Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount" xml:lang="en-US">License agreement potential aggregate milestone payments amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount" xlink:to="lab_teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount" xml:lang="en-US">License agreement potential aggregate milestone payments amount.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_MilestonePayment" xlink:label="loc_teva_MilestonePayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_MilestonePayment" xml:lang="en-US">Milestone Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_MilestonePayment" xml:lang="en-US">Milestone payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_MilestonePayment" xlink:to="lab_teva_MilestonePayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_MilestonePayment" xml:lang="en-US">Milestone payment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xml:lang="en-US">Lease Contractual Term [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xml:lang="en-US">Lease Contractual Term [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xml:lang="en-US">Lease Contractual Term [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xml:lang="en-US">Lease Contractual Term [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xml:lang="en-US">Business Combinations [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Goodwill, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" xml:lang="en-US">Goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xml:lang="en-US">Total liabilities of the disposal group classified as held for sale in the consolidated balance sheets, recorded under accrued expenses and other long-term liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xml:lang="en-US">Inventories</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueAdjustment" xlink:label="loc_us-gaap_AssetsFairValueAdjustment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsFairValueAdjustment" xml:lang="en-US">Assets, Fair Value Adjustment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsFairValueAdjustment" xml:lang="en-US">Adjustments of assets held for sale to fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueAdjustment" xlink:to="lab_us-gaap_AssetsFairValueAdjustment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xml:lang="en-US">Property, plant and equipment, net and others</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="loc_us-gaap_RevenueRecognitionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionAbstract" xml:lang="en-US">Revenue Recognition [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionAbstract" xlink:to="lab_us-gaap_RevenueRecognitionAbstract" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RevenueRecognitionTable" xlink:label="loc_teva_RevenueRecognitionTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RevenueRecognitionTable" xml:lang="en-US">Revenue Recognition [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_RevenueRecognitionTable" xml:lang="en-US">Revenue Recognition [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RevenueRecognitionTable" xlink:to="lab_teva_RevenueRecognitionTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_RevenueRecognitionTable" xml:lang="en-US">Revenue Recognition [Table]</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RevenueRecognitionLineItems" xlink:label="loc_teva_RevenueRecognitionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RevenueRecognitionLineItems" xml:lang="en-US">Revenue Recognition [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_RevenueRecognitionLineItems" xml:lang="en-US">Revenue Recognition [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RevenueRecognitionLineItems" xlink:to="lab_teva_RevenueRecognitionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_RevenueRecognitionLineItems" xml:lang="en-US">Revenue Recognition [Line Items]</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SalesReservesAndAllowancesToCustomersPercentage" xlink:label="loc_teva_SalesReservesAndAllowancesToCustomersPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SalesReservesAndAllowancesToCustomersPercentage" xml:lang="en-US">Sales Reserves and Allowances to Customers Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SalesReservesAndAllowancesToCustomersPercentage" xml:lang="en-US">Percentage sales reserves and allowances to U.S. customers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SalesReservesAndAllowancesToCustomersPercentage" xlink:to="lab_teva_SalesReservesAndAllowancesToCustomersPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SalesReservesAndAllowancesToCustomersPercentage" xml:lang="en-US">Sales reserves and allowances to customers percentage.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementGeographicalAxis" xml:lang="en-US">Geographical [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_StatementGeographicalAxis" xml:lang="en-US">Geographical [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_SegmentGeographicalDomain" xml:lang="en-US">Geographical [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_SegmentGeographicalDomain" xml:lang="en-US">Geographical [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_US" xml:lang="en-US">UNITED STATES</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_US" xml:lang="en-US">United States [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract" xml:lang="en-US">Disaggregation of Revenue [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract" xlink:to="lab_us-gaap_DisaggregationOfRevenueAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xml:lang="en-US">Disaggregation of Revenue [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xml:lang="en-US">Disaggregation of Revenue [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xml:lang="en-US">Disaggregation of Revenue [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xml:lang="en-US">Disaggregation of Revenue [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xml:lang="en-US">Segments [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xml:lang="en-US">Segments [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentDomain" xml:lang="en-US">Segments [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentDomain" xml:lang="en-US">Segments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_InternationalMarketsMember" xlink:label="loc_teva_InternationalMarketsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_InternationalMarketsMember" xml:lang="en-US">International Markets [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_InternationalMarketsMember" xml:lang="en-US">International Markets [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_InternationalMarketsMember" xlink:to="lab_teva_InternationalMarketsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_InternationalMarketsMember" xml:lang="en-US">International markets.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OtherActivitiesMember" xlink:label="loc_teva_OtherActivitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OtherActivitiesMember" xml:lang="en-US">Other Activities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OtherActivitiesMember" xml:lang="en-US">Other activities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OtherActivitiesMember" xlink:to="lab_teva_OtherActivitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OtherActivitiesMember" xml:lang="en-US">Other Activities [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DistributionServiceMember" xlink:label="loc_us-gaap_DistributionServiceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DistributionServiceMember" xml:lang="en-US">Distribution Service [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DistributionServiceMember" xml:lang="en-US">Distribution [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DistributionServiceMember" xlink:to="lab_us-gaap_DistributionServiceMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xml:lang="en-US">Product and Service, Other [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xml:lang="en-US">Other [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LicenseMember" xml:lang="en-US">License [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LicenseMember" xml:lang="en-US">Licensing Arrangements [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProductMember" xml:lang="en-US">Product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProductMember" xml:lang="en-US">Sale of Goods [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_EuropeMember" xml:lang="en-US">Europe [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_EuropeMember" xml:lang="en-US">Europe [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NorthAmericaMember" xlink:label="loc_srt_NorthAmericaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_NorthAmericaMember" xml:lang="en-US">North America [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_NorthAmericaMember" xml:lang="en-US">North America [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NorthAmericaMember" xlink:to="lab_srt_NorthAmericaMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_TotalReservesIncludedInSalesReservesAndAllowancesMember" xlink:label="loc_teva_TotalReservesIncludedInSalesReservesAndAllowancesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_TotalReservesIncludedInSalesReservesAndAllowancesMember" xml:lang="en-US">Total Reserves Included In Sales Reserves And Allowances [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_TotalReservesIncludedInSalesReservesAndAllowancesMember" xml:lang="en-US">Total Reserves Included in Sales Reserves and Allowances [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_TotalReservesIncludedInSalesReservesAndAllowancesMember" xlink:to="lab_teva_TotalReservesIncludedInSalesReservesAndAllowancesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_TotalReservesIncludedInSalesReservesAndAllowancesMember" xml:lang="en-US">Total reserves included in sales reserves and allowances.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ChargebacksMember" xlink:label="loc_teva_ChargebacksMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ChargebacksMember" xml:lang="en-US">Chargebacks [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ChargebacksMember" xml:lang="en-US">Chargebacks [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ChargebacksMember" xlink:to="lab_teva_ChargebacksMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ChargebacksMember" xml:lang="en-US">Chargebacks.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OtherSalesReservesAndAllowancesMember" xlink:label="loc_teva_OtherSalesReservesAndAllowancesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OtherSalesReservesAndAllowancesMember" xml:lang="en-US">Other Sales Reserves And Allowances [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OtherSalesReservesAndAllowancesMember" xml:lang="en-US">Other [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OtherSalesReservesAndAllowancesMember" xlink:to="lab_teva_OtherSalesReservesAndAllowancesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OtherSalesReservesAndAllowancesMember" xml:lang="en-US">Other sales reserves and allowances.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ReservesIncludedInAccountsReceivableNetMember" xlink:label="loc_teva_ReservesIncludedInAccountsReceivableNetMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ReservesIncludedInAccountsReceivableNetMember" xml:lang="en-US">Reserves Included In Accounts Receivable Net [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ReservesIncludedInAccountsReceivableNetMember" xml:lang="en-US">Reserves Included in Accounts Receivable, Net [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ReservesIncludedInAccountsReceivableNetMember" xlink:to="lab_teva_ReservesIncludedInAccountsReceivableNetMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ReservesIncludedInAccountsReceivableNetMember" xml:lang="en-US">Reserves included in accounts receivable net.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ReturnsMember" xlink:label="loc_teva_ReturnsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ReturnsMember" xml:lang="en-US">Returns [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ReturnsMember" xml:lang="en-US">Returns [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ReturnsMember" xlink:to="lab_teva_ReturnsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ReturnsMember" xml:lang="en-US">Returns.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_MedicaidAndOtherGovernmentalAllowancesMember" xlink:label="loc_teva_MedicaidAndOtherGovernmentalAllowancesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_MedicaidAndOtherGovernmentalAllowancesMember" xml:lang="en-US">Medicaid And Other Governmental Allowances [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_MedicaidAndOtherGovernmentalAllowancesMember" xml:lang="en-US">Medicaid and Other Governmental Allowances [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_MedicaidAndOtherGovernmentalAllowancesMember" xlink:to="lab_teva_MedicaidAndOtherGovernmentalAllowancesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_MedicaidAndOtherGovernmentalAllowancesMember" xml:lang="en-US">Medicaid and other governmental allowances.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RebatesMember" xlink:label="loc_teva_RebatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RebatesMember" xml:lang="en-US">Rebates [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_RebatesMember" xml:lang="en-US">Rebates [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RebatesMember" xlink:to="lab_teva_RebatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_RebatesMember" xml:lang="en-US">Rebates.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xml:lang="en-US">Balance at end of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xml:lang="en-US">Balance at beginning of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" xlink:label="loc_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" xml:lang="en-US">Valuation Allowances And Reserves Related To Current Period Sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" xml:lang="en-US">Provisions related to sales made in current year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" xlink:to="lab_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" xml:lang="en-US">Valuation allowances and reserves related to current period sales.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xml:lang="en-US">Credits and payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ValuationAllowancesAndReservesForeignCurrencyTranslation" xlink:label="loc_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation" xml:lang="en-US">Valuation Allowances And Reserves Foreign Currency Translation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation" xml:lang="en-US">Translation differences</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation" xlink:to="lab_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation" xml:lang="en-US">Valuation allowances and reserves foreign currency translation.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales" xlink:label="loc_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales" xml:lang="en-US">Valuation Allowances And Reserves Related To Prior Period Sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales" xml:lang="en-US">Provisions related to sales made in prior periods</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales" xlink:to="lab_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales" xml:lang="en-US">Valuation allowances and reserves related to prior period sales.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_InventoriesTable" xlink:label="loc_teva_InventoriesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_InventoriesTable" xml:lang="en-US">Inventories [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_InventoriesTable" xml:lang="en-US">Inventories [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_InventoriesTable" xlink:to="lab_teva_InventoriesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_InventoriesTable" xml:lang="en-US">Inventories [Table]</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_InventoriesLineItems" xlink:label="loc_teva_InventoriesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_InventoriesLineItems" xml:lang="en-US">Inventories [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_InventoriesLineItems" xml:lang="en-US">Inventories [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_InventoriesLineItems" xlink:to="lab_teva_InventoriesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_InventoriesLineItems" xml:lang="en-US">Inventories [Line Items]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xml:lang="en-US">Raw and packaging materials</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xml:lang="en-US">Products in process</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xml:lang="en-US">Finished products</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventoryInTransit" xlink:label="loc_us-gaap_OtherInventoryInTransit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherInventoryInTransit" xml:lang="en-US">Other Inventory, in Transit, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherInventoryInTransit" xml:lang="en-US">Materials in transit and payments on account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInventoryInTransit" xlink:to="lab_us-gaap_OtherInventoryInTransit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xml:lang="en-US">Accumulated amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xml:lang="en-US">Gross carrying amount net of impairment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TradeNamesMember" xml:lang="en-US">Trade Names [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TradeNamesMember" xml:lang="en-US">Trade names [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ProductRightsMember" xlink:label="loc_teva_ProductRightsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ProductRightsMember" xml:lang="en-US">Product Rights [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_teva_ProductRightsMember" xml:lang="en-US">Product rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ProductRightsMember" xml:lang="en-US">Identifiable product rights [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ProductRightsMember" xlink:to="lab_teva_ProductRightsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ProductRightsMember" xml:lang="en-US">Product Rights [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xml:lang="en-US">In Process Research and Development [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xml:lang="en-US">In process research and development [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xml:lang="en-US">In Process Research and Development [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_GenericPipelineProductsMember" xlink:label="loc_teva_GenericPipelineProductsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_GenericPipelineProductsMember" xml:lang="en-US">Generic Pipeline Products [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_GenericPipelineProductsMember" xlink:to="lab_teva_GenericPipelineProductsMember" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_DiscontinuationOfBusinessAxis" xlink:label="loc_teva_DiscontinuationOfBusinessAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DiscontinuationOfBusinessAxis" xml:lang="en-US">Discontinuation Of Business [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DiscontinuationOfBusinessAxis" xlink:to="lab_teva_DiscontinuationOfBusinessAxis" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_DiscontinuationOfBusinessDomain" xlink:label="loc_teva_DiscontinuationOfBusinessDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DiscontinuationOfBusinessDomain" xml:lang="en-US">Discontinuation Of Business [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DiscontinuationOfBusinessDomain" xlink:to="lab_teva_DiscontinuationOfBusinessDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTypeAxis" xlink:label="loc_us-gaap_ReclassificationTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReclassificationTypeAxis" xml:lang="en-US">Reclassification, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationTypeAxis" xlink:to="lab_us-gaap_ReclassificationTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTypeDomain" xlink:label="loc_us-gaap_ReclassificationTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReclassificationTypeDomain" xml:lang="en-US">Reclassification, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationTypeDomain" xlink:to="lab_us-gaap_ReclassificationTypeDomain" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_InprocessresearchandDevelopmenttoProductRightsMember" xlink:label="loc_teva_InprocessresearchandDevelopmenttoProductRightsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_InprocessresearchandDevelopmenttoProductRightsMember" xml:lang="en-US">In Process Research And Development To Product Rights [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_InprocessresearchandDevelopmenttoProductRightsMember" xml:lang="en-US">In Process Research And Development To Product Rights [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_InprocessresearchandDevelopmenttoProductRightsMember" xlink:to="lab_teva_InprocessresearchandDevelopmenttoProductRightsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_InprocessresearchandDevelopmenttoProductRightsMember" xml:lang="en-US">In Process Research And Development To Product Rights [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ActavisMember" xlink:label="loc_teva_ActavisMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ActavisMember" xml:lang="en-US">Actavis [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ActavisMember" xml:lang="en-US">Actavis [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ActavisMember" xlink:to="lab_teva_ActavisMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ActavisMember" xml:lang="en-US">Actavis [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xml:lang="en-US">Business combination recognized identifiable assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Amortization of Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Amortization of intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xml:lang="en-US">Impairment of intangible assets excluding goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xml:lang="en-US">Intangible assets impairments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xml:lang="en-US">Business combination, contingent consideration, liability, measurement input</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xml:lang="en-US">Amortization of intangible assets useful life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis" xlink:label="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis" xml:lang="en-US">Impairment Of Intangible Assets Reasons For Impairment [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis" xlink:to="lab_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis" xml:lang="en-US">Impairment Of Intangible Assets Reasons For Impairment.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain" xlink:label="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain" xml:lang="en-US">Impairment Of Intangible Assets Reasons For Impairment [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain" xlink:to="lab_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain" xml:lang="en-US">Impairment Of Intangible Assets Reasons For Impairment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xml:lang="en-US">Measurement Input Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xml:lang="en-US">Measurement Input Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xml:lang="en-US">Measurement Input, Discount Rate [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xml:lang="en-US">Measurement input, discount rate [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillRollForward" xml:lang="en-US">Goodwill [Roll Forward]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xml:lang="en-US">Schedule of Goodwill [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xml:lang="en-US">Schedule of Goodwill [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ConsolidationItemsAxis" xml:lang="en-US">Consolidation Items [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ConsolidationItemsDomain" xml:lang="en-US">Consolidation Items [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillLineItems" xml:lang="en-US">Goodwill [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GoodwillLineItems" xml:lang="en-US">Goodwill [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xml:lang="en-US">Translation differences</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xml:lang="en-US">Goodwill, Acquired During Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xml:lang="en-US">Goodwill acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OtherCountriesMember" xlink:label="loc_teva_OtherCountriesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OtherCountriesMember" xml:lang="en-US">Other Countries [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OtherCountriesMember" xml:lang="en-US">Other [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OtherCountriesMember" xlink:to="lab_teva_OtherCountriesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OtherCountriesMember" xml:lang="en-US">Other countries.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xml:lang="en-US">Accumulated goodwill impairment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xml:lang="en-US">Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xml:lang="en-US">Reporting unit percentage of fair value in excess of carrying amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:to="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_MeasurementInputTerminalGrowthRateMember" xlink:label="loc_teva_MeasurementInputTerminalGrowthRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_MeasurementInputTerminalGrowthRateMember" xml:lang="en-US">Measurement Input Terminal Growth Rate [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_MeasurementInputTerminalGrowthRateMember" xlink:to="lab_teva_MeasurementInputTerminalGrowthRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_MeasurementInputTerminalGrowthRateMember" xml:lang="en-US">Measurement input terminal growth rate.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis" xlink:label="loc_us-gaap_ReportingUnitAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReportingUnitAxis" xml:lang="en-US">Reporting Unit [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitAxis" xlink:to="lab_us-gaap_ReportingUnitAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain" xlink:label="loc_us-gaap_ReportingUnitDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReportingUnitDomain" xml:lang="en-US">Reporting Unit [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitDomain" xlink:to="lab_us-gaap_ReportingUnitDomain" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_NorthAmericaAndMedisReportingUnitsMember" xlink:label="loc_teva_NorthAmericaAndMedisReportingUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_NorthAmericaAndMedisReportingUnitsMember" xml:lang="en-US">North America and Medis Reporting Units [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_NorthAmericaAndMedisReportingUnitsMember" xlink:to="lab_teva_NorthAmericaAndMedisReportingUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_NorthAmericaAndMedisReportingUnitsMember" xml:lang="en-US">North america and medis reporting units.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_InternationalMarketsReportingUnitMember" xlink:label="loc_teva_InternationalMarketsReportingUnitMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_InternationalMarketsReportingUnitMember" xml:lang="en-US">International Markets Reporting Unit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_InternationalMarketsReportingUnitMember" xlink:to="lab_teva_InternationalMarketsReportingUnitMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_InternationalMarketsReportingUnitMember" xml:lang="en-US">International markets reporting unit.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_TevasEuropeReportingUnitMember" xlink:label="loc_teva_TevasEuropeReportingUnitMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_TevasEuropeReportingUnitMember" xml:lang="en-US">Tevas Europe Reporting Unit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_TevasEuropeReportingUnitMember" xlink:to="lab_teva_TevasEuropeReportingUnitMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_TevasEuropeReportingUnitMember" xml:lang="en-US">Teva's europe reporting unit.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_TevasApiReportingUnitMember" xlink:label="loc_teva_TevasApiReportingUnitMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_TevasApiReportingUnitMember" xml:lang="en-US">Tevas API Reporting Unit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_TevasApiReportingUnitMember" xlink:to="lab_teva_TevasApiReportingUnitMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_TevasApiReportingUnitMember" xml:lang="en-US">Teva's API reporting unit.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentTable" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentTable" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityAxis" xml:lang="en-US">Credit Facility [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CreditFacilityAxis" xml:lang="en-US">Credit Facility [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityDomain" xml:lang="en-US">Credit Facility [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CreditFacilityDomain" xml:lang="en-US">Credit Facility [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_CurrencyAxis" xml:lang="en-US">Currency [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_CurrencyAxis" xml:lang="en-US">Currency [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_AllCurrenciesDomain" xml:lang="en-US">All Currencies [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_currency_AllCurrenciesDomain" xml:lang="en-US">All Currencies [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ShortCreditAgreement2026Member" xlink:label="loc_teva_ShortCreditAgreement2026Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ShortCreditAgreement2026Member" xml:lang="en-US">Short Credit Agreement 2026 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ShortCreditAgreement2026Member" xml:lang="en-US">Convertible senior debentures [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ShortCreditAgreement2026Member" xlink:to="lab_teva_ShortCreditAgreement2026Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ShortCreditAgreement2026Member" xml:lang="en-US">Short credit agreement 2026.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtCurrent" xml:lang="en-US">Long-term Debt, Current Maturities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtCurrent" xml:lang="en-US">Current maturities of long-term liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LongTermDebtCurrent" xml:lang="en-US">Less current maturities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaap_ShortTermBorrowings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermBorrowings" xml:lang="en-US">Short-term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermBorrowings" xml:lang="en-US">Convertible senior debentures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings" xlink:to="lab_us-gaap_ShortTermBorrowings" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_DebtInstrumentMaturityYear" xlink:label="loc_teva_DebtInstrumentMaturityYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DebtInstrumentMaturityYear" xml:lang="en-US">Debt Instrument Maturity Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_DebtInstrumentMaturityYear" xml:lang="en-US">Maturity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DebtInstrumentMaturityYear" xlink:to="lab_teva_DebtInstrumentMaturityYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_DebtInstrumentMaturityYear" xml:lang="en-US">Debt Instrument Maturity Year</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xml:lang="en-US">Weighted average interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableRateAxis" xml:lang="en-US">Variable Rate [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_VariableRateAxis" xml:lang="en-US">Variable Rate [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableRateDomain" xml:lang="en-US">Variable Rate [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_VariableRateDomain" xml:lang="en-US">Variable Rate [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2046Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2046Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2046Member" xml:lang="en-US">Subsidiary Senior Notes Due 2046 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2046Member" xml:lang="en-US">Senior notes USD 2,000 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2046Member" xlink:to="lab_teva_SubsidiarySeniorNotesDue2046Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2046Member" xml:lang="en-US">Subsidiary senior notes due 2046.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2028OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2028OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2028OneMember" xml:lang="en-US">Subsidiary Senior Notes Due 2028 One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2028OneMember" xml:lang="en-US">Senior notes USD 1,250 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2028OneMember" xlink:to="lab_teva_SubsidiarySeniorNotesDue2028OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2028OneMember" xml:lang="en-US">Subsidiary Senior Notes Due 2028 One [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OtherDebentures2026Member" xlink:label="loc_teva_OtherDebentures2026Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OtherDebentures2026Member" xml:lang="en-US">Other Debentures 2026 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OtherDebentures2026Member" xml:lang="en-US">Other Debentures [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OtherDebentures2026Member" xlink:to="lab_teva_OtherDebentures2026Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OtherDebentures2026Member" xml:lang="en-US">Other debentures 2026.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2026OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2026OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2026OneMember" xml:lang="en-US">Subsidiary Senior Notes Due 2026 One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2026OneMember" xml:lang="en-US">Senior notes USD 3,500 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2026OneMember" xlink:to="lab_teva_SubsidiarySeniorNotesDue2026OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2026OneMember" xml:lang="en-US">Subsidiary senior notes due 2026 one.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2025ThreeMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025ThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2025ThreeMember" xml:lang="en-US">Subsidiary Senior Notes Due 2025 Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2025ThreeMember" xml:lang="en-US">Senior notes CHF 350 Million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2025ThreeMember" xlink:to="lab_teva_SubsidiarySeniorNotesDue2025ThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2025ThreeMember" xml:lang="en-US">Subsidiary senior notes due 2025 three.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2023OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2023OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2023OneMember" xml:lang="en-US">Subsidiary Senior Notes Due 2023 One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2023OneMember" xml:lang="en-US">Senior notes EUR 1,300 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2023OneMember" xlink:to="lab_teva_SubsidiarySeniorNotesDue2023OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2023OneMember" xml:lang="en-US">Subsidiary senior notes due 2023 one.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2036Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2036Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2036Member" xml:lang="en-US">Subsidiary Senior Notes Due 2036 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2036Member" xml:lang="en-US">Senior notes USD 789 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2036Member" xlink:to="lab_teva_SubsidiarySeniorNotesDue2036Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2036Member" xml:lang="en-US">Subsidiary senior notes due 2036.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2025TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025TwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2025TwoMember" xml:lang="en-US">Subsidiary Senior Notes Due 2025 Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2025TwoMember" xml:lang="en-US">Senior notes USD 1,000 million [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2025TwoMember" xml:lang="en-US">Senior notes USD 1,000 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2025TwoMember" xlink:to="lab_teva_SubsidiarySeniorNotesDue2025TwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2025TwoMember" xml:lang="en-US">Subsidiary senior notes due 2025 two.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2024OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2024OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2024OneMember" xml:lang="en-US">Subsidiary Senior Notes Due 2024 One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2024OneMember" xml:lang="en-US">Senior notes USD 1,250 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2024OneMember" xlink:to="lab_teva_SubsidiarySeniorNotesDue2024OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2024OneMember" xml:lang="en-US">Subsidiary Senior Notes Due 2024 One [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2024Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2024Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2024Member" xml:lang="en-US">Subsidiary Senior Notes Due 2024 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2024Member" xml:lang="en-US">Senior notes EUR 1,500 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2024Member" xlink:to="lab_teva_SubsidiarySeniorNotesDue2024Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2024Member" xml:lang="en-US">Subsidiary senior notes due 2024.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2027Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2027Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2027Member" xml:lang="en-US">Subsidiary Senior Notes Due 2027 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2027Member" xml:lang="en-US">Senior notes EUR 700 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2027Member" xlink:to="lab_teva_SubsidiarySeniorNotesDue2027Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2027Member" xml:lang="en-US">Subsidiary senior notes due 2027.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2022OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2022OneMember" xml:lang="en-US">Subsidiary Senior Notes Due 2022 One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2022OneMember" xml:lang="en-US">Senior notes EUR 700 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2022OneMember" xlink:to="lab_teva_SubsidiarySeniorNotesDue2022OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2022OneMember" xml:lang="en-US">Subsidiary senior notes due 2022 one.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2023TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2023TwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2023TwoMember" xml:lang="en-US">Subsidiary Senior Notes Due 2023 Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2023TwoMember" xml:lang="en-US">Senior notes USD 3,000 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2023TwoMember" xlink:to="lab_teva_SubsidiarySeniorNotesDue2023TwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2023TwoMember" xml:lang="en-US">Subsidiary senior notes due 2023 two.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SustainabilityLinkedSeniorNotesDue2030Member" xlink:label="loc_teva_SustainabilityLinkedSeniorNotesDue2030Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SustainabilityLinkedSeniorNotesDue2030Member" xml:lang="en-US">Sustainability Linked Senior Notes Due 2030 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SustainabilityLinkedSeniorNotesDue2030Member" xml:lang="en-US">Sustainability-linked senior notes EUR 1,500&#160;million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SustainabilityLinkedSeniorNotesDue2030Member" xlink:to="lab_teva_SustainabilityLinkedSeniorNotesDue2030Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SustainabilityLinkedSeniorNotesDue2030Member" xml:lang="en-US">Sustainability linked senior notes due 2030.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2028Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2028Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2028Member" xml:lang="en-US">Subsidiary Senior Notes Due 2028 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2028Member" xml:lang="en-US">Senior notes EUR 750 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2028Member" xlink:to="lab_teva_SubsidiarySeniorNotesDue2028Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2028Member" xml:lang="en-US">Subsidiary senior notes due 2028.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2022TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022TwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2022TwoMember" xml:lang="en-US">Subsidiary Senior Notes Due 2022 Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2022TwoMember" xml:lang="en-US">Senior notes USD 844 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2022TwoMember" xlink:to="lab_teva_SubsidiarySeniorNotesDue2022TwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2022TwoMember" xml:lang="en-US">Subsidiary senior notes due 2022 two.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2022ThreeMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022ThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2022ThreeMember" xml:lang="en-US">Subsidiary Senior Notes Due 2022 Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2022ThreeMember" xml:lang="en-US">Senior notes CHF 350 Million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2022ThreeMember" xlink:to="lab_teva_SubsidiarySeniorNotesDue2022ThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2022ThreeMember" xml:lang="en-US">Subsidiary Senior Notes Due 2022 Three [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2025Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2025Member" xml:lang="en-US">Subsidiary Senior Notes Due 2025 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2025Member" xml:lang="en-US">Senior notes EUR 900 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2025Member" xlink:to="lab_teva_SubsidiarySeniorNotesDue2025Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2025Member" xml:lang="en-US">Subsidiary Senior Notes Due 2025 Member</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2025OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2025OneMember" xml:lang="en-US">Subsidiary Senior Notes Due 2025 One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2025OneMember" xml:lang="en-US">Senior notes EUR 1,000 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2025OneMember" xlink:to="lab_teva_SubsidiarySeniorNotesDue2025OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2025OneMember" xml:lang="en-US">Subsidiary Senior Notes Due 2025 One [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SustainabilityLinkedSeniorNotesDue2027Member" xlink:label="loc_teva_SustainabilityLinkedSeniorNotesDue2027Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SustainabilityLinkedSeniorNotesDue2027Member" xml:lang="en-US">Sustainability Linked Senior Notes Due 2027 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SustainabilityLinkedSeniorNotesDue2027Member" xml:lang="en-US">Sustainability-linked senior notes EUR 1,100&#160;million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SustainabilityLinkedSeniorNotesDue2027Member" xlink:to="lab_teva_SustainabilityLinkedSeniorNotesDue2027Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SustainabilityLinkedSeniorNotesDue2027Member" xml:lang="en-US">Sustainability linked senior notes due 2027.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SustainabilityLinkedSeniorNotesDue2027TwoMember" xlink:label="loc_teva_SustainabilityLinkedSeniorNotesDue2027TwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SustainabilityLinkedSeniorNotesDue2027TwoMember" xml:lang="en-US">Sustainability Linked Senior Notes Due 2027 Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SustainabilityLinkedSeniorNotesDue2027TwoMember" xml:lang="en-US">Sustainability-linked senior notes USD 1,000&#160;million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SustainabilityLinkedSeniorNotesDue2027TwoMember" xlink:to="lab_teva_SustainabilityLinkedSeniorNotesDue2027TwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SustainabilityLinkedSeniorNotesDue2027TwoMember" xml:lang="en-US">Sustainability linked senior notes due 2027 two.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SustainabilityLinkedSeniorNotesDue2029Member" xlink:label="loc_teva_SustainabilityLinkedSeniorNotesDue2029Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SustainabilityLinkedSeniorNotesDue2029Member" xml:lang="en-US">Sustainability Linked Senior Notes Due 2029 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SustainabilityLinkedSeniorNotesDue2029Member" xml:lang="en-US">Sustainability-linked senior notes USD 1,000&#160;million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SustainabilityLinkedSeniorNotesDue2029Member" xlink:to="lab_teva_SustainabilityLinkedSeniorNotesDue2029Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SustainabilityLinkedSeniorNotesDue2029Member" xml:lang="en-US">Sustainability linked senior notes due 2029.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotes" xlink:label="loc_us-gaap_SeniorNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeniorNotes" xml:lang="en-US">Senior Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeniorNotes" xml:lang="en-US">Total senior notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotes" xlink:to="lab_us-gaap_SeniorNotes" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xml:lang="en-US">Debt Issuance Costs, Noncurrent, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xml:lang="en-US">Less debt issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:label="loc_us-gaap_LongtermDebtWeightedAverageInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtWeightedAverageInterestRate" xml:lang="en-US">Long-term Debt, Weighted Average Interest Rate, at Point in Time</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LongtermDebtWeightedAverageInterestRate" xml:lang="en-US">Weighted average interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_LongtermDebtWeightedAverageInterestRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xml:lang="en-US">Long-term Debt, Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xml:lang="en-US">Long-term Debt, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xml:lang="en-US">Long-term Debt, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xml:lang="en-US">Long-term Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeniorNotesMember" xml:lang="en-US">Senior Notes [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt instrument face amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xml:lang="en-US">Debt Instrument, Interest Rate, Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xml:lang="en-US">Debt Instrument, Interest Rate, Increase (Decrease)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:to="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Debt Instrument, Maturity Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Debt Instrument, Maturity Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SeniorNotesRepaidAmount" xlink:label="loc_teva_SeniorNotesRepaidAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SeniorNotesRepaidAmount" xml:lang="en-US">Senior Notes Repaid Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_teva_SeniorNotesRepaidAmount" xml:lang="en-US">Senior notes repaid amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SeniorNotesRepaidAmount" xlink:to="lab_teva_SeniorNotesRepaidAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SeniorNotesRepaidAmount" xml:lang="en-US">Senior notes repaid amount.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SeniorNotesMaturityPercentage" xlink:label="loc_teva_SeniorNotesMaturityPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SeniorNotesMaturityPercentage" xml:lang="en-US">Senior Notes Maturity Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_teva_SeniorNotesMaturityPercentage" xml:lang="en-US">Senior notes maturity percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SeniorNotesMaturityPercentage" xlink:to="lab_teva_SeniorNotesMaturityPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SeniorNotesMaturityPercentage" xml:lang="en-US">Senior notes maturity percentage.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2030Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2030Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2030Member" xml:lang="en-US">Subsidiary Senior Notes Due 2030 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2030Member" xml:lang="en-US">Sustainability-linked senior notes EUR 1,500 million</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2030Member" xlink:to="lab_teva_SubsidiarySeniorNotesDue2030Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2030Member" xml:lang="en-US">Subsidiary senior notes due 2030.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_InterestRateIncreaseMember" xlink:label="loc_teva_InterestRateIncreaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_InterestRateIncreaseMember" xml:lang="en-US">Interest Rate Increase [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_InterestRateIncreaseMember" xlink:to="lab_teva_InterestRateIncreaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_InterestRateIncreaseMember" xml:lang="en-US">Interest rate increase.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OneTimePremiumPaymentMember" xlink:label="loc_teva_OneTimePremiumPaymentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OneTimePremiumPaymentMember" xml:lang="en-US">One Time Premium Payment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OneTimePremiumPaymentMember" xlink:to="lab_teva_OneTimePremiumPaymentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OneTimePremiumPaymentMember" xml:lang="en-US">One time&#160;premium payment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xml:lang="en-US">Lender Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LongTermDebtCurrencyPortionCHF" xlink:label="loc_teva_LongTermDebtCurrencyPortionCHF" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LongTermDebtCurrencyPortionCHF" xml:lang="en-US">Long Term Debt Currency Portion C H F</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LongTermDebtCurrencyPortionCHF" xml:lang="en-US">Long term debt currency portion CHF</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LongTermDebtCurrencyPortionCHF" xlink:to="lab_teva_LongTermDebtCurrencyPortionCHF" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LongTermDebtCurrencyPortionCHF" xml:lang="en-US">Long term debt currency portion C H F.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LongTermDebtCurrencyPortionEUR" xlink:label="loc_teva_LongTermDebtCurrencyPortionEUR" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LongTermDebtCurrencyPortionEUR" xml:lang="en-US">Long Term Debt Currency Portion E U R</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LongTermDebtCurrencyPortionEUR" xml:lang="en-US">Long term debt currency portion EUR</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LongTermDebtCurrencyPortionEUR" xlink:to="lab_teva_LongTermDebtCurrencyPortionEUR" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LongTermDebtCurrencyPortionEUR" xml:lang="en-US">Long term debt currency portion E U R.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xml:lang="en-US">Long-term Debt, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xml:lang="en-US">Principal amount currently outstanding on the debt instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LongTermDebtCurrencyPortionUSD" xlink:label="loc_teva_LongTermDebtCurrencyPortionUSD" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LongTermDebtCurrencyPortionUSD" xml:lang="en-US">Long Term Debt Currency Portion U S D</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LongTermDebtCurrencyPortionUSD" xml:lang="en-US">Long term debt currency portion USD</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LongTermDebtCurrencyPortionUSD" xlink:to="lab_teva_LongTermDebtCurrencyPortionUSD" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LongTermDebtCurrencyPortionUSD" xml:lang="en-US">Long term debt currency portion U S D.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCovenantDescription" xlink:label="loc_us-gaap_DebtInstrumentCovenantDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentCovenantDescription" xml:lang="en-US">Debt Instrument, Covenant Description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCovenantDescription" xlink:to="lab_us-gaap_DebtInstrumentCovenantDescription" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LineOfCreditExtentionPeriod" xlink:label="loc_teva_LineOfCreditExtentionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LineOfCreditExtentionPeriod" xml:lang="en-US">Line Of Credit Extention Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LineOfCreditExtentionPeriod" xlink:to="lab_teva_LineOfCreditExtentionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LineOfCreditExtentionPeriod" xml:lang="en-US">Line of credit extention period.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LeverageRatio" xlink:label="loc_teva_LeverageRatio" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LeverageRatio" xml:lang="en-US">Leverage Ratio</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LeverageRatio" xlink:to="lab_teva_LeverageRatio" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LeverageRatio" xml:lang="en-US">Leverage ratio.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xml:lang="en-US">Short-term Debt, Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xml:lang="en-US">Short-term Debt, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xml:lang="en-US">Short-term Debt, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xml:lang="en-US">Short-term Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtMember" xml:lang="en-US">Convertible Debt [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebtMember" xml:lang="en-US">Convertible Debt [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xml:lang="en-US">Revolving Credit Facility [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xml:lang="en-US">Revolving Credit Facility [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_UnsecuredSyndicatedRevolvingCreditFacilityMember" xlink:label="loc_teva_UnsecuredSyndicatedRevolvingCreditFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_UnsecuredSyndicatedRevolvingCreditFacilityMember" xml:lang="en-US">Unsecured Syndicated Revolving Credit Facility [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_UnsecuredSyndicatedRevolvingCreditFacilityMember" xlink:to="lab_teva_UnsecuredSyndicatedRevolvingCreditFacilityMember" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AgreementAxis" xlink:label="loc_teva_AgreementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AgreementAxis" xml:lang="en-US">Agreement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AgreementAxis" xlink:to="lab_teva_AgreementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AgreementAxis" xml:lang="en-US">Agreement.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AgreementDomain" xlink:label="loc_teva_AgreementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AgreementDomain" xml:lang="en-US">Agreement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AgreementDomain" xlink:to="lab_teva_AgreementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AgreementDomain" xml:lang="en-US">Agreement.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_TrancheAxis" xlink:label="loc_teva_TrancheAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_TrancheAxis" xml:lang="en-US">Tranche [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_TrancheAxis" xlink:to="lab_teva_TrancheAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_TrancheAxis" xml:lang="en-US">Tranche.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_TrancheDomain" xlink:label="loc_teva_TrancheDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_TrancheDomain" xml:lang="en-US">Tranche [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_TrancheDomain" xlink:to="lab_teva_TrancheDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_TrancheDomain" xml:lang="en-US">Tranche.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentDetailAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeInstrumentDetailAbstract" xml:lang="en-US">Derivative Instrument Detail [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentDetailAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeTable" xml:lang="en-US">Derivative [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeTable" xml:lang="en-US">Derivative [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLineItems" xml:lang="en-US">Derivative [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeLineItems" xml:lang="en-US">Derivative [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xml:lang="en-US">Liability derivatives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xml:lang="en-US">Asset derivatives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xml:lang="en-US">Hedging Relationship [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xml:lang="en-US">Hedging Relationship [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xml:lang="en-US">Hedging Relationship [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xml:lang="en-US">Hedging Relationship [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xml:lang="en-US">Derivative Instrument [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xml:lang="en-US">Derivative Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xml:lang="en-US">Derivative Contract [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xml:lang="en-US">Derivative Contract [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xml:lang="en-US">Foreign Exchange Contract [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xml:lang="en-US">Foreign Exchange Contract [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HedgingDesignationAxis" xml:lang="en-US">Hedging Designation [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_HedgingDesignationAxis" xml:lang="en-US">Hedging Designation [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HedgingDesignationDomain" xml:lang="en-US">Hedging Designation [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_HedgingDesignationDomain" xml:lang="en-US">Hedging Designation [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NondesignatedMember" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NondesignatedMember" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xml:lang="en-US">Balance Sheet Location [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xml:lang="en-US">Balance Sheet Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xml:lang="en-US">Balance Sheet Location [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xml:lang="en-US">Balance Sheet Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SeniorNotesAndLoansMember" xlink:label="loc_teva_SeniorNotesAndLoansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SeniorNotesAndLoansMember" xml:lang="en-US">Senior Notes And Loans [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SeniorNotesAndLoansMember" xml:lang="en-US">Accounts Payable [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SeniorNotesAndLoansMember" xlink:to="lab_teva_SeniorNotesAndLoansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SeniorNotesAndLoansMember" xml:lang="en-US">Senior notes and loans.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xml:lang="en-US">Other Current Assets [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_NetRevenuesMember" xlink:label="loc_teva_NetRevenuesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_NetRevenuesMember" xml:lang="en-US">Net Revenues [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_NetRevenuesMember" xml:lang="en-US">Net Revenues [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_NetRevenuesMember" xlink:to="lab_teva_NetRevenuesMember" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_FinancialExpensesMember" xlink:label="loc_teva_FinancialExpensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_FinancialExpensesMember" xml:lang="en-US">Financial expenses [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_FinancialExpensesMember" xml:lang="en-US">Financial expenses [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_FinancialExpensesMember" xlink:to="lab_teva_FinancialExpensesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotDesignatedAsHedgingInstrumentTradingMember" xlink:label="loc_us-gaap_NotDesignatedAsHedgingInstrumentTradingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotDesignatedAsHedgingInstrumentTradingMember" xml:lang="en-US">Not Designated as Hedging Instrument, Trading [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NotDesignatedAsHedgingInstrumentTradingMember" xml:lang="en-US">Not Designated as Hedging Instrument, Trading [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotDesignatedAsHedgingInstrumentTradingMember" xlink:to="lab_us-gaap_NotDesignatedAsHedgingInstrumentTradingMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember" xlink:label="loc_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember" xml:lang="en-US">Not Designated as Hedging Instrument, Economic Hedge [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember" xml:lang="en-US">Not Designated as Hedging Instrument, Economic Hedge [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember" xlink:to="lab_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfSalesMember" xml:lang="en-US">Cost of sales [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SeniorNotesDue2023TwoMember" xlink:label="loc_teva_SeniorNotesDue2023TwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SeniorNotesDue2023TwoMember" xml:lang="en-US">Senior Notes Due 2023 Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SeniorNotesDue2023TwoMember" xml:lang="en-US">Senior Notes Due 2023 Two [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SeniorNotesDue2023TwoMember" xlink:to="lab_teva_SeniorNotesDue2023TwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SeniorNotesDue2023TwoMember" xml:lang="en-US">Senior notes due 2023 two.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SeniorNotesDue2022Member" xlink:label="loc_teva_SeniorNotesDue2022Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SeniorNotesDue2022Member" xml:lang="en-US">Senior Notes Due 2022 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SeniorNotesDue2022Member" xml:lang="en-US">Senior Notes Due 2022 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SeniorNotesDue2022Member" xlink:to="lab_teva_SeniorNotesDue2022Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SeniorNotesDue2022Member" xml:lang="en-US">Senior notes due 2022.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SeniorNotesDue2021Member" xlink:label="loc_teva_SeniorNotesDue2021Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SeniorNotesDue2021Member" xml:lang="en-US">Senior Notes Due 2021 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SeniorNotesDue2021Member" xml:lang="en-US">Senior Notes Due 2021 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SeniorNotesDue2021Member" xlink:to="lab_teva_SeniorNotesDue2021Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SeniorNotesDue2021Member" xml:lang="en-US">Senior Notes Due 2021 [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RevenuesOtherThanUsd" xlink:label="loc_teva_RevenuesOtherThanUsd" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RevenuesOtherThanUsd" xml:lang="en-US">Revenues Other Than Usd</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_RevenuesOtherThanUsd" xml:lang="en-US">Revenues other than USD</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RevenuesOtherThanUsd" xlink:to="lab_teva_RevenuesOtherThanUsd" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_RevenuesOtherThanUsd" xml:lang="en-US">Revenues other than US Dollar.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_PreviouslyHedgeDebtRate" xlink:label="loc_teva_PreviouslyHedgeDebtRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_PreviouslyHedgeDebtRate" xml:lang="en-US">Previously Hedge Debt Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_PreviouslyHedgeDebtRate" xml:lang="en-US">Previously hedge debt rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_PreviouslyHedgeDebtRate" xlink:to="lab_teva_PreviouslyHedgeDebtRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_PreviouslyHedgeDebtRate" xml:lang="en-US">Previously hedge debt rate.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_NotionalAmountHedgeDebt" xlink:label="loc_teva_NotionalAmountHedgeDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_NotionalAmountHedgeDebt" xml:lang="en-US">Notional Amount Hedge Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_NotionalAmountHedgeDebt" xml:lang="en-US">Notional amount hedge debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_NotionalAmountHedgeDebt" xlink:to="lab_teva_NotionalAmountHedgeDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_NotionalAmountHedgeDebt" xml:lang="en-US">Notional amount hedge debt.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="loc_us-gaap_DerivativeGainOnDerivative" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeGainOnDerivative" xml:lang="en-US">Derivative, Gain on Derivative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainOnDerivative" xlink:to="lab_us-gaap_DerivativeGainOnDerivative" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" xlink:label="loc_teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" xml:lang="en-US">Forward Starting Interest Rate Swaps And Treasury Lock Agreements Losses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" xml:lang="en-US">Forward starting interest rate swaps and treasury lock agreements losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" xlink:to="lab_teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" xml:lang="en-US">Forward starting interest rate swaps and treasury lock agreements losses.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="loc_us-gaap_DerivativeLossOnDerivative" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLossOnDerivative" xml:lang="en-US">Derivative, Loss on Derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeLossOnDerivative" xml:lang="en-US">Teva other comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLossOnDerivative" xlink:to="lab_us-gaap_DerivativeLossOnDerivative" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_CashReceivedOnSettlementOfPosition" xlink:label="loc_teva_CashReceivedOnSettlementOfPosition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_CashReceivedOnSettlementOfPosition" xml:lang="en-US">Cash Received On Settlement Of Position</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_CashReceivedOnSettlementOfPosition" xml:lang="en-US">Cash received on settlement of position</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_CashReceivedOnSettlementOfPosition" xlink:to="lab_teva_CashReceivedOnSettlementOfPosition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_CashReceivedOnSettlementOfPosition" xml:lang="en-US">Notional amount hedge debt.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_InterestRateSwapLoss" xlink:label="loc_teva_InterestRateSwapLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_InterestRateSwapLoss" xml:lang="en-US">Interest Rate Swap Loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_InterestRateSwapLoss" xlink:to="lab_teva_InterestRateSwapLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_InterestRateSwapLoss" xml:lang="en-US">Interest rate swap loss.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss" xlink:label="loc_us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss" xml:lang="en-US">Derivative, Fair Value Hedge, Included in Effectiveness, Gain (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss" xml:lang="en-US">Derivative, Fair Value Hedge, Included in Effectiveness, Gain (Loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss" xlink:to="lab_us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingenciesTable" xml:lang="en-US">Loss Contingencies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingenciesTable" xml:lang="en-US">Loss Contingencies [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingenciesLineItems" xml:lang="en-US">Loss Contingencies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingenciesLineItems" xml:lang="en-US">Loss Contingencies [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xml:lang="en-US">Loss Contingency Accrual</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xml:lang="en-US">Accrued amount for legal settlements and loss contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xml:lang="en-US">Generic modafinil, and imposed fines amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LitigationSettlementExpense" xml:lang="en-US">Litigation Settlement, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LitigationSettlementExpense" xml:lang="en-US">Legal settlements and loss contingencies, expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LitigationSettlementExpense" xml:lang="en-US">Litigation Settlement, Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RestructuringExpenseAndIncome" xlink:label="loc_teva_RestructuringExpenseAndIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RestructuringExpenseAndIncome" xml:lang="en-US">Restructuring expense and income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_RestructuringExpenseAndIncome" xml:lang="en-US">Restructuring expense and income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RestructuringExpenseAndIncome" xlink:to="lab_teva_RestructuringExpenseAndIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_RestructuringExpenseAndIncome" xml:lang="en-US">Restructuring expense and income</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_LitigationCaseAxis" xml:lang="en-US">Litigation Case [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_LitigationCaseTypeDomain" xml:lang="en-US">Litigation Case [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SettlementOnAccountOfProductLiabilityMember" xlink:label="loc_teva_SettlementOnAccountOfProductLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SettlementOnAccountOfProductLiabilityMember" xml:lang="en-US">Settlement On Account Of Product Liability [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SettlementOnAccountOfProductLiabilityMember" xlink:to="lab_teva_SettlementOnAccountOfProductLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SettlementOnAccountOfProductLiabilityMember" xml:lang="en-US">Settlement On Account Of Product Liability.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_CommitmentAndContingenciesTable" xlink:label="loc_teva_CommitmentAndContingenciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_CommitmentAndContingenciesTable" xml:lang="en-US">Commitment And Contingencies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_CommitmentAndContingenciesTable" xml:lang="en-US">Commitment And Contingencies [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_CommitmentAndContingenciesTable" xlink:to="lab_teva_CommitmentAndContingenciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_CommitmentAndContingenciesTable" xml:lang="en-US">Commitment And Contingencies [Table]</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_CommitmentAndContingenciesLineItems" xlink:label="loc_teva_CommitmentAndContingenciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_CommitmentAndContingenciesLineItems" xml:lang="en-US">Commitment And Contingencies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_CommitmentAndContingenciesLineItems" xml:lang="en-US">Commitment And Contingencies [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_CommitmentAndContingenciesLineItems" xlink:to="lab_teva_CommitmentAndContingenciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_CommitmentAndContingenciesLineItems" xml:lang="en-US">Commitment And Contingencies [Line Items]</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AnnualSalesOfCopaxone" xlink:label="loc_teva_AnnualSalesOfCopaxone" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AnnualSalesOfCopaxone" xml:lang="en-US">Annual Sales Of Copaxone</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AnnualSalesOfCopaxone" xml:lang="en-US">Annual sales of Copaxone</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AnnualSalesOfCopaxone" xlink:to="lab_teva_AnnualSalesOfCopaxone" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AnnualSalesOfCopaxone" xml:lang="en-US">Annual Sales Of Copaxone.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AnnualSalesOfSensipar" xlink:label="loc_teva_AnnualSalesOfSensipar" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AnnualSalesOfSensipar" xml:lang="en-US">Annual Sales Of Sensipar</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AnnualSalesOfSensipar" xlink:to="lab_teva_AnnualSalesOfSensipar" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AnnualSalesOfSensipar" xml:lang="en-US">Represents Annual Sales Of Sensipar.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_DamagesAssessment" xlink:label="loc_teva_DamagesAssessment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DamagesAssessment" xml:lang="en-US">Damages Assessment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_DamagesAssessment" xml:lang="en-US">Damages assessment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DamagesAssessment" xlink:to="lab_teva_DamagesAssessment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_DamagesAssessment" xml:lang="en-US">Damages assessment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xml:lang="en-US">Litigation settlement amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LitigationSettlementAmountAwardedDistributionPeriod" xlink:label="loc_teva_LitigationSettlementAmountAwardedDistributionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LitigationSettlementAmountAwardedDistributionPeriod" xml:lang="en-US">Litigation Settlement Amount Awarded Distribution Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LitigationSettlementAmountAwardedDistributionPeriod" xml:lang="en-US">Litigation settlement amount awarded distribution period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LitigationSettlementAmountAwardedDistributionPeriod" xlink:to="lab_teva_LitigationSettlementAmountAwardedDistributionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LitigationSettlementAmountAwardedDistributionPeriod" xml:lang="en-US">Litigation settlement amount awarded distribution period.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AnnualSalesOfNiaspan" xlink:label="loc_teva_AnnualSalesOfNiaspan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AnnualSalesOfNiaspan" xml:lang="en-US">Annual Sales Of Niaspan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AnnualSalesOfNiaspan" xml:lang="en-US">Annual sales of Niaspan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AnnualSalesOfNiaspan" xlink:to="lab_teva_AnnualSalesOfNiaspan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AnnualSalesOfNiaspan" xml:lang="en-US">Annual sales of Niaspan.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AnnualSalesOfActoplus" xlink:label="loc_teva_AnnualSalesOfActoplus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AnnualSalesOfActoplus" xml:lang="en-US">Annual Sales Of Actoplus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AnnualSalesOfActoplus" xml:lang="en-US">Annual sales of Acto plus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AnnualSalesOfActoplus" xlink:to="lab_teva_AnnualSalesOfActoplus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AnnualSalesOfActoplus" xml:lang="en-US">Annual sales of Acto plus.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LitigationSettlementAmountAwardedCashAmountDistributionPeriod" xlink:label="loc_teva_LitigationSettlementAmountAwardedCashAmountDistributionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LitigationSettlementAmountAwardedCashAmountDistributionPeriod" xml:lang="en-US">Litigation Settlement Amount Awarded Cash Amount Distribution Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LitigationSettlementAmountAwardedCashAmountDistributionPeriod" xml:lang="en-US">Litigation settlement amount awarded cash amount distribution period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LitigationSettlementAmountAwardedCashAmountDistributionPeriod" xlink:to="lab_teva_LitigationSettlementAmountAwardedCashAmountDistributionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LitigationSettlementAmountAwardedCashAmountDistributionPeriod" xml:lang="en-US">Litigation settlement amount awarded cash amount distribution period.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AnnualSalesAtTimeOfSettlement" xlink:label="loc_teva_AnnualSalesAtTimeOfSettlement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AnnualSalesAtTimeOfSettlement" xml:lang="en-US">Annual Sales At Time Of Settlement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AnnualSalesAtTimeOfSettlement" xml:lang="en-US">Annual sales at the time of settlement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AnnualSalesAtTimeOfSettlement" xlink:to="lab_teva_AnnualSalesAtTimeOfSettlement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AnnualSalesAtTimeOfSettlement" xml:lang="en-US">Annual sales at time of settlement.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AnnualSalesOfActos" xlink:label="loc_teva_AnnualSalesOfActos" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AnnualSalesOfActos" xml:lang="en-US">Annual Sales Of Actos</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AnnualSalesOfActos" xml:lang="en-US">Annual sales of Actos</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AnnualSalesOfActos" xlink:to="lab_teva_AnnualSalesOfActos" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AnnualSalesOfActos" xml:lang="en-US">Annual sales of Actos.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LitigationSettlementAmountAwardedCashAmount" xlink:label="loc_teva_LitigationSettlementAmountAwardedCashAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LitigationSettlementAmountAwardedCashAmount" xml:lang="en-US">Litigation Settlement Amount Awarded Cash Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LitigationSettlementAmountAwardedCashAmount" xml:lang="en-US">Litigation settlement amount awarded cash amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LitigationSettlementAmountAwardedCashAmount" xlink:to="lab_teva_LitigationSettlementAmountAwardedCashAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LitigationSettlementAmountAwardedCashAmount" xml:lang="en-US">Litigation settlement amount awarded cash amount.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualProvision" xlink:label="loc_us-gaap_LossContingencyAccrualProvision" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyAccrualProvision" xml:lang="en-US">Loss Contingency Accrual, Provision</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyAccrualProvision" xml:lang="en-US">Loss Contingency Accrual, Provision</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualProvision" xlink:to="lab_us-gaap_LossContingencyAccrualProvision" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LitigationSettlementAmountDistributableinKind" xlink:label="loc_teva_LitigationSettlementAmountDistributableinKind" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LitigationSettlementAmountDistributableinKind" xml:lang="en-US">Litigation Settlement Amount DistributableIn Kind</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LitigationSettlementAmountDistributableinKind" xml:lang="en-US">Litigation Settlement Amount DistributableIn Kind</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LitigationSettlementAmountDistributableinKind" xlink:to="lab_teva_LitigationSettlementAmountDistributableinKind" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LitigationSettlementAmountDistributableinKind" xml:lang="en-US">Litigation settlement amount distributableIn kind.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AnnualSalesOfLamictal" xlink:label="loc_teva_AnnualSalesOfLamictal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AnnualSalesOfLamictal" xml:lang="en-US">Annual Sales Of Lamictal</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AnnualSalesOfLamictal" xml:lang="en-US">Annual sales of Lamictal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AnnualSalesOfLamictal" xlink:to="lab_teva_AnnualSalesOfLamictal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AnnualSalesOfLamictal" xml:lang="en-US">Annual sales of Lamictal.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AnnualSalesOfNarcan" xlink:label="loc_teva_AnnualSalesOfNarcan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AnnualSalesOfNarcan" xml:lang="en-US">Annual sales of Narcan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AnnualSalesOfNarcan" xml:lang="en-US">Annual sales of Narcan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AnnualSalesOfNarcan" xlink:to="lab_teva_AnnualSalesOfNarcan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AnnualSalesOfNarcan" xml:lang="en-US">Annual sales of narcan.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xml:lang="en-US">Loss Contingency, Damages Sought, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xml:lang="en-US">Damage claimed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LossContingenciesOnEnvironmentalLawsPenalty" xlink:label="loc_teva_LossContingenciesOnEnvironmentalLawsPenalty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LossContingenciesOnEnvironmentalLawsPenalty" xml:lang="en-US">Loss Contingencies On Environmental Laws Penalty</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LossContingenciesOnEnvironmentalLawsPenalty" xml:lang="en-US">Loss Contingencies On Environmental Laws Penalty</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LossContingenciesOnEnvironmentalLawsPenalty" xlink:to="lab_teva_LossContingenciesOnEnvironmentalLawsPenalty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LossContingenciesOnEnvironmentalLawsPenalty" xml:lang="en-US">Loss contingencies on environmental laws penalty.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AnnualSalesOfEffexor" xlink:label="loc_teva_AnnualSalesOfEffexor" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AnnualSalesOfEffexor" xml:lang="en-US">Annual Sales Of Effexor</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AnnualSalesOfEffexor" xml:lang="en-US">Annual sales of Effexor</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AnnualSalesOfEffexor" xlink:to="lab_teva_AnnualSalesOfEffexor" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AnnualSalesOfEffexor" xml:lang="en-US">Annual sales of effexor.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyDamagesPaidValue" xml:lang="en-US">Loss Contingency, Damages Paid, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyDamagesPaidValue" xml:lang="en-US">Loss contingency payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesPaidValue" xlink:to="lab_us-gaap_LossContingencyDamagesPaidValue" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LossContingencyClaimsDismissedValue" xlink:label="loc_teva_LossContingencyClaimsDismissedValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LossContingencyClaimsDismissedValue" xml:lang="en-US">Loss Contingency Claims Dismissed Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LossContingencyClaimsDismissedValue" xml:lang="en-US">Loss Contingency Claims Dismissed Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LossContingencyClaimsDismissedValue" xlink:to="lab_teva_LossContingencyClaimsDismissedValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LossContingencyClaimsDismissedValue" xml:lang="en-US">Loss contingency claims dismissed value.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccrualForEnvironmentalLossContingencies" xlink:label="loc_us-gaap_AccrualForEnvironmentalLossContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccrualForEnvironmentalLossContingencies" xml:lang="en-US">Accrual for Environmental Loss Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccrualForEnvironmentalLossContingencies" xml:lang="en-US">Accrual for Environmental Loss Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccrualForEnvironmentalLossContingencies" xlink:to="lab_us-gaap_AccrualForEnvironmentalLossContingencies" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_PercentageOfPopulationOfSubdivisionsWillFormallyReleaseAsAPartOfSettlement" xlink:label="loc_teva_PercentageOfPopulationOfSubdivisionsWillFormallyReleaseAsAPartOfSettlement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_PercentageOfPopulationOfSubdivisionsWillFormallyReleaseAsAPartOfSettlement" xml:lang="en-US">Percentage of population of subdivisions will formally release as a part of settlement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_PercentageOfPopulationOfSubdivisionsWillFormallyReleaseAsAPartOfSettlement" xml:lang="en-US">Percentage of population of subdivisions will formally release as a part of settlement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_PercentageOfPopulationOfSubdivisionsWillFormallyReleaseAsAPartOfSettlement" xlink:to="lab_teva_PercentageOfPopulationOfSubdivisionsWillFormallyReleaseAsAPartOfSettlement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_PercentageOfPopulationOfSubdivisionsWillFormallyReleaseAsAPartOfSettlement" xml:lang="en-US">Percentage of population of subdivisions will formally release as a part of settlement</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AnnualSalesAtTheTimeOfLaunchOfProduct" xlink:label="loc_teva_AnnualSalesAtTheTimeOfLaunchOfProduct" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AnnualSalesAtTheTimeOfLaunchOfProduct" xml:lang="en-US">Annual Sales At The Time Of Launch Of Product</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AnnualSalesAtTheTimeOfLaunchOfProduct" xlink:to="lab_teva_AnnualSalesAtTheTimeOfLaunchOfProduct" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AnnualSalesAtTheTimeOfLaunchOfProduct" xml:lang="en-US">Annual sales at the time of launch of product.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LitigationAmountIncludingAlreadyPaid" xlink:label="loc_teva_LitigationAmountIncludingAlreadyPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LitigationAmountIncludingAlreadyPaid" xml:lang="en-US">Litigation Amount Including Already Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LitigationAmountIncludingAlreadyPaid" xml:lang="en-US">Litigation amount including already paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LitigationAmountIncludingAlreadyPaid" xlink:to="lab_teva_LitigationAmountIncludingAlreadyPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LitigationAmountIncludingAlreadyPaid" xml:lang="en-US">Litigation amount including already paid.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LitigationSettlementTerm" xlink:label="loc_teva_LitigationSettlementTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LitigationSettlementTerm" xml:lang="en-US">Litigation Settlement Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LitigationSettlementTerm" xml:lang="en-US">Litigation settlement term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LitigationSettlementTerm" xlink:to="lab_teva_LitigationSettlementTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LitigationSettlementTerm" xml:lang="en-US">Litigation settlement term.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ProductOfferingSettlementAtWholesaleAcquisitionCosts" xlink:label="loc_teva_ProductOfferingSettlementAtWholesaleAcquisitionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ProductOfferingSettlementAtWholesaleAcquisitionCosts" xml:lang="en-US">Product Offering Settlement At Wholesale Acquisition Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ProductOfferingSettlementAtWholesaleAcquisitionCosts" xml:lang="en-US">Product offering in settlement at wholesale acquistion costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ProductOfferingSettlementAtWholesaleAcquisitionCosts" xlink:to="lab_teva_ProductOfferingSettlementAtWholesaleAcquisitionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ProductOfferingSettlementAtWholesaleAcquisitionCosts" xml:lang="en-US">Product offering settlement at wholesale acquisition costs.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ProductToBeSettledValuationTerm" xlink:label="loc_teva_ProductToBeSettledValuationTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ProductToBeSettledValuationTerm" xml:lang="en-US">Product To Be Settled Valuation Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ProductToBeSettledValuationTerm" xml:lang="en-US">Product to be settled valuation term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ProductToBeSettledValuationTerm" xlink:to="lab_teva_ProductToBeSettledValuationTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ProductToBeSettledValuationTerm" xml:lang="en-US">Product settlement term.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_PercentageOfWholesaleAcquisitionCostValueInCashInLieuOfProductToBePaidUnderSettlementAgreement" xlink:label="loc_teva_PercentageOfWholesaleAcquisitionCostValueInCashInLieuOfProductToBePaidUnderSettlementAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_PercentageOfWholesaleAcquisitionCostValueInCashInLieuOfProductToBePaidUnderSettlementAgreement" xml:lang="en-US">Percentage Of Wholesale Acquisition Cost Value In Cash In Lieu Of Product To Be Paid Under Settlement Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_PercentageOfWholesaleAcquisitionCostValueInCashInLieuOfProductToBePaidUnderSettlementAgreement" xml:lang="en-US">Percentage of wholesale acquisition cost value in cash in lieu of product to be paid under settlement agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_PercentageOfWholesaleAcquisitionCostValueInCashInLieuOfProductToBePaidUnderSettlementAgreement" xlink:to="lab_teva_PercentageOfWholesaleAcquisitionCostValueInCashInLieuOfProductToBePaidUnderSettlementAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_PercentageOfWholesaleAcquisitionCostValueInCashInLieuOfProductToBePaidUnderSettlementAgreement" xml:lang="en-US">Percentage of wholesale acquisition cost value in cash in lieu of product to be paid under settlement agreement.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LitigationAmountToBePaidToTribes" xlink:label="loc_teva_LitigationAmountToBePaidToTribes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LitigationAmountToBePaidToTribes" xml:lang="en-US">Litigation Amount To Be Paid To Tribes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LitigationAmountToBePaidToTribes" xml:lang="en-US">Litigation amount to be paid to tribes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LitigationAmountToBePaidToTribes" xlink:to="lab_teva_LitigationAmountToBePaidToTribes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LitigationAmountToBePaidToTribes" xml:lang="en-US">Litigation amount to be paid to tribes.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_WholesaleAcquisitionCostValueInCashAmountInLieuOfProductToBePaidUnderSettlementAgreement" xlink:label="loc_teva_WholesaleAcquisitionCostValueInCashAmountInLieuOfProductToBePaidUnderSettlementAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_WholesaleAcquisitionCostValueInCashAmountInLieuOfProductToBePaidUnderSettlementAgreement" xml:lang="en-US">Wholesale Acquisition Cost Value In Cash Amount In Lieu Of Product To Be Paid Under Settlement Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_WholesaleAcquisitionCostValueInCashAmountInLieuOfProductToBePaidUnderSettlementAgreement" xml:lang="en-US">Wholesale acquisition cost value in cash amount in lieu of product to be paid under settlement agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_WholesaleAcquisitionCostValueInCashAmountInLieuOfProductToBePaidUnderSettlementAgreement" xlink:to="lab_teva_WholesaleAcquisitionCostValueInCashAmountInLieuOfProductToBePaidUnderSettlementAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_WholesaleAcquisitionCostValueInCashAmountInLieuOfProductToBePaidUnderSettlementAgreement" xml:lang="en-US">Wholesale acquisition cost value in cash amount in lieu of product to be paid under settlement agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xml:lang="en-US">Loss Contingency Nature [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xml:lang="en-US">Loss Contingency Nature [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xml:lang="en-US">Loss Contingency, Nature [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xml:lang="en-US">Loss Contingency, Nature [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_EosinophilicEsophagitisMember" xlink:label="loc_teva_EosinophilicEsophagitisMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_EosinophilicEsophagitisMember" xml:lang="en-US">Eosinophilic Esophagitis [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_EosinophilicEsophagitisMember" xml:lang="en-US">Eosinophilic Esophagitis [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_EosinophilicEsophagitisMember" xlink:to="lab_teva_EosinophilicEsophagitisMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_EosinophilicEsophagitisMember" xml:lang="en-US">Eosinophilic Esophagitis [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AttorneyGeneralOfLouisanaMember" xlink:label="loc_teva_AttorneyGeneralOfLouisanaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AttorneyGeneralOfLouisanaMember" xml:lang="en-US">Attorney General Of Louisana [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AttorneyGeneralOfLouisanaMember" xml:lang="en-US">Attorney General Of Louisana [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AttorneyGeneralOfLouisanaMember" xlink:to="lab_teva_AttorneyGeneralOfLouisanaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AttorneyGeneralOfLouisanaMember" xml:lang="en-US">Attorney general of louisana.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AttorneyGeneralOfRhodeIslandMember" xlink:label="loc_teva_AttorneyGeneralOfRhodeIslandMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AttorneyGeneralOfRhodeIslandMember" xml:lang="en-US">Attorney General of Rhode Island [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AttorneyGeneralOfRhodeIslandMember" xlink:to="lab_teva_AttorneyGeneralOfRhodeIslandMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AttorneyGeneralOfRhodeIslandMember" xml:lang="en-US">Attorney General of Rhode Island</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AttorneyGeneralOfFloridaMember" xlink:label="loc_teva_AttorneyGeneralOfFloridaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AttorneyGeneralOfFloridaMember" xml:lang="en-US">Attorney General of Florida [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AttorneyGeneralOfFloridaMember" xlink:to="lab_teva_AttorneyGeneralOfFloridaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AttorneyGeneralOfFloridaMember" xml:lang="en-US">Attorney General of Florida</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AttorneyGeneralOfWestVirginiaMember" xlink:label="loc_teva_AttorneyGeneralOfWestVirginiaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AttorneyGeneralOfWestVirginiaMember" xml:lang="en-US">Attorney General of West Virginia [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AttorneyGeneralOfWestVirginiaMember" xlink:to="lab_teva_AttorneyGeneralOfWestVirginiaMember" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AndroGelRateAtOnePercentageMember" xlink:label="loc_teva_AndroGelRateAtOnePercentageMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AndroGelRateAtOnePercentageMember" xml:lang="en-US">Andro Gel Rate At One Percentage [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AndroGelRateAtOnePercentageMember" xml:lang="en-US">AndroGel Rate at 1% [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AndroGelRateAtOnePercentageMember" xlink:to="lab_teva_AndroGelRateAtOnePercentageMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AndroGelRateAtOnePercentageMember" xml:lang="en-US">Andro gel rate at one percentage.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AtripalaMember" xlink:label="loc_teva_AtripalaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AtripalaMember" xml:lang="en-US">Atripala [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AtripalaMember" xlink:to="lab_teva_AtripalaMember" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_TiruvadaMember" xlink:label="loc_teva_TiruvadaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_TiruvadaMember" xml:lang="en-US">Tiruvada [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_TiruvadaMember" xlink:to="lab_teva_TiruvadaMember" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_VireadMember" xlink:label="loc_teva_VireadMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_VireadMember" xml:lang="en-US">Viread [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_VireadMember" xlink:to="lab_teva_VireadMember" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ColcysMember" xlink:label="loc_teva_ColcysMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ColcysMember" xml:lang="en-US">Colcys [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ColcysMember" xlink:to="lab_teva_ColcysMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_LA" xlink:label="loc_stpr_LA" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_stpr_LA" xml:lang="en-US">LOUISIANA</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_stpr_LA" xml:lang="en-US">Laos [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_LA" xlink:to="lab_stpr_LA" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA" xlink:label="loc_country_CA" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_CA" xml:lang="en-US">CANADA</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CA" xlink:to="lab_country_CA" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_DefendantsAxis" xlink:label="loc_teva_DefendantsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DefendantsAxis" xml:lang="en-US">Defendants [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DefendantsAxis" xlink:to="lab_teva_DefendantsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_DefendantsAxis" xml:lang="en-US">Defendants.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_DefendantsMember" xlink:label="loc_teva_DefendantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DefendantsMember" xml:lang="en-US">Defendants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DefendantsMember" xlink:to="lab_teva_DefendantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_DefendantsMember" xml:lang="en-US">Defendants.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_FourOtherDefendantsOtherThanTevaMember" xlink:label="loc_teva_FourOtherDefendantsOtherThanTevaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_FourOtherDefendantsOtherThanTevaMember" xml:lang="en-US">Four Other Defendants Other Than Teva [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_FourOtherDefendantsOtherThanTevaMember" xml:lang="en-US">Four Other Defendants Other Than Teva [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_FourOtherDefendantsOtherThanTevaMember" xlink:to="lab_teva_FourOtherDefendantsOtherThanTevaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_FourOtherDefendantsOtherThanTevaMember" xml:lang="en-US">Four other defendants other than teva.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_CompaniesShareMember" xlink:label="loc_teva_CompaniesShareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_CompaniesShareMember" xml:lang="en-US">Companies Share [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_CompaniesShareMember" xlink:to="lab_teva_CompaniesShareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_CompaniesShareMember" xml:lang="en-US">Companies share.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OpioidLitigationMember" xlink:label="loc_teva_OpioidLitigationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OpioidLitigationMember" xml:lang="en-US">Opioid Litigation [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OpioidLitigationMember" xlink:to="lab_teva_OpioidLitigationMember" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_NationwideSettlementMember" xlink:label="loc_teva_NationwideSettlementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_NationwideSettlementMember" xml:lang="en-US">Nationwide Settlement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_NationwideSettlementMember" xml:lang="en-US">Nationwide Settlement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_NationwideSettlementMember" xlink:to="lab_teva_NationwideSettlementMember" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_StatesPoliticalSubdivisionsAndTribesMember" xlink:label="loc_teva_StatesPoliticalSubdivisionsAndTribesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_StatesPoliticalSubdivisionsAndTribesMember" xml:lang="en-US">States Political Subdivisions And Tribes [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_StatesPoliticalSubdivisionsAndTribesMember" xml:lang="en-US">States Political Subdivisions and Tribes [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_StatesPoliticalSubdivisionsAndTribesMember" xlink:to="lab_teva_StatesPoliticalSubdivisionsAndTribesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_StatesPoliticalSubdivisionsAndTribesMember" xml:lang="en-US">States political subdivisions and tribes.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_IncomeTaxTable" xlink:label="loc_teva_IncomeTaxTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_IncomeTaxTable" xml:lang="en-US">Income Tax [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_IncomeTaxTable" xml:lang="en-US">Income Tax [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_IncomeTaxTable" xlink:to="lab_teva_IncomeTaxTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_IncomeTaxTable" xml:lang="en-US">Income Tax [Table]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodAxis" xml:lang="en-US">Tax Period [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxPeriodAxis" xml:lang="en-US">Tax Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodDomain" xml:lang="en-US">Tax Period [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxPeriodDomain" xml:lang="en-US">Tax Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_TaxYear2008To2011Member" xlink:label="loc_teva_TaxYear2008To2011Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_TaxYear2008To2011Member" xml:lang="en-US">Tax Year 2008 To 2011 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_TaxYear2008To2011Member" xlink:to="lab_teva_TaxYear2008To2011Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xml:lang="en-US">Income Tax Authority, Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xml:lang="en-US">Income Tax Authority, Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xml:lang="en-US">Income Tax Authority, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xml:lang="en-US">Income Tax Authority, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IsraelTaxAuthorityMember" xlink:label="loc_us-gaap_IsraelTaxAuthorityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IsraelTaxAuthorityMember" xml:lang="en-US">Israel Tax Authority [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IsraelTaxAuthorityMember" xml:lang="en-US">Israel Tax Authority [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IsraelTaxAuthorityMember" xlink:to="lab_us-gaap_IsraelTaxAuthorityMember" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_IncomeTaxLineItems" xlink:label="loc_teva_IncomeTaxLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_IncomeTaxLineItems" xml:lang="en-US">Income Tax [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_IncomeTaxLineItems" xml:lang="en-US">Income Tax [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_IncomeTaxLineItems" xlink:to="lab_teva_IncomeTaxLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_IncomeTaxLineItems" xml:lang="en-US">Income Tax [Line Items]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Statutory tax rate in Israel</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:label="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xml:lang="en-US">Income Tax Examination, Estimate of Possible Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xml:lang="en-US">Income Tax Examination, Estimate of Possible Loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:to="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ExpectedImpairmentOfIncomeTaxBenefit" xlink:label="loc_teva_ExpectedImpairmentOfIncomeTaxBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ExpectedImpairmentOfIncomeTaxBenefit" xml:lang="en-US">Expected Impairment OF Income Tax Benefit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ExpectedImpairmentOfIncomeTaxBenefit" xml:lang="en-US">Expected impairment of income tax benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ExpectedImpairmentOfIncomeTaxBenefit" xlink:to="lab_teva_ExpectedImpairmentOfIncomeTaxBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ExpectedImpairmentOfIncomeTaxBenefit" xml:lang="en-US">Expected impairment of income tax benefit.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryWriteDown" xml:lang="en-US">Inventory Write-down</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryWriteDown" xml:lang="en-US">Obsolete stock written off</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_EffectiveIncomeTaxReconciliationAmountInventoryWrittenOff" xlink:label="loc_teva_EffectiveIncomeTaxReconciliationAmountInventoryWrittenOff" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_EffectiveIncomeTaxReconciliationAmountInventoryWrittenOff" xml:lang="en-US">Effective Income Tax Reconciliation Amount Inventory Written Off</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_EffectiveIncomeTaxReconciliationAmountInventoryWrittenOff" xml:lang="en-US">Effective income tax reconciliation amount inventory written off</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_EffectiveIncomeTaxReconciliationAmountInventoryWrittenOff" xlink:to="lab_teva_EffectiveIncomeTaxReconciliationAmountInventoryWrittenOff" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_EffectiveIncomeTaxReconciliationAmountInventoryWrittenOff" xml:lang="en-US">Effective income tax reconciliation amount inventory written off.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xml:lang="en-US">Category of Item Purchased [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xml:lang="en-US">Category of Item Purchased [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xml:lang="en-US">Long-term Purchase Commitment, Category of Item Purchased [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xml:lang="en-US">Long-term Purchase Commitment, Category of Item Purchased [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xml:lang="en-US">Tax Credit Carryforward [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xml:lang="en-US">Tax Credit Carryforward [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RestructuringAndImpairmentAbstract" xlink:label="loc_teva_RestructuringAndImpairmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RestructuringAndImpairmentAbstract" xml:lang="en-US">Restructuring And Impairment [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RestructuringAndImpairmentAbstract" xlink:to="lab_teva_RestructuringAndImpairmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_RestructuringAndImpairmentAbstract" xml:lang="en-US">Restructuring and impairment.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RestructuringAndImpairmentCostsTable" xlink:label="loc_teva_RestructuringAndImpairmentCostsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RestructuringAndImpairmentCostsTable" xml:lang="en-US">Restructuring And Impairment Costs [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_RestructuringAndImpairmentCostsTable" xml:lang="en-US">Restructuring And Impairment Costs [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable" xlink:to="lab_teva_RestructuringAndImpairmentCostsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_RestructuringAndImpairmentCostsTable" xml:lang="en-US">Restructuring And Impairment Costs [Table]</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RestructuringAndImpairmentCostsLineItems" xlink:label="loc_teva_RestructuringAndImpairmentCostsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RestructuringAndImpairmentCostsLineItems" xml:lang="en-US">Restructuring And Impairment Costs [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_RestructuringAndImpairmentCostsLineItems" xml:lang="en-US">Restructuring and Impairment Costs [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems" xlink:to="lab_teva_RestructuringAndImpairmentCostsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_RestructuringAndImpairmentCostsLineItems" xml:lang="en-US">Restructuring and impairment costs.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses" xlink:label="loc_teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses" xml:lang="en-US">Legal Settlements Loss Contingencies Impairments Other Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses" xlink:to="lab_teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses" xml:lang="en-US">Legal settlements loss contingencies impairments other expenses.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCharges" xml:lang="en-US">Restructuring Charges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestructuringCharges" xml:lang="en-US">Restructuring</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_RestructuringCharges" xml:lang="en-US">Restructuring costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestructuringCharges" xml:lang="en-US">Restructuring charges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xml:lang="en-US">Impairment of Long-Lived Assets Held-for-use</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xml:lang="en-US">Impairments of long-lived tangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ImpairmentAndRestructuring" xlink:label="loc_teva_ImpairmentAndRestructuring" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ImpairmentAndRestructuring" xml:lang="en-US">Impairment And Restructuring</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_teva_ImpairmentAndRestructuring" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ImpairmentAndRestructuring" xlink:to="lab_teva_ImpairmentAndRestructuring" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ImpairmentAndRestructuring" xml:lang="en-US">Impairment and restructuring.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xml:lang="en-US">Contingent consideration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xml:lang="en-US">Business combination contingent consideration arrangements change in amount of contingent consideration liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xml:lang="en-US">Tangible Asset Impairment Charges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xml:lang="en-US">Impairments of property, plant and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:to="lab_us-gaap_TangibleAssetImpairmentCharges" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Development Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xml:lang="en-US">Restructuring and Related Activities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xml:lang="en-US">Restructuring Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xml:lang="en-US">Restructuring Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xml:lang="en-US">Type of Restructuring [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xml:lang="en-US">Type of Restructuring [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember" xlink:label="loc_us-gaap_OtherRestructuringMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherRestructuringMember" xml:lang="en-US">Other Restructuring [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherRestructuringMember" xml:lang="en-US">Other [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringMember" xlink:to="lab_us-gaap_OtherRestructuringMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="loc_us-gaap_EmployeeSeveranceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xml:lang="en-US">Employee Severance [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xml:lang="en-US">Employee termination [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ExitAndDisposalAxis" xlink:label="loc_teva_ExitAndDisposalAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ExitAndDisposalAxis" xml:lang="en-US">Exit And Disposal [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ExitAndDisposalAxis" xml:lang="en-US">Exit And Disposal [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ExitAndDisposalAxis" xlink:to="lab_teva_ExitAndDisposalAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ExitAndDisposalAxis" xml:lang="en-US">Exit And Disposal [Axis]</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ExitAndDisposalDomain" xlink:label="loc_teva_ExitAndDisposalDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ExitAndDisposalDomain" xml:lang="en-US">Exit And Disposal [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ExitAndDisposalDomain" xml:lang="en-US">Exit And Disposal [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ExitAndDisposalDomain" xlink:to="lab_teva_ExitAndDisposalDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ExitAndDisposalDomain" xml:lang="en-US">Exit And Disposal [Domain]</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OtherExitAndDisposalMember" xlink:label="loc_teva_OtherExitAndDisposalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OtherExitAndDisposalMember" xml:lang="en-US">Other Exit And Disposal [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OtherExitAndDisposalMember" xml:lang="en-US">Other Exit and Disposal [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OtherExitAndDisposalMember" xlink:to="lab_teva_OtherExitAndDisposalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OtherExitAndDisposalMember" xml:lang="en-US">Other exit and disposal.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_EmployeeTerminationMember" xlink:label="loc_teva_EmployeeTerminationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_EmployeeTerminationMember" xml:lang="en-US">Employee Termination [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_EmployeeTerminationMember" xml:lang="en-US">Employee termination costs [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_EmployeeTerminationMember" xlink:to="lab_teva_EmployeeTerminationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_EmployeeTerminationMember" xml:lang="en-US">Employee termination.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_UtilizationAndOther" xlink:label="loc_teva_UtilizationAndOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_UtilizationAndOther" xml:lang="en-US">Utilization And Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_UtilizationAndOther" xml:lang="en-US">Utilization and other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_UtilizationAndOther" xlink:to="lab_teva_UtilizationAndOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_UtilizationAndOther" xml:lang="en-US">Utilization and other.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringReserve" xml:lang="en-US">Restructuring Reserve</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="lab_us-gaap_RestructuringReserve" xml:lang="en-US">Ending balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="lab_us-gaap_RestructuringReserve" xml:lang="en-US">Beginning balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RestructuringAccrualProvision" xlink:label="loc_teva_RestructuringAccrualProvision" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RestructuringAccrualProvision" xml:lang="en-US">Restructuring Accrual Provision</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_teva_RestructuringAccrualProvision" xml:lang="en-US">Provision</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RestructuringAccrualProvision" xlink:to="lab_teva_RestructuringAccrualProvision" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_RestructuringAccrualProvision" xml:lang="en-US">Restructuring Accrual Provision</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Weighted average shares with anti-dilutive effect on earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xml:lang="en-US">Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xml:lang="en-US">Convertible Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xml:lang="en-US">Benefit Plans [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xml:lang="en-US">Derivative Financial Instruments [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xml:lang="en-US">Foreign Currency Translation Adjustments [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xml:lang="en-US">Reclassification from AOCI, Current Period, before Tax, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xml:lang="en-US">Amounts reclassified to the statements of income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xml:lang="en-US">Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xml:lang="en-US">Corresponding income tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xml:lang="en-US">Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xml:lang="en-US">Net other comprehensive income (loss) before tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xml:lang="en-US">OCI, before Reclassifications, before Tax, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xml:lang="en-US">Other comprehensive income (loss) before reclassifications</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:to="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xml:lang="en-US">Net other comprehensive income (loss) after tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingStandardsUpdate201601Member" xml:lang="en-US">Accounting Standards Update 2016-01 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountingStandardsUpdate201601Member" xml:lang="en-US">Accounting Standards Update 2016-01 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201601Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201601Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Foreign currency translation attributable to non-controlling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Noncontrolling Interest [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember" xml:lang="en-US">Foreign Currency Translation Adjustments Attributable to Non-controlling Interests [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OtherOperatingIncomeExpense" xlink:label="loc_teva_OtherOperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OtherOperatingIncomeExpense" xml:lang="en-US">Other Operating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_teva_OtherOperatingIncomeExpense" xml:lang="en-US">Other (income) expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OtherOperatingIncomeExpense" xlink:to="lab_teva_OtherOperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OtherOperatingIncomeExpense" xml:lang="en-US">Other Operating Income (Expense)</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_EuropeSegmentMember" xlink:label="loc_teva_EuropeSegmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_EuropeSegmentMember" xml:lang="en-US">Europe Segment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_EuropeSegmentMember" xml:lang="en-US">Europe [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_EuropeSegmentMember" xlink:to="lab_teva_EuropeSegmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_EuropeSegmentMember" xml:lang="en-US">Europe segment.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_NorthAmericaSegmentMember" xlink:label="loc_teva_NorthAmericaSegmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_NorthAmericaSegmentMember" xml:lang="en-US">North America Segment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_NorthAmericaSegmentMember" xml:lang="en-US">North America [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_NorthAmericaSegmentMember" xlink:to="lab_teva_NorthAmericaSegmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_NorthAmericaSegmentMember" xml:lang="en-US">North America segment.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AmountsAllocatedToSegmentsAbstract" xlink:label="loc_teva_AmountsAllocatedToSegmentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AmountsAllocatedToSegmentsAbstract" xml:lang="en-US">Amounts Allocated To Segments [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AmountsAllocatedToSegmentsAbstract" xml:lang="en-US">Amounts allocated to segments:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AmountsAllocatedToSegmentsAbstract" xlink:to="lab_teva_AmountsAllocatedToSegmentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AmountsAllocatedToSegmentsAbstract" xml:lang="en-US">Amounts allocated to segments.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AmountsNotAllocatedToSegmentsAbstract" xlink:label="loc_teva_AmountsNotAllocatedToSegmentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AmountsNotAllocatedToSegmentsAbstract" xml:lang="en-US">Amounts Not Allocated To Segments [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AmountsNotAllocatedToSegmentsAbstract" xml:lang="en-US">Amounts not allocated to segments:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract" xlink:to="lab_teva_AmountsNotAllocatedToSegmentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AmountsNotAllocatedToSegmentsAbstract" xml:lang="en-US">Amounts not allocated to segments.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OtherUnallocatedAmounts" xlink:label="loc_teva_OtherUnallocatedAmounts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OtherUnallocatedAmounts" xml:lang="en-US">Other Unallocated Amounts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OtherUnallocatedAmounts" xml:lang="en-US">Other unallocated amounts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OtherUnallocatedAmounts" xlink:to="lab_teva_OtherUnallocatedAmounts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OtherUnallocatedAmounts" xml:lang="en-US">Other unallocated amounts.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentForAmortization" xml:lang="en-US">Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentForAmortization" xml:lang="en-US">Amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization" xlink:to="lab_us-gaap_AdjustmentForAmortization" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SegmentsAndOtherActivitiesMember" xlink:label="loc_teva_SegmentsAndOtherActivitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SegmentsAndOtherActivitiesMember" xml:lang="en-US">Segments And Other Activities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SegmentsAndOtherActivitiesMember" xml:lang="en-US">Segments and Other Activities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SegmentsAndOtherActivitiesMember" xlink:to="lab_teva_SegmentsAndOtherActivitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SegmentsAndOtherActivitiesMember" xml:lang="en-US">Segments and other activities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateMember" xlink:label="loc_us-gaap_CorporateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CorporateMember" xml:lang="en-US">Corporate Segment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CorporateMember" xml:lang="en-US">Corporate Segment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateMember" xlink:to="lab_us-gaap_CorporateMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember" xlink:label="loc_us-gaap_AllOtherSegmentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xml:lang="en-US">Other Segments [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xml:lang="en-US">Other Segments [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllOtherSegmentsMember" xlink:to="lab_us-gaap_AllOtherSegmentsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfProductInformationTable" xml:lang="en-US">Schedule of Product Information [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfProductInformationTable" xml:lang="en-US">Schedule of Product Information [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable" xlink:to="lab_us-gaap_ScheduleOfProductInformationTable" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RevenueTypeAxis" xlink:label="loc_teva_RevenueTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RevenueTypeAxis" xml:lang="en-US">Revenue Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RevenueTypeAxis" xlink:to="lab_teva_RevenueTypeAxis" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RevenueTypeDomain" xlink:label="loc_teva_RevenueTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RevenueTypeDomain" xml:lang="en-US">Revenue Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RevenueTypeDomain" xlink:to="lab_teva_RevenueTypeDomain" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_BendekaAndTreandaMember" xlink:label="loc_teva_BendekaAndTreandaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_BendekaAndTreandaMember" xml:lang="en-US">BENDEKA and TREANDA [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_teva_BendekaAndTreandaMember" xml:lang="en-US">BENDEKA and TREANDA [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_BendekaAndTreandaMember" xlink:to="lab_teva_BendekaAndTreandaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_BendekaAndTreandaMember" xml:lang="en-US">BENDEKA and TREANDA.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_COPAXONEMember" xlink:label="loc_teva_COPAXONEMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_COPAXONEMember" xml:lang="en-US">COPAXONE [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_COPAXONEMember" xml:lang="en-US">COPAXONE [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_COPAXONEMember" xlink:to="lab_teva_COPAXONEMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_COPAXONEMember" xml:lang="en-US">COPAXONE.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AndaMember" xlink:label="loc_teva_AndaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AndaMember" xml:lang="en-US">Anda [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AndaMember" xml:lang="en-US">Anda [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AndaMember" xlink:to="lab_teva_AndaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AndaMember" xml:lang="en-US">Anda [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OtherProductsMember" xlink:label="loc_teva_OtherProductsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OtherProductsMember" xml:lang="en-US">Other Products [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OtherProductsMember" xml:lang="en-US">Other [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OtherProductsMember" xlink:to="lab_teva_OtherProductsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OtherProductsMember" xml:lang="en-US">Other Products [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RespiratoryProductMember" xlink:label="loc_teva_RespiratoryProductMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RespiratoryProductMember" xml:lang="en-US">Respiratory Product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_RespiratoryProductMember" xml:lang="en-US">Respiratory Product [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RespiratoryProductMember" xlink:to="lab_teva_RespiratoryProductMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_RespiratoryProductMember" xml:lang="en-US">Respiratory product.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AustedoMember" xlink:label="loc_teva_AustedoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AustedoMember" xml:lang="en-US">Austedo [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AustedoMember" xml:lang="en-US">AUSTEDO [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AustedoMember" xlink:to="lab_teva_AustedoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AustedoMember" xml:lang="en-US">Austedo [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_GenericsMediciansMember" xlink:label="loc_teva_GenericsMediciansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_GenericsMediciansMember" xml:lang="en-US">Generics Medicians [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_GenericsMediciansMember" xml:lang="en-US">Generic products [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_GenericsMediciansMember" xlink:to="lab_teva_GenericsMediciansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_GenericsMediciansMember" xml:lang="en-US">Generics Medicians.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AjovyMember" xlink:label="loc_teva_AjovyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AjovyMember" xml:lang="en-US">AJOVY [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AjovyMember" xlink:to="lab_teva_AjovyMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaap_ProductInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProductInformationLineItems" xml:lang="en-US">Product Information [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProductInformationLineItems" xml:lang="en-US">Product Information [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductInformationLineItems" xlink:to="lab_us-gaap_ProductInformationLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xml:lang="en-US">Concentration Risk Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xml:lang="en-US">Concentration Risk Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xml:lang="en-US">Concentration Risk Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xml:lang="en-US">Concentration Risk Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xml:lang="en-US">Segment Reporting Information [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xml:lang="en-US">Segment Reporting Information [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NumberOfReportableSegments" xml:lang="en-US">Number of Reportable Segments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NumberOfReportableSegments" xml:lang="en-US">Number of reportable segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xml:lang="en-US">Investments, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xml:lang="en-US">Investment in securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets" xlink:label="loc_us-gaap_DerivativeAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeAssets" xml:lang="en-US">Derivative Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeAssets" xml:lang="en-US">Derivatives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xml:lang="en-US">Contingent consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaap_FairValueNetAssetLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueNetAssetLiability" xml:lang="en-US">Fair Value, Net Asset (Liability)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueNetAssetLiability" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetAssetLiability" xlink:to="lab_us-gaap_FairValueNetAssetLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilities" xml:lang="en-US">Derivative Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DerivativeLiabilities" xml:lang="en-US">Derivatives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCash" xml:lang="en-US">Restricted Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCash" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xml:lang="en-US">Asset Class [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xml:lang="en-US">Asset Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xml:lang="en-US">Asset Class [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xml:lang="en-US">Asset Class [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xml:lang="en-US">Money Market Funds [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xml:lang="en-US">Money Markets [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DemandDepositsMember" xlink:label="loc_us-gaap_DemandDepositsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DemandDepositsMember" xml:lang="en-US">Demand Deposits [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DemandDepositsMember" xml:lang="en-US">Cash, Deposits and Other [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DemandDepositsMember" xlink:to="lab_us-gaap_DemandDepositsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquitySecuritiesMember" xml:lang="en-US">Equity Securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquitySecuritiesMember" xml:lang="en-US">Equity Securities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OtherRestrictedCashMember" xlink:label="loc_teva_OtherRestrictedCashMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OtherRestrictedCashMember" xml:lang="en-US">Other Restricted Cash [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OtherRestrictedCashMember" xml:lang="en-US">Other [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OtherRestrictedCashMember" xlink:to="lab_teva_OtherRestrictedCashMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OtherRestrictedCashMember" xml:lang="en-US">Other restricted cash.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xml:lang="en-US">Liability Class [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xml:lang="en-US">Liability Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xml:lang="en-US">Fair Value by Liability Class [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xml:lang="en-US">Fair Value by Liability Class [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OptionsAndForwardContractsDerivativeLiabilitiesMember" xlink:label="loc_teva_OptionsAndForwardContractsDerivativeLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OptionsAndForwardContractsDerivativeLiabilitiesMember" xml:lang="en-US">Options And Forward Contracts Derivative Liabilities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OptionsAndForwardContractsDerivativeLiabilitiesMember" xml:lang="en-US">Liability Derivatives Options and Forward Contracts [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OptionsAndForwardContractsDerivativeLiabilitiesMember" xlink:to="lab_teva_OptionsAndForwardContractsDerivativeLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OptionsAndForwardContractsDerivativeLiabilitiesMember" xml:lang="en-US">Options and forward contracts derivative liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xml:lang="en-US">Financial Instrument [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xml:lang="en-US">Financial Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US">Financial Instruments [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US">Financial Instruments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestRateSwapMember" xml:lang="en-US">Interest Rate Swap [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestRateSwapMember" xml:lang="en-US">Asset Derivatives - Options and Forward Contracts [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xml:lang="en-US">Cross Currency Interest Rate Contract [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xml:lang="en-US">Liabilities Derivatives - Interest Rate and Cross Currency Swaps [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CrossCurrencyInterestRateContractMember" xlink:to="lab_us-gaap_CrossCurrencyInterestRateContractMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Level 3 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Level 2 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Level 1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xlink:label="loc_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xml:lang="en-US">Fresh-Start Adjustments [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xml:lang="en-US">Fresh-Start Adjustments [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xlink:to="lab_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfFreshStartAdjustmentDomain" xlink:label="loc_us-gaap_TypeOfFreshStartAdjustmentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfFreshStartAdjustmentDomain" xml:lang="en-US">Type of Fresh-Start Adjustment [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TypeOfFreshStartAdjustmentDomain" xml:lang="en-US">Type of Fresh-Start Adjustment [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfFreshStartAdjustmentDomain" xlink:to="lab_us-gaap_TypeOfFreshStartAdjustmentDomain" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_MeasurementInputProbabilityOfSuccessMember" xlink:label="loc_teva_MeasurementInputProbabilityOfSuccessMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_MeasurementInputProbabilityOfSuccessMember" xml:lang="en-US">Measurement Input Probability Of Success [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_MeasurementInputProbabilityOfSuccessMember" xml:lang="en-US">Measurement input probability of success [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_MeasurementInputProbabilityOfSuccessMember" xlink:to="lab_teva_MeasurementInputProbabilityOfSuccessMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_MeasurementInputProbabilityOfSuccessMember" xml:lang="en-US">Measurement input probability of success.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_WeightedAverageMember" xml:lang="en-US">Weighted Average [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_WeightedAverageMember" xml:lang="en-US">Weighted Average [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_NoveTideAcquisitionMember" xlink:label="loc_teva_NoveTideAcquisitionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_NoveTideAcquisitionMember" xml:lang="en-US">Nove tide Acquisition [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_NoveTideAcquisitionMember" xlink:to="lab_teva_NoveTideAcquisitionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_NoveTideAcquisitionMember" xml:lang="en-US">Nove tide Acquisition.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xml:lang="en-US">Redemption of debt securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Fair value at the beginning of the period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Fair value at the end of the period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_BifurcatedEmbeddedDerivatives" xlink:label="loc_teva_BifurcatedEmbeddedDerivatives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_BifurcatedEmbeddedDerivatives" xml:lang="en-US">Bifurcated Embedded Derivatives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_BifurcatedEmbeddedDerivatives" xml:lang="en-US">Bifurcated embedded derivatives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_BifurcatedEmbeddedDerivatives" xlink:to="lab_teva_BifurcatedEmbeddedDerivatives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_BifurcatedEmbeddedDerivatives" xml:lang="en-US">Bifurcated embedded derivatives.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xml:lang="en-US">Settlement of contingent consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod" xlink:label="loc_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Contingent Consideration Arising During Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod" xml:lang="en-US">Actavis Generics transaction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod" xlink:to="lab_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod" xml:lang="en-US">Fair value measurement with unobservable inputs reconciliation recurring basis liability contingent consideration arising during period.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" xlink:label="loc_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Contingent Consideration Increase Decrease</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" xml:lang="en-US">Adjustments to provisions for contingent consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" xlink:to="lab_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" xml:lang="en-US">Fair value measurement with unobservable inputs reconciliation recurring basis liability contingent consideration increase decrease.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ActavisGenericsMember" xlink:label="loc_teva_ActavisGenericsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ActavisGenericsMember" xml:lang="en-US">Actavis Generics [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ActavisGenericsMember" xml:lang="en-US">Actavis Generics [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ActavisGenericsMember" xlink:to="lab_teva_ActavisGenericsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ActavisGenericsMember" xml:lang="en-US">Actavis Generics [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_EagleTransactionMember" xlink:label="loc_teva_EagleTransactionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_EagleTransactionMember" xml:lang="en-US">Eagle Transaction [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_EagleTransactionMember" xml:lang="en-US">Eagle Transaction [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_EagleTransactionMember" xlink:to="lab_teva_EagleTransactionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_EagleTransactionMember" xml:lang="en-US">Eagle transaction.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xml:lang="en-US">Business acquisition, Percentage of voting interests acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SeniornotesandconvertibleseniordebenturesMember" xlink:label="loc_teva_SeniornotesandconvertibleseniordebenturesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SeniornotesandconvertibleseniordebenturesMember" xml:lang="en-US">Seniornotesandconvertibleseniordebentures [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SeniornotesandconvertibleseniordebenturesMember" xml:lang="en-US">Senior Notes and Convertible Senior Debentures Included Under Short-Term Debt [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SeniornotesandconvertibleseniordebenturesMember" xlink:to="lab_teva_SeniornotesandconvertibleseniordebenturesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SeniornotesandconvertibleseniordebenturesMember" xml:lang="en-US">Senior notes and convertible senior debentures.</label>
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SeniorNotesAndSustainabilityLinkedSeniorNotesMember" xlink:label="loc_teva_SeniorNotesAndSustainabilityLinkedSeniorNotesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SeniorNotesAndSustainabilityLinkedSeniorNotesMember" xml:lang="en-US">Senior Notes And Sustainability Linked Senior Notes [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SeniorNotesAndSustainabilityLinkedSeniorNotesMember" xml:lang="en-US">Senior Notes And Sustainability Linked Senior Notes [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SeniorNotesAndSustainabilityLinkedSeniorNotesMember" xlink:to="lab_teva_SeniorNotesAndSustainabilityLinkedSeniorNotesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SeniorNotesAndSustainabilityLinkedSeniorNotesMember" xml:lang="en-US">Senior notes and sustainability linked senior notes.</label>
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>teva-20220630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 27-July-2022 [08:44:53] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#CoverPage" roleURI="http://www.tevapharm.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#ConsolidatedBalanceSheets" roleURI="http://www.tevapharm.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#ConsolidatedStatementsOfIncomeLoss" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#ConsolidatedStatementsOfComprehensiveIncomeLoss" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#ConsolidatedStatementsOfChangesInEquity" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#ConsolidatedStatementsOfChangesInEquityParenthetical" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#BasisOfPresentation" roleURI="http://www.tevapharm.com/role/BasisOfPresentation" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#CertainTransactions" roleURI="http://www.tevapharm.com/role/CertainTransactions" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#RevenueFromContractsWithCustomers" roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomers" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#Inventories" roleURI="http://www.tevapharm.com/role/Inventories" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#IdentifiableIntangibleAssets" roleURI="http://www.tevapharm.com/role/IdentifiableIntangibleAssets" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#Goodwill" roleURI="http://www.tevapharm.com/role/Goodwill" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#DebtObligations" roleURI="http://www.tevapharm.com/role/DebtObligations" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#DerivativeInstrumentsAndHedgingActivities" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#LegalSettlementsAndLossContingencies" roleURI="http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#CommitmentsAndContingencies" roleURI="http://www.tevapharm.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#IncomeTaxes" roleURI="http://www.tevapharm.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#OtherAssetsImpairmentsRestructuringAndOtherItems" roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#EarningsLossPerShare" roleURI="http://www.tevapharm.com/role/EarningsLossPerShare" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#AccumulatedOtherComprehensiveIncomeLoss" roleURI="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLoss" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#Segments" roleURI="http://www.tevapharm.com/role/Segments" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#FairValueMeasurement" roleURI="http://www.tevapharm.com/role/FairValueMeasurement" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#BasisOfPresentationPolicies" roleURI="http://www.tevapharm.com/role/BasisOfPresentationPolicies" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#CertainTransactionsTables" roleURI="http://www.tevapharm.com/role/CertainTransactionsTables" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#RevenueFromContractsWithCustomersTables" roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#InventoriesTables" roleURI="http://www.tevapharm.com/role/InventoriesTables" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#IdentifiableIntangibleAssetsTables" roleURI="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#GoodwillTables" roleURI="http://www.tevapharm.com/role/GoodwillTables" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#DebtObligationsTables" roleURI="http://www.tevapharm.com/role/DebtObligationsTables" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#DerivativeInstrumentsAndHedgingActivitiesTables" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#OtherAssetsImpairmentsRestructuringAndOtherItemsTables" roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#AccumulatedOtherComprehensiveIncomeLossTables" roleURI="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossTables" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#SegmentsTables" roleURI="http://www.tevapharm.com/role/SegmentsTables" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#FairValueMeasurementTables" roleURI="http://www.tevapharm.com/role/FairValueMeasurementTables" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#CertainTransactionsOtherTransactionsAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail" roleURI="http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#RevenueFromContractsWithCustomersAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail" roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#InventoriesSummaryOfInventoriesDetail" roleURI="http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail" roleURI="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#IdentifiableIntangibleAssetsAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail" roleURI="http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail" roleURI="http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#GoodwillAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#DebtObligationsScheduleOfShortTermDebtDetail" roleURI="http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#DebtObligationsScheduleOfSeniorNotesAndLoansDetail" roleURI="http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" roleURI="http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#DebtObligationsAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#LegalSettlementsAndLossContingenciesAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#IncomeTaxesAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail" roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail" roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail" roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#EarningsLossPerShareAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#AccumulatedOtherComprehensiveIncomeLossDetail" roleURI="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#AccumulatedOtherComprehensiveIncomeLossParentheticalDetail" roleURI="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#SegmentsSummaryOfSegmentProfitDetail" roleURI="http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail" roleURI="http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail" roleURI="http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#SegmentsAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" roleURI="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#FairValueMeasurementAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail" roleURI="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail" roleURI="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20220630.xsd#FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail" roleURI="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail" />
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_187796" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_486714" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_DocumentType_486714" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_507077" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_AmendmentFlag_507077" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_507079" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_DocumentFiscalYearFocus_507079" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_486701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_DocumentTransitionReport_486701" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_486682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_DocumentPeriodEndDate_486682" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_507080" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_DocumentFiscalPeriodFocus_507080" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_673334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_DocumentQuarterlyReport_673334" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_486687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityRegistrantName_486687" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_507081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityCentralIndexKey_507081" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_507082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_CurrentFiscalYearEndDate_507082" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_486685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityCurrentReportingStatus_486685" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_486688" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityInteractiveDataCurrent_486688" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_486689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_486689" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_486709" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_Security12bTitle_486709" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_486710" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_TradingSymbol_486710" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_486711" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_SecurityExchangeName_486711" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_486691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityIncorporationStateCountryCode_486691" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_486690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityFileNumber_486690" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_486693" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityAddressAddressLine1_486693" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_486692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityTaxIdentificationNumber_486692" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_486694" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityAddressCityOrTown_486694" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_486695" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityAddressPostalZipCode_486695" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_486708" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityAddressCountry_486708" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_486698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_CityAreaCode_486698" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_486699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_LocalPhoneNumber_486699" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_486715" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityFilerCategory_486715" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_555878" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntitySmallBusiness_555878" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_486704" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityEmergingGrowthCompany_486704" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_486702" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityShellCompany_486702" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_26" xlink:to="loc_us-gaap_StatementTable_34" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_34" xlink:to="loc_dei_LegalEntityAxis_29" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_49" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_29" xlink:to="loc_dei_EntityDomain_49" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_34" xlink:to="loc_us-gaap_StatementLineItems_33" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_33" xlink:to="loc_us-gaap_AssetsAbstract_27" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_AssetsCurrentAbstract_28" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_42" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_42" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_43" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_43" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_44" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_InventoryNet_44" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_45" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_45" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_46" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_OtherAssetsCurrent_46" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_47" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_47" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_48" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_AssetsCurrent_48" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_36" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_37" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_38" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_389976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_389976" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_39" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_40" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_Goodwill_40" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_41" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_Assets_41" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_33" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_31" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_55" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_us-gaap_DebtCurrent_55" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SalesReservesAndAllowances" xlink:label="loc_teva_SalesReservesAndAllowances_56" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_teva_SalesReservesAndAllowances_56" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_57" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_57" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_58" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_58" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AccruedExpenses" xlink:label="loc_teva_AccruedExpenses_59" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_teva_AccruedExpenses_59" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_60" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_60" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_62" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_us-gaap_LiabilitiesCurrent_62" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_63" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_63" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_64" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_64" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesAndLoans" xlink:label="loc_us-gaap_LongTermNotesAndLoans_65" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" xlink:to="loc_us-gaap_LongTermNotesAndLoans_65" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_389981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_389981" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_66" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_66" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_50" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_CommitmentsAndContingencies_50" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_51" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_Liabilities_51" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_StockholdersEquityAbstract_35" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_68" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_CommonStockValue_68" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_69" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_AdditionalPaidInCapital_69" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_70" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_70" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_71" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_71" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_72" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_TreasuryStockValue_72" use="optional" order="43" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_73" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_StockholdersEquity_73" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_52" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_MinorityInterest_52" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_53" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_53" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_54" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_54" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_75" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_78" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_75" xlink:to="loc_us-gaap_StatementTable_78" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_76" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_78" xlink:to="loc_dei_LegalEntityAxis_76" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_79" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_76" xlink:to="loc_dei_EntityDomain_79" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_77" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_78" xlink:to="loc_us-gaap_StatementLineItems_77" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_688255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_688255" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_83" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_83" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_84" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_84" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_85" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77" xlink:to="loc_us-gaap_CommonStockSharesIssued_85" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_86" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77" xlink:to="loc_us-gaap_TreasuryStockShares_86" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_88" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_92" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_88" xlink:to="loc_us-gaap_StatementTable_92" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_90" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_92" xlink:to="loc_dei_LegalEntityAxis_90" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_96" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_90" xlink:to="loc_dei_EntityDomain_96" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_91" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_92" xlink:to="loc_us-gaap_StatementLineItems_91" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_97" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_97" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_98" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_98" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_99" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_GrossProfit_99" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_100" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_SellingAndMarketingExpense_101" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_102" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_IntangibleAssetsImpairments" xlink:label="loc_teva_IntangibleAssetsImpairments_103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_teva_IntangibleAssetsImpairments_103" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_104" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ImpairmentsRestructuringAndOthers" xlink:label="loc_teva_ImpairmentsRestructuringAndOthers_408527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_teva_ImpairmentsRestructuringAndOthers_408527" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LegalSettlementsAndLossContingencies" xlink:label="loc_teva_LegalSettlementsAndLossContingencies_412170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_teva_LegalSettlementsAndLossContingencies_412170" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_107" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_OperatingIncomeLoss_108" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_109" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_110" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_111" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_112" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_ProfitLoss_113" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_114" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_NetIncomeLoss_115" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_89" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_EarningsPerShareAbstract_89" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_94" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_89" xlink:to="loc_us-gaap_EarningsPerShareBasic_94" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_95" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_89" xlink:to="loc_us-gaap_EarningsPerShareDiluted_95" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_93" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_93" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_93" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_118" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_93" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_119" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_121" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_121" xlink:to="loc_us-gaap_StatementTable_125" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_125" xlink:to="loc_dei_LegalEntityAxis_122" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_122" xlink:to="loc_dei_EntityDomain_126" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_125" xlink:to="loc_us-gaap_StatementLineItems_124" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_ProfitLoss_132" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_123" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_123" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_127" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_UnrealizedGainLossOnDerivativeNetOfTax" xlink:label="loc_teva_UnrealizedGainLossOnDerivativeNetOfTax_128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_123" xlink:to="loc_teva_UnrealizedGainLossOnDerivativeNetOfTax_128" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax_720057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_123" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax_720057" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_131" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_133" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_134" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_135" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_137" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_137" xlink:to="loc_us-gaap_StatementTable_142" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_142" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_140" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_140" xlink:to="loc_us-gaap_EquityComponentDomain_138" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_CommonStockMember_143" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_145" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_RetainedEarningsMember_146" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_147" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_TreasuryStockMember_148" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_ParentMember_149" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_NoncontrollingInterestMember_150" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_142" xlink:to="loc_us-gaap_StatementLineItems_141" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_152" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_SharesIssued_154" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_720066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_ProfitLoss_720066" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_155" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_760310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_760310" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_158" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_162" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_167" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_SharesIssued_168" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_170" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_170" xlink:to="loc_us-gaap_StatementTable_177" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_177" xlink:to="loc_srt_RangeAxis_173" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_173" xlink:to="loc_srt_RangeMember_174" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_174" xlink:to="loc_srt_MaximumMember_180" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_177" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_175" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_175" xlink:to="loc_us-gaap_EquityComponentDomain_171" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_171" xlink:to="loc_us-gaap_CommonStockMember_178" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_472726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_177" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_472726" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_472727" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_472726" xlink:to="loc_us-gaap_TypeOfAdoptionMember_472727" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_177" xlink:to="loc_us-gaap_StatementLineItems_176" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_176" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_181" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_183" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_183" xlink:to="loc_us-gaap_StatementTable_191" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_191" xlink:to="loc_dei_LegalEntityAxis_186" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_186" xlink:to="loc_dei_EntityDomain_210" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_191" xlink:to="loc_us-gaap_StatementLineItems_190" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_189" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_189" xlink:to="loc_us-gaap_ProfitLoss_229" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_189" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_us-gaap_DepreciationAndAmortization_194" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_us-gaap_AssetImpairmentCharges_193" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapital" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital_195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapital_195" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_DeferredIncomeTaxesNetAndUncertainTaxPositions" xlink:label="loc_teva_DeferredIncomeTaxesNetAndUncertainTaxPositions_196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_teva_DeferredIncomeTaxesNetAndUncertainTaxPositions_196" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_412174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_us-gaap_ShareBasedCompensation_412174" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_515089" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_515089" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ProfitFromSaleOfLongLivedAssetsAndInvestment" xlink:label="loc_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment_200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment_200" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_189" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_230" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" xlink:label="loc_teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables_222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables_222" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_1260619" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_1260619" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_555980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_555980" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_224" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets" xlink:label="loc_teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets_225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets_225" use="optional" order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_1260620" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_1260620" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_226" use="optional" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_228" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_1260621" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_1260621" use="optional" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSeniorDebt" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_1559573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_1559573" use="optional" order="27" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_214" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_221" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_231" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_232" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_233" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_234" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1260697" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1260697" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1260699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1260697" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1260699" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1260700" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1260697" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1260700" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1260701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1260697" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1260701" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_192" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" xlink:label="loc_teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables_235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_192" xlink:to="loc_teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables_235" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/BasisOfPresentation">
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_BasisOfPresentationAbstract" xlink:label="loc_teva_BasisOfPresentationAbstract_389321" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_671372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_BasisOfPresentationAbstract_389321" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_671372" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CertainTransactions">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract_1694" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1697" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_1694" xlink:to="loc_us-gaap_StatementTable_1697" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1695" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1697" xlink:to="loc_dei_LegalEntityAxis_1695" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1695" xlink:to="loc_dei_EntityDomain_1698" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1696" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1697" xlink:to="loc_us-gaap_StatementLineItems_1696" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_CertainTransactionsDisclosureTextBlock" xlink:label="loc_teva_CertainTransactionsDisclosureTextBlock_1699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1696" xlink:to="loc_teva_CertainTransactionsDisclosureTextBlock_1699" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/RevenueFromContractsWithCustomers">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1795" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1795" xlink:to="loc_us-gaap_StatementTable_1798" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1798" xlink:to="loc_dei_LegalEntityAxis_1796" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1796" xlink:to="loc_dei_EntityDomain_1799" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1798" xlink:to="loc_us-gaap_StatementLineItems_1797" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_1800" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1797" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_1800" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/Inventories">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_1739" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1739" xlink:to="loc_us-gaap_StatementTable_1742" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1742" xlink:to="loc_dei_LegalEntityAxis_1740" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1743" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1740" xlink:to="loc_dei_EntityDomain_1743" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1741" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1742" xlink:to="loc_us-gaap_StatementLineItems_1741" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_1744" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1741" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_1744" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IdentifiableIntangibleAssets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1781" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1781" xlink:to="loc_us-gaap_StatementTable_1784" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1784" xlink:to="loc_dei_LegalEntityAxis_1782" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1782" xlink:to="loc_dei_EntityDomain_1785" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1784" xlink:to="loc_us-gaap_StatementLineItems_1783" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_1786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1783" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_1786" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/Goodwill">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1767" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1770" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1767" xlink:to="loc_us-gaap_StatementTable_1770" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1770" xlink:to="loc_dei_LegalEntityAxis_1768" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1771" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1768" xlink:to="loc_dei_EntityDomain_1771" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1770" xlink:to="loc_us-gaap_StatementLineItems_1769" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillDisclosureTextBlock_1772" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1769" xlink:to="loc_us-gaap_GoodwillDisclosureTextBlock_1772" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1824" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1824" xlink:to="loc_us-gaap_StatementTable_1827" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1827" xlink:to="loc_dei_LegalEntityAxis_1825" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1828" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1825" xlink:to="loc_dei_EntityDomain_1828" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1827" xlink:to="loc_us-gaap_StatementLineItems_1826" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_1829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1826" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_1829" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1901" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1901" xlink:to="loc_us-gaap_StatementTable_1904" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1904" xlink:to="loc_dei_LegalEntityAxis_1902" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1902" xlink:to="loc_dei_EntityDomain_1905" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1904" xlink:to="loc_us-gaap_StatementLineItems_1903" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1906" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1903" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1906" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1947" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1950" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1947" xlink:to="loc_us-gaap_StatementTable_1950" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1948" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1950" xlink:to="loc_dei_LegalEntityAxis_1948" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1951" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1948" xlink:to="loc_dei_EntityDomain_1951" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1949" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1950" xlink:to="loc_us-gaap_StatementLineItems_1949" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_1952" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1949" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_1952" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1854" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1857" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1854" xlink:to="loc_us-gaap_StatementTable_1857" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1857" xlink:to="loc_dei_LegalEntityAxis_1855" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1855" xlink:to="loc_dei_EntityDomain_1858" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1856" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1857" xlink:to="loc_us-gaap_StatementLineItems_1856" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1856" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1859" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1882" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1882" xlink:to="loc_us-gaap_StatementTable_1885" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1885" xlink:to="loc_dei_LegalEntityAxis_1883" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1883" xlink:to="loc_dei_EntityDomain_1886" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1885" xlink:to="loc_us-gaap_StatementLineItems_1884" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1884" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1887" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract_1931" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1934" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_1931" xlink:to="loc_us-gaap_StatementTable_1934" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1934" xlink:to="loc_dei_LegalEntityAxis_1932" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1935" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1932" xlink:to="loc_dei_EntityDomain_1935" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1934" xlink:to="loc_us-gaap_StatementLineItems_1933" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OtherExpensesTextBlock" xlink:label="loc_teva_OtherExpensesTextBlock_1936" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1933" xlink:to="loc_teva_OtherExpensesTextBlock_1936" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/EarningsLossPerShare">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1972" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1975" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1972" xlink:to="loc_us-gaap_StatementTable_1975" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1973" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1975" xlink:to="loc_dei_LegalEntityAxis_1973" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1973" xlink:to="loc_dei_EntityDomain_1976" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1974" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1975" xlink:to="loc_us-gaap_StatementLineItems_1974" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1974" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_1977" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_390011" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_390014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_390011" xlink:to="loc_us-gaap_StatementTable_390014" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_390018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_390014" xlink:to="loc_dei_LegalEntityAxis_390018" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_390019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_390018" xlink:to="loc_dei_EntityDomain_390019" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_390015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_390014" xlink:to="loc_us-gaap_StatementLineItems_390015" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_390022" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_390015" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_390022" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/Segments">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_1954" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1957" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1954" xlink:to="loc_us-gaap_StatementTable_1957" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1955" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1957" xlink:to="loc_dei_LegalEntityAxis_1955" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1958" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1955" xlink:to="loc_dei_EntityDomain_1958" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1956" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1957" xlink:to="loc_us-gaap_StatementLineItems_1956" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_1959" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1956" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_1959" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurement">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1708" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1711" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1708" xlink:to="loc_us-gaap_StatementTable_1711" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1709" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1711" xlink:to="loc_dei_LegalEntityAxis_1709" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1712" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1709" xlink:to="loc_dei_EntityDomain_1712" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1710" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1711" xlink:to="loc_us-gaap_StatementLineItems_1710" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_1713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1710" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_1713" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/BasisOfPresentationPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1659" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1662" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1659" xlink:to="loc_us-gaap_StatementTable_1662" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1660" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1662" xlink:to="loc_dei_LegalEntityAxis_1660" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1663" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1660" xlink:to="loc_dei_EntityDomain_1663" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1661" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1662" xlink:to="loc_us-gaap_StatementLineItems_1661" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1665" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="loc_teva_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_514943" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_teva_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_514943" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CertainTransactionsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract_1701" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1704" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_1701" xlink:to="loc_us-gaap_StatementTable_1704" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1702" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1704" xlink:to="loc_dei_LegalEntityAxis_1702" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1705" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1702" xlink:to="loc_dei_EntityDomain_1705" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1703" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1704" xlink:to="loc_us-gaap_StatementLineItems_1703" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" xlink:label="loc_teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock_1706" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1703" xlink:to="loc_teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock_1706" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1802" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1802" xlink:to="loc_us-gaap_StatementTable_1805" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1803" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1805" xlink:to="loc_dei_LegalEntityAxis_1803" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1803" xlink:to="loc_dei_EntityDomain_1806" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1805" xlink:to="loc_us-gaap_StatementLineItems_1804" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_1807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1804" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_1807" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SalesReservesAndAllowancesCurrentTableTextBlock" xlink:label="loc_teva_SalesReservesAndAllowancesCurrentTableTextBlock_1808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1804" xlink:to="loc_teva_SalesReservesAndAllowancesCurrentTableTextBlock_1808" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/InventoriesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_1746" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1749" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1746" xlink:to="loc_us-gaap_StatementTable_1749" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1747" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1749" xlink:to="loc_dei_LegalEntityAxis_1747" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1750" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1747" xlink:to="loc_dei_EntityDomain_1750" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1748" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1749" xlink:to="loc_us-gaap_StatementLineItems_1748" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1751" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1748" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1751" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1788" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1788" xlink:to="loc_us-gaap_StatementTable_1791" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1791" xlink:to="loc_dei_LegalEntityAxis_1789" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1789" xlink:to="loc_dei_EntityDomain_1792" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1790" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1791" xlink:to="loc_us-gaap_StatementLineItems_1790" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1793" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1790" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1793" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/GoodwillTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1774" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1777" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1774" xlink:to="loc_us-gaap_StatementTable_1777" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1777" xlink:to="loc_dei_LegalEntityAxis_1775" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1775" xlink:to="loc_dei_EntityDomain_1778" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1776" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1777" xlink:to="loc_us-gaap_StatementLineItems_1776" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_1779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1776" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_1779" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligationsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1831" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1831" xlink:to="loc_us-gaap_StatementTable_1834" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1832" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1834" xlink:to="loc_dei_LegalEntityAxis_1832" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1832" xlink:to="loc_dei_EntityDomain_1835" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1834" xlink:to="loc_us-gaap_StatementLineItems_1833" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTextBlock_1836" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1833" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTextBlock_1836" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_556360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1833" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_556360" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1908" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1908" xlink:to="loc_us-gaap_StatementTable_1911" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1911" xlink:to="loc_dei_LegalEntityAxis_1909" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1912" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1909" xlink:to="loc_dei_EntityDomain_1912" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1911" xlink:to="loc_us-gaap_StatementLineItems_1910" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_1914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1910" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_1914" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_390224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1910" xlink:to="loc_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_390224" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract_1938" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1941" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_1938" xlink:to="loc_us-gaap_StatementTable_1941" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1939" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1941" xlink:to="loc_dei_LegalEntityAxis_1939" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1942" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1939" xlink:to="loc_dei_EntityDomain_1942" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1941" xlink:to="loc_us-gaap_StatementLineItems_1940" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_1943" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1940" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_1943" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ScheduleOfRestructuringChargesTableTextBlock" xlink:label="loc_teva_ScheduleOfRestructuringChargesTableTextBlock_1944" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1940" xlink:to="loc_teva_ScheduleOfRestructuringChargesTableTextBlock_1944" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_1945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1940" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_1945" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_390174" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_390175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_390174" xlink:to="loc_us-gaap_StatementTable_390175" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_390177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_390175" xlink:to="loc_dei_LegalEntityAxis_390177" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_390178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_390177" xlink:to="loc_dei_EntityDomain_390178" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_390179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_390175" xlink:to="loc_us-gaap_StatementLineItems_390179" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_390181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_390179" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_390181" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SegmentsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_1961" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1964" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1961" xlink:to="loc_us-gaap_StatementTable_1964" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1964" xlink:to="loc_dei_LegalEntityAxis_1962" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1965" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1962" xlink:to="loc_dei_EntityDomain_1965" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1964" xlink:to="loc_us-gaap_StatementLineItems_1963" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_1966" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1963" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_1966" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock" xlink:label="loc_teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock_1967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1963" xlink:to="loc_teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock_1967" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_1968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1963" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_1968" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurementTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1715" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1718" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1715" xlink:to="loc_us-gaap_StatementTable_1718" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1716" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1718" xlink:to="loc_dei_LegalEntityAxis_1716" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1716" xlink:to="loc_dei_EntityDomain_1719" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1717" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1718" xlink:to="loc_us-gaap_StatementLineItems_1717" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1720" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1717" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1720" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1721" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1717" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1721" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1717" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1722" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_300" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionsTable" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_300" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_dei_LegalEntityAxis_304" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_304" xlink:to="loc_dei_EntityDomain_319" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1241737" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1241737" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1241738" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1241737" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1241738" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_302" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_302" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AlderMember" xlink:label="loc_teva_AlderMember_313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" xlink:to="loc_teva_AlderMember_313" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OtsukaMember" xlink:label="loc_teva_OtsukaMember_314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" xlink:to="loc_teva_OtsukaMember_314" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RegeneronMember" xlink:label="loc_teva_RegeneronMember_318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" xlink:to="loc_teva_RegeneronMember_318" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AlvotechMember" xlink:label="loc_teva_AlvotechMember_758265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" xlink:to="loc_teva_AlvotechMember_758265" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_MedincellMember" xlink:label="loc_teva_MedincellMember_1241907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" xlink:to="loc_teva_MedincellMember_1241907" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ModagMember" xlink:label="loc_teva_ModagMember_1241734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" xlink:to="loc_teva_ModagMember_1241734" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_TakedaMember" xlink:label="loc_teva_TakedaMember_1559574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" xlink:to="loc_teva_TakedaMember_1559574" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_srt_ProductOrServiceAxis_307" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_307" xlink:to="loc_srt_ProductsAndServicesDomain_308" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_srt_CounterpartyNameAxis_303" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_303" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_311" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_310" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_310" xlink:to="loc_us-gaap_RelatedPartyDomain_309" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_758266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_758266" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_758267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_758266" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_758267" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_758268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_758267" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_758268" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis_758271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_us-gaap_LeaseContractualTermAxis_758271" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_758272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_758271" xlink:to="loc_us-gaap_LeaseContractualTermDomain_758272" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_765341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_srt_RangeAxis_765341" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_765342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_765341" xlink:to="loc_srt_RangeMember_765342" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionsLineItems" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_UpfrontPayments" xlink:label="loc_teva_UpfrontPayments_326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_teva_UpfrontPayments_326" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_MilestonePayment" xlink:label="loc_teva_MilestonePayment_572506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_teva_MilestonePayment_572506" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_CollaborativeAgreementMilestonePayments" xlink:label="loc_teva_CollaborativeAgreementMilestonePayments_327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_teva_CollaborativeAgreementMilestonePayments_327" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ResearchAndDevelopmentCosts" xlink:label="loc_teva_ResearchAndDevelopmentCosts_335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_teva_ResearchAndDevelopmentCosts_335" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount" xlink:label="loc_teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount_1241741" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount_1241741" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_340" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_340" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_347" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_340" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_348" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent_350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_340" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent_350" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueAdjustment" xlink:label="loc_us-gaap_AssetsFairValueAdjustment_718560" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_340" xlink:to="loc_us-gaap_AssetsFairValueAdjustment_718560" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_340" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_351" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1279723" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_340" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1279723" use="optional" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_603" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RevenueRecognitionTable" xlink:label="loc_teva_RevenueRecognitionTable_608" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_603" xlink:to="loc_teva_RevenueRecognitionTable_608" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_604" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionTable_608" xlink:to="loc_dei_LegalEntityAxis_604" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_611" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_604" xlink:to="loc_dei_EntityDomain_611" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_610" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionTable_608" xlink:to="loc_srt_StatementGeographicalAxis_610" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_609" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_610" xlink:to="loc_srt_SegmentGeographicalDomain_609" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_617" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_609" xlink:to="loc_country_US_617" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RevenueRecognitionLineItems" xlink:label="loc_teva_RevenueRecognitionLineItems_607" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionTable_608" xlink:to="loc_teva_RevenueRecognitionLineItems_607" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SalesReservesAndAllowancesToCustomersPercentage" xlink:label="loc_teva_SalesReservesAndAllowancesToCustomersPercentage_616" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionLineItems_607" xlink:to="loc_teva_SalesReservesAndAllowancesToCustomersPercentage_616" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_619" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_621" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_619" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_621" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_622" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_621" xlink:to="loc_dei_LegalEntityAxis_622" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_630" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_622" xlink:to="loc_dei_EntityDomain_630" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_628" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_621" xlink:to="loc_srt_StatementGeographicalAxis_628" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_626" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_628" xlink:to="loc_srt_SegmentGeographicalDomain_626" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NorthAmericaMember" xlink:label="loc_srt_NorthAmericaMember_637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_626" xlink:to="loc_srt_NorthAmericaMember_637" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_626" xlink:to="loc_srt_EuropeMember_638" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_627" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_621" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_627" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_625" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_627" xlink:to="loc_us-gaap_SegmentDomain_625" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_InternationalMarketsMember" xlink:label="loc_teva_InternationalMarketsMember_635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_625" xlink:to="loc_teva_InternationalMarketsMember_635" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OtherActivitiesMember" xlink:label="loc_teva_OtherActivitiesMember_636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_625" xlink:to="loc_teva_OtherActivitiesMember_636" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_623" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_621" xlink:to="loc_srt_ProductOrServiceAxis_623" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_624" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_623" xlink:to="loc_srt_ProductsAndServicesDomain_624" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_631" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_624" xlink:to="loc_us-gaap_ProductMember_631" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_632" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_624" xlink:to="loc_us-gaap_LicenseMember_632" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DistributionServiceMember" xlink:label="loc_us-gaap_DistributionServiceMember_633" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_624" xlink:to="loc_us-gaap_DistributionServiceMember_633" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_624" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_634" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_620" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_621" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_620" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_629" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_620" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_629" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_640" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RevenueRecognitionTable" xlink:label="loc_teva_RevenueRecognitionTable_643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_640" xlink:to="loc_teva_RevenueRecognitionTable_643" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionTable_643" xlink:to="loc_dei_LegalEntityAxis_641" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_641" xlink:to="loc_dei_EntityDomain_646" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_645" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionTable_643" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_645" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_645" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ReservesIncludedInAccountsReceivableNetMember" xlink:label="loc_teva_ReservesIncludedInAccountsReceivableNetMember_653" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_ReservesIncludedInAccountsReceivableNetMember_653" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RebatesMember" xlink:label="loc_teva_RebatesMember_654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_RebatesMember_654" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_MedicaidAndOtherGovernmentalAllowancesMember" xlink:label="loc_teva_MedicaidAndOtherGovernmentalAllowancesMember_655" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_MedicaidAndOtherGovernmentalAllowancesMember_655" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ChargebacksMember" xlink:label="loc_teva_ChargebacksMember_656" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_ChargebacksMember_656" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ReturnsMember" xlink:label="loc_teva_ReturnsMember_657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_ReturnsMember_657" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OtherSalesReservesAndAllowancesMember" xlink:label="loc_teva_OtherSalesReservesAndAllowancesMember_658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_OtherSalesReservesAndAllowancesMember_658" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_TotalReservesIncludedInSalesReservesAndAllowancesMember" xlink:label="loc_teva_TotalReservesIncludedInSalesReservesAndAllowancesMember_659" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_TotalReservesIncludedInSalesReservesAndAllowancesMember_659" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RevenueRecognitionLineItems" xlink:label="loc_teva_RevenueRecognitionLineItems_642" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionTable_643" xlink:to="loc_teva_RevenueRecognitionLineItems_642" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionLineItems_642" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_647" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" xlink:label="loc_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales_648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionLineItems_642" xlink:to="loc_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales_648" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales" xlink:label="loc_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales_649" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionLineItems_642" xlink:to="loc_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales_649" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_650" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionLineItems_642" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_650" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ValuationAllowancesAndReservesForeignCurrencyTranslation" xlink:label="loc_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation_651" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionLineItems_642" xlink:to="loc_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation_651" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_652" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionLineItems_642" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_652" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_451" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_InventoriesTable" xlink:label="loc_teva_InventoriesTable_453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_451" xlink:to="loc_teva_InventoriesTable_453" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_InventoriesTable_453" xlink:to="loc_dei_LegalEntityAxis_454" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_460" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_454" xlink:to="loc_dei_EntityDomain_460" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_InventoriesLineItems" xlink:label="loc_teva_InventoriesLineItems_452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_InventoriesTable_453" xlink:to="loc_teva_InventoriesLineItems_452" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_InventoriesLineItems_452" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_455" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_InventoriesLineItems_452" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_456" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_457" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_InventoriesLineItems_452" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_457" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventoryInTransit" xlink:label="loc_us-gaap_OtherInventoryInTransit_458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_InventoriesLineItems_452" xlink:to="loc_us-gaap_OtherInventoryInTransit_458" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_InventoriesLineItems_452" xlink:to="loc_us-gaap_InventoryNet_459" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_558" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_563" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_558" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_563" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_559" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_563" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_559" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_561" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_559" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_561" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ProductRightsMember" xlink:label="loc_teva_ProductRightsMember_567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_561" xlink:to="loc_teva_ProductRightsMember_567" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember_568" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_561" xlink:to="loc_us-gaap_TradeNamesMember_568" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_561" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_569" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_560" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_563" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_560" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_564" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_560" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_564" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_565" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_560" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_565" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_566" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_560" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_566" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_572" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_572" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_dei_LegalEntityAxis_578" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_578" xlink:to="loc_dei_EntityDomain_599" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_srt_StatementGeographicalAxis_581" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_581" xlink:to="loc_srt_SegmentGeographicalDomain_580" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_682394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_580" xlink:to="loc_country_US_682394" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_574" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_574" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_573" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ActavisMember" xlink:label="loc_teva_ActavisMember_582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_573" xlink:to="loc_teva_ActavisMember_582" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_575" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_575" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_577" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_577" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_597" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ProductRightsMember" xlink:label="loc_teva_ProductRightsMember_598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_577" xlink:to="loc_teva_ProductRightsMember_598" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_408202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_srt_ProductOrServiceAxis_408202" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_408203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_408202" xlink:to="loc_srt_ProductsAndServicesDomain_408203" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_GenericPipelineProductsMember" xlink:label="loc_teva_GenericPipelineProductsMember_473346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_408203" xlink:to="loc_teva_GenericPipelineProductsMember_473346" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_DiscontinuationOfBusinessAxis" xlink:label="loc_teva_DiscontinuationOfBusinessAxis_581599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_teva_DiscontinuationOfBusinessAxis_581599" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_DiscontinuationOfBusinessDomain" xlink:label="loc_teva_DiscontinuationOfBusinessDomain_581600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_DiscontinuationOfBusinessAxis_581599" xlink:to="loc_teva_DiscontinuationOfBusinessDomain_581600" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_764548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_srt_RangeAxis_764548" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_764549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_764548" xlink:to="loc_srt_RangeMember_764549" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_764550" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_764549" xlink:to="loc_srt_MinimumMember_764550" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_764551" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_764549" xlink:to="loc_srt_MaximumMember_764551" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_764554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_764554" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_764555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_764554" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_764555" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_764556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_764555" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_764556" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis" xlink:label="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis_764580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis_764580" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain" xlink:label="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain_764582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis_764580" xlink:to="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain_764582" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTypeAxis" xlink:label="loc_us-gaap_ReclassificationTypeAxis_1261963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_us-gaap_ReclassificationTypeAxis_1261963" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTypeDomain" xlink:label="loc_us-gaap_ReclassificationTypeDomain_1261964" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationTypeAxis_1261963" xlink:to="loc_us-gaap_ReclassificationTypeDomain_1261964" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_InprocessresearchandDevelopmenttoProductRightsMember" xlink:label="loc_teva_InprocessresearchandDevelopmenttoProductRightsMember_1261965" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationTypeDomain_1261964" xlink:to="loc_teva_InprocessresearchandDevelopmenttoProductRightsMember_1261965" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_587" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_587" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_588" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_594" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_596" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_596" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_764546" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_764546" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_498" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_501" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_498" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_501" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_500" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_501" xlink:to="loc_dei_LegalEntityAxis_500" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_500" xlink:to="loc_dei_EntityDomain_514" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_391588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_501" xlink:to="loc_srt_ConsolidationItemsAxis_391588" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_391589" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_391588" xlink:to="loc_srt_ConsolidationItemsDomain_391589" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_501" xlink:to="loc_srt_StatementGeographicalAxis_505" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_503" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_505" xlink:to="loc_srt_SegmentGeographicalDomain_503" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NorthAmericaMember" xlink:label="loc_srt_NorthAmericaMember_518" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_503" xlink:to="loc_srt_NorthAmericaMember_518" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_503" xlink:to="loc_srt_EuropeMember_519" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_InternationalMarketsMember" xlink:label="loc_teva_InternationalMarketsMember_520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_503" xlink:to="loc_teva_InternationalMarketsMember_520" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OtherCountriesMember" xlink:label="loc_teva_OtherCountriesMember_521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_503" xlink:to="loc_teva_OtherCountriesMember_521" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_501" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_504" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_502" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_504" xlink:to="loc_us-gaap_SegmentDomain_502" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_499" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_501" xlink:to="loc_us-gaap_GoodwillLineItems_499" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_499" xlink:to="loc_us-gaap_Goodwill_506" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_1403742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_499" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_1403742" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_499" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_509" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_511" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_499" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_511" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_499" xlink:to="loc_us-gaap_Goodwill_512" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_523" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_523" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_526" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_526" xlink:to="loc_dei_LegalEntityAxis_525" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_528" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_525" xlink:to="loc_dei_EntityDomain_528" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_526" xlink:to="loc_us-gaap_GoodwillLineItems_524" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_524" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_527" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_530" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_536" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_530" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_536" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_dei_LegalEntityAxis_532" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_532" xlink:to="loc_dei_EntityDomain_545" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_539" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_539" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_537" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_539" xlink:to="loc_us-gaap_SegmentDomain_537" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_srt_StatementGeographicalAxis_540" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_538" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_540" xlink:to="loc_srt_SegmentGeographicalDomain_538" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_533" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_srt_RangeAxis_533" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_533" xlink:to="loc_srt_RangeMember_534" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_546" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_534" xlink:to="loc_srt_MaximumMember_546" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_534" xlink:to="loc_srt_MinimumMember_547" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_556283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_srt_StatementScenarioAxis_556283" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_556284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_556283" xlink:to="loc_srt_ScenarioUnspecifiedDomain_556284" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis" xlink:label="loc_us-gaap_ReportingUnitAxis_1562930" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_us-gaap_ReportingUnitAxis_1562930" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain" xlink:label="loc_us-gaap_ReportingUnitDomain_1562931" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_1562930" xlink:to="loc_us-gaap_ReportingUnitDomain_1562931" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_InternationalMarketsReportingUnitMember" xlink:label="loc_teva_InternationalMarketsReportingUnitMember_1562933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_1562931" xlink:to="loc_teva_InternationalMarketsReportingUnitMember_1562933" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_TevasApiReportingUnitMember" xlink:label="loc_teva_TevasApiReportingUnitMember_1562934" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_1562931" xlink:to="loc_teva_TevasApiReportingUnitMember_1562934" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_TevasEuropeReportingUnitMember" xlink:label="loc_teva_TevasEuropeReportingUnitMember_1562935" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_1562931" xlink:to="loc_teva_TevasEuropeReportingUnitMember_1562935" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_NorthAmericaAndMedisReportingUnitsMember" xlink:label="loc_teva_NorthAmericaAndMedisReportingUnitsMember_1562936" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_1562931" xlink:to="loc_teva_NorthAmericaAndMedisReportingUnitsMember_1562936" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1562937" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1562937" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1562938" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1562937" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1562938" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_MeasurementInputTerminalGrowthRateMember" xlink:label="loc_teva_MeasurementInputTerminalGrowthRateMember_1562939" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1562938" xlink:to="loc_teva_MeasurementInputTerminalGrowthRateMember_1562939" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_1562940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1562938" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_1562940" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_us-gaap_GoodwillLineItems_531" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_543" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_531" xlink:to="loc_us-gaap_Goodwill_543" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_412047" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_531" xlink:to="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_412047" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_718483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_531" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_718483" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_684" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_684" xlink:to="loc_us-gaap_DebtInstrumentTable_690" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_690" xlink:to="loc_dei_LegalEntityAxis_691" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_705" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_691" xlink:to="loc_dei_EntityDomain_705" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_690" xlink:to="loc_us-gaap_DebtInstrumentAxis_687" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_687" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_689" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ShortCreditAgreement2026Member" xlink:label="loc_teva_ShortCreditAgreement2026Member_704" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_689" xlink:to="loc_teva_ShortCreditAgreement2026Member_704" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_690" xlink:to="loc_us-gaap_VariableRateAxis_692" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_693" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_692" xlink:to="loc_us-gaap_VariableRateDomain_693" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_686" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_690" xlink:to="loc_srt_CurrencyAxis_686" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_686" xlink:to="loc_currency_AllCurrenciesDomain_685" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_504448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_690" xlink:to="loc_us-gaap_CreditFacilityAxis_504448" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_504449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_504448" xlink:to="loc_us-gaap_CreditFacilityDomain_504449" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_688" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_690" xlink:to="loc_us-gaap_DebtInstrumentLineItems_688" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_695" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_688" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_695" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_DebtInstrumentMaturityYear" xlink:label="loc_teva_DebtInstrumentMaturityYear_698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_688" xlink:to="loc_teva_DebtInstrumentMaturityYear_698" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaap_ShortTermBorrowings_699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_688" xlink:to="loc_us-gaap_ShortTermBorrowings_699" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_700" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_688" xlink:to="loc_us-gaap_LongTermDebtCurrent_700" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_688" xlink:to="loc_us-gaap_DebtCurrent_701" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_758" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_758" xlink:to="loc_us-gaap_DebtInstrumentTable_764" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_765" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_764" xlink:to="loc_dei_LegalEntityAxis_765" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_765" xlink:to="loc_dei_EntityDomain_815" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_761" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_764" xlink:to="loc_us-gaap_DebtInstrumentAxis_761" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_761" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_763" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OtherDebentures2026Member" xlink:label="loc_teva_OtherDebentures2026Member_814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_OtherDebentures2026Member_814" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2024Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2024Member_783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2024Member_783" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SustainabilityLinkedSeniorNotesDue2030Member" xlink:label="loc_teva_SustainabilityLinkedSeniorNotesDue2030Member_1260375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SustainabilityLinkedSeniorNotesDue2030Member_1260375" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2023OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2023OneMember_784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2023OneMember_784" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SustainabilityLinkedSeniorNotesDue2027Member" xlink:label="loc_teva_SustainabilityLinkedSeniorNotesDue2027Member_1260377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SustainabilityLinkedSeniorNotesDue2027Member_1260377" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2025OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025OneMember_572204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025OneMember_572204" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2025Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025Member_786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025Member_786" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2028Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2028Member_787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2028Member_787" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2022OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022OneMember_788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2022OneMember_788" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2026OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2026OneMember_790" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2026OneMember_790" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2027Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2027Member_789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2027Member_789" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2023TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2023TwoMember_673253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2023TwoMember_673253" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2046Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2046Member_794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2046Member_794" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2024OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2024OneMember_796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2024OneMember_796" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2028OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2028OneMember_797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2028OneMember_797" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2025TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025TwoMember_572603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025TwoMember_572603" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SustainabilityLinkedSeniorNotesDue2027TwoMember" xlink:label="loc_teva_SustainabilityLinkedSeniorNotesDue2027TwoMember_1260378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SustainabilityLinkedSeniorNotesDue2027TwoMember_1260378" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SustainabilityLinkedSeniorNotesDue2029Member" xlink:label="loc_teva_SustainabilityLinkedSeniorNotesDue2029Member_1260379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SustainabilityLinkedSeniorNotesDue2029Member_1260379" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2022TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022TwoMember_798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2022TwoMember_798" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2036Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2036Member_799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2036Member_799" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2022ThreeMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022ThreeMember_804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2022ThreeMember_804" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2025ThreeMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025ThreeMember_572585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025ThreeMember_572585" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_766" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_764" xlink:to="loc_us-gaap_VariableRateAxis_766" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_767" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_766" xlink:to="loc_us-gaap_VariableRateDomain_767" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_760" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_764" xlink:to="loc_srt_CurrencyAxis_760" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_759" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_760" xlink:to="loc_currency_AllCurrenciesDomain_759" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_762" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_764" xlink:to="loc_us-gaap_DebtInstrumentLineItems_762" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_DebtInstrumentMaturityYear" xlink:label="loc_teva_DebtInstrumentMaturityYear_772" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_762" xlink:to="loc_teva_DebtInstrumentMaturityYear_772" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotes" xlink:label="loc_us-gaap_SeniorNotes_775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_762" xlink:to="loc_us-gaap_SeniorNotes_775" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_762" xlink:to="loc_us-gaap_LongTermDebtCurrent_778" use="optional" order="35" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_762" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_780" use="optional" order="36" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesAndLoans" xlink:label="loc_us-gaap_LongTermNotesAndLoans_781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_762" xlink:to="loc_us-gaap_LongTermNotesAndLoans_781" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:label="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_1522385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_762" xlink:to="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_1522385" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_818" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_818" xlink:to="loc_us-gaap_DebtInstrumentTable_822" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_819" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_822" xlink:to="loc_us-gaap_DebtInstrumentAxis_819" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_819" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_821" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2024Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2024Member_826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2024Member_826" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2030Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2030Member_1241820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2030Member_1241820" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2023OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2023OneMember_827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2023OneMember_827" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SustainabilityLinkedSeniorNotesDue2027Member" xlink:label="loc_teva_SustainabilityLinkedSeniorNotesDue2027Member_1260398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SustainabilityLinkedSeniorNotesDue2027Member_1260398" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2025OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025OneMember_572208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025OneMember_572208" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2025Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025Member_829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025Member_829" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2028Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2028Member_830" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2028Member_830" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2022OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022OneMember_831" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2022OneMember_831" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2027Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2027Member_832" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2027Member_832" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2026OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2026OneMember_833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2026OneMember_833" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2023TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2023TwoMember_835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2023TwoMember_835" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2046Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2046Member_837" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2046Member_837" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2024OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2024OneMember_839" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2024OneMember_839" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2028OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2028OneMember_840" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2028OneMember_840" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2025TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025TwoMember_572210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025TwoMember_572210" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SustainabilityLinkedSeniorNotesDue2027TwoMember" xlink:label="loc_teva_SustainabilityLinkedSeniorNotesDue2027TwoMember_1260399" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SustainabilityLinkedSeniorNotesDue2027TwoMember_1260399" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SustainabilityLinkedSeniorNotesDue2029Member" xlink:label="loc_teva_SustainabilityLinkedSeniorNotesDue2029Member_1260400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SustainabilityLinkedSeniorNotesDue2029Member_1260400" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2022TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022TwoMember_841" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2022TwoMember_841" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2036Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2036Member_842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2036Member_842" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2022ThreeMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022ThreeMember_847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2022ThreeMember_847" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SubsidiarySeniorNotesDue2025ThreeMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025ThreeMember_848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025ThreeMember_848" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_InterestRateIncreaseMember" xlink:label="loc_teva_InterestRateIncreaseMember_1413582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_InterestRateIncreaseMember_1413582" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OneTimePremiumPaymentMember" xlink:label="loc_teva_OneTimePremiumPaymentMember_1413597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_OneTimePremiumPaymentMember_1413597" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1413583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_822" xlink:to="loc_srt_RangeAxis_1413583" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1413584" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1413583" xlink:to="loc_srt_RangeMember_1413584" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1413585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1413584" xlink:to="loc_srt_MinimumMember_1413585" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1413586" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1413584" xlink:to="loc_srt_MaximumMember_1413586" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1413574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_822" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1413574" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1413575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1413574" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1413575" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1413601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_822" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1413601" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1413602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1413601" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1413602" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_1413603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1413602" xlink:to="loc_us-gaap_SeniorNotesMember_1413603" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_822" xlink:to="loc_us-gaap_DebtInstrumentLineItems_820" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_824" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_1413590" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820" xlink:to="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_1413590" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_1413592" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_1413592" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SeniorNotesRepaidAmount" xlink:label="loc_teva_SeniorNotesRepaidAmount_1413593" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820" xlink:to="loc_teva_SeniorNotesRepaidAmount_1413593" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SeniorNotesMaturityPercentage" xlink:label="loc_teva_SeniorNotesMaturityPercentage_1413595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820" xlink:to="loc_teva_SeniorNotesMaturityPercentage_1413595" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_718" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_718" xlink:to="loc_us-gaap_DebtInstrumentTable_724" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_725" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_dei_LegalEntityAxis_725" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_755" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_725" xlink:to="loc_dei_EntityDomain_755" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_us-gaap_CreditFacilityAxis_719" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_720" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_719" xlink:to="loc_us-gaap_CreditFacilityDomain_720" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_720" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_728" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_UnsecuredSyndicatedRevolvingCreditFacilityMember" xlink:label="loc_teva_UnsecuredSyndicatedRevolvingCreditFacilityMember_1388216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_720" xlink:to="loc_teva_UnsecuredSyndicatedRevolvingCreditFacilityMember_1388216" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_726" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_727" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_726" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_727" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_756" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_727" xlink:to="loc_us-gaap_ConvertibleDebtMember_756" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_721" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_us-gaap_DebtInstrumentAxis_721" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_723" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_721" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_723" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_408262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_408262" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_408264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_408262" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_408264" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_466637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_466637" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_466638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_466637" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_466638" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_466640" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_466638" xlink:to="loc_us-gaap_SubsequentEventMember_466640" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_TrancheAxis" xlink:label="loc_teva_TrancheAxis_682383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_teva_TrancheAxis_682383" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_TrancheDomain" xlink:label="loc_teva_TrancheDomain_682384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_TrancheAxis_682383" xlink:to="loc_teva_TrancheDomain_682384" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_682892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_682892" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_682893" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_682892" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_682893" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_765345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_srt_RangeAxis_765345" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_765346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_765345" xlink:to="loc_srt_RangeMember_765346" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AgreementAxis" xlink:label="loc_teva_AgreementAxis_1280331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_teva_AgreementAxis_1280331" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AgreementDomain" xlink:label="loc_teva_AgreementDomain_1280332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_AgreementAxis_1280331" xlink:to="loc_teva_AgreementDomain_1280332" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_us-gaap_DebtInstrumentLineItems_722" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_732" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_732" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_735" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LongTermDebtCurrencyPortionUSD" xlink:label="loc_teva_LongTermDebtCurrencyPortionUSD_739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_teva_LongTermDebtCurrencyPortionUSD_739" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LongTermDebtCurrencyPortionEUR" xlink:label="loc_teva_LongTermDebtCurrencyPortionEUR_740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_teva_LongTermDebtCurrencyPortionEUR_740" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LongTermDebtCurrencyPortionCHF" xlink:label="loc_teva_LongTermDebtCurrencyPortionCHF_741" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_teva_LongTermDebtCurrencyPortionCHF_741" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCovenantDescription" xlink:label="loc_us-gaap_DebtInstrumentCovenantDescription_466634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_DebtInstrumentCovenantDescription_466634" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_682881" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_682881" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_1241835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_1241835" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LineOfCreditExtentionPeriod" xlink:label="loc_teva_LineOfCreditExtentionPeriod_1403836" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_teva_LineOfCreditExtentionPeriod_1403836" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LeverageRatio" xlink:label="loc_teva_LeverageRatio_1403837" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_teva_LeverageRatio_1403837" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentDetailAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract_1333" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_1340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_1333" xlink:to="loc_us-gaap_DerivativeTable_1340" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1340" xlink:to="loc_dei_LegalEntityAxis_1344" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1357" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1344" xlink:to="loc_dei_EntityDomain_1357" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_1341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1340" xlink:to="loc_us-gaap_HedgingDesignationAxis_1341" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_1342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_1341" xlink:to="loc_us-gaap_HedgingDesignationDomain_1342" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_1354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_1342" xlink:to="loc_us-gaap_NondesignatedMember_1354" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_1337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1340" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_1337" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1337" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1336" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_1348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1336" xlink:to="loc_us-gaap_ForeignExchangeContractMember_1348" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1340" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1334" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1334" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1335" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SeniorNotesAndLoansMember" xlink:label="loc_teva_SeniorNotesAndLoansMember_1346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1335" xlink:to="loc_teva_SeniorNotesAndLoansMember_1346" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_390198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1335" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_390198" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1340" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1338" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_1343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1338" xlink:to="loc_us-gaap_HedgingRelationshipDomain_1343" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_1339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1340" xlink:to="loc_us-gaap_DerivativeLineItems_1339" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_1351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1339" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_1351" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_1352" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1339" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_1352" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentDetailAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract_390514" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_390515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_390514" xlink:to="loc_us-gaap_DerivativeTable_390515" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_390519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_390515" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_390519" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_390520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_390519" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_390520" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_NetRevenuesMember" xlink:label="loc_teva_NetRevenuesMember_406886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_390520" xlink:to="loc_teva_NetRevenuesMember_406886" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_FinancialExpensesMember" xlink:label="loc_teva_FinancialExpensesMember_406916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_390520" xlink:to="loc_teva_FinancialExpensesMember_406916" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_406887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_390515" xlink:to="loc_us-gaap_HedgingDesignationAxis_406887" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_406888" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_406887" xlink:to="loc_us-gaap_HedgingDesignationDomain_406888" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_406890" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_406888" xlink:to="loc_us-gaap_NondesignatedMember_406890" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotDesignatedAsHedgingInstrumentTradingMember" xlink:label="loc_us-gaap_NotDesignatedAsHedgingInstrumentTradingMember_406891" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_406888" xlink:to="loc_us-gaap_NotDesignatedAsHedgingInstrumentTradingMember_406891" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember" xlink:label="loc_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember_466838" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_406888" xlink:to="loc_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember_466838" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_682286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_390515" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_682286" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_682287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_682286" xlink:to="loc_us-gaap_HedgingRelationshipDomain_682287" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_390516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_390515" xlink:to="loc_us-gaap_DerivativeLineItems_390516" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_406900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_390516" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_406900" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1281" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_1286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1281" xlink:to="loc_us-gaap_DerivativeTable_1286" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_dei_LegalEntityAxis_1290" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1290" xlink:to="loc_dei_EntityDomain_1312" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_1283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_1283" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1283" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1282" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SeniorNotesDue2023TwoMember" xlink:label="loc_teva_SeniorNotesDue2023TwoMember_1291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1282" xlink:to="loc_teva_SeniorNotesDue2023TwoMember_1291" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SeniorNotesDue2022Member" xlink:label="loc_teva_SeniorNotesDue2022Member_1294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1282" xlink:to="loc_teva_SeniorNotesDue2022Member_1294" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SeniorNotesDue2021Member" xlink:label="loc_teva_SeniorNotesDue2021Member_1297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1282" xlink:to="loc_teva_SeniorNotesDue2021Member_1297" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1288" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1288" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1289" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_688628" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1289" xlink:to="loc_us-gaap_CostOfSalesMember_688628" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1284" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_1287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1284" xlink:to="loc_us-gaap_HedgingRelationshipDomain_1287" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_558657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_us-gaap_HedgingDesignationAxis_558657" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_558658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_558657" xlink:to="loc_us-gaap_HedgingDesignationDomain_558658" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_817877" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_srt_RangeAxis_817877" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_817878" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_817877" xlink:to="loc_srt_RangeMember_817878" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_1285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_us-gaap_DerivativeLineItems_1285" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RevenuesOtherThanUsd" xlink:label="loc_teva_RevenuesOtherThanUsd_1298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_teva_RevenuesOtherThanUsd_1298" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_NotionalAmountHedgeDebt" xlink:label="loc_teva_NotionalAmountHedgeDebt_1300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_teva_NotionalAmountHedgeDebt_1300" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="loc_us-gaap_DerivativeLossOnDerivative_1301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_us-gaap_DerivativeLossOnDerivative_1301" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" xlink:label="loc_teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses_1303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses_1303" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_PreviouslyHedgeDebtRate" xlink:label="loc_teva_PreviouslyHedgeDebtRate_1304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_teva_PreviouslyHedgeDebtRate_1304" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_CashReceivedOnSettlementOfPosition" xlink:label="loc_teva_CashReceivedOnSettlementOfPosition_581646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_teva_CashReceivedOnSettlementOfPosition_581646" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="loc_us-gaap_DerivativeGainOnDerivative_688630" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_us-gaap_DerivativeGainOnDerivative_688630" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss" xlink:label="loc_us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss_718504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss_718504" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_InterestRateSwapLoss" xlink:label="loc_teva_InterestRateSwapLoss_1403869" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_teva_InterestRateSwapLoss_1403869" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1456" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_1459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1456" xlink:to="loc_us-gaap_LossContingenciesTable_1459" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1457" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1459" xlink:to="loc_dei_LegalEntityAxis_1457" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1460" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1457" xlink:to="loc_dei_EntityDomain_1460" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_471102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1459" xlink:to="loc_srt_LitigationCaseAxis_471102" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_471103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_471102" xlink:to="loc_srt_LitigationCaseTypeDomain_471103" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SettlementOnAccountOfProductLiabilityMember" xlink:label="loc_teva_SettlementOnAccountOfProductLiabilityMember_720064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_471103" xlink:to="loc_teva_SettlementOnAccountOfProductLiabilityMember_720064" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_720032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1459" xlink:to="loc_srt_StatementGeographicalAxis_720032" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_720033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_720032" xlink:to="loc_srt_SegmentGeographicalDomain_720033" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_1458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1459" xlink:to="loc_us-gaap_LossContingenciesLineItems_1458" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_1461" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1458" xlink:to="loc_us-gaap_LitigationSettlementExpense_1461" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1458" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1462" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RestructuringExpenseAndIncome" xlink:label="loc_teva_RestructuringExpenseAndIncome_720065" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1458" xlink:to="loc_teva_RestructuringExpenseAndIncome_720065" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_899" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_CommitmentAndContingenciesTable" xlink:label="loc_teva_CommitmentAndContingenciesTable_901" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_899" xlink:to="loc_teva_CommitmentAndContingenciesTable_901" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_906" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_srt_ProductOrServiceAxis_906" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_906" xlink:to="loc_srt_ProductsAndServicesDomain_907" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AndroGelRateAtOnePercentageMember" xlink:label="loc_teva_AndroGelRateAtOnePercentageMember_937" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_907" xlink:to="loc_teva_AndroGelRateAtOnePercentageMember_937" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AtripalaMember" xlink:label="loc_teva_AtripalaMember_1562952" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_907" xlink:to="loc_teva_AtripalaMember_1562952" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_TiruvadaMember" xlink:label="loc_teva_TiruvadaMember_1562953" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_907" xlink:to="loc_teva_TiruvadaMember_1562953" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_VireadMember" xlink:label="loc_teva_VireadMember_1562955" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_907" xlink:to="loc_teva_VireadMember_1562955" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ColcysMember" xlink:label="loc_teva_ColcysMember_1562959" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_907" xlink:to="loc_teva_ColcysMember_1562959" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_srt_CounterpartyNameAxis_902" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_902" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_908" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_904" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_904" xlink:to="loc_us-gaap_LossContingencyNatureDomain_905" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_EosinophilicEsophagitisMember" xlink:label="loc_teva_EosinophilicEsophagitisMember_936" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_905" xlink:to="loc_teva_EosinophilicEsophagitisMember_936" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_srt_StatementGeographicalAxis_910" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_910" xlink:to="loc_srt_SegmentGeographicalDomain_909" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_909" xlink:to="loc_country_US_940" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_941" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_909" xlink:to="loc_srt_EuropeMember_941" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_LA" xlink:label="loc_stpr_LA_1411614" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_909" xlink:to="loc_stpr_LA_1411614" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA" xlink:label="loc_country_CA_1562951" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_909" xlink:to="loc_country_CA_1562951" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_471076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_srt_LitigationCaseAxis_471076" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_471078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_471076" xlink:to="loc_srt_LitigationCaseTypeDomain_471078" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OpioidLitigationMember" xlink:label="loc_teva_OpioidLitigationMember_471080" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_471078" xlink:to="loc_teva_OpioidLitigationMember_471080" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_NationwideSettlementMember" xlink:label="loc_teva_NationwideSettlementMember_515110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_471078" xlink:to="loc_teva_NationwideSettlementMember_515110" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_StatesPoliticalSubdivisionsAndTribesMember" xlink:label="loc_teva_StatesPoliticalSubdivisionsAndTribesMember_1566427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_471078" xlink:to="loc_teva_StatesPoliticalSubdivisionsAndTribesMember_1566427" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_515106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_515106" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_515107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_515106" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_515107" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_515108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_515107" xlink:to="loc_us-gaap_SubsequentEventMember_515108" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_DefendantsAxis" xlink:label="loc_teva_DefendantsAxis_1280170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_teva_DefendantsAxis_1280170" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_DefendantsMember" xlink:label="loc_teva_DefendantsMember_1280172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_DefendantsAxis_1280170" xlink:to="loc_teva_DefendantsMember_1280172" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_FourOtherDefendantsOtherThanTevaMember" xlink:label="loc_teva_FourOtherDefendantsOtherThanTevaMember_1280174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_DefendantsMember_1280172" xlink:to="loc_teva_FourOtherDefendantsOtherThanTevaMember_1280174" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_CompaniesShareMember" xlink:label="loc_teva_CompaniesShareMember_1566425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_DefendantsMember_1280172" xlink:to="loc_teva_CompaniesShareMember_1566425" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AgreementAxis" xlink:label="loc_teva_AgreementAxis_1280188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_teva_AgreementAxis_1280188" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AgreementDomain" xlink:label="loc_teva_AgreementDomain_1281018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_AgreementAxis_1280188" xlink:to="loc_teva_AgreementDomain_1281018" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AttorneyGeneralOfLouisanaMember" xlink:label="loc_teva_AttorneyGeneralOfLouisanaMember_1280191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_AgreementDomain_1281018" xlink:to="loc_teva_AttorneyGeneralOfLouisanaMember_1280191" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AttorneyGeneralOfRhodeIslandMember" xlink:label="loc_teva_AttorneyGeneralOfRhodeIslandMember_1411784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_AgreementDomain_1281018" xlink:to="loc_teva_AttorneyGeneralOfRhodeIslandMember_1411784" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AttorneyGeneralOfFloridaMember" xlink:label="loc_teva_AttorneyGeneralOfFloridaMember_1411785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_AgreementDomain_1281018" xlink:to="loc_teva_AttorneyGeneralOfFloridaMember_1411785" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AttorneyGeneralOfWestVirginiaMember" xlink:label="loc_teva_AttorneyGeneralOfWestVirginiaMember_1562962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_AgreementDomain_1281018" xlink:to="loc_teva_AttorneyGeneralOfWestVirginiaMember_1562962" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_CommitmentAndContingenciesLineItems" xlink:label="loc_teva_CommitmentAndContingenciesLineItems_900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_teva_CommitmentAndContingenciesLineItems_900" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_DamagesAssessment" xlink:label="loc_teva_DamagesAssessment_911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_DamagesAssessment_911" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AnnualSalesAtTimeOfSettlement" xlink:label="loc_teva_AnnualSalesAtTimeOfSettlement_919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesAtTimeOfSettlement_919" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AnnualSalesOfEffexor" xlink:label="loc_teva_AnnualSalesOfEffexor_920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfEffexor_920" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AnnualSalesOfLamictal" xlink:label="loc_teva_AnnualSalesOfLamictal_921" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfLamictal_921" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AnnualSalesOfNiaspan" xlink:label="loc_teva_AnnualSalesOfNiaspan_922" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfNiaspan_922" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AnnualSalesOfActos" xlink:label="loc_teva_AnnualSalesOfActos_925" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfActos_925" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AnnualSalesOfActoplus" xlink:label="loc_teva_AnnualSalesOfActoplus_926" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfActoplus_926" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_932" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue_933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_LossContingencyDamagesPaidValue_933" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_934" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_934" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AnnualSalesOfSensipar" xlink:label="loc_teva_AnnualSalesOfSensipar_471045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfSensipar_471045" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LitigationSettlementAmountAwardedDistributionPeriod" xlink:label="loc_teva_LitigationSettlementAmountAwardedDistributionPeriod_515103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_LitigationSettlementAmountAwardedDistributionPeriod_515103" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LitigationSettlementAmountAwardedCashAmount" xlink:label="loc_teva_LitigationSettlementAmountAwardedCashAmount_515111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_LitigationSettlementAmountAwardedCashAmount_515111" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LitigationSettlementAmountAwardedCashAmountDistributionPeriod" xlink:label="loc_teva_LitigationSettlementAmountAwardedCashAmountDistributionPeriod_515113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_LitigationSettlementAmountAwardedCashAmountDistributionPeriod_515113" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AnnualSalesOfCopaxone" xlink:label="loc_teva_AnnualSalesOfCopaxone_720069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfCopaxone_720069" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_818712" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_818712" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualProvision" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_1279981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_1279981" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AnnualSalesOfNarcan" xlink:label="loc_teva_AnnualSalesOfNarcan_1279997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfNarcan_1279997" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LossContingencyClaimsDismissedValue" xlink:label="loc_teva_LossContingencyClaimsDismissedValue_1280153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_LossContingencyClaimsDismissedValue_1280153" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LitigationSettlementAmountDistributableinKind" xlink:label="loc_teva_LitigationSettlementAmountDistributableinKind_1280198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_LitigationSettlementAmountDistributableinKind_1280198" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_1280206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_LitigationSettlementExpense_1280206" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccrualForEnvironmentalLossContingencies" xlink:label="loc_us-gaap_AccrualForEnvironmentalLossContingencies_1280219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_AccrualForEnvironmentalLossContingencies_1280219" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LossContingenciesOnEnvironmentalLawsPenalty" xlink:label="loc_teva_LossContingenciesOnEnvironmentalLawsPenalty_1280223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_LossContingenciesOnEnvironmentalLawsPenalty_1280223" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_PercentageOfPopulationOfSubdivisionsWillFormallyReleaseAsAPartOfSettlement" xlink:label="loc_teva_PercentageOfPopulationOfSubdivisionsWillFormallyReleaseAsAPartOfSettlement_1284351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_PercentageOfPopulationOfSubdivisionsWillFormallyReleaseAsAPartOfSettlement_1284351" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AnnualSalesAtTheTimeOfLaunchOfProduct" xlink:label="loc_teva_AnnualSalesAtTheTimeOfLaunchOfProduct_1562958" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesAtTheTimeOfLaunchOfProduct_1562958" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LitigationAmountIncludingAlreadyPaid" xlink:label="loc_teva_LitigationAmountIncludingAlreadyPaid_1566438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_LitigationAmountIncludingAlreadyPaid_1566438" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LitigationSettlementTerm" xlink:label="loc_teva_LitigationSettlementTerm_1566420" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_LitigationSettlementTerm_1566420" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ProductOfferingSettlementAtWholesaleAcquisitionCosts" xlink:label="loc_teva_ProductOfferingSettlementAtWholesaleAcquisitionCosts_1566421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_ProductOfferingSettlementAtWholesaleAcquisitionCosts_1566421" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ProductToBeSettledValuationTerm" xlink:label="loc_teva_ProductToBeSettledValuationTerm_1566422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_ProductToBeSettledValuationTerm_1566422" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_PercentageOfWholesaleAcquisitionCostValueInCashInLieuOfProductToBePaidUnderSettlementAgreement" xlink:label="loc_teva_PercentageOfWholesaleAcquisitionCostValueInCashInLieuOfProductToBePaidUnderSettlementAgreement_1568578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_PercentageOfWholesaleAcquisitionCostValueInCashInLieuOfProductToBePaidUnderSettlementAgreement_1568578" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LitigationAmountToBePaidToTribes" xlink:label="loc_teva_LitigationAmountToBePaidToTribes_1568814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_LitigationAmountToBePaidToTribes_1568814" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_WholesaleAcquisitionCostValueInCashAmountInLieuOfProductToBePaidUnderSettlementAgreement" xlink:label="loc_teva_WholesaleAcquisitionCostValueInCashAmountInLieuOfProductToBePaidUnderSettlementAgreement_1568816" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_WholesaleAcquisitionCostValueInCashAmountInLieuOfProductToBePaidUnderSettlementAgreement_1568816" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1206" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_IncomeTaxTable" xlink:label="loc_teva_IncomeTaxTable_1210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1206" xlink:to="loc_teva_IncomeTaxTable_1210" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_dei_LegalEntityAxis_1211" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1211" xlink:to="loc_dei_EntityDomain_1242" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_srt_RangeAxis_1214" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1214" xlink:to="loc_srt_RangeMember_1215" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_1216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_1216" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_1217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1216" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_1217" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_1207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_1207" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_1208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_1207" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_1208" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IsraelTaxAuthorityMember" xlink:label="loc_us-gaap_IsraelTaxAuthorityMember_1220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_1208" xlink:to="loc_us-gaap_IsraelTaxAuthorityMember_1220" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_1218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_us-gaap_TaxPeriodAxis_1218" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_1219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_1218" xlink:to="loc_us-gaap_TaxPeriodDomain_1219" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_TaxYear2008To2011Member" xlink:label="loc_teva_TaxYear2008To2011Member_1280227" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_1219" xlink:to="loc_teva_TaxYear2008To2011Member_1280227" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1212" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1212" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1213" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_581719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_581719" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_581720" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_581719" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_581720" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_673833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_srt_StatementScenarioAxis_673833" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_673834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_673833" xlink:to="loc_srt_ScenarioUnspecifiedDomain_673834" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_IncomeTaxLineItems" xlink:label="loc_teva_IncomeTaxLineItems_1209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_teva_IncomeTaxLineItems_1209" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1229" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ExpectedImpairmentOfIncomeTaxBenefit" xlink:label="loc_teva_ExpectedImpairmentOfIncomeTaxBenefit_581718" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_teva_ExpectedImpairmentOfIncomeTaxBenefit_581718" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_671996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_671996" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_672012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_672012" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:label="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_1280226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_1280226" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_1566443" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_InventoryWriteDown_1566443" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_EffectiveIncomeTaxReconciliationAmountInventoryWrittenOff" xlink:label="loc_teva_EffectiveIncomeTaxReconciliationAmountInventoryWrittenOff_1566444" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_teva_EffectiveIncomeTaxReconciliationAmountInventoryWrittenOff_1566444" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail">
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RestructuringAndImpairmentAbstract" xlink:label="loc_teva_RestructuringAndImpairmentAbstract_1390" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RestructuringAndImpairmentCostsTable" xlink:label="loc_teva_RestructuringAndImpairmentCostsTable_1393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentAbstract_1390" xlink:to="loc_teva_RestructuringAndImpairmentCostsTable_1393" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1393" xlink:to="loc_dei_LegalEntityAxis_1391" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1391" xlink:to="loc_dei_EntityDomain_1394" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RestructuringAndImpairmentCostsLineItems" xlink:label="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1393" xlink:to="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_1395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_1395" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1396" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_1398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" xlink:to="loc_us-gaap_RestructuringCharges_1398" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses" xlink:label="loc_teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses_1400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" xlink:to="loc_teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses_1400" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ImpairmentAndRestructuring" xlink:label="loc_teva_ImpairmentAndRestructuring_1401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" xlink:to="loc_teva_ImpairmentAndRestructuring_1401" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RestructuringAndImpairmentAbstract" xlink:label="loc_teva_RestructuringAndImpairmentAbstract_1403" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RestructuringAndImpairmentCostsTable" xlink:label="loc_teva_RestructuringAndImpairmentCostsTable_1412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentAbstract_1403" xlink:to="loc_teva_RestructuringAndImpairmentCostsTable_1412" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1412" xlink:to="loc_dei_LegalEntityAxis_1406" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1406" xlink:to="loc_dei_EntityDomain_1416" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1412" xlink:to="loc_srt_ProductOrServiceAxis_1407" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1407" xlink:to="loc_srt_ProductsAndServicesDomain_1408" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1412" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1404" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1404" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1405" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1412" xlink:to="loc_srt_StatementGeographicalAxis_1414" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1414" xlink:to="loc_srt_SegmentGeographicalDomain_1413" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_515346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1412" xlink:to="loc_srt_StatementScenarioAxis_515346" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_515347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_515346" xlink:to="loc_srt_ScenarioUnspecifiedDomain_515347" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RestructuringAndImpairmentCostsLineItems" xlink:label="loc_teva_RestructuringAndImpairmentCostsLineItems_1411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1412" xlink:to="loc_teva_RestructuringAndImpairmentCostsLineItems_1411" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_1419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1411" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_1419" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_758336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1411" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_758336" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_1421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1411" xlink:to="loc_us-gaap_RestructuringCharges_1421" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1403736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1411" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1403736" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1431" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1435" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1431" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1435" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1435" xlink:to="loc_dei_LegalEntityAxis_1432" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1432" xlink:to="loc_dei_EntityDomain_1437" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_1433" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1435" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_1433" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1433" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_1436" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="loc_us-gaap_EmployeeSeveranceMember_1439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1436" xlink:to="loc_us-gaap_EmployeeSeveranceMember_1439" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember" xlink:label="loc_us-gaap_OtherRestructuringMember_1440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1436" xlink:to="loc_us-gaap_OtherRestructuringMember_1440" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_390248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1435" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_390248" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_390250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_390248" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_390250" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_1434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1435" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_1434" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_1438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1434" xlink:to="loc_us-gaap_RestructuringCharges_1438" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1442" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1442" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1447" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1445" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1447" xlink:to="loc_dei_LegalEntityAxis_1445" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1450" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1445" xlink:to="loc_dei_EntityDomain_1450" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ExitAndDisposalAxis" xlink:label="loc_teva_ExitAndDisposalAxis_1443" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1447" xlink:to="loc_teva_ExitAndDisposalAxis_1443" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ExitAndDisposalDomain" xlink:label="loc_teva_ExitAndDisposalDomain_1444" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_ExitAndDisposalAxis_1443" xlink:to="loc_teva_ExitAndDisposalDomain_1444" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_EmployeeTerminationMember" xlink:label="loc_teva_EmployeeTerminationMember_1448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_ExitAndDisposalDomain_1444" xlink:to="loc_teva_EmployeeTerminationMember_1448" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OtherExitAndDisposalMember" xlink:label="loc_teva_OtherExitAndDisposalMember_1449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_ExitAndDisposalDomain_1444" xlink:to="loc_teva_OtherExitAndDisposalMember_1449" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_1446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1447" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_1446" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_1451" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1446" xlink:to="loc_us-gaap_RestructuringReserve_1451" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RestructuringAccrualProvision" xlink:label="loc_teva_RestructuringAccrualProvision_1452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1446" xlink:to="loc_teva_RestructuringAccrualProvision_1452" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_UtilizationAndOther" xlink:label="loc_teva_UtilizationAndOther_1453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1446" xlink:to="loc_teva_UtilizationAndOther_1453" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_1454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1446" xlink:to="loc_us-gaap_RestructuringReserve_1454" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1591" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1596" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1591" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1596" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1596" xlink:to="loc_dei_LegalEntityAxis_1595" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1595" xlink:to="loc_dei_EntityDomain_1603" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1592" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1596" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1592" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1592" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1594" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_1601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1594" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_1601" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1593" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1596" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1593" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1593" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1597" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_718513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1593" xlink:to="loc_us-gaap_EarningsPerShareBasic_718513" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_718514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1593" xlink:to="loc_us-gaap_EarningsPerShareDiluted_718514" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1411267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1593" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1411267" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_390025" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_390027" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_390025" xlink:to="loc_us-gaap_StatementTable_390027" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_390028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_390027" xlink:to="loc_dei_LegalEntityAxis_390028" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_390029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_390028" xlink:to="loc_dei_EntityDomain_390029" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_390055" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_390027" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_390055" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_390057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_390055" xlink:to="loc_us-gaap_EquityComponentDomain_390057" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_390087" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_390057" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_390087" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_390089" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_390057" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_390089" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_390090" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_390057" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_390090" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_390091" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_390057" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_390091" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_390027" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390030" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_390031" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390030" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_390031" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_390032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390030" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_390032" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_390033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390030" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_390033" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_390034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390030" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_390034" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_466595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390030" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_466595" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_390049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390030" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_390049" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_390052" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390030" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_390052" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_390129" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_390130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_390129" xlink:to="loc_us-gaap_StatementTable_390130" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_390133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_390130" xlink:to="loc_dei_LegalEntityAxis_390133" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_390134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_390133" xlink:to="loc_dei_EntityDomain_390134" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_390142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_390130" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_390142" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_390143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_390142" xlink:to="loc_us-gaap_EquityComponentDomain_390143" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember_390145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_390143" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember_390145" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_390146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_390130" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_390146" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_390148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_390146" xlink:to="loc_us-gaap_TypeOfAdoptionMember_390148" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_390149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_390148" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_390149" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_720088" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_390130" xlink:to="loc_srt_RangeAxis_720088" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_720089" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_720088" xlink:to="loc_srt_RangeMember_720089" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_390130" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390135" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_390137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390135" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_390137" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract_1481" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract_1481" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1483" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1483" xlink:to="loc_dei_LegalEntityAxis_1482" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1487" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1482" xlink:to="loc_dei_EntityDomain_1487" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1486" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1483" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1486" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1484" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1486" xlink:to="loc_us-gaap_SegmentDomain_1484" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_NorthAmericaSegmentMember" xlink:label="loc_teva_NorthAmericaSegmentMember_1488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1484" xlink:to="loc_teva_NorthAmericaSegmentMember_1488" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_EuropeSegmentMember" xlink:label="loc_teva_EuropeSegmentMember_1489" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1484" xlink:to="loc_teva_EuropeSegmentMember_1489" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_InternationalMarketsMember" xlink:label="loc_teva_InternationalMarketsMember_1490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1484" xlink:to="loc_teva_InternationalMarketsMember_1490" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1483" xlink:to="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1491" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_1492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_us-gaap_GrossProfit_1492" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1493" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1493" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_1494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_us-gaap_SellingAndMarketingExpense_1494" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1495" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1495" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OtherOperatingIncomeExpense" xlink:label="loc_teva_OtherOperatingIncomeExpense_1496" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_teva_OtherOperatingIncomeExpense_1496" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_1497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_us-gaap_OperatingIncomeLoss_1497" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract_1499" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1503" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract_1499" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1503" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1502" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1503" xlink:to="loc_dei_LegalEntityAxis_1502" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1518" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1502" xlink:to="loc_dei_EntityDomain_1518" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1503" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1506" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1506" xlink:to="loc_us-gaap_SegmentDomain_1504" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_NorthAmericaSegmentMember" xlink:label="loc_teva_NorthAmericaSegmentMember_1519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1504" xlink:to="loc_teva_NorthAmericaSegmentMember_1519" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_EuropeSegmentMember" xlink:label="loc_teva_EuropeSegmentMember_1520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1504" xlink:to="loc_teva_EuropeSegmentMember_1520" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_InternationalMarketsMember" xlink:label="loc_teva_InternationalMarketsMember_1521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1504" xlink:to="loc_teva_InternationalMarketsMember_1521" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateMember" xlink:label="loc_us-gaap_CorporateMember_1522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1504" xlink:to="loc_us-gaap_CorporateMember_1522" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember" xlink:label="loc_us-gaap_AllOtherSegmentsMember_1523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1504" xlink:to="loc_us-gaap_AllOtherSegmentsMember_1523" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SegmentsAndOtherActivitiesMember" xlink:label="loc_teva_SegmentsAndOtherActivitiesMember_1524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1504" xlink:to="loc_teva_SegmentsAndOtherActivitiesMember_1524" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1503" xlink:to="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1505" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AmountsAllocatedToSegmentsAbstract" xlink:label="loc_teva_AmountsAllocatedToSegmentsAbstract_1500" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1505" xlink:to="loc_teva_AmountsAllocatedToSegmentsAbstract_1500" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_1507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_AmountsAllocatedToSegmentsAbstract_1500" xlink:to="loc_us-gaap_OperatingIncomeLoss_1507" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AmountsNotAllocatedToSegmentsAbstract" xlink:label="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1505" xlink:to="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_1508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_us-gaap_AdjustmentForAmortization_1508" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ImpairmentsRestructuringAndOthers" xlink:label="loc_teva_ImpairmentsRestructuringAndOthers_1509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_teva_ImpairmentsRestructuringAndOthers_1509" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_1510" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_1510" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1511" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1511" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_LegalSettlementsAndLossContingencies" xlink:label="loc_teva_LegalSettlementsAndLossContingencies_1516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_teva_LegalSettlementsAndLossContingencies_1516" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OtherUnallocatedAmounts" xlink:label="loc_teva_OtherUnallocatedAmounts_1517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_teva_OtherUnallocatedAmounts_1517" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_390232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1505" xlink:to="loc_us-gaap_OperatingIncomeLoss_390232" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_1525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1505" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_1525" use="optional" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1505" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1526" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1528" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable_1533" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1528" xlink:to="loc_us-gaap_ScheduleOfProductInformationTable_1533" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1529" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_1533" xlink:to="loc_dei_LegalEntityAxis_1529" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1536" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1529" xlink:to="loc_dei_EntityDomain_1536" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_1533" xlink:to="loc_srt_ProductOrServiceAxis_1531" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1531" xlink:to="loc_srt_ProductsAndServicesDomain_1532" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_GenericsMediciansMember" xlink:label="loc_teva_GenericsMediciansMember_1538" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_GenericsMediciansMember_1538" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_COPAXONEMember" xlink:label="loc_teva_COPAXONEMember_1539" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_COPAXONEMember_1539" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_BendekaAndTreandaMember" xlink:label="loc_teva_BendekaAndTreandaMember_1540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_BendekaAndTreandaMember_1540" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AjovyMember" xlink:label="loc_teva_AjovyMember_408213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_AjovyMember_408213" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AustedoMember" xlink:label="loc_teva_AustedoMember_1543" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_AustedoMember_1543" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RespiratoryProductMember" xlink:label="loc_teva_RespiratoryProductMember_1545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_RespiratoryProductMember_1545" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_AndaMember" xlink:label="loc_teva_AndaMember_1546" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_AndaMember_1546" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OtherProductsMember" xlink:label="loc_teva_OtherProductsMember_1547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_OtherProductsMember_1547" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1535" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_1533" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1535" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1535" xlink:to="loc_us-gaap_SegmentDomain_1534" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_NorthAmericaSegmentMember" xlink:label="loc_teva_NorthAmericaSegmentMember_1548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1534" xlink:to="loc_teva_NorthAmericaSegmentMember_1548" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_EuropeSegmentMember" xlink:label="loc_teva_EuropeSegmentMember_1549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1534" xlink:to="loc_teva_EuropeSegmentMember_1549" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_InternationalMarketsMember" xlink:label="loc_teva_InternationalMarketsMember_1550" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1534" xlink:to="loc_teva_InternationalMarketsMember_1550" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RevenueTypeAxis" xlink:label="loc_teva_RevenueTypeAxis_558204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_1533" xlink:to="loc_teva_RevenueTypeAxis_558204" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_RevenueTypeDomain" xlink:label="loc_teva_RevenueTypeDomain_558211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueTypeAxis_558204" xlink:to="loc_teva_RevenueTypeDomain_558211" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaap_ProductInformationLineItems_1530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_1533" xlink:to="loc_us-gaap_ProductInformationLineItems_1530" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1537" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_1530" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1537" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_1464" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1464" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" xlink:to="loc_dei_LegalEntityAxis_1469" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1476" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1469" xlink:to="loc_dei_EntityDomain_1476" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" xlink:to="loc_srt_StatementGeographicalAxis_1473" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1471" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1473" xlink:to="loc_srt_SegmentGeographicalDomain_1471" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1466" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1466" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1465" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1466" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1465" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1467" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_1467" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1468" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1467" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1468" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1260429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1260429" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1260430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1260429" xlink:to="loc_us-gaap_SegmentDomain_1260430" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_1472" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_1472" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_1478" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1472" xlink:to="loc_us-gaap_NumberOfReportableSegments_1478" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_356" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_356" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" xlink:to="loc_dei_LegalEntityAxis_366" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_366" xlink:to="loc_dei_EntityDomain_383" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_361" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_361" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_364" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_364" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_380" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_364" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_381" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_364" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_382" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_360" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_360" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359" xlink:to="loc_us-gaap_MoneyMarketFundsMember_374" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DemandDepositsMember" xlink:label="loc_us-gaap_DemandDepositsMember_375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359" xlink:to="loc_us-gaap_DemandDepositsMember_375" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359" xlink:to="loc_us-gaap_EquitySecuritiesMember_376" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OtherRestrictedCashMember" xlink:label="loc_teva_OtherRestrictedCashMember_1260419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359" xlink:to="loc_teva_OtherRestrictedCashMember_1260419" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_362" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_362" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_363" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_OptionsAndForwardContractsDerivativeLiabilitiesMember" xlink:label="loc_teva_OptionsAndForwardContractsDerivativeLiabilitiesMember_379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_363" xlink:to="loc_teva_OptionsAndForwardContractsDerivativeLiabilitiesMember_379" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" xlink:to="loc_us-gaap_FinancialInstrumentAxis_365" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_365" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_367" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_367" xlink:to="loc_us-gaap_InterestRateSwapMember_384" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_367" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_385" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_368" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_369" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_1280201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_RestrictedCash_1280201" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets" xlink:label="loc_us-gaap_DerivativeAssets_370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_DerivativeAssets_370" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_DerivativeLiabilities_371" use="optional" order="27" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_372" use="optional" order="28" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaap_FairValueNetAssetLiability_373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_FairValueNetAssetLiability_373" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_682369" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_682370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_682369" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_682370" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_682372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_682370" xlink:to="loc_srt_RangeAxis_682372" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_682373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_682372" xlink:to="loc_srt_RangeMember_682373" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_682374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_682373" xlink:to="loc_srt_MaximumMember_682374" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_682375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_682373" xlink:to="loc_srt_MinimumMember_682375" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember_688250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_682373" xlink:to="loc_srt_WeightedAverageMember_688250" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_682378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_682370" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_682378" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_682379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_682378" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_682379" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_MeasurementInputProbabilityOfSuccessMember" xlink:label="loc_teva_MeasurementInputProbabilityOfSuccessMember_682380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_682379" xlink:to="loc_teva_MeasurementInputProbabilityOfSuccessMember_682380" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_682382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_682379" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_682382" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xlink:label="loc_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis_764533" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_682370" xlink:to="loc_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis_764533" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfFreshStartAdjustmentDomain" xlink:label="loc_us-gaap_TypeOfFreshStartAdjustmentDomain_764534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis_764533" xlink:to="loc_us-gaap_TypeOfFreshStartAdjustmentDomain_764534" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_682371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_682370" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_682371" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_682381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_682371" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_682381" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_387" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_387" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_391" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_391" xlink:to="loc_dei_LegalEntityAxis_394" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_394" xlink:to="loc_dei_EntityDomain_407" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_391" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_392" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_392" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_393" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_ActavisGenericsMember" xlink:label="loc_teva_ActavisGenericsMember_404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_393" xlink:to="loc_teva_ActavisGenericsMember_404" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_EagleTransactionMember" xlink:label="loc_teva_EagleTransactionMember_406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_393" xlink:to="loc_teva_EagleTransactionMember_406" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_391" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_389" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_389" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_388" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_NoveTideAcquisitionMember" xlink:label="loc_teva_NoveTideAcquisitionMember_1411437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_388" xlink:to="loc_teva_NoveTideAcquisitionMember_1411437" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_391" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_397" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_1280210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_1280210" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_BifurcatedEmbeddedDerivatives" xlink:label="loc_teva_BifurcatedEmbeddedDerivatives_1280215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_teva_BifurcatedEmbeddedDerivatives_1280215" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" xlink:label="loc_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease_401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease_401" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod" xlink:label="loc_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod_400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod_400" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_402" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_403" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1411471" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1411484" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1411471" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1411484" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1411486" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1411484" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1411486" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1411490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1411486" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1411490" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_NoveTideAcquisitionMember" xlink:label="loc_teva_NoveTideAcquisitionMember_1411494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1411490" xlink:to="loc_teva_NoveTideAcquisitionMember_1411494" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1411496" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1411484" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1411496" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_1411497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1411496" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_1411497" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_409" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_409" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_411" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_411" xlink:to="loc_dei_LegalEntityAxis_412" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_412" xlink:to="loc_dei_EntityDomain_416" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_411" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_413" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_413" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_414" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SeniorNotesAndSustainabilityLinkedSeniorNotesMember" xlink:label="loc_teva_SeniorNotesAndSustainabilityLinkedSeniorNotesMember_1260415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_414" xlink:to="loc_teva_SeniorNotesAndSustainabilityLinkedSeniorNotesMember_1260415" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20220630.xsd#teva_SeniornotesandconvertibleseniordebenturesMember" xlink:label="loc_teva_SeniornotesandconvertibleseniordebenturesMember_418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_414" xlink:to="loc_teva_SeniornotesandconvertibleseniordebenturesMember_418" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_411" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_410" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_410" xlink:to="loc_us-gaap_DebtInstrumentFairValue_415" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684979071680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TEVA PHARMACEUTICAL INDUSTRIES LIMITED<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000818686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">1,110,564,656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares, each representing one Ordinary Share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TEVA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-16174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">124 Dvora HaNevi&#8217;a St.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Tel Aviv<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">6944020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">914-8213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Smaller Reporting Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684978120128">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,058<span></span>
</td>
<td class="nump">$ 2,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivables, net of allowance for credit losses of $95 million and $90 million as of June 30, 2022 and December 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,471<span></span>
</td>
<td class="nump">4,529<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,049<span></span>
</td>
<td class="nump">3,818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,052<span></span>
</td>
<td class="nump">1,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">518<span></span>
</td>
<td class="nump">965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Assets held for sale</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,164<span></span>
</td>
<td class="nump">12,573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,595<span></span>
</td>
<td class="nump">596<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other&#160;non-current&#160;assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">454<span></span>
</td>
<td class="nump">515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,740<span></span>
</td>
<td class="nump">5,982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">441<span></span>
</td>
<td class="nump">495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Identifiable intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,700<span></span>
</td>
<td class="nump">7,466<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">18,837<span></span>
</td>
<td class="nump">20,040<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45,932<span></span>
</td>
<td class="nump">47,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Short-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,719<span></span>
</td>
<td class="nump">1,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_SalesReservesAndAllowances', window );">Sales reserves and allowances</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,880<span></span>
</td>
<td class="nump">4,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Accounts payables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,901<span></span>
</td>
<td class="nump">1,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee-related obligations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">467<span></span>
</td>
<td class="nump">563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AccruedExpenses', window );">Accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,112<span></span>
</td>
<td class="nump">2,208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">916<span></span>
</td>
<td class="nump">903<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,996<span></span>
</td>
<td class="nump">11,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent', window );">Deferred income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">532<span></span>
</td>
<td class="nump">784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other taxes and long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,842<span></span>
</td>
<td class="nump">2,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesAndLoans', window );">Senior notes and loans</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,363<span></span>
</td>
<td class="nump">21,617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">371<span></span>
</td>
<td class="nump">416<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,107<span></span>
</td>
<td class="nump">25,395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies, see note 10</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">36,103<span></span>
</td>
<td class="nump">36,422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Teva shareholders' equity:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares of NIS 0.10 par value per share; June 30, 2022 and December 31, 2021: authorized 2,495 million shares; issued 1,216 million shares and 1,209 million shares, respectively.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">57<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional&#160;paid-in&#160;capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27,625<span></span>
</td>
<td class="nump">27,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(11,716)<span></span>
</td>
<td class="num">(10,529)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,801)<span></span>
</td>
<td class="num">(2,683)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury shares as of June 30, 2022 and December 31, 2021: 106 million ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,128)<span></span>
</td>
<td class="num">(4,128)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity attributable to Teva shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,037<span></span>
</td>
<td class="nump">10,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">791<span></span>
</td>
<td class="nump">966<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,828<span></span>
</td>
<td class="nump">11,244<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 45,932<span></span>
</td>
<td class="nump">$ 47,666<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Accumulated goodwill impairment as of June 30, 2022 and December 31, 2021 was approximately $26.3 billion and $25.6 billion, respectively.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_SalesReservesAndAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the balance sheet amounts of the allowances for chargebacks, returns, rebates, other promotional items and price protection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_SalesReservesAndAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesAndLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesAndLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139685066170816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for credit losses</a></td>
<td class="nump">$ 95,000,000<span></span>
</td>
<td class="nump">$ 90,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par or stated value per share</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, authorized</a></td>
<td class="nump">2,495<span></span>
</td>
<td class="nump">2,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, issued</a></td>
<td class="nump">1,216<span></span>
</td>
<td class="nump">1,209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury shares</a></td>
<td class="nump">106,000,000<span></span>
</td>
<td class="nump">106,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684979219696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income (Loss) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">$ 3,786<span></span>
</td>
<td class="nump">$ 3,910<span></span>
</td>
<td class="nump">$ 7,447<span></span>
</td>
<td class="nump">$ 7,892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">1,992<span></span>
</td>
<td class="nump">2,037<span></span>
</td>
<td class="nump">3,913<span></span>
</td>
<td class="nump">4,141<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">1,794<span></span>
</td>
<td class="nump">1,873<span></span>
</td>
<td class="nump">3,534<span></span>
</td>
<td class="nump">3,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="nump">228<span></span>
</td>
<td class="nump">248<span></span>
</td>
<td class="nump">453<span></span>
</td>
<td class="nump">501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing expenses</a></td>
<td class="nump">594<span></span>
</td>
<td class="nump">615<span></span>
</td>
<td class="nump">1,178<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">313<span></span>
</td>
<td class="nump">242<span></span>
</td>
<td class="nump">609<span></span>
</td>
<td class="nump">532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_IntangibleAssetsImpairments', window );">Intangible assets impairments</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">195<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="nump">274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">745<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">745<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ImpairmentsRestructuringAndOthers', window );">Other asset impairments, restructuring and other items</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">246<span></span>
</td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LegalSettlementsAndLossContingencies', window );">Legal settlements and loss contingencies</a></td>
<td class="nump">729<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">1,854<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="num">(87)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">(949)<span></span>
</td>
<td class="nump">582<span></span>
</td>
<td class="num">(1,662)<span></span>
</td>
<td class="nump">1,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Financial expenses, net</a></td>
<td class="nump">211<span></span>
</td>
<td class="nump">274<span></span>
</td>
<td class="nump">468<span></span>
</td>
<td class="nump">564<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before income taxes</a></td>
<td class="num">(1,160)<span></span>
</td>
<td class="nump">308<span></span>
</td>
<td class="num">(2,131)<span></span>
</td>
<td class="nump">451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes (benefit)</a></td>
<td class="num">(900)<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="num">(899)<span></span>
</td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in (profits) losses of associated companies, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(259)<span></span>
</td>
<td class="nump">221<span></span>
</td>
<td class="num">(1,211)<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to non-controlling interests</a></td>
<td class="num">(27)<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Teva</a></td>
<td class="num">$ (232)<span></span>
</td>
<td class="nump">$ 207<span></span>
</td>
<td class="num">$ (1,187)<span></span>
</td>
<td class="nump">$ 284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (loss) per share attributable to ordinary shareholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="num">$ (1.07)<span></span>
</td>
<td class="nump">$ 0.26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="num">$ (1.07)<span></span>
</td>
<td class="nump">$ 0.26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of shares (in millions):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="nump">1,110<span></span>
</td>
<td class="nump">1,103<span></span>
</td>
<td class="nump">1,109<span></span>
</td>
<td class="nump">1,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">1,110<span></span>
</td>
<td class="nump">1,109<span></span>
</td>
<td class="nump">1,109<span></span>
</td>
<td class="nump">1,108<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ImpairmentsRestructuringAndOthers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impairments restructuring and others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ImpairmentsRestructuringAndOthers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_IntangibleAssetsImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets Impairments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_IntangibleAssetsImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LegalSettlementsAndLossContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net proceeds or assets obtained in excess of (less than) the net carrying amount of assets recorded, or assets distributed and liabilities assumed less than (in excess of) litigation reserves extinguished, in settlement of a litigation matter. Represents (for other than an insurance entity in its normal claims settlement process), the amount of income (expense) recognized in the period to settle pending or threatened litigation and insurance claims and the aggregate amount provided for estimated restructuring charges, remediation costs, and asset impairment loss during an accounting period. Generally, these items are either unusual or infrequent, but not both (in which case they would be extraordinary items).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LegalSettlementsAndLossContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684980091568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">$ (259)<span></span>
</td>
<td class="nump">$ 221<span></span>
</td>
<td class="num">$ (1,211)<span></span>
</td>
<td class="nump">$ 306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss), net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="num">(219)<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="num">(282)<span></span>
</td>
<td class="num">(130)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_UnrealizedGainLossOnDerivativeNetOfTax', window );">Unrealized gain (loss) from derivative financial instruments, net</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax', window );">Unrealized loss on defined benefit plans</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income (loss)</a></td>
<td class="num">(212)<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="num">(268)<span></span>
</td>
<td class="num">(115)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Total comprehensive income (loss)</a></td>
<td class="num">(471)<span></span>
</td>
<td class="nump">308<span></span>
</td>
<td class="num">(1,479)<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to non-controlling interests</a></td>
<td class="num">(125)<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="num">(174)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss) attributable to Teva</a></td>
<td class="num">$ (346)<span></span>
</td>
<td class="nump">$ 295<span></span>
</td>
<td class="num">$ (1,305)<span></span>
</td>
<td class="nump">$ 238<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_UnrealizedGainLossOnDerivativeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrealized gain (loss) on derivative net of tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_UnrealizedGainLossOnDerivativeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of increase (decrease) to other comprehensive income from settlement and curtailment gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684977648288">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Equity - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Ordinary Shares [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Treasury Shares [Member]</div></th>
<th class="th"><div>Total Teva Shareholders' Equity [Member]</div></th>
<th class="th"><div>Non-controlling Interests [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 11,061<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">$ 27,443<span></span>
</td>
<td class="num">$ (10,946)<span></span>
</td>
<td class="num">$ (2,399)<span></span>
</td>
<td class="num">$ (4,128)<span></span>
</td>
<td class="nump">$ 10,026<span></span>
</td>
<td class="nump">$ 1,035<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance, shares at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="num">(68)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Shares, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,311<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">27,503<span></span>
</td>
<td class="num">(10,662)<span></span>
</td>
<td class="num">(2,446)<span></span>
</td>
<td class="num">(4,128)<span></span>
</td>
<td class="nump">10,324<span></span>
</td>
<td class="nump">987<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares at Jun. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,975<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">27,474<span></span>
</td>
<td class="num">(10,869)<span></span>
</td>
<td class="num">(2,534)<span></span>
</td>
<td class="num">(4,128)<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">975<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance, shares at Mar. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Shares, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,311<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">27,503<span></span>
</td>
<td class="num">(10,662)<span></span>
</td>
<td class="num">(2,446)<span></span>
</td>
<td class="num">(4,128)<span></span>
</td>
<td class="nump">10,324<span></span>
</td>
<td class="nump">987<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares at Jun. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,244<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">27,561<span></span>
</td>
<td class="num">(10,529)<span></span>
</td>
<td class="num">(2,683)<span></span>
</td>
<td class="num">(4,128)<span></span>
</td>
<td class="nump">10,278<span></span>
</td>
<td class="nump">966<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,211)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,187)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,187)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(268)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(118)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(118)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Shares, value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Shares, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,828<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">27,625<span></span>
</td>
<td class="num">(11,716)<span></span>
</td>
<td class="num">(2,801)<span></span>
</td>
<td class="num">(4,128)<span></span>
</td>
<td class="nump">9,037<span></span>
</td>
<td class="nump">791<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares at Jun. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,260<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">27,587<span></span>
</td>
<td class="num">(11,484)<span></span>
</td>
<td class="num">(2,687)<span></span>
</td>
<td class="num">(4,128)<span></span>
</td>
<td class="nump">9,344<span></span>
</td>
<td class="nump">916<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance, shares at Mar. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(259)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(232)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(232)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(212)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(114)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(114)<span></span>
</td>
<td class="num">(98)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 9,828<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">$ 27,625<span></span>
</td>
<td class="num">$ (11,716)<span></span>
</td>
<td class="num">$ (2,801)<span></span>
</td>
<td class="num">$ (4,128)<span></span>
</td>
<td class="nump">$ 9,037<span></span>
</td>
<td class="nump">$ 791<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares at Jun. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents an amount less than $0.5 million.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684980027360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Equity (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options by employees and vested RSUs</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684980398512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">$ (1,211)<span></span>
</td>
<td class="nump">$ 306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">681<span></span>
</td>
<td class="nump">681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of goodwill long-lived assets and assets held for sale</a></td>
<td class="nump">975<span></span>
</td>
<td class="nump">354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapital', window );">Net change in operating assets and liabilities</a></td>
<td class="nump">913<span></span>
</td>
<td class="num">(1,679)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DeferredIncomeTaxesNetAndUncertainTaxPositions', window );">Deferred income taxes &#8211; net and uncertain tax positions</a></td>
<td class="num">(1,258)<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other items</a></td>
<td class="num">(77)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment', window );">Net loss (gain) from investments and from sale of long lived assets</a></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">74<span></span>
</td>
<td class="num">(187)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables', window );">Beneficial interest collected in exchange for securitized trade receivables</a></td>
<td class="nump">592<span></span>
</td>
<td class="nump">881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from sale of business and long lived assets</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of businesses, net of cash acquired</a></td>
<td class="num">(7)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(284)<span></span>
</td>
<td class="num">(263)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets', window );">Purchases of investments and other assets</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from sale of investments</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other investing activities</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">341<span></span>
</td>
<td class="nump">989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Redemption of convertible senior notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(491)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayment of senior notes and loans</a></td>
<td class="num">(296)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other financing activities</a></td>
<td class="num">(40)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="num">(336)<span></span>
</td>
<td class="num">(494)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Translation adjustment on cash and cash equivalents</a></td>
<td class="num">(185)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="num">(107)<span></span>
</td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Balance of cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">2,198<span></span>
</td>
<td class="nump">2,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Balance of cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">2,091<span></span>
</td>
<td class="nump">2,436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash reported in the consolidated balance sheets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">2,058<span></span>
</td>
<td class="nump">2,436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash included in other current assets</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash shown in the statement of cash flows</a></td>
<td class="nump">2,091<span></span>
</td>
<td class="nump">2,436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Non-cash&#160;financing and investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables', window );">Beneficial interest obtained in exchange for securitized accounts receivables</a></td>
<td class="nump">$ 590<span></span>
</td>
<td class="nump">$ 878<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Beneficial Interest Obtained in Exchange for Securitized Trade Receivables</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_DeferredIncomeTaxesNetAndUncertainTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred income taxes net and uncertain tax positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_DeferredIncomeTaxesNetAndUncertainTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from purchase of available for sales securities and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from beneficial interest in exchange for securitized trade receivables</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Profit from sale of long lived assets and investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ProfitFromSaleOfLongLivedAssetsAndInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684985935696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_BasisOfPresentationAbstract', window );"><strong>Basis of Presentation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 1 &#8211; Basis of presentation: </div></div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">a.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of presentation </div></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The accompanying unaudited consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements. In the opinion of management, the financial statements reflect all normal and recurring adjustments necessary to fairly state the financial position and results of operations of Teva. The information included in this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the year ended December&#160;31, 2021, as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;). The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-end</div> balance sheet data was derived from the audited consolidated financial statements as of December&#160;31, 2021, but not all disclosures required by generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;) are included. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In the process of preparing the consolidated financial statements, management makes estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. The inputs into Teva&#8217;s judgments and estimates also consider the economic implications of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on its critical and significant accounting estimates, most significantly in relation to sales, reserves and allowances, IPR&amp;D assets, marketed product rights and goodwill, all of which will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and the actions taken to contain or treat it, as well as the economic impact on Teva&#8217;s employees, third-party manufacturers and suppliers, customers and markets. All estimates made by Teva related to the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic within its financial statements may change in future periods. Actual results could differ from those estimates. </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">In February 2022, Russia launched an invasion of Ukraine. As of the date of this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q,</div> sustained conflict and disruption in the region is ongoing. Russia and Ukraine markets are included in Teva&#8217;s International Markets segment results. Teva has no manufacturing or R&amp;D facilities in these markets. As part of the Company&#8217;s annual goodwill analysis, it identified an increase in the discount rate, which led to a goodwill impairment charge in its International Markets and Teva&#8217;s API reporting units. This increase was a result of an increase in certain components of the discount rate that were partially attributed to higher risk associated with country-specific characteristics of several countries, such as Russia, that might be a consequence of the conflict. Other than its impact on the goodwill impairment charge, during the three and six months ended June 30, 2022, the impact of this conflict on Teva&#8217;s results of operations and financial condition was immaterial. See also note 6. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The results of operations for the three and six months ended June&#160;30, 2022 are not necessarily indicative of results that could be expected for the entire fiscal year. Certain amounts in the consolidated financial statements and associated notes may not add up due to rounding. All percentages have been calculated using unrounded amounts. </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">b.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant accounting policies </div></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recently adopted accounting pronouncements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In August 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> &#8220;Debt &#8211; Debt with Conversion and Other Options (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20)</div> and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211; 40).&#8221; This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. The amendments to this guidance are effective for fiscal years beginning after December&#160;15, 2021, and interim periods within those fiscal years. The adoption of this guidance did not have a significant impact on the Company&#8217;s consolidated financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In March 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-04</div> &#8220;Reference Rate Reform (Topic 848)&#8212;Facilitation of the Effects of Reference Rate Reform on Financial Reporting.&#8221; This guidance provides optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The guidance applies only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. This guidance is effective for all entities as of March&#160;12, 2020 through December&#160;31, 2022. There was no material impact to the Company&#8217;s consolidated financial statements for the period ended June&#160;30, 2022 as a result of adopting this standard update. The Company has completed negotiations to transform the facility base rate of its securitization program and evaluated the potential impact of the replacement of the LIBOR benchmark on its interest rate risk management activities. The adoption of this guidance did not have a material impact on the Company&#8217;s consolidated financial results of operations, financial position or cash flows. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recently issued accounting pronouncements, not yet adopted </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In November 2021, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2021-10</div> &#8220;Government Assistance (Topic 832)&#8221;, which requires annual disclosures that increase the transparency of transactions involving government grants, including (1)&#160;the types of transactions, (2)&#160;the accounting for those transactions, and (3)&#160;the effect of those transactions on an entity&#8217;s financial statements. The amendments in this update are effective for financial statements issued for annual periods beginning after December&#160;15, 2021. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In October 2021, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2021-08</div> &#8220;Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#8221;, which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers. The guidance will result in the acquirer recognizing contract assets and contract liabilities at the same amounts recorded by the acquiree. The guidance should be applied prospectively to acquisitions occurring on or after the effective date. The guidance is effective for fiscal years beginning after December&#160;15, 2022, including interim periods within those fiscal years. Early adoption is permitted, including in interim periods, for any financial statements that have not yet been issued. Adoption in an interim period other than the first fiscal quarter requires an entity to apply the new guidance to all prior business combinations that have occurred since the beginning of the annual period in which the new guidance is adopted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements. </div><br/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_BasisOfPresentationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_BasisOfPresentationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684983043440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CertainTransactionsDisclosureTextBlock', window );">Certain transactions</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 2 &#8211; Certain transactions: </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has entered into alliances and other arrangements with third parties to acquire rights to products it does not have, to access markets it does not operate in and to otherwise share development costs or business risks. The Company&#8217;s most significant agreements of this nature are summarized below. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MODAG </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In October 2021, Teva announced a license agreement with MODAG GmbH (&#8220;Modag&#8221;) that will provide Teva an exclusive global license to develop, manufacture and commercialize Modag&#8217;s lead compound <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(TEV-56286)</div> and a related compound <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(TEV-56287).</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TEV-56286</div> was initially developed for the treatment of Multiple System Atrophy (&#8220;MSA&#8221;) and Parkinson&#8217;s disease, and has the potential to be applied to other treatments for neurodegenerative disorders, such as Alzheimer&#8217;s disease. A phase 1b clinical trial is currently being completed for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TEV-56286.</div> In the fourth quarter of 2021, Teva made an upfront payment of $10&#160;million to Modag that was recorded as an R&amp;D expense. Modag may be eligible for future development milestone payments, totaling an aggregate amount of up to $70&#160;million, as well as future commercial milestones and royalties. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Alvotech </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">In August 2020, Teva entered into an agreement with biopharmaceutical company Alvotech for the exclusive commercialization in the U.S. of five biosimilar product candidates. The initial pipeline for this collaboration contains biosimilar candidates addressing multiple therapeutic areas, including a proposed biosimilar to Humira<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>. Under this agreement, Alvotech is responsible for the development, registration and supply of the biosimilar product candidates and Teva will exclusively commercialize the products in the United States. Teva paid an upfront payment in the third quarter of 2020 and additional upfront and milestone payments in the second quarter of 2021 that were recorded as R&amp;D expenses. Additional development and commercial milestone payments of up to</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> $455&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million, as well as royalty payments, may be payable by Teva over the next few years. Teva and Alvotech will share profit from the commercialization of these biosimilars. Alvotech was previously involved in litigation involving certain IP and trade secrets claims filed by Abbvie in relation to Alvotech&#8217;s proposed biosimilar to Humira<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>, all of which were settled on March&#160;8, 2022.&#160;Pursuant to that settlement, Alvotech and Teva may sell Alvotech&#8217;s proposed biosimilar to Humira<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"> </div>in the United States beginning on July&#160;1, 2023, provided that U.S. regulatory approval is obtained by that date. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Eli Lilly and Alder BioPharmaceuticals</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2018, Teva entered into an agreement with Eli Lilly&#160;&amp; Co. (&#8220;Lilly&#8221;) resolving the European Patent Office opposition they had filed against Teva&#8217;s AJOVY<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> patents. The settlement agreement with Lilly also resolved Lilly&#8217;s action to revoke the patent protecting AJOVY in the United&#160;Kingdom. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On January&#160;8, 2018, Teva signed a global license agreement with Alder BioPharmaceuticals (&#8220;Alder&#8221;). The agreement validates Teva&#8217;s intellectual property and resolves Alder&#8217;s opposition to Teva&#8217;s European patent with respect to anti-calcitonin gene-related peptide (CGRP) antibodies, including the withdrawal of Alder&#8217;s appeal before the European Patent Office. Under the terms of the agreement, Alder received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> license to Teva&#8217;s anti-CGRP antibodies patent portfolio to develop, manufacture and commercialize eptinezumab in the United States and worldwide, excluding Japan. Teva received a $25&#160;million upfront payment that was recognized as revenue during the first quarter of 2018, and a $25&#160;million milestone payment in March 2020 that was recognized as revenue in the first quarter of 2020. The agreement stipulates additional development and commercial milestone payments to Teva of up to $150&#160;million, as well as future royalties. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Otsuka </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On May&#160;12, 2017, Teva entered into a license and collaboration agreement with Otsuka Pharmaceutical Co. Ltd. (&#8220;Otsuka&#8221;) providing Otsuka with an exclusive license to develop and commercialize AJOVY in Japan. Otsuka paid Teva an upfront payment of $50&#160;million in consideration for the transaction. In the third quarter of 2020, Otsuka submitted an application to obtain manufacturing and marketing approval for AJOVY in Japan and, as a result, paid Teva a milestone payment of $15&#160;million, which was recognized as revenue in the third quarter of 2020. AJOVY was approved in Japan in June 2021 and launched on August&#160;30, 2021. As a result of the launch, Otsuka paid Teva a milestone payment of $35&#160;million, which was recognized as revenue in the third quarter of 2021. Teva may receive additional milestone payments upon achievement of certain revenue targets. Otsuka also pays Teva royalties on AJOVY sales in Japan. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Takeda </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2016, Teva entered into a license agreement with a subsidiary of Takeda Pharmaceutical Company Ltd. (&#8220;Takeda&#8221;), for the research, development, manufacture and commercialization of </div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Attenukine<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> technology.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Teva received a $30&#160;million upfront payment as well as a milestone payment of $20&#160;million in 2017. During the second quarter of 2022, Takeda initiated Phase II study of modakafusp alfa (formerly TAK 573 or TEV 48573) and as a result paid Teva a milestone payment of $25&#160;million, which was recognized as revenues in the second quarter of 2022. The license agreement stipulates additional milestone payments to Teva of up to $519&#160;million in respect of this product, as well as future royalties. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Regeneron </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In September 2016, Teva and Regeneron Pharmaceuticals, Inc. (&#8220;Regeneron&#8221;) entered into a collaborative agreement to develop and commercialize Regeneron&#8217;s pain medication product, fasinumab. Teva and Regeneron share in the global commercial rights to this product (excluding Japan, Korea and nine other Asian countries), as well as ongoing associated R&amp;D costs of approximately $1&#160;billion. Teva made an upfront payment of $250&#160;million to Regeneron in the third quarter of 2016 and additional payments for achievement of development milestones in an aggregate amount of $120&#160;million were paid during 2017 and 2018. The agreement stipulates additional development and commercial milestone payments of up to $2,230&#160;million, as well as future royalties. Currently, all <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-essential</div> activities and related expenditures for fasinumab have been put on hold. Next steps will be assessed together with Regeneron, with the intention of discussing data with the FDA. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MedinCell </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In November 2013, Teva entered into an agreement with MedinCell for the development and commercialization of multiple long-acting injectable products. The lead product candidate selected was risperidone LAI <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(TV-46000)</div> suspension for subcutaneous use for the treatment of schizophrenia. In August 2021, the FDA accepted the new drug application (&#8220;NDA&#8221;) for risperidone LAI, based on phase 3 data from two pivotal studies. Teva leads the clinical development and regulatory process and is responsible for commercialization of this product candidate. MedinCell may be eligible for development milestones, and future commercial milestones of up to $112&#160;million in respect of risperidone LAI. Teva will also pay MedinCell royalties on net sales. In April 2022, the FDA issued a Complete Response Letter (&#8220;CRL&#8221;) regarding the NDA for risperidone LAI. Teva is working to address the issues raised in the CRL with a view to resubmission.</div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets and Liabilities Held For Sale: </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets held for sale as of June&#160;30, 2022 included certain assets that are expected to be sold within the next year. Assets and liabilities held for sale as of December&#160;31, 2021 included certain manufacturing assets sold during the first and second quarters of 2022.<div style="display:inline;">&#160;</div>The table below summarizes all Teva assets and liabilities included as held for sale as of June&#160;30, 2022 and December&#160;31, 2021:</div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventories</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property, plant and equipment, net and others</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">86</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments of assets held for sale to fair value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(30</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(76</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets of the disposal group classified as held for sale in the consolidated balance sheets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities of the disposal group classified as held for sale in the consolidated balance sheets, recorded under accrued expenses and other long-term liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(43</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_CertainTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element may be used for the entire related party transactions disclosure as a single block of text. Disclosure may include: business acquisitions, agreements with related parties, significant cooperation agreements, the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_CertainTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684986151104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from contracts with customers<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue from contracts with customers</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 3 &#8211; Revenue from contracts with customers: </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disaggregation of revenue </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table disaggregates Teva&#8217;s revenues by major revenue streams. For additional information on disaggregation of revenues, see note 15. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="18" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended June&#160;30, 2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North<br/>America</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International<br/>Markets</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other<br/>activities</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="18" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sale of goods</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,538</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,127</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">448</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">176</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,289</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing arrangements</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">54</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">308</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">318</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9</td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">81</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">106</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,904</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,171</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">454</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">257</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,786</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#167; Represents an amount less t<div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">han $0.5&#160;</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">million.&#160; &#160;&#160;</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="18" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended June&#160;30, 2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North<br/>America</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International<br/>Markets</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other<br/>activities</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="18" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sale of goods</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,621</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,185</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">462</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">198</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,465</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing arrangements</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">316</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">330</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2)</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">99</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">96</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,943</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,184</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">485</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">298</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,910</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#167; Represents an amount less than $0.5&#160;million. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six months ended June&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North<br/> America</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International<br/> Markets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other<br/> activities</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sale of goods</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,915</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,261</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">894</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">356</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,425</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing arrangements</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">74</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">110</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">650</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">677</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">39</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">175</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">234</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,641</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,327</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">946</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">532</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,447</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#167; Represents an amount less than $0.5&#160;million. </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="18" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six months ended June&#160;30, 2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North<br/>America</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International<br/>Markets</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other<br/>activities</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="18" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sale of goods</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,289</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,363</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">902</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">374</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,928</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing arrangements</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">68</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">605</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">639</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2)</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">210</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">257</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,932</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,398</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">975</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">587</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,892</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#167; Represents an amount less than $0.5&#160;million. </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Variable consideration</div></div></div> <div style="clear: both; max-height: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Variable consideration mainly includes sales reserves and allowances (&#8220;SR&amp;A&#8221;), comprised of rebates (including Medicaid and other governmental program discounts), chargebacks, returns and other promotional (including shelf stock adjustments) items. Provisions for prompt payment discounts are netted against accounts receivables. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes these provisions at the time of sale and adjusts them if the actual amounts differ from the estimated provisions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SR&amp;A to U.S. customers comprised approximately <div style="letter-spacing: 0px; top: 0px;;display:inline;">74</div>% of the Company&#8217;s total SR&amp;A as of June&#160;30, 2022, with the remaining balance primarily in Canada and Germany. The changes in SR&amp;A for third-party sales for the six months ended June&#160;30, 2022 and 2021 were as follows:</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 37%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="26" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sales Reserves and Allowances</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reserves<br/>included in<br/>Accounts<br/>Receivable,&#160;net</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Rebates</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Medicaid and<br/>other<br/>governmental<br/>allowances</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Chargebacks</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Returns</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total&#160;reserves<br/>included&#160;in&#160;SR&amp;A</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="30" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">68</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,655</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">854</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,085</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">535</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">112</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,241</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,309</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions related to sales made in current year</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">181</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,889</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">446</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3,836</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">147</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">152</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,470</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,651</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions related to sales made in prior periods</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(102</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(8</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(16</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(2</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(108</td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(108</td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Credits and payments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(185</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1,901</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(497</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(3,922</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(211</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(145</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,676</td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,861</td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Translation differences</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(33</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(6</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(7</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(4</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(47</td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(47</td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at June&#160;30, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">64</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,508</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">817</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">984</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">451</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">120</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,880</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,944</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 37%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reserves<br/> included in<br/> Accounts<br/> Receivable,&#160;net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Rebates</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Medicaid and<br/> other<br/> governmental<br/> allowances</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Chargebacks</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Returns</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total&#160;reserves<br/> included&#160;in&#160;SR&amp;A</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="30" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.$ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,054</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">828</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,108</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">686</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">148</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,824</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,904</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions related to sales made in current year</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">192</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,139</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">391</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,995</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">143</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">177</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,845</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,037</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions related to sales made in prior periods</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(82</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(35</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(40</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(23</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(191</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(196</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Credits and payments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(196</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,355</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(362</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,934</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(186</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(176</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,013</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,209</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Translation differences</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at June&#160;30, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">71</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,748</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">819</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,157</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">602</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">127</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,453</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,524</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684986151632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 4 &#8211; Inventories:</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventories, net of reserves, consisted of the following:</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finished products</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,875</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,932</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Raw and packaging materials</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,346</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,136</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Products in process</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">624</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">587</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Materials in transit and payments on account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">204</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">163</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,049</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,818</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684986124384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Identifiable Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Identifiable Intangible Assets</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 5 &#8211; Identifiable intangible assets:</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Identifiable intangible assets consisted of the following:</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 54%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross&#160;carrying&#160;amount&#160;net</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">of impairment</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">amortization</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net carrying amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="22" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product rights</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,987</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,815</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,181</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,318</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,806</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,497</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trade names</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">570</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">590</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">211</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">198</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">359</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">392</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In process research and development</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">535</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">577</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">535</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">577</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,092</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,982</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,392</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,516</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,466</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product rights and trade names </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product rights and trade names are assets presented at amortized cost. Product rights and trade names represent a portfolio of pharmaceutical products from various therapeutic categories from various acquisitions with a weighted average life of approximately 10 years. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization of intangible assets was $212&#160;million and $173&#160;million in the three months ended June&#160;30, 2022 and 2021, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization of intangible assets was $412&#160;million and $414&#160;million in the six months ended June&#160;30, 2022 and 2021, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">IPR&amp;D </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva&#8217;s IPR&amp;D are assets that have not yet been approved in major markets. Teva&#8217;s IPR&amp;D is comprised mainly of various generic products from the Actavis Generics acquisition of $503&#160;million. IPR&amp;D carries intrinsic risks that the asset might not succeed in advanced phases and may be impaired in future periods. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Intangible assets impairments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairments of long-lived intangible assets for the three months ended June&#160;30, 2022 and 2021&#160;were $51&#160;million and $195&#160;million, respectively. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairments in the second quarter of 2022 consisted of: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Identifiable product rights of $32&#160;million related to updated market assumptions regarding price and volume of products acquired from Actavis Generics, and</div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(b)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D assets of $19&#160;million due to generic pipeline products acquired from Actavis Generics resulting from development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape, launch date). </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairments in the second quarter of 2021 consisted of: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Identifiable product rights of $168&#160;million due to: <div style="text-indent: 0px; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(i) $138 million, mainly related to updated market assumptions regarding price and </div></div><br/></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="text-indent: 0px; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">volume of products acquired from Actavis Generics that are primarily marketed in the United States, and (ii) </div>$30&#160;million related to </div><br/></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">lenalidomide (generic equivalent of Revlimid<div style="font-size: 75%; vertical-align: top; text-indent: 0px; white-space: nowrap;;display:inline;;font-size:8.3px">&#174;</div>), resulting from modified competition assumptions as a result of settlements between the </div><br/></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">innovator and other generic filers, and&#160;</div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(b)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D assets of $27&#160;million due to generic pipeline products acquired from Actavis Generics resulting from development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape, launch date) in the United States. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairments of long-lived intangible assets for the six months ended June&#160;30, 2022 and 2021&#160;were $199&#160;million and $274&#160;million, respectively.</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairments in the first </div>six<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> months of </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> consisted mainly of:</div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Identifiable product rights of $161&#160;million related to updated market assumptions regarding price and volume of products acquired from Actavis Generics, and</div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(b)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D assets of $21&#160;million due to generic pipeline products acquired from Actavis Generics resulting from development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape, launch date) in the United States. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairments in the first six months of 2021 consisted of: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Identifiable product rights of $196&#160;million <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">due to: (i) $166 million</div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">, mainly related to updated market assumptions regarding price and </div></div><br/></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">volume of products acquired from Actavis Generics that are primarily marketed in the United States<div style="display:inline;">,</div>&#160;and (ii) </div>$30&#160;million related to lenalidomide (generic equivalent of Revlimid<div style="font-size: 75%; vertical-align: top;;text-indent: 0px;;display:inline;;font-size:8.3px">&#174;</div>), resulting from modified competition assumptions as a result of settlements between the innovator and other generic filers<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(b)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D assets of $78&#160;million, due to generic pipeline products acquired from Actavis Generics resulting from development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape, launch date) in the United States. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value measurement of the impaired intangible assets in the first six months of 2022 is based on significant unobservable inputs in the market and thus represents a Level&#160;3 measurement within the fair value hierarchy. The discount rate applied ranged from 7.25% to 8.25%. A probability of success factor ranging from 20% to 90% was used in the fair value calculation to reflect inherent regulatory and commercial risk of IPR&amp;D. </div><br/></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684986094992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillDisclosureTextBlock', window );">Goodwill</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 6 &#8211; Goodwill:</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The changes in the carrying amount of goodwill for the period ended June&#160;30, 2022 were as follows:</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North&#160;America</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International<br/>Markets</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2021 (1)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,474</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,544</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,328</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,694</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,040</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes during the period:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill impairment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(479</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(266</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(745</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill acquired</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Translation differences</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(320</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16</td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(130</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(470</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of June&#160;30, 2022 (1)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,470</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,224</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,833</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,310</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,837</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated goodwill impairment as of June&#160;30, 2022 and December&#160;31, 2021 was approximately $26.3&#160;billion and $25.6&#160;billion, respectively. </div><br/></div> </td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Teva determines the fair value of its reporting units using the income approach. The income approach is a forward-looking approach for estimating fair value. Within the income approach, the method used is the discounted cash flow method. Teva starts with a forecast of all the expected net cash flows associated with the reporting unit, which includes the application of a terminal value, and then applies a discount rate to arrive at a net present value amount. Cash flow projections are based on Teva&#8217;s estimates of revenue growth rates and operating margins, taking into consideration industry and market conditions. The discount rate used is based on the weighted average cost of capital (&#8220;WACC&#8221;), adjusted for the relevant risk associated with country-specific and business-specific characteristics. If any of these expectations were to vary materially from Teva&#8217;s assumptions, Teva may record an impairment of goodwill allocated to these reporting units in the future.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">During</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="font-size: 10pt; letter-spacing: 0px; text-align: center; text-indent: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">the second qu</div>arter of </div>2022<div style="font-size: 10pt; letter-spacing: 0px; text-align: center; text-indent: 0px; top: 0px;;display:inline;">, Teva completed its long-range planning (&#8220;LRP&#8221;) process. The LRP is part of Teva&#8217;s internal financial planning and budgeting processes and is discussed and reviewed by Teva&#8217;s management and its board of directors.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, Teva conducted a quantitative analysis of all reporting units as part of its annual goodwill impairment test with the assistance of an independent valuation expert. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva identified an increase in certain components of the discount rate, mainly attributable to: (i)&#160;the risk-free interest rate, which resulted in an increase in the WACC; and (ii)&#160;the risk associated with country-specific characteristics of several countries. </div></div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on this quantitative analysis, in the second quarter of 2022, Teva recorded a goodwill impairment charge of</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>$745&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million as follows: (i) </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> $479&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">million related to its International Markets reporting unit, mainly due to the increase in the discount rate; and (ii)</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>$266&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million related to its Teva&#8217;s API reporting unit, mainly due to the increase in the discount rate, as well as updated assumptions supporting the cash flow projections, including certain revenue growth assumptions and the associated operating profit margins. Teva&#8217;s API reporting unit is included under &#8220;Other&#8221; in the table above. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following the goodwill impairment charges recorded in relation to Teva&#8217;s International Markets and Teva&#8217;s API reporting units, the carrying values of </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">those reporting units </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> equaled their fair value as of June&#160;30, 2022. Therefore, if business conditions or expectations were to change materially, it may be necessary to record further impairment charges to Teva&#8217;s International Markets or Teva&#8217;s API reporting units in the future. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The estimated fair value of Teva&#8217;s Europe reporting unit exceeds its estimated carrying amount by 9% based on a terminal growth rate of 1.41% and a discount rate of 10.04%. If Teva holds all other assumptions constant, a reduction in the terminal growth rate of 0.50% to 0.91% or an increase in the discount rate of 0.50% to 10.54% would result in a reduction of the excess of fair value over carrying amount with respect to Teva&#8217;s Europe reporting unit to 5%. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Teva&#8217;s</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> North America and Medis reporting units have<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;a</div> fair value in excess of 10% over their book values as of June&#160;30, 2022</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva noted its market capitalization has been below management&#8217;s assessment of the aggregated fair value of the Company&#8217;s reporting units. However, as of June 30, 2022, the Company&#8217;s market capitalization plus a reasonable control premium exceeded its book value. </div></div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684983027744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt obligations<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt obligations</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 7 &#8211; Debt obligations:&#160; &#160;&#160;</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a. Short-term debt:</div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 89%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average&#160;interest<br/>rate as of June&#160;30, 2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Maturity</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Convertible senior debentures</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.25</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2026</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current maturities of long-term liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,696</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,403</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total short-term debt</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,719</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,426</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Convertible senior debentures</div></div></div></div></div> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The principal amount of Teva&#8217;s 0.25% convertible senior debentures due 2026 was $23&#160;million as of June&#160;30, 2022 and December&#160;31, 2021. These convertible senior debentures include a &#8220;net share settlement&#8221; feature according to which the principal amount will be paid in cash and in case of conversion, only the residual conversion value above the principal amount will be paid in Teva shares. Due to the &#8220;net share settlement&#8221; feature, exercisable at any time, these convertible senior debentures are classified in the Balance Sheet under short-term debt.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">b. Long-term debt:</div></div><br/></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 87%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average&#160;interest<br/>rate as of June&#160;30, 2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Maturity</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR 1,500&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1.13</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2024</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">653</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">708</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: pre-wrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: pre-wrap;;display:inline;">Sustainability-linked senior notes EUR 1,500&#160;million&#160;(1)<div style="letter-spacing: 0px; top: 0px; white-space: pre-wrap;;display:inline;">&#160;</div>(*)</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">4.38</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">2030</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">1,566</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">1,699</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR 1,300&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1.25</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2023</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">616</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">670</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sustainability-linked senior notes EUR 1,100&#160;million&#160;(2)<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>(*)</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">3.75</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">2027</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">1,150</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">1,246</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR 1,000&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">6.00</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2025</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1,043</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1,134</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR 900&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">4.50</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">2025</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">942</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">1,020</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR 750&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1.63</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2028</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">779</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">844</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR 700&#160;million (3)</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">3.25</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">2022</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">307</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR 700&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1.88</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2027</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">729</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">792</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 3,500&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">3.15</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">2026</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">3,496</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">3,496</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 3,000&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2.80</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2023</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1,453</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1,453</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 2,000&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">4.10</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">2046</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">1,986</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">1,986</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 1,250&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">6.00</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2024</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1,250</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1,250</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 1,250&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">6.75</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">2028</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">1,250</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">1,250</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 1,000&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">7.13</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2025</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1,000</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1,000</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sustainability-linked senior notes USD 1,000&#160;million&#160;(2)<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>(*)</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">4.75</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">2027</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">1,000</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">1,000</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sustainability-linked senior notes USD 1,000&#160;million&#160;(1)<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>(*)</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">5.13</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2029</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1,000</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1,000</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 844&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">2.95</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">2022</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">715</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">715</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 789&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">6.15</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2036</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">783</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">783</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes CHF 350&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">0.50</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">2022</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">366</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">382</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes CHF 350&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2025</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">367</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">383</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total senior notes</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">22,144</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">23,118</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long-term debt</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less current maturities</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(1,696</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(1,403</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less debt issuance costs</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(87</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(100</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total senior notes and loa<div style="letter-spacing: 0px; top: 0px;;display:inline;">n</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;;text-align:right;">20,363</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;;text-align:right;">21,617</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/>  <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="clear: both; max-height: 0px; text-indent: 0px;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">0.125%-0.375%</div> per annum, from and including May 9, 2026.&#160;</div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">If Teva fails to achieve certain sustainability performance targets, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> premium payment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">0.15%-0.45%</div> out of the principal amount will be paid at maturity or upon earlier redemption, if such redemption is on or after May 9, 2026. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In April 2022, Teva repaid $296&#160;million of its 3.25% senior notes at maturity. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(*)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Interest rate adjustments and a potential <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> premium payment related to the sustainability-linked bonds are treated as bifurcated embedded derivatives. See note 8<div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>. </div> </td> </tr> </table> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term debt was issued by several indirect wholly-owned subsidiaries of the Company and is fully and unconditionally guaranteed by the Company as to payment of all principal, interest, discount and additional amounts, if any. The long-term debt outlined in the above table is generally redeemable at any time at varying redemption prices plus accrued and unpaid interest. </div><br/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva&#8217;s </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">debt as of June&#160;30, 2022 <div style="letter-spacing: 0px; top: 0px;;display:inline;">was</div> effectively denominated in the following currencies: 63% in U.S. dollar, 34% in euro and 3% in Swiss franc. </div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva&#8217;s principal sources of short-term liquidity are its cash on hand, existing cash investments, liquid securities and available credit facilities, primarily, as of June&#160;30, 2022, its $1.8&#160;billion unsecured syndicated sustainability-linked revolving credit facility&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">entered into in April 2022 (&#8220;RCF&#8221;). </div></div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;">In April 2022, Teva entered into an unsecured syndicated sustainability-linked revolving credit facility of $1.8&#160;billion with a maturity date of <span style="-sec-ix-hidden:hidden52308335">April</span> 2026, with two <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> extension options. The RCF contains certain covenants, including certain limitations on incurring liens and indebtedness and maintenance of certain financial ratios, including a maximum leverage ratio, which becomes more restrictive over time. In addition, the RCF is linked to two sustainability performance targets, (i)&#160;the company&#8217;s S&amp;P ESG Score and (ii)&#160;number of new regulatory submissions in low and middle-income countries. The RCF margin may increase or decrease depending on the Company&#8217;s sustainability performance.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the terms of the RCF, the leverage ratio shall not exceed 4.50x in the second and third quarters of 2022, 4.25x in the fourth quarter of 2022, 4.00x in the first, second and third quarters of 2023, 3.75x in the fourth quarter of 2023 and 3.50x in 2024 and onwards. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The RCF can be used for general corporate purposes, including repaying existing debt. As of June 30, 2022 and as of the date of this Quarterly Report on Form 10-Q, no amounts were outstanding under the RCF. Based on current and forecasted results, the Company expects that it will not exceed the financial covenant thresholds set forth in the RCF within one year from the date the financial statements are issued. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under specified circumstances, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with any of the covenants described above and the unavailability of any waiver, amendment or other modification thereto, the Company will not be able to borrow under the RCF. Additionally, violations of the covenants, under the above-mentioned circumstances, would result in an event of default in all borrowings under the RCF and, when greater than a specified threshold amount as set forth in each series of senior notes and sustainability-linked senior notes is outstanding, could lead to an event of default under the Company&#8217;s senior notes and sustainability-linked senior notes due to cross acceleration provisions.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva expects that it will continue to have sufficient cash resources to support its debt service payments and all other financial obligations within one year from the date that the financial statements are issued.</div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684983032800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments and hedging activities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments and Hedging Activities</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 8 &#8211; Derivative instruments and hedging activities: </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">a. Foreign exchange risk management:</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-style: normal; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the first six months of 2022, approximately 48% of Teva&#8217;s revenues were denominated in currencies other than the U.S. dollar. As a result, Teva is subject to significant foreign currency risks. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company enters into forward exchange contracts, purchases and writes options in order to hedge the currency exposure on balance sheet items, revenues and expenses. In addition, the Company takes measures to reduce exposure by using natural hedging. The Company also acts to offset risks in opposite directions among the subsidiaries within Teva. The currency hedged items are usually denominated in the following main currencies: the euro, the Swiss franc, the Japanese yen, the British pound, the Russian ruble, the Canadian dollar, the Polish zloty, new Israeli shekel, the Indian rupee and other European and Latin American currencies. Depending on market conditions, foreign currency risk is also managed through the use of foreign currency debt. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may choose to hedge against possible fluctuations in foreign subsidiaries net assets (&#8220;net investment hedge&#8221;) and entered into cross currency swaps and forward contracts in the past in order to hedge such an exposure. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Most of the counterparties to the derivatives are major banks and the Company is monitoring the associated inherent credit risks. The Company does not enter into derivative transactions for trading purposes. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">b. Interest risk management: </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company raises capital through various debt instruments, including senior notes, sustainability-linked senior notes, bank loans, convertible debentures and syndicated revolving credit facility that bear a fixed or variable interest rate. In some cases, the Company has swapped from a fixed to a variable interest rate (&#8220;fair value hedge&#8221;) and from a fixed to a fixed interest rate with an exchange from a currency other than the functional currency (&#8220;cash flow hedge&#8221;), thereby reducing overall interest expenses or hedging risks associated with interest rate fluctuations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">c. Bifurcated embedded derivatives: </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Upon issuance of sustainability-linked senior notes, Teva recognized embedded derivatives related to interest rate adjustments and a potential <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> premium payment upon failure to achieve certain sustainability performance targets, such as access to medicines in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-to-middle-income</div></div> countries and absolute greenhouse gas emissions reduction, which were bifurcated and are accounted for separately as derivative financial instruments. As of June&#160;30, 2022<div style="letter-spacing: 0px; top: 0px;;display:inline;">,</div> the fair value of these derivative instruments is negligible.</div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">d. Derivative instruments outstanding: </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the classification and fair values of derivative instruments:</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Not designated as hedging</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">instruments</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">June&#160;30,</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31,</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td colspan="5" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Reported under</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asset derivatives:</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets:</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Option and forward contracts</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liability derivatives:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Option and forward contracts</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(37</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(23</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The table below provides information regarding the location and amount of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> (gains) losses from derivatives not designated as hedging instruments:</div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial&#160;expenses,&#160;net</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net revenues</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months&#160;ended,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Reported under</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Line items in which effects of hedges are recorded</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">211</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">274</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,786</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,910</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Option and forward contracts (1)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(38</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Option and forward contracts economic hedge (2)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr></table>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial&#160;expenses,&#160;net</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net revenues</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six months ended,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six months ended,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Reported under</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 11pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Line items in which effects of hedges are recorded</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">468</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">564</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,447</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,892</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Option and forward contracts (1)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(43</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(43</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Option and forward contracts economic hedge (2)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(35</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Teva uses foreign exchange contracts (mainly option and forward contracts) to hedge balance sheet items from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, Teva recognizes gains or losses that offset the revaluation of the balance sheet items also recorded under financial expenses, net.</div></td></tr></table><div style="clear: both; max-height: 0px;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on projected revenues and expenses recorded in euro, the Swiss franc, the Japanese yen, the British pound, the Russian ruble, the Canadian dollar and some other currencies to protect its projected operating results for 2022 and 2021. These derivative instruments do not meet the criteria for hedge accounting, however, they are accounted for as an economic hedge. These derivative instruments, which may include hedging transactions against future projected revenues and expenses, are<br/></div> </div></div></td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. In the first six months of 2022, the positive impact from these derivatives recognized under revenues was $35&#160;million. In the first six months of 2021, the positive impact from these derivatives recognized under revenues was $13&#160;million. Changes in the fair value of the derivative instruments are recognized in the same line item in the statements of income as the underlying exposure being hedged. The cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows. </div></td></tr></table><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">e. Amortizations due to terminated derivative instruments: </div></div></div><div style="clear: both; max-height: 0px;"/><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forward starting interest rate swaps and treasury lock agreements </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2015, Teva entered into forward starting interest rate swaps and treasury lock agreements to protect the Company from interest rate fluctuations in connection with a future debt issuance the Company was planning. These forward starting interest rate swaps and treasury lock agreements were terminated in July 2016 upon the debt issuance. The termination of these transactions resulted in a loss position of $493&#160;million, which was recorded in other comprehensive income (loss) and is amortized under financial expenses, net over the life of the debt. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">With respect to these forward starting interest rate swaps and treasury lock agreements, losses of $7&#160;million and $8&#160;million were recognized under financial expenses, net for each of the three months ended June&#160;30, 2022 and 2021, respectively, and losses of $15&#160;million and $16&#160;million were recognized under financial expenses, net for each of the six months ended June&#160;30, 2022 and 2021, respectively. </div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value hedge </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the third quarter of 2016, Teva terminated interest rate swap agreements designated as a fair value hedge relating to its 2.95% senior notes due 2022 with respect to $844&#160;million notional amount and its 3.65% senior notes due 2021 with respect to $450&#160;million notional amount. Settlement of these transactions resulted in a gain position of $41&#160;million. The fair value hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt as additional interest expense. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the third quarter of 2019, Teva terminated $500&#160;million interest rate swap agreements designated as a fair value hedge relating to its 2.8% senior notes due 2023 with respect to $3,000&#160;million notional amount. Settlement of these transactions resulted in cash proceeds of $10&#160;million. The fair value hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">With respect to the interest rate swap and cross-currency swap agreements, gains of $</div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million were recognized under financial expenses, net for each of the three months ended June&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively, and gains of $</div>2<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million were recognized under financial expenses, net for the six months ended June&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>202<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>202<div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively.</div><br/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI https://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684986132912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Settlements and Loss Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Legal Settlements and Loss Contingencies</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 9 &#8211; Legal settlements and loss contingencies: </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the second quarter of 2022, Teva recorded expenses of $729&#160;million in legal settlements and loss contingencies, compared to $6&#160;million in the second quarter of 2021. The expenses in the second quarter of 2022 were mainly related to an update of the estimated settlement provision recorded in connection with the remaining opioid cases.</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;See note 10. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the first six months of 2022, Teva recorded an expense of $1,854&#160;million in legal settlements and loss contingencies, compared <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">to an&#160;</div></div>expense of $110&#160;million in the first six months of 2021. The expense in the first six months of 2022 was mainly related to an update of the estimated settlement provision recorded in connection with the remaining opioid cases. The expense in the first six months of 2021 was mainly due to the provision for the carvedilol patent litigation. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2022 and December&#160;31, 2021, Teva&#8217;s provision for legal settlements and loss contingencies recorded under accrued expenses and other taxes and long-term liabilities was $3,928&#160;million and $2,710&#160;million, respectively. In connection with Teva&#8217;s provision for legal settlements and loss contingencies as of December&#160;31, 2021, related to the Ontario Teachers Securities Litigation, Teva also recognized an insurance receivable.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684986139616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and contingencies</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 10 &#8211; Commitments and contingencies: </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time, Teva and/or its subsidiaries are subject to claims for damages and/or equitable relief arising in the ordinary course of business. In addition, as described below, in large part as a result of the nature of its business, Teva is frequently subject to litigation. Teva generally believes that it has meritorious defenses to the actions brought against it and vigorously pursues the defense or settlement of each such action. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva records a provision in its financial statements to the extent that it concludes that a contingent liability is probable and the amount thereof is estimable. Based upon the status of the cases described below, management&#8217;s assessments of the likelihood of damages, and the advice of counsel, no provisions have been made regarding the matters disclosed in this note, except as noted below. Litigation outcomes and contingencies are unpredictable, and excessive verdicts can occur. Accordingly, management&#8217;s assessments involve complex judgments about future events and often rely heavily on estimates and assumptions. Teva continuously reviews the matters described below and may, from time to time, remove previously disclosed matters where the exposures were fully resolved in the prior year, or determined to no longer meet the materiality threshold for disclosure, or were substantially resolved. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If one or more of such proceedings described below were to result in final judgments against Teva, such judgments could be material to its results of operations and cash flows in a given period. In addition, Teva incurs significant legal fees and related expenses in the course of defending its positions even if the facts and circumstances of a particular litigation do not give rise to a provision in the financial statements. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with third-party agreements, Teva may under certain circumstances be required to indemnify, and may be indemnified by, in unspecified amounts, the parties to such agreements against third-party claims. Among other things, Teva&#8217;s agreements with third parties may require Teva to indemnify them, or require them to indemnify Teva, for the costs and damages incurred in connection with product liability claims, in specified or unspecified amounts. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Except as otherwise noted, all of the litigation matters disclosed below involve claims arising in the United States. Except as otherwise noted, all third party sales figures given below are based on IQVIA data. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intellectual Property Litigation </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time, Teva seeks to develop generic and biosimilar versions of patent-protected pharmaceuticals and biopharmaceuticals for sale prior to patent expiration in various markets. In the United States, to obtain approval for most generics prior to the expiration of the originator&#8217;s patents, Teva must challenge the patents under the procedures set forth in the Hatch-Waxman Act of 1984, as amended. For many biosimilar products that are covered by patents, Teva participates in the &#8220;patent dance&#8221; procedures of the Biologics Price Competition and Innovation Act (BPCIA), which allow for the challenge to originator patents prior to obtaining biosimilar product approval. To the extent that Teva seeks to utilize such patent challenge procedures, Teva is and expects to be involved in patent litigation regarding the validity, enforceability or infringement of the originator&#8217;s patents. Teva may also be involved in patent litigation involving the extent to which its product or manufacturing process techniques may infringe other originator or third-party patents. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, depending upon a complex analysis of a variety of legal and commercial factors, Teva may, in certain circumstances, elect to market a generic or biosimilar version of the product even though litigation is still pending. To the extent Teva elects to proceed in this manner, it could face substantial liability for patent infringement if the final court decision is adverse to Teva, which could be material to its results of operations and cash flows in a given period. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva could also be sued for patent infringement outside of the context of the Hatch-Waxman Act or BPCIA. For example, Teva could be sued for patent infringement after commencing sales of a product. This type of litigation can involve any of Teva&#8217;s pharmaceutical products, not just its generic and biosimilar products. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The general rule for damages in patent infringement cases in the United States is that the patentee should be compensated by no less than a reasonable royalty and it may also be able, in certain circumstances, to be compensated for its lost profits. The amount of a reasonable royalty award would generally be calculated based on the sales of Teva&#8217;s product. The amount of lost profits would generally be based on the lost sales of the patentee&#8217;s product. In addition, the patentee may seek consequential damages as well as enhanced damages of up to three times the profits lost by the patent holder for willful infringement, although courts have typically awarded much lower multiples. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva is also involved in litigation regarding patents in other countries where it does business, particularly in Europe. The laws concerning generic pharmaceuticals and patents differ from country to country. Damages for patent infringement in Europe may include lost profits or a reasonable royalty, but enhanced damages for willful infringement are generally not available. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In July 2014, GlaxoSmithKline (&#8220;GSK&#8221;) sued Teva in the District Court for the District of Delaware for infringement of a patent directed to using carvedilol in a specified manner to decrease the risk of mortality in patients with congestive heart failure. Teva and eight other generic producers began selling their carvedilol tablets (the generic version of GSK&#8217;s Coreg<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>) in September 2007. A jury trial was held and the jury returned a verdict in GSK&#8217;s favor finding Teva liable for induced infringement, including willful infringement, and assessing damages of $235.5&#160;million, not including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-</div> or post-judgment interest or a multiplier for willfulness. Thereafter, the judge overturned the jury verdict, finding no induced infringement by Teva and that Teva did not owe any damages. On August&#160;5, 2021, the Court of Appeals for the Federal Circuit issued a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-to-one</div></div> decision reinstating the $235.5&#160;million verdict and finding Teva liable for patent infringement. On February&#160;11, 2022, the Court of Appeals for the Federal Circuit denied rehearing. Teva appealed this decision to the U.S. Supreme Court on July&#160;11, 2022. While that appeal is pending, the case is remanded to the district court for proceedings on Teva&#8217;s other legal and equitable defenses that have not yet been considered by the district court. In the first quarter of 2021, Teva recognized a provision based on its offer to settle such matter. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October 2016, Adapt and Emergent Biosciences Inc. (&#8220;EBSI&#8221;) sued Teva in the District Court for the District of New Jersey, asserting infringement of its patents expiring in 2035, as a result of Teva&#8217;s filing of its Abbreviated New Drug Application (&#8220;ANDA&#8221;) seeking to market a generic version of Narcan<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> nasal spray. In June 2020, the court issued a decision finding all of EBSI&#8217;s patents expiring in 2035, to be invalid. On December&#160;22, 2021, Teva launched its generic version of Narcan<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> nasal spray. On February&#160;10, 2022, the Court of Appeals for the Federal Circuit affirmed the lower court decision finding that EBSI&#8217;s patents are invalid. On May&#160;5, 2022, the Court of Appeals for the Federal Circuit denied EBSI&#8217;s petition for rehearing. EBSI still has the opportunity to seek further review from the U.S. Supreme Court. If Teva ultimately loses the case, Teva may be ordered to cease commercial sales or donations of its generic product and/or pay damages to EBSI. Annual sales of Narcan<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> in the U.S. were approximately $434&#160;million at the time Teva launched its generic version in December 2021. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product Liability Litigation </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva&#8217;s business inherently exposes it to potential product liability claims. Teva maintains a program of insurance, which may include commercial insurance, self-insurance (including direct risk retention), or a combination of both types of insurance, in amounts and on terms that it believes are reasonable and prudent in light of its business and related risks. However, Teva sells, and will continue to sell, pharmaceuticals that are not covered by its product liability insurance; in addition, it may be subject to claims for which insurance coverage is denied as well as claims that exceed its policy limits. Product liability coverage for pharmaceutical companies is becoming more expensive and increasingly difficult to obtain. As a result, Teva may not be able to obtain the type and amount of insurance it desires, or any insurance on reasonable terms, in all of its markets. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva and its subsidiaries are parties to litigation relating to previously unknown nitrosamine impurities discovered in certain products. The discovery led to a global recall of single and combination valsartan medicines around the world starting in July 2018 and to subsequent recalls on other products. The nitrosamine impurities in valsartan are allegedly found in the active pharmaceutical ingredient (&#8220;API&#8221;) supplied by multiple API manufacturers. Teva&#8217;s products allegedly at issue in the various nitrosamine-related litigations pending in the United States include valsartan, losartan, metformin and ranitidine. There are currently two Multi-District Litigations (&#8220;MDL&#8221;) pending in the United States District Courts against Teva and numerous other manufacturers. One MDL is pending in the United States District Court for the District of New Jersey for valsartan, losartan and irbesartan. Teva is not named in complaints with respect to irbesartan. The second MDL is pending in the United States District Court for the Southern District of Florida for ranitidine. The lawsuits against Teva in the MDLs consist of individual personal injury and/or product liability claims and economic damages claims brought by consumers and end payors on behalf of purported classes of other consumers and end payors as well as medical monitoring class claims. Defendants&#8217; motions to dismiss in the valsartan, losartan and irbesartan MDL were denied in part and granted in part and plaintiffs have filed amended complaints.&#160;In the ranitidine MDL, the generics manufacturers&#8217; motions to dismiss have been granted, although certain plaintiffs have appeals pending. Teva, as well as </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">other generic manufacturers, is also named in several state court actions asserting allegations similar to those in the ranitidine MDL and the valsartan and losartan MDL. The state court valsartan and losartan actions are pending in New Jersey and Delaware and are currently stayed. The state court ranitidine cases naming Teva are pending in California, Illinois, Pennsylvania and New York. In addition to these MDLs, Teva has also been named in a consolidated proceeding pending in the United States District Court for the District of New Jersey brought by individuals and end payors seeking economic damages on behalf of purported classes of consumers and end payors who purchased Teva&#8217;s, as well as other generic manufacturers&#8217; metformin products. Defendants&#8217; motion to dismiss the plaintiffs&#8217; amended metformin complaint from June 2021, was granted without prejudice with respect to the consumer economic loss plaintiffs and granted in part and denied in part with respect to the end payor plaintiffs. Plaintiffs were granted leave to file a second amended complaint. Similar lawsuits are pending in Canada and Germany.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Competition Matters </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of its generic pharmaceuticals business, Teva has challenged a number of patents covering branded pharmaceuticals, some of which are among the most widely-prescribed and well-known drugs on the market. Many of Teva&#8217;s patent challenges have resulted in litigation relating to Teva&#8217;s attempts to market generic versions of such pharmaceuticals under the federal Hatch-Waxman Act. Some of this litigation has been resolved through settlement agreements in which Teva obtained a license to market a generic version of the drug, often years before the patents expire. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva and its subsidiaries have been named as defendants in cases that allege antitrust violations arising from such settlement agreements. The plaintiffs in these cases are usually direct and indirect purchasers of pharmaceutical products, some of whom assert claims on behalf of classes of all direct and indirect purchasers, and they typically allege that (i)&#160;Teva received something of value from the innovator in exchange for an agreement to delay generic entry, and (ii)&#160;significant savings could have been realized if there had been no settlement agreement and generic competition had commenced earlier. These plaintiffs seek various forms of injunctive and monetary relief, including damages based on the difference between the brand price and what the generic price allegedly would have been and disgorgement of profits, which are often automatically tripled under the relevant statutes, plus attorneys&#8217; fees and costs. The alleged damages generally depend on the size of the branded market and the length of the alleged delay, and can be substantial&#8212;potentially measured in multiples of the annual brand sales&#8212;particularly where the alleged delays are lengthy or branded drugs with annual sales in the billions of dollars are involved. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva believes that its settlement agreements are lawful and serve to increase competition, and has defended them vigorously. In Teva&#8217;s experience to date, these cases have typically settled for a fraction of the high end of the damages sought, although there can be no assurance that such outcomes will continue. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2013, the U.S. Supreme Court held, in Federal Trade Commission (&#8220;FTC&#8221;) v. Actavis, Inc., that a rule of reason test should be applied in analyzing whether such settlements potentially violate the federal antitrust laws. The Supreme Court held that a trial court must analyze each agreement in its entirety in order to determine whether it violates the antitrust laws. This new test has resulted in increased scrutiny of Teva&#8217;s patent settlements, additional action by the FTC and state and local authorities, and an increased risk of liability in Teva&#8217;s currently pending antitrust litigations. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2015, Cephalon Inc., a Teva subsidiary (&#8220;Cephalon&#8221;), entered into a consent decree with the FTC (the &#8220;Modafinil Consent Decree&#8221;) under which the FTC dismissed antitrust claims against Cephalon related to certain finished modafinil products (marketed as PROVIGIL<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>) in exchange for Cephalon and Teva agreeing to, among other things, abide by certain restrictions and limitations, for a period of ten years, when entering into settlement agreements to resolve patent litigation in the United States. Those restrictions and limitations were further refined in connection with the settlement of other unrelated FTC antitrust lawsuits and the term of the Modafinil Consent Decree was extended until 2029. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In November 2020, the European Commission issued a final decision in its proceedings against both Cephalon and Teva, finding that the 2005 settlement agreement between the parties had the object and effect of hindering the entry of generic modafinil, and imposed fines totaling euro 60.5&#160;million on Teva and Cephalon. Teva and Cephalon filed an appeal against the decision in February 2021. A provision for this matter was included in the financial statements. Teva has provided the European Commission with a bank guarantee in the amount of the imposed fines. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2011, three groups of plaintiffs sued Wyeth and Teva for alleged violations of the antitrust laws in connection with their November 2005 settlement of patent litigation involving extended release venlafaxine (generic Effexor XR<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>). The cases were filed by a purported class of direct purchasers, by a purported class of indirect purchasers and by certain chain pharmacies in the U.S. District Court for the District of New Jersey. The plaintiffs claim that the settlement agreement between Wyeth and Teva unlawfully delayed generic entry. In March 2020, the district court temporarily stayed discovery and referred the case to mediation, and discovery remains stayed. Annual sales of Effexor XR<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> were approximately $2.6&#160;billion at the time of settlement and at the time Teva launched its generic version of Effexor XR<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> in July 2010. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In February 2012, two purported classes of direct-purchaser plaintiffs sued GSK and Teva in New Jersey federal court for alleged violations of the antitrust laws in connection with their settlement of patent litigation involving lamotrigine (generic Lamictal<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>) entered into in February 2005. The plaintiffs claim that the settlement agreement unlawfully delayed generic entry and seek unspecified damages. On April&#160;9, 2021, the district court, which had previously granted an initial motion for class certification by the direct purchaser plaintiffs but was reversed on that ruling by the Third Circuit in April 2020, denied the direct purchaser plaintiffs&#8217; renewed motion for class certification. Plaintiffs thereafter sought leave to file a supplemental expert report in an effort to show that they could still meet the class certification standard on certain of their claims, but on January&#160;21, 2022, the district court denied that request in full, and on April&#160;21, 2022, the court entered a schedule for additional briefing on the remaining class certification issues. Annual sales of Lamictal<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> were approximately $950&#160;million at the time of the settlement and approximately $2.3&#160;billion at the time Teva launched its generic version of Lamictal<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> in July 2008. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In April 2013, purported classes of direct purchasers of, and end payers for, Niaspan<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> (extended release niacin) sued Teva and Abbott for violating the antitrust laws by entering into a settlement agreement in April 2005, to resolve patent litigation over the product. A multidistrict litigation has been established in the U.S. District Court for the Eastern District of Pennsylvania. Throughout 2015 and in January 2016, several individual direct-purchaser <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">opt-out</div> plaintiffs filed complaints with allegations nearly identical to those of the direct purchasers&#8217; class. In August 2019, the district court certified the direct-purchaser class, but in June 2020, the court denied the indirect purchasers&#8217; motion for class certification without prejudice. On September&#160;4, 2020, the indirect purchasers filed a renewed motion for class certification, which was subsequently denied with prejudice by the district court and is now on appeal before the Court of Appeals for the Third Circuit. In October 2016, the District Attorney for Orange County, California, filed a similar complaint in California state court, alleging violations of state law and seeking restitution and civil penalties. Annual sales of Niaspan<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> were approximately $416&#160;million at the time of the settlement and approximately $1.1&#160;billion at the time Teva launched its generic version of Niaspan<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> in September 2013. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Since January 2014, numerous lawsuits have been filed in the U.S. District Court for the Southern District of New York by purported classes of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">end-payers</div> for, and direct-purchasers of, Actos<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> and Actoplus Met (pioglitazone and pioglitazone plus metformin) against Takeda, the innovator, and several generic manufacturers, including Teva, Actavis and Watson. The lawsuits allege, among other things, that the settlement agreements between Takeda and the generic manufacturers violated the antitrust laws. The court dismissed the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">end-payers&#8217;</div> lawsuits against all defendants in September 2015. On February&#160;8, 2017, the Court of Appeals for the Second Circuit affirmed the dismissal in part and vacated and remanded the dismissal in part with respect to the claims against Takeda. The direct purchasers&#8217; case had been stayed pending resolution of the appeal in the end payer matter and the direct purchasers amended their complaint for a second time following the Second Circuit&#8217;s decision, but on October&#160;8, 2019, the district court dismissed, with prejudice, the direct purchasers&#8217; claims against the generic manufacturers (including Teva, Actavis, and Watson). At the time of Teva&#8217;s settlement, annual sales of Actos<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> and Actoplus Met were approximately $3.7&#160;billion and approximately $500&#160;million, respectively. At the time Teva launched its authorized generic version of Actos<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> and Actoplus Met in August 2012, annual sales of Actos<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> and Actoplus Met were approximately $2.8&#160;billion and approximately $430&#160;million, respectively. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Putative classes of direct-purchaser and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">end-payer</div> plaintiffs have filed antitrust lawsuits (which have since been coordinated in federal court in Delaware) against Amgen and Teva alleging that the January&#160;2, 2019 settlement agreement between Amgen and Teva, resolving patent litigation over cinacalcet (generic Sensipar<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>), violated the antitrust laws. On November&#160;30, 2020, the district court denied Teva&#8217;s motion to dismiss in part, and on February&#160;16, 2021, plaintiffs filed amended complaints. On March&#160;30, 2021, Teva again moved to dismiss those claims based on plaintiffs&#8217; failure to allege both&#160;that the settlement violated the antitrust laws and&#160;that the settlement caused any actual injury to plaintiffs. On March&#160;11, 2022, the district court denied Teva&#8217;s motion to dismiss in part. Teva has requested that the district court certify its rulings for review by the United States Court of Appeals for the Third Circuit, and is awaiting the court&#8217;s decision. Annual sales of Sensipar<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> in the United States were approximately $1.4&#160;billion at the time Teva launched its generic version of Sensipar<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> in December 2018, and at the time of the January&#160;2, 2019 settlement. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2019, certain direct-purchaser plaintiffs filed claims in federal court in Philadelphia naming Teva and its affiliates as defendants alleging that certain patent litigation settlement agreements relating to AndroGel<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> 1% (testosterone gel) violate the antitrust laws, specifically the September 2006 patent litigation settlement between Watson Pharmaceuticals, Inc. (&#8220;Watson&#8221;), from which Teva later acquired certain assets and liabilities, and Solvay Pharmaceuticals, Inc. (&#8220;Solvay&#8221;), and a December 2011 settlement between Teva and AbbVie. Those claims remain pending. Annual sales of AndroGel<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> 1% were approximately $350&#160;million at the time of the earlier Watson/Solvay settlement and approximately $140&#160;million at the time Actavis launched its generic version of AndroGel<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> 1% in November 2015. A provision for these matters and related litigations in Georgia that have since been settled was included in the financial statements. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Between September&#160;1, 2020 and December&#160;20, 2020, separate plaintiffs purporting to represent putative classes of direct and indirect purchasers and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">opt-out</div> retailer purchasers of Bystolic<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> (nebivolol hydrochloride) filed separate complaints in the U.S. District Court for the Southern District of New York against several generic manufacturers, including Teva, Actavis, and Watson, alleging, among other things, that the settlement agreements these generic manufacturers entered into with Forest Laboratories, Inc., the innovator, to resolve patent litigation over Bystolic<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> violated the antitrust laws. The cases were coordinated and on March&#160;15, 2021, plaintiffs filed amended complaints, which Teva, Actavis, and Watson moved to dismiss. On January&#160;24, 2022, the court dismissed plaintiffs&#8217; amended complaints without prejudice. The plaintiffs filed amended complaints on February&#160;22, 2022, which defendants (including Teva, Actavis and Watson) moved to dismiss on April&#160;19, 2022, and those motions remain pending. Annual sales of Bystolic<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> in the United States were approximately $700&#160;million at the time of Watson&#8217;s 2013 settlement with Forest. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In February 2021, the State of New Mexico filed a lawsuit against Teva and certain other defendants related to various medicines used to treat HIV. Between September and December 2021, several private plaintiffs including retailers and health insurance providers filed similar claims in federal court in the Northern District of California and in the District of Minnesota. As they relate to Teva, the lawsuits challenge settlement agreements Teva entered into with Gilead in 2013 and 2014 to resolve patent litigation relating to Teva&#8217;s generic versions of Viread<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>, Truvada<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>, and Atripla<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>. Plaintiffs allege that the settlements contain improper reverse payments that delayed the availability of Teva&#8217;s generic products, in violation of the federal antitrust laws and state law. Several recently filed cases are in the process of being coordinated with the existing litigation in the Northern District of California, and any effect those cases may have on the overall case schedule remains unclear. On February&#160;16, 2022, Teva moved to dismiss the claims by certain private plaintiffs but that motion was denied. However, Teva has successfully moved to limit the potential damages period as to certain private plaintiffs. On August&#160;5, 2021, Teva moved to dismiss the complaint brought by the State of New Mexico, and on December&#160;20, 2021, the trial court denied Teva&#8217;s motion. The trial court certified the decision as appropriate for interlocutory appeal, but on April&#160;8, 2022, the appellate court in New Mexico declined to accept the appeal. Teva has appealed the decision to the New Mexico Supreme Court, and that appeal remains pending. Annual sales in the United States at the time of the settlement of Viread<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>, Truvada<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> and Atripla<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> were approximately $582&#160;million, $2.4&#160;billion, and $2.9&#160;billion, respectively. Annual sales in the United States at the time Teva launched its generic version of Viread<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> in 2017, Truvada<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> in 2020 and Atripla<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> in 2020 were approximately $728&#160;million, $2.1&#160;billion and $444&#160;million, respectively. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In March 2021, following the 2019 European Commission&#8217;s inspection of Teva and subsequent request for information, the European Commission opened a formal antitrust investigation to assess whether Teva may have abused a dominant position by delaying the market entry and uptake of medicines that compete with COPAXONE. Annual sales of COPAXONE in the European Economic Area for 2021 were approximately $373&#160;million. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On July&#160;15, 2021, the U.K. Competition and Markets Authority (&#8220;CMA&#8221;) issued a decision imposing fines for breaches of U.K. competition law by Allergan, Actavis UK and Auden Mckenzie and a number of other companies in connection with the supply of 10mg and 20mg hydrocortisone tablets in the U.K. The decision combines the CMA&#8217;s three prior investigations into the supply of hydrocortisone tablets in the U.K. and encompasses those allegations which were subject to prior statements of objections (a provisional finding of breach of the Competition Act), in particular those under case <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">50277-1</div> (unfair pricing, originally subject to a statement of objections on December&#160;16, 2016), case <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">50277-2</div> (anti-competitive agreement with AMCo, originally subject to a statement of objections on March&#160;3, 2017) as well as the CMA&#8217;s subsequent investigation relating to an anti-competitive agreement with Waymade. On January&#160;9, 2017, Teva completed the sale of Actavis UK to Accord Healthcare Limited, in connection with which Teva will indemnify Accord Healthcare for potential fines imposed by the CMA and/or damages awarded by a court against Actavis UK in relation to the December&#160;16, 2016 and March&#160;3, 2017 statements of objections, and resulting from conduct prior to the closing date of the sale. In addition, Teva agreed to indemnify Allergan against losses arising from this matter in the event of any such fines or damages. On October&#160;6, 2021, Accord UK and Auden Mckenzie appealed the CMA&#8217;s decision. A provision for the estimated exposure for Teva related to the fines and/or damages has been recorded in the financial statements. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In August 2021, a plaintiff filed a putative class action suit in the United States District Court for the Eastern District of Pennsylvania against Takeda and several generic manufacturers, including Watson and Teva, alleging violations of the antitrust laws in connection with their settlement of patent litigation involving colchicine tablets (generic Colcrys<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>), entered into in January 2016. Plaintiff claims that the settlement was part of a horizontal conspiracy among Takeda and the generic manufacturers to unlawfully restrict output of colchicine by delaying generic entry. Defendants moved to dismiss the complaint for failure to state a claim. On December&#160;28, 2021, the Court granted the defendants&#8217; motion to dismiss, finding that plaintiff&#8217;s allegations were implausible, but granted plaintiff leave to amend, and on January&#160;18, 2022, plaintiff filed its amended complaint, making substantively the same antitrust allegations as before, but with certain new allegations regarding the nature of the alleged conspiracy. On March&#160;30, 2022, the Court granted in part and denied in part defendants&#8217; motion to dismiss, dismissing the newly pled bilateral conspiracy claims but allowing the revised overarching conspiracy claim to proceed against all defendants. On April&#160;8, 2022, Teva and Watson, along with their codefendant Amneal, moved the court to reconsider its partial <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">motion-to-dismiss</div></div> denial or, in the alternative, to certify that denial for immediate appellate review. However, that motion was denied on April&#160;25, 2022. Annual sales of Colcrys<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> in the United States were approximately $187&#160;million at the time of the settlement. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government Investigations and Litigation Relating to Pricing and Marketing </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva is involved in government investigations and litigation arising from the marketing and promotion of its pharmaceutical products in the United States. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In 2015 and 2016, Actavis and Teva USA each respectively received subpoenas from the U.S. Department of Justice (&#8220;DOJ&#8221;) Antitrust Division seeking documents and other information relating to the marketing and pricing of certain Teva USA generic products and communications with competitors about such products. On August&#160;25, 2020, a federal grand jury in the Eastern District of Pennsylvania returned a three count indictment charging Teva USA with criminal felony Sherman Act violations. See <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;20-cr-200</div></div> (E.D. Pa.). The indictment alleges Teva USA participated in three separate conspiracies with certain other generic drug manufacturers to maintain and fix prices, allocate customers, and other alleged antitrust offenses concerning the sale of generic drugs. The indictment identified the following generic drugs: Pravastatin, Carbamazepine, Clotrimazole, Etodolac (IR and ER), Fluocinonide (Cream <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">E-Cream,</div> Gel, and Ointment), Warfarin, Nadolol, Temozolomide, and Tobramycin. On September&#160;8, 2020, Teva USA pled not guilty to all counts. A tentative trial date is yet to be scheduled. While the Company is unable to estimate a range of loss at this time, a conviction on these criminal charges could have a material adverse impact on the Company&#8217;s business, including monetary penalties and debarment from federally funded health care programs. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2018, Teva received a civil investigative demand from the DOJ Civil Division, pursuant to the federal False Claims Act, seeking documents and information produced since January&#160;1, 2009 relevant to the Civil Division&#8217;s investigation concerning allegations that generic pharmaceutical manufacturers, including Teva, engaged in market allocation and price-fixing agreements, paid illegal remuneration, and caused false claims to be submitted in violation of the False Claims Act. An adverse resolution of this matter may include fines, penalties, financial forfeiture and compliance conditions. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2015 and 2016, Actavis and Teva USA each respectively received a subpoena from the Connecticut Attorney General seeking documents and other information relating to potential state antitrust law violations. Subsequently, on December&#160;15, 2016, a civil action was brought by the attorneys general of twenty states against Teva USA and several other companies asserting claims under federal antitrust law alleging price fixing of generic products in the United States. That complaint was later amended to add new states as named plaintiffs, as well as new allegations and new state law claims, and on June&#160;18, 2018, the attorneys general of 49 states plus Puerto Rico and the District of Columbia filed a consolidated amended complaint against Actavis and Teva, as well as other companies and individuals. On May&#160;10, 2019, most (though not all) of these attorneys general filed another antitrust complaint against Actavis, Teva and other companies and individuals, alleging price-fixing and market allocation with respect to additional generic products. On November&#160;1, 2019, the state attorneys general filed an amended complaint, bringing the total number of plaintiff states and territories to 54. The amended complaint alleges that Teva was at the center of a conspiracy in the generic pharmaceutical industry, and asserts that Teva and others fixed prices, rigged bids, and allocated customers and market share with respect to certain additional products. On June&#160;10, 2020, most, but not all, of the same states, with the addition </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of the U.S. Virgin Islands, filed a third complaint in the District of Connecticut naming, among other defendants, Actavis, but not Teva USA, in a similar complaint relating to dermatological generics products. On September&#160;9, 2021, the states&#8217; attorneys general amended their third complaint to, among other things, add California as a plaintiff. In the various complaints described above, the states seek a finding that the defendants&#8217; actions violated federal antitrust law and state antitrust and consumer protection laws, as well as injunctive relief, disgorgement, damages on behalf of various state and governmental entities and consumers, civil penalties and costs. All such complaints have been transferred to the generic drug multidistrict litigation in the Eastern District of Pennsylvania (&#8220;Pennsylvania MDL&#8221;). On July&#160;13, 2020, the court overseeing the Pennsylvania MDL chose the attorneys&#8217; general November&#160;1, 2019 amended complaint, referenced above, along with certain complaints filed by private plaintiffs, to proceed first in the litigation as bellwether complaints. On February&#160;9, 2021, Teva&#8217;s motion to reconsider that ruling was granted, and on May&#160;7, 2021, the Court chose the attorneys&#8217; general third complaint filed on June&#160;10, 2020 and subsequently amended to serve as a bellwether complaint in the Pennsylvania MDL, along with certain complaints filed by private plaintiffs. Teva settled with the State of Mississippi for $925,000 in June 2021 and with the State of Louisiana for $1,450,000 in March 2022. Pursuant to these settlements, both states have dismissed their claims against Actavis and Teva USA, as well as certain former employees of Actavis and Teva USA. On December&#160;9, 2021, the Court entered an order setting the schedule for the proceedings in the bellwether cases. The order did not include trial dates, but provides for the parties to complete briefing on motions for summary judgement in early 2024. On March&#160;30, 2022, the State of Alabama voluntarily dismissed all of its claims in the litigation, including its claims against Actavis and Teva USA, without prejudice. On June&#160;7, 2022, the Court dismissed the attorneys&#8217; general claims for monetary relief under federal law, concluding that the federal statute under which the attorneys general brought suit authorizes injunctive relief only. However, the attorneys general have pending claims for monetary relief under state law.&#160;&#160;&#160;&#160; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Beginning on March&#160;2, 2016, and continuing through December 2020, numerous complaints have been filed in the United States on behalf of putative classes of direct and indirect purchasers of several generic drug products, as well as several individual direct and indirect purchaser <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">opt-out</div> plaintiffs. These complaints, which allege that the defendants engaged in conspiracies to fix prices and/or allocate market share of generic products have been brought against various manufacturer defendants, including Teva USA and Actavis. The plaintiffs generally seek injunctive relief and damages under federal antitrust law, and damages under various state laws. On October&#160;16, 2018, the court denied certain of the defendants&#8217; motions to dismiss as to certain federal claims, pending as of that date, and on February&#160;15, 2019, the court granted in part and denied in part defendants&#8217; motions to dismiss as to certain state law claims. On July&#160;18, 2019, May&#160;6, 2020 and October&#160;8, 2021, certain individual plaintiffs commenced civil actions in the Pennsylvania Court of Common Pleas of Philadelphia County against many of the defendants in the Pennsylvania MDL, including Teva and Actavis, but no complaints have been filed in the actions and each of the three of the cases have been placed in deferred status. Certain counties in New&#160;York and Texas have also commenced civil actions against many of the defendants in the Pennsylvania MDL, including Teva and Actavis, and the complaints have been transferred to the Pennsylvania MDL. There is also one similar complaint brought in Canada, which alleges that the defendants engaged in conspiracies to fix prices and/or allocate market share of generic drug products to the detriment of a class of private payors. The action is in its early stages. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In March 2017, Teva received a subpoena from the U.S. Attorney&#8217;s office in Boston, Massachusetts requesting documents related to Teva&#8217;s donations to patient assistance programs. Subsequently, in August 2020, the U.S. Attorney&#8217;s office in Boston, Massachusetts brought a civil action in the U.S. District Court for the District of Massachusetts alleging violations of the federal Anti-Kickback Statute, and asserting causes of action under the federal False Claims Act and state law. It is alleged that Teva caused the submission of false claims to Medicare through Teva&#8217;s donations to bona fide independent charities that provide financial assistance to patients. An adverse judgment may involve damages, civil penalties and injunctive remedies. On September&#160;10, 2021, the Court granted Teva&#8217;s motion to dismiss the unjust enrichment claim and denied the remainder of the motion. On October&#160;15, 2021, Teva filed an answer to the complaint. The proceeding is in early stages. Additionally, on January&#160;8, 2021, Humana, Inc. filed an action against Teva in the United States District Court for the Middle District of Florida based on the allegations raised in the August 2020 complaint filed by the U.S. Attorney&#8217;s Office in Boston. On April&#160;2, 2021, Teva filed a motion to dismiss the claims on the grounds that the claims are time-barred and/or insufficiently pled, and that motion remains pending. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In April 2021, a city and county in Washington sued Teva in the United States District Court for the Western District of Washington for alleged violations of the Racketeer Influenced and Corrupt Organizations Act, Washington&#8217;s Consumer Protection Act, and unjust enrichment concerning Teva&#8217;s sale of COPAXONE. Plaintiffs purport to represent a nationwide class of health plans and a subclass of Washington-based health plans that purchased and/or reimbursed health plan members for COPAXONE. Plaintiffs allege that Teva engaged in several fraudulent schemes that resulted in </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><br/></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">plaintiffs and the putative class members purchasing and/or reimbursing plan members for additional prescriptions of COPAXONE and/or at inflated COPAXONE prices. Plaintiffs seek treble damages for the excess reimbursements and inflated costs, as well as injunctive relief. On September&#160;28, 2021, plaintiffs filed an amended complaint. On November&#160;17, 2021, Teva moved to dismiss the suit, on the grounds that plaintiffs&#8217; claims are barred by the applicable statutes of limitations and the direct purchaser rule, suffer from jurisdictional defects, and fail to plausibly allege fraud or other elements of their claims. That motion is fully briefed and a decision remains pending. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;29, 2021, Mylan Pharmaceuticals (&#8220;Mylan&#8221;) sued Teva in the District Court for the District of New Jersey. On March&#160;11, 2022 and March&#160;15, 2022, FWK Holdings, LLC, KPH Healthcare Servs., Inc. d/b/a Kinney Drugs, Inc., Meijer Inc., Meijer Distribution, Inc., Labor-Management Healthcare Fund, the Mayor and City Council of Baltimore, and the New York State Teamsters Council Health and Hospital Fund sued Teva in the District Court for the District of New Jersey on behalf of themselves and others similarly situated direct and indirect purchasers of COPAXONE. The complaints assert claims for alleged violations of the Lanham Act, state and federal unfair competition and monopolization laws, tortious interference, trade libel, and a violation of the Racketeer Influenced and Corrupt Organizations Act. Plaintiffs claim Teva was involved in an unlawful scheme to delay and hinder generic competition concerning COPAXONE sales. Plaintiffs seek damages for lost profits and expenses, disgorgement, restitution, treble damages, attorneys&#8217; fees and costs, and injunctive relief. Teva has moved to dismiss the complaint filed by Mylan on the grounds, among others, that none of its challenged conduct violates the law. That motion is fully briefed and a decision remains pending. Teva has also moved to dismiss the remaining complaints on similar grounds and the briefing on that motion is ongoing. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opioids Litigation</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Since May 2014, more than 3,500 complaints have been filed with respect to opioid sales and distribution against various Teva affiliates, along with several other pharmaceutical companies, by a number of cities, counties, states, other governmental agencies, tribes and private plaintiffs (including various putative class actions of individuals) in both state and federal courts. Most of the federal cases have been consolidated into a multidistrict litigation in the Northern District of Ohio (&#8220;MDL Opioid Proceeding&#8221;) and many of the cases filed in state court have been removed to federal court and consolidated into the MDL Opioid Proceeding. Two cases that were included in the MDL Opioid Proceeding were transferred back to federal district court for additional discovery, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-trial</div> proceedings and trial. Those cases are: City of Chicago v. Purdue Pharma L.P. et al., <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;14-cv-04361</div></div> (N.D. Ill.) and City and County of San Francisco v. Purdue Pharma L.P. et al., <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;18-cv-07591-CRB</div></div></div> (N.D. Cal.). Other cases remain pending in various states. In some jurisdictions, such as Illinois, New York, Pennsylvania, South Carolina, Texas, Utah and West Virginia, certain state court cases have been transferred to a single court within their respective state court systems for coordinated pretrial proceedings. Complaints asserting claims under similar provisions of different state law generally contend that the defendants allegedly engaged in improper marketing and distribution of opioids, including ACTIQ<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> and FENTORA<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>. The complaints also assert claims related to Teva&#8217;s generic opioid products. In addition, over 950 personal injury plaintiffs, including various putative class actions of individuals, have asserted personal injury and wrongful death claims in over 600 complaints, nearly all of which are consolidated in the MDL Opioid Proceeding.&#160;Furthermore, approximately 700 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-personal</div> injury complaints and approximately 100 personal injury complaints have named Anda, Inc. (and other distributors and manufacturers) alleging that Anda failed to develop and implement systems sufficient to identify suspicious orders of opioid products and prevent the abuse and diversion of such products to individuals who used them for other than legitimate medical purposes. Plaintiffs seek a variety of remedies, including restitution, civil penalties, disgorgement of profits, treble damages,&#160;attorneys&#8217; fees and injunctive relief. Certain plaintiffs assert that the measure of damages is the entirety of the costs associated with addressing the abuse of opioids and opioid addiction and certain plaintiffs specify multiple billions of dollars in the aggregate as alleged damages. The individual personal injury plaintiffs further seek <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-economic</div> damages. In many of these cases, plaintiffs are seeking joint and several damages among all defendants. </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">On April&#160;19, 2021, a bench trial in California (The People of the State of California, acting by and through Santa Clara County Counsel James R. Williams, et. al. v. Purdue Pharma L.P., et. al.) commenced against Teva and other defendants focused on the marketing of branded opioids. On December&#160;14, 2021, the court issued its final judgment in favor of the defendants on all claims. Plaintiffs filed a notice of appeal of this judgment in February 2022. On June&#160;29, 2021, a jury trial in New York (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">In re Opioid Litigation</div></div>, Index No.&#160;400000/2017) commenced against Teva and other defendants, focused on the marketing and distribution of opioids. The case was bifurcated between liability and damages. On December&#160;30, 2021, the jury returned a liability verdict in favor of plaintiffs (the County of Suffolk, the County of Nassau and the State of New York) on the plaintiffs&#8217; public nuisance claim. Teva and the plaintiffs filed post-trial motions with respect to the liability portion of the case, and Teva intends to appeal if its post-trial motions are denied. The court has not yet set a schedule for damages discovery or a date for the relief phase of the trial. Teva, the State of New York and its subdivisions remain actively engaged in settlement negotiations. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2019, Teva settled the Oklahoma litigation brought by the Oklahoma Attorney General (State of Oklahoma, ex. rel. Mike Hunter, Attorney General of Oklahoma vs. Purdue Pharma L.P., et. al.) for $85&#160;million. The settlement did not include any admission of violation of law for any of the claims or allegations made. As the Company demonstrated a willingness to settle part of the litigation, for accounting purposes, management considered a portion of opioid-related cases as probable and, as such, recorded an estimated provision in the second quarter of 2019. Given the relatively early stage of the cases, management viewed no amount within the range to be the most likely outcome. Therefore, management recorded a provision for the reasonably estimable minimum amount in the assessed range for such opioid-related cases in accordance with Accounting Standards Codification 450 &#8220;Accounting for Contingencies.&#8221; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, on October&#160;21, 2019, Teva reached a settlement with the two plaintiffs in the MDL Opioid Proceeding that was scheduled for trial for the Track One case, Cuyahoga and Summit Counties of Ohio. Under the terms of the settlement, Teva agreed to provide the two counties with opioid treatment medication, buprenorphine naloxone (sublingual tablets), known by the brand name Suboxone<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>, with a value of $25&#160;million at wholesale acquisition cost and distributed over three years to help in the care and treatment of people suffering from addiction, and a cash payment in the amount of $20&#160;million, which has been paid. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;21, 2021, it was announced that four other defendants (not including Teva) reached nationwide settlements, subject to certain conditions, which include payment of up to approximately $26&#160;billion spread over up to </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"> 18 years. Teva has continued to work toward a nationwide settlement with the working group of States&#8217; Attorneys General, the Multi-District Litigation Plaintiffs&#8217; Executive Committee and counsel for Native American tribes (&#8220;Tribes&#8221;). In July 2022, the parties reached an agreement in principle on the financial terms of a final nationwide settlement similar in structure to the nationwide settlements of other defendants. The parties continue to work on memorializing the non-financial terms of the proposed nationwide settlement agreement. Under the financial terms of the proposed nationwide settlement agreement, Teva will pay <div style="letter-spacing: 0px; top: 0px;;display:inline;">up to</div>&#160;$4.25 </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">billion (including the already settled cases) plus approximately $100 million for the Tribes, spread over</div> </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"> 13 <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">years. This total includes the supply of up to</div>&#160;</div>$1.2 <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">billion of Teva&#8217;s generic version of Narcan&#174; (naloxone hydrochloride nasal spray)<div style="letter-spacing: 0px; top: 0px;;display:inline;">,</div> valued at wholesale acquisition cost<div style="letter-spacing: 0px; top: 0px;;display:inline;">,</div> over&#160;</div>10 <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">years or <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">cash at&#160;</div>20% of the wholesale acquisition cost <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">($240 million) in lieu of product. The nationwide settlement agreement is contingent upon (i) final documentation among the working group and Teva, and reaching the thresholds for participation that will be set forth in the final agreement; and (ii) Teva reaching an agreement with Allergan with respect to any indemnification obligations, and Allergan reaching a nationwide opioids settlement. No other trials currently are scheduled against Teva in 2022 in any opioids matter, with the possible exception of the relief phase of the trial in the New York opioids litigation. If the nationwide settlement agreement is not finalized, additional trials are expected to proceed in several states in 2023.</div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On September&#160;28, 2021, Teva reached an agreement with the Attorney General of Louisiana that settles the state&#8217;s opioid-related claims. The agreement was contingent that all political subdivisions of Louisiana will formally release Teva as part of the settlement, which Teva was advised has occurred by the Attorney General of Louisiana. Under the terms of the settlement, Teva will pay Louisiana $15&#160;million over an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">18-year</div> period and will provide buprenorphine naloxone (sublingual tablets) valued at $3&#160;million (wholesale acquisition cost). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On February&#160;4, 2022, the Company reached an agreement with the Attorney General of the State of Texas that settles Texas&#8217; and its subdivisions&#8217; opioid-related claims. On March&#160;10, 2022, Texas confirmed that at least 96% of the population of subdivisions formally released Teva as part of the settlement. Under the terms of the settlement, Teva will pay Texas $150&#160;million over a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15-year</div> period and will provide its generic version of Narcan<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> (naloxone hydrochloride nasal spray), valued at $75&#160;million (wholesale acquisition cost) over 10 years. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;21, 2022, Teva reached an agreement with the Attorney General of Rhode Island that settles Rhode Island&#8217;s and its subdivisions&#8217; opioid-related claims. Under the terms of the settlement, Teva will pay Rhode Island $21&#160;million over 13 years, in addition to attorneys&#8217; fees and costs, and will provide its generic version of Narcan<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> (naloxone hydrochloride nasal spray) and a significant amount of buprenorphine naloxone sublingual tablets known by the brand name Suboxone<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>, together valued at $78.5&#160;million (wholesale acquisition cost) over 10 years. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">On March&#160;30, 2022, Teva reached an agreement with the Attorney General of Florida that settles Florida&#8217;s and its subdivisions&#8217; opioid-related claims. Under the terms of the settlement, Teva will pay Florida $177&#160;million over <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15-years,</div> in addition to attorneys&#8217; fees and costs, and will provide its generic version of Narcan<div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:7.1px">&#174;</div></div> (naloxone hydrochloride nasal spray) valued at $84&#160;million (wholesale acquisition cost) over 10 years. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On May&#160;24, 2022, Teva reached an agreement in principle with the Attorney General of West Virginia that settles West Virginia&#8217;s and its subdivisions&#8217; opioid-related claims. Under the terms of the settlement, Teva will pay West Virginia $75&#160;million over <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15-years,</div> in addition to attorneys&#8217; fees and costs, and will provide its generic version of Narcan<div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:7.1px">&#174;</div></div> (naloxone hydrochloride nasal spray) valued at $27&#160;million (wholesale acquisition cost) over 10 years. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;12, 2022, Teva reached an agreement in principle with the City and County of San Francisco and the People of the State of California that settles opioid-related claims asserted on behalf of the City and County of San Francisco. Teva will provide San Francisco $20.3&#160;million over 13 years, in addition to attorneys&#8217; fees and costs, and will provide its generic version of Narcan</div><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:7.1px">&#174;</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (naloxone hydrochloride nasal spray), valued at $20&#160;million (wholesale acquisition cost), over 10 years. </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In light of the agreement in principle on the nationwide settlement between Teva, and the States&#8217; Attorneys General, their subdivisions and the Tribes, Teva&#8217;s potential indemnification obligations arising from Teva&#8217;s acquisition of the Actavis Generics business for opioid-related claims, prior settlements with Texas, Florida, Louisiana, Rhode Island, West Virginia and San Francisco, the verdict in New York, decisions in California and Oklahoma, as well as an estimate for a number of items including, but not limited to, costs associated with administering injunctive terms, and most favored nations clauses associated with prior settlements, the Company has reconsidered the potential settlement outcome and revised its provision. The revised provision is a reasonable estimate of the ultimate costs in the likely event that the nationwide settlement is finalized under its current proposed terms and conditions, after discounting payments to states to their net present value. However, if the nationwide settlement is not finalized for the entirety of the remaining cases, a reasonable upper end of a range of loss cannot be determined. An adverse resolution of any of these lawsuits or investigations may involve large monetary penalties, damages, and/or other forms of monetary and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-monetary</div> relief and could have a material and adverse effect on Teva&#8217;s reputation, business, results of operations and cash flows. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2019, Teva received a grand jury subpoena from the United States Attorney&#8217;s Office for the Eastern District of New York for documents related to the Company&#8217;s anti-diversion policies and procedures and distribution of its opioid medications, in what the Company understands to be part of a broader investigation into manufacturers&#8217; and distributors&#8217; monitoring programs and reporting under the Controlled Substances Act. In September 2019, Teva received subpoenas from the New York State Department of Financial Services (NYDFS) as part of an industry-wide inquiry into the effect of opioid prescriptions on New York health insurance premiums. This was followed by a Statement of Charges and Notice of Hearing filed by the NYDFS, although no merits hearing date is currently set. Currently, Teva cannot predict how <div style="letter-spacing: 0px; top: 0px;;display:inline;">the</div> nationwide settlement (if finalized) will affect these investigations and administrative actions. In addition, a number of State Attorneys General, including a coordinated multistate effort, have initiated investigations into sales and marketing practices of Teva and its affiliates with respect to opioids. Other states are conducting their own investigations outside of the multistate group. Teva is cooperating with these ongoing investigations and cannot predict their outcome at this time. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, several jurisdictions and consumers in Canada have initiated litigation regarding opioids alleging similar claims as those in the United States. The cases in Canada are in their early stages. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shareholder Litigation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On November&#160;6, 2016 and December&#160;27, 2016, two putative securities class actions were filed in the U.S. District Court for the Central District of California against Teva and certain of its current and former officers and directors. Those lawsuits were consolidated and transferred to the U.S. District Court for the District of Connecticut (the &#8220;Ontario Teachers Securities Litigation&#8221;). On December&#160;13, 2019, the lead plaintiff in that action filed an amended complaint, purportedly on behalf of purchasers of Teva&#8217;s securities between February&#160;6, 2014 and May&#160;10, 2019. The amended complaint asserts that Teva and certain of its current and former officers and directors violated federal securities and common laws in connection with Teva&#8217;s alleged failure to disclose pricing strategies for various drugs in its generic drug portfolio and by making allegedly false or misleading statements in certain offering materials. The amended complaint seeks unspecified damages, legal fees, interest, and costs. In July 2017,&#160;August 2017, and June 2019, other putative securities class actions were filed in other federal courts based on similar allegations, and those cases have been transferred to the U.S. District Court for the District of Connecticut. Between August 2017 and January 2022, twenty-three complaints were filed against Teva and certain of its current and former officers and directors seeking unspecified compensatory damages, legal fees, costs and expenses. The similar claims in these complaints have been brought on behalf of plaintiffs, in various forums across the country, who have indicated that they intend to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;opt-out&#8221;</div> of the Ontario Teachers Securities Litigation. On March&#160;10, 2020, the Court consolidated the Ontario Teachers Securities Litigation with all of the above-referenced putative class actions for all purposes and the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;opt-out&#8221;</div> cases for pretrial purposes. Pursuant to that consolidation order, plaintiffs in several of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;opt-out&#8221;</div> cases filed amended complaints on May&#160;28, 2020. On January&#160;22, 2021, the Court </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">dismissed the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;opt-out&#8221;</div> plaintiffs&#8217; claims arising from statements made prior to the five year statute of repose, but denied Teva&#8217;s motion to dismiss their claims under Israeli laws. Those <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;opt-out&#8221;</div> plaintiffs moved for reconsideration, which was denied on March&#160;30, 2021. On May&#160;24, 2021, Teva moved to dismiss a majority of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;opt-out&#8221;</div> complaints on various other grounds. Those motions are still pending. The Ontario Teachers Securities Litigation plaintiffs&#8217; Motion for Class&#160;Certification and Appointment of Class&#160;Representatives and Class&#160;Counsel was granted on March&#160;9, 2021, to which Teva&#8217;s appeal was denied. On January&#160;18, 2022, Teva entered into a settlement in the Ontario Teachers Securities Litigation for $420&#160;million, which received final approval from the court on June&#160;2, 2022. Pursuant to an agreement between the Company and its insurance carriers, the insurance carriers provided the vast majority of the total settlement amount, with a small portion contributed by Teva. Additionally, as part of the settlement, Teva admitted no liability and denied all allegations of wrongdoing. A number of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;opt-out&#8221;</div> complaints still remain outstanding, and motions to approve securities class actions were also filed in the Tel Aviv District Court in Israel with similar allegations to those made in the Ontario Teachers Securities Litigation. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;23, 2020, a putative securities class action was filed in the U.S. District Court for the Eastern District of Pennsylvania against Teva and certain of its former officers. On August&#160;10, 2021, the lead plaintiff filed a corrected amended class action complaint, purportedly on behalf of persons who purchased or otherwise acquired Teva securities between October&#160;29, 2015 and August&#160;18, 2020. The corrected amended complaint alleges that Teva and certain of its current and former officers violated federal securities laws by allegedly making false and misleading statements regarding the commercial performance of COPAXONE, namely, by failing to disclose that Teva had allegedly caused the submission of false claims to Medicare through Teva&#8217;s donations to bona fide independent charities that provide financial assistance to patients, which allegedly impacted COPAXONE&#8217;s commercial success and the sustainability of its revenues and resulted in the above referenced August 2020 False Claims Act complaint filed by the DOJ. The corrected amended complaint seeks unspecified damages and legal fees. On March&#160;25, 2022, the court granted in part and denied in part Teva&#8217;s and the individual defendants&#8217; motion to dismiss the corrected amended complaint, (i)&#160;holding that the plaintiffs&#8217; complaint failed to plead that certain public statements regarding Teva&#8217;s compliance with the law were misleading, (ii)&#160;holding that two alleged partial corrective disclosures did not establish loss causation and cannot serve as the basis for plaintiff&#8217;s claimed loss, (iii)&#160;dismissing all claims against one of the individual defendants, and (iv)&#160;otherwise denying the motion to dismiss. A motion to approve a securities class action was also filed in the Central District Court in Israel, which has been stayed pending the U.S. litigation, with similar allegations to those made in the above complaint filed in the U.S. District Court for the Eastern District of Pennsylvania. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Motions to approve derivative actions seeking monetary damages against certain past and present directors and officers have been filed in Israeli Courts alleging negligence and recklessness. Motions for document disclosure prior to initiating derivative actions were filed with respect to several U.S. and EU settlement agreements, opioids, the U.S. price-fixing investigations and allegations related to the DOJ&#8217;s complaint regarding Copaxone patient assistance program in the U.S. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Environmental Matters </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva or its subsidiaries are party to a number of environmental proceedings, or have received claims, including under the federal Superfund law or other federal, provincial or state and local laws, imposing liability for alleged noncompliance, or for the investigation and remediation of releases of hazardous substances and for natural resource damages. Many of these proceedings and claims seek to require the generators of hazardous wastes disposed of at a third party-owned site, or the party responsible for a release of hazardous substances that impacted a site, to investigate and clean the site or to pay or reimburse others for such activities, including for oversight by governmental authorities and any related damages to natural resources. Teva or its subsidiaries have received claims, or been made a party to these proceedings, along with others, as an alleged generator of wastes that were disposed of or treated at third-party waste disposal sites, or as a result of an alleged release from one of Teva&#8217;s facilities or former facilities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Although liability among the responsible parties, under certain circumstances, may be joint and several, these proceedings are frequently resolved so that the allocation of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">clean-up</div> and other costs among the parties reflects the relative contributions of the parties to the site conditions and takes into account other pertinent factors. Teva&#8217;s potential liability varies greatly at each of the sites; for some sites the costs of the investigation, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">clean-up</div> and natural resource damages have not yet been determined, and for others Teva&#8217;s allocable share of liability has not been determined. At other sites, Teva has taken an active role in identifying those costs, to the extent they are identifiable and estimable, which do not include reductions for potential recoveries of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">clean-up</div> costs from insurers, indemnitors, former site owners or </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">operators or other potentially responsible parties. In addition, enforcement proceedings relating to alleged violations of federal, state, commonwealth or local requirements at some of Teva&#8217;s facilities may result in the imposition of significant penalties (in amounts not expected to materially adversely affect Teva&#8217;s results of operations) and the recovery of certain costs and natural resource damages, and may require that corrective actions and enhanced compliance measures be implemented. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;103 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-K</div> promulgated by the SEC requires disclosure of certain environmental matters when a governmental authority is a party to the proceedings and such proceedings involve potential monetary sanctions, unless the Company reasonably believes that the matter will result in no monetary sanctions, or in monetary sanctions, exclusive of interest and costs, of less than $300,000. The following matter is disclosed in accordance with that requirement. On July&#160;8, 2021, the National Green Tribunal Principal Bench, New Delhi, issued an order against Teva&#8217;s subsidiary in India, Teva API India Private Limited, finding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with environmental laws and assessed a penalty of $1.4&#160;million. The Company disputed certain of the findings and the amount of the penalty and filed an appeal before the Supreme Court of India. On August&#160;5, 2021, the Supreme Court of India admitted the appeal for hearing and granted an interim unconditional stay on the National Green Tribunal&#8217;s order. The Company does not believe that the eventual outcome of such matter will have a material effect on its business. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Matters </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;1, 2018, former shareholders of Ception Therapeutics, Inc., a company that was acquired by and merged into Cephalon in 2010, prior to Cephalon&#8217;s acquisition by Teva, filed breach of contract and other related claims against the Company, Teva USA and Cephalon in the Delaware Court of Chancery.&#160;Among other things, the plaintiffs allege that Cephalon breached the terms of the 2010 Ception-Cephalon merger agreement by failing to exercise commercially reasonable efforts to develop and commercialize CINQAIR<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> (reslizumab) for the treatment of eosinophilic esophagitis (&#8220;EE&#8221;). The plaintiffs claim damages of at least $200&#160;million, an amount they allege is equivalent to the milestones payable to the former shareholders of Ception in the event Cephalon were to obtain regulatory approval for EE in the United States ($150 million) and Europe ($50 million). Defendants moved to dismiss the complaint and on December&#160;28, 2018, the court granted the motion in part and dismissed all of plaintiffs&#8217; claims, except for their claim against Cephalon for breach of contract. In November 2021, plaintiffs moved to amend their complaint to, among other things, reassert claims against the Company and Teva USA, but the plaintiffs </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">later stipulated to filing a new amended complaint that includes claims against Teva USA but not the Company, in exchange for Teva USA&#8217;s agreement to guarantee any judgment entered against Cephalon in the litigation. Plaintiffs filed that amended complaint on July 12, 2022. Trial in this matter is currently scheduled for September 2022.</div></div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684983047792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 11 &#8211; Income taxes: </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In the second quarter of 2022, Teva recognized a tax benefit of $900&#160;million, on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> loss of $1,160&#160;million. In the second quarter of 2021, Teva recognized a tax expense of $98&#160;million, on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> income of $308&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the second quarter of 2022, one of Teva&#8217;s U.S. subsidiaries was determined to be insolvent for tax purposes (i.e., its liabilities exceeded the fair market value of its assets), mainly in light of its accumulated operational losses. Consequently, Teva will recognize on its 2022 tax return, a worthless stock deduction of approximately $4.2 billion, with related tax benefit of approximately $850 million. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva&#8217;s tax rate for the second quarter of 2022 was mainly affected by the realization of losses related to its investment in one of its U.S. subsidiaries mentioned above, as well as impairments, legal settlements, adjustments to valuation allowances on deferred tax assets and interest expense disallowances. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In the first six months of 2022, Teva recognized a tax benefit of $899&#160;million, on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> loss of $2,131&#160;million. In the first six months of 2021, Teva recognized a tax expense of $159&#160;million, on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> income of $451&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva&#8217;s tax rate for the first six months of 2022 was mainly affected by the realization of losses related to its investment in one of its U.S. subsidiaries mentioned above, as well as impairments, legal settlements, adjustments to valuation allowances on deferred tax assets and interest expense disallowances. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The statutory Israeli corporate tax rate is 23% in 2022. Teva&#8217;s tax rate differs from the Israeli statutory tax rate, mainly due to generation of profits in various jurisdictions in which tax rates are different than the Israeli tax rate, interest expense disallowances, tax benefits in Israel and other countries, as well as infrequent or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-recurring</div> items. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Teva filed a claim seeking the refund of withholding taxes paid to the Indian tax authorities in 2012. Trial in this case is scheduled to begin in November 2022. A final and binding decision against Teva in this case may lead to an impairment of</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> $133&#160;million.</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Israeli tax authorities issued tax assessment decrees for 2008-2012 and 2013-2016, challenging the Company&#8217;s positions on several issues. Teva has protested the 2008-2012 and 2013-2016 decrees before the Central District Court in Israel. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">In October 2021, the Central District Court in Israel held in favor of the Israeli tax authorities with respect to 2008-2011 decrees. The case with respect to 2012-2016 remains pending with similar legal claims. The October 2021 Central District Court decision found that Teva has a tax liability to the Israeli government for 2008-2011 of approximately $350&#160;million,<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;of which a portion is being paid in cash during 2022 and 2023, and the remaining portion is being offset by carried forward losses that Teva would otherwise be entitled to. Teva appealed the decision to the Israeli Supreme Court and expects the appeal hearings to begin in early 2023.&#160;</div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company believes it has adequately provided for all of its uncertain tax positions, including those items currently under dispute, however, adverse results could be material. </div><br/></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684983038368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other assets impairments, restructuring and other items<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_OtherExpensesTextBlock', window );">Other assets impairments, restructuring and other items</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 12 &#8211; Other assets impairments, restructuring and other </div></div><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">items: </div></div></div><br/></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months&#160;ended<br/>June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six&#160;months&#160;ended<br/>June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairments of long-lived tangible assets (1)</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">61</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(19</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restructuring</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13</td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">92</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%; line-height: 11pt; font-size: 11pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size:11pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 11pt;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom; width: 5%; line-height: 11pt; font-size: 11pt;"><div style="font-size:11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size:11pt;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;">118</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size:11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 5%; line-height: 11pt; font-size: 11pt;"><div style="font-size:11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size:11pt;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;">28</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size:11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%; line-height: 11pt; font-size: 11pt;"><div style="font-size:11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size:11pt;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;">246</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size:11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 5%; line-height: 11pt; font-size: 11pt;"><div style="font-size:11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size:11pt;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;">165</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size:11pt;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="width: 26%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Including impairments related to exit and disposal activities. </div></div> </td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impairments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairments of tangible assets for the three months ended June&#160;30, 2022 and 2021 were $14&#160;million and $32&#160;million, respectively.&#160;The impairment for the three months ended June&#160;30, 2021 was mainly related to certain assets in Europe. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Impairments of tangible assets for the six months ended June&#160;30, 2022 and 2021 were $30&#160;million and $80&#160;million, respectively.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;The impairment for the six months ended June 30, 2022 was mainly related to certain assets in North America. The impairment for the six months ended June 30, 2021 was mainly related to certain assets in Europe.&#160;</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva may record additional impairments in the future, to the extent it changes its plans on any given asset and/or the assumptions underlying such plans, as a result of its network consolidation activities. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contingent consideration </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the three months ended June&#160;30, 2022, Teva recorded an expense of $61&#160;million for contingent consideration, compared to an income of $19&#160;</div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million in the three months ended June&#160;30, 2021. The expense in the second quarter of 2022 and the income in the second quarter of 2021 were mainly related to changes in the estimated future royalty payments to Allergan in connection with lenalidomide (generic equivalent of Revlimid<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>), which was part of the Actavis Generics acquisition. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the six months ended June&#160;30, 2022, Teva recorded an expense of $94&#160;million for contingent consideration, compared to an income of $16&#160;million in the six months ended June&#160;30, 2021. The expense in the first six months of 2022</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, and the income in the first six months of 2021 were </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> mainly related to change<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div> in the estimated future royalty payments to Allergan in connection with lenalidomide (generic equivalent of Revlimid<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>), which was part of the Actavis Generics acquisition.</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restructuring </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the three months ended June&#160;30, 2022, Teva recorded $35&#160;million of restructuring expenses, compared to $13&#160;million of restructuring <div style="letter-spacing: 0px; top: 0px;;display:inline;">income</div>&#160;in the three months ended June&#160;30, 2021. </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">The expenses for the three months </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ended June&#160;30, 2022 were primarily related to network consolidation activities and residual expenses of the restructuring plan announced in 2017. The income for the three months ended June&#160;30, 2021 was primarily related to reassessment of the estimate of a prior employee termination provision. </div></div><br/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the six months ended June&#160;30, 2022, Teva recorded $</div>92<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of restructuring expenses, compared to $</div>69<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in the six months ended June&#160;30, 2021. The expenses for the six months ended June&#160;30, 2022 and June&#160;30, 2021 were primarily related to network consolidation activities and residual expenses of the restructuring plan announced in 2017.</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables provide the components of restructuring costs: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months&#160;ended&#160;June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restructuring</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee termination</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(19</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six&#160;months&#160;ended&#160;June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restructuring</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee termination</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">63</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">61</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">92</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides the components of and changes in the Company&#8217;s restructuring accruals: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employee&#160;termination<br/> costs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of January&#160;1, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(131</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(138</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provision</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(63</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(29</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(92</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Utilization and other*</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">74</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">103</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of June&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(120</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(127</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"/>
<td colspan="4" style="height: 12pt;"/>
<td colspan="4" style="height: 12pt;"/>
<td colspan="4" style="height: 12pt;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employee&#160;termination<br/> costs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of January&#160;1, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(115</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(122</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provision</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(61</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(69</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Utilization and other*</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">56</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">64</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of June&#160;30, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(120</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(127</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="width: 26%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">*</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Includes adjustments for foreign currency translation. </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Significant regulatory and other events </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In July 2018, Teva announced the voluntary recall of valsartan and certain combination valsartan medicines in various countries due to the detection of trace amounts of a previously unknown nitrosamine impurity called NDMA found in valsartan API supplied by Zhejiang Huahai Pharmaceuticals Co. Ltd. (&#8220;Huahai&#8221;). Since July 2018, Teva has been actively engaged with global regulatory authorities in reviewing its sartan and other products to determine whether NDMA and/or other related nitrosamine impurities are present in specific products. Where necessary, Teva has initiated additional voluntary recalls. In December 2019, Teva reached a settlement with Huahai resolving Teva&#8217;s claims related to certain sartan API supplied by Huahai. Under the settlement agreement, Huahai agreed to compensate Teva for some of </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">its direct losses and provide it with prospective cost reductions for API. The settlement does not release Huahai from liability for any losses Teva may incur as a result of third party personal injury or product liability claims relating to the sartan API at issue. In addition, multiple lawsuits have been filed in connection with this matter, which may lead to additional customer penalties, impairments and litigation costs. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the second quarter of 2020, Teva&#8217;s operations in its manufacturing facilities in Goa, India were temporarily suspended due to a water supply issue. During the second half of 2020, Teva completed partial remediation of this issue and restarted limited supply from its Goa facilities. The site experienced some additional delays in the first quarter of 2021 due to labor related issues, but the situation stabilized during the second quarter of 2021. The water supply remediation is expected to be completed during the third quarter of 2022, and in the meantime the site is operating under an interim water solution without any material impact expected on compliance and supply capacity. The impact to Teva&#8217;s financial results for the three and six months ended June&#160;30, 2022 was immaterial. </div></div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In June 2021, the Company temporarily paused manufacturing at its Irvine, California facility in the United States, and suspended release of product from the facility pending completion of an open manufacturing investigation. In July 2021, the FDA initiated an establishment inspection at the facility. On August&#160;18, 2021, the Company issued field alert reports to the FDA for products manufactured at the Irvine facility and put Irvine manufactured products in Teva&#8217;s distribution center on hold. On August&#160;20, 2021, the FDA completed its inspection and issued a Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-483</div> to the Irvine facility with ten observations and, on December&#160;17, 2021, the FDA notified the Company that the inspection classification of this site is &#8220;official action indicated&#8221; (&#8220;OAI&#8221;). Teva began working diligently to address the FDA&#8217;s concerns in a manner consistent with current good manufacturing practice (&#8220;CGMP&#8221;) requirements, and was in discussions with the FDA Drug Shortage Staff (DSS) and FDA Office of Manufacturing Quality (OMQ) to recommence distribution, release and manufacture of certain medically necessary products from the site under defined controls and protocols. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;22, 2022, the Company announced its decision to permanently cease all manufacturing activities and to close the site, and to transfer certain products to other facilities. Teva will remain in contact with FDA regarding the status of the Irvine, California site to ensure that the Company continues to comply with all relevant CGMP requirements, particularly those involved with product transfers to other sites within the Teva network. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If Teva is unable to address FDA inspection issues satisfactorily, it could be subject to additional regulatory actions. Teva has considered these developments and, during the six months ended June&#160;30, 2022, recorded $73&#160;million costs in its financial statements related to this matter. Teva will continue to assess potential financial implications, including loss of revenues, impairments, inventory write offs, customer penalties, costs of additional remediation and/or FDA enforcement actions. </div><br/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_OtherExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Expenses [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_OtherExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684986136448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings (Loss) per Share</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 13 &#8211; Earnings (Loss) per share: </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic earnings and loss per share are computed by dividing net income (loss) attributable to Teva&#8217;s ordinary shareholders by the weighted average number of ordinary shares outstanding, including fully vested restricted share units (&#8220;RSUs&#8221;) and performance share units (&#8220;PSUs&#8221;) during the period, net of treasury shares. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In computing diluted loss per share for the three months ended June&#160;30, 2022, no account was taken of the potential dilution that could occur upon the exercise of options and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> RSUs and PSUs granted under employee stock compensation plans, and convertible senior debentures, since they had an anti-dilutive effect on loss per share. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In computing diluted earnings per share for the three months ended June&#160;30, 2021, basic earnings per share were adjusted to take into account the potential dilution that could occur upon the exercise of options and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> RSUs granted under employee stock compensation plans. No account was taken of the potential dilution by the convertible senior debentures, since they had an anti-dilutive effect on earnings per share. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In computing diluted loss per share for the six months ended June&#160;30, 2022, no account was taken of the potential dilution that could occur upon the exercise of options and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> RSUs and PSUs granted under employee stock compensation plans, and convertible senior debentures, since they had an anti-dilutive effect on loss per share. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In computing diluted earnings per share for the six months ended June&#160;30, 2021, basic earnings per share were adjusted to take into account the potential dilution that could occur upon the exercise of options and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> RSUs granted under employee stock compensation plans. No account was taken of the potential dilution by the convertible senior debentures, since they had an anti-dilutive effect on earnings per share.</div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The weighted average diluted shares outstanding used for the fully diluted share calculations for the three months ended June&#160;30, 2022, and 2021, were 1,110 and 1,109 shares, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The weighted average diluted shares outstanding used for the fully diluted share calculations for the six months ended June&#160;30, 2022, and 2021, were 1,109 and 1,108 shares, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted loss per share was $0.21 for the three months ended June&#160;30, 2022, compared to basic and diluted earnings per share of $0.19 for the three months ended June&#160;30, 2021. Basic and diluted loss per share was $1.07 for the six months ended June&#160;30, 2022, compared to basic and diluted earnings per share of $0.26 for the six months ended June&#160;30, 2021. </div><br/></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684986165248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated other comprehensive income (loss)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 14 &#8211; Accumulated other comprehensive income (loss): </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of, and changes within, accumulated other comprehensive income (loss) attributable to Teva are presented in the table below: </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net&#160;Unrealized&#160;Gains&#160;(Losses)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Benefit&#160;Plans</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign<br/> currency<br/> translation<br/> adjustments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Derivative<br/> financial<br/> instruments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Actuarial&#160;gains<br/> (losses)&#160;and<br/> prior&#160;service<br/> (costs)&#160;credits</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2021, net of taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,274</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(324</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(85</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,683</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income (loss) before reclassifications</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(127</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(127</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts reclassified to the statements of income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Net other comprehensive income (loss) before tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(127</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(113</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Corresponding income tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Net other comprehensive income (loss) after tax*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(132</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(118</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of June&#160;30, 2022, net of taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,406</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(310</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(85</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,801</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="width: 26%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family:Times New Roman,Times,serif;;display:inline;">Amounts do not include a $150&#160;million loss from foreign currency translation adjustments attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests.&#160;</div></div> </td> </tr> </table> <div style="font-family:Times New Roman,Times,serif;;display:inline;"> </div> <div style="font-family:Times New Roman,Times,serif;;display:inline;"> </div> <div style="font-family:Times New Roman,Times,serif;;display:inline;"> </div> <div style="font-family:Times New Roman,Times,serif;;display:inline;"> </div> <div style="font-family:Times New Roman,Times,serif;;display:inline;"> </div> <div style="font-family:Times New Roman,Times,serif;;display:inline;"> </div> <div style="font-family:Times New Roman,Times,serif;;display:inline;"> </div> <div style="font-family:Times New Roman,Times,serif;;display:inline;"> </div> <div style="clear: both; max-height: 0px;"/> <div style="font-family:Times New Roman,Times,serif;;display:inline;"> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net&#160;Unrealized&#160;Gains&#160;(Losses)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Benefit&#160;Plans</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign<br/> currency<br/> translation<br/> adjustments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Derivative<br/> financial<br/> instruments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Actuarial&#160;gains<br/> (losses)&#160;and<br/> prior&#160;service<br/> (costs)&#160;credits</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2020, net of taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,919</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(363</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(117</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,399</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income (loss) before reclassifications</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(77</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(77</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts reclassified to the statements of income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Net other comprehensive income (loss) before tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(77</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(58</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Corresponding income tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Net other comprehensive income (loss) after tax*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(62</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(47</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of June&#160;30, 2021, net of taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,981</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(349</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(116</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,446</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="width: 26%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Amounts do not include a $68&#160;million loss from foreign currency translation adjustments attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests. </div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684983032800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segments</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 15 &#8211; Segments: </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva operates its business and reports its financial results in three segments: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">North America segment, which includes the United States and Canada. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(b)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Europe segment, which includes the European Union, the United Kingdom and certain other European countries. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(c)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International Markets segment, which includes all countries other than those in the North America and Europe segments. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In addition to these three segments, Teva has other sources of revenues, primarily the sale of APIs to third parties, certain contract manufacturing services and an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licensing</div> platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva&#8217;s<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chief Executive Officer (&#8220;CEO&#8221;), who is the chief operating decision maker (&#8220;CODM&#8221;), reviews financial information prepared on a consolidated basis, accompanied by disaggregated information about revenues and contributed profit by the </div>three<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> identified reportable segments, namely North America, Europe and International Markets, to make decisions about resources to be allocated to the segments and assess their performance.</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit is comprised of gross profit for the segment less R&amp;D expenses, S&amp;M expenses, G&amp;A expenses and other income related to the segment. Segment profit does not include amortization and certain other items. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva manages its assets on a company basis, not by segments, as many of its assets are shared or commingled. Teva&#8217;s CODM does not regularly review asset information by reportable segment and, therefore, Teva does not report asset information by reportable segment. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Teva&#8217;s</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;CEO may review its strategy and organizational structure from time to time. Any changes in strategy may lead to a reevaluation of the Company&#8217;s segments and goodwill allocation to reporting units, as well as fair value attributable to its reporting units. See note 3 and note 6. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>  <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></div></div></div></div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 10pt; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>Seg<div style="font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 10pt; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ment </div></div></div></div></div><div style="font-size: 8pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">information:</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North&#160;America</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International&#160;Markets</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,904</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,171</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">454</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,010</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">703</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">242</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">147</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">56</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">256</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">196</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">99</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">127</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">63</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">481</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">389</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">95</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North&#160;America</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International&#160;Markets</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,943</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,184</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">485</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,040</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">661</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">270</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">162</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">63</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">255</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">209</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">105</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">106</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">47</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">521</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">343</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">123</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#167; Represents an amount less than $0.5&#160;million. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six months ended June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North&#160;America</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International&#160;Markets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,641</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,327</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">946</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,899</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,397</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">528</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">289</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">114</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">39</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">501</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">393</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">196</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">239</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">122</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(41</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">883</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">769</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">274</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six months ended June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North&#160;America</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International&#160;Markets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,932</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,398</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">975</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,114</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,349</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">530</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">322</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">129</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">483</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">424</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">201</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">218</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">117</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">51</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,098</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">680</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">245</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents a reconciliation of Teva&#8217;s segment profits to its consolidated operating income (loss) and to consolidated income (loss) before income taxes for the three and six months ended June&#160;30, 2022 and 2021: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>  <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended </div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six months ended </div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $&#160;in millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $&#160;in millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-size: 0px;">
<td style="width: 82%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 0.5%; vertical-align: bottom;"/>
<td style="width: 0.25%; vertical-align: bottom;"/>
<td style="width: 0.125%; vertical-align: bottom;"/>
<td style="width: 0.0625%; vertical-align: bottom;"/>
<td style="width: 0.03125%; vertical-align: bottom;"/>
<td style="width: 0.015625%; vertical-align: bottom;"/>
<td style="width: 0.015625%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">North America profit</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div>&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">481</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">521</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">883</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,098</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Europe profit</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">389</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">343</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">769</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">680</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International Markets profit</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">95</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">123</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">274</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">245</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr>
<td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total reportable segments profit</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">964</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">987</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,926</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,023</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Profit of other activities</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">55</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">47</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">107</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">87</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr>
<td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total segments profit</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;">1,019</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,034</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,032</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,111</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts not allocated to segments:</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; padding: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; padding: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; padding: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; padding: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; padding: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; padding: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; padding: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; padding: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">212</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">173</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">412</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">414</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets impairments, restructuring and other items</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">118</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">28</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">246</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">165</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill impairment</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">745</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; width: 4%;;text-align:right;"><div style="line-height: normal;">&#8212;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">745</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets impairments</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">51</div><br/></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">195</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">274</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legal settlements and loss contingencies</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">729</div><br/></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div><br/></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,854</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">110</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other unallocated amounts</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">113</div><br/></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">50</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">240</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">132</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr>
<td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated operating income (loss)</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(949</div><br/></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div><br/></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">582</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,662</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,015</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr>
<td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial expenses, net</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">211</div><br/></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">274</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">468</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">564</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr>
<td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated income (loss) before income taxes</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1,160</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div>&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">308</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,131</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">451</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr>
<td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 1.25pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 1.25pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 1.25pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 1.25pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 1.25pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">b. Segment revenues by major products and activities: </div></div></div></div> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables present revenues by major products and activities for the three and six months ended June&#160;30, 2022 and 2021: </div></div></div>  <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 81%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North America</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months&#160;ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 81%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic products</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">1,026</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">951</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AJOVY</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">49</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">46</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AUSTEDO</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">204</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">174</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">BENDEKA&#174;/TREANDA&#174;<br/></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">83</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">106</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">152</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Anda</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">308</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">316</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">139</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,904</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,943</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North America</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six&#160;months&#160;ended<br/>June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic products</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,925</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,004</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AJOVY</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">86</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">77</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AUSTEDO</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">358</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">320</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BENDEKA/TREANDA</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">165</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">197</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">180</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">315</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Anda</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">650</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">605</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">278</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">414</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,641</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,932</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 1px;">
<td/></tr></table>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 82%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months&#160;ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 82%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic products</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">873</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">878</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AJOVY</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Respiratory products</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">65</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">85</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">131</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">102</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,171</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,184</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six&#160;months&#160;ended<br/> June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 80%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic products</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,749</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,742</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 80%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AJOVY</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 80%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">144</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">201</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 80%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Respiratory products</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">137</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">179</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 80%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">238</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">242</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 80%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; width: 80%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,327</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,398</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 80%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 84%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International markets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months&#160;ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic products</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">394</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">407</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AJOVY</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">65</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">454</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">485</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 84%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International markets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six&#160;months&#160;ended<br/> June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic products</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">782</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">799</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AJOVY</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">128</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">150</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">946</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">975</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684986110128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurement<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair value measurement</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 16 &#8211; Fair value measurement: </div></div></div></div> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial items carried at fair value on a recurring basis as of June&#160;30, 2022 and December&#160;31, 2021 are classified in the tables below in one of the three categories of fair value levels: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money markets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">451</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">451</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, deposits and other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,607</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,607</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in securities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity securities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivatives:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asset derivatives&#8212;options and forward contracts</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liability derivatives:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options and forward contracts</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(37</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(37</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bifurcated embedded derivatives</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(205</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(205</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,106</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(204</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,934</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money markets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">220</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">220</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, deposits and other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,945</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,945</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in securities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity securities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivatives:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asset derivatives&#8212;options and forward contracts</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liability derivatives:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options and forward contracts</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(23</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(23</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bifurcated embedded derivatives</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(176</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(176</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,222</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(175</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,054</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="width: 26%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#167;</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than $0.5&#160;million. </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">*</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration represents liabilities recorded at fair value in connection with acquisitions. </div></div></div> </td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva determined the fair value of the liabilities for the contingent consideration based on a probability-weighted discounted cash flow analysis. This fair value measurement is based on significant unobservable inputs in the market and thus represents a Level&#160;3 measurement within the fair value hierarchy. The fair value of the contingent consideration is based on several factors, such as: the cash flows projected from the success of unapproved product candidates; the probability of success of product candidates, including risks associated with uncertainty regarding achievement and payment of milestone events; the time and resources needed to complete the development and approval of product candidates; the life of the potential commercialized products and associated risks of obtaining regulatory approvals in the United States and Europe, and the risk adjusted discount rate for fair value measurement. A probability of success factor of 100% was used in the fair value calculation to reflect inherent regulatory and commercial risk of the contingent payments and IPR&amp;D. The discount rate applied ranged from 8.3% to 11.2%. The weighted average discount rate, calculated based on the relative fair value of Teva&#8217;s contingent consideration liabilities, was 8.8%. The contingent</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">consideration is evaluated quarterly, or more frequently, if circumstances dictate. Changes in the fair value of contingent consideration are recorded in consolidated statements of income. Significant changes in unobservable inputs, mainly the probability of success and cash flows projected, could result in material changes to the contingent consideration liabilities. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"> <div style="top: 0px; letter-spacing: 0px; font-family: 'Times New Roman'; font-size: 10pt; display: inline;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the activity for those financial assets and liabilities where fair value measurements are estimated utilizing Level&#160;3 inputs: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six&#160;months<br/>ended&#160;June&#160;30,<br/>2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six&#160;months<br/>ended<br/>June&#160;30,<br/>2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value at the beginning of the period</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(175</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(258</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Redemption of debt securities</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bifurcated embedded derivatives</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to provisions for contingent consideration:</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Actavis Generics transaction</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(92</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Eagle transaction</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Settlement of contingent consideration:</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Actavis Generics transaction</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Eagle transaction</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Additional contingent consideration resulting from Novetide acquisition*</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 75%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value at the end of the period</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(204</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(204</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 75%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </div> </div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> </div> <div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="width: 26%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#167;</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than $0.5&#160;million. </div></div></div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">In January 2022, Teva acquired 100% ownership of Novetide Ltd. (&#8220;Novetide&#8221;), which was previously accounted for as &#8220;investment in associated <div style="display:inline;">companies.&#8221; This</div>&#160;transaction was accounted for as a business combination. Total consideration for the transaction included cash and certain contingent royalty payments through 2034. As part of the transaction, Teva recognized a gain under &#8220;Share in (profits) losses of associated companies, net&#8221;, reflecting the difference between the book value of its investment in Novetide and its fair value as of the date Teva completed its acquisition. </div></div> </td> </tr> </table>  <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments not measured at fair value </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments measured on a basis other than fair value mostly consist of senior notes and convertible senior debentures (see note 7) and are presented in the table below in terms of fair value (level 1 inputs): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated fair value*</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes and sustainability-linked senior notes included under senior notes and loans</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,481</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,477</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes and convertible senior debentures included under short-term debt</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,702</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,426</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,183</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,903</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="width: 26%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value was estimated based on quoted market prices. </div></div> </td> </tr> </table>  <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684986003456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently adopted and issued accounting pronouncements</a></td>
<td class="text"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recently adopted accounting pronouncements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In August 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> &#8220;Debt &#8211; Debt with Conversion and Other Options (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20)</div> and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211; 40).&#8221; This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. The amendments to this guidance are effective for fiscal years beginning after December&#160;15, 2021, and interim periods within those fiscal years. The adoption of this guidance did not have a significant impact on the Company&#8217;s consolidated financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In March 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-04</div> &#8220;Reference Rate Reform (Topic 848)&#8212;Facilitation of the Effects of Reference Rate Reform on Financial Reporting.&#8221; This guidance provides optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The guidance applies only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. This guidance is effective for all entities as of March&#160;12, 2020 through December&#160;31, 2022. There was no material impact to the Company&#8217;s consolidated financial statements for the period ended June&#160;30, 2022 as a result of adopting this standard update. The Company has completed negotiations to transform the facility base rate of its securitization program and evaluated the potential impact of the replacement of the LIBOR benchmark on its interest rate risk management activities. The adoption of this guidance did not have a material impact on the Company&#8217;s consolidated financial results of operations, financial position or cash flows. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock', window );">Recently issued accounting pronouncements, not yet adopted</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recently issued accounting pronouncements, not yet adopted </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In November 2021, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2021-10</div> &#8220;Government Assistance (Topic 832)&#8221;, which requires annual disclosures that increase the transparency of transactions involving government grants, including (1)&#160;the types of transactions, (2)&#160;the accounting for those transactions, and (3)&#160;the effect of those transactions on an entity&#8217;s financial statements. The amendments in this update are effective for financial statements issued for annual periods beginning after December&#160;15, 2021. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In October 2021, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2021-08</div> &#8220;Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#8221;, which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers. The guidance will result in the acquirer recognizing contract assets and contract liabilities at the same amounts recorded by the acquiree. The guidance should be applied prospectively to acquisitions occurring on or after the effective date. The guidance is effective for fiscal years beginning after December&#160;15, 2022, including interim periods within those fiscal years. Early adoption is permitted, including in interim periods, for any financial statements that have not yet been issued. Adoption in an interim period other than the first fiscal quarter requires an entity to apply the new guidance to all prior business combinations that have occurred since the beginning of the annual period in which the new guidance is adopted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements. </div><br/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recently issued accounting pronouncements not yet adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684986119888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock', window );">Summary of Major Classes of Assets and Liabilities Included as Held for Sale</a></td>
<td class="text">The table below summarizes all Teva assets and liabilities included as held for sale as of June&#160;30, 2022 and December&#160;31, 2021: <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventories</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property, plant and equipment, net and others</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">86</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments of assets held for sale to fair value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(30</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(76</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets of the disposal group classified as held for sale in the consolidated balance sheets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities of the disposal group classified as held for sale in the consolidated balance sheets, recorded under accrued expenses and other long-term liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(43</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Assets And Liabilities Held For Sale [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684985993872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from contracts with customers (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Summary of disaggregates revenues by major revenue streams</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table disaggregates Teva&#8217;s revenues by major revenue streams. For additional information on disaggregation of revenues, see note 15. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="18" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended June&#160;30, 2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North<br/>America</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International<br/>Markets</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other<br/>activities</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="18" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sale of goods</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,538</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,127</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">448</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">176</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,289</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing arrangements</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">54</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">308</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">318</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9</td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">81</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">106</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,904</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,171</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">454</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">257</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,786</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#167; Represents an amount less t<div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">han $0.5&#160;</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">million.&#160; &#160;&#160;</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="18" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended June&#160;30, 2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North<br/>America</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International<br/>Markets</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other<br/>activities</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="18" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sale of goods</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,621</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,185</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">462</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">198</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,465</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing arrangements</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">316</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">330</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2)</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">99</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">96</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,943</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,184</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">485</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">298</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,910</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#167; Represents an amount less than $0.5&#160;million. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six months ended June&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North<br/> America</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International<br/> Markets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other<br/> activities</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sale of goods</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,915</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,261</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">894</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">356</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,425</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing arrangements</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">74</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">110</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">650</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">677</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">39</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">175</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">234</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,641</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,327</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">946</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">532</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,447</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#167; Represents an amount less than $0.5&#160;million. </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="18" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six months ended June&#160;30, 2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North<br/>America</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International<br/>Markets</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other<br/>activities</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="18" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sale of goods</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,289</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,363</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">902</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">374</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,928</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing arrangements</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">68</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">605</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">639</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2)</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">210</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">257</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,932</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,398</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">975</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">587</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,892</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#167; Represents an amount less than $0.5&#160;million. </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_SalesReservesAndAllowancesCurrentTableTextBlock', window );">Summary of Sales Reserves and Allowances</a></td>
<td class="text">The changes in SR&amp;A for third-party sales for the six months ended June&#160;30, 2022 and 2021 were as follows:
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 37%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="26" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sales Reserves and Allowances</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reserves<br/>included in<br/>Accounts<br/>Receivable,&#160;net</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Rebates</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Medicaid and<br/>other<br/>governmental<br/>allowances</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Chargebacks</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Returns</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total&#160;reserves<br/>included&#160;in&#160;SR&amp;A</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="30" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">68</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,655</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">854</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,085</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">535</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">112</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,241</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,309</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions related to sales made in current year</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">181</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,889</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">446</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3,836</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">147</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">152</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,470</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,651</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions related to sales made in prior periods</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(102</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(8</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(16</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(2</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(108</td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(108</td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Credits and payments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(185</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1,901</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(497</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(3,922</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(211</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(145</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,676</td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,861</td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Translation differences</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(33</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(6</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(7</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(4</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(47</td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(47</td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at June&#160;30, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">64</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,508</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">817</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">984</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">451</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">120</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,880</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,944</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 37%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reserves<br/> included in<br/> Accounts<br/> Receivable,&#160;net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Rebates</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Medicaid and<br/> other<br/> governmental<br/> allowances</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Chargebacks</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Returns</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total&#160;reserves<br/> included&#160;in&#160;SR&amp;A</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="30" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.$ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,054</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">828</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,108</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">686</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">148</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,824</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,904</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions related to sales made in current year</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">192</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,139</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">391</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,995</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">143</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">177</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,845</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,037</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions related to sales made in prior periods</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(82</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(35</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(40</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(23</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(191</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(196</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Credits and payments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(196</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,355</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(362</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,934</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(186</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(176</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,013</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,209</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Translation differences</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at June&#160;30, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">71</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,748</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">819</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,157</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">602</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">127</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,453</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,524</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_SalesReservesAndAllowancesCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of sales reserves and allowances current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_SalesReservesAndAllowancesCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684983064720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Summary of Inventories</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventories, net of reserves, consisted of the following:</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finished products</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,875</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,932</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Raw and packaging materials</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,346</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,136</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Products in process</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">624</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">587</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Materials in transit and payments on account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">204</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">163</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,049</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,818</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684986110128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Identifiable Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Summary of Identifiable Intangible Assets</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Identifiable intangible assets consisted of the following:</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 54%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross&#160;carrying&#160;amount&#160;net</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">of impairment</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">amortization</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net carrying amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="22" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product rights</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,987</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,815</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,181</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,318</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,806</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,497</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trade names</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">570</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">590</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">211</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">198</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">359</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">392</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In process research and development</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">535</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">577</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">535</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">577</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,092</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,982</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,392</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,516</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,466</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684983039968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Summary of Changes in the Carrying Amount of Goodwill by Segment</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The changes in the carrying amount of goodwill for the period ended June&#160;30, 2022 were as follows:</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North&#160;America</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International<br/>Markets</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2021 (1)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,474</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,544</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,328</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,694</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,040</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes during the period:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill impairment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(479</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(266</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(745</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill acquired</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Translation differences</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(320</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16</td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(130</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(470</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of June&#160;30, 2022 (1)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,470</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,224</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,833</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,310</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,837</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated goodwill impairment as of June&#160;30, 2022 and December&#160;31, 2021 was approximately $26.3&#160;billion and $25.6&#160;billion, respectively. </div><br/></div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684983051872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt obligations (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShortTermDebtTextBlock', window );">Schedule of Short-term Debt</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a. Short-term debt:</div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 89%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average&#160;interest<br/>rate as of June&#160;30, 2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Maturity</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Convertible senior debentures</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.25</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2026</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current maturities of long-term liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,696</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,403</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total short-term debt</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,719</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,426</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Required Annual Principal Payments of Long-term Debt, Excluding Debt Issuance Cost</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">b. Long-term debt:</div></div><br/></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 87%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average&#160;interest<br/>rate as of June&#160;30, 2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Maturity</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR 1,500&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1.13</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2024</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">653</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">708</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: pre-wrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: pre-wrap;;display:inline;">Sustainability-linked senior notes EUR 1,500&#160;million&#160;(1)<div style="letter-spacing: 0px; top: 0px; white-space: pre-wrap;;display:inline;">&#160;</div>(*)</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">4.38</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">2030</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">1,566</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">1,699</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR 1,300&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1.25</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2023</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">616</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">670</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sustainability-linked senior notes EUR 1,100&#160;million&#160;(2)<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>(*)</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">3.75</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">2027</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">1,150</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">1,246</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR 1,000&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">6.00</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2025</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1,043</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1,134</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR 900&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">4.50</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">2025</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">942</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">1,020</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR 750&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1.63</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2028</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">779</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">844</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR 700&#160;million (3)</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">3.25</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">2022</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">307</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR 700&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1.88</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2027</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">729</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">792</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 3,500&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">3.15</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">2026</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">3,496</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">3,496</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 3,000&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2.80</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2023</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1,453</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1,453</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 2,000&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">4.10</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">2046</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">1,986</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">1,986</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 1,250&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">6.00</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2024</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1,250</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1,250</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 1,250&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">6.75</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">2028</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">1,250</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">1,250</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 1,000&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">7.13</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2025</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1,000</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1,000</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sustainability-linked senior notes USD 1,000&#160;million&#160;(2)<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>(*)</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">4.75</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">2027</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">1,000</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">1,000</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sustainability-linked senior notes USD 1,000&#160;million&#160;(1)<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>(*)</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">5.13</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2029</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1,000</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1,000</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 844&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">2.95</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">2022</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">715</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">715</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 789&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">6.15</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2036</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">783</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">783</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes CHF 350&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">0.50</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">2022</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">366</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">382</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes CHF 350&#160;million</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2025</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">367</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">383</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total senior notes</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">22,144</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">23,118</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long-term debt</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less current maturities</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(1,696</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(1,403</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less debt issuance costs</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(87</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(100</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total senior notes and loa<div style="letter-spacing: 0px; top: 0px;;display:inline;">n</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;;text-align:right;">20,363</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;;text-align:right;">21,617</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684985888592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments and hedging activities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of Classification and Fair Values of Derivative Instruments</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the classification and fair values of derivative instruments:</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Not designated as hedging</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">instruments</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">June&#160;30,</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31,</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td colspan="5" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Reported under</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asset derivatives:</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets:</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Option and forward contracts</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liability derivatives:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Option and forward contracts</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(37</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(23</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Information Regarding The Location And Amount Of Pretax (Gains) Losses Of Derivatives Designated In Fair Value Or Cash Flow Hedging Relationships</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The table below provides information regarding the location and amount of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> (gains) losses from derivatives not designated as hedging instruments:</div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial&#160;expenses,&#160;net</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net revenues</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months&#160;ended,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Reported under</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Line items in which effects of hedges are recorded</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">211</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">274</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,786</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,910</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Option and forward contracts (1)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(38</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Option and forward contracts economic hedge (2)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr></table>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial&#160;expenses,&#160;net</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net revenues</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six months ended,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six months ended,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Reported under</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 11pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Line items in which effects of hedges are recorded</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">468</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">564</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,447</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,892</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Option and forward contracts (1)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(43</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(43</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Option and forward contracts economic hedge (2)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(35</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Teva uses foreign exchange contracts (mainly option and forward contracts) to hedge balance sheet items from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, Teva recognizes gains or losses that offset the revaluation of the balance sheet items also recorded under financial expenses, net.</div></td></tr></table><div style="clear: both; max-height: 0px;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on projected revenues and expenses recorded in euro, the Swiss franc, the Japanese yen, the British pound, the Russian ruble, the Canadian dollar and some other currencies to protect its projected operating results for 2022 and 2021. These derivative instruments do not meet the criteria for hedge accounting, however, they are accounted for as an economic hedge. These derivative instruments, which may include hedging transactions against future projected revenues and expenses, are<br/></div> </div></div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. In the first six months of 2022, the positive impact from these derivatives recognized under revenues was $35&#160;million. In the first six months of 2021, the positive impact from these derivatives recognized under revenues was $13&#160;million. Changes in the fair value of the derivative instruments are recognized in the same line item in the statements of income as the underlying exposure being hedged. The cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows. </div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for cash flow hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684980070688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other assets impairments, restructuring and other items (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Other Assets Impairments, Restructuring and Other Items</a></td>
<td class="text"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months&#160;ended<br/>June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six&#160;months&#160;ended<br/>June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairments of long-lived tangible assets (1)</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">61</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(19</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restructuring</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13</td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">92</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%; line-height: 11pt; font-size: 11pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size:11pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 11pt;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom; width: 5%; line-height: 11pt; font-size: 11pt;"><div style="font-size:11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size:11pt;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;">118</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size:11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 5%; line-height: 11pt; font-size: 11pt;"><div style="font-size:11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size:11pt;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;">28</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size:11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%; line-height: 11pt; font-size: 11pt;"><div style="font-size:11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size:11pt;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;">246</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size:11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 5%; line-height: 11pt; font-size: 11pt;"><div style="font-size:11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size:11pt;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;">165</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"><div style="font-size:11pt;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="width: 26%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Including impairments related to exit and disposal activities. </div></div> </td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ScheduleOfRestructuringChargesTableTextBlock', window );">Summary of Restructuring Plan Including Costs Related to Exit and Disposal</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables provide the components of restructuring costs: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months&#160;ended&#160;June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restructuring</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee termination</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(19</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six&#160;months&#160;ended&#160;June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restructuring</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee termination</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">63</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">61</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">92</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Summary of Restructuring Accruals</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides the components of and changes in the Company&#8217;s restructuring accruals: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employee&#160;termination<br/> costs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of January&#160;1, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(131</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(138</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provision</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(63</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(29</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(92</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Utilization and other*</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">74</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">103</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of June&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(120</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(127</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"/>
<td colspan="4" style="height: 12pt;"/>
<td colspan="4" style="height: 12pt;"/>
<td colspan="4" style="height: 12pt;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employee&#160;termination<br/> costs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of January&#160;1, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(115</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(122</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provision</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(61</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(69</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Utilization and other*</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">56</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">64</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of June&#160;30, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(120</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(127</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="width: 26%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">*</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Includes adjustments for foreign currency translation. </div></div></div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ScheduleOfRestructuringChargesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Restructuring Charges [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ScheduleOfRestructuringChargesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684986147728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated other comprehensive income (loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Accumulated Other Comprehensive Income/(Loss) (Net of Tax)</a></td>
<td class="text">The components of, and changes within, accumulated other comprehensive income (loss) attributable to Teva are presented in the table below: <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net&#160;Unrealized&#160;Gains&#160;(Losses)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Benefit&#160;Plans</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign<br/> currency<br/> translation<br/> adjustments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Derivative<br/> financial<br/> instruments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Actuarial&#160;gains<br/> (losses)&#160;and<br/> prior&#160;service<br/> (costs)&#160;credits</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2021, net of taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,274</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(324</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(85</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,683</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income (loss) before reclassifications</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(127</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(127</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts reclassified to the statements of income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Net other comprehensive income (loss) before tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(127</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(113</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Corresponding income tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Net other comprehensive income (loss) after tax*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(132</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(118</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of June&#160;30, 2022, net of taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,406</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(310</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(85</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,801</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="width: 26%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family:Times New Roman,Times,serif;;display:inline;">Amounts do not include a $150&#160;million loss from foreign currency translation adjustments attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests.&#160;</div></div> </td> </tr> </table> <div style="font-family:Times New Roman,Times,serif;;display:inline;"> </div> <div style="font-family:Times New Roman,Times,serif;;display:inline;"> </div> <div style="font-family:Times New Roman,Times,serif;;display:inline;"> </div> <div style="font-family:Times New Roman,Times,serif;;display:inline;"> </div> <div style="font-family:Times New Roman,Times,serif;;display:inline;"> </div> <div style="font-family:Times New Roman,Times,serif;;display:inline;"> </div> <div style="font-family:Times New Roman,Times,serif;;display:inline;"> </div> <div style="font-family:Times New Roman,Times,serif;;display:inline;"> </div> <div style="clear: both; max-height: 0px;"/> <div style="font-family:Times New Roman,Times,serif;;display:inline;"> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net&#160;Unrealized&#160;Gains&#160;(Losses)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Benefit&#160;Plans</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign<br/> currency<br/> translation<br/> adjustments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Derivative<br/> financial<br/> instruments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Actuarial&#160;gains<br/> (losses)&#160;and<br/> prior&#160;service<br/> (costs)&#160;credits</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2020, net of taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,919</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(363</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(117</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,399</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income (loss) before reclassifications</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(77</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(77</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts reclassified to the statements of income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Net other comprehensive income (loss) before tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(77</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(58</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Corresponding income tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Net other comprehensive income (loss) after tax*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(62</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(47</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of June&#160;30, 2021, net of taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,981</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(349</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(116</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,446</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="width: 26%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Amounts do not include a $68&#160;million loss from foreign currency translation adjustments attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests. </div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684980070688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Summary of Segment Profit</a></td>
<td class="text"><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></div></div></div></div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 10pt; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>Seg<div style="font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 10pt; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ment </div></div></div></div></div><div style="font-size: 8pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">information:</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North&#160;America</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International&#160;Markets</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,904</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,171</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">454</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,010</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">703</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">242</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">147</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">56</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">256</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">196</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">99</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">127</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">63</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">481</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">389</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">95</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North&#160;America</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International&#160;Markets</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,943</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,184</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">485</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,040</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">661</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">270</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">162</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">63</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">255</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">209</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">105</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">106</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">47</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">521</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">343</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">123</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#167; Represents an amount less than $0.5&#160;million. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six months ended June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North&#160;America</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International&#160;Markets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,641</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,327</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">946</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,899</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,397</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">528</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">289</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">114</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">39</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">501</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">393</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">196</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">239</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">122</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(41</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">883</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">769</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">274</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six months ended June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North&#160;America</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International&#160;Markets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,932</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,398</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">975</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,114</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,349</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">530</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">322</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">129</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">483</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">424</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">201</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">218</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">117</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">51</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,098</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">680</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">245</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock', window );">Schedule Of Consolidated Income Before Income Tax</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents a reconciliation of Teva&#8217;s segment profits to its consolidated operating income (loss) and to consolidated income (loss) before income taxes for the three and six months ended June&#160;30, 2022 and 2021: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended </div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six months ended </div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $&#160;in millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $&#160;in millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-size: 0px;">
<td style="width: 82%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 0.5%; vertical-align: bottom;"/>
<td style="width: 0.25%; vertical-align: bottom;"/>
<td style="width: 0.125%; vertical-align: bottom;"/>
<td style="width: 0.0625%; vertical-align: bottom;"/>
<td style="width: 0.03125%; vertical-align: bottom;"/>
<td style="width: 0.015625%; vertical-align: bottom;"/>
<td style="width: 0.015625%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">North America profit</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div>&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">481</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">521</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">883</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,098</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Europe profit</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">389</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">343</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">769</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">680</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International Markets profit</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">95</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">123</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">274</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">245</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr>
<td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total reportable segments profit</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">964</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">987</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,926</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,023</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Profit of other activities</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">55</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">47</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">107</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">87</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr>
<td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total segments profit</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;">1,019</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,034</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,032</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,111</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts not allocated to segments:</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; padding: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; padding: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; padding: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; padding: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; padding: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; padding: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; padding: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; padding: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">212</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">173</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">412</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">414</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets impairments, restructuring and other items</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">118</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">28</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">246</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">165</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill impairment</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">745</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; width: 4%;;text-align:right;"><div style="line-height: normal;">&#8212;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">745</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets impairments</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">51</div><br/></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">195</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">274</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legal settlements and loss contingencies</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">729</div><br/></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div><br/></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,854</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">110</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other unallocated amounts</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">113</div><br/></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">50</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">240</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">132</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr>
<td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated operating income (loss)</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(949</div><br/></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div><br/></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">582</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,662</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,015</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr>
<td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial expenses, net</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">211</div><br/></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">274</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">468</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">564</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr>
<td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated income (loss) before income taxes</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1,160</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div>&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">308</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,131</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">451</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr>
<td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 1.25pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 1.25pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 1.25pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 1.25pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 1.25pt; line-height: 1pt; font-size: 1pt;;text-align:right;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of Net Sales by Product Line</a></td>
<td class="text"> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 81%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North America</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months&#160;ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 81%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic products</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">1,026</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">951</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AJOVY</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">49</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">46</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AUSTEDO</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">204</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">174</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">BENDEKA&#174;/TREANDA&#174;<br/></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">83</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">106</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">152</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Anda</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">308</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">316</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">139</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,904</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,943</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North America</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six&#160;months&#160;ended<br/>June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic products</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,925</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,004</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AJOVY</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">86</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">77</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AUSTEDO</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">358</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">320</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BENDEKA/TREANDA</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">165</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">197</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">180</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">315</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Anda</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">650</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">605</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">278</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">414</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,641</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,932</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 1px;">
<td/></tr></table>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 82%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months&#160;ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 82%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic products</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">873</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">878</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AJOVY</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Respiratory products</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">65</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">85</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">131</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">102</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,171</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,184</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six&#160;months&#160;ended<br/> June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 80%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic products</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,749</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,742</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 80%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AJOVY</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 80%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">144</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">201</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 80%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Respiratory products</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">137</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">179</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 80%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">238</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">242</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 80%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; width: 80%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,327</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,398</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 80%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 84%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International markets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months&#160;ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic products</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">394</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">407</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AJOVY</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">65</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">454</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">485</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 84%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International markets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six&#160;months&#160;ended<br/> June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic products</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">782</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">799</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AJOVY</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">128</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">150</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">946</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">975</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of consolidated income before income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684980066464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Financial Items Carried at Fair Value</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial items carried at fair value on a recurring basis as of June&#160;30, 2022 and December&#160;31, 2021 are classified in the tables below in one of the three categories of fair value levels: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money markets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">451</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">451</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, deposits and other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,607</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,607</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in securities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity securities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivatives:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asset derivatives&#8212;options and forward contracts</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liability derivatives:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options and forward contracts</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(37</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(37</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bifurcated embedded derivatives</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(205</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(205</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,106</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(204</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,934</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money markets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">220</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">220</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, deposits and other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,945</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,945</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in securities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity securities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivatives:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asset derivatives&#8212;options and forward contracts</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liability derivatives:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options and forward contracts</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(23</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(23</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bifurcated embedded derivatives</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(176</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(176</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,222</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(175</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,054</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="width: 26%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#167;</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than $0.5&#160;million. </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">*</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration represents liabilities recorded at fair value in connection with acquisitions. </div></div></div> </td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs</a></td>
<td class="text">The following table summarizes the activity for those financial assets and liabilities where fair value measurements are estimated utilizing Level&#160;3 inputs:
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six&#160;months<br/>ended&#160;June&#160;30,<br/>2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six&#160;months<br/>ended<br/>June&#160;30,<br/>2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value at the beginning of the period</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(175</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(258</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Redemption of debt securities</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bifurcated embedded derivatives</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to provisions for contingent consideration:</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Actavis Generics transaction</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(92</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Eagle transaction</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Settlement of contingent consideration:</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Actavis Generics transaction</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Eagle transaction</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Additional contingent consideration resulting from Novetide acquisition*</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 75%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value at the end of the period</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(204</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(204</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 75%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#167;</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than $0.5&#160;million. </div></div></div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">In January 2022, Teva acquired 100% ownership of Novetide Ltd. (&#8220;Novetide&#8221;), which was previously accounted for as &#8220;investment in associated <div style="display:inline;">companies.&#8221; This</div>&#160;transaction was accounted for as a business combination. Total consideration for the transaction included cash and certain contingent royalty payments through 2034. As part of the transaction, Teva recognized a gain under &#8220;Share in (profits) losses of associated companies, net&#8221;, reflecting the difference between the book value of its investment in Novetide and its fair value as of the date Teva completed its acquisition. </div></div> </td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Financial Instrument Measured on a Basis Other Than Fair Value</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments measured on a basis other than fair value mostly consist of senior notes and convertible senior debentures (see note 7) and are presented in the table below in terms of fair value (level 1 inputs): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated fair value*</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes and sustainability-linked senior notes included under senior notes and loans</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,481</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,477</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes and convertible senior debentures included under short-term debt</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,702</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,426</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,183</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,903</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="width: 26%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value was estimated based on quoted market prices. </div></div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684977352928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Transactions - Other Transactions - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 08, 2018</div></th>
<th class="th"><div>May 12, 2017</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=teva_AlderMember', window );">Alder [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems', window );"><strong>Noncash or Part Noncash Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_UpfrontPayments', window );">Upfront payment</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CollaborativeAgreementMilestonePayments', window );">Collaborative agreement milestone payments</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=teva_OtsukaMember', window );">Otsuka [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems', window );"><strong>Noncash or Part Noncash Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_UpfrontPayments', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=teva_RegeneronMember', window );">Regeneron [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems', window );"><strong>Noncash or Part Noncash Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_UpfrontPayments', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CollaborativeAgreementMilestonePayments', window );">Collaborative agreement milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ResearchAndDevelopmentCosts', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=teva_AlvotechMember', window );">Alvotech [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems', window );"><strong>Noncash or Part Noncash Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CollaborativeAgreementMilestonePayments', window );">Collaborative agreement milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=teva_MedincellMember', window );">MedinCell [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems', window );"><strong>Noncash or Part Noncash Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CollaborativeAgreementMilestonePayments', window );">Collaborative agreement milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=teva_ModagMember', window );">MODAG [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems', window );"><strong>Noncash or Part Noncash Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount', window );">License agreement potential aggregate milestone payments amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=teva_ModagMember', window );">MODAG [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems', window );"><strong>Noncash or Part Noncash Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=teva_TakedaMember', window );">Takeda [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems', window );"><strong>Noncash or Part Noncash Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_UpfrontPayments', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CollaborativeAgreementMilestonePayments', window );">Collaborative agreement milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_CollaborativeAgreementMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_CollaborativeAgreementMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement potential aggregate milestone payments amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_UpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_UpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=teva_AlderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=teva_AlderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=teva_OtsukaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=teva_OtsukaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=teva_RegeneronMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=teva_RegeneronMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=teva_AlvotechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=teva_AlvotechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=teva_MedincellMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=teva_MedincellMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=teva_ModagMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=teva_ModagMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=teva_TakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=teva_TakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684978218304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Transactions - Business Acquisitions - Summary of Major Classes of Assets and Liabilities Included as Held for Sale (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent', window );">Inventories</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent', window );">Property, plant and equipment, net and others</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent', window );">Goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueAdjustment', window );">Adjustments of assets held for sale to fair value</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(76)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total assets of the disposal group classified as held for sale in the consolidated balance sheets</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total liabilities of the disposal group classified as held for sale in the consolidated balance sheets, recorded under accrued expenses and other long-term liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (43)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which an asset could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684980032848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from Contracts with Customers - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_RevenueRecognitionLineItems', window );"><strong>Revenue Recognition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_SalesReservesAndAllowancesToCustomersPercentage', window );">Percentage sales reserves and allowances to U.S. customers</a></td>
<td class="nump">74.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_RevenueRecognitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_RevenueRecognitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_SalesReservesAndAllowancesToCustomersPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales reserves and allowances to customers percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_SalesReservesAndAllowancesToCustomersPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684977994560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from Contracts with Customers - Summary of Disaggregation of Revenues by Major Revenue Streams (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 3,786<span></span>
</td>
<td class="nump">$ 3,910<span></span>
</td>
<td class="nump">$ 7,447<span></span>
</td>
<td class="nump">$ 7,892<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Sale of Goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">3,289<span></span>
</td>
<td class="nump">3,465<span></span>
</td>
<td class="nump">6,425<span></span>
</td>
<td class="nump">6,928<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Licensing Arrangements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_DistributionServiceMember', window );">Distribution [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">318<span></span>
</td>
<td class="nump">330<span></span>
</td>
<td class="nump">677<span></span>
</td>
<td class="nump">639<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">106<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="nump">234<span></span>
</td>
<td class="nump">257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember', window );">International Markets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">454<span></span>
</td>
<td class="nump">485<span></span>
</td>
<td class="nump">946<span></span>
</td>
<td class="nump">975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember', window );">International Markets [Member] | Sale of Goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">448<span></span>
</td>
<td class="nump">462<span></span>
</td>
<td class="nump">894<span></span>
</td>
<td class="nump">902<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember', window );">International Markets [Member] | Licensing Arrangements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember', window );">International Markets [Member] | Distribution [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember', window );">International Markets [Member] | Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="num">(9)<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_OtherActivitiesMember', window );">Other activities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">257<span></span>
</td>
<td class="nump">298<span></span>
</td>
<td class="nump">532<span></span>
</td>
<td class="nump">587<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_OtherActivitiesMember', window );">Other activities [Member] | Sale of Goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">198<span></span>
</td>
<td class="nump">356<span></span>
</td>
<td class="nump">374<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_OtherActivitiesMember', window );">Other activities [Member] | Licensing Arrangements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_OtherActivitiesMember', window );">Other activities [Member] | Distribution [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_OtherActivitiesMember', window );">Other activities [Member] | Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember', window );">North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1,904<span></span>
</td>
<td class="nump">1,943<span></span>
</td>
<td class="nump">3,641<span></span>
</td>
<td class="nump">3,932<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember', window );">North America [Member] | Sale of Goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1,538<span></span>
</td>
<td class="nump">1,621<span></span>
</td>
<td class="nump">2,915<span></span>
</td>
<td class="nump">3,289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember', window );">North America [Member] | Licensing Arrangements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember', window );">North America [Member] | Distribution [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">308<span></span>
</td>
<td class="nump">316<span></span>
</td>
<td class="nump">650<span></span>
</td>
<td class="nump">605<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember', window );">North America [Member] | Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">3<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1,171<span></span>
</td>
<td class="nump">1,184<span></span>
</td>
<td class="nump">2,327<span></span>
</td>
<td class="nump">2,398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe [Member] | Sale of Goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1,127<span></span>
</td>
<td class="nump">1,185<span></span>
</td>
<td class="nump">2,261<span></span>
</td>
<td class="nump">2,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe [Member] | Licensing Arrangements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe [Member] | Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="num">$ (8)<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_DistributionServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_DistributionServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=teva_OtherActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=teva_OtherActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_NorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684977167696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from Contracts with Customers - Schedule of Sales Reserves and Allowances (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_RevenueRecognitionLineItems', window );"><strong>Revenue Recognition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">$ 4,309<span></span>
</td>
<td class="nump">$ 4,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales', window );">Provisions related to sales made in current year</a></td>
<td class="nump">6,651<span></span>
</td>
<td class="nump">7,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales', window );">Provisions related to sales made in prior periods</a></td>
<td class="num">(108)<span></span>
</td>
<td class="num">(196)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits and payments</a></td>
<td class="num">(6,861)<span></span>
</td>
<td class="num">(7,209)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation', window );">Translation differences</a></td>
<td class="num">(47)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">3,944<span></span>
</td>
<td class="nump">4,524<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_ReservesIncludedInAccountsReceivableNetMember', window );">Reserves Included in Accounts Receivable, Net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_RevenueRecognitionLineItems', window );"><strong>Revenue Recognition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales', window );">Provisions related to sales made in current year</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales', window );">Provisions related to sales made in prior periods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits and payments</a></td>
<td class="num">(185)<span></span>
</td>
<td class="num">(196)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_RebatesMember', window );">Rebates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_RevenueRecognitionLineItems', window );"><strong>Revenue Recognition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">1,655<span></span>
</td>
<td class="nump">2,054<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales', window );">Provisions related to sales made in current year</a></td>
<td class="nump">1,889<span></span>
</td>
<td class="nump">2,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales', window );">Provisions related to sales made in prior periods</a></td>
<td class="num">(102)<span></span>
</td>
<td class="num">(82)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits and payments</a></td>
<td class="num">(1,901)<span></span>
</td>
<td class="num">(2,355)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation', window );">Translation differences</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">1,508<span></span>
</td>
<td class="nump">1,748<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_MedicaidAndOtherGovernmentalAllowancesMember', window );">Medicaid and Other Governmental Allowances [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_RevenueRecognitionLineItems', window );"><strong>Revenue Recognition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">854<span></span>
</td>
<td class="nump">828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales', window );">Provisions related to sales made in current year</a></td>
<td class="nump">446<span></span>
</td>
<td class="nump">391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales', window );">Provisions related to sales made in prior periods</a></td>
<td class="nump">20<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits and payments</a></td>
<td class="num">(497)<span></span>
</td>
<td class="num">(362)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation', window );">Translation differences</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">817<span></span>
</td>
<td class="nump">819<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_ChargebacksMember', window );">Chargebacks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_RevenueRecognitionLineItems', window );"><strong>Revenue Recognition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">1,085<span></span>
</td>
<td class="nump">1,108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales', window );">Provisions related to sales made in current year</a></td>
<td class="nump">3,836<span></span>
</td>
<td class="nump">3,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales', window );">Provisions related to sales made in prior periods</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits and payments</a></td>
<td class="num">(3,922)<span></span>
</td>
<td class="num">(3,934)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation', window );">Translation differences</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">984<span></span>
</td>
<td class="nump">1,157<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_ReturnsMember', window );">Returns [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_RevenueRecognitionLineItems', window );"><strong>Revenue Recognition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">535<span></span>
</td>
<td class="nump">686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales', window );">Provisions related to sales made in current year</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales', window );">Provisions related to sales made in prior periods</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits and payments</a></td>
<td class="num">(211)<span></span>
</td>
<td class="num">(186)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation', window );">Translation differences</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">451<span></span>
</td>
<td class="nump">602<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_OtherSalesReservesAndAllowancesMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_RevenueRecognitionLineItems', window );"><strong>Revenue Recognition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales', window );">Provisions related to sales made in current year</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales', window );">Provisions related to sales made in prior periods</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits and payments</a></td>
<td class="num">(145)<span></span>
</td>
<td class="num">(176)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation', window );">Translation differences</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_TotalReservesIncludedInSalesReservesAndAllowancesMember', window );">Total Reserves Included in Sales Reserves and Allowances [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_RevenueRecognitionLineItems', window );"><strong>Revenue Recognition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">4,241<span></span>
</td>
<td class="nump">4,824<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales', window );">Provisions related to sales made in current year</a></td>
<td class="nump">6,470<span></span>
</td>
<td class="nump">6,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales', window );">Provisions related to sales made in prior periods</a></td>
<td class="num">(108)<span></span>
</td>
<td class="num">(191)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits and payments</a></td>
<td class="num">(6,676)<span></span>
</td>
<td class="num">(7,013)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation', window );">Translation differences</a></td>
<td class="num">(47)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">$ 3,880<span></span>
</td>
<td class="nump">$ 4,453<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_RevenueRecognitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_RevenueRecognitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation allowances and reserves foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ValuationAllowancesAndReservesForeignCurrencyTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation allowances and reserves related to current period sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation allowances and reserves related to prior period sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_ReservesIncludedInAccountsReceivableNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_ReservesIncludedInAccountsReceivableNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_RebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_RebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_MedicaidAndOtherGovernmentalAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_MedicaidAndOtherGovernmentalAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_ChargebacksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_ChargebacksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_ReturnsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_ReturnsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_OtherSalesReservesAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_OtherSalesReservesAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_TotalReservesIncludedInSalesReservesAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_TotalReservesIncludedInSalesReservesAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684979082128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Summary of Inventories (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_InventoriesLineItems', window );"><strong>Inventories [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished products</a></td>
<td class="nump">$ 1,875<span></span>
</td>
<td class="nump">$ 1,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw and packaging materials</a></td>
<td class="nump">1,346<span></span>
</td>
<td class="nump">1,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Products in process</a></td>
<td class="nump">624<span></span>
</td>
<td class="nump">587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInventoryInTransit', window );">Materials in transit and payments on account</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">$ 4,049<span></span>
</td>
<td class="nump">$ 3,818<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_InventoriesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_InventoriesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventoryInTransit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of merchandise or supplies to which the entity holds the title but does not hold physical possession because the goods are currently being transported.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventoryInTransit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684979864272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Identifiable Intangible Assets - Summary of Identifiable Intangible Assets (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount net of impairment</a></td>
<td class="nump">$ 19,092<span></span>
</td>
<td class="nump">$ 19,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">12,392<span></span>
</td>
<td class="nump">12,516<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net carrying amount</a></td>
<td class="nump">6,700<span></span>
</td>
<td class="nump">7,466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=teva_ProductRightsMember', window );">Product rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount net of impairment</a></td>
<td class="nump">17,987<span></span>
</td>
<td class="nump">18,815<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">12,181<span></span>
</td>
<td class="nump">12,318<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net carrying amount</a></td>
<td class="nump">5,806<span></span>
</td>
<td class="nump">6,497<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount net of impairment</a></td>
<td class="nump">570<span></span>
</td>
<td class="nump">590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">211<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net carrying amount</a></td>
<td class="nump">359<span></span>
</td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In process research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount net of impairment</a></td>
<td class="nump">535<span></span>
</td>
<td class="nump">577<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net carrying amount</a></td>
<td class="nump">$ 535<span></span>
</td>
<td class="nump">$ 577<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=teva_ProductRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=teva_ProductRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684977711456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Identifiable Intangible Assets - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization of intangible assets useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 212<span></span>
</td>
<td class="nump">$ 173<span></span>
</td>
<td class="nump">$ 412<span></span>
</td>
<td class="nump">$ 414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets excluding goodwill</a></td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">195<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="nump">274<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Measurement input, discount rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">8.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Measurement input, discount rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">11.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_GenericPipelineProductsMember', window );">Generic Pipeline Products [Member] | In Process Research And Development To Product Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets excluding goodwill</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">0.0725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member] | Minimum [Member] | Measurement input, discount rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">0.0825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member] | Maximum [Member] | Measurement input, discount rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=teva_ProductRightsMember', window );">Identifiable product rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets excluding goodwill</a></td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="nump">$ 161<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=teva_ActavisMember', window );">Actavis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets excluding goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=teva_ActavisMember', window );">Actavis [Member] | In Process Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Business combination recognized identifiable assets</a></td>
<td class="nump">$ 503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member] | Actavis [Member] | Identifiable product rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets excluding goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=teva_GenericPipelineProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=teva_GenericPipelineProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationTypeAxis=teva_InprocessresearchandDevelopmenttoProductRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationTypeAxis=teva_InprocessresearchandDevelopmenttoProductRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=teva_ProductRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=teva_ProductRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=teva_ActavisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=teva_ActavisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684977138016">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (745)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(745)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Translation differences</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(470)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">18,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember', window );">North America [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Translation differences</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Translation differences</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(320)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">8,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=teva_InternationalMarketsMember', window );">International Markets [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(479)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Translation differences</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=teva_OtherCountriesMember', window );">Other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(266)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Translation differences</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(130)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 2,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Accumulated goodwill impairment as of June 30, 2022 and December 31, 2021 was approximately $26.3 billion and $25.6 billion, respectively.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_NorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=teva_InternationalMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=teva_InternationalMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=teva_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=teva_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139685092111216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Parenthetical) (Detail) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated goodwill impairment</a></td>
<td class="nump">$ 26.3<span></span>
</td>
<td class="nump">$ 25.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684977590640">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Goodwill - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 18,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Reporting unit percentage of fair value in excess of carrying amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 745<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 745<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=teva_MeasurementInputTerminalGrowthRateMember', window );">Measurement Input Terminal Growth Rate [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Reporting unit percentage of fair value in excess of carrying amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Measurement Input, Discount Rate [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Reporting unit percentage of fair value in excess of carrying amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10.04%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.04%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=teva_InternationalMarketsReportingUnitMember', window );">International Markets Reporting Unit [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=teva_TevasApiReportingUnitMember', window );">Tevas API Reporting Unit [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=teva_TevasEuropeReportingUnitMember', window );">Tevas Europe Reporting Unit [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Reporting unit percentage of fair value in excess of carrying amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=teva_NorthAmericaAndMedisReportingUnitsMember', window );">North America and Medis Reporting Units [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Reporting unit percentage of fair value in excess of carrying amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Measurement Input Terminal Growth Rate [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Reporting unit percentage of fair value in excess of carrying amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.91%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.91%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Measurement Input, Discount Rate [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Reporting unit percentage of fair value in excess of carrying amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10.54%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.54%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Measurement Input Terminal Growth Rate [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Reporting unit percentage of fair value in excess of carrying amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Measurement Input, Discount Rate [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Reporting unit percentage of fair value in excess of carrying amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Accumulated goodwill impairment as of June 30, 2022 and December 31, 2021 was approximately $26.3 billion and $25.6 billion, respectively.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of fair value of reporting unit in excess of carrying amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=teva_MeasurementInputTerminalGrowthRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=teva_MeasurementInputTerminalGrowthRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=teva_InternationalMarketsReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=teva_InternationalMarketsReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=teva_TevasApiReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=teva_TevasApiReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=teva_TevasEuropeReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=teva_TevasEuropeReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=teva_NorthAmericaAndMedisReportingUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=teva_NorthAmericaAndMedisReportingUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684982718352">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations - Schedule of Short-term Debt (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current maturities of long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,696<span></span>
</td>
<td class="nump">$ 1,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Total short term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,719<span></span>
</td>
<td class="nump">1,426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_ShortCreditAgreement2026Member', window );">Convertible senior debentures [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Convertible senior debentures</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">In April 2022, Teva repaid $296 million of its 3.25% senior notes at maturity.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_DebtInstrumentMaturityYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Maturity Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_DebtInstrumentMaturityYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_ShortCreditAgreement2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_ShortCreditAgreement2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684975471408">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations - Schedule of Senior Notes and Loans (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 22,144<span></span>
</td>
<td class="nump">$ 23,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less current maturities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(1,696)<span></span>
</td>
<td class="num">(1,403)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">Less debt issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(87)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesAndLoans', window );">Total senior notes and loans</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,363<span></span>
</td>
<td class="nump">21,617<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_OtherDebentures2026Member', window );">Other Debentures [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesAndLoans', window );">Total senior notes and loans</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024Member', window );">Senior notes EUR 1,500 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 653<span></span>
</td>
<td class="nump">708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.13%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2030Member', window );">Sustainability-linked senior notes EUR 1,500&#160;million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="text">2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="nump">$ 1,566<span></span>
</td>
<td class="nump">1,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="nump">4.38%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2023OneMember', window );">Senior notes EUR 1,300 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 616<span></span>
</td>
<td class="nump">670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2027Member', window );">Sustainability-linked senior notes EUR 1,100&#160;million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[4]</sup></td>
<td class="text">2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[4]</sup></td>
<td class="nump">$ 1,150<span></span>
</td>
<td class="nump">1,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[4]</sup></td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025OneMember', window );">Senior notes EUR 1,000 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,043<span></span>
</td>
<td class="nump">1,134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025Member', window );">Senior notes EUR 900 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 942<span></span>
</td>
<td class="nump">1,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028Member', window );">Senior notes EUR 750 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 779<span></span>
</td>
<td class="nump">844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.63%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022OneMember', window );">Senior notes EUR 700 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2026OneMember', window );">Senior notes USD 3,500 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,496<span></span>
</td>
<td class="nump">3,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2027Member', window );">Senior notes EUR 700 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 729<span></span>
</td>
<td class="nump">792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.88%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2023TwoMember', window );">Senior notes USD 3,000 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,453<span></span>
</td>
<td class="nump">1,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2046Member', window );">Senior notes USD 2,000 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,986<span></span>
</td>
<td class="nump">1,986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024OneMember', window );">Senior notes USD 1,250 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028OneMember', window );">Senior notes USD 1,250 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025TwoMember', window );">Senior notes USD 1,000 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7.13%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2027TwoMember', window );">Sustainability-linked senior notes USD 1,000&#160;million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[4]</sup></td>
<td class="text">2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[4]</sup></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[4]</sup></td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2029Member', window );">Sustainability-linked senior notes USD 1,000&#160;million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="text">2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="nump">5.13%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022TwoMember', window );">Senior notes USD 844 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 715<span></span>
</td>
<td class="nump">715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2036Member', window );">Senior notes USD 789 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 783<span></span>
</td>
<td class="nump">783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022ThreeMember', window );">Senior notes CHF 350 Million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 366<span></span>
</td>
<td class="nump">382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025ThreeMember', window );">Senior notes CHF 350 Million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 367<span></span>
</td>
<td class="nump">$ 383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">In April 2022, Teva repaid $296 million of its 3.25% senior notes at maturity.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.125%-0.375% per annum, from and including May 9, 2026.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Interest rate adjustments and a potential one-time premium payment related to the sustainability-linked bonds are treated as bifurcated embedded derivatives. See note 8d.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">If Teva fails to achieve certain sustainability performance targets, a one-time premium payment of 0.15%-0.45% out of the principal amount will be paid at maturity or upon earlier redemption, if such redemption is on or after May 9, 2026.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_DebtInstrumentMaturityYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Maturity Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_DebtInstrumentMaturityYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNoncurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesAndLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesAndLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of long-term debt outstanding calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.16)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_OtherDebentures2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_OtherDebentures2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2023OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2023OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2026OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2026OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2023TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2023TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2046Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2046Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2027TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2027TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022ThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022ThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025ThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025ThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684975073056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations - Schedule of Senior Notes and Loans (Parenthetical) (Detail)<br> &#8364; in Millions, SFr in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_SeniorNotesRepaidAmount', window );">Senior notes repaid amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_SeniorNotesMaturityPercentage', window );">Senior notes maturity percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024Member', window );">Senior notes EUR 1,500 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount | &#8364;</a></td>
<td class="nump">&#8364; 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2030Member', window );">Sustainability-linked senior notes EUR 1,500 million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount | &#8364;</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2023OneMember', window );">Senior notes EUR 1,300 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount | &#8364;</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2027Member', window );">Sustainability-linked senior notes EUR 1,100&#160;million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount | &#8364;</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025OneMember', window );">Senior notes EUR 1,000 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount | &#8364;</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025Member', window );">Senior notes EUR 900 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount | &#8364;</a></td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028Member', window );">Senior notes EUR 750 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount | &#8364;</a></td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022OneMember', window );">Senior notes EUR 700 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount | &#8364;</a></td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2027Member', window );">Senior notes EUR 700 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount | &#8364;</a></td>
<td class="nump">&#8364; 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2026OneMember', window );">Senior notes USD 3,500 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2023TwoMember', window );">Senior notes USD 3,000 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2046Member', window );">Senior notes USD 2,000 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024OneMember', window );">Senior notes USD 1,250 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028OneMember', window );">Senior notes USD 1,250 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025TwoMember', window );">Senior notes USD 1,000 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2027TwoMember', window );">Sustainability-linked senior notes USD 1,000&#160;million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2029Member', window );">Sustainability-linked senior notes USD 1,000&#160;million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022TwoMember', window );">Senior notes USD 844 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2036Member', window );">Senior notes USD 789 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022ThreeMember', window );">Senior notes CHF 350 Million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025ThreeMember', window );">Senior notes CHF 350 Million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_InterestRateIncreaseMember', window );">Interest Rate Increase [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">May  09,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_InterestRateIncreaseMember', window );">Interest Rate Increase [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Debt Instrument, Interest Rate, Increase (Decrease)</a></td>
<td class="nump">0.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_InterestRateIncreaseMember', window );">Interest Rate Increase [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Debt Instrument, Interest Rate, Increase (Decrease)</a></td>
<td class="nump">0.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_OneTimePremiumPaymentMember', window );">One Time Premium Payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">May  09,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_OneTimePremiumPaymentMember', window );">One Time Premium Payment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Debt Instrument, Interest Rate, Increase (Decrease)</a></td>
<td class="nump">0.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_OneTimePremiumPaymentMember', window );">One Time Premium Payment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Debt Instrument, Interest Rate, Increase (Decrease)</a></td>
<td class="nump">0.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_SeniorNotesMaturityPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Senior notes maturity percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_SeniorNotesMaturityPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_SeniorNotesRepaidAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Senior notes repaid amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_SeniorNotesRepaidAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage increase (decrease) in the stated rate on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2023OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2023OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2026OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2026OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2023TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2023TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2046Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2046Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2027TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2027TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022ThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022ThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025ThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025ThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_InterestRateIncreaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_InterestRateIncreaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_OneTimePremiumPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_OneTimePremiumPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684977013952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="7">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LongTermDebtCurrencyPortionUSD', window );">Long term debt currency portion USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63.00%<span></span>
</td>
<td class="nump">63.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LongTermDebtCurrencyPortionEUR', window );">Long term debt currency portion EUR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LongTermDebtCurrencyPortionCHF', window );">Long term debt currency portion CHF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount currently outstanding on the debt instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.0<span></span>
</td>
<td class="nump">$ 23.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Weighted average interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCovenantDescription', window );">Debt Instrument, Covenant Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The RCF can be used for general corporate purposes, including repaying existing debt. As of June 30, 2022 and as of the date of this Quarterly Report on Form 10-Q, no amounts were outstanding under the RCF. Based on current and forecasted results, the Company expects that it will not exceed the financial covenant thresholds set forth in the RCF within one year from the date the financial statements are issued<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800.0<span></span>
</td>
<td class="nump">$ 1,800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LeverageRatio', window );">Leverage Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LeverageRatio', window );">Leverage Ratio</a></td>
<td class="text">3.75<span></span>
</td>
<td class="text">4.00<span></span>
</td>
<td class="text">4.00<span></span>
</td>
<td class="text">4.00<span></span>
</td>
<td class="text">4.25<span></span>
</td>
<td class="text">4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=teva_UnsecuredSyndicatedRevolvingCreditFacilityMember', window );">Unsecured Syndicated Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 30,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LineOfCreditExtentionPeriod', window );">Line Of Credit Extention Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Leverage ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LineOfCreditExtentionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of credit extention period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LineOfCreditExtentionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LongTermDebtCurrencyPortionCHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term debt currency portion C H F.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LongTermDebtCurrencyPortionCHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LongTermDebtCurrencyPortionEUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term debt currency portion E U R.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LongTermDebtCurrencyPortionEUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LongTermDebtCurrencyPortionUSD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term debt currency portion U S D.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LongTermDebtCurrencyPortionUSD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCovenantDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of minimum financial levels (for example, tangible net worth and working capital) and achievement of certain financial ratios (for example, working capital ratio and debt service coverage ratio), and adherence to certain clauses which generally require or restrict certain actions (for example, entering into a debt arrangement with equal or greater seniority, and selling or discontinuing a certain business segment or material subsidiary) to be in compliance with the covenant clauses of the debt agreement. May also include a discussion of the adverse consequences that would result if the entity violates or fails to satisfy the covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCovenantDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=teva_UnsecuredSyndicatedRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=teva_UnsecuredSyndicatedRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684979980928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Instruments and Hedging Activities - Summary of Classification and Fair Values of Derivative Instruments (Detail) - Not Designated as Hedging Instrument [Member] - Foreign Exchange Contract [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Accounts Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Liability derivatives</a></td>
<td class="num">$ (37)<span></span>
</td>
<td class="num">$ (23)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Other Current Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Asset derivatives</a></td>
<td class="nump">$ 69<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=teva_SeniorNotesAndLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=teva_SeniorNotesAndLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684978056400">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments and Hedging Activities - Schedule Of Other Derivatives Not Designated As Hedging Instruments Statements OfFinancial Performance And Financial Position Location (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=teva_NetRevenuesMember', window );">Net Revenues [Member] | Not Designated as Hedging Instrument [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (Loss) on Derivative Instruments, Net, Pretax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (3,786)<span></span>
</td>
<td class="num">$ (3,910)<span></span>
</td>
<td class="num">$ (7,447)<span></span>
</td>
<td class="num">$ (7,892)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=teva_NetRevenuesMember', window );">Net Revenues [Member] | Not Designated as Hedging Instrument, Trading [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (Loss) on Derivative Instruments, Net, Pretax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=teva_NetRevenuesMember', window );">Net Revenues [Member] | Not Designated as Hedging Instrument, Economic Hedge [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (Loss) on Derivative Instruments, Net, Pretax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(16)<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=teva_FinancialExpensesMember', window );">Financial expenses [Member] | Not Designated as Hedging Instrument [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (Loss) on Derivative Instruments, Net, Pretax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">211<span></span>
</td>
<td class="nump">274<span></span>
</td>
<td class="nump">468<span></span>
</td>
<td class="nump">564<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=teva_FinancialExpensesMember', window );">Financial expenses [Member] | Not Designated as Hedging Instrument, Trading [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (Loss) on Derivative Instruments, Net, Pretax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(38)<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=teva_FinancialExpensesMember', window );">Financial expenses [Member] | Not Designated as Hedging Instrument, Economic Hedge [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (Loss) on Derivative Instruments, Net, Pretax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Teva uses foreign exchange contracts (mainly option and forward contracts) to hedge balance sheet items from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, Teva recognizes gains or losses that offset the revaluation of the balance sheet items also recorded under financial expenses, net. [Ruble -to check 10K language]</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on projected revenues and expenses recorded in euro, the Swiss franc, the Japanese yen, the British pound, the Russian ruble, the Canadian dollar and some other currencies to protect its projected operating results for 2021 and 2022. These derivative instruments do not meet the criteria for hedge accounting, however, they are accounted for as an economic hedge. These derivative instruments, which may include hedging transactions against future projected revenues and expenses, are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. In the first six months of 2022, the positive impact from these derivatives recognized under revenues was $35 million. In the first six months of 2021, the positive impact from these derivatives recognized under revenues was $13 million. Changes in the fair value of the derivative instruments are recognized in the same line item in the statements of income as the underlying exposure being hedged. The cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=teva_NetRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=teva_NetRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NotDesignatedAsHedgingInstrumentTradingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NotDesignatedAsHedgingInstrumentTradingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=teva_FinancialExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=teva_FinancialExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684977726320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments and Hedging Activities - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_RevenuesOtherThanUsd', window );">Revenues other than USD</a></td>
<td class="nump">48.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLossOnDerivative', window );">Teva other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses', window );">Forward starting interest rate swaps and treasury lock agreements losses</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_InterestRateSwapLoss', window );">Interest Rate Swap Loss</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Derivative, Gain on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=teva_SeniorNotesDue2023TwoMember', window );">Senior Notes Due 2023 Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_NotionalAmountHedgeDebt', window );">Notional amount hedge debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_PreviouslyHedgeDebtRate', window );">Previously hedge debt rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CashReceivedOnSettlementOfPosition', window );">Cash received on settlement of position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss', window );">Derivative, Fair Value Hedge, Included in Effectiveness, Gain (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=teva_SeniorNotesDue2022Member', window );">Senior Notes Due 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_NotionalAmountHedgeDebt', window );">Notional amount hedge debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_PreviouslyHedgeDebtRate', window );">Previously hedge debt rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=teva_SeniorNotesDue2021Member', window );">Senior Notes Due 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_NotionalAmountHedgeDebt', window );">Notional amount hedge debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_PreviouslyHedgeDebtRate', window );">Previously hedge debt rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_CashReceivedOnSettlementOfPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Notional amount hedge debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_CashReceivedOnSettlementOfPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Forward starting interest rate swaps and treasury lock agreements losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_InterestRateSwapLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rate swap loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_InterestRateSwapLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_NotionalAmountHedgeDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Notional amount hedge debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_NotionalAmountHedgeDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_PreviouslyHedgeDebtRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Previously hedge debt rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_PreviouslyHedgeDebtRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_RevenuesOtherThanUsd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues other than US Dollar.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_RevenuesOtherThanUsd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on derivative instrument designated and qualifying as fair value hedge included in assessment of hedge effectiveness, recognized in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061172-113977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLossOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLossOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=teva_SeniorNotesDue2023TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=teva_SeniorNotesDue2023TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=teva_SeniorNotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=teva_SeniorNotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=teva_SeniorNotesDue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=teva_SeniorNotesDue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684980048432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Settlements and Loss Contingencies - Additional Information (Detail)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 02, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Legal settlements and loss contingencies, expense</a></td>
<td class="nump">$ 420<span></span>
</td>
<td class="nump">$ 729<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 1,854<span></span>
</td>
<td class="nump">$ 110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Accrued amount for legal settlements and loss contingencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 60.5<span></span>
</td>
<td class="nump">$ 2,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_RestructuringExpenseAndIncome', window );">Restructuring expense and income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The expense in the first six months of 2021 was mainly due to the provision for the carvedilol patent litigation.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=teva_SettlementOnAccountOfProductLiabilityMember', window );">Settlement On Account Of Product Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_RestructuringExpenseAndIncome', window );">Restructuring expense and income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The expenses in the second quarter of 2022 were mainly related to an update of the estimated settlement provision recorded in connection with the remaining opioid cases.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_RestructuringExpenseAndIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring expense and income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_RestructuringExpenseAndIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=teva_SettlementOnAccountOfProductLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=teva_SettlementOnAccountOfProductLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684965196656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1">48 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 12, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 02, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 24, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 21, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 04, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 28, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 05, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 21, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 21, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2010 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 21, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 08, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2008 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2005 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DamagesAssessment', window );">Damages assessment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 235,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 235,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AnnualSalesAtTimeOfSettlement', window );">Annual sales at the time of settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000,000<span></span>
</td>
<td class="nump">$ 350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AnnualSalesOfEffexor', window );">Annual sales of Effexor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AnnualSalesOfLamictal', window );">Annual sales of Lamictal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000,000<span></span>
</td>
<td class="nump">$ 950,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AnnualSalesOfNiaspan', window );">Annual sales of Niaspan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000,000<span></span>
</td>
<td class="nump">$ 416,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AnnualSalesOfActos', window );">Annual sales of Actos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000,000<span></span>
</td>
<td class="nump">$ 3,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AnnualSalesOfActoplus', window );">Annual sales of Acto plus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 430,000,000<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AnnualSalesOfSensipar', window );">Annual Sales Of Sensipar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AnnualSalesOfCopaxone', window );">Annual sales of Copaxone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 373,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Generic modafinil, and imposed fines amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,928,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,928,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,710,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 60.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Loss Contingency Accrual, Provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 235,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AnnualSalesOfNarcan', window );">Annual sales of Narcan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 434,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LossContingencyClaimsDismissedValue', window );">Loss Contingency Claims Dismissed Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 925,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 925,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation Settlement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 420,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">729,000,000<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="nump">1,854,000,000<span></span>
</td>
<td class="nump">$ 110,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccrualForEnvironmentalLossContingencies', window );">Accrual for Environmental Loss Contingencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LossContingenciesOnEnvironmentalLawsPenalty', window );">Loss Contingencies On Environmental Laws Penalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_PercentageOfPopulationOfSubdivisionsWillFormallyReleaseAsAPartOfSettlement', window );">Percentage of population of subdivisions will formally release as a part of settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AgreementAxis=teva_AttorneyGeneralOfLouisanaMember', window );">Attorney General Of Louisana [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LitigationSettlementAmountDistributableinKind', window );">Litigation Settlement Amount DistributableIn Kind</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AgreementAxis=teva_AttorneyGeneralOfRhodeIslandMember', window );">Attorney General of Rhode Island [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LitigationSettlementAmountDistributableinKind', window );">Litigation Settlement Amount DistributableIn Kind</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AgreementAxis=teva_AttorneyGeneralOfFloridaMember', window );">Attorney General of Florida [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LitigationSettlementAmountDistributableinKind', window );">Litigation Settlement Amount DistributableIn Kind</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AgreementAxis=teva_AttorneyGeneralOfWestVirginiaMember', window );">Attorney General of West Virginia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LitigationSettlementAmountDistributableinKind', window );">Litigation Settlement Amount DistributableIn Kind</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_PercentageOfWholesaleAcquisitionCostValueInCashInLieuOfProductToBePaidUnderSettlementAgreement', window );">Percentage of wholesale acquisition cost value in cash in lieu of product to be paid under settlement agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=teva_OpioidLitigationMember', window );">Opioid Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement amount</a></td>
<td class="nump">$ 20,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="nump">$ 177,000,000<span></span>
</td>
<td class="nump">$ 21,000,000<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LitigationSettlementAmountAwardedCashAmount', window );">Litigation settlement amount awarded cash amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LitigationSettlementAmountAwardedCashAmountDistributionPeriod', window );">Litigation settlement amount awarded cash amount distribution period</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LitigationSettlementAmountDistributableinKind', window );">Litigation Settlement Amount DistributableIn Kind</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=teva_NationwideSettlementMember', window );">Nationwide Settlement [Member] | Four Other Defendants Other Than Teva [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesPaidValue', window );">Loss contingency payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LitigationSettlementAmountAwardedDistributionPeriod', window );">Litigation settlement amount awarded distribution period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=teva_StatesPoliticalSubdivisionsAndTribesMember', window );">States Political Subdivisions and Tribes [Member] | Subsequent Event [Member] | Companies Share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LitigationAmountIncludingAlreadyPaid', window );">Litigation amount including already paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LitigationSettlementTerm', window );">Litigation settlement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ProductOfferingSettlementAtWholesaleAcquisitionCosts', window );">Product offering in settlement at wholesale acquistion costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ProductToBeSettledValuationTerm', window );">Product to be settled valuation term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LitigationAmountToBePaidToTribes', window );">Litigation amount to be paid to tribes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_WholesaleAcquisitionCostValueInCashAmountInLieuOfProductToBePaidUnderSettlementAgreement', window );">Wholesale acquisition cost value in cash amount in lieu of product to be paid under settlement agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 240,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damage claimed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_LA', window );">Laos [Member] | Opioid Litigation [Member] | Attorney General Of Louisana [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LitigationSettlementAmountAwardedCashAmountDistributionPeriod', window );">Litigation settlement amount awarded cash amount distribution period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LitigationSettlementAmountDistributableinKind', window );">Litigation Settlement Amount DistributableIn Kind</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=teva_EosinophilicEsophagitisMember', window );">Eosinophilic Esophagitis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damage claimed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=teva_EosinophilicEsophagitisMember', window );">Eosinophilic Esophagitis [Member] | United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damage claimed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_AndroGelRateAtOnePercentageMember', window );">AndroGel Rate at 1% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AnnualSalesAtTimeOfSettlement', window );">Annual sales at the time of settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_AtripalaMember', window );">Atripala [Member] | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AnnualSalesAtTimeOfSettlement', window );">Annual sales at the time of settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AnnualSalesAtTheTimeOfLaunchOfProduct', window );">Annual Sales At The Time Of Launch Of Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 444,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_TiruvadaMember', window );">Tiruvada [Member] | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AnnualSalesAtTimeOfSettlement', window );">Annual sales at the time of settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AnnualSalesAtTheTimeOfLaunchOfProduct', window );">Annual Sales At The Time Of Launch Of Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_VireadMember', window );">Viread [Member] | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AnnualSalesAtTimeOfSettlement', window );">Annual sales at the time of settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">582,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AnnualSalesAtTheTimeOfLaunchOfProduct', window );">Annual Sales At The Time Of Launch Of Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 728,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_ColcysMember', window );">Colcys [Member] | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AnnualSalesAtTimeOfSettlement', window );">Annual sales at the time of settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 187,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AnnualSalesAtTheTimeOfLaunchOfProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual sales at the time of launch of product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AnnualSalesAtTheTimeOfLaunchOfProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AnnualSalesAtTimeOfSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual sales at time of settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AnnualSalesAtTimeOfSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AnnualSalesOfActoplus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual sales of Acto plus.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AnnualSalesOfActoplus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AnnualSalesOfActos">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual sales of Actos.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AnnualSalesOfActos</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AnnualSalesOfCopaxone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual Sales Of Copaxone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AnnualSalesOfCopaxone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AnnualSalesOfEffexor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual sales of effexor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AnnualSalesOfEffexor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AnnualSalesOfLamictal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual sales of Lamictal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AnnualSalesOfLamictal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AnnualSalesOfNarcan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual sales of narcan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AnnualSalesOfNarcan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AnnualSalesOfNiaspan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual sales of Niaspan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AnnualSalesOfNiaspan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AnnualSalesOfSensipar">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents Annual Sales Of Sensipar.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AnnualSalesOfSensipar</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_CommitmentAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment And Contingencies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_CommitmentAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_DamagesAssessment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Damages assessment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_DamagesAssessment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LitigationAmountIncludingAlreadyPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation amount including already paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LitigationAmountIncludingAlreadyPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LitigationAmountToBePaidToTribes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation amount to be paid to tribes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LitigationAmountToBePaidToTribes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LitigationSettlementAmountAwardedCashAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation settlement amount awarded cash amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LitigationSettlementAmountAwardedCashAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LitigationSettlementAmountAwardedCashAmountDistributionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation settlement amount awarded cash amount distribution period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LitigationSettlementAmountAwardedCashAmountDistributionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LitigationSettlementAmountAwardedDistributionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation settlement amount awarded distribution period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LitigationSettlementAmountAwardedDistributionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LitigationSettlementAmountDistributableinKind">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation settlement amount distributableIn kind.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LitigationSettlementAmountDistributableinKind</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LitigationSettlementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation settlement term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LitigationSettlementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LossContingenciesOnEnvironmentalLawsPenalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss contingencies on environmental laws penalty.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LossContingenciesOnEnvironmentalLawsPenalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LossContingencyClaimsDismissedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss contingency claims dismissed value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LossContingencyClaimsDismissedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_PercentageOfPopulationOfSubdivisionsWillFormallyReleaseAsAPartOfSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of population of subdivisions will formally release as a part of settlement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_PercentageOfPopulationOfSubdivisionsWillFormallyReleaseAsAPartOfSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_PercentageOfWholesaleAcquisitionCostValueInCashInLieuOfProductToBePaidUnderSettlementAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of wholesale acquisition cost value in cash in lieu of product to be paid under settlement agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_PercentageOfWholesaleAcquisitionCostValueInCashInLieuOfProductToBePaidUnderSettlementAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ProductOfferingSettlementAtWholesaleAcquisitionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product offering settlement at wholesale acquisition costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ProductOfferingSettlementAtWholesaleAcquisitionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ProductToBeSettledValuationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product settlement term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ProductToBeSettledValuationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_WholesaleAcquisitionCostValueInCashAmountInLieuOfProductToBePaidUnderSettlementAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Wholesale acquisition cost value in cash amount in lieu of product to be paid under settlement agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_WholesaleAcquisitionCostValueInCashAmountInLieuOfProductToBePaidUnderSettlementAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccrualForEnvironmentalLossContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs accrued as of the balance sheet date for environmental loss contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 30<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=6393242&amp;loc=d3e13237-110859<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149879-122751<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 30<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=6393242&amp;loc=d3e13207-110859<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 5: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 30<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6393242&amp;loc=d3e13237-110859<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 30<br> -Section 55<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=6571209&amp;loc=d3e13703-110860<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccrualForEnvironmentalLossContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesPaidValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of damages paid to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesPaidValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AgreementAxis=teva_AttorneyGeneralOfLouisanaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AgreementAxis=teva_AttorneyGeneralOfLouisanaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AgreementAxis=teva_AttorneyGeneralOfRhodeIslandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AgreementAxis=teva_AttorneyGeneralOfRhodeIslandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AgreementAxis=teva_AttorneyGeneralOfFloridaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AgreementAxis=teva_AttorneyGeneralOfFloridaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AgreementAxis=teva_AttorneyGeneralOfWestVirginiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AgreementAxis=teva_AttorneyGeneralOfWestVirginiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=teva_OpioidLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=teva_OpioidLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=teva_NationwideSettlementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=teva_NationwideSettlementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_DefendantsAxis=teva_FourOtherDefendantsOtherThanTevaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_DefendantsAxis=teva_FourOtherDefendantsOtherThanTevaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=teva_StatesPoliticalSubdivisionsAndTribesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=teva_StatesPoliticalSubdivisionsAndTribesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_DefendantsAxis=teva_CompaniesShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_DefendantsAxis=teva_CompaniesShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_LA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_LA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=teva_EosinophilicEsophagitisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=teva_EosinophilicEsophagitisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=teva_AndroGelRateAtOnePercentageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=teva_AndroGelRateAtOnePercentageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=teva_AtripalaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=teva_AtripalaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=teva_TiruvadaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=teva_TiruvadaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=teva_VireadMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=teva_VireadMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=teva_ColcysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=teva_ColcysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684977729184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ExpectedImpairmentOfIncomeTaxBenefit', window );">Expected impairment of income tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (900)<span></span>
</td>
<td class="nump">$ 98<span></span>
</td>
<td class="num">(899)<span></span>
</td>
<td class="nump">$ 159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Pre-tax income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,160)<span></span>
</td>
<td class="nump">$ 308<span></span>
</td>
<td class="num">$ (2,131)<span></span>
</td>
<td class="nump">$ 451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Obsolete stock written off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_EffectiveIncomeTaxReconciliationAmountInventoryWrittenOff', window );">Effective income tax reconciliation amount inventory written off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember', window );">Israel Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory tax rate in Israel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember', window );">Israel Tax Authority [Member] | Tax Year 2008 To 2011 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss', window );">Income Tax Examination, Estimate of Possible Loss</a></td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_EffectiveIncomeTaxReconciliationAmountInventoryWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax reconciliation amount inventory written off.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_EffectiveIncomeTaxReconciliationAmountInventoryWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ExpectedImpairmentOfIncomeTaxBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected impairment of income tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ExpectedImpairmentOfIncomeTaxBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_IncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_IncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated amount of loss resulting from an adverse tax position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=teva_TaxYear2008To2011Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=teva_TaxYear2008To2011Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684975381424">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Other assets impairments, restructuring and other items - Schedule of Other Assets Impairments, Restructuring and Other Items (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_RestructuringAndImpairmentCostsLineItems', window );"><strong>Restructuring and Impairment Costs [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairments of long-lived tangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">61<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">35<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ImpairmentAndRestructuring', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 118<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 246<span></span>
</td>
<td class="nump">$ 165<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Including impairments related to exit and disposal activities.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ImpairmentAndRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impairment and restructuring.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ImpairmentAndRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Legal settlements loss contingencies impairments other expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_RestructuringAndImpairmentCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring and impairment costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_RestructuringAndImpairmentCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684986889136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other assets impairments, restructuring and other items - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_RestructuringAndImpairmentCostsLineItems', window );"><strong>Restructuring and Impairment Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Impairments of property, plant and equipment</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Business combination contingent consideration arrangements change in amount of contingent consideration liability</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="num">$ (13)<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_RestructuringAndImpairmentCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring and impairment costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_RestructuringAndImpairmentCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684977727184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other assets impairments, restructuring and other items - Components of costs associated with restructuring plan including costs related to exit and disposal activities (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="num">$ (13)<span></span>
</td>
<td class="nump">$ 92<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee termination [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">11<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684985322064">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Other assets impairments, restructuring and other items - Summary of Restructuring Accruals (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (138)<span></span>
</td>
<td class="num">$ (122)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_RestructuringAccrualProvision', window );">Provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(92)<span></span>
</td>
<td class="num">(69)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_UtilizationAndOther', window );">Utilization and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">103<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(127)<span></span>
</td>
<td class="num">(127)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ExitAndDisposalAxis=teva_EmployeeTerminationMember', window );">Employee termination costs [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(131)<span></span>
</td>
<td class="num">(115)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_RestructuringAccrualProvision', window );">Provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(63)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_UtilizationAndOther', window );">Utilization and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">74<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(120)<span></span>
</td>
<td class="num">(120)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ExitAndDisposalAxis=teva_OtherExitAndDisposalMember', window );">Other Exit and Disposal [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_RestructuringAccrualProvision', window );">Provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_UtilizationAndOther', window );">Utilization and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">29<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (7)<span></span>
</td>
<td class="num">$ (7)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes adjustments for foreign currency translation.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_RestructuringAccrualProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring Accrual Provision</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_RestructuringAccrualProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_UtilizationAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Utilization and other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_UtilizationAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ExitAndDisposalAxis=teva_EmployeeTerminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ExitAndDisposalAxis=teva_EmployeeTerminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ExitAndDisposalAxis=teva_OtherExitAndDisposalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ExitAndDisposalAxis=teva_OtherExitAndDisposalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684977977824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) per Share - Additional Information (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share, Basic</a></td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="num">$ (1.07)<span></span>
</td>
<td class="nump">$ 0.26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share, Diluted</a></td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="num">$ (1.07)<span></span>
</td>
<td class="nump">$ 0.26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Number of Shares Outstanding, Diluted</a></td>
<td class="nump">1,110,000,000<span></span>
</td>
<td class="nump">1,109,000,000<span></span>
</td>
<td class="nump">1,109,000,000<span></span>
</td>
<td class="nump">1,108,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Weighted average shares with anti-dilutive effect on earnings per share</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684980100416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">6 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Jun. 30, 2022</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Beginning Balance</a></td>
<td class="num">$ (2,683)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Ending Balance</a></td>
<td class="num">(2,801)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Translation Adjustments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Beginning Balance</a></td>
<td class="num">(2,274)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (1,919)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(127)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(77)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent', window );">Net other comprehensive income (loss) before tax</a></td>
<td class="num">(127)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(77)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Corresponding income tax</a></td>
<td class="num">(5)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net other comprehensive income (loss) after tax</a></td>
<td class="num">(132)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(62)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Ending Balance</a></td>
<td class="num">(2,406)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,981)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Derivative Financial Instruments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Beginning Balance</a></td>
<td class="num">(324)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(363)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Amounts reclassified to the statements of income</a></td>
<td class="nump">14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent', window );">Net other comprehensive income (loss) before tax</a></td>
<td class="nump">14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Corresponding income tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net other comprehensive income (loss) after tax</a></td>
<td class="nump">14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Ending Balance</a></td>
<td class="num">(310)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(349)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Benefit Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Beginning Balance</a></td>
<td class="num">(85)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(117)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Amounts reclassified to the statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent', window );">Net other comprehensive income (loss) before tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net other comprehensive income (loss) after tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Ending Balance</a></td>
<td class="num">(85)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(116)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI Attributable to Parent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Beginning Balance</a></td>
<td class="num">(2,683)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,399)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(127)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(77)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Amounts reclassified to the statements of income</a></td>
<td class="nump">14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">19<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent', window );">Net other comprehensive income (loss) before tax</a></td>
<td class="num">(113)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(58)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Corresponding income tax</a></td>
<td class="num">(5)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">11<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net other comprehensive income (loss) after tax</a></td>
<td class="num">(118)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(47)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Ending Balance</a></td>
<td class="num">$ (2,801)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (2,446)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Amounts do not include a $150 million loss from foreign currency translation adjustments attributable to non-controlling interests.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Amounts do not include a $68 million loss from foreign currency translation adjustments attributable to non-controlling interests.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684986901296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss)  (Parenthetical) (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest', window );">Foreign currency translation attributable to non-controlling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember', window );">Foreign Currency Translation Adjustments Attributable to Non-controlling Interests [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest', window );">Foreign currency translation attributable to non-controlling interests</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684977326016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Summary of Segment Profit (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 3,786<span></span>
</td>
<td class="nump">$ 3,910<span></span>
</td>
<td class="nump">$ 7,447<span></span>
</td>
<td class="nump">$ 7,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">1,794<span></span>
</td>
<td class="nump">1,873<span></span>
</td>
<td class="nump">3,534<span></span>
</td>
<td class="nump">3,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">R&amp;D expenses</a></td>
<td class="nump">228<span></span>
</td>
<td class="nump">248<span></span>
</td>
<td class="nump">453<span></span>
</td>
<td class="nump">501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">S&amp;M expenses</a></td>
<td class="nump">594<span></span>
</td>
<td class="nump">615<span></span>
</td>
<td class="nump">1,178<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">G&amp;A expenses</a></td>
<td class="nump">313<span></span>
</td>
<td class="nump">242<span></span>
</td>
<td class="nump">609<span></span>
</td>
<td class="nump">532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segment profit</a></td>
<td class="num">(949)<span></span>
</td>
<td class="nump">582<span></span>
</td>
<td class="num">(1,662)<span></span>
</td>
<td class="nump">1,015<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_NorthAmericaSegmentMember', window );">North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,904<span></span>
</td>
<td class="nump">1,943<span></span>
</td>
<td class="nump">3,641<span></span>
</td>
<td class="nump">3,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">1,010<span></span>
</td>
<td class="nump">1,040<span></span>
</td>
<td class="nump">1,899<span></span>
</td>
<td class="nump">2,114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">R&amp;D expenses</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="nump">289<span></span>
</td>
<td class="nump">322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">S&amp;M expenses</a></td>
<td class="nump">256<span></span>
</td>
<td class="nump">255<span></span>
</td>
<td class="nump">501<span></span>
</td>
<td class="nump">483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">G&amp;A expenses</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="nump">239<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_OtherOperatingIncomeExpense', window );">Other (income) expense</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segment profit</a></td>
<td class="nump">481<span></span>
</td>
<td class="nump">521<span></span>
</td>
<td class="nump">883<span></span>
</td>
<td class="nump">1,098<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_EuropeSegmentMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,171<span></span>
</td>
<td class="nump">1,184<span></span>
</td>
<td class="nump">2,327<span></span>
</td>
<td class="nump">2,398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">703<span></span>
</td>
<td class="nump">661<span></span>
</td>
<td class="nump">1,397<span></span>
</td>
<td class="nump">1,349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">R&amp;D expenses</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">S&amp;M expenses</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">209<span></span>
</td>
<td class="nump">393<span></span>
</td>
<td class="nump">424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">G&amp;A expenses</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_OtherOperatingIncomeExpense', window );">Other (income) expense</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segment profit</a></td>
<td class="nump">389<span></span>
</td>
<td class="nump">343<span></span>
</td>
<td class="nump">769<span></span>
</td>
<td class="nump">680<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember', window );">International Markets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">454<span></span>
</td>
<td class="nump">485<span></span>
</td>
<td class="nump">946<span></span>
</td>
<td class="nump">975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">242<span></span>
</td>
<td class="nump">270<span></span>
</td>
<td class="nump">528<span></span>
</td>
<td class="nump">530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">R&amp;D expenses</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">S&amp;M expenses</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">G&amp;A expenses</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_OtherOperatingIncomeExpense', window );">Other (income) expense</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segment profit</a></td>
<td class="nump">$ 95<span></span>
</td>
<td class="nump">$ 123<span></span>
</td>
<td class="nump">$ 274<span></span>
</td>
<td class="nump">$ 245<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_OtherOperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Operating Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_OtherOperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=teva_NorthAmericaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=teva_NorthAmericaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=teva_EuropeSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=teva_EuropeSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684975414960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Summary of Profit by Segments and Reconciliation of Segments Profit to Consolidated Income Before Income Taxes (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AmountsAllocatedToSegmentsAbstract', window );"><strong>Amounts allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segments profit</a></td>
<td class="num">$ (949)<span></span>
</td>
<td class="nump">$ 582<span></span>
</td>
<td class="num">$ (1,662)<span></span>
</td>
<td class="nump">$ 1,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AmountsNotAllocatedToSegmentsAbstract', window );"><strong>Amounts not allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">212<span></span>
</td>
<td class="nump">173<span></span>
</td>
<td class="nump">412<span></span>
</td>
<td class="nump">414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ImpairmentsRestructuringAndOthers', window );">Other asset impairments, restructuring and other items</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">246<span></span>
</td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">745<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">745<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible assets impairments</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">195<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="nump">274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LegalSettlementsAndLossContingencies', window );">Legal settlements and loss contingencies</a></td>
<td class="nump">729<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">1,854<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_OtherUnallocatedAmounts', window );">Other unallocated amounts</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">240<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Consolidated operating income (loss)</a></td>
<td class="num">(949)<span></span>
</td>
<td class="nump">582<span></span>
</td>
<td class="num">(1,662)<span></span>
</td>
<td class="nump">1,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Financial expenses, net</a></td>
<td class="nump">211<span></span>
</td>
<td class="nump">274<span></span>
</td>
<td class="nump">468<span></span>
</td>
<td class="nump">564<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before income taxes</a></td>
<td class="num">(1,160)<span></span>
</td>
<td class="nump">308<span></span>
</td>
<td class="num">(2,131)<span></span>
</td>
<td class="nump">451<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_NorthAmericaSegmentMember', window );">North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AmountsAllocatedToSegmentsAbstract', window );"><strong>Amounts allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segments profit</a></td>
<td class="nump">481<span></span>
</td>
<td class="nump">521<span></span>
</td>
<td class="nump">883<span></span>
</td>
<td class="nump">1,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AmountsNotAllocatedToSegmentsAbstract', window );"><strong>Amounts not allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Consolidated operating income (loss)</a></td>
<td class="nump">481<span></span>
</td>
<td class="nump">521<span></span>
</td>
<td class="nump">883<span></span>
</td>
<td class="nump">1,098<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_EuropeSegmentMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AmountsAllocatedToSegmentsAbstract', window );"><strong>Amounts allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segments profit</a></td>
<td class="nump">389<span></span>
</td>
<td class="nump">343<span></span>
</td>
<td class="nump">769<span></span>
</td>
<td class="nump">680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AmountsNotAllocatedToSegmentsAbstract', window );"><strong>Amounts not allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Consolidated operating income (loss)</a></td>
<td class="nump">389<span></span>
</td>
<td class="nump">343<span></span>
</td>
<td class="nump">769<span></span>
</td>
<td class="nump">680<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember', window );">International Markets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AmountsAllocatedToSegmentsAbstract', window );"><strong>Amounts allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segments profit</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="nump">274<span></span>
</td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AmountsNotAllocatedToSegmentsAbstract', window );"><strong>Amounts not allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Consolidated operating income (loss)</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="nump">274<span></span>
</td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember', window );">Corporate Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AmountsAllocatedToSegmentsAbstract', window );"><strong>Amounts allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segments profit</a></td>
<td class="nump">964<span></span>
</td>
<td class="nump">987<span></span>
</td>
<td class="nump">1,926<span></span>
</td>
<td class="nump">2,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AmountsNotAllocatedToSegmentsAbstract', window );"><strong>Amounts not allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Consolidated operating income (loss)</a></td>
<td class="nump">964<span></span>
</td>
<td class="nump">987<span></span>
</td>
<td class="nump">1,926<span></span>
</td>
<td class="nump">2,023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AmountsAllocatedToSegmentsAbstract', window );"><strong>Amounts allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segments profit</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AmountsNotAllocatedToSegmentsAbstract', window );"><strong>Amounts not allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Consolidated operating income (loss)</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_SegmentsAndOtherActivitiesMember', window );">Segments and Other Activities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AmountsAllocatedToSegmentsAbstract', window );"><strong>Amounts allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segments profit</a></td>
<td class="nump">1,019<span></span>
</td>
<td class="nump">1,034<span></span>
</td>
<td class="nump">2,032<span></span>
</td>
<td class="nump">2,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AmountsNotAllocatedToSegmentsAbstract', window );"><strong>Amounts not allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Consolidated operating income (loss)</a></td>
<td class="nump">$ 1,019<span></span>
</td>
<td class="nump">$ 1,034<span></span>
</td>
<td class="nump">$ 2,032<span></span>
</td>
<td class="nump">$ 2,111<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AmountsAllocatedToSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts allocated to segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AmountsAllocatedToSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AmountsNotAllocatedToSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts not allocated to segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AmountsNotAllocatedToSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ImpairmentsRestructuringAndOthers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impairments restructuring and others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ImpairmentsRestructuringAndOthers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LegalSettlementsAndLossContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net proceeds or assets obtained in excess of (less than) the net carrying amount of assets recorded, or assets distributed and liabilities assumed less than (in excess of) litigation reserves extinguished, in settlement of a litigation matter. Represents (for other than an insurance entity in its normal claims settlement process), the amount of income (expense) recognized in the period to settle pending or threatened litigation and insurance claims and the aggregate amount provided for estimated restructuring charges, remediation costs, and asset impairment loss during an accounting period. Generally, these items are either unusual or infrequent, but not both (in which case they would be extraordinary items).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LegalSettlementsAndLossContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_OtherUnallocatedAmounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other unallocated amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_OtherUnallocatedAmounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=teva_NorthAmericaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=teva_NorthAmericaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=teva_EuropeSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=teva_EuropeSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=teva_SegmentsAndOtherActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=teva_SegmentsAndOtherActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684975874240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Schedule of Revenues by Major Products and Activities (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 3,786<span></span>
</td>
<td class="nump">$ 3,910<span></span>
</td>
<td class="nump">$ 7,447<span></span>
</td>
<td class="nump">$ 7,892<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_NorthAmericaSegmentMember', window );">North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,904<span></span>
</td>
<td class="nump">1,943<span></span>
</td>
<td class="nump">3,641<span></span>
</td>
<td class="nump">3,932<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_EuropeSegmentMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,171<span></span>
</td>
<td class="nump">1,184<span></span>
</td>
<td class="nump">2,327<span></span>
</td>
<td class="nump">2,398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember', window );">International Markets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">454<span></span>
</td>
<td class="nump">485<span></span>
</td>
<td class="nump">946<span></span>
</td>
<td class="nump">975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_GenericsMediciansMember', window );">Generic products [Member] | North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,026<span></span>
</td>
<td class="nump">951<span></span>
</td>
<td class="nump">1,925<span></span>
</td>
<td class="nump">2,004<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_GenericsMediciansMember', window );">Generic products [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">873<span></span>
</td>
<td class="nump">878<span></span>
</td>
<td class="nump">1,749<span></span>
</td>
<td class="nump">1,742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_GenericsMediciansMember', window );">Generic products [Member] | International Markets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">394<span></span>
</td>
<td class="nump">407<span></span>
</td>
<td class="nump">782<span></span>
</td>
<td class="nump">799<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_COPAXONEMember', window );">COPAXONE [Member] | North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">152<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_COPAXONEMember', window );">COPAXONE [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_COPAXONEMember', window );">COPAXONE [Member] | International Markets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_BendekaAndTreandaMember', window );">BENDEKA and TREANDA [Member] | North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_AjovyMember', window );">AJOVY [Member] | North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_AjovyMember', window );">AJOVY [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_AjovyMember', window );">AJOVY [Member] | International Markets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_AustedoMember', window );">AUSTEDO [Member] | North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">174<span></span>
</td>
<td class="nump">358<span></span>
</td>
<td class="nump">320<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_RespiratoryProductMember', window );">Respiratory Product [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_AndaMember', window );">Anda [Member] | North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">308<span></span>
</td>
<td class="nump">316<span></span>
</td>
<td class="nump">650<span></span>
</td>
<td class="nump">605<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_OtherProductsMember', window );">Other [Member] | North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="nump">278<span></span>
</td>
<td class="nump">414<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_OtherProductsMember', window );">Other [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="nump">238<span></span>
</td>
<td class="nump">242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_OtherProductsMember', window );">Other [Member] | International Markets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">$ 128<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=teva_NorthAmericaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=teva_NorthAmericaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=teva_EuropeSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=teva_EuropeSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=teva_GenericsMediciansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=teva_GenericsMediciansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=teva_COPAXONEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=teva_COPAXONEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=teva_BendekaAndTreandaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=teva_BendekaAndTreandaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=teva_AjovyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=teva_AjovyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=teva_AustedoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=teva_AustedoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=teva_RespiratoryProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=teva_RespiratoryProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=teva_AndaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=teva_AndaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=teva_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=teva_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684983151328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684975297104">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Summary of Financial Items Carried at Fair Value (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(205)<span></span>
</td>
<td class="num">(176)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,934<span></span>
</td>
<td class="nump">2,054<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_InterestRateSwapMember', window );">Asset Derivatives - Options and Forward Contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivatives</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">69<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Liabilities Derivatives - Interest Rate and Cross Currency Swaps [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivatives</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=teva_OptionsAndForwardContractsDerivativeLiabilitiesMember', window );">Liability Derivatives Options and Forward Contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivatives</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(37)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Markets [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">451<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_DemandDepositsMember', window );">Cash, Deposits and Other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,607<span></span>
</td>
<td class="nump">1,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment in securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=teva_OtherRestrictedCashMember', window );">Other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment in securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,106<span></span>
</td>
<td class="nump">2,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Money Markets [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">451<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Cash, Deposits and Other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,607<span></span>
</td>
<td class="nump">1,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Equity Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment in securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment in securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">32<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Asset Derivatives - Options and Forward Contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivatives</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">69<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Liability Derivatives Options and Forward Contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivatives</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(37)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(205)<span></span>
</td>
<td class="num">(176)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(204)<span></span>
</td>
<td class="num">(175)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment in securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Contingent consideration represents liabilities recorded at fair value in connection with acquisitions.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=teva_OptionsAndForwardContractsDerivativeLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=teva_OptionsAndForwardContractsDerivativeLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_DemandDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_DemandDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=teva_OtherRestrictedCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=teva_OtherRestrictedCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139685078324432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value measurement - Additional Information (Detail)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=teva_MeasurementInputProbabilityOfSuccessMember', window );">Measurement input probability of success [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Measurement input, discount rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">11.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Measurement input, discount rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">8.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">8.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=teva_MeasurementInputProbabilityOfSuccessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=teva_MeasurementInputProbabilityOfSuccessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684979169088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value at the beginning of the period</a></td>
<td class="num">$ (175)<span></span>
</td>
<td class="num">$ (258)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Redemption of debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_BifurcatedEmbeddedDerivatives', window );">Bifurcated embedded derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value at the end of the period</a></td>
<td class="num">(204)<span></span>
</td>
<td class="num">(204)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=teva_NoveTideAcquisitionMember', window );">Nove tide Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Redemption of debt securities</a></td>
<td class="num">(11)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=teva_ActavisGenericsMember', window );">Actavis Generics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod', window );">Actavis Generics transaction</a></td>
<td class="num">(92)<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Settlement of contingent consideration</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=teva_EagleTransactionMember', window );">Eagle Transaction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease', window );">Adjustments to provisions for contingent consideration</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Settlement of contingent consideration</a></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_BifurcatedEmbeddedDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Bifurcated embedded derivatives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_BifurcatedEmbeddedDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation recurring basis liability contingent consideration arising during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation recurring basis liability contingent consideration increase decrease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=teva_NoveTideAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=teva_NoveTideAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=teva_ActavisGenericsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=teva_ActavisGenericsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=teva_EagleTransactionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=teva_EagleTransactionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684985899456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Parenthetical) (Detail)<br></strong></div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=teva_NoveTideAcquisitionMember', window );">Nove tide Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition, Percentage of voting interests acquired</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=teva_NoveTideAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=teva_NoveTideAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139684987069424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Summary of Financial Instrument Measured on a Basis Other Than Fair Value (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Total</a></td>
<td class="nump">$ 19,183<span></span>
</td>
<td class="nump">$ 22,903<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=teva_SeniorNotesAndSustainabilityLinkedSeniorNotesMember', window );">Senior Notes And Sustainability Linked Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Total</a></td>
<td class="nump">17,481<span></span>
</td>
<td class="nump">21,477<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=teva_SeniornotesandconvertibleseniordebenturesMember', window );">Senior Notes and Convertible Senior Debentures Included Under Short-Term Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Total</a></td>
<td class="nump">$ 1,702<span></span>
</td>
<td class="nump">$ 1,426<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=teva_SeniorNotesAndSustainabilityLinkedSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=teva_SeniorNotesAndSustainabilityLinkedSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=teva_SeniornotesandconvertibleseniordebenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=teva_SeniornotesandconvertibleseniordebenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>d360666d10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:teva="http://www.tevapharm.com/20220630"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="teva-20220630.xsd" xlink:type="simple"/>
    <context id="P01_01_2022To06_30_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn09_01_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <instant>2020-09-01</instant>
        </period>
    </context>
    <context id="PAsOn08_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P08_21_2017To08_21_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2017-08-21</startDate>
            <endDate>2021-08-21</endDate>
        </period>
    </context>
    <context id="PAsOn07_31_2008">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <instant>2008-07-31</instant>
        </period>
    </context>
    <context id="PAsOn02_28_2005">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <instant>2005-02-28</instant>
        </period>
    </context>
    <context id="P04_01_2013To04_30_2013">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2013-04-01</startDate>
            <endDate>2013-04-30</endDate>
        </period>
    </context>
    <context id="P09_01_2013To09_30_2013">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2013-09-01</startDate>
            <endDate>2013-09-30</endDate>
        </period>
    </context>
    <context id="P12_01_2010To12_31_2010">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2010-12-01</startDate>
            <endDate>2010-12-31</endDate>
        </period>
    </context>
    <context id="P08_01_2012To08_31_2012">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2012-08-01</startDate>
            <endDate>2012-08-31</endDate>
        </period>
    </context>
    <context id="PAsOn06_30_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2014To12_31_2014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="P08_05_2021To08_05_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2021-08-05</startDate>
            <endDate>2021-08-05</endDate>
        </period>
    </context>
    <context id="PAsOn03_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="P06_02_2022To06_02_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2022-06-02</startDate>
            <endDate>2022-06-02</endDate>
        </period>
    </context>
    <context id="PAsOn07_08_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <instant>2021-07-08</instant>
        </period>
    </context>
    <context id="P02_04_2022To02_04_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2022-02-04</startDate>
            <endDate>2022-02-04</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DemandDepositsMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DemandDepositsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">teva:OtherRestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">teva:OtherRestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">teva:OtherRestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SeniornotesandconvertibleseniordebenturesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">teva:SeniornotesandconvertibleseniordebenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SeniorNotesAndSustainabilityLinkedSeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">teva:SeniorNotesAndSustainabilityLinkedSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">teva:ProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_InterestRateSwapMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_InterestRateSwapMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherCurrentAssetsMemberusgaapBalanceSheetLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:ShortCreditAgreement2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_SeniorNotesAndLoansMemberusgaapBalanceSheetLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">teva:SeniorNotesAndLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2028OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2024OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2046Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2023TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2026OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SubsidiarySeniorNotesDue2027MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2022OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2022ThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SubsidiarySeniorNotesDue2025ThreeMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2025ThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SubsidiarySeniorNotesDue2022TwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2022TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SustainabilityLinkedSeniorNotesDue2029MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilityLinkedSeniorNotesDue2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SustainabilityLinkedSeniorNotesDue2027TwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilityLinkedSeniorNotesDue2027TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2025TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2025OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SustainabilityLinkedSeniorNotesDue2027MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilityLinkedSeniorNotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2023OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SustainabilityLinkedSeniorNotesDue2030MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilityLinkedSeniorNotesDue2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_OtherDebentures2026MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:OtherDebentures2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">teva:OptionsAndForwardContractsDerivativeLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">teva:OptionsAndForwardContractsDerivativeLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CrossCurrencyInterestRateContractMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_DemandDepositsMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_DemandDepositsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_TevasApiReportingUnitMemberusgaapReportingUnitAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">teva:TevasApiReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_InternationalMarketsReportingUnitMemberusgaapReportingUnitAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">teva:InternationalMarketsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">teva:OtherRestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">teva:OtherRestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">teva:OtherRestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_SeniornotesandconvertibleseniordebenturesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">teva:SeniornotesandconvertibleseniordebenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_SeniorNotesAndSustainabilityLinkedSeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">teva:SeniorNotesAndSustainabilityLinkedSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">teva:ProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:ShortCreditAgreement2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_InterestRateSwapMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_InterestRateSwapMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_ActavisMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:ActavisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherCurrentAssetsMemberusgaapBalanceSheetLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_SeniorNotesAndLoansMemberusgaapBalanceSheetLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">teva:SeniorNotesAndLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2022ThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_SubsidiarySeniorNotesDue2025ThreeMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2025ThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2024OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2046Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2023TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2026OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_SubsidiarySeniorNotesDue2027MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2022OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2025OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_SustainabilityLinkedSeniorNotesDue2027MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilityLinkedSeniorNotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2023OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_SubsidiarySeniorNotesDue2030MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2028OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2025TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_SustainabilityLinkedSeniorNotesDue2027TwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilityLinkedSeniorNotesDue2027TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_SustainabilityLinkedSeniorNotesDue2029MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilityLinkedSeniorNotesDue2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_SubsidiarySeniorNotesDue2022TwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2022TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_SustainabilityLinkedSeniorNotesDue2030MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilityLinkedSeniorNotesDue2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_OtherDebentures2026MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:OtherDebentures2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_MeasurementInputTerminalGrowthRateMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">teva:MeasurementInputTerminalGrowthRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_MeasurementInputTerminalGrowthRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">teva:MeasurementInputTerminalGrowthRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_MaximumMembersrtRangeAxis_MeasurementInputTerminalGrowthRateMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">teva:MeasurementInputTerminalGrowthRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_TevasEuropeReportingUnitMemberusgaapReportingUnitAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">teva:TevasEuropeReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_NorthAmericaAndMedisReportingUnitsMemberusgaapReportingUnitAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">teva:NorthAmericaAndMedisReportingUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_MeasurementInputProbabilityOfSuccessMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">teva:MeasurementInputProbabilityOfSuccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_WeightedAverageMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">teva:OptionsAndForwardContractsDerivativeLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">teva:OptionsAndForwardContractsDerivativeLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_CrossCurrencyInterestRateContractMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_NorthAmericaMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_EuropeMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_LicenseMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_EuropeMembersrtStatementGeographicalAxis_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_LicenseMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_DistributionServiceMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:DistributionServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_DistributionServiceMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:DistributionServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_DistributionServiceMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:DistributionServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_DistributionServiceMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:DistributionServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_NorthAmericaMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_EuropeMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_NorthAmericaMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_EuropeMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_COPAXONEMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:COPAXONEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_AjovyMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AjovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_GenericsMediciansMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:GenericsMediciansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_RespiratoryProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:RespiratoryProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_COPAXONEMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:COPAXONEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_AjovyMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AjovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_GenericsMediciansMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:GenericsMediciansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_AndaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AndaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_COPAXONEMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:COPAXONEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_BendekaAndTreandaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:BendekaAndTreandaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_AustedoMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AustedoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_AjovyMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AjovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_GenericsMediciansMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:GenericsMediciansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_ParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">teva:ProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_GenericPipelineProductsMembersrtProductOrServiceAxis_InprocessresearchandDevelopmenttoProductRightsMemberusgaapReclassificationTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:GenericPipelineProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationTypeAxis">teva:InprocessresearchandDevelopmenttoProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_CorporateMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_AllOtherSegmentsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_SegmentsAndOtherActivitiesMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:SegmentsAndOtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:NetRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NotDesignatedAsHedgingInstrumentTradingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NotDesignatedAsHedgingInstrumentTradingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:NetRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:NetRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_SettlementOnAccountOfProductLiabilityMembersrtLitigationCaseAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">teva:SettlementOnAccountOfProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_DistributionServiceMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:DistributionServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_DistributionServiceMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:DistributionServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_NorthAmericaMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_EuropeMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_NorthAmericaMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_EuropeMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_NorthAmericaMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_EuropeMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_LicenseMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_EuropeMembersrtStatementGeographicalAxis_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_LicenseMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_DistributionServiceMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:DistributionServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_DistributionServiceMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:DistributionServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_COPAXONEMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:COPAXONEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_AjovyMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AjovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_GenericsMediciansMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:GenericsMediciansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_RespiratoryProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:RespiratoryProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_COPAXONEMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:COPAXONEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_AjovyMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AjovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_GenericsMediciansMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:GenericsMediciansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_AndaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AndaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_COPAXONEMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:COPAXONEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_BendekaAndTreandaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:BendekaAndTreandaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_AustedoMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AustedoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_AjovyMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AjovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_GenericsMediciansMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:GenericsMediciansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_ParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_ActavisMemberusgaapBusinessAcquisitionAxis_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:ActavisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">teva:ProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_GenericPipelineProductsMembersrtProductOrServiceAxis_InprocessresearchandDevelopmenttoProductRightsMemberusgaapReclassificationTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:GenericPipelineProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationTypeAxis">teva:InprocessresearchandDevelopmenttoProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_ActavisMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:ActavisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">teva:ProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_CorporateMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_AllOtherSegmentsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_SegmentsAndOtherActivitiesMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:SegmentsAndOtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:NetRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NotDesignatedAsHedgingInstrumentTradingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NotDesignatedAsHedgingInstrumentTradingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:NetRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:NetRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_EuropeMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_NorthAmericaMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_EuropeMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_LicenseMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_EuropeMembersrtStatementGeographicalAxis_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_LicenseMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_DistributionServiceMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:DistributionServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_DistributionServiceMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:DistributionServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_DistributionServiceMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:DistributionServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_DistributionServiceMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:DistributionServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_NorthAmericaMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_EuropeMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_NorthAmericaMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_COPAXONEMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:COPAXONEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_AjovyMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AjovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_GenericsMediciansMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:GenericsMediciansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_GenericsMediciansMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:GenericsMediciansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_AjovyMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AjovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_COPAXONEMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:COPAXONEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_RespiratoryProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:RespiratoryProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_AndaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AndaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_COPAXONEMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:COPAXONEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_BendekaAndTreandaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:BendekaAndTreandaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_AustedoMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AustedoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_AjovyMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AjovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_GenericsMediciansMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:GenericsMediciansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_EmployeeTerminationMemberTEVAExitAndDisposalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis">teva:EmployeeTerminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis">teva:OtherExitAndDisposalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_ParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_NoveTideAcquisitionMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:NoveTideAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ReservesIncludedInAccountsReceivableNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:RebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:MedicaidAndOtherGovernmentalAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:OtherSalesReservesAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:TotalReservesIncludedInSalesReservesAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_ActavisMemberusgaapBusinessAcquisitionAxis_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:ActavisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">teva:ProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_GenericPipelineProductsMembersrtProductOrServiceAxis_InprocessresearchandDevelopmenttoProductRightsMemberusgaapReclassificationTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:GenericPipelineProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationTypeAxis">teva:InprocessresearchandDevelopmenttoProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_ActavisMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:ActavisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">teva:ProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_SegmentsAndOtherActivitiesMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:SegmentsAndOtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_AllOtherSegmentsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_CorporateMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_AccountingStandardsUpdate201601MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:NetRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NotDesignatedAsHedgingInstrumentTradingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NotDesignatedAsHedgingInstrumentTradingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:NetRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:NetRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_CostOfSalesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_EagleTransactionMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:EagleTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_ActavisGenericsMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:ActavisGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_NorthAmericaMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_EuropeMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_LicenseMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_EuropeMembersrtStatementGeographicalAxis_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_LicenseMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_DistributionServiceMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:DistributionServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_DistributionServiceMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:DistributionServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_DistributionServiceMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:DistributionServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_DistributionServiceMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:DistributionServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_EuropeMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_NorthAmericaMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_EuropeMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_NorthAmericaMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_COPAXONEMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:COPAXONEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_AjovyMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AjovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_GenericsMediciansMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:GenericsMediciansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_RespiratoryProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:RespiratoryProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_AjovyMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AjovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_COPAXONEMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:COPAXONEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_GenericsMediciansMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:GenericsMediciansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_AndaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AndaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_COPAXONEMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:COPAXONEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_BendekaAndTreandaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:BendekaAndTreandaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_AustedoMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AustedoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_AjovyMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AjovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_GenericsMediciansMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:GenericsMediciansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_EmployeeTerminationMemberTEVAExitAndDisposalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis">teva:EmployeeTerminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis">teva:OtherExitAndDisposalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_ParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_NoveTideAcquisitionMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:NoveTideAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_OtherCountriesMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">teva:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:ShortCreditAgreement2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_TakedaMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:TakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_AlvotechMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:AlvotechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:TotalReservesIncludedInSalesReservesAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ReservesIncludedInAccountsReceivableNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:RebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:MedicaidAndOtherGovernmentalAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:OtherSalesReservesAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">teva:ProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_GenericPipelineProductsMembersrtProductOrServiceAxis_InprocessresearchandDevelopmenttoProductRightsMemberusgaapReclassificationTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:GenericPipelineProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationTypeAxis">teva:InprocessresearchandDevelopmenttoProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_SegmentsAndOtherActivitiesMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:SegmentsAndOtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_AllOtherSegmentsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_CorporateMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_EosinophilicEsophagitisMemberusgaapLossContingenciesByNatureOfContingencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">teva:EosinophilicEsophagitisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_EosinophilicEsophagitisMemberusgaapLossContingenciesByNatureOfContingencyAxis_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">teva:EosinophilicEsophagitisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_SustainabilityLinkedSeniorNotesDue2030MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilityLinkedSeniorNotesDue2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2023OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_SustainabilityLinkedSeniorNotesDue2027MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilityLinkedSeniorNotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2025OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_SustainabilityLinkedSeniorNotesDue2027TwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilityLinkedSeniorNotesDue2027TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_SustainabilityLinkedSeniorNotesDue2029MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilityLinkedSeniorNotesDue2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2022TwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2022TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2025ThreeMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2025ThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2022ThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2022OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2027MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2026OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2023TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2046Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2024OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2025TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2028OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:NetRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NotDesignatedAsHedgingInstrumentTradingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NotDesignatedAsHedgingInstrumentTradingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:NetRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:NetRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_InternationalMarketsMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_CostOfSalesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_EagleTransactionMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:EagleTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_ActavisGenericsMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:ActavisGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_UnsecuredSyndicatedRevolvingCreditFacilityMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">teva:UnsecuredSyndicatedRevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_InterestRateIncreaseMemberusgaapDebtInstrumentAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:InterestRateIncreaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_InterestRateIncreaseMemberusgaapDebtInstrumentAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:InterestRateIncreaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_MaximumMembersrtRangeAxis_OneTimePremiumPaymentMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:OneTimePremiumPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_MinimumMembersrtRangeAxis_OneTimePremiumPaymentMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:OneTimePremiumPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_OneTimePremiumPaymentMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:OneTimePremiumPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_InterestRateIncreaseMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:InterestRateIncreaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="PAsOn04_30_2022_UnsecuredSyndicatedRevolvingCreditFacilityMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">teva:UnsecuredSyndicatedRevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="PAsOn04_30_2022_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P10_01_2022To12_31_2022_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P04_01_2023To06_30_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P10_01_2023To12_31_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P07_01_2016To09_30_2016_RegeneronMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:RegeneronMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2016To09_30_2016_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">teva:SeniorNotesDue2023TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="PAsOn09_30_2016_SeniorNotesDue2022MemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">teva:SeniorNotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2016_SeniorNotesDue2021MemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">teva:SeniorNotesDue2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2016_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">teva:SeniorNotesDue2023TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2019_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">teva:SeniorNotesDue2023TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="P10_01_2021To10_31_2021_ModagMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:ModagMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="P10_01_2021To10_31_2021_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis_TaxYear2008To2011MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">teva:TaxYear2008To2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="P10_01_2021To12_31_2021_ModagMemberusgaapBusinessAcquisitionAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:ModagMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_08_2018To01_08_2018_AlderMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:AlderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-08</startDate>
            <endDate>2018-01-08</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_AlderMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:AlderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P05_12_2017To05_12_2017_OtsukaMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:OtsukaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-12</startDate>
            <endDate>2017-05-12</endDate>
        </period>
    </context>
    <context id="P01_01_2020To09_30_2020_OtsukaMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:OtsukaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To09_30_2021_OtsukaMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:OtsukaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P09_01_2016To09_30_2016_RegeneronMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:RegeneronMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2017To12_31_2017_RegeneronMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:RegeneronMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2017To12_31_2017_CAsrtStatementGeographicalAxis_VireadMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:VireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_RegeneronMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:RegeneronMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P08_01_2021To08_31_2021_MedincellMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:MedincellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="P12_01_2016To12_31_2016_TakedaMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:TakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn01_01_2022_NoveTideAcquisitionMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:NoveTideAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="PAsOn08_31_2019_AndroGelRateAtOnePercentageMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AndroGelRateAtOnePercentageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="PAsOn02_01_2021_AtripalaMembersrtProductOrServiceAxis_CAsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AtripalaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-01</instant>
        </period>
    </context>
    <context id="PAsOn02_01_2021_CAsrtStatementGeographicalAxis_ColcysMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:ColcysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-01</instant>
        </period>
    </context>
    <context id="PAsOn02_01_2021_CAsrtStatementGeographicalAxis_VireadMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:VireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-01</instant>
        </period>
    </context>
    <context id="PAsOn02_01_2021_CAsrtStatementGeographicalAxis_TiruvadaMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:TiruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-01</instant>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CAsrtStatementGeographicalAxis_TiruvadaMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:TiruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AtripalaMembersrtProductOrServiceAxis_CAsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AtripalaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P05_01_2019To05_31_2019_OpioidLitigationMembersrtLitigationCaseAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">teva:OpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="P10_21_2019To10_21_2019_OpioidLitigationMembersrtLitigationCaseAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">teva:OpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-21</startDate>
            <endDate>2019-10-21</endDate>
        </period>
    </context>
    <context id="P07_21_2021To07_21_2021_FourOtherDefendantsOtherThanTevaMemberTEVADefendantsAxis_NationwideSettlementMembersrtLitigationCaseAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">teva:NationwideSettlementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="teva:DefendantsAxis">teva:FourOtherDefendantsOtherThanTevaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-21</startDate>
            <endDate>2021-07-21</endDate>
        </period>
    </context>
    <context id="PAsOn02_04_2022_AttorneyGeneralOfLouisanaMemberTEVAAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="teva:AgreementAxis">teva:AttorneyGeneralOfLouisanaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-04</instant>
        </period>
    </context>
    <context id="P02_04_2022To02_04_2022_OpioidLitigationMembersrtLitigationCaseAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">teva:OpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-04</startDate>
            <endDate>2022-02-04</endDate>
        </period>
    </context>
    <context id="PAsOn03_30_2022_AttorneyGeneralOfFloridaMemberTEVAAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="teva:AgreementAxis">teva:AttorneyGeneralOfFloridaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-30</instant>
        </period>
    </context>
    <context id="P03_30_2022To03_30_2022_OpioidLitigationMembersrtLitigationCaseAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">teva:OpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-30</startDate>
            <endDate>2022-03-30</endDate>
        </period>
    </context>
    <context id="P05_24_2022To05_24_2022_OpioidLitigationMembersrtLitigationCaseAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">teva:OpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="PAsOn05_24_2022_AttorneyGeneralOfWestVirginiaMemberTEVAAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="teva:AgreementAxis">teva:AttorneyGeneralOfWestVirginiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="P07_12_2022To07_12_2022_OpioidLitigationMembersrtLitigationCaseAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">teva:OpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-12</startDate>
            <endDate>2022-07-12</endDate>
        </period>
    </context>
    <context id="PAsOn07_12_2022_OpioidLitigationMembersrtLitigationCaseAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">teva:OpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-12</instant>
        </period>
    </context>
    <context id="P09_28_2021To09_28_2021_AttorneyGeneralOfLouisanaMemberTEVAAgreementAxis_LAsrtStatementGeographicalAxis_OpioidLitigationMembersrtLitigationCaseAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">teva:OpioidLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:LA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="teva:AgreementAxis">teva:AttorneyGeneralOfLouisanaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-28</startDate>
            <endDate>2021-09-28</endDate>
        </period>
    </context>
    <context id="PAsOn09_28_2021_AttorneyGeneralOfLouisanaMemberTEVAAgreementAxis_LAsrtStatementGeographicalAxis_OpioidLitigationMembersrtLitigationCaseAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">teva:OpioidLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:LA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="teva:AgreementAxis">teva:AttorneyGeneralOfLouisanaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-28</instant>
        </period>
    </context>
    <context id="P03_21_2022To03_21_2022_OpioidLitigationMembersrtLitigationCaseAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">teva:OpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-21</startDate>
            <endDate>2022-03-21</endDate>
        </period>
    </context>
    <context id="PAsOn03_21_2022_AttorneyGeneralOfRhodeIslandMemberTEVAAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="teva:AgreementAxis">teva:AttorneyGeneralOfRhodeIslandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-21</instant>
        </period>
    </context>
    <context id="PAsOn07_01_2022_CompaniesShareMemberTEVADefendantsAxis_StatesPoliticalSubdivisionsAndTribesMembersrtLitigationCaseAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">teva:StatesPoliticalSubdivisionsAndTribesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="teva:DefendantsAxis">teva:CompaniesShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="P07_01_2022To07_31_2022_CompaniesShareMemberTEVADefendantsAxis_StatesPoliticalSubdivisionsAndTribesMembersrtLitigationCaseAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">teva:StatesPoliticalSubdivisionsAndTribesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="teva:DefendantsAxis">teva:CompaniesShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="PAsOn07_31_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="PAsOn07_31_2022_CompaniesShareMemberTEVADefendantsAxis_StatesPoliticalSubdivisionsAndTribesMembersrtLitigationCaseAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">teva:StatesPoliticalSubdivisionsAndTribesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="teva:DefendantsAxis">teva:CompaniesShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_TreasuryStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_ParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_TreasuryStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_TreasuryStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_TreasuryStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_ParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_TreasuryStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_EmployeeTerminationMemberTEVAExitAndDisposalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis">teva:EmployeeTerminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis">teva:OtherExitAndDisposalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_EmployeeTerminationMemberTEVAExitAndDisposalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis">teva:EmployeeTerminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis">teva:OtherExitAndDisposalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ReservesIncludedInAccountsReceivableNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:RebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:MedicaidAndOtherGovernmentalAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:OtherSalesReservesAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:TotalReservesIncludedInSalesReservesAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ReservesIncludedInAccountsReceivableNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:RebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:MedicaidAndOtherGovernmentalAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:OtherSalesReservesAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:TotalReservesIncludedInSalesReservesAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_TreasuryStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_NorthAmericaMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EuropeMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_InternationalMarketsMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_OtherCountriesMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">teva:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EmployeeTerminationMemberTEVAExitAndDisposalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis">teva:EmployeeTerminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis">teva:OtherExitAndDisposalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_EmployeeTerminationMemberTEVAExitAndDisposalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis">teva:EmployeeTerminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis">teva:OtherExitAndDisposalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ReservesIncludedInAccountsReceivableNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:RebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:MedicaidAndOtherGovernmentalAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:OtherSalesReservesAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:TotalReservesIncludedInSalesReservesAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ReservesIncludedInAccountsReceivableNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:RebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:MedicaidAndOtherGovernmentalAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:OtherSalesReservesAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:TotalReservesIncludedInSalesReservesAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_NorthAmericaMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_EuropeMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_InternationalMarketsMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_OtherCountriesMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">teva:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_CHF">
        <measure>iso4217:CHF</measure>
    </unit>
    <unit id="Unit_EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Segment">
        <measure>teva:Segment</measure>
    </unit>
    <dei:AmendmentFlag contextRef="P01_01_2022To06_30_2022">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="P01_01_2022To06_30_2022">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="P01_01_2022To06_30_2022">0000818686</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="P01_01_2022To06_30_2022">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityTaxIdentificationNumber contextRef="P01_01_2022To06_30_2022" id="hidden52307726">00-0000000</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressCountry contextRef="P01_01_2022To06_30_2022" id="hidden52307730">IL</dei:EntityAddressCountry>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P01_01_2022To06_30_2022_UnsecuredSyndicatedRevolvingCreditFacilityMemberusgaapCreditFacilityAxis"
      id="hidden52308335">2026-04-30</us-gaap:DebtInstrumentMaturityDate>
    <dei:DocumentType contextRef="P01_01_2022To06_30_2022">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="P01_01_2022To06_30_2022">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="P01_01_2022To06_30_2022">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="P01_01_2022To06_30_2022">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="P01_01_2022To06_30_2022">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="P01_01_2022To06_30_2022">001-16174</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="P01_01_2022To06_30_2022">TEVA PHARMACEUTICAL INDUSTRIES LIMITED</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="P01_01_2022To06_30_2022">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="P01_01_2022To06_30_2022">124 Dvora HaNevi&#x2019;a St.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="P01_01_2022To06_30_2022">Tel Aviv</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="P01_01_2022To06_30_2022">6944020</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="P01_01_2022To06_30_2022">3</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P01_01_2022To06_30_2022">914-8213</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="P01_01_2022To06_30_2022">American Depositary Shares, each representing one Ordinary Share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="P01_01_2022To06_30_2022">TEVA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="P01_01_2022To06_30_2022">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="P01_01_2022To06_30_2022">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="P01_01_2022To06_30_2022">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="P01_01_2022To06_30_2022">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="P01_01_2022To06_30_2022">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="P01_01_2022To06_30_2022">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="P01_01_2022To06_30_2022">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="PAsOn06_30_2022"
      decimals="INF"
      unitRef="Unit_shares">1110564656</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">2058000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">2165000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="PAsOn06_30_2022"
      decimals="INF"
      unitRef="Unit_USD">95000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_USD">90000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">4471000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">4529000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">4049000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">3818000000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">1052000000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">1075000000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">518000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">965000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">16000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">19000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">12164000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">12573000000</us-gaap:AssetsCurrent>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">1595000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">596000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">454000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">515000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">5740000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">5982000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">441000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">495000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">6700000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">7466000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">18837000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">20040000000</us-gaap:Goodwill>
    <us-gaap:Assets
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">45932000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">47666000000</us-gaap:Assets>
    <us-gaap:DebtCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">1719000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">1426000000</us-gaap:DebtCurrent>
    <teva:SalesReservesAndAllowances
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">3880000000</teva:SalesReservesAndAllowances>
    <teva:SalesReservesAndAllowances
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">4241000000</teva:SalesReservesAndAllowances>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">1901000000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">1686000000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">467000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">563000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <teva:AccruedExpenses
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">2112000000</teva:AccruedExpenses>
    <teva:AccruedExpenses
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">2208000000</teva:AccruedExpenses>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">916000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">903000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">10996000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">11027000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">532000000</us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent>
    <us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">784000000</us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">3842000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">2578000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LongTermNotesAndLoans
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">20363000000</us-gaap:LongTermNotesAndLoans>
    <us-gaap:LongTermNotesAndLoans
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">21617000000</us-gaap:LongTermNotesAndLoans>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">371000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">416000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">25107000000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">25395000000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn06_30_2022"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2021"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:Liabilities
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">36103000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">36422000000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.1</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn06_30_2022"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.1</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">2495</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn06_30_2022"
      decimals="INF"
      unitRef="Unit_shares">2495</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn06_30_2022"
      decimals="INF"
      unitRef="Unit_shares">1216</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">1209</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">57000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">57000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">27625000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">27561000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-11716000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">-10529000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-2801000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">-2683000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockShares
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">106000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="PAsOn06_30_2022"
      decimals="INF"
      unitRef="Unit_shares">106000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">4128000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">4128000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">9037000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">10278000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">791000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">966000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">9828000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">11244000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">45932000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">47666000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">3786000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">3910000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">7447000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">7892000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">1992000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">2037000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">3913000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">4141000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">1794000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">1873000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">3534000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">3750000000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">228000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">248000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">453000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">501000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">594000000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">615000000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">1178000000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">1200000000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">313000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">242000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">609000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">532000000</us-gaap:GeneralAndAdministrativeExpense>
    <teva:IntangibleAssetsImpairments
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">51000000</teva:IntangibleAssetsImpairments>
    <teva:IntangibleAssetsImpairments
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">195000000</teva:IntangibleAssetsImpairments>
    <teva:IntangibleAssetsImpairments
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">199000000</teva:IntangibleAssetsImpairments>
    <teva:IntangibleAssetsImpairments
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">274000000</teva:IntangibleAssetsImpairments>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">745000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">745000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:GoodwillImpairmentLoss>
    <teva:ImpairmentsRestructuringAndOthers
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">118000000</teva:ImpairmentsRestructuringAndOthers>
    <teva:ImpairmentsRestructuringAndOthers
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">28000000</teva:ImpairmentsRestructuringAndOthers>
    <teva:ImpairmentsRestructuringAndOthers
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">246000000</teva:ImpairmentsRestructuringAndOthers>
    <teva:ImpairmentsRestructuringAndOthers
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">165000000</teva:ImpairmentsRestructuringAndOthers>
    <teva:LegalSettlementsAndLossContingencies
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">729000000</teva:LegalSettlementsAndLossContingencies>
    <teva:LegalSettlementsAndLossContingencies
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">6000000</teva:LegalSettlementsAndLossContingencies>
    <teva:LegalSettlementsAndLossContingencies
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">1854000000</teva:LegalSettlementsAndLossContingencies>
    <teva:LegalSettlementsAndLossContingencies
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">110000000</teva:LegalSettlementsAndLossContingencies>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">34000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">43000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">87000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">48000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OperatingIncomeLoss
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-949000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">582000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-1662000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">1015000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-211000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">-274000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-468000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">-564000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-1160000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">308000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-2131000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">451000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-900000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">98000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-899000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">159000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">11000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">21000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">14000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-259000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">221000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-1211000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">306000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-27000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">14000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-24000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">21000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-232000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">207000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-1187000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">284000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="P04_01_2022To06_30_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P04_01_2021To06_30_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To06_30_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-1.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2021To06_30_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.26</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P04_01_2022To06_30_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P04_01_2021To06_30_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To06_30_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-1.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2021To06_30_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_shares">1110000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_shares">1103000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_shares">1109000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_shares">1101000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_shares">1110000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_shares">1109000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_shares">1109000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_shares">1108000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-259000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">221000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-1211000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">306000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-219000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">79000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-282000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">-130000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <teva:UnrealizedGainLossOnDerivativeNetOfTax
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">7000000</teva:UnrealizedGainLossOnDerivativeNetOfTax>
    <teva:UnrealizedGainLossOnDerivativeNetOfTax
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">7000000</teva:UnrealizedGainLossOnDerivativeNetOfTax>
    <teva:UnrealizedGainLossOnDerivativeNetOfTax
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">14000000</teva:UnrealizedGainLossOnDerivativeNetOfTax>
    <teva:UnrealizedGainLossOnDerivativeNetOfTax
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">14000000</teva:UnrealizedGainLossOnDerivativeNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">1000000</us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">1000000</us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-212000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">87000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-268000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">-115000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-471000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">308000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-1479000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">191000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-125000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">13000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-174000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">-47000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-346000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">295000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-1305000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">238000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesIssued
      contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_shares">1216000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">57000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">27587000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-11484000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-2687000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2022_TreasuryStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-4128000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2022_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">9344000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">916000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">10260000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2022To06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-232000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2022To06_30_2022_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-232000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2022To06_30_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-27000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-259000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P04_01_2022To06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-114000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P04_01_2022To06_30_2022_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-114000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P04_01_2022To06_30_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-98000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-212000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_01_2022To06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">39000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_01_2022To06_30_2022_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">39000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">39000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesIssued
      contextRef="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_shares">1216000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">57000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">27625000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-11716000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-2801000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2022_TreasuryStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-4128000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2022_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">9037000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">791000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">9828000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P04_01_2022To06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis"
      decimals="-5"
      unitRef="Unit_USD">500000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:SharesIssued
      contextRef="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_shares">1208000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">57000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">27474000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-10869000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-2534000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2021_TreasuryStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-4128000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2021_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">10000000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">975000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_USD">10975000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2021To06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">207000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2021To06_30_2021_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">207000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2021To06_30_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">14000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">221000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P04_01_2021To06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">88000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P04_01_2021To06_30_2021_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">88000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P04_01_2021To06_30_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">87000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P04_01_2021To06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_52307110"
      unitRef="Unit_shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_01_2021To06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">29000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_01_2021To06_30_2021_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">29000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">29000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesIssued
      contextRef="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_shares">1209000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">57000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">27503000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-10662000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-2446000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2021_TreasuryStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-4128000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2021_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">10324000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">987000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">11311000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P04_01_2021To06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis"
      decimals="-5"
      unitRef="Unit_USD">500000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_shares">1209000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">57000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">27561000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-10529000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-2683000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021_TreasuryStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-4128000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">10278000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">966000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">11244000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2022To06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-1187000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2022To06_30_2022_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-1187000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2022To06_30_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-24000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-1211000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2022To06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-118000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2022To06_30_2022_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-118000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2022To06_30_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-150000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-268000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2022To06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_52307132"
      unitRef="Unit_shares">7000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2022To06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2022To06_30_2022_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">1000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2022To06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">63000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2022To06_30_2022_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">63000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">63000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesIssued
      contextRef="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_shares">1216000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">57000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">27625000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-11716000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-2801000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2022_TreasuryStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-4128000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2022_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">9037000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">791000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">9828000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2022To06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis"
      decimals="-5"
      unitRef="Unit_USD">500000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_shares">1202000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">57000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">27443000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-10946000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-2399000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020_TreasuryStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-4128000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">10026000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1035000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">11061000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2021To06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">284000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2021To06_30_2021_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">284000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2021To06_30_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">21000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">306000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2021To06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-47000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2021To06_30_2021_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-47000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2021To06_30_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-68000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">-115000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2021To06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_52307165"
      unitRef="Unit_shares">6000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2021To06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">60000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2021To06_30_2021_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">60000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">60000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesIssued
      contextRef="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_shares">1209000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">57000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">27503000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-10662000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-2446000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2021_TreasuryStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-4128000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2021_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">10324000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">987000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">11311000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2021To06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis"
      decimals="-5"
      unitRef="Unit_USD">500000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-1211000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">306000000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">681000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">681000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AssetImpairmentCharges
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">975000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">354000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:IncreaseDecreaseInOperatingCapital
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-913000000</us-gaap:IncreaseDecreaseInOperatingCapital>
    <us-gaap:IncreaseDecreaseInOperatingCapital
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">1679000000</us-gaap:IncreaseDecreaseInOperatingCapital>
    <teva:DeferredIncomeTaxesNetAndUncertainTaxPositions
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-1258000000</teva:DeferredIncomeTaxesNetAndUncertainTaxPositions>
    <teva:DeferredIncomeTaxesNetAndUncertainTaxPositions
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">5000000</teva:DeferredIncomeTaxesNetAndUncertainTaxPositions>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">63000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">60000000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-77000000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">-7000000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <teva:ProfitFromSaleOfLongLivedAssetsAndInvestment
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">12000000</teva:ProfitFromSaleOfLongLivedAssetsAndInvestment>
    <teva:ProfitFromSaleOfLongLivedAssetsAndInvestment
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">-93000000</teva:ProfitFromSaleOfLongLivedAssetsAndInvestment>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">74000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">-187000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <teva:ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">592000000</teva:ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables>
    <teva:ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">881000000</teva:ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">43000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">254000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">7000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">284000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">263000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <teva:PaymentToAcquireMarketableSecuritiesAndOtherAssets
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">4000000</teva:PaymentToAcquireMarketableSecuritiesAndOtherAssets>
    <teva:PaymentToAcquireMarketableSecuritiesAndOtherAssets
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">36000000</teva:PaymentToAcquireMarketableSecuritiesAndOtherAssets>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">3000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">153000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">2000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">341000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">989000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">491000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">296000000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-40000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">-3000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-336000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">-494000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-185000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">-49000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-107000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">259000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">2198000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">2177000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">2091000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">2436000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">2058000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">2436000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">33000000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">2091000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">2436000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <teva:BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">590000000</teva:BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables>
    <teva:BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables
      contextRef="PAsOn06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">878000000</teva:BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="P01_01_2022To06_30_2022">&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 1 &#x2013; Basis of presentation: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;a.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basis of presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying unaudited consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements. In the opinion of management, the financial statements reflect all normal and recurring adjustments necessary to fairly state the financial position and results of operations of Teva. The information included in this Quarterly Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-Q&lt;/div&gt; should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company&#x2019;s Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-K&lt;/div&gt; for the year ended December&#160;31, 2021, as filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;). The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;year-end&lt;/div&gt; balance sheet data was derived from the audited consolidated financial statements as of December&#160;31, 2021, but not all disclosures required by generally accepted accounting principles in the United States (&#x201c;U.S. GAAP&#x201d;) are included. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the process of preparing the consolidated financial statements, management makes estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. The inputs into Teva&#x2019;s judgments and estimates also consider the economic implications of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic on its critical and significant accounting estimates, most significantly in relation to sales, reserves and allowances, IPR&amp;amp;D assets, marketed product rights and goodwill, all of which will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic and the actions taken to contain or treat it, as well as the economic impact on Teva&#x2019;s employees, third-party manufacturers and suppliers, customers and markets. All estimates made by Teva related to the impact of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic within its financial statements may change in future periods. Actual results could differ from those estimates. &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;In February 2022, Russia launched an invasion of Ukraine. As of the date of this Quarterly Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-Q,&lt;/div&gt; sustained conflict and disruption in the region is ongoing. Russia and Ukraine markets are included in Teva&#x2019;s International Markets segment results. Teva has no manufacturing or R&amp;amp;D facilities in these markets. As part of the Company&#x2019;s annual goodwill analysis, it identified an increase in the discount rate, which led to a goodwill impairment charge in its International Markets and Teva&#x2019;s API reporting units. This increase was a result of an increase in certain components of the discount rate that were partially attributed to higher risk associated with country-specific characteristics of several countries, such as Russia, that might be a consequence of the conflict. Other than its impact on the goodwill impairment charge, during the three and six months ended June 30, 2022, the impact of this conflict on Teva&#x2019;s results of operations and financial condition was immaterial. See also note 6. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The results of operations for the three and six months ended June&#160;30, 2022 are not necessarily indicative of results that could be expected for the entire fiscal year. Certain amounts in the consolidated financial statements and associated notes may not add up due to rounding. All percentages have been calculated using unrounded amounts. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;b.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Significant accounting policies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Recently adopted accounting pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In August 2020, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; &#x201c;Debt &#x2013; Debt with Conversion and Other Options (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;470-20)&lt;/div&gt; and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815 &#x2013; 40).&#x201d; This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#x2019;s own equity. The amendments to this guidance are effective for fiscal years beginning after December&#160;15, 2021, and interim periods within those fiscal years. The adoption of this guidance did not have a significant impact on the Company&#x2019;s consolidated financial statements. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In March 2020, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-04&lt;/div&gt; &#x201c;Reference Rate Reform (Topic 848)&#x2014;Facilitation of the Effects of Reference Rate Reform on Financial Reporting.&#x201d; This guidance provides optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The guidance applies only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. This guidance is effective for all entities as of March&#160;12, 2020 through December&#160;31, 2022. There was no material impact to the Company&#x2019;s consolidated financial statements for the period ended June&#160;30, 2022 as a result of adopting this standard update. The Company has completed negotiations to transform the facility base rate of its securitization program and evaluated the potential impact of the replacement of the LIBOR benchmark on its interest rate risk management activities. The adoption of this guidance did not have a material impact on the Company&#x2019;s consolidated financial results of operations, financial position or cash flows. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Recently issued accounting pronouncements, not yet adopted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In November 2021, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021-10&lt;/div&gt; &#x201c;Government Assistance (Topic 832)&#x201d;, which requires annual disclosures that increase the transparency of transactions involving government grants, including (1)&#160;the types of transactions, (2)&#160;the accounting for those transactions, and (3)&#160;the effect of those transactions on an entity&#x2019;s financial statements. The amendments in this update are effective for financial statements issued for annual periods beginning after December&#160;15, 2021. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In October 2021, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021-08&lt;/div&gt; &#x201c;Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#x201d;, which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers. The guidance will result in the acquirer recognizing contract assets and contract liabilities at the same amounts recorded by the acquiree. The guidance should be applied prospectively to acquisitions occurring on or after the effective date. The guidance is effective for fiscal years beginning after December&#160;15, 2022, including interim periods within those fiscal years. Early adoption is permitted, including in interim periods, for any financial statements that have not yet been issued. Adoption in an interim period other than the first fiscal quarter requires an entity to apply the new guidance to all prior business combinations that have occurred since the beginning of the annual period in which the new guidance is adopted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements. &lt;/div&gt;&lt;br/&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2022To06_30_2022">&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Recently adopted accounting pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In August 2020, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; &#x201c;Debt &#x2013; Debt with Conversion and Other Options (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;470-20)&lt;/div&gt; and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815 &#x2013; 40).&#x201d; This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#x2019;s own equity. The amendments to this guidance are effective for fiscal years beginning after December&#160;15, 2021, and interim periods within those fiscal years. The adoption of this guidance did not have a significant impact on the Company&#x2019;s consolidated financial statements. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In March 2020, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-04&lt;/div&gt; &#x201c;Reference Rate Reform (Topic 848)&#x2014;Facilitation of the Effects of Reference Rate Reform on Financial Reporting.&#x201d; This guidance provides optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The guidance applies only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. This guidance is effective for all entities as of March&#160;12, 2020 through December&#160;31, 2022. There was no material impact to the Company&#x2019;s consolidated financial statements for the period ended June&#160;30, 2022 as a result of adopting this standard update. The Company has completed negotiations to transform the facility base rate of its securitization program and evaluated the potential impact of the replacement of the LIBOR benchmark on its interest rate risk management activities. The adoption of this guidance did not have a material impact on the Company&#x2019;s consolidated financial results of operations, financial position or cash flows. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <teva:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock contextRef="P01_01_2022To06_30_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Recently issued accounting pronouncements, not yet adopted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In November 2021, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021-10&lt;/div&gt; &#x201c;Government Assistance (Topic 832)&#x201d;, which requires annual disclosures that increase the transparency of transactions involving government grants, including (1)&#160;the types of transactions, (2)&#160;the accounting for those transactions, and (3)&#160;the effect of those transactions on an entity&#x2019;s financial statements. The amendments in this update are effective for financial statements issued for annual periods beginning after December&#160;15, 2021. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In October 2021, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021-08&lt;/div&gt; &#x201c;Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#x201d;, which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers. The guidance will result in the acquirer recognizing contract assets and contract liabilities at the same amounts recorded by the acquiree. The guidance should be applied prospectively to acquisitions occurring on or after the effective date. The guidance is effective for fiscal years beginning after December&#160;15, 2022, including interim periods within those fiscal years. Early adoption is permitted, including in interim periods, for any financial statements that have not yet been issued. Adoption in an interim period other than the first fiscal quarter requires an entity to apply the new guidance to all prior business combinations that have occurred since the beginning of the annual period in which the new guidance is adopted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements. &lt;/div&gt;&lt;br/&gt;&lt;/div&gt;</teva:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock>
    <teva:CertainTransactionsDisclosureTextBlock contextRef="P01_01_2022To06_30_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 2 &#x2013; Certain transactions: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has entered into alliances and other arrangements with third parties to acquire rights to products it does not have, to access markets it does not operate in and to otherwise share development costs or business risks. The Company&#x2019;s most significant agreements of this nature are summarized below. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;MODAG &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In October 2021, Teva announced a license agreement with MODAG GmbH (&#x201c;Modag&#x201d;) that will provide Teva an exclusive global license to develop, manufacture and commercialize Modag&#x2019;s lead compound &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(TEV-56286)&lt;/div&gt; and a related compound &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(TEV-56287).&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;TEV-56286&lt;/div&gt; was initially developed for the treatment of Multiple System Atrophy (&#x201c;MSA&#x201d;) and Parkinson&#x2019;s disease, and has the potential to be applied to other treatments for neurodegenerative disorders, such as Alzheimer&#x2019;s disease. A phase 1b clinical trial is currently being completed for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;TEV-56286.&lt;/div&gt; In the fourth quarter of 2021, Teva made an upfront payment of $10&#160;million to Modag that was recorded as an R&amp;amp;D expense. Modag may be eligible for future development milestone payments, totaling an aggregate amount of up to $70&#160;million, as well as future commercial milestones and royalties. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Alvotech &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;In August 2020, Teva entered into an agreement with biopharmaceutical company Alvotech for the exclusive commercialization in the U.S. of five biosimilar product candidates. The initial pipeline for this collaboration contains biosimilar candidates addressing multiple therapeutic areas, including a proposed biosimilar to Humira&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;. Under this agreement, Alvotech is responsible for the development, registration and supply of the biosimilar product candidates and Teva will exclusively commercialize the products in the United States. Teva paid an upfront payment in the third quarter of 2020 and additional upfront and milestone payments in the second quarter of 2021 that were recorded as R&amp;amp;D expenses. Additional development and commercial milestone payments of up to&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; $455&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million, as well as royalty payments, may be payable by Teva over the next few years. Teva and Alvotech will share profit from the commercialization of these biosimilars. Alvotech was previously involved in litigation involving certain IP and trade secrets claims filed by Abbvie in relation to Alvotech&#x2019;s proposed biosimilar to Humira&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;, all of which were settled on March&#160;8, 2022.&#160;Pursuant to that settlement, Alvotech and Teva may sell Alvotech&#x2019;s proposed biosimilar to Humira&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt; &lt;/div&gt;in the United States beginning on July&#160;1, 2023, provided that U.S. regulatory approval is obtained by that date. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 10pt;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Eli Lilly and Alder BioPharmaceuticals&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In December 2018, Teva entered into an agreement with Eli Lilly&#160;&amp;amp; Co. (&#x201c;Lilly&#x201d;) resolving the European Patent Office opposition they had filed against Teva&#x2019;s AJOVY&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; patents. The settlement agreement with Lilly also resolved Lilly&#x2019;s action to revoke the patent protecting AJOVY in the United&#160;Kingdom. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On January&#160;8, 2018, Teva signed a global license agreement with Alder BioPharmaceuticals (&#x201c;Alder&#x201d;). The agreement validates Teva&#x2019;s intellectual property and resolves Alder&#x2019;s opposition to Teva&#x2019;s European patent with respect to anti-calcitonin gene-related peptide (CGRP) antibodies, including the withdrawal of Alder&#x2019;s appeal before the European Patent Office. Under the terms of the agreement, Alder received a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-exclusive&lt;/div&gt; license to Teva&#x2019;s anti-CGRP antibodies patent portfolio to develop, manufacture and commercialize eptinezumab in the United States and worldwide, excluding Japan. Teva received a $25&#160;million upfront payment that was recognized as revenue during the first quarter of 2018, and a $25&#160;million milestone payment in March 2020 that was recognized as revenue in the first quarter of 2020. The agreement stipulates additional development and commercial milestone payments to Teva of up to $150&#160;million, as well as future royalties. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Otsuka &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On May&#160;12, 2017, Teva entered into a license and collaboration agreement with Otsuka Pharmaceutical Co. Ltd. (&#x201c;Otsuka&#x201d;) providing Otsuka with an exclusive license to develop and commercialize AJOVY in Japan. Otsuka paid Teva an upfront payment of $50&#160;million in consideration for the transaction. In the third quarter of 2020, Otsuka submitted an application to obtain manufacturing and marketing approval for AJOVY in Japan and, as a result, paid Teva a milestone payment of $15&#160;million, which was recognized as revenue in the third quarter of 2020. AJOVY was approved in Japan in June 2021 and launched on August&#160;30, 2021. As a result of the launch, Otsuka paid Teva a milestone payment of $35&#160;million, which was recognized as revenue in the third quarter of 2021. Teva may receive additional milestone payments upon achievement of certain revenue targets. Otsuka also pays Teva royalties on AJOVY sales in Japan. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Takeda &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In December 2016, Teva entered into a license agreement with a subsidiary of Takeda Pharmaceutical Company Ltd. (&#x201c;Takeda&#x201d;), for the research, development, manufacture and commercialization of &lt;/div&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;Attenukine&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; technology.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Teva received a $30&#160;million upfront payment as well as a milestone payment of $20&#160;million in 2017. During the second quarter of 2022, Takeda initiated Phase II study of modakafusp alfa (formerly TAK 573 or TEV 48573) and as a result paid Teva a milestone payment of $25&#160;million, which was recognized as revenues in the second quarter of 2022. The license agreement stipulates additional milestone payments to Teva of up to $519&#160;million in respect of this product, as well as future royalties. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Regeneron &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In September 2016, Teva and Regeneron Pharmaceuticals, Inc. (&#x201c;Regeneron&#x201d;) entered into a collaborative agreement to develop and commercialize Regeneron&#x2019;s pain medication product, fasinumab. Teva and Regeneron share in the global commercial rights to this product (excluding Japan, Korea and nine other Asian countries), as well as ongoing associated R&amp;amp;D costs of approximately $1&#160;billion. Teva made an upfront payment of $250&#160;million to Regeneron in the third quarter of 2016 and additional payments for achievement of development milestones in an aggregate amount of $120&#160;million were paid during 2017 and 2018. The agreement stipulates additional development and commercial milestone payments of up to $2,230&#160;million, as well as future royalties. Currently, all &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-essential&lt;/div&gt; activities and related expenditures for fasinumab have been put on hold. Next steps will be assessed together with Regeneron, with the intention of discussing data with the FDA. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;MedinCell &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In November 2013, Teva entered into an agreement with MedinCell for the development and commercialization of multiple long-acting injectable products. The lead product candidate selected was risperidone LAI &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(TV-46000)&lt;/div&gt; suspension for subcutaneous use for the treatment of schizophrenia. In August 2021, the FDA accepted the new drug application (&#x201c;NDA&#x201d;) for risperidone LAI, based on phase 3 data from two pivotal studies. Teva leads the clinical development and regulatory process and is responsible for commercialization of this product candidate. MedinCell may be eligible for development milestones, and future commercial milestones of up to $112&#160;million in respect of risperidone LAI. Teva will also pay MedinCell royalties on net sales. In April 2022, the FDA issued a Complete Response Letter (&#x201c;CRL&#x201d;) regarding the NDA for risperidone LAI. Teva is working to address the issues raised in the CRL with a view to resubmission.&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets and Liabilities Held For Sale: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets held for sale as of June&#160;30, 2022 included certain assets that are expected to be sold within the next year. Assets and liabilities held for sale as of December&#160;31, 2021 included certain manufacturing assets sold during the first and second quarters of 2022.&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;The table below summarizes all Teva assets and liabilities included as held for sale as of June&#160;30, 2022 and December&#160;31, 2021:&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inventories&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property, plant and equipment, net and others&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;46&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;86&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Adjustments of assets held for sale to fair value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(76&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets of the disposal group classified as held for sale in the consolidated balance sheets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total liabilities of the disposal group classified as held for sale in the consolidated balance sheets, recorded under accrued expenses and other long-term liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(43&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </teva:CertainTransactionsDisclosureTextBlock>
    <teva:MilestonePayment
      contextRef="P10_01_2021To12_31_2021_ModagMemberusgaapBusinessAcquisitionAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">10000000</teva:MilestonePayment>
    <teva:LicenseAgreementPotentialAggregateMilestonePaymentsAmount
      contextRef="P10_01_2021To10_31_2021_ModagMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">70000000</teva:LicenseAgreementPotentialAggregateMilestonePaymentsAmount>
    <teva:CollaborativeAgreementMilestonePayments
      contextRef="P01_01_2022To06_30_2022_AlvotechMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">455000000</teva:CollaborativeAgreementMilestonePayments>
    <teva:UpfrontPayments
      contextRef="P01_08_2018To01_08_2018_AlderMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">25000000</teva:UpfrontPayments>
    <teva:MilestonePayment
      contextRef="P01_01_2020To03_31_2020_AlderMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">25000000</teva:MilestonePayment>
    <teva:CollaborativeAgreementMilestonePayments
      contextRef="P01_08_2018To01_08_2018_AlderMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">150000000</teva:CollaborativeAgreementMilestonePayments>
    <teva:UpfrontPayments
      contextRef="P05_12_2017To05_12_2017_OtsukaMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">50000000</teva:UpfrontPayments>
    <teva:MilestonePayment
      contextRef="P01_01_2020To09_30_2020_OtsukaMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">15000000</teva:MilestonePayment>
    <teva:MilestonePayment
      contextRef="P01_01_2021To09_30_2021_OtsukaMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">35000000</teva:MilestonePayment>
    <teva:UpfrontPayments
      contextRef="P12_01_2016To12_31_2016_TakedaMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">30000000</teva:UpfrontPayments>
    <teva:MilestonePayment
      contextRef="P12_01_2016To12_31_2016_TakedaMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">20000000</teva:MilestonePayment>
    <teva:MilestonePayment
      contextRef="P01_01_2022To06_30_2022_TakedaMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">25000000</teva:MilestonePayment>
    <teva:CollaborativeAgreementMilestonePayments
      contextRef="P12_01_2016To12_31_2016_TakedaMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">519000000</teva:CollaborativeAgreementMilestonePayments>
    <teva:ResearchAndDevelopmentCosts
      contextRef="P09_01_2016To09_30_2016_RegeneronMemberusgaapBusinessAcquisitionAxis"
      decimals="-9"
      unitRef="Unit_USD">1000000000</teva:ResearchAndDevelopmentCosts>
    <teva:UpfrontPayments
      contextRef="P07_01_2016To09_30_2016_RegeneronMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">250000000</teva:UpfrontPayments>
    <teva:CollaborativeAgreementMilestonePayments
      contextRef="P01_01_2018To12_31_2018_RegeneronMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">120000000</teva:CollaborativeAgreementMilestonePayments>
    <teva:CollaborativeAgreementMilestonePayments
      contextRef="P01_01_2017To12_31_2017_RegeneronMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">120000000</teva:CollaborativeAgreementMilestonePayments>
    <teva:CollaborativeAgreementMilestonePayments
      contextRef="P09_01_2016To09_30_2016_RegeneronMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">2230000000</teva:CollaborativeAgreementMilestonePayments>
    <teva:CollaborativeAgreementMilestonePayments
      contextRef="P08_01_2021To08_31_2021_MedincellMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">112000000</teva:CollaborativeAgreementMilestonePayments>
    <teva:ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock contextRef="P01_01_2022To06_30_2022">The table below summarizes all Teva assets and liabilities included as held for sale as of June&#160;30, 2022 and December&#160;31, 2021: &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inventories&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property, plant and equipment, net and others&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;46&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;86&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Adjustments of assets held for sale to fair value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(76&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets of the disposal group classified as held for sale in the consolidated balance sheets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total liabilities of the disposal group classified as held for sale in the consolidated balance sheets, recorded under accrued expenses and other long-term liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(43&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </teva:ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">2000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">46000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">86000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">7000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent>
    <us-gaap:AssetsFairValueAdjustment
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-30000000</us-gaap:AssetsFairValueAdjustment>
    <us-gaap:AssetsFairValueAdjustment
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">-76000000</us-gaap:AssetsFairValueAdjustment>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">16000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">19000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">43000000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="P01_01_2022To06_30_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 3 &#x2013; Revenue from contracts with customers: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Disaggregation of revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table disaggregates Teva&#x2019;s revenues by major revenue streams. For additional information on disaggregation of revenues, see note 15. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 68%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three months ended June&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&lt;br/&gt;America&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&lt;br/&gt;Markets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;br/&gt;activities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sale of goods&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,538&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,127&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;448&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;176&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,289&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Licensing arrangements&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;54&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;72&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Distribution&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;308&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;318&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;31&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;81&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;106&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,904&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,171&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;454&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;257&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,786&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xa7; Represents an amount less t&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;han $0.5&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;million.&#160; &#160;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 71%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three months ended June&#160;30, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&lt;br/&gt;America&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&lt;br/&gt;Markets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;br/&gt;activities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sale of goods&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,621&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,185&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;462&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;198&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,465&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Licensing arrangements&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Distribution&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;316&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;330&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;99&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;96&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,943&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,184&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;485&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;298&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,910&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xa7; Represents an amount less than $0.5&#160;million. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six months ended June&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&lt;br/&gt; America&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&lt;br/&gt; Markets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;br/&gt; activities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sale of goods&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,915&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,261&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;894&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;356&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,425&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Licensing arrangements&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;74&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;110&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Distribution&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;650&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;677&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;39&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;175&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;234&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,641&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,327&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;946&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;532&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,447&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xa7; Represents an amount less than $0.5&#160;million. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 68%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six months ended June&#160;30, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&lt;br/&gt;America&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&lt;br/&gt;Markets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;br/&gt;activities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sale of goods&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,289&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,363&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;902&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;374&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,928&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Licensing arrangements&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;68&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Distribution&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;605&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;34&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;639&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;210&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;257&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,932&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,398&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;975&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;587&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,892&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xa7; Represents an amount less than $0.5&#160;million. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Variable consideration&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Variable consideration mainly includes sales reserves and allowances (&#x201c;SR&amp;amp;A&#x201d;), comprised of rebates (including Medicaid and other governmental program discounts), chargebacks, returns and other promotional (including shelf stock adjustments) items. Provisions for prompt payment discounts are netted against accounts receivables. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes these provisions at the time of sale and adjusts them if the actual amounts differ from the estimated provisions. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SR&amp;amp;A to U.S. customers comprised approximately &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;74&lt;/div&gt;% of the Company&#x2019;s total SR&amp;amp;A as of June&#160;30, 2022, with the remaining balance primarily in Canada and Germany. The changes in SR&amp;amp;A for third-party sales for the six months ended June&#160;30, 2022 and 2021 were as follows:&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 37%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="26" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Sales Reserves and Allowances&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reserves&lt;br/&gt;included in&lt;br/&gt;Accounts&lt;br/&gt;Receivable,&#160;net&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rebates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Medicaid and&lt;br/&gt;other&lt;br/&gt;governmental&lt;br/&gt;allowances&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Chargebacks&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Returns&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&#160;reserves&lt;br/&gt;included&#160;in&#160;SR&amp;amp;A&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="30" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at December&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;68&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,655&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;854&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,085&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;535&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;112&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,241&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,309&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provisions related to sales made in current year&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;181&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,889&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;446&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,836&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;147&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;152&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,470&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,651&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provisions related to sales made in prior periods&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(102&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;20&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(8&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(16&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(108&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(108&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Credits and payments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(185&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,901&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(497&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3,922&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(211&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(145&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,676&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,861&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Translation differences&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(33&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(6&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(7&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(4&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(47&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(47&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at June&#160;30, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;64&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,508&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;817&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;984&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;451&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;120&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,880&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,944&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 37%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reserves&lt;br/&gt; included in&lt;br/&gt; Accounts&lt;br/&gt; Receivable,&#160;net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rebates&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Medicaid and&lt;br/&gt; other&lt;br/&gt; governmental&lt;br/&gt; allowances&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Chargebacks&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Returns&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&#160;reserves&lt;br/&gt; included&#160;in&#160;SR&amp;amp;A&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="30" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.$ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,054&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;828&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,108&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;686&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;148&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,824&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,904&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provisions related to sales made in current year&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;192&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,139&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;391&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,995&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;143&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;177&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,845&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provisions related to sales made in prior periods&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(82&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(35&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(23&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(191&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(196&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Credits and payments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(196&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,355&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(362&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,934&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(186&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(176&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,013&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,209&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Translation differences&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at June&#160;30, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;71&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,748&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;819&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,157&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;602&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;127&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,453&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,524&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="P01_01_2022To06_30_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table disaggregates Teva&#x2019;s revenues by major revenue streams. For additional information on disaggregation of revenues, see note 15. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 68%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three months ended June&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&lt;br/&gt;America&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&lt;br/&gt;Markets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;br/&gt;activities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sale of goods&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,538&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,127&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;448&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;176&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,289&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Licensing arrangements&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;54&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;72&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Distribution&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;308&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;318&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;31&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;81&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;106&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,904&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,171&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;454&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;257&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,786&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xa7; Represents an amount less t&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;han $0.5&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;million.&#160; &#160;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 71%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three months ended June&#160;30, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&lt;br/&gt;America&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&lt;br/&gt;Markets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;br/&gt;activities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sale of goods&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,621&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,185&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;462&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;198&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,465&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Licensing arrangements&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Distribution&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;316&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;330&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;99&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;96&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,943&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,184&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;485&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;298&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,910&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xa7; Represents an amount less than $0.5&#160;million. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six months ended June&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&lt;br/&gt; America&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&lt;br/&gt; Markets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;br/&gt; activities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sale of goods&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,915&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,261&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;894&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;356&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,425&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Licensing arrangements&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;74&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;110&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Distribution&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;650&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;677&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;39&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;175&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;234&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,641&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,327&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;946&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;532&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,447&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xa7; Represents an amount less than $0.5&#160;million. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 68%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six months ended June&#160;30, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&lt;br/&gt;America&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&lt;br/&gt;Markets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;br/&gt;activities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sale of goods&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,289&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,363&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;902&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;374&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,928&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Licensing arrangements&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;68&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Distribution&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;605&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;34&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;639&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;210&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;257&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,932&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,398&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;975&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;587&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,892&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xa7; Represents an amount less than $0.5&#160;million. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_NorthAmericaMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">1538000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_EuropeMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">1127000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">448000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">176000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">3289000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_LicenseMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">54000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_EuropeMembersrtStatementGeographicalAxis_LicenseMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_LicenseMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_LicenseMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_LicenseMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">72000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_DistributionServiceMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">308000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_DistributionServiceMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_DistributionServiceMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_DistributionServiceMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">318000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_NorthAmericaMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_EuropeMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">31000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">-9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">81000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">106000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">1904000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_EuropeMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">1171000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">454000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">257000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">3786000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_NorthAmericaMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">1621000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_EuropeMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">1185000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">462000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">198000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">3465000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_LicenseMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_EuropeMembersrtStatementGeographicalAxis_LicenseMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_LicenseMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_LicenseMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_LicenseMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">19000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_DistributionServiceMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">316000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_DistributionServiceMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_DistributionServiceMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_DistributionServiceMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">330000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_NorthAmericaMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">-2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_EuropeMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">-8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">99000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">96000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">1943000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_EuropeMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">1184000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">485000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">298000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">3910000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_NorthAmericaMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">2915000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_EuropeMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">2261000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">894000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">356000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">6425000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_LicenseMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">74000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_EuropeMembersrtStatementGeographicalAxis_LicenseMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">26000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_LicenseMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_LicenseMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_LicenseMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">110000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_DistributionServiceMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">650000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_DistributionServiceMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">26000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_DistributionServiceMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_DistributionServiceMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">677000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_NorthAmericaMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_EuropeMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">39000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">19000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">175000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">234000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">3641000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_EuropeMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">2327000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">946000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">532000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">7447000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_NorthAmericaMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">3289000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_EuropeMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">2363000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">902000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">374000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">6928000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_LicenseMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">40000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_EuropeMembersrtStatementGeographicalAxis_LicenseMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">21000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_LicenseMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_LicenseMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_LicenseMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">68000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_DistributionServiceMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">605000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_DistributionServiceMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">34000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_DistributionServiceMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_DistributionServiceMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">639000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_NorthAmericaMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">-2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_EuropeMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">14000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">35000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">210000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">257000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">3932000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_EuropeMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">2398000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">975000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">587000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">7892000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <teva:SalesReservesAndAllowancesToCustomersPercentage
      contextRef="P01_01_2022To06_30_2022_USsrtStatementGeographicalAxis"
      decimals="2"
      unitRef="Unit_pure">0.74</teva:SalesReservesAndAllowancesToCustomersPercentage>
    <teva:SalesReservesAndAllowancesCurrentTableTextBlock contextRef="P01_01_2022To06_30_2022">The changes in SR&amp;amp;A for third-party sales for the six months ended June&#160;30, 2022 and 2021 were as follows:
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 37%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="26" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Sales Reserves and Allowances&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reserves&lt;br/&gt;included in&lt;br/&gt;Accounts&lt;br/&gt;Receivable,&#160;net&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rebates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Medicaid and&lt;br/&gt;other&lt;br/&gt;governmental&lt;br/&gt;allowances&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Chargebacks&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Returns&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&#160;reserves&lt;br/&gt;included&#160;in&#160;SR&amp;amp;A&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="30" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at December&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;68&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,655&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;854&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,085&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;535&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;112&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,241&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,309&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provisions related to sales made in current year&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;181&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,889&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;446&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,836&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;147&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;152&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,470&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,651&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provisions related to sales made in prior periods&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(102&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;20&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(8&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(16&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(108&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(108&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Credits and payments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(185&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,901&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(497&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3,922&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(211&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(145&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,676&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,861&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Translation differences&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(33&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(6&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(7&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(4&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(47&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(47&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at June&#160;30, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;64&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,508&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;817&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;984&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;451&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;120&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,880&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,944&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 37%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reserves&lt;br/&gt; included in&lt;br/&gt; Accounts&lt;br/&gt; Receivable,&#160;net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rebates&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Medicaid and&lt;br/&gt; other&lt;br/&gt; governmental&lt;br/&gt; allowances&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Chargebacks&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Returns&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&#160;reserves&lt;br/&gt; included&#160;in&#160;SR&amp;amp;A&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="30" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.$ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,054&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;828&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,108&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;686&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;148&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,824&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,904&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provisions related to sales made in current year&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;192&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,139&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;391&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,995&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;143&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;177&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,845&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provisions related to sales made in prior periods&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(82&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(35&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(23&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(191&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(196&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Credits and payments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(196&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,355&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(362&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,934&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(186&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(176&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,013&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,209&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Translation differences&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at June&#160;30, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;71&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,748&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;819&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,157&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;602&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;127&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,453&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,524&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </teva:SalesReservesAndAllowancesCurrentTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2021_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">68000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2021_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">1655000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2021_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">854000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2021_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">1085000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2021_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">535000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2021_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">112000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2021_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">4241000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">4309000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2022To06_30_2022_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">181000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2022To06_30_2022_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">1889000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2022To06_30_2022_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">446000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2022To06_30_2022_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">3836000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2022To06_30_2022_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">147000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2022To06_30_2022_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">152000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2022To06_30_2022_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">6470000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">6651000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2022To06_30_2022_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-102000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2022To06_30_2022_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">20000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2022To06_30_2022_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-8000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2022To06_30_2022_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-16000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2022To06_30_2022_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-2000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2022To06_30_2022_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-108000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-108000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2022To06_30_2022_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">185000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2022To06_30_2022_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">1901000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2022To06_30_2022_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">497000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2022To06_30_2022_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">3922000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2022To06_30_2022_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">211000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2022To06_30_2022_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">145000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2022To06_30_2022_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">6676000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">6861000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2022To06_30_2022_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-33000000</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2022To06_30_2022_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-6000000</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2022To06_30_2022_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-7000000</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2022To06_30_2022_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-4000000</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2022To06_30_2022_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">3000000</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2022To06_30_2022_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-47000000</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-47000000</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn06_30_2022_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">64000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn06_30_2022_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">1508000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn06_30_2022_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">817000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn06_30_2022_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">984000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn06_30_2022_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">451000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn06_30_2022_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">120000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn06_30_2022_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">3880000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">3944000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2020_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">80000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2020_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">2054000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2020_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">828000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2020_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">1108000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2020_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">686000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2020_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">148000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2020_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">4824000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">4904000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2021To06_30_2021_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">192000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2021To06_30_2021_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">2139000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2021To06_30_2021_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">391000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2021To06_30_2021_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">3995000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2021To06_30_2021_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">143000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2021To06_30_2021_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">177000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2021To06_30_2021_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">6845000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">7037000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2021To06_30_2021_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-5000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2021To06_30_2021_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-82000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2021To06_30_2021_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-35000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2021To06_30_2021_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-11000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2021To06_30_2021_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-40000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2021To06_30_2021_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-23000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2021To06_30_2021_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-191000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">-196000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2021To06_30_2021_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">196000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2021To06_30_2021_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">2355000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2021To06_30_2021_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">362000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2021To06_30_2021_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">3934000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2021To06_30_2021_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">186000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2021To06_30_2021_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">176000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2021To06_30_2021_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">7013000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">7209000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2021To06_30_2021_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-8000000</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2021To06_30_2021_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-3000000</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2021To06_30_2021_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-1000000</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2021To06_30_2021_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-1000000</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2021To06_30_2021_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2021To06_30_2021_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-12000000</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">-12000000</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn06_30_2021_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">71000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn06_30_2021_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">1748000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn06_30_2021_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">819000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn06_30_2021_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">1157000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn06_30_2021_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">602000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn06_30_2021_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">127000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn06_30_2021_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">4453000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">4524000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:InventoryDisclosureTextBlock contextRef="P01_01_2022To06_30_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 4 &#x2013; Inventories:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inventories, net of reserves, consisted of the following:&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Finished products&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,875&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,932&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Raw and packaging materials&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,346&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,136&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Products in process&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;624&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;587&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Materials in transit and payments on account&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;204&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;163&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,049&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,818&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="P01_01_2022To06_30_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inventories, net of reserves, consisted of the following:&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Finished products&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,875&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,932&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Raw and packaging materials&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,346&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,136&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Products in process&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;624&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;587&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Materials in transit and payments on account&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;204&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;163&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,049&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,818&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">1875000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">1932000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">1346000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">1136000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">624000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">587000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:OtherInventoryInTransit
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">204000000</us-gaap:OtherInventoryInTransit>
    <us-gaap:OtherInventoryInTransit
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">163000000</us-gaap:OtherInventoryInTransit>
    <us-gaap:InventoryNet
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">4049000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">3818000000</us-gaap:InventoryNet>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="P01_01_2022To06_30_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 5 &#x2013; Identifiable intangible assets:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Identifiable intangible assets consisted of the following:&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 54%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&#160;carrying&#160;amount&#160;net&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;of impairment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;amortization&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net carrying amount&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="22" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Product rights&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,987&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,815&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,181&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,318&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,806&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,497&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Trade names&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;570&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;590&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;211&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;198&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;359&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;392&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In process research and development&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;535&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;577&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;535&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;577&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,092&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,982&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,392&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,516&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,466&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Product rights and trade names &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Product rights and trade names are assets presented at amortized cost. Product rights and trade names represent a portfolio of pharmaceutical products from various therapeutic categories from various acquisitions with a weighted average life of approximately 10 years. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortization of intangible assets was $212&#160;million and $173&#160;million in the three months ended June&#160;30, 2022 and 2021, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortization of intangible assets was $412&#160;million and $414&#160;million in the six months ended June&#160;30, 2022 and 2021, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;IPR&amp;amp;D &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva&#x2019;s IPR&amp;amp;D are assets that have not yet been approved in major markets. Teva&#x2019;s IPR&amp;amp;D is comprised mainly of various generic products from the Actavis Generics acquisition of $503&#160;million. IPR&amp;amp;D carries intrinsic risks that the asset might not succeed in advanced phases and may be impaired in future periods. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Intangible assets impairments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Impairments of long-lived intangible assets for the three months ended June&#160;30, 2022 and 2021&#160;were $51&#160;million and $195&#160;million, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Impairments in the second quarter of 2022 consisted of: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;(a)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Identifiable product rights of $32&#160;million related to updated market assumptions regarding price and volume of products acquired from Actavis Generics, and&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;(b)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;IPR&amp;amp;D assets of $19&#160;million due to generic pipeline products acquired from Actavis Generics resulting from development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape, launch date). &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Impairments in the second quarter of 2021 consisted of: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;(a)&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;Identifiable product rights of $168&#160;million due to: &lt;div style="text-indent: 0px; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(i) $138 million, mainly related to updated market assumptions regarding price and &lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="text-indent: 0px; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;volume of products acquired from Actavis Generics that are primarily marketed in the United States, and (ii) &lt;/div&gt;$30&#160;million related to &lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;lenalidomide (generic equivalent of Revlimid&lt;div style="font-size: 75%; vertical-align: top; text-indent: 0px; white-space: nowrap;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;), resulting from modified competition assumptions as a result of settlements between the &lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;innovator and other generic filers, and&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;(b)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;IPR&amp;amp;D assets of $27&#160;million due to generic pipeline products acquired from Actavis Generics resulting from development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape, launch date) in the United States. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Impairments of long-lived intangible assets for the six months ended June&#160;30, 2022 and 2021&#160;were $199&#160;million and $274&#160;million, respectively.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Impairments in the first &lt;/div&gt;six&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; months of &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; consisted mainly of:&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;(a)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Identifiable product rights of $161&#160;million related to updated market assumptions regarding price and volume of products acquired from Actavis Generics, and&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;(b)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;IPR&amp;amp;D assets of $21&#160;million due to generic pipeline products acquired from Actavis Generics resulting from development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape, launch date) in the United States. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Impairments in the first six months of 2021 consisted of: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;(a)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Identifiable product rights of $196&#160;million &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;due to: (i) $166 million&lt;/div&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, mainly related to updated market assumptions regarding price and &lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;volume of products acquired from Actavis Generics that are primarily marketed in the United States&lt;div style="display:inline;"&gt;,&lt;/div&gt;&#160;and (ii) &lt;/div&gt;$30&#160;million related to lenalidomide (generic equivalent of Revlimid&lt;div style="font-size: 75%; vertical-align: top;;text-indent: 0px;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;), resulting from modified competition assumptions as a result of settlements between the innovator and other generic filers&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;(b)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;IPR&amp;amp;D assets of $78&#160;million, due to generic pipeline products acquired from Actavis Generics resulting from development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape, launch date) in the United States. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value measurement of the impaired intangible assets in the first six months of 2022 is based on significant unobservable inputs in the market and thus represents a Level&#160;3 measurement within the fair value hierarchy. The discount rate applied ranged from 7.25% to 8.25%. A probability of success factor ranging from 20% to 90% was used in the fair value calculation to reflect inherent regulatory and commercial risk of IPR&amp;amp;D. &lt;/div&gt;&lt;br/&gt;&lt;/div&gt; </us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="P01_01_2022To06_30_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Identifiable intangible assets consisted of the following:&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 54%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&#160;carrying&#160;amount&#160;net&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;of impairment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;amortization&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net carrying amount&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="22" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Product rights&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,987&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,815&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,181&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,318&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,806&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,497&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Trade names&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;570&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;590&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;211&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;198&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;359&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;392&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In process research and development&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;535&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;577&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;535&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;577&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,092&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,982&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,392&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,516&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,466&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn06_30_2022_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">17987000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2021_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">18815000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn06_30_2022_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">12181000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2021_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">12318000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn06_30_2022_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">5806000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2021_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">6497000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn06_30_2022_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">570000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2021_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">590000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn06_30_2022_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">211000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2021_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">198000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn06_30_2022_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">359000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2021_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">392000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn06_30_2022_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">535000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2021_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">577000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn06_30_2022_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">535000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2021_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">577000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">19092000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">19982000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">12392000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">12516000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">6700000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">7466000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="P01_01_2022To06_30_2022">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">212000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">173000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">412000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">414000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="PAsOn06_30_2022_ActavisMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">503000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">51000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">195000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P04_01_2022To06_30_2022_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">32000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P04_01_2022To06_30_2022_GenericPipelineProductsMembersrtProductOrServiceAxis_InprocessresearchandDevelopmenttoProductRightsMemberusgaapReclassificationTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">19000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P04_01_2021To06_30_2021_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">168000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P04_01_2021To06_30_2021_ActavisMemberusgaapBusinessAcquisitionAxis_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_USsrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">138000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P04_01_2021To06_30_2021_ActavisMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">30000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P04_01_2021To06_30_2021_GenericPipelineProductsMembersrtProductOrServiceAxis_InprocessresearchandDevelopmenttoProductRightsMemberusgaapReclassificationTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">27000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">199000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">274000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2022To06_30_2022_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">161000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2022To06_30_2022_GenericPipelineProductsMembersrtProductOrServiceAxis_InprocessresearchandDevelopmenttoProductRightsMemberusgaapReclassificationTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">21000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2021To06_30_2021_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">196000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2021To06_30_2021_ActavisMemberusgaapBusinessAcquisitionAxis_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_USsrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">166000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2021To06_30_2021_ActavisMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">30000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2021To06_30_2021_GenericPipelineProductsMembersrtProductOrServiceAxis_InprocessresearchandDevelopmenttoProductRightsMemberusgaapReclassificationTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">78000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="PAsOn06_30_2022_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MinimumMembersrtRangeAxis"
      decimals="INF"
      unitRef="Unit_pure">0.0725</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="PAsOn06_30_2022_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MaximumMembersrtRangeAxis"
      decimals="INF"
      unitRef="Unit_pure">0.0825</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="PAsOn06_30_2022_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis"
      decimals="0"
      unitRef="Unit_pure">20</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="PAsOn06_30_2022_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis"
      decimals="0"
      unitRef="Unit_pure">90</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:GoodwillDisclosureTextBlock contextRef="P01_01_2022To06_30_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 6 &#x2013; Goodwill:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The changes in the carrying amount of goodwill for the period ended June&#160;30, 2022 were as follows:&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&#160;America&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&lt;br/&gt;Markets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of December&#160;31, 2021 (1)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,474&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,544&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,328&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,694&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20,040&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes during the period:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill impairment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(479&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(266&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(745&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill acquired&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Translation differences&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(320&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(130&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(470&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of June&#160;30, 2022 (1)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,470&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,224&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,833&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,310&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,837&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accumulated goodwill impairment as of June&#160;30, 2022 and December&#160;31, 2021 was approximately $26.3&#160;billion and $25.6&#160;billion, respectively. &lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Teva determines the fair value of its reporting units using the income approach. The income approach is a forward-looking approach for estimating fair value. Within the income approach, the method used is the discounted cash flow method. Teva starts with a forecast of all the expected net cash flows associated with the reporting unit, which includes the application of a terminal value, and then applies a discount rate to arrive at a net present value amount. Cash flow projections are based on Teva&#x2019;s estimates of revenue growth rates and operating margins, taking into consideration industry and market conditions. The discount rate used is based on the weighted average cost of capital (&#x201c;WACC&#x201d;), adjusted for the relevant risk associated with country-specific and business-specific characteristics. If any of these expectations were to vary materially from Teva&#x2019;s assumptions, Teva may record an impairment of goodwill allocated to these reporting units in the future.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;During&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-align: center; text-indent: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;the second qu&lt;/div&gt;arter of &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; text-align: center; text-indent: 0px; top: 0px;;display:inline;"&gt;, Teva completed its long-range planning (&#x201c;LRP&#x201d;) process. The LRP is part of Teva&#x2019;s internal financial planning and budgeting processes and is discussed and reviewed by Teva&#x2019;s management and its board of directors.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additionally, Teva conducted a quantitative analysis of all reporting units as part of its annual goodwill impairment test with the assistance of an independent valuation expert. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva identified an increase in certain components of the discount rate, mainly attributable to: (i)&#160;the risk-free interest rate, which resulted in an increase in the WACC; and (ii)&#160;the risk associated with country-specific characteristics of several countries. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Based on this quantitative analysis, in the second quarter of 2022, Teva recorded a goodwill impairment charge of&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;$745&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million as follows: (i) &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; $479&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;million related to its International Markets reporting unit, mainly due to the increase in the discount rate; and (ii)&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;$266&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million related to its Teva&#x2019;s API reporting unit, mainly due to the increase in the discount rate, as well as updated assumptions supporting the cash flow projections, including certain revenue growth assumptions and the associated operating profit margins. Teva&#x2019;s API reporting unit is included under &#x201c;Other&#x201d; in the table above. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Following the goodwill impairment charges recorded in relation to Teva&#x2019;s International Markets and Teva&#x2019;s API reporting units, the carrying values of &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;those reporting units &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; equaled their fair value as of June&#160;30, 2022. Therefore, if business conditions or expectations were to change materially, it may be necessary to record further impairment charges to Teva&#x2019;s International Markets or Teva&#x2019;s API reporting units in the future. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The estimated fair value of Teva&#x2019;s Europe reporting unit exceeds its estimated carrying amount by 9% based on a terminal growth rate of 1.41% and a discount rate of 10.04%. If Teva holds all other assumptions constant, a reduction in the terminal growth rate of 0.50% to 0.91% or an increase in the discount rate of 0.50% to 10.54% would result in a reduction of the excess of fair value over carrying amount with respect to Teva&#x2019;s Europe reporting unit to 5%. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;Teva&#x2019;s&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; North America and Medis reporting units have&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;a&lt;/div&gt; fair value in excess of 10% over their book values as of June&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva noted its market capitalization has been below management&#x2019;s assessment of the aggregated fair value of the Company&#x2019;s reporting units. However, as of June 30, 2022, the Company&#x2019;s market capitalization plus a reasonable control premium exceeded its book value. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </us-gaap:GoodwillDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="P01_01_2022To06_30_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The changes in the carrying amount of goodwill for the period ended June&#160;30, 2022 were as follows:&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&#160;America&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&lt;br/&gt;Markets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of December&#160;31, 2021 (1)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,474&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,544&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,328&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,694&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20,040&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes during the period:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill impairment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(479&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(266&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(745&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill acquired&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Translation differences&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(320&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(130&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(470&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of June&#160;30, 2022 (1)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,470&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,224&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,833&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,310&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,837&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accumulated goodwill impairment as of June&#160;30, 2022 and December&#160;31, 2021 was approximately $26.3&#160;billion and $25.6&#160;billion, respectively. &lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2021_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      id="Fact_52307391"
      unitRef="Unit_USD">6474000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2021_EuropeMembersrtStatementGeographicalAxis"
      decimals="-6"
      id="Fact_52307392"
      unitRef="Unit_USD">8544000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2021_InternationalMarketsMembersrtStatementGeographicalAxis"
      decimals="-6"
      id="Fact_52307393"
      unitRef="Unit_USD">2328000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2021_OtherCountriesMembersrtStatementGeographicalAxis"
      decimals="-6"
      id="Fact_52307394"
      unitRef="Unit_USD">2694000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      id="Fact_52307395"
      unitRef="Unit_USD">20040000000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="P01_01_2022To06_30_2022_InternationalMarketsMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">479000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="P01_01_2022To06_30_2022_OtherCountriesMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">266000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">745000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="P01_01_2022To06_30_2022_OtherCountriesMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">12000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">12000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="P01_01_2022To06_30_2022_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">4000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="P01_01_2022To06_30_2022_EuropeMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">320000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="P01_01_2022To06_30_2022_InternationalMarketsMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">16000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="P01_01_2022To06_30_2022_OtherCountriesMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">130000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">470000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="PAsOn06_30_2022_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      id="Fact_52307401"
      unitRef="Unit_USD">6470000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn06_30_2022_EuropeMembersrtStatementGeographicalAxis"
      decimals="-6"
      id="Fact_52307402"
      unitRef="Unit_USD">8224000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn06_30_2022_InternationalMarketsMembersrtStatementGeographicalAxis"
      decimals="-6"
      id="Fact_52307403"
      unitRef="Unit_USD">1833000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn06_30_2022_OtherCountriesMembersrtStatementGeographicalAxis"
      decimals="-6"
      id="Fact_52307404"
      unitRef="Unit_USD">2310000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      id="Fact_52307405"
      unitRef="Unit_USD">18837000000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="PAsOn06_30_2022"
      decimals="-8"
      unitRef="Unit_USD">26300000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="PAsOn12_31_2021"
      decimals="-8"
      unitRef="Unit_USD">25600000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">745000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:Goodwill
      contextRef="PAsOn06_30_2022_InternationalMarketsReportingUnitMemberusgaapReportingUnitAxis"
      decimals="-6"
      unitRef="Unit_USD">479000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn06_30_2022_TevasApiReportingUnitMemberusgaapReportingUnitAxis"
      decimals="-6"
      unitRef="Unit_USD">266000000</us-gaap:Goodwill>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="PAsOn06_30_2022"
      decimals="2"
      unitRef="Unit_pure">0.09</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="PAsOn06_30_2022_MeasurementInputTerminalGrowthRateMemberusgaapMeasurementInputTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0141</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="PAsOn06_30_2022_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.1004</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="PAsOn06_30_2022_MeasurementInputTerminalGrowthRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis"
      decimals="4"
      unitRef="Unit_pure">0.005</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="PAsOn06_30_2022_MaximumMembersrtRangeAxis_MeasurementInputTerminalGrowthRateMemberusgaapMeasurementInputTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0091</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="PAsOn06_30_2022_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis"
      decimals="4"
      unitRef="Unit_pure">0.005</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="PAsOn06_30_2022_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.1054</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="PAsOn06_30_2022_TevasEuropeReportingUnitMemberusgaapReportingUnitAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="PAsOn06_30_2022_NorthAmericaAndMedisReportingUnitsMemberusgaapReportingUnitAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:DebtDisclosureTextBlock contextRef="P01_01_2022To06_30_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 10pt;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 7 &#x2013; Debt obligations:&#160; &#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;a. Short-term debt:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 89%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&#160;interest&lt;br/&gt;rate as of June&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Maturity&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Convertible senior debentures&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2026&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current maturities of long-term liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,696&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,403&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total short-term debt&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,719&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,426&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Convertible senior debentures&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The principal amount of Teva&#x2019;s 0.25% convertible senior debentures due 2026 was $23&#160;million as of June&#160;30, 2022 and December&#160;31, 2021. These convertible senior debentures include a &#x201c;net share settlement&#x201d; feature according to which the principal amount will be paid in cash and in case of conversion, only the residual conversion value above the principal amount will be paid in Teva shares. Due to the &#x201c;net share settlement&#x201d; feature, exercisable at any time, these convertible senior debentures are classified in the Balance Sheet under short-term debt.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 10pt;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;b. Long-term debt:&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 87%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&#160;interest&lt;br/&gt;rate as of June&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Maturity&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$&#160;in&#160;millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes EUR 1,500&#160;million&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1.13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2024&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;653&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;708&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: pre-wrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: pre-wrap;;display:inline;"&gt;Sustainability-linked senior notes EUR 1,500&#160;million&#160;(1)&lt;div style="letter-spacing: 0px; top: 0px; white-space: pre-wrap;;display:inline;"&gt;&#160;&lt;/div&gt;(*)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;4.38&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;2030&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1,566&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1,699&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes EUR 1,300&#160;million&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1.25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;616&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;670&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sustainability-linked senior notes EUR 1,100&#160;million&#160;(2)&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;(*)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;3.75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;2027&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1,150&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1,246&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes EUR 1,000&#160;million&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;6.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,043&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,134&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes EUR 900&#160;million&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;4.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;2025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;942&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1,020&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes EUR 750&#160;million&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1.63&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2028&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;779&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;844&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes EUR 700&#160;million (3)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;3.25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;307&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes EUR 700&#160;million&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1.88&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2027&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;729&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;792&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 3,500&#160;million&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;3.15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;2026&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;3,496&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;3,496&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 3,000&#160;million&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2.80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,453&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,453&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 2,000&#160;million&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;4.10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;2046&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1,986&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1,986&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 1,250&#160;million&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;6.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2024&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 1,250&#160;million&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;6.75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;2028&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1,250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1,250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 1,000&#160;million&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;7.13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sustainability-linked senior notes USD 1,000&#160;million&#160;(2)&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;(*)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;4.75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;2027&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sustainability-linked senior notes USD 1,000&#160;million&#160;(1)&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;(*)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;5.13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2029&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 844&#160;million&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;2.95&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;715&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;715&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 789&#160;million&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;6.15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2036&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;783&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;783&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes CHF 350&#160;million&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;0.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;366&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;382&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes CHF 350&#160;million&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;367&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;383&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total senior notes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;22,144&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;23,118&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other long-term debt&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less current maturities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(1,696&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(1,403&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less debt issuance costs&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(87&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total senior notes and loa&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;n&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;;text-align:right;"&gt;20,363&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;;text-align:right;"&gt;21,617&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;  &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.125%-0.375%&lt;/div&gt; per annum, from and including May 9, 2026.&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;If Teva fails to achieve certain sustainability performance targets, a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-time&lt;/div&gt; premium payment of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.15%-0.45%&lt;/div&gt; out of the principal amount will be paid at maturity or upon earlier redemption, if such redemption is on or after May 9, 2026. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(3)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In April 2022, Teva repaid $296&#160;million of its 3.25% senior notes at maturity. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(*)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;Interest rate adjustments and a potential &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-time&lt;/div&gt; premium payment related to the sustainability-linked bonds are treated as bifurcated embedded derivatives. See note 8&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;c&lt;/div&gt;. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term debt was issued by several indirect wholly-owned subsidiaries of the Company and is fully and unconditionally guaranteed by the Company as to payment of all principal, interest, discount and additional amounts, if any. The long-term debt outlined in the above table is generally redeemable at any time at varying redemption prices plus accrued and unpaid interest. &lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva&#x2019;s &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;debt as of June&#160;30, 2022 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;was&lt;/div&gt; effectively denominated in the following currencies: 63% in U.S. dollar, 34% in euro and 3% in Swiss franc. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva&#x2019;s principal sources of short-term liquidity are its cash on hand, existing cash investments, liquid securities and available credit facilities, primarily, as of June&#160;30, 2022, its $1.8&#160;billion unsecured syndicated sustainability-linked revolving credit facility&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;entered into in April 2022 (&#x201c;RCF&#x201d;). &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;"&gt;In April 2022, Teva entered into an unsecured syndicated sustainability-linked revolving credit facility of $1.8&#160;billion with a maturity date of &lt;span style="-sec-ix-hidden:hidden52308335"&gt;April&lt;/span&gt; 2026, with two &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-year&lt;/div&gt; extension options. The RCF contains certain covenants, including certain limitations on incurring liens and indebtedness and maintenance of certain financial ratios, including a maximum leverage ratio, which becomes more restrictive over time. In addition, the RCF is linked to two sustainability performance targets, (i)&#160;the company&#x2019;s S&amp;amp;P ESG Score and (ii)&#160;number of new regulatory submissions in low and middle-income countries. The RCF margin may increase or decrease depending on the Company&#x2019;s sustainability performance.&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under the terms of the RCF, the leverage ratio shall not exceed 4.50x in the second and third quarters of 2022, 4.25x in the fourth quarter of 2022, 4.00x in the first, second and third quarters of 2023, 3.75x in the fourth quarter of 2023 and 3.50x in 2024 and onwards. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The RCF can be used for general corporate purposes, including repaying existing debt. As of June 30, 2022 and as of the date of this Quarterly Report on Form 10-Q, no amounts were outstanding under the RCF. Based on current and forecasted results, the Company expects that it will not exceed the financial covenant thresholds set forth in the RCF within one year from the date the financial statements are issued. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Under specified circumstances, including &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-compliance&lt;/div&gt; with any of the covenants described above and the unavailability of any waiver, amendment or other modification thereto, the Company will not be able to borrow under the RCF. Additionally, violations of the covenants, under the above-mentioned circumstances, would result in an event of default in all borrowings under the RCF and, when greater than a specified threshold amount as set forth in each series of senior notes and sustainability-linked senior notes is outstanding, could lead to an event of default under the Company&#x2019;s senior notes and sustainability-linked senior notes due to cross acceleration provisions.&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva expects that it will continue to have sufficient cash resources to support its debt service payments and all other financial obligations within one year from the date that the financial statements are issued.&lt;/div&gt;&lt;/div&gt; </us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfShortTermDebtTextBlock contextRef="P01_01_2022To06_30_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;a. Short-term debt:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 89%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&#160;interest&lt;br/&gt;rate as of June&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Maturity&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Convertible senior debentures&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2026&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current maturities of long-term liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,696&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,403&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total short-term debt&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,719&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,426&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfShortTermDebtTextBlock>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn06_30_2022_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0025</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2022To06_30_2022_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis">2026</teva:DebtInstrumentMaturityYear>
    <us-gaap:ShortTermBorrowings
      contextRef="PAsOn06_30_2022_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">23000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="PAsOn12_31_2021_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">23000000</us-gaap:ShortTermBorrowings>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      id="Fact_52307410"
      unitRef="Unit_USD">1696000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      id="Fact_52307411"
      unitRef="Unit_USD">1403000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">1719000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">1426000000</us-gaap:DebtCurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn06_30_2022_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0025</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn06_30_2022_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">23000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn12_31_2021_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">23000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="P01_01_2022To06_30_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 10pt;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;b. Long-term debt:&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 87%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&#160;interest&lt;br/&gt;rate as of June&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Maturity&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$&#160;in&#160;millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes EUR 1,500&#160;million&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1.13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2024&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;653&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;708&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: pre-wrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: pre-wrap;;display:inline;"&gt;Sustainability-linked senior notes EUR 1,500&#160;million&#160;(1)&lt;div style="letter-spacing: 0px; top: 0px; white-space: pre-wrap;;display:inline;"&gt;&#160;&lt;/div&gt;(*)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;4.38&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;2030&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1,566&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1,699&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes EUR 1,300&#160;million&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1.25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;616&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;670&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sustainability-linked senior notes EUR 1,100&#160;million&#160;(2)&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;(*)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;3.75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;2027&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1,150&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1,246&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes EUR 1,000&#160;million&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;6.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,043&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,134&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes EUR 900&#160;million&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;4.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;2025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;942&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1,020&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes EUR 750&#160;million&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1.63&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2028&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;779&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;844&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes EUR 700&#160;million (3)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;3.25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;307&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes EUR 700&#160;million&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1.88&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2027&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;729&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;792&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 3,500&#160;million&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;3.15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;2026&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;3,496&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;3,496&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 3,000&#160;million&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2.80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,453&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,453&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 2,000&#160;million&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;4.10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;2046&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1,986&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1,986&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 1,250&#160;million&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;6.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2024&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 1,250&#160;million&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;6.75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;2028&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1,250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1,250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 1,000&#160;million&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;7.13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sustainability-linked senior notes USD 1,000&#160;million&#160;(2)&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;(*)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;4.75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;2027&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sustainability-linked senior notes USD 1,000&#160;million&#160;(1)&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;(*)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;5.13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2029&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 844&#160;million&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;2.95&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;715&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;715&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 789&#160;million&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;6.15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2036&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;783&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;783&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes CHF 350&#160;million&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;0.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;366&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;382&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes CHF 350&#160;million&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;367&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;383&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total senior notes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;22,144&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;23,118&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other long-term debt&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less current maturities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(1,696&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(1,403&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less debt issuance costs&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(87&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total senior notes and loa&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;n&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;;text-align:right;"&gt;20,363&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;;text-align:right;"&gt;21,617&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; </us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_EUR">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongtermDebtWeightedAverageInterestRate
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0113</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis">2024</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">653000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2021_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">708000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2030MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_EUR">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongtermDebtWeightedAverageInterestRate
      contextRef="PAsOn06_30_2022_SustainabilityLinkedSeniorNotesDue2030MemberusgaapDebtInstrumentAxis"
      decimals="4"
      id="Fact_52308383"
      unitRef="Unit_pure">0.0438</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <teva:DebtInstrumentMaturityYear
      contextRef="P01_01_2022To06_30_2022_SustainabilityLinkedSeniorNotesDue2030MemberusgaapDebtInstrumentAxis"
      id="Fact_52307419">2030</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn06_30_2022_SustainabilityLinkedSeniorNotesDue2030MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_52307420"
      unitRef="Unit_USD">1566000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2021_SustainabilityLinkedSeniorNotesDue2030MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_52307421"
      unitRef="Unit_USD">1699000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_EUR">1300000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongtermDebtWeightedAverageInterestRate
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0125</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis">2023</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">616000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2021_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">670000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn06_30_2022_SustainabilityLinkedSeniorNotesDue2027MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_EUR">1100000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongtermDebtWeightedAverageInterestRate
      contextRef="PAsOn06_30_2022_SustainabilityLinkedSeniorNotesDue2027MemberusgaapDebtInstrumentAxis"
      decimals="4"
      id="Fact_52308385"
      unitRef="Unit_pure">0.0375</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <teva:DebtInstrumentMaturityYear
      contextRef="P01_01_2022To06_30_2022_SustainabilityLinkedSeniorNotesDue2027MemberusgaapDebtInstrumentAxis"
      id="Fact_52307425">2027</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn06_30_2022_SustainabilityLinkedSeniorNotesDue2027MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_52307426"
      unitRef="Unit_USD">1150000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2021_SustainabilityLinkedSeniorNotesDue2027MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_52307427"
      unitRef="Unit_USD">1246000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_EUR">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongtermDebtWeightedAverageInterestRate
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.06</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis">2025</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1043000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2021_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1134000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_EUR">900000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongtermDebtWeightedAverageInterestRate
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.045</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis">2025</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">942000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2021_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1020000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_EUR">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongtermDebtWeightedAverageInterestRate
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0163</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis">2028</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">779000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2021_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">844000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_EUR">700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongtermDebtWeightedAverageInterestRate
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis"
      decimals="4"
      id="Fact_52308389"
      unitRef="Unit_pure">0.0325</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <teva:DebtInstrumentMaturityYear
      contextRef="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis"
      id="Fact_52307617">2022</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_52307618"
      unitRef="Unit_USD">0</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2021_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_52307619"
      unitRef="Unit_USD">307000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2027MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_EUR">700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongtermDebtWeightedAverageInterestRate
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2027MemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0188</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2027MemberusgaapDebtInstrumentAxis">2027</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2027MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">729000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2021_SubsidiarySeniorNotesDue2027MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">792000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">3500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongtermDebtWeightedAverageInterestRate
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0315</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis">2026</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">3496000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2021_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">3496000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">3000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongtermDebtWeightedAverageInterestRate
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.028</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis">2023</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1453000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2021_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1453000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">2000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongtermDebtWeightedAverageInterestRate
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.041</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis">2046</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1986000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2021_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1986000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongtermDebtWeightedAverageInterestRate
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.06</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis">2024</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1250000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2021_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1250000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongtermDebtWeightedAverageInterestRate
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0675</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis">2028</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1250000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2021_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1250000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongtermDebtWeightedAverageInterestRate
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0713</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis">2025</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2021_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn06_30_2022_SustainabilityLinkedSeniorNotesDue2027TwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongtermDebtWeightedAverageInterestRate
      contextRef="PAsOn06_30_2022_SustainabilityLinkedSeniorNotesDue2027TwoMemberusgaapDebtInstrumentAxis"
      decimals="4"
      id="Fact_52308397"
      unitRef="Unit_pure">0.0475</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <teva:DebtInstrumentMaturityYear
      contextRef="P01_01_2022To06_30_2022_SustainabilityLinkedSeniorNotesDue2027TwoMemberusgaapDebtInstrumentAxis"
      id="Fact_52307452">2027</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn06_30_2022_SustainabilityLinkedSeniorNotesDue2027TwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_52307453"
      unitRef="Unit_USD">1000000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2021_SustainabilityLinkedSeniorNotesDue2027TwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_52307454"
      unitRef="Unit_USD">1000000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn06_30_2022_SustainabilityLinkedSeniorNotesDue2029MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongtermDebtWeightedAverageInterestRate
      contextRef="PAsOn06_30_2022_SustainabilityLinkedSeniorNotesDue2029MemberusgaapDebtInstrumentAxis"
      decimals="4"
      id="Fact_52308398"
      unitRef="Unit_pure">0.0513</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <teva:DebtInstrumentMaturityYear
      contextRef="P01_01_2022To06_30_2022_SustainabilityLinkedSeniorNotesDue2029MemberusgaapDebtInstrumentAxis"
      id="Fact_52307455">2029</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn06_30_2022_SustainabilityLinkedSeniorNotesDue2029MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_52307456"
      unitRef="Unit_USD">1000000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2021_SustainabilityLinkedSeniorNotesDue2029MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_52307457"
      unitRef="Unit_USD">1000000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2022TwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">844000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongtermDebtWeightedAverageInterestRate
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2022TwoMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0295</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2022TwoMemberusgaapDebtInstrumentAxis">2022</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2022TwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">715000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2021_SubsidiarySeniorNotesDue2022TwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">715000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">789000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongtermDebtWeightedAverageInterestRate
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0615</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis">2036</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">783000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2021_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">783000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_CHF">350000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongtermDebtWeightedAverageInterestRate
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.005</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis">2022</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">366000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2021_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">382000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2025ThreeMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_CHF">350000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongtermDebtWeightedAverageInterestRate
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2025ThreeMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.01</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2022To06_30_2022_SubsidiarySeniorNotesDue2025ThreeMemberusgaapDebtInstrumentAxis">2025</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn06_30_2022_SubsidiarySeniorNotesDue2025ThreeMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">367000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2021_SubsidiarySeniorNotesDue2025ThreeMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">383000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">22144000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">23118000000</us-gaap:SeniorNotes>
    <us-gaap:LongTermNotesAndLoans
      contextRef="PAsOn06_30_2022_OtherDebentures2026MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">2000000</us-gaap:LongTermNotesAndLoans>
    <us-gaap:LongTermNotesAndLoans
      contextRef="PAsOn12_31_2021_OtherDebentures2026MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">2000000</us-gaap:LongTermNotesAndLoans>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">1696000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">1403000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DeferredFinanceCostsNoncurrentNet
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">87000000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:DeferredFinanceCostsNoncurrentNet
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">100000000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:LongTermNotesAndLoans
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">20363000000</us-gaap:LongTermNotesAndLoans>
    <us-gaap:LongTermNotesAndLoans
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">21617000000</us-gaap:LongTermNotesAndLoans>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="P01_01_2022To06_30_2022_InterestRateIncreaseMemberusgaapDebtInstrumentAxis_MinimumMembersrtRangeAxis"
      decimals="5"
      unitRef="Unit_pure">0.00125</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="P01_01_2022To06_30_2022_InterestRateIncreaseMemberusgaapDebtInstrumentAxis_MaximumMembersrtRangeAxis"
      decimals="5"
      unitRef="Unit_pure">0.00375</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentMaturityDate contextRef="P01_01_2022To06_30_2022_InterestRateIncreaseMemberusgaapDebtInstrumentAxis">2026-05-09</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="P01_01_2022To06_30_2022_MinimumMembersrtRangeAxis_OneTimePremiumPaymentMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0015</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="P01_01_2022To06_30_2022_MaximumMembersrtRangeAxis_OneTimePremiumPaymentMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0045</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentMaturityDate contextRef="P01_01_2022To06_30_2022_OneTimePremiumPaymentMemberusgaapDebtInstrumentAxis">2026-05-09</us-gaap:DebtInstrumentMaturityDate>
    <teva:SeniorNotesRepaidAmount
      contextRef="PAsOn04_30_2022_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">296000000</teva:SeniorNotesRepaidAmount>
    <teva:SeniorNotesMaturityPercentage
      contextRef="PAsOn04_30_2022_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0325</teva:SeniorNotesMaturityPercentage>
    <teva:LongTermDebtCurrencyPortionUSD
      contextRef="PAsOn06_30_2022"
      decimals="2"
      unitRef="Unit_pure">0.63</teva:LongTermDebtCurrencyPortionUSD>
    <teva:LongTermDebtCurrencyPortionEUR
      contextRef="PAsOn06_30_2022"
      decimals="2"
      unitRef="Unit_pure">0.34</teva:LongTermDebtCurrencyPortionEUR>
    <teva:LongTermDebtCurrencyPortionCHF
      contextRef="PAsOn06_30_2022"
      decimals="2"
      unitRef="Unit_pure">0.03</teva:LongTermDebtCurrencyPortionCHF>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="PAsOn06_30_2022_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"
      decimals="-8"
      unitRef="Unit_USD">1800000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="PAsOn04_30_2022_UnsecuredSyndicatedRevolvingCreditFacilityMemberusgaapCreditFacilityAxis"
      decimals="-5"
      unitRef="Unit_USD">1800000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <teva:LineOfCreditExtentionPeriod contextRef="P01_01_2022To06_30_2022_UnsecuredSyndicatedRevolvingCreditFacilityMemberusgaapCreditFacilityAxis">one-year</teva:LineOfCreditExtentionPeriod>
    <teva:LeverageRatio contextRef="P07_01_2022To09_30_2022_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">4.50</teva:LeverageRatio>
    <teva:LeverageRatio contextRef="P04_01_2022To06_30_2022_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis">4.50</teva:LeverageRatio>
    <teva:LeverageRatio contextRef="P10_01_2022To12_31_2022_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">4.25</teva:LeverageRatio>
    <teva:LeverageRatio contextRef="P01_01_2023To03_31_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">4.00</teva:LeverageRatio>
    <teva:LeverageRatio contextRef="P07_01_2023To09_30_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">4.00</teva:LeverageRatio>
    <teva:LeverageRatio contextRef="P04_01_2023To06_30_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">4.00</teva:LeverageRatio>
    <teva:LeverageRatio contextRef="P10_01_2023To12_31_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">3.75</teva:LeverageRatio>
    <teva:LeverageRatio contextRef="P01_01_2024To12_31_2024_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">3.50</teva:LeverageRatio>
    <us-gaap:DebtInstrumentCovenantDescription contextRef="P01_01_2022To06_30_2022_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis">The RCF can be used for general corporate purposes, including repaying existing debt. As of June 30, 2022 and as of the date of this Quarterly Report on Form 10-Q, no amounts were outstanding under the RCF. Based on current and forecasted results, the Company expects that it will not exceed the financial covenant thresholds set forth in the RCF within one year from the date the financial statements are issued</us-gaap:DebtInstrumentCovenantDescription>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="P01_01_2022To06_30_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 8 &#x2013; Derivative instruments and hedging activities: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;a. Foreign exchange risk management:&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the first six months of 2022, approximately 48% of Teva&#x2019;s revenues were denominated in currencies other than the U.S. dollar. As a result, Teva is subject to significant foreign currency risks. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company enters into forward exchange contracts, purchases and writes options in order to hedge the currency exposure on balance sheet items, revenues and expenses. In addition, the Company takes measures to reduce exposure by using natural hedging. The Company also acts to offset risks in opposite directions among the subsidiaries within Teva. The currency hedged items are usually denominated in the following main currencies: the euro, the Swiss franc, the Japanese yen, the British pound, the Russian ruble, the Canadian dollar, the Polish zloty, new Israeli shekel, the Indian rupee and other European and Latin American currencies. Depending on market conditions, foreign currency risk is also managed through the use of foreign currency debt. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company may choose to hedge against possible fluctuations in foreign subsidiaries net assets (&#x201c;net investment hedge&#x201d;) and entered into cross currency swaps and forward contracts in the past in order to hedge such an exposure. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Most of the counterparties to the derivatives are major banks and the Company is monitoring the associated inherent credit risks. The Company does not enter into derivative transactions for trading purposes. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;b. Interest risk management: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company raises capital through various debt instruments, including senior notes, sustainability-linked senior notes, bank loans, convertible debentures and syndicated revolving credit facility that bear a fixed or variable interest rate. In some cases, the Company has swapped from a fixed to a variable interest rate (&#x201c;fair value hedge&#x201d;) and from a fixed to a fixed interest rate with an exchange from a currency other than the functional currency (&#x201c;cash flow hedge&#x201d;), thereby reducing overall interest expenses or hedging risks associated with interest rate fluctuations. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;c. Bifurcated embedded derivatives: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Upon issuance of sustainability-linked senior notes, Teva recognized embedded derivatives related to interest rate adjustments and a potential &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-time&lt;/div&gt; premium payment upon failure to achieve certain sustainability performance targets, such as access to medicines in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;low-to-middle-income&lt;/div&gt;&lt;/div&gt; countries and absolute greenhouse gas emissions reduction, which were bifurcated and are accounted for separately as derivative financial instruments. As of June&#160;30, 2022&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt; the fair value of these derivative instruments is negligible.&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;d. Derivative instruments outstanding: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the classification and fair values of derivative instruments:&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 77%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Not designated as hedging&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;instruments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="5" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reported under&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Asset derivatives:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other current assets:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Option and forward contracts&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;69&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liability derivatives:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other current liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Option and forward contracts&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(37&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(23&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The table below provides information regarding the location and amount of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-tax&lt;/div&gt; (gains) losses from derivatives not designated as hedging instruments:&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial&#160;expenses,&#160;net&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net revenues&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;months&#160;ended,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three months ended,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reported under&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Line items in which effects of hedges are recorded&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;211&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;274&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,786&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,910&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Option and forward contracts (1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(38&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;27&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Option and forward contracts economic hedge (2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial&#160;expenses,&#160;net&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net revenues&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six months ended,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six months ended,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reported under&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 11pt; break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Line items in which effects of hedges are recorded&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;468&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;564&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,447&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,892&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Option and forward contracts (1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(43&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(43&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Option and forward contracts economic hedge (2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(35&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;Teva uses foreign exchange contracts (mainly option and forward contracts) to hedge balance sheet items from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, Teva recognizes gains or losses that offset the revaluation of the balance sheet items also recorded under financial expenses, net.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on projected revenues and expenses recorded in euro, the Swiss franc, the Japanese yen, the British pound, the Russian ruble, the Canadian dollar and some other currencies to protect its projected operating results for 2022 and 2021. These derivative instruments do not meet the criteria for hedge accounting, however, they are accounted for as an economic hedge. These derivative instruments, which may include hedging transactions against future projected revenues and expenses, are&lt;br/&gt;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. In the first six months of 2022, the positive impact from these derivatives recognized under revenues was $35&#160;million. In the first six months of 2021, the positive impact from these derivatives recognized under revenues was $13&#160;million. Changes in the fair value of the derivative instruments are recognized in the same line item in the statements of income as the underlying exposure being hedged. The cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;e. Amortizations due to terminated derivative instruments: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward starting interest rate swaps and treasury lock agreements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In 2015, Teva entered into forward starting interest rate swaps and treasury lock agreements to protect the Company from interest rate fluctuations in connection with a future debt issuance the Company was planning. These forward starting interest rate swaps and treasury lock agreements were terminated in July 2016 upon the debt issuance. The termination of these transactions resulted in a loss position of $493&#160;million, which was recorded in other comprehensive income (loss) and is amortized under financial expenses, net over the life of the debt. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;With respect to these forward starting interest rate swaps and treasury lock agreements, losses of $7&#160;million and $8&#160;million were recognized under financial expenses, net for each of the three months ended June&#160;30, 2022 and 2021, respectively, and losses of $15&#160;million and $16&#160;million were recognized under financial expenses, net for each of the six months ended June&#160;30, 2022 and 2021, respectively. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value hedge &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the third quarter of 2016, Teva terminated interest rate swap agreements designated as a fair value hedge relating to its 2.95% senior notes due 2022 with respect to $844&#160;million notional amount and its 3.65% senior notes due 2021 with respect to $450&#160;million notional amount. Settlement of these transactions resulted in a gain position of $41&#160;million. The fair value hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt as additional interest expense. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the third quarter of 2019, Teva terminated $500&#160;million interest rate swap agreements designated as a fair value hedge relating to its 2.8% senior notes due 2023 with respect to $3,000&#160;million notional amount. Settlement of these transactions resulted in cash proceeds of $10&#160;million. The fair value hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;With respect to the interest rate swap and cross-currency swap agreements, gains of $&lt;/div&gt;1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million were recognized under financial expenses, net for each of the three months ended June&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, respectively, and gains of $&lt;/div&gt;2&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million were recognized under financial expenses, net for the six months ended June&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, respectively.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <teva:RevenuesOtherThanUsd
      contextRef="PAsOn06_30_2022"
      decimals="2"
      unitRef="Unit_pure">0.48</teva:RevenuesOtherThanUsd>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock contextRef="P01_01_2022To06_30_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the classification and fair values of derivative instruments:&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 77%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Not designated as hedging&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;instruments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="5" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reported under&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Asset derivatives:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other current assets:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Option and forward contracts&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;69&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liability derivatives:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other current liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Option and forward contracts&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(37&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(23&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="PAsOn06_30_2022_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherCurrentAssetsMemberusgaapBalanceSheetLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">69000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="PAsOn12_31_2021_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherCurrentAssetsMemberusgaapBalanceSheetLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">30000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="PAsOn06_30_2022_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_SeniorNotesAndLoansMemberusgaapBalanceSheetLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">37000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="PAsOn12_31_2021_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_SeniorNotesAndLoansMemberusgaapBalanceSheetLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">23000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock contextRef="P01_01_2022To06_30_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The table below provides information regarding the location and amount of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-tax&lt;/div&gt; (gains) losses from derivatives not designated as hedging instruments:&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial&#160;expenses,&#160;net&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net revenues&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;months&#160;ended,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three months ended,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reported under&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Line items in which effects of hedges are recorded&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;211&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;274&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,786&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,910&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Option and forward contracts (1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(38&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;27&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Option and forward contracts economic hedge (2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial&#160;expenses,&#160;net&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net revenues&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six months ended,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six months ended,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reported under&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 11pt; break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Line items in which effects of hedges are recorded&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;468&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;564&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,447&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,892&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Option and forward contracts (1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(43&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(43&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Option and forward contracts economic hedge (2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(35&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;Teva uses foreign exchange contracts (mainly option and forward contracts) to hedge balance sheet items from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, Teva recognizes gains or losses that offset the revaluation of the balance sheet items also recorded under financial expenses, net.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on projected revenues and expenses recorded in euro, the Swiss franc, the Japanese yen, the British pound, the Russian ruble, the Canadian dollar and some other currencies to protect its projected operating results for 2022 and 2021. These derivative instruments do not meet the criteria for hedge accounting, however, they are accounted for as an economic hedge. These derivative instruments, which may include hedging transactions against future projected revenues and expenses, are&lt;br/&gt;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. In the first six months of 2022, the positive impact from these derivatives recognized under revenues was $35&#160;million. In the first six months of 2021, the positive impact from these derivatives recognized under revenues was $13&#160;million. Changes in the fair value of the derivative instruments are recognized in the same line item in the statements of income as the underlying exposure being hedged. The cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P04_01_2022To06_30_2022_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      unitRef="Unit_USD">211000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P04_01_2021To06_30_2021_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      unitRef="Unit_USD">274000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P04_01_2022To06_30_2022_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      unitRef="Unit_USD">-3786000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P04_01_2021To06_30_2021_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      unitRef="Unit_USD">-3910000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P04_01_2022To06_30_2022_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      id="Fact_52307503"
      unitRef="Unit_USD">-38000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P04_01_2021To06_30_2021_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      id="Fact_52307504"
      unitRef="Unit_USD">27000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P04_01_2022To06_30_2022_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      id="Fact_52307505"
      unitRef="Unit_USD">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P04_01_2021To06_30_2021_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      id="Fact_52307506"
      unitRef="Unit_USD">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P04_01_2022To06_30_2022_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      id="Fact_52307507"
      unitRef="Unit_USD">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P04_01_2021To06_30_2021_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      id="Fact_52307508"
      unitRef="Unit_USD">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P04_01_2022To06_30_2022_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      id="Fact_52307509"
      unitRef="Unit_USD">-16000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P04_01_2021To06_30_2021_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      id="Fact_52307510"
      unitRef="Unit_USD">15000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2022To06_30_2022_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      unitRef="Unit_USD">468000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2021To06_30_2021_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      unitRef="Unit_USD">564000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2022To06_30_2022_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      unitRef="Unit_USD">-7447000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2021To06_30_2021_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      unitRef="Unit_USD">-7892000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2022To06_30_2022_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      id="Fact_52307515"
      unitRef="Unit_USD">-43000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2021To06_30_2021_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      id="Fact_52307516"
      unitRef="Unit_USD">-43000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2022To06_30_2022_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      id="Fact_52307517"
      unitRef="Unit_USD">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2021To06_30_2021_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      id="Fact_52307518"
      unitRef="Unit_USD">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2022To06_30_2022_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      id="Fact_52307519"
      unitRef="Unit_USD">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2021To06_30_2021_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      id="Fact_52307520"
      unitRef="Unit_USD">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2022To06_30_2022_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      id="Fact_52307521"
      unitRef="Unit_USD">-35000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2021To06_30_2021_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      id="Fact_52307522"
      unitRef="Unit_USD">-13000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:DerivativeGainOnDerivative
      contextRef="P01_01_2022To06_30_2022_CostOfSalesMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">35000000</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative
      contextRef="P01_01_2021To06_30_2021_CostOfSalesMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">13000000</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeLossOnDerivative
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">493000000</us-gaap:DerivativeLossOnDerivative>
    <teva:ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">7000000</teva:ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses>
    <teva:ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">8000000</teva:ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses>
    <teva:ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">15000000</teva:ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses>
    <teva:ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">16000000</teva:ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses>
    <teva:PreviouslyHedgeDebtRate
      contextRef="PAsOn09_30_2016_SeniorNotesDue2022MemberusgaapDerivativeInstrumentRiskAxis"
      decimals="4"
      unitRef="Unit_pure">0.0295</teva:PreviouslyHedgeDebtRate>
    <teva:NotionalAmountHedgeDebt
      contextRef="PAsOn09_30_2016_SeniorNotesDue2022MemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-6"
      unitRef="Unit_USD">844000000</teva:NotionalAmountHedgeDebt>
    <teva:PreviouslyHedgeDebtRate
      contextRef="PAsOn09_30_2016_SeniorNotesDue2021MemberusgaapDerivativeInstrumentRiskAxis"
      decimals="4"
      unitRef="Unit_pure">0.0365</teva:PreviouslyHedgeDebtRate>
    <teva:NotionalAmountHedgeDebt
      contextRef="PAsOn09_30_2016_SeniorNotesDue2021MemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-6"
      unitRef="Unit_USD">450000000</teva:NotionalAmountHedgeDebt>
    <us-gaap:DerivativeFairValueHedgeIncludedInEffectivenessGainLoss
      contextRef="P07_01_2016To09_30_2016_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-6"
      unitRef="Unit_USD">41000000</us-gaap:DerivativeFairValueHedgeIncludedInEffectivenessGainLoss>
    <teva:NotionalAmountHedgeDebt
      contextRef="PAsOn09_30_2019_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-6"
      unitRef="Unit_USD">500000000</teva:NotionalAmountHedgeDebt>
    <teva:PreviouslyHedgeDebtRate
      contextRef="PAsOn09_30_2019_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="3"
      unitRef="Unit_pure">0.028</teva:PreviouslyHedgeDebtRate>
    <teva:NotionalAmountHedgeDebt
      contextRef="PAsOn09_30_2016_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-6"
      unitRef="Unit_USD">3000000000</teva:NotionalAmountHedgeDebt>
    <teva:CashReceivedOnSettlementOfPosition
      contextRef="PAsOn09_30_2019_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-6"
      unitRef="Unit_USD">10000000</teva:CashReceivedOnSettlementOfPosition>
    <teva:InterestRateSwapLoss
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">1000000</teva:InterestRateSwapLoss>
    <teva:InterestRateSwapLoss
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">1000000</teva:InterestRateSwapLoss>
    <teva:InterestRateSwapLoss
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">2000000</teva:InterestRateSwapLoss>
    <teva:InterestRateSwapLoss
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">1000000</teva:InterestRateSwapLoss>
    <us-gaap:LegalMattersAndContingenciesTextBlock contextRef="P01_01_2022To06_30_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 9 &#x2013; Legal settlements and loss contingencies: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the second quarter of 2022, Teva recorded expenses of $729&#160;million in legal settlements and loss contingencies, compared to $6&#160;million in the second quarter of 2021. The expenses in the second quarter of 2022 were mainly related to an update of the estimated settlement provision recorded in connection with the remaining opioid cases.&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;See note 10. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the first six months of 2022, Teva recorded an expense of $1,854&#160;million in legal settlements and loss contingencies, compared &lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;to an&#160;&lt;/div&gt;&lt;/div&gt;expense of $110&#160;million in the first six months of 2021. The expense in the first six months of 2022 was mainly related to an update of the estimated settlement provision recorded in connection with the remaining opioid cases. The expense in the first six months of 2021 was mainly due to the provision for the carvedilol patent litigation. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of June&#160;30, 2022 and December&#160;31, 2021, Teva&#x2019;s provision for legal settlements and loss contingencies recorded under accrued expenses and other taxes and long-term liabilities was $3,928&#160;million and $2,710&#160;million, respectively. In connection with Teva&#x2019;s provision for legal settlements and loss contingencies as of December&#160;31, 2021, related to the Ontario Teachers Securities Litigation, Teva also recognized an insurance receivable.&lt;/div&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:LitigationSettlementExpense
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">729000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">6000000</us-gaap:LitigationSettlementExpense>
    <teva:RestructuringExpenseAndIncome contextRef="P04_01_2022To06_30_2022_SettlementOnAccountOfProductLiabilityMembersrtLitigationCaseAxis">The expenses in the second quarter of 2022 were mainly related to an update of the estimated settlement provision recorded in connection with the remaining opioid cases.</teva:RestructuringExpenseAndIncome>
    <us-gaap:LitigationSettlementExpense
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">1854000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">110000000</us-gaap:LitigationSettlementExpense>
    <teva:RestructuringExpenseAndIncome contextRef="P01_01_2021To06_30_2021">The expense in the first six months of 2021 was mainly due to the provision for the carvedilol patent litigation.</teva:RestructuringExpenseAndIncome>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">3928000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">2710000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2022To06_30_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 10 &#x2013; Commitments and contingencies: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;From time to time, Teva and/or its subsidiaries are subject to claims for damages and/or equitable relief arising in the ordinary course of business. In addition, as described below, in large part as a result of the nature of its business, Teva is frequently subject to litigation. Teva generally believes that it has meritorious defenses to the actions brought against it and vigorously pursues the defense or settlement of each such action. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva records a provision in its financial statements to the extent that it concludes that a contingent liability is probable and the amount thereof is estimable. Based upon the status of the cases described below, management&#x2019;s assessments of the likelihood of damages, and the advice of counsel, no provisions have been made regarding the matters disclosed in this note, except as noted below. Litigation outcomes and contingencies are unpredictable, and excessive verdicts can occur. Accordingly, management&#x2019;s assessments involve complex judgments about future events and often rely heavily on estimates and assumptions. Teva continuously reviews the matters described below and may, from time to time, remove previously disclosed matters where the exposures were fully resolved in the prior year, or determined to no longer meet the materiality threshold for disclosure, or were substantially resolved. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If one or more of such proceedings described below were to result in final judgments against Teva, such judgments could be material to its results of operations and cash flows in a given period. In addition, Teva incurs significant legal fees and related expenses in the course of defending its positions even if the facts and circumstances of a particular litigation do not give rise to a provision in the financial statements. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In connection with third-party agreements, Teva may under certain circumstances be required to indemnify, and may be indemnified by, in unspecified amounts, the parties to such agreements against third-party claims. Among other things, Teva&#x2019;s agreements with third parties may require Teva to indemnify them, or require them to indemnify Teva, for the costs and damages incurred in connection with product liability claims, in specified or unspecified amounts. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Except as otherwise noted, all of the litigation matters disclosed below involve claims arising in the United States. Except as otherwise noted, all third party sales figures given below are based on IQVIA data. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intellectual Property Litigation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;From time to time, Teva seeks to develop generic and biosimilar versions of patent-protected pharmaceuticals and biopharmaceuticals for sale prior to patent expiration in various markets. In the United States, to obtain approval for most generics prior to the expiration of the originator&#x2019;s patents, Teva must challenge the patents under the procedures set forth in the Hatch-Waxman Act of 1984, as amended. For many biosimilar products that are covered by patents, Teva participates in the &#x201c;patent dance&#x201d; procedures of the Biologics Price Competition and Innovation Act (BPCIA), which allow for the challenge to originator patents prior to obtaining biosimilar product approval. To the extent that Teva seeks to utilize such patent challenge procedures, Teva is and expects to be involved in patent litigation regarding the validity, enforceability or infringement of the originator&#x2019;s patents. Teva may also be involved in patent litigation involving the extent to which its product or manufacturing process techniques may infringe other originator or third-party patents. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additionally, depending upon a complex analysis of a variety of legal and commercial factors, Teva may, in certain circumstances, elect to market a generic or biosimilar version of the product even though litigation is still pending. To the extent Teva elects to proceed in this manner, it could face substantial liability for patent infringement if the final court decision is adverse to Teva, which could be material to its results of operations and cash flows in a given period. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva could also be sued for patent infringement outside of the context of the Hatch-Waxman Act or BPCIA. For example, Teva could be sued for patent infringement after commencing sales of a product. This type of litigation can involve any of Teva&#x2019;s pharmaceutical products, not just its generic and biosimilar products. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The general rule for damages in patent infringement cases in the United States is that the patentee should be compensated by no less than a reasonable royalty and it may also be able, in certain circumstances, to be compensated for its lost profits. The amount of a reasonable royalty award would generally be calculated based on the sales of Teva&#x2019;s product. The amount of lost profits would generally be based on the lost sales of the patentee&#x2019;s product. In addition, the patentee may seek consequential damages as well as enhanced damages of up to three times the profits lost by the patent holder for willful infringement, although courts have typically awarded much lower multiples. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva is also involved in litigation regarding patents in other countries where it does business, particularly in Europe. The laws concerning generic pharmaceuticals and patents differ from country to country. Damages for patent infringement in Europe may include lost profits or a reasonable royalty, but enhanced damages for willful infringement are generally not available. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In July 2014, GlaxoSmithKline (&#x201c;GSK&#x201d;) sued Teva in the District Court for the District of Delaware for infringement of a patent directed to using carvedilol in a specified manner to decrease the risk of mortality in patients with congestive heart failure. Teva and eight other generic producers began selling their carvedilol tablets (the generic version of GSK&#x2019;s Coreg&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;) in September 2007. A jury trial was held and the jury returned a verdict in GSK&#x2019;s favor finding Teva liable for induced infringement, including willful infringement, and assessing damages of $235.5&#160;million, not including &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-&lt;/div&gt; or post-judgment interest or a multiplier for willfulness. Thereafter, the judge overturned the jury verdict, finding no induced infringement by Teva and that Teva did not owe any damages. On August&#160;5, 2021, the Court of Appeals for the Federal Circuit issued a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-to-one&lt;/div&gt;&lt;/div&gt; decision reinstating the $235.5&#160;million verdict and finding Teva liable for patent infringement. On February&#160;11, 2022, the Court of Appeals for the Federal Circuit denied rehearing. Teva appealed this decision to the U.S. Supreme Court on July&#160;11, 2022. While that appeal is pending, the case is remanded to the district court for proceedings on Teva&#x2019;s other legal and equitable defenses that have not yet been considered by the district court. In the first quarter of 2021, Teva recognized a provision based on its offer to settle such matter. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In October 2016, Adapt and Emergent Biosciences Inc. (&#x201c;EBSI&#x201d;) sued Teva in the District Court for the District of New Jersey, asserting infringement of its patents expiring in 2035, as a result of Teva&#x2019;s filing of its Abbreviated New Drug Application (&#x201c;ANDA&#x201d;) seeking to market a generic version of Narcan&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; nasal spray. In June 2020, the court issued a decision finding all of EBSI&#x2019;s patents expiring in 2035, to be invalid. On December&#160;22, 2021, Teva launched its generic version of Narcan&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; nasal spray. On February&#160;10, 2022, the Court of Appeals for the Federal Circuit affirmed the lower court decision finding that EBSI&#x2019;s patents are invalid. On May&#160;5, 2022, the Court of Appeals for the Federal Circuit denied EBSI&#x2019;s petition for rehearing. EBSI still has the opportunity to seek further review from the U.S. Supreme Court. If Teva ultimately loses the case, Teva may be ordered to cease commercial sales or donations of its generic product and/or pay damages to EBSI. Annual sales of Narcan&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; in the U.S. were approximately $434&#160;million at the time Teva launched its generic version in December 2021. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Product Liability Litigation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva&#x2019;s business inherently exposes it to potential product liability claims. Teva maintains a program of insurance, which may include commercial insurance, self-insurance (including direct risk retention), or a combination of both types of insurance, in amounts and on terms that it believes are reasonable and prudent in light of its business and related risks. However, Teva sells, and will continue to sell, pharmaceuticals that are not covered by its product liability insurance; in addition, it may be subject to claims for which insurance coverage is denied as well as claims that exceed its policy limits. Product liability coverage for pharmaceutical companies is becoming more expensive and increasingly difficult to obtain. As a result, Teva may not be able to obtain the type and amount of insurance it desires, or any insurance on reasonable terms, in all of its markets. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva and its subsidiaries are parties to litigation relating to previously unknown nitrosamine impurities discovered in certain products. The discovery led to a global recall of single and combination valsartan medicines around the world starting in July 2018 and to subsequent recalls on other products. The nitrosamine impurities in valsartan are allegedly found in the active pharmaceutical ingredient (&#x201c;API&#x201d;) supplied by multiple API manufacturers. Teva&#x2019;s products allegedly at issue in the various nitrosamine-related litigations pending in the United States include valsartan, losartan, metformin and ranitidine. There are currently two Multi-District Litigations (&#x201c;MDL&#x201d;) pending in the United States District Courts against Teva and numerous other manufacturers. One MDL is pending in the United States District Court for the District of New Jersey for valsartan, losartan and irbesartan. Teva is not named in complaints with respect to irbesartan. The second MDL is pending in the United States District Court for the Southern District of Florida for ranitidine. The lawsuits against Teva in the MDLs consist of individual personal injury and/or product liability claims and economic damages claims brought by consumers and end payors on behalf of purported classes of other consumers and end payors as well as medical monitoring class claims. Defendants&#x2019; motions to dismiss in the valsartan, losartan and irbesartan MDL were denied in part and granted in part and plaintiffs have filed amended complaints.&#160;In the ranitidine MDL, the generics manufacturers&#x2019; motions to dismiss have been granted, although certain plaintiffs have appeals pending. Teva, as well as &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;other generic manufacturers, is also named in several state court actions asserting allegations similar to those in the ranitidine MDL and the valsartan and losartan MDL. The state court valsartan and losartan actions are pending in New Jersey and Delaware and are currently stayed. The state court ranitidine cases naming Teva are pending in California, Illinois, Pennsylvania and New York. In addition to these MDLs, Teva has also been named in a consolidated proceeding pending in the United States District Court for the District of New Jersey brought by individuals and end payors seeking economic damages on behalf of purported classes of consumers and end payors who purchased Teva&#x2019;s, as well as other generic manufacturers&#x2019; metformin products. Defendants&#x2019; motion to dismiss the plaintiffs&#x2019; amended metformin complaint from June 2021, was granted without prejudice with respect to the consumer economic loss plaintiffs and granted in part and denied in part with respect to the end payor plaintiffs. Plaintiffs were granted leave to file a second amended complaint. Similar lawsuits are pending in Canada and Germany.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Competition Matters &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As part of its generic pharmaceuticals business, Teva has challenged a number of patents covering branded pharmaceuticals, some of which are among the most widely-prescribed and well-known drugs on the market. Many of Teva&#x2019;s patent challenges have resulted in litigation relating to Teva&#x2019;s attempts to market generic versions of such pharmaceuticals under the federal Hatch-Waxman Act. Some of this litigation has been resolved through settlement agreements in which Teva obtained a license to market a generic version of the drug, often years before the patents expire. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva and its subsidiaries have been named as defendants in cases that allege antitrust violations arising from such settlement agreements. The plaintiffs in these cases are usually direct and indirect purchasers of pharmaceutical products, some of whom assert claims on behalf of classes of all direct and indirect purchasers, and they typically allege that (i)&#160;Teva received something of value from the innovator in exchange for an agreement to delay generic entry, and (ii)&#160;significant savings could have been realized if there had been no settlement agreement and generic competition had commenced earlier. These plaintiffs seek various forms of injunctive and monetary relief, including damages based on the difference between the brand price and what the generic price allegedly would have been and disgorgement of profits, which are often automatically tripled under the relevant statutes, plus attorneys&#x2019; fees and costs. The alleged damages generally depend on the size of the branded market and the length of the alleged delay, and can be substantial&#x2014;potentially measured in multiples of the annual brand sales&#x2014;particularly where the alleged delays are lengthy or branded drugs with annual sales in the billions of dollars are involved. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva believes that its settlement agreements are lawful and serve to increase competition, and has defended them vigorously. In Teva&#x2019;s experience to date, these cases have typically settled for a fraction of the high end of the damages sought, although there can be no assurance that such outcomes will continue. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In June 2013, the U.S. Supreme Court held, in Federal Trade Commission (&#x201c;FTC&#x201d;) v. Actavis, Inc., that a rule of reason test should be applied in analyzing whether such settlements potentially violate the federal antitrust laws. The Supreme Court held that a trial court must analyze each agreement in its entirety in order to determine whether it violates the antitrust laws. This new test has resulted in increased scrutiny of Teva&#x2019;s patent settlements, additional action by the FTC and state and local authorities, and an increased risk of liability in Teva&#x2019;s currently pending antitrust litigations. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In May 2015, Cephalon Inc., a Teva subsidiary (&#x201c;Cephalon&#x201d;), entered into a consent decree with the FTC (the &#x201c;Modafinil Consent Decree&#x201d;) under which the FTC dismissed antitrust claims against Cephalon related to certain finished modafinil products (marketed as PROVIGIL&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;) in exchange for Cephalon and Teva agreeing to, among other things, abide by certain restrictions and limitations, for a period of ten years, when entering into settlement agreements to resolve patent litigation in the United States. Those restrictions and limitations were further refined in connection with the settlement of other unrelated FTC antitrust lawsuits and the term of the Modafinil Consent Decree was extended until 2029. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In November 2020, the European Commission issued a final decision in its proceedings against both Cephalon and Teva, finding that the 2005 settlement agreement between the parties had the object and effect of hindering the entry of generic modafinil, and imposed fines totaling euro 60.5&#160;million on Teva and Cephalon. Teva and Cephalon filed an appeal against the decision in February 2021. A provision for this matter was included in the financial statements. Teva has provided the European Commission with a bank guarantee in the amount of the imposed fines. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In December 2011, three groups of plaintiffs sued Wyeth and Teva for alleged violations of the antitrust laws in connection with their November 2005 settlement of patent litigation involving extended release venlafaxine (generic Effexor XR&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;). The cases were filed by a purported class of direct purchasers, by a purported class of indirect purchasers and by certain chain pharmacies in the U.S. District Court for the District of New Jersey. The plaintiffs claim that the settlement agreement between Wyeth and Teva unlawfully delayed generic entry. In March 2020, the district court temporarily stayed discovery and referred the case to mediation, and discovery remains stayed. Annual sales of Effexor XR&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; were approximately $2.6&#160;billion at the time of settlement and at the time Teva launched its generic version of Effexor XR&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; in July 2010. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In February 2012, two purported classes of direct-purchaser plaintiffs sued GSK and Teva in New Jersey federal court for alleged violations of the antitrust laws in connection with their settlement of patent litigation involving lamotrigine (generic Lamictal&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;) entered into in February 2005. The plaintiffs claim that the settlement agreement unlawfully delayed generic entry and seek unspecified damages. On April&#160;9, 2021, the district court, which had previously granted an initial motion for class certification by the direct purchaser plaintiffs but was reversed on that ruling by the Third Circuit in April 2020, denied the direct purchaser plaintiffs&#x2019; renewed motion for class certification. Plaintiffs thereafter sought leave to file a supplemental expert report in an effort to show that they could still meet the class certification standard on certain of their claims, but on January&#160;21, 2022, the district court denied that request in full, and on April&#160;21, 2022, the court entered a schedule for additional briefing on the remaining class certification issues. Annual sales of Lamictal&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; were approximately $950&#160;million at the time of the settlement and approximately $2.3&#160;billion at the time Teva launched its generic version of Lamictal&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; in July 2008. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In April 2013, purported classes of direct purchasers of, and end payers for, Niaspan&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; (extended release niacin) sued Teva and Abbott for violating the antitrust laws by entering into a settlement agreement in April 2005, to resolve patent litigation over the product. A multidistrict litigation has been established in the U.S. District Court for the Eastern District of Pennsylvania. Throughout 2015 and in January 2016, several individual direct-purchaser &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;opt-out&lt;/div&gt; plaintiffs filed complaints with allegations nearly identical to those of the direct purchasers&#x2019; class. In August 2019, the district court certified the direct-purchaser class, but in June 2020, the court denied the indirect purchasers&#x2019; motion for class certification without prejudice. On September&#160;4, 2020, the indirect purchasers filed a renewed motion for class certification, which was subsequently denied with prejudice by the district court and is now on appeal before the Court of Appeals for the Third Circuit. In October 2016, the District Attorney for Orange County, California, filed a similar complaint in California state court, alleging violations of state law and seeking restitution and civil penalties. Annual sales of Niaspan&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; were approximately $416&#160;million at the time of the settlement and approximately $1.1&#160;billion at the time Teva launched its generic version of Niaspan&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; in September 2013. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Since January 2014, numerous lawsuits have been filed in the U.S. District Court for the Southern District of New York by purported classes of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;end-payers&lt;/div&gt; for, and direct-purchasers of, Actos&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; and Actoplus Met (pioglitazone and pioglitazone plus metformin) against Takeda, the innovator, and several generic manufacturers, including Teva, Actavis and Watson. The lawsuits allege, among other things, that the settlement agreements between Takeda and the generic manufacturers violated the antitrust laws. The court dismissed the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;end-payers&#x2019;&lt;/div&gt; lawsuits against all defendants in September 2015. On February&#160;8, 2017, the Court of Appeals for the Second Circuit affirmed the dismissal in part and vacated and remanded the dismissal in part with respect to the claims against Takeda. The direct purchasers&#x2019; case had been stayed pending resolution of the appeal in the end payer matter and the direct purchasers amended their complaint for a second time following the Second Circuit&#x2019;s decision, but on October&#160;8, 2019, the district court dismissed, with prejudice, the direct purchasers&#x2019; claims against the generic manufacturers (including Teva, Actavis, and Watson). At the time of Teva&#x2019;s settlement, annual sales of Actos&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; and Actoplus Met were approximately $3.7&#160;billion and approximately $500&#160;million, respectively. At the time Teva launched its authorized generic version of Actos&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; and Actoplus Met in August 2012, annual sales of Actos&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; and Actoplus Met were approximately $2.8&#160;billion and approximately $430&#160;million, respectively. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Putative classes of direct-purchaser and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;end-payer&lt;/div&gt; plaintiffs have filed antitrust lawsuits (which have since been coordinated in federal court in Delaware) against Amgen and Teva alleging that the January&#160;2, 2019 settlement agreement between Amgen and Teva, resolving patent litigation over cinacalcet (generic Sensipar&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;), violated the antitrust laws. On November&#160;30, 2020, the district court denied Teva&#x2019;s motion to dismiss in part, and on February&#160;16, 2021, plaintiffs filed amended complaints. On March&#160;30, 2021, Teva again moved to dismiss those claims based on plaintiffs&#x2019; failure to allege both&#160;that the settlement violated the antitrust laws and&#160;that the settlement caused any actual injury to plaintiffs. On March&#160;11, 2022, the district court denied Teva&#x2019;s motion to dismiss in part. Teva has requested that the district court certify its rulings for review by the United States Court of Appeals for the Third Circuit, and is awaiting the court&#x2019;s decision. Annual sales of Sensipar&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; in the United States were approximately $1.4&#160;billion at the time Teva launched its generic version of Sensipar&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; in December 2018, and at the time of the January&#160;2, 2019 settlement. &lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In August 2019, certain direct-purchaser plaintiffs filed claims in federal court in Philadelphia naming Teva and its affiliates as defendants alleging that certain patent litigation settlement agreements relating to AndroGel&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; 1% (testosterone gel) violate the antitrust laws, specifically the September 2006 patent litigation settlement between Watson Pharmaceuticals, Inc. (&#x201c;Watson&#x201d;), from which Teva later acquired certain assets and liabilities, and Solvay Pharmaceuticals, Inc. (&#x201c;Solvay&#x201d;), and a December 2011 settlement between Teva and AbbVie. Those claims remain pending. Annual sales of AndroGel&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; 1% were approximately $350&#160;million at the time of the earlier Watson/Solvay settlement and approximately $140&#160;million at the time Actavis launched its generic version of AndroGel&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; 1% in November 2015. A provision for these matters and related litigations in Georgia that have since been settled was included in the financial statements. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Between September&#160;1, 2020 and December&#160;20, 2020, separate plaintiffs purporting to represent putative classes of direct and indirect purchasers and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;opt-out&lt;/div&gt; retailer purchasers of Bystolic&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; (nebivolol hydrochloride) filed separate complaints in the U.S. District Court for the Southern District of New York against several generic manufacturers, including Teva, Actavis, and Watson, alleging, among other things, that the settlement agreements these generic manufacturers entered into with Forest Laboratories, Inc., the innovator, to resolve patent litigation over Bystolic&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; violated the antitrust laws. The cases were coordinated and on March&#160;15, 2021, plaintiffs filed amended complaints, which Teva, Actavis, and Watson moved to dismiss. On January&#160;24, 2022, the court dismissed plaintiffs&#x2019; amended complaints without prejudice. The plaintiffs filed amended complaints on February&#160;22, 2022, which defendants (including Teva, Actavis and Watson) moved to dismiss on April&#160;19, 2022, and those motions remain pending. Annual sales of Bystolic&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; in the United States were approximately $700&#160;million at the time of Watson&#x2019;s 2013 settlement with Forest. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In February 2021, the State of New Mexico filed a lawsuit against Teva and certain other defendants related to various medicines used to treat HIV. Between September and December 2021, several private plaintiffs including retailers and health insurance providers filed similar claims in federal court in the Northern District of California and in the District of Minnesota. As they relate to Teva, the lawsuits challenge settlement agreements Teva entered into with Gilead in 2013 and 2014 to resolve patent litigation relating to Teva&#x2019;s generic versions of Viread&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;, Truvada&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;, and Atripla&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;. Plaintiffs allege that the settlements contain improper reverse payments that delayed the availability of Teva&#x2019;s generic products, in violation of the federal antitrust laws and state law. Several recently filed cases are in the process of being coordinated with the existing litigation in the Northern District of California, and any effect those cases may have on the overall case schedule remains unclear. On February&#160;16, 2022, Teva moved to dismiss the claims by certain private plaintiffs but that motion was denied. However, Teva has successfully moved to limit the potential damages period as to certain private plaintiffs. On August&#160;5, 2021, Teva moved to dismiss the complaint brought by the State of New Mexico, and on December&#160;20, 2021, the trial court denied Teva&#x2019;s motion. The trial court certified the decision as appropriate for interlocutory appeal, but on April&#160;8, 2022, the appellate court in New Mexico declined to accept the appeal. Teva has appealed the decision to the New Mexico Supreme Court, and that appeal remains pending. Annual sales in the United States at the time of the settlement of Viread&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;, Truvada&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; and Atripla&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; were approximately $582&#160;million, $2.4&#160;billion, and $2.9&#160;billion, respectively. Annual sales in the United States at the time Teva launched its generic version of Viread&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; in 2017, Truvada&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; in 2020 and Atripla&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; in 2020 were approximately $728&#160;million, $2.1&#160;billion and $444&#160;million, respectively. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In March 2021, following the 2019 European Commission&#x2019;s inspection of Teva and subsequent request for information, the European Commission opened a formal antitrust investigation to assess whether Teva may have abused a dominant position by delaying the market entry and uptake of medicines that compete with COPAXONE. Annual sales of COPAXONE in the European Economic Area for 2021 were approximately $373&#160;million. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On July&#160;15, 2021, the U.K. Competition and Markets Authority (&#x201c;CMA&#x201d;) issued a decision imposing fines for breaches of U.K. competition law by Allergan, Actavis UK and Auden Mckenzie and a number of other companies in connection with the supply of 10mg and 20mg hydrocortisone tablets in the U.K. The decision combines the CMA&#x2019;s three prior investigations into the supply of hydrocortisone tablets in the U.K. and encompasses those allegations which were subject to prior statements of objections (a provisional finding of breach of the Competition Act), in particular those under case &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;50277-1&lt;/div&gt; (unfair pricing, originally subject to a statement of objections on December&#160;16, 2016), case &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;50277-2&lt;/div&gt; (anti-competitive agreement with AMCo, originally subject to a statement of objections on March&#160;3, 2017) as well as the CMA&#x2019;s subsequent investigation relating to an anti-competitive agreement with Waymade. On January&#160;9, 2017, Teva completed the sale of Actavis UK to Accord Healthcare Limited, in connection with which Teva will indemnify Accord Healthcare for potential fines imposed by the CMA and/or damages awarded by a court against Actavis UK in relation to the December&#160;16, 2016 and March&#160;3, 2017 statements of objections, and resulting from conduct prior to the closing date of the sale. In addition, Teva agreed to indemnify Allergan against losses arising from this matter in the event of any such fines or damages. On October&#160;6, 2021, Accord UK and Auden Mckenzie appealed the CMA&#x2019;s decision. A provision for the estimated exposure for Teva related to the fines and/or damages has been recorded in the financial statements. &lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;In August 2021, a plaintiff filed a putative class action suit in the United States District Court for the Eastern District of Pennsylvania against Takeda and several generic manufacturers, including Watson and Teva, alleging violations of the antitrust laws in connection with their settlement of patent litigation involving colchicine tablets (generic Colcrys&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;), entered into in January 2016. Plaintiff claims that the settlement was part of a horizontal conspiracy among Takeda and the generic manufacturers to unlawfully restrict output of colchicine by delaying generic entry. Defendants moved to dismiss the complaint for failure to state a claim. On December&#160;28, 2021, the Court granted the defendants&#x2019; motion to dismiss, finding that plaintiff&#x2019;s allegations were implausible, but granted plaintiff leave to amend, and on January&#160;18, 2022, plaintiff filed its amended complaint, making substantively the same antitrust allegations as before, but with certain new allegations regarding the nature of the alleged conspiracy. On March&#160;30, 2022, the Court granted in part and denied in part defendants&#x2019; motion to dismiss, dismissing the newly pled bilateral conspiracy claims but allowing the revised overarching conspiracy claim to proceed against all defendants. On April&#160;8, 2022, Teva and Watson, along with their codefendant Amneal, moved the court to reconsider its partial &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;motion-to-dismiss&lt;/div&gt;&lt;/div&gt; denial or, in the alternative, to certify that denial for immediate appellate review. However, that motion was denied on April&#160;25, 2022. Annual sales of Colcrys&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; in the United States were approximately $187&#160;million at the time of the settlement. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Government Investigations and Litigation Relating to Pricing and Marketing &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva is involved in government investigations and litigation arising from the marketing and promotion of its pharmaceutical products in the United States. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In 2015 and 2016, Actavis and Teva USA each respectively received subpoenas from the U.S. Department of Justice (&#x201c;DOJ&#x201d;) Antitrust Division seeking documents and other information relating to the marketing and pricing of certain Teva USA generic products and communications with competitors about such products. On August&#160;25, 2020, a federal grand jury in the Eastern District of Pennsylvania returned a three count indictment charging Teva USA with criminal felony Sherman Act violations. See &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;20-cr-200&lt;/div&gt;&lt;/div&gt; (E.D. Pa.). The indictment alleges Teva USA participated in three separate conspiracies with certain other generic drug manufacturers to maintain and fix prices, allocate customers, and other alleged antitrust offenses concerning the sale of generic drugs. The indictment identified the following generic drugs: Pravastatin, Carbamazepine, Clotrimazole, Etodolac (IR and ER), Fluocinonide (Cream &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;E-Cream,&lt;/div&gt; Gel, and Ointment), Warfarin, Nadolol, Temozolomide, and Tobramycin. On September&#160;8, 2020, Teva USA pled not guilty to all counts. A tentative trial date is yet to be scheduled. While the Company is unable to estimate a range of loss at this time, a conviction on these criminal charges could have a material adverse impact on the Company&#x2019;s business, including monetary penalties and debarment from federally funded health care programs. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In May 2018, Teva received a civil investigative demand from the DOJ Civil Division, pursuant to the federal False Claims Act, seeking documents and information produced since January&#160;1, 2009 relevant to the Civil Division&#x2019;s investigation concerning allegations that generic pharmaceutical manufacturers, including Teva, engaged in market allocation and price-fixing agreements, paid illegal remuneration, and caused false claims to be submitted in violation of the False Claims Act. An adverse resolution of this matter may include fines, penalties, financial forfeiture and compliance conditions. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In 2015 and 2016, Actavis and Teva USA each respectively received a subpoena from the Connecticut Attorney General seeking documents and other information relating to potential state antitrust law violations. Subsequently, on December&#160;15, 2016, a civil action was brought by the attorneys general of twenty states against Teva USA and several other companies asserting claims under federal antitrust law alleging price fixing of generic products in the United States. That complaint was later amended to add new states as named plaintiffs, as well as new allegations and new state law claims, and on June&#160;18, 2018, the attorneys general of 49 states plus Puerto Rico and the District of Columbia filed a consolidated amended complaint against Actavis and Teva, as well as other companies and individuals. On May&#160;10, 2019, most (though not all) of these attorneys general filed another antitrust complaint against Actavis, Teva and other companies and individuals, alleging price-fixing and market allocation with respect to additional generic products. On November&#160;1, 2019, the state attorneys general filed an amended complaint, bringing the total number of plaintiff states and territories to 54. The amended complaint alleges that Teva was at the center of a conspiracy in the generic pharmaceutical industry, and asserts that Teva and others fixed prices, rigged bids, and allocated customers and market share with respect to certain additional products. On June&#160;10, 2020, most, but not all, of the same states, with the addition &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;of the U.S. Virgin Islands, filed a third complaint in the District of Connecticut naming, among other defendants, Actavis, but not Teva USA, in a similar complaint relating to dermatological generics products. On September&#160;9, 2021, the states&#x2019; attorneys general amended their third complaint to, among other things, add California as a plaintiff. In the various complaints described above, the states seek a finding that the defendants&#x2019; actions violated federal antitrust law and state antitrust and consumer protection laws, as well as injunctive relief, disgorgement, damages on behalf of various state and governmental entities and consumers, civil penalties and costs. All such complaints have been transferred to the generic drug multidistrict litigation in the Eastern District of Pennsylvania (&#x201c;Pennsylvania MDL&#x201d;). On July&#160;13, 2020, the court overseeing the Pennsylvania MDL chose the attorneys&#x2019; general November&#160;1, 2019 amended complaint, referenced above, along with certain complaints filed by private plaintiffs, to proceed first in the litigation as bellwether complaints. On February&#160;9, 2021, Teva&#x2019;s motion to reconsider that ruling was granted, and on May&#160;7, 2021, the Court chose the attorneys&#x2019; general third complaint filed on June&#160;10, 2020 and subsequently amended to serve as a bellwether complaint in the Pennsylvania MDL, along with certain complaints filed by private plaintiffs. Teva settled with the State of Mississippi for $925,000 in June 2021 and with the State of Louisiana for $1,450,000 in March 2022. Pursuant to these settlements, both states have dismissed their claims against Actavis and Teva USA, as well as certain former employees of Actavis and Teva USA. On December&#160;9, 2021, the Court entered an order setting the schedule for the proceedings in the bellwether cases. The order did not include trial dates, but provides for the parties to complete briefing on motions for summary judgement in early 2024. On March&#160;30, 2022, the State of Alabama voluntarily dismissed all of its claims in the litigation, including its claims against Actavis and Teva USA, without prejudice. On June&#160;7, 2022, the Court dismissed the attorneys&#x2019; general claims for monetary relief under federal law, concluding that the federal statute under which the attorneys general brought suit authorizes injunctive relief only. However, the attorneys general have pending claims for monetary relief under state law.&#160;&#160;&#160;&#160; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Beginning on March&#160;2, 2016, and continuing through December 2020, numerous complaints have been filed in the United States on behalf of putative classes of direct and indirect purchasers of several generic drug products, as well as several individual direct and indirect purchaser &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;opt-out&lt;/div&gt; plaintiffs. These complaints, which allege that the defendants engaged in conspiracies to fix prices and/or allocate market share of generic products have been brought against various manufacturer defendants, including Teva USA and Actavis. The plaintiffs generally seek injunctive relief and damages under federal antitrust law, and damages under various state laws. On October&#160;16, 2018, the court denied certain of the defendants&#x2019; motions to dismiss as to certain federal claims, pending as of that date, and on February&#160;15, 2019, the court granted in part and denied in part defendants&#x2019; motions to dismiss as to certain state law claims. On July&#160;18, 2019, May&#160;6, 2020 and October&#160;8, 2021, certain individual plaintiffs commenced civil actions in the Pennsylvania Court of Common Pleas of Philadelphia County against many of the defendants in the Pennsylvania MDL, including Teva and Actavis, but no complaints have been filed in the actions and each of the three of the cases have been placed in deferred status. Certain counties in New&#160;York and Texas have also commenced civil actions against many of the defendants in the Pennsylvania MDL, including Teva and Actavis, and the complaints have been transferred to the Pennsylvania MDL. There is also one similar complaint brought in Canada, which alleges that the defendants engaged in conspiracies to fix prices and/or allocate market share of generic drug products to the detriment of a class of private payors. The action is in its early stages. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In March 2017, Teva received a subpoena from the U.S. Attorney&#x2019;s office in Boston, Massachusetts requesting documents related to Teva&#x2019;s donations to patient assistance programs. Subsequently, in August 2020, the U.S. Attorney&#x2019;s office in Boston, Massachusetts brought a civil action in the U.S. District Court for the District of Massachusetts alleging violations of the federal Anti-Kickback Statute, and asserting causes of action under the federal False Claims Act and state law. It is alleged that Teva caused the submission of false claims to Medicare through Teva&#x2019;s donations to bona fide independent charities that provide financial assistance to patients. An adverse judgment may involve damages, civil penalties and injunctive remedies. On September&#160;10, 2021, the Court granted Teva&#x2019;s motion to dismiss the unjust enrichment claim and denied the remainder of the motion. On October&#160;15, 2021, Teva filed an answer to the complaint. The proceeding is in early stages. Additionally, on January&#160;8, 2021, Humana, Inc. filed an action against Teva in the United States District Court for the Middle District of Florida based on the allegations raised in the August 2020 complaint filed by the U.S. Attorney&#x2019;s Office in Boston. On April&#160;2, 2021, Teva filed a motion to dismiss the claims on the grounds that the claims are time-barred and/or insufficiently pled, and that motion remains pending. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In April 2021, a city and county in Washington sued Teva in the United States District Court for the Western District of Washington for alleged violations of the Racketeer Influenced and Corrupt Organizations Act, Washington&#x2019;s Consumer Protection Act, and unjust enrichment concerning Teva&#x2019;s sale of COPAXONE. Plaintiffs purport to represent a nationwide class of health plans and a subclass of Washington-based health plans that purchased and/or reimbursed health plan members for COPAXONE. Plaintiffs allege that Teva engaged in several fraudulent schemes that resulted in &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;plaintiffs and the putative class members purchasing and/or reimbursing plan members for additional prescriptions of COPAXONE and/or at inflated COPAXONE prices. Plaintiffs seek treble damages for the excess reimbursements and inflated costs, as well as injunctive relief. On September&#160;28, 2021, plaintiffs filed an amended complaint. On November&#160;17, 2021, Teva moved to dismiss the suit, on the grounds that plaintiffs&#x2019; claims are barred by the applicable statutes of limitations and the direct purchaser rule, suffer from jurisdictional defects, and fail to plausibly allege fraud or other elements of their claims. That motion is fully briefed and a decision remains pending. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On June&#160;29, 2021, Mylan Pharmaceuticals (&#x201c;Mylan&#x201d;) sued Teva in the District Court for the District of New Jersey. On March&#160;11, 2022 and March&#160;15, 2022, FWK Holdings, LLC, KPH Healthcare Servs., Inc. d/b/a Kinney Drugs, Inc., Meijer Inc., Meijer Distribution, Inc., Labor-Management Healthcare Fund, the Mayor and City Council of Baltimore, and the New York State Teamsters Council Health and Hospital Fund sued Teva in the District Court for the District of New Jersey on behalf of themselves and others similarly situated direct and indirect purchasers of COPAXONE. The complaints assert claims for alleged violations of the Lanham Act, state and federal unfair competition and monopolization laws, tortious interference, trade libel, and a violation of the Racketeer Influenced and Corrupt Organizations Act. Plaintiffs claim Teva was involved in an unlawful scheme to delay and hinder generic competition concerning COPAXONE sales. Plaintiffs seek damages for lost profits and expenses, disgorgement, restitution, treble damages, attorneys&#x2019; fees and costs, and injunctive relief. Teva has moved to dismiss the complaint filed by Mylan on the grounds, among others, that none of its challenged conduct violates the law. That motion is fully briefed and a decision remains pending. Teva has also moved to dismiss the remaining complaints on similar grounds and the briefing on that motion is ongoing. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Opioids Litigation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Since May 2014, more than 3,500 complaints have been filed with respect to opioid sales and distribution against various Teva affiliates, along with several other pharmaceutical companies, by a number of cities, counties, states, other governmental agencies, tribes and private plaintiffs (including various putative class actions of individuals) in both state and federal courts. Most of the federal cases have been consolidated into a multidistrict litigation in the Northern District of Ohio (&#x201c;MDL Opioid Proceeding&#x201d;) and many of the cases filed in state court have been removed to federal court and consolidated into the MDL Opioid Proceeding. Two cases that were included in the MDL Opioid Proceeding were transferred back to federal district court for additional discovery, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-trial&lt;/div&gt; proceedings and trial. Those cases are: City of Chicago v. Purdue Pharma L.P. et al., &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;14-cv-04361&lt;/div&gt;&lt;/div&gt; (N.D. Ill.) and City and County of San Francisco v. Purdue Pharma L.P. et al., &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;18-cv-07591-CRB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; (N.D. Cal.). Other cases remain pending in various states. In some jurisdictions, such as Illinois, New York, Pennsylvania, South Carolina, Texas, Utah and West Virginia, certain state court cases have been transferred to a single court within their respective state court systems for coordinated pretrial proceedings. Complaints asserting claims under similar provisions of different state law generally contend that the defendants allegedly engaged in improper marketing and distribution of opioids, including ACTIQ&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; and FENTORA&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;. The complaints also assert claims related to Teva&#x2019;s generic opioid products. In addition, over 950 personal injury plaintiffs, including various putative class actions of individuals, have asserted personal injury and wrongful death claims in over 600 complaints, nearly all of which are consolidated in the MDL Opioid Proceeding.&#160;Furthermore, approximately 700 &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-personal&lt;/div&gt; injury complaints and approximately 100 personal injury complaints have named Anda, Inc. (and other distributors and manufacturers) alleging that Anda failed to develop and implement systems sufficient to identify suspicious orders of opioid products and prevent the abuse and diversion of such products to individuals who used them for other than legitimate medical purposes. Plaintiffs seek a variety of remedies, including restitution, civil penalties, disgorgement of profits, treble damages,&#160;attorneys&#x2019; fees and injunctive relief. Certain plaintiffs assert that the measure of damages is the entirety of the costs associated with addressing the abuse of opioids and opioid addiction and certain plaintiffs specify multiple billions of dollars in the aggregate as alleged damages. The individual personal injury plaintiffs further seek &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-economic&lt;/div&gt; damages. In many of these cases, plaintiffs are seeking joint and several damages among all defendants. &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;On April&#160;19, 2021, a bench trial in California (The People of the State of California, acting by and through Santa Clara County Counsel James R. Williams, et. al. v. Purdue Pharma L.P., et. al.) commenced against Teva and other defendants focused on the marketing of branded opioids. On December&#160;14, 2021, the court issued its final judgment in favor of the defendants on all claims. Plaintiffs filed a notice of appeal of this judgment in February 2022. On June&#160;29, 2021, a jury trial in New York (&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;In re Opioid Litigation&lt;/div&gt;&lt;/div&gt;, Index No.&#160;400000/2017) commenced against Teva and other defendants, focused on the marketing and distribution of opioids. The case was bifurcated between liability and damages. On December&#160;30, 2021, the jury returned a liability verdict in favor of plaintiffs (the County of Suffolk, the County of Nassau and the State of New York) on the plaintiffs&#x2019; public nuisance claim. Teva and the plaintiffs filed post-trial motions with respect to the liability portion of the case, and Teva intends to appeal if its post-trial motions are denied. The court has not yet set a schedule for damages discovery or a date for the relief phase of the trial. Teva, the State of New York and its subdivisions remain actively engaged in settlement negotiations. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In May 2019, Teva settled the Oklahoma litigation brought by the Oklahoma Attorney General (State of Oklahoma, ex. rel. Mike Hunter, Attorney General of Oklahoma vs. Purdue Pharma L.P., et. al.) for $85&#160;million. The settlement did not include any admission of violation of law for any of the claims or allegations made. As the Company demonstrated a willingness to settle part of the litigation, for accounting purposes, management considered a portion of opioid-related cases as probable and, as such, recorded an estimated provision in the second quarter of 2019. Given the relatively early stage of the cases, management viewed no amount within the range to be the most likely outcome. Therefore, management recorded a provision for the reasonably estimable minimum amount in the assessed range for such opioid-related cases in accordance with Accounting Standards Codification 450 &#x201c;Accounting for Contingencies.&#x201d; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additionally, on October&#160;21, 2019, Teva reached a settlement with the two plaintiffs in the MDL Opioid Proceeding that was scheduled for trial for the Track One case, Cuyahoga and Summit Counties of Ohio. Under the terms of the settlement, Teva agreed to provide the two counties with opioid treatment medication, buprenorphine naloxone (sublingual tablets), known by the brand name Suboxone&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;, with a value of $25&#160;million at wholesale acquisition cost and distributed over three years to help in the care and treatment of people suffering from addiction, and a cash payment in the amount of $20&#160;million, which has been paid. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On July&#160;21, 2021, it was announced that four other defendants (not including Teva) reached nationwide settlements, subject to certain conditions, which include payment of up to approximately $26&#160;billion spread over up to &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt; 18 years. Teva has continued to work toward a nationwide settlement with the working group of States&#x2019; Attorneys General, the Multi-District Litigation Plaintiffs&#x2019; Executive Committee and counsel for Native American tribes (&#x201c;Tribes&#x201d;). In July 2022, the parties reached an agreement in principle on the financial terms of a final nationwide settlement similar in structure to the nationwide settlements of other defendants. The parties continue to work on memorializing the non-financial terms of the proposed nationwide settlement agreement. Under the financial terms of the proposed nationwide settlement agreement, Teva will pay &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;up to&lt;/div&gt;&#160;$4.25 &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;billion (including the already settled cases) plus approximately $100 million for the Tribes, spread over&lt;/div&gt; &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt; 13 &lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;years. This total includes the supply of up to&lt;/div&gt;&#160;&lt;/div&gt;$1.2 &lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;billion of Teva&#x2019;s generic version of Narcan&#xae; (naloxone hydrochloride nasal spray)&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt; valued at wholesale acquisition cost&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt; over&#160;&lt;/div&gt;10 &lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;years or &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;cash at&#160;&lt;/div&gt;20% of the wholesale acquisition cost &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;($240 million) in lieu of product. The nationwide settlement agreement is contingent upon (i) final documentation among the working group and Teva, and reaching the thresholds for participation that will be set forth in the final agreement; and (ii) Teva reaching an agreement with Allergan with respect to any indemnification obligations, and Allergan reaching a nationwide opioids settlement. No other trials currently are scheduled against Teva in 2022 in any opioids matter, with the possible exception of the relief phase of the trial in the New York opioids litigation. If the nationwide settlement agreement is not finalized, additional trials are expected to proceed in several states in 2023.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On September&#160;28, 2021, Teva reached an agreement with the Attorney General of Louisiana that settles the state&#x2019;s opioid-related claims. The agreement was contingent that all political subdivisions of Louisiana will formally release Teva as part of the settlement, which Teva was advised has occurred by the Attorney General of Louisiana. Under the terms of the settlement, Teva will pay Louisiana $15&#160;million over an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;18-year&lt;/div&gt; period and will provide buprenorphine naloxone (sublingual tablets) valued at $3&#160;million (wholesale acquisition cost). &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On February&#160;4, 2022, the Company reached an agreement with the Attorney General of the State of Texas that settles Texas&#x2019; and its subdivisions&#x2019; opioid-related claims. On March&#160;10, 2022, Texas confirmed that at least 96% of the population of subdivisions formally released Teva as part of the settlement. Under the terms of the settlement, Teva will pay Texas $150&#160;million over a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;15-year&lt;/div&gt; period and will provide its generic version of Narcan&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; (naloxone hydrochloride nasal spray), valued at $75&#160;million (wholesale acquisition cost) over 10 years. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;21, 2022, Teva reached an agreement with the Attorney General of Rhode Island that settles Rhode Island&#x2019;s and its subdivisions&#x2019; opioid-related claims. Under the terms of the settlement, Teva will pay Rhode Island $21&#160;million over 13 years, in addition to attorneys&#x2019; fees and costs, and will provide its generic version of Narcan&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; (naloxone hydrochloride nasal spray) and a significant amount of buprenorphine naloxone sublingual tablets known by the brand name Suboxone&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;, together valued at $78.5&#160;million (wholesale acquisition cost) over 10 years. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;On March&#160;30, 2022, Teva reached an agreement with the Attorney General of Florida that settles Florida&#x2019;s and its subdivisions&#x2019; opioid-related claims. Under the terms of the settlement, Teva will pay Florida $177&#160;million over &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;15-years,&lt;/div&gt; in addition to attorneys&#x2019; fees and costs, and will provide its generic version of Narcan&lt;div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:7.1px"&gt;&#xae;&lt;/div&gt;&lt;/div&gt; (naloxone hydrochloride nasal spray) valued at $84&#160;million (wholesale acquisition cost) over 10 years. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On May&#160;24, 2022, Teva reached an agreement in principle with the Attorney General of West Virginia that settles West Virginia&#x2019;s and its subdivisions&#x2019; opioid-related claims. Under the terms of the settlement, Teva will pay West Virginia $75&#160;million over &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;15-years,&lt;/div&gt; in addition to attorneys&#x2019; fees and costs, and will provide its generic version of Narcan&lt;div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:7.1px"&gt;&#xae;&lt;/div&gt;&lt;/div&gt; (naloxone hydrochloride nasal spray) valued at $27&#160;million (wholesale acquisition cost) over 10 years. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On July&#160;12, 2022, Teva reached an agreement in principle with the City and County of San Francisco and the People of the State of California that settles opioid-related claims asserted on behalf of the City and County of San Francisco. Teva will provide San Francisco $20.3&#160;million over 13 years, in addition to attorneys&#x2019; fees and costs, and will provide its generic version of Narcan&lt;/div&gt;&lt;div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:7.1px"&gt;&#xae;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (naloxone hydrochloride nasal spray), valued at $20&#160;million (wholesale acquisition cost), over 10 years. &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In light of the agreement in principle on the nationwide settlement between Teva, and the States&#x2019; Attorneys General, their subdivisions and the Tribes, Teva&#x2019;s potential indemnification obligations arising from Teva&#x2019;s acquisition of the Actavis Generics business for opioid-related claims, prior settlements with Texas, Florida, Louisiana, Rhode Island, West Virginia and San Francisco, the verdict in New York, decisions in California and Oklahoma, as well as an estimate for a number of items including, but not limited to, costs associated with administering injunctive terms, and most favored nations clauses associated with prior settlements, the Company has reconsidered the potential settlement outcome and revised its provision. The revised provision is a reasonable estimate of the ultimate costs in the likely event that the nationwide settlement is finalized under its current proposed terms and conditions, after discounting payments to states to their net present value. However, if the nationwide settlement is not finalized for the entirety of the remaining cases, a reasonable upper end of a range of loss cannot be determined. An adverse resolution of any of these lawsuits or investigations may involve large monetary penalties, damages, and/or other forms of monetary and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-monetary&lt;/div&gt; relief and could have a material and adverse effect on Teva&#x2019;s reputation, business, results of operations and cash flows. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In August 2019, Teva received a grand jury subpoena from the United States Attorney&#x2019;s Office for the Eastern District of New York for documents related to the Company&#x2019;s anti-diversion policies and procedures and distribution of its opioid medications, in what the Company understands to be part of a broader investigation into manufacturers&#x2019; and distributors&#x2019; monitoring programs and reporting under the Controlled Substances Act. In September 2019, Teva received subpoenas from the New York State Department of Financial Services (NYDFS) as part of an industry-wide inquiry into the effect of opioid prescriptions on New York health insurance premiums. This was followed by a Statement of Charges and Notice of Hearing filed by the NYDFS, although no merits hearing date is currently set. Currently, Teva cannot predict how &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;the&lt;/div&gt; nationwide settlement (if finalized) will affect these investigations and administrative actions. In addition, a number of State Attorneys General, including a coordinated multistate effort, have initiated investigations into sales and marketing practices of Teva and its affiliates with respect to opioids. Other states are conducting their own investigations outside of the multistate group. Teva is cooperating with these ongoing investigations and cannot predict their outcome at this time. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In addition, several jurisdictions and consumers in Canada have initiated litigation regarding opioids alleging similar claims as those in the United States. The cases in Canada are in their early stages. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Shareholder Litigation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On November&#160;6, 2016 and December&#160;27, 2016, two putative securities class actions were filed in the U.S. District Court for the Central District of California against Teva and certain of its current and former officers and directors. Those lawsuits were consolidated and transferred to the U.S. District Court for the District of Connecticut (the &#x201c;Ontario Teachers Securities Litigation&#x201d;). On December&#160;13, 2019, the lead plaintiff in that action filed an amended complaint, purportedly on behalf of purchasers of Teva&#x2019;s securities between February&#160;6, 2014 and May&#160;10, 2019. The amended complaint asserts that Teva and certain of its current and former officers and directors violated federal securities and common laws in connection with Teva&#x2019;s alleged failure to disclose pricing strategies for various drugs in its generic drug portfolio and by making allegedly false or misleading statements in certain offering materials. The amended complaint seeks unspecified damages, legal fees, interest, and costs. In July 2017,&#160;August 2017, and June 2019, other putative securities class actions were filed in other federal courts based on similar allegations, and those cases have been transferred to the U.S. District Court for the District of Connecticut. Between August 2017 and January 2022, twenty-three complaints were filed against Teva and certain of its current and former officers and directors seeking unspecified compensatory damages, legal fees, costs and expenses. The similar claims in these complaints have been brought on behalf of plaintiffs, in various forums across the country, who have indicated that they intend to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;opt-out&#x201d;&lt;/div&gt; of the Ontario Teachers Securities Litigation. On March&#160;10, 2020, the Court consolidated the Ontario Teachers Securities Litigation with all of the above-referenced putative class actions for all purposes and the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;opt-out&#x201d;&lt;/div&gt; cases for pretrial purposes. Pursuant to that consolidation order, plaintiffs in several of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;opt-out&#x201d;&lt;/div&gt; cases filed amended complaints on May&#160;28, 2020. On January&#160;22, 2021, the Court &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;dismissed the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;opt-out&#x201d;&lt;/div&gt; plaintiffs&#x2019; claims arising from statements made prior to the five year statute of repose, but denied Teva&#x2019;s motion to dismiss their claims under Israeli laws. Those &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;opt-out&#x201d;&lt;/div&gt; plaintiffs moved for reconsideration, which was denied on March&#160;30, 2021. On May&#160;24, 2021, Teva moved to dismiss a majority of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;opt-out&#x201d;&lt;/div&gt; complaints on various other grounds. Those motions are still pending. The Ontario Teachers Securities Litigation plaintiffs&#x2019; Motion for Class&#160;Certification and Appointment of Class&#160;Representatives and Class&#160;Counsel was granted on March&#160;9, 2021, to which Teva&#x2019;s appeal was denied. On January&#160;18, 2022, Teva entered into a settlement in the Ontario Teachers Securities Litigation for $420&#160;million, which received final approval from the court on June&#160;2, 2022. Pursuant to an agreement between the Company and its insurance carriers, the insurance carriers provided the vast majority of the total settlement amount, with a small portion contributed by Teva. Additionally, as part of the settlement, Teva admitted no liability and denied all allegations of wrongdoing. A number of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;opt-out&#x201d;&lt;/div&gt; complaints still remain outstanding, and motions to approve securities class actions were also filed in the Tel Aviv District Court in Israel with similar allegations to those made in the Ontario Teachers Securities Litigation. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On September&#160;23, 2020, a putative securities class action was filed in the U.S. District Court for the Eastern District of Pennsylvania against Teva and certain of its former officers. On August&#160;10, 2021, the lead plaintiff filed a corrected amended class action complaint, purportedly on behalf of persons who purchased or otherwise acquired Teva securities between October&#160;29, 2015 and August&#160;18, 2020. The corrected amended complaint alleges that Teva and certain of its current and former officers violated federal securities laws by allegedly making false and misleading statements regarding the commercial performance of COPAXONE, namely, by failing to disclose that Teva had allegedly caused the submission of false claims to Medicare through Teva&#x2019;s donations to bona fide independent charities that provide financial assistance to patients, which allegedly impacted COPAXONE&#x2019;s commercial success and the sustainability of its revenues and resulted in the above referenced August 2020 False Claims Act complaint filed by the DOJ. The corrected amended complaint seeks unspecified damages and legal fees. On March&#160;25, 2022, the court granted in part and denied in part Teva&#x2019;s and the individual defendants&#x2019; motion to dismiss the corrected amended complaint, (i)&#160;holding that the plaintiffs&#x2019; complaint failed to plead that certain public statements regarding Teva&#x2019;s compliance with the law were misleading, (ii)&#160;holding that two alleged partial corrective disclosures did not establish loss causation and cannot serve as the basis for plaintiff&#x2019;s claimed loss, (iii)&#160;dismissing all claims against one of the individual defendants, and (iv)&#160;otherwise denying the motion to dismiss. A motion to approve a securities class action was also filed in the Central District Court in Israel, which has been stayed pending the U.S. litigation, with similar allegations to those made in the above complaint filed in the U.S. District Court for the Eastern District of Pennsylvania. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Motions to approve derivative actions seeking monetary damages against certain past and present directors and officers have been filed in Israeli Courts alleging negligence and recklessness. Motions for document disclosure prior to initiating derivative actions were filed with respect to several U.S. and EU settlement agreements, opioids, the U.S. price-fixing investigations and allegations related to the DOJ&#x2019;s complaint regarding Copaxone patient assistance program in the U.S. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Environmental Matters &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva or its subsidiaries are party to a number of environmental proceedings, or have received claims, including under the federal Superfund law or other federal, provincial or state and local laws, imposing liability for alleged noncompliance, or for the investigation and remediation of releases of hazardous substances and for natural resource damages. Many of these proceedings and claims seek to require the generators of hazardous wastes disposed of at a third party-owned site, or the party responsible for a release of hazardous substances that impacted a site, to investigate and clean the site or to pay or reimburse others for such activities, including for oversight by governmental authorities and any related damages to natural resources. Teva or its subsidiaries have received claims, or been made a party to these proceedings, along with others, as an alleged generator of wastes that were disposed of or treated at third-party waste disposal sites, or as a result of an alleged release from one of Teva&#x2019;s facilities or former facilities. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Although liability among the responsible parties, under certain circumstances, may be joint and several, these proceedings are frequently resolved so that the allocation of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;clean-up&lt;/div&gt; and other costs among the parties reflects the relative contributions of the parties to the site conditions and takes into account other pertinent factors. Teva&#x2019;s potential liability varies greatly at each of the sites; for some sites the costs of the investigation, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;clean-up&lt;/div&gt; and natural resource damages have not yet been determined, and for others Teva&#x2019;s allocable share of liability has not been determined. At other sites, Teva has taken an active role in identifying those costs, to the extent they are identifiable and estimable, which do not include reductions for potential recoveries of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;clean-up&lt;/div&gt; costs from insurers, indemnitors, former site owners or &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;operators or other potentially responsible parties. In addition, enforcement proceedings relating to alleged violations of federal, state, commonwealth or local requirements at some of Teva&#x2019;s facilities may result in the imposition of significant penalties (in amounts not expected to materially adversely affect Teva&#x2019;s results of operations) and the recovery of certain costs and natural resource damages, and may require that corrective actions and enhanced compliance measures be implemented. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Item&#160;103 of Regulation &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-K&lt;/div&gt; promulgated by the SEC requires disclosure of certain environmental matters when a governmental authority is a party to the proceedings and such proceedings involve potential monetary sanctions, unless the Company reasonably believes that the matter will result in no monetary sanctions, or in monetary sanctions, exclusive of interest and costs, of less than $300,000. The following matter is disclosed in accordance with that requirement. On July&#160;8, 2021, the National Green Tribunal Principal Bench, New Delhi, issued an order against Teva&#x2019;s subsidiary in India, Teva API India Private Limited, finding &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-compliance&lt;/div&gt; with environmental laws and assessed a penalty of $1.4&#160;million. The Company disputed certain of the findings and the amount of the penalty and filed an appeal before the Supreme Court of India. On August&#160;5, 2021, the Supreme Court of India admitted the appeal for hearing and granted an interim unconditional stay on the National Green Tribunal&#x2019;s order. The Company does not believe that the eventual outcome of such matter will have a material effect on its business. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other Matters &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On February&#160;1, 2018, former shareholders of Ception Therapeutics, Inc., a company that was acquired by and merged into Cephalon in 2010, prior to Cephalon&#x2019;s acquisition by Teva, filed breach of contract and other related claims against the Company, Teva USA and Cephalon in the Delaware Court of Chancery.&#160;Among other things, the plaintiffs allege that Cephalon breached the terms of the 2010 Ception-Cephalon merger agreement by failing to exercise commercially reasonable efforts to develop and commercialize CINQAIR&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; (reslizumab) for the treatment of eosinophilic esophagitis (&#x201c;EE&#x201d;). The plaintiffs claim damages of at least $200&#160;million, an amount they allege is equivalent to the milestones payable to the former shareholders of Ception in the event Cephalon were to obtain regulatory approval for EE in the United States ($150 million) and Europe ($50 million). Defendants moved to dismiss the complaint and on December&#160;28, 2018, the court granted the motion in part and dismissed all of plaintiffs&#x2019; claims, except for their claim against Cephalon for breach of contract. In November 2021, plaintiffs moved to amend their complaint to, among other things, reassert claims against the Company and Teva USA, but the plaintiffs &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;later stipulated to filing a new amended complaint that includes claims against Teva USA but not the Company, in exchange for Teva USA&#x2019;s agreement to guarantee any judgment entered against Cephalon in the litigation. Plaintiffs filed that amended complaint on July 12, 2022. Trial in this matter is currently scheduled for September 2022.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <teva:DamagesAssessment
      contextRef="PAsOn06_30_2022"
      decimals="-5"
      unitRef="Unit_USD">235500000</teva:DamagesAssessment>
    <us-gaap:LossContingencyAccrualProvision
      contextRef="P08_05_2021To08_05_2021"
      decimals="-5"
      unitRef="Unit_USD">235500000</us-gaap:LossContingencyAccrualProvision>
    <teva:AnnualSalesOfNarcan
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">434000000</teva:AnnualSalesOfNarcan>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="PAsOn06_30_2022"
      decimals="-5"
      unitRef="Unit_EUR">60500000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <teva:AnnualSalesOfEffexor
      contextRef="P08_21_2017To08_21_2021"
      decimals="-8"
      unitRef="Unit_USD">2600000000</teva:AnnualSalesOfEffexor>
    <teva:AnnualSalesOfLamictal
      contextRef="PAsOn02_28_2005"
      decimals="-9"
      unitRef="Unit_USD">950000000000</teva:AnnualSalesOfLamictal>
    <teva:AnnualSalesOfLamictal
      contextRef="PAsOn07_31_2008"
      decimals="-8"
      unitRef="Unit_USD">2300000000</teva:AnnualSalesOfLamictal>
    <teva:AnnualSalesOfNiaspan
      contextRef="P04_01_2013To04_30_2013"
      decimals="-6"
      unitRef="Unit_USD">416000000</teva:AnnualSalesOfNiaspan>
    <teva:AnnualSalesOfNiaspan
      contextRef="P09_01_2013To09_30_2013"
      decimals="-8"
      unitRef="Unit_USD">1100000000</teva:AnnualSalesOfNiaspan>
    <teva:AnnualSalesOfActos
      contextRef="P12_01_2010To12_31_2010"
      decimals="-8"
      unitRef="Unit_USD">3700000000</teva:AnnualSalesOfActos>
    <teva:AnnualSalesOfActoplus
      contextRef="P12_01_2010To12_31_2010"
      decimals="-6"
      unitRef="Unit_USD">500000000</teva:AnnualSalesOfActoplus>
    <teva:AnnualSalesOfActos
      contextRef="P08_01_2012To08_31_2012"
      decimals="-8"
      unitRef="Unit_USD">2800000000</teva:AnnualSalesOfActos>
    <teva:AnnualSalesOfActoplus
      contextRef="P08_01_2012To08_31_2012"
      decimals="-6"
      unitRef="Unit_USD">430000000</teva:AnnualSalesOfActoplus>
    <teva:AnnualSalesOfSensipar
      contextRef="P01_01_2019To12_31_2019"
      decimals="-8"
      unitRef="Unit_USD">1400000000</teva:AnnualSalesOfSensipar>
    <teva:AnnualSalesAtTimeOfSettlement
      contextRef="PAsOn08_31_2019"
      decimals="-6"
      unitRef="Unit_USD">350000000</teva:AnnualSalesAtTimeOfSettlement>
    <teva:AnnualSalesAtTimeOfSettlement
      contextRef="PAsOn08_31_2019_AndroGelRateAtOnePercentageMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">140000000</teva:AnnualSalesAtTimeOfSettlement>
    <teva:AnnualSalesAtTimeOfSettlement
      contextRef="PAsOn09_01_2020"
      decimals="-6"
      unitRef="Unit_USD">700000000</teva:AnnualSalesAtTimeOfSettlement>
    <teva:AnnualSalesAtTimeOfSettlement
      contextRef="PAsOn02_01_2021_CAsrtStatementGeographicalAxis_VireadMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">582000000</teva:AnnualSalesAtTimeOfSettlement>
    <teva:AnnualSalesAtTimeOfSettlement
      contextRef="PAsOn02_01_2021_CAsrtStatementGeographicalAxis_TiruvadaMembersrtProductOrServiceAxis"
      decimals="-8"
      unitRef="Unit_USD">2400000000</teva:AnnualSalesAtTimeOfSettlement>
    <teva:AnnualSalesAtTimeOfSettlement
      contextRef="PAsOn02_01_2021_AtripalaMembersrtProductOrServiceAxis_CAsrtStatementGeographicalAxis"
      decimals="-8"
      unitRef="Unit_USD">2900000000</teva:AnnualSalesAtTimeOfSettlement>
    <teva:AnnualSalesAtTheTimeOfLaunchOfProduct
      contextRef="P01_01_2017To12_31_2017_CAsrtStatementGeographicalAxis_VireadMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">728000000</teva:AnnualSalesAtTheTimeOfLaunchOfProduct>
    <teva:AnnualSalesAtTheTimeOfLaunchOfProduct
      contextRef="P01_01_2020To12_31_2020_CAsrtStatementGeographicalAxis_TiruvadaMembersrtProductOrServiceAxis"
      decimals="-8"
      unitRef="Unit_USD">2100000000</teva:AnnualSalesAtTheTimeOfLaunchOfProduct>
    <teva:AnnualSalesAtTheTimeOfLaunchOfProduct
      contextRef="P01_01_2020To12_31_2020_AtripalaMembersrtProductOrServiceAxis_CAsrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">444000000</teva:AnnualSalesAtTheTimeOfLaunchOfProduct>
    <teva:AnnualSalesOfCopaxone
      contextRef="P01_01_2014To12_31_2014"
      decimals="-6"
      unitRef="Unit_USD">373000000</teva:AnnualSalesOfCopaxone>
    <teva:AnnualSalesAtTimeOfSettlement
      contextRef="PAsOn02_01_2021_CAsrtStatementGeographicalAxis_ColcysMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">187000000</teva:AnnualSalesAtTimeOfSettlement>
    <teva:LossContingencyClaimsDismissedValue
      contextRef="PAsOn06_30_2021"
      decimals="0"
      unitRef="Unit_USD">925000</teva:LossContingencyClaimsDismissedValue>
    <teva:LossContingencyClaimsDismissedValue
      contextRef="PAsOn03_31_2022"
      decimals="0"
      unitRef="Unit_USD">1450000</teva:LossContingencyClaimsDismissedValue>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="P05_01_2019To05_31_2019_OpioidLitigationMembersrtLitigationCaseAxis"
      decimals="-6"
      unitRef="Unit_USD">85000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="P10_21_2019To10_21_2019_OpioidLitigationMembersrtLitigationCaseAxis"
      decimals="-6"
      unitRef="Unit_USD">25000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <teva:LitigationSettlementAmountAwardedCashAmount
      contextRef="P10_21_2019To10_21_2019_OpioidLitigationMembersrtLitigationCaseAxis"
      decimals="-6"
      unitRef="Unit_USD">20000000</teva:LitigationSettlementAmountAwardedCashAmount>
    <us-gaap:LossContingencyDamagesPaidValue
      contextRef="P07_21_2021To07_21_2021_FourOtherDefendantsOtherThanTevaMemberTEVADefendantsAxis_NationwideSettlementMembersrtLitigationCaseAxis"
      decimals="-9"
      unitRef="Unit_USD">26000000000</us-gaap:LossContingencyDamagesPaidValue>
    <teva:LitigationSettlementAmountAwardedDistributionPeriod contextRef="P07_21_2021To07_21_2021_FourOtherDefendantsOtherThanTevaMemberTEVADefendantsAxis_NationwideSettlementMembersrtLitigationCaseAxis">P18Y</teva:LitigationSettlementAmountAwardedDistributionPeriod>
    <teva:LitigationAmountIncludingAlreadyPaid
      contextRef="PAsOn07_01_2022_CompaniesShareMemberTEVADefendantsAxis_StatesPoliticalSubdivisionsAndTribesMembersrtLitigationCaseAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-7"
      unitRef="Unit_USD">4250000000</teva:LitigationAmountIncludingAlreadyPaid>
    <teva:LitigationAmountToBePaidToTribes
      contextRef="PAsOn07_01_2022_CompaniesShareMemberTEVADefendantsAxis_StatesPoliticalSubdivisionsAndTribesMembersrtLitigationCaseAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">100000000</teva:LitigationAmountToBePaidToTribes>
    <teva:LitigationSettlementTerm contextRef="P07_01_2022To07_31_2022_CompaniesShareMemberTEVADefendantsAxis_StatesPoliticalSubdivisionsAndTribesMembersrtLitigationCaseAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">P13Y</teva:LitigationSettlementTerm>
    <teva:ProductOfferingSettlementAtWholesaleAcquisitionCosts
      contextRef="P07_01_2022To07_31_2022_CompaniesShareMemberTEVADefendantsAxis_StatesPoliticalSubdivisionsAndTribesMembersrtLitigationCaseAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-8"
      unitRef="Unit_USD">1200000000</teva:ProductOfferingSettlementAtWholesaleAcquisitionCosts>
    <teva:ProductToBeSettledValuationTerm contextRef="P07_01_2022To07_31_2022_CompaniesShareMemberTEVADefendantsAxis_StatesPoliticalSubdivisionsAndTribesMembersrtLitigationCaseAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">P10Y</teva:ProductToBeSettledValuationTerm>
    <teva:PercentageOfWholesaleAcquisitionCostValueInCashInLieuOfProductToBePaidUnderSettlementAgreement
      contextRef="PAsOn07_31_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.20</teva:PercentageOfWholesaleAcquisitionCostValueInCashInLieuOfProductToBePaidUnderSettlementAgreement>
    <teva:WholesaleAcquisitionCostValueInCashAmountInLieuOfProductToBePaidUnderSettlementAgreement
      contextRef="PAsOn07_31_2022_CompaniesShareMemberTEVADefendantsAxis_StatesPoliticalSubdivisionsAndTribesMembersrtLitigationCaseAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">240000000</teva:WholesaleAcquisitionCostValueInCashAmountInLieuOfProductToBePaidUnderSettlementAgreement>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="P09_28_2021To09_28_2021_AttorneyGeneralOfLouisanaMemberTEVAAgreementAxis_LAsrtStatementGeographicalAxis_OpioidLitigationMembersrtLitigationCaseAxis"
      decimals="-6"
      unitRef="Unit_USD">15000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <teva:LitigationSettlementAmountAwardedCashAmountDistributionPeriod contextRef="P09_28_2021To09_28_2021_AttorneyGeneralOfLouisanaMemberTEVAAgreementAxis_LAsrtStatementGeographicalAxis_OpioidLitigationMembersrtLitigationCaseAxis">P18Y</teva:LitigationSettlementAmountAwardedCashAmountDistributionPeriod>
    <teva:LitigationSettlementAmountDistributableinKind
      contextRef="PAsOn09_28_2021_AttorneyGeneralOfLouisanaMemberTEVAAgreementAxis_LAsrtStatementGeographicalAxis_OpioidLitigationMembersrtLitigationCaseAxis"
      decimals="-6"
      unitRef="Unit_USD">3000000</teva:LitigationSettlementAmountDistributableinKind>
    <teva:PercentageOfPopulationOfSubdivisionsWillFormallyReleaseAsAPartOfSettlement
      contextRef="P02_04_2022To02_04_2022"
      decimals="0"
      unitRef="Unit_pure">96</teva:PercentageOfPopulationOfSubdivisionsWillFormallyReleaseAsAPartOfSettlement>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="P02_04_2022To02_04_2022_OpioidLitigationMembersrtLitigationCaseAxis"
      decimals="-6"
      unitRef="Unit_USD">150000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <teva:LitigationSettlementAmountAwardedCashAmountDistributionPeriod contextRef="P02_04_2022To02_04_2022_OpioidLitigationMembersrtLitigationCaseAxis">P15Y</teva:LitigationSettlementAmountAwardedCashAmountDistributionPeriod>
    <teva:LitigationSettlementAmountDistributableinKind
      contextRef="PAsOn02_04_2022_AttorneyGeneralOfLouisanaMemberTEVAAgreementAxis"
      decimals="-6"
      unitRef="Unit_USD">75000000</teva:LitigationSettlementAmountDistributableinKind>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="P03_21_2022To03_21_2022_OpioidLitigationMembersrtLitigationCaseAxis"
      decimals="-6"
      unitRef="Unit_USD">21000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <teva:LitigationSettlementAmountAwardedCashAmountDistributionPeriod contextRef="P03_21_2022To03_21_2022_OpioidLitigationMembersrtLitigationCaseAxis">P13Y</teva:LitigationSettlementAmountAwardedCashAmountDistributionPeriod>
    <teva:LitigationSettlementAmountDistributableinKind
      contextRef="PAsOn03_21_2022_AttorneyGeneralOfRhodeIslandMemberTEVAAgreementAxis"
      decimals="-5"
      unitRef="Unit_USD">78500000</teva:LitigationSettlementAmountDistributableinKind>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="P03_30_2022To03_30_2022_OpioidLitigationMembersrtLitigationCaseAxis"
      decimals="-6"
      unitRef="Unit_USD">177000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <teva:LitigationSettlementAmountAwardedCashAmountDistributionPeriod contextRef="P03_30_2022To03_30_2022_OpioidLitigationMembersrtLitigationCaseAxis">P15Y</teva:LitigationSettlementAmountAwardedCashAmountDistributionPeriod>
    <teva:LitigationSettlementAmountDistributableinKind
      contextRef="PAsOn03_30_2022_AttorneyGeneralOfFloridaMemberTEVAAgreementAxis"
      decimals="-6"
      unitRef="Unit_USD">84000000</teva:LitigationSettlementAmountDistributableinKind>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="P05_24_2022To05_24_2022_OpioidLitigationMembersrtLitigationCaseAxis"
      decimals="-6"
      unitRef="Unit_USD">75000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <teva:LitigationSettlementAmountAwardedCashAmountDistributionPeriod contextRef="P05_24_2022To05_24_2022_OpioidLitigationMembersrtLitigationCaseAxis">P15Y</teva:LitigationSettlementAmountAwardedCashAmountDistributionPeriod>
    <teva:LitigationSettlementAmountDistributableinKind
      contextRef="PAsOn05_24_2022_AttorneyGeneralOfWestVirginiaMemberTEVAAgreementAxis"
      decimals="-6"
      unitRef="Unit_USD">27000000</teva:LitigationSettlementAmountDistributableinKind>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="P07_12_2022To07_12_2022_OpioidLitigationMembersrtLitigationCaseAxis"
      decimals="-5"
      unitRef="Unit_USD">20300000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <teva:LitigationSettlementAmountAwardedCashAmountDistributionPeriod contextRef="P07_12_2022To07_12_2022_OpioidLitigationMembersrtLitigationCaseAxis">P13Y</teva:LitigationSettlementAmountAwardedCashAmountDistributionPeriod>
    <teva:LitigationSettlementAmountDistributableinKind
      contextRef="PAsOn07_12_2022_OpioidLitigationMembersrtLitigationCaseAxis"
      decimals="-6"
      unitRef="Unit_USD">20000000</teva:LitigationSettlementAmountDistributableinKind>
    <us-gaap:LitigationSettlementExpense
      contextRef="P06_02_2022To06_02_2022"
      decimals="-6"
      unitRef="Unit_USD">420000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:AccrualForEnvironmentalLossContingencies
      contextRef="PAsOn06_30_2022"
      decimals="0"
      unitRef="Unit_USD">300000</us-gaap:AccrualForEnvironmentalLossContingencies>
    <teva:LossContingenciesOnEnvironmentalLawsPenalty
      contextRef="PAsOn07_08_2021"
      decimals="-5"
      unitRef="Unit_USD">1400000</teva:LossContingenciesOnEnvironmentalLawsPenalty>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="P01_01_2022To06_30_2022_EosinophilicEsophagitisMemberusgaapLossContingenciesByNatureOfContingencyAxis"
      decimals="-6"
      unitRef="Unit_USD">200000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="P01_01_2022To06_30_2022_EosinophilicEsophagitisMemberusgaapLossContingenciesByNatureOfContingencyAxis_USsrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">150000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="P01_01_2022To06_30_2022_EuropeMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">50000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2022To06_30_2022">&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 11 &#x2013; Income taxes: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In the second quarter of 2022, Teva recognized a tax benefit of $900&#160;million, on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-tax&lt;/div&gt; loss of $1,160&#160;million. In the second quarter of 2021, Teva recognized a tax expense of $98&#160;million, on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-tax&lt;/div&gt; income of $308&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the second quarter of 2022, one of Teva&#x2019;s U.S. subsidiaries was determined to be insolvent for tax purposes (i.e., its liabilities exceeded the fair market value of its assets), mainly in light of its accumulated operational losses. Consequently, Teva will recognize on its 2022 tax return, a worthless stock deduction of approximately $4.2 billion, with related tax benefit of approximately $850 million. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva&#x2019;s tax rate for the second quarter of 2022 was mainly affected by the realization of losses related to its investment in one of its U.S. subsidiaries mentioned above, as well as impairments, legal settlements, adjustments to valuation allowances on deferred tax assets and interest expense disallowances. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In the first six months of 2022, Teva recognized a tax benefit of $899&#160;million, on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-tax&lt;/div&gt; loss of $2,131&#160;million. In the first six months of 2021, Teva recognized a tax expense of $159&#160;million, on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-tax&lt;/div&gt; income of $451&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva&#x2019;s tax rate for the first six months of 2022 was mainly affected by the realization of losses related to its investment in one of its U.S. subsidiaries mentioned above, as well as impairments, legal settlements, adjustments to valuation allowances on deferred tax assets and interest expense disallowances. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The statutory Israeli corporate tax rate is 23% in 2022. Teva&#x2019;s tax rate differs from the Israeli statutory tax rate, mainly due to generation of profits in various jurisdictions in which tax rates are different than the Israeli tax rate, interest expense disallowances, tax benefits in Israel and other countries, as well as infrequent or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-recurring&lt;/div&gt; items. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;Teva filed a claim seeking the refund of withholding taxes paid to the Indian tax authorities in 2012. Trial in this case is scheduled to begin in November 2022. A final and binding decision against Teva in this case may lead to an impairment of&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; $133&#160;million.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Israeli tax authorities issued tax assessment decrees for 2008-2012 and 2013-2016, challenging the Company&#x2019;s positions on several issues. Teva has protested the 2008-2012 and 2013-2016 decrees before the Central District Court in Israel. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;In October 2021, the Central District Court in Israel held in favor of the Israeli tax authorities with respect to 2008-2011 decrees. The case with respect to 2012-2016 remains pending with similar legal claims. The October 2021 Central District Court decision found that Teva has a tax liability to the Israeli government for 2008-2011 of approximately $350&#160;million,&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;of which a portion is being paid in cash during 2022 and 2023, and the remaining portion is being offset by carried forward losses that Teva would otherwise be entitled to. Teva appealed the decision to the Israeli Supreme Court and expects the appeal hearings to begin in early 2023.&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company believes it has adequately provided for all of its uncertain tax positions, including those items currently under dispute, however, adverse results could be material. &lt;/div&gt;&lt;br/&gt;&lt;/div&gt; </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-900000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-1160000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">98000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">308000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:InventoryWriteDown
      contextRef="P04_01_2022To06_30_2022"
      decimals="-8"
      unitRef="Unit_USD">4200000000</us-gaap:InventoryWriteDown>
    <teva:EffectiveIncomeTaxReconciliationAmountInventoryWrittenOff
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">850000000</teva:EffectiveIncomeTaxReconciliationAmountInventoryWrittenOff>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-899000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-2131000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">159000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">451000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2022To06_30_2022_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <teva:ExpectedImpairmentOfIncomeTaxBenefit
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">133000000</teva:ExpectedImpairmentOfIncomeTaxBenefit>
    <us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss
      contextRef="P10_01_2021To10_31_2021_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis_TaxYear2008To2011MemberusgaapTaxPeriodAxis"
      decimals="-6"
      unitRef="Unit_USD">350000000</us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss>
    <teva:OtherExpensesTextBlock contextRef="P01_01_2022To06_30_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 12 &#x2013; Other assets impairments, restructuring and other &lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;items: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;months&#160;ended&lt;br/&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six&#160;months&#160;ended&lt;br/&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$&#160;in&#160;millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$&#160;in&#160;millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Impairments of long-lived tangible assets (1)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent consideration&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;61&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restructuring&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;92&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;69&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;33&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 66%; line-height: 11pt; font-size: 11pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"&gt;&lt;div style="font-size:11pt;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px; line-height: 11pt;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%; line-height: 11pt; font-size: 11pt;"&gt;&lt;div style="font-size:11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"&gt;&lt;div style="font-size:11pt;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;"&gt;118&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"&gt;&lt;div style="font-size:11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%; line-height: 11pt; font-size: 11pt;"&gt;&lt;div style="font-size:11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"&gt;&lt;div style="font-size:11pt;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;"&gt;28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"&gt;&lt;div style="font-size:11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; line-height: 11pt; font-size: 11pt;"&gt;&lt;div style="font-size:11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"&gt;&lt;div style="font-size:11pt;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;"&gt;246&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"&gt;&lt;div style="font-size:11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%; line-height: 11pt; font-size: 11pt;"&gt;&lt;div style="font-size:11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"&gt;&lt;div style="font-size:11pt;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;"&gt;165&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"&gt;&lt;div style="font-size:11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="width: 26%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Including impairments related to exit and disposal activities. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Impairments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Impairments of tangible assets for the three months ended June&#160;30, 2022 and 2021 were $14&#160;million and $32&#160;million, respectively.&#160;The impairment for the three months ended June&#160;30, 2021 was mainly related to certain assets in Europe. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;Impairments of tangible assets for the six months ended June&#160;30, 2022 and 2021 were $30&#160;million and $80&#160;million, respectively.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;The impairment for the six months ended June 30, 2022 was mainly related to certain assets in North America. The impairment for the six months ended June 30, 2021 was mainly related to certain assets in Europe.&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva may record additional impairments in the future, to the extent it changes its plans on any given asset and/or the assumptions underlying such plans, as a result of its network consolidation activities. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Contingent consideration &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the three months ended June&#160;30, 2022, Teva recorded an expense of $61&#160;million for contingent consideration, compared to an income of $19&#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million in the three months ended June&#160;30, 2021. The expense in the second quarter of 2022 and the income in the second quarter of 2021 were mainly related to changes in the estimated future royalty payments to Allergan in connection with lenalidomide (generic equivalent of Revlimid&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;), which was part of the Actavis Generics acquisition. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the six months ended June&#160;30, 2022, Teva recorded an expense of $94&#160;million for contingent consideration, compared to an income of $16&#160;million in the six months ended June&#160;30, 2021. The expense in the first six months of 2022&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, and the income in the first six months of 2021 were &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; mainly related to change&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt; in the estimated future royalty payments to Allergan in connection with lenalidomide (generic equivalent of Revlimid&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;), which was part of the Actavis Generics acquisition.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Restructuring &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the three months ended June&#160;30, 2022, Teva recorded $35&#160;million of restructuring expenses, compared to $13&#160;million of restructuring &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;income&lt;/div&gt;&#160;in the three months ended June&#160;30, 2021. &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The expenses for the three months &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ended June&#160;30, 2022 were primarily related to network consolidation activities and residual expenses of the restructuring plan announced in 2017. The income for the three months ended June&#160;30, 2021 was primarily related to reassessment of the estimate of a prior employee termination provision. &lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the six months ended June&#160;30, 2022, Teva recorded $&lt;/div&gt;92&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million of restructuring expenses, compared to $&lt;/div&gt;69&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in the six months ended June&#160;30, 2021. The expenses for the six months ended June&#160;30, 2022 and June&#160;30, 2021 were primarily related to network consolidation activities and residual expenses of the restructuring plan announced in 2017.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following tables provide the components of restructuring costs: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;months&#160;ended&#160;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restructuring&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Employee termination&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six&#160;months&#160;ended&#160;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restructuring&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Employee termination&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;61&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;92&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;69&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table provides the components of and changes in the Company&#x2019;s restructuring accruals: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 68%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employee&#160;termination&lt;br/&gt; costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of January&#160;1, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(131&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(138&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provision&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(63&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(92&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Utilization and other*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;74&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;103&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of June&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(120&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(127&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 68%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt;"/&gt;
&lt;td colspan="4" style="height: 12pt;"/&gt;
&lt;td colspan="4" style="height: 12pt;"/&gt;
&lt;td colspan="4" style="height: 12pt;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employee&#160;termination&lt;br/&gt; costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of January&#160;1, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(115&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(122&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provision&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(61&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(69&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Utilization and other*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;56&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;64&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of June&#160;30, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(120&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(127&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="width: 26%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;*&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Includes adjustments for foreign currency translation. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Significant regulatory and other events &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In July 2018, Teva announced the voluntary recall of valsartan and certain combination valsartan medicines in various countries due to the detection of trace amounts of a previously unknown nitrosamine impurity called NDMA found in valsartan API supplied by Zhejiang Huahai Pharmaceuticals Co. Ltd. (&#x201c;Huahai&#x201d;). Since July 2018, Teva has been actively engaged with global regulatory authorities in reviewing its sartan and other products to determine whether NDMA and/or other related nitrosamine impurities are present in specific products. Where necessary, Teva has initiated additional voluntary recalls. In December 2019, Teva reached a settlement with Huahai resolving Teva&#x2019;s claims related to certain sartan API supplied by Huahai. Under the settlement agreement, Huahai agreed to compensate Teva for some of &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;its direct losses and provide it with prospective cost reductions for API. The settlement does not release Huahai from liability for any losses Teva may incur as a result of third party personal injury or product liability claims relating to the sartan API at issue. In addition, multiple lawsuits have been filed in connection with this matter, which may lead to additional customer penalties, impairments and litigation costs. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the second quarter of 2020, Teva&#x2019;s operations in its manufacturing facilities in Goa, India were temporarily suspended due to a water supply issue. During the second half of 2020, Teva completed partial remediation of this issue and restarted limited supply from its Goa facilities. The site experienced some additional delays in the first quarter of 2021 due to labor related issues, but the situation stabilized during the second quarter of 2021. The water supply remediation is expected to be completed during the third quarter of 2022, and in the meantime the site is operating under an interim water solution without any material impact expected on compliance and supply capacity. The impact to Teva&#x2019;s financial results for the three and six months ended June&#160;30, 2022 was immaterial. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In June 2021, the Company temporarily paused manufacturing at its Irvine, California facility in the United States, and suspended release of product from the facility pending completion of an open manufacturing investigation. In July 2021, the FDA initiated an establishment inspection at the facility. On August&#160;18, 2021, the Company issued field alert reports to the FDA for products manufactured at the Irvine facility and put Irvine manufactured products in Teva&#x2019;s distribution center on hold. On August&#160;20, 2021, the FDA completed its inspection and issued a Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;FDA-483&lt;/div&gt; to the Irvine facility with ten observations and, on December&#160;17, 2021, the FDA notified the Company that the inspection classification of this site is &#x201c;official action indicated&#x201d; (&#x201c;OAI&#x201d;). Teva began working diligently to address the FDA&#x2019;s concerns in a manner consistent with current good manufacturing practice (&#x201c;CGMP&#x201d;) requirements, and was in discussions with the FDA Drug Shortage Staff (DSS) and FDA Office of Manufacturing Quality (OMQ) to recommence distribution, release and manufacture of certain medically necessary products from the site under defined controls and protocols. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;22, 2022, the Company announced its decision to permanently cease all manufacturing activities and to close the site, and to transfer certain products to other facilities. Teva will remain in contact with FDA regarding the status of the Irvine, California site to ensure that the Company continues to comply with all relevant CGMP requirements, particularly those involved with product transfers to other sites within the Teva network. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If Teva is unable to address FDA inspection issues satisfactorily, it could be subject to additional regulatory actions. Teva has considered these developments and, during the six months ended June&#160;30, 2022, recorded $73&#160;million costs in its financial statements related to this matter. Teva will continue to assess potential financial implications, including loss of revenues, impairments, inventory write offs, customer penalties, costs of additional remediation and/or FDA enforcement actions. &lt;/div&gt;&lt;br/&gt;&lt;/div&gt;</teva:OtherExpensesTextBlock>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock contextRef="P01_01_2022To06_30_2022"> &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;months&#160;ended&lt;br/&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six&#160;months&#160;ended&lt;br/&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$&#160;in&#160;millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$&#160;in&#160;millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Impairments of long-lived tangible assets (1)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent consideration&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;61&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restructuring&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;92&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;69&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;33&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 66%; line-height: 11pt; font-size: 11pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"&gt;&lt;div style="font-size:11pt;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px; line-height: 11pt;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%; line-height: 11pt; font-size: 11pt;"&gt;&lt;div style="font-size:11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"&gt;&lt;div style="font-size:11pt;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;"&gt;118&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"&gt;&lt;div style="font-size:11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%; line-height: 11pt; font-size: 11pt;"&gt;&lt;div style="font-size:11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"&gt;&lt;div style="font-size:11pt;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;"&gt;28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"&gt;&lt;div style="font-size:11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; line-height: 11pt; font-size: 11pt;"&gt;&lt;div style="font-size:11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"&gt;&lt;div style="font-size:11pt;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;"&gt;246&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"&gt;&lt;div style="font-size:11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%; line-height: 11pt; font-size: 11pt;"&gt;&lt;div style="font-size:11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"&gt;&lt;div style="font-size:11pt;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;;text-align:right;"&gt;165&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt;"&gt;&lt;div style="font-size:11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="width: 26%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Including impairments related to exit and disposal activities. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      id="Fact_52307555"
      unitRef="Unit_USD">14000000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      id="Fact_52307556"
      unitRef="Unit_USD">32000000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      id="Fact_52307557"
      unitRef="Unit_USD">30000000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      id="Fact_52307558"
      unitRef="Unit_USD">80000000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">61000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">19000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">94000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">16000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:RestructuringCharges
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">35000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">-13000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">92000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">69000000</us-gaap:RestructuringCharges>
    <teva:LegalSettlementsLossContingenciesImpairmentsOtherExpenses
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">8000000</teva:LegalSettlementsLossContingenciesImpairmentsOtherExpenses>
    <teva:LegalSettlementsLossContingenciesImpairmentsOtherExpenses
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">28000000</teva:LegalSettlementsLossContingenciesImpairmentsOtherExpenses>
    <teva:LegalSettlementsLossContingenciesImpairmentsOtherExpenses
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">30000000</teva:LegalSettlementsLossContingenciesImpairmentsOtherExpenses>
    <teva:LegalSettlementsLossContingenciesImpairmentsOtherExpenses
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">33000000</teva:LegalSettlementsLossContingenciesImpairmentsOtherExpenses>
    <teva:ImpairmentAndRestructuring
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">118000000</teva:ImpairmentAndRestructuring>
    <teva:ImpairmentAndRestructuring
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">28000000</teva:ImpairmentAndRestructuring>
    <teva:ImpairmentAndRestructuring
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">246000000</teva:ImpairmentAndRestructuring>
    <teva:ImpairmentAndRestructuring
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">165000000</teva:ImpairmentAndRestructuring>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">14000000</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">32000000</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">30000000</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">80000000</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">61000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">19000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">94000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">16000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:RestructuringCharges
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">35000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">-13000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">92000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">69000000</us-gaap:RestructuringCharges>
    <teva:ScheduleOfRestructuringChargesTableTextBlock contextRef="P01_01_2022To06_30_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following tables provide the components of restructuring costs: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;months&#160;ended&#160;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restructuring&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Employee termination&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six&#160;months&#160;ended&#160;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restructuring&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Employee termination&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;61&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;92&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;69&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</teva:ScheduleOfRestructuringChargesTableTextBlock>
    <us-gaap:RestructuringCharges
      contextRef="P04_01_2022To06_30_2022_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-6"
      unitRef="Unit_USD">11000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P04_01_2021To06_30_2021_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-6"
      unitRef="Unit_USD">-19000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P04_01_2022To06_30_2022_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-6"
      unitRef="Unit_USD">24000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P04_01_2021To06_30_2021_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-6"
      unitRef="Unit_USD">6000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">35000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">-13000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2022To06_30_2022_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-6"
      unitRef="Unit_USD">63000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2021To06_30_2021_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-6"
      unitRef="Unit_USD">61000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2022To06_30_2022_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-6"
      unitRef="Unit_USD">29000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2021To06_30_2021_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-6"
      unitRef="Unit_USD">8000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">92000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">69000000</us-gaap:RestructuringCharges>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="P01_01_2022To06_30_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table provides the components of and changes in the Company&#x2019;s restructuring accruals: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 68%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employee&#160;termination&lt;br/&gt; costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of January&#160;1, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(131&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(138&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provision&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(63&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(92&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Utilization and other*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;74&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;103&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of June&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(120&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(127&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 68%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt;"/&gt;
&lt;td colspan="4" style="height: 12pt;"/&gt;
&lt;td colspan="4" style="height: 12pt;"/&gt;
&lt;td colspan="4" style="height: 12pt;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employee&#160;termination&lt;br/&gt; costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of January&#160;1, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(115&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(122&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provision&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(61&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(69&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Utilization and other*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;56&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;64&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of June&#160;30, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(120&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(127&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="width: 26%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;*&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Includes adjustments for foreign currency translation. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn12_31_2021_EmployeeTerminationMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      unitRef="Unit_USD">131000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn12_31_2021_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      unitRef="Unit_USD">7000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">138000000</us-gaap:RestructuringReserve>
    <teva:RestructuringAccrualProvision
      contextRef="P01_01_2022To06_30_2022_EmployeeTerminationMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      unitRef="Unit_USD">63000000</teva:RestructuringAccrualProvision>
    <teva:RestructuringAccrualProvision
      contextRef="P01_01_2022To06_30_2022_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      unitRef="Unit_USD">29000000</teva:RestructuringAccrualProvision>
    <teva:RestructuringAccrualProvision
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">92000000</teva:RestructuringAccrualProvision>
    <teva:UtilizationAndOther
      contextRef="P01_01_2022To06_30_2022_EmployeeTerminationMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      id="Fact_52308226"
      unitRef="Unit_USD">74000000</teva:UtilizationAndOther>
    <teva:UtilizationAndOther
      contextRef="P01_01_2022To06_30_2022_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      id="Fact_52308225"
      unitRef="Unit_USD">29000000</teva:UtilizationAndOther>
    <teva:UtilizationAndOther
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      id="Fact_52307908"
      unitRef="Unit_USD">103000000</teva:UtilizationAndOther>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn06_30_2022_EmployeeTerminationMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      unitRef="Unit_USD">120000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn06_30_2022_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      unitRef="Unit_USD">7000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">127000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn12_31_2020_EmployeeTerminationMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      unitRef="Unit_USD">115000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn12_31_2020_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      unitRef="Unit_USD">7000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">122000000</us-gaap:RestructuringReserve>
    <teva:RestructuringAccrualProvision
      contextRef="P01_01_2021To06_30_2021_EmployeeTerminationMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      unitRef="Unit_USD">61000000</teva:RestructuringAccrualProvision>
    <teva:RestructuringAccrualProvision
      contextRef="P01_01_2021To06_30_2021_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      unitRef="Unit_USD">8000000</teva:RestructuringAccrualProvision>
    <teva:RestructuringAccrualProvision
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">69000000</teva:RestructuringAccrualProvision>
    <teva:UtilizationAndOther
      contextRef="P01_01_2021To06_30_2021_EmployeeTerminationMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      id="Fact_52307612"
      unitRef="Unit_USD">56000000</teva:UtilizationAndOther>
    <teva:UtilizationAndOther
      contextRef="P01_01_2021To06_30_2021_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      id="Fact_52307613"
      unitRef="Unit_USD">8000000</teva:UtilizationAndOther>
    <teva:UtilizationAndOther
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      id="Fact_52307614"
      unitRef="Unit_USD">64000000</teva:UtilizationAndOther>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn06_30_2021_EmployeeTerminationMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      unitRef="Unit_USD">120000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn06_30_2021_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      unitRef="Unit_USD">7000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">127000000</us-gaap:RestructuringReserve>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">73000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2022To06_30_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 13 &#x2013; Earnings (Loss) per share: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic earnings and loss per share are computed by dividing net income (loss) attributable to Teva&#x2019;s ordinary shareholders by the weighted average number of ordinary shares outstanding, including fully vested restricted share units (&#x201c;RSUs&#x201d;) and performance share units (&#x201c;PSUs&#x201d;) during the period, net of treasury shares. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In computing diluted loss per share for the three months ended June&#160;30, 2022, no account was taken of the potential dilution that could occur upon the exercise of options and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-vested&lt;/div&gt; RSUs and PSUs granted under employee stock compensation plans, and convertible senior debentures, since they had an anti-dilutive effect on loss per share. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In computing diluted earnings per share for the three months ended June&#160;30, 2021, basic earnings per share were adjusted to take into account the potential dilution that could occur upon the exercise of options and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-vested&lt;/div&gt; RSUs granted under employee stock compensation plans. No account was taken of the potential dilution by the convertible senior debentures, since they had an anti-dilutive effect on earnings per share. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In computing diluted loss per share for the six months ended June&#160;30, 2022, no account was taken of the potential dilution that could occur upon the exercise of options and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-vested&lt;/div&gt; RSUs and PSUs granted under employee stock compensation plans, and convertible senior debentures, since they had an anti-dilutive effect on loss per share. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In computing diluted earnings per share for the six months ended June&#160;30, 2021, basic earnings per share were adjusted to take into account the potential dilution that could occur upon the exercise of options and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-vested&lt;/div&gt; RSUs granted under employee stock compensation plans. No account was taken of the potential dilution by the convertible senior debentures, since they had an anti-dilutive effect on earnings per share.&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The weighted average diluted shares outstanding used for the fully diluted share calculations for the three months ended June&#160;30, 2022, and 2021, were 1,110 and 1,109 shares, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The weighted average diluted shares outstanding used for the fully diluted share calculations for the six months ended June&#160;30, 2022, and 2021, were 1,109 and 1,108 shares, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted loss per share was $0.21 for the three months ended June&#160;30, 2022, compared to basic and diluted earnings per share of $0.19 for the three months ended June&#160;30, 2021. Basic and diluted loss per share was $1.07 for the six months ended June&#160;30, 2022, compared to basic and diluted earnings per share of $0.26 for the six months ended June&#160;30, 2021. &lt;/div&gt;&lt;br/&gt;&lt;/div&gt; </us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P04_01_2022To06_30_2022_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P04_01_2021To06_30_2021_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To06_30_2022_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To06_30_2021_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_shares">1110000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_shares">1109000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_shares">1109000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_shares">1108000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P04_01_2022To06_30_2022"
      decimals="INF"
      unitRef="Unit_USD_per_Share">-0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P04_01_2022To06_30_2022"
      decimals="INF"
      unitRef="Unit_USD_per_Share">-0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P04_01_2021To06_30_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P04_01_2021To06_30_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To06_30_2022"
      decimals="INF"
      unitRef="Unit_USD_per_Share">-1.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To06_30_2022"
      decimals="INF"
      unitRef="Unit_USD_per_Share">-1.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2021To06_30_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2021To06_30_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.26</us-gaap:EarningsPerShareBasic>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2022To06_30_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 14 &#x2013; Accumulated other comprehensive income (loss): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The components of, and changes within, accumulated other comprehensive income (loss) attributable to Teva are presented in the table below: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 58%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net&#160;Unrealized&#160;Gains&#160;(Losses)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Benefit&#160;Plans&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Foreign&lt;br/&gt; currency&lt;br/&gt; translation&lt;br/&gt; adjustments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Derivative&lt;br/&gt; financial&lt;br/&gt; instruments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Actuarial&#160;gains&lt;br/&gt; (losses)&#160;and&lt;br/&gt; prior&#160;service&lt;br/&gt; (costs)&#160;credits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of December&#160;31, 2021, net of taxes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,274&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(324&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(85&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,683&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other comprehensive income (loss) before reclassifications&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(127&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(127&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amounts reclassified to the statements of income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net other comprehensive income (loss) before tax&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(127&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(113&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corresponding income tax&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net other comprehensive income (loss) after tax*&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(132&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(118&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of June&#160;30, 2022, net of taxes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,406&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(310&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(85&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,801&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="width: 26%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family:Times New Roman,Times,serif;;display:inline;"&gt;Amounts do not include a $150&#160;million loss from foreign currency translation adjustments attributable to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interests.&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-family:Times New Roman,Times,serif;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family:Times New Roman,Times,serif;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family:Times New Roman,Times,serif;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family:Times New Roman,Times,serif;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family:Times New Roman,Times,serif;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family:Times New Roman,Times,serif;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family:Times New Roman,Times,serif;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family:Times New Roman,Times,serif;;display:inline;"&gt; &lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family:Times New Roman,Times,serif;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net&#160;Unrealized&#160;Gains&#160;(Losses)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Benefit&#160;Plans&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Foreign&lt;br/&gt; currency&lt;br/&gt; translation&lt;br/&gt; adjustments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Derivative&lt;br/&gt; financial&lt;br/&gt; instruments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Actuarial&#160;gains&lt;br/&gt; (losses)&#160;and&lt;br/&gt; prior&#160;service&lt;br/&gt; (costs)&#160;credits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of December&#160;31, 2020, net of taxes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,919&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(363&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(117&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,399&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other comprehensive income (loss) before reclassifications&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(77&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(77&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amounts reclassified to the statements of income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net other comprehensive income (loss) before tax&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(77&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(58&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corresponding income tax&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net other comprehensive income (loss) after tax*&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(62&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(47&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of June&#160;30, 2021, net of taxes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,981&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(349&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(116&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,446&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="width: 26%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;Amounts do not include a $68&#160;million loss from foreign currency translation adjustments attributable to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interests. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="P01_01_2022To06_30_2022">The components of, and changes within, accumulated other comprehensive income (loss) attributable to Teva are presented in the table below: &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 58%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net&#160;Unrealized&#160;Gains&#160;(Losses)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Benefit&#160;Plans&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Foreign&lt;br/&gt; currency&lt;br/&gt; translation&lt;br/&gt; adjustments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Derivative&lt;br/&gt; financial&lt;br/&gt; instruments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Actuarial&#160;gains&lt;br/&gt; (losses)&#160;and&lt;br/&gt; prior&#160;service&lt;br/&gt; (costs)&#160;credits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of December&#160;31, 2021, net of taxes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,274&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(324&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(85&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,683&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other comprehensive income (loss) before reclassifications&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(127&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(127&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amounts reclassified to the statements of income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net other comprehensive income (loss) before tax&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(127&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(113&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corresponding income tax&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net other comprehensive income (loss) after tax*&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(132&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(118&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of June&#160;30, 2022, net of taxes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,406&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(310&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(85&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,801&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="width: 26%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family:Times New Roman,Times,serif;;display:inline;"&gt;Amounts do not include a $150&#160;million loss from foreign currency translation adjustments attributable to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interests.&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-family:Times New Roman,Times,serif;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family:Times New Roman,Times,serif;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family:Times New Roman,Times,serif;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family:Times New Roman,Times,serif;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family:Times New Roman,Times,serif;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family:Times New Roman,Times,serif;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family:Times New Roman,Times,serif;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family:Times New Roman,Times,serif;;display:inline;"&gt; &lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family:Times New Roman,Times,serif;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net&#160;Unrealized&#160;Gains&#160;(Losses)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Benefit&#160;Plans&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Foreign&lt;br/&gt; currency&lt;br/&gt; translation&lt;br/&gt; adjustments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Derivative&lt;br/&gt; financial&lt;br/&gt; instruments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Actuarial&#160;gains&lt;br/&gt; (losses)&#160;and&lt;br/&gt; prior&#160;service&lt;br/&gt; (costs)&#160;credits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of December&#160;31, 2020, net of taxes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,919&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(363&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(117&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,399&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other comprehensive income (loss) before reclassifications&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(77&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(77&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amounts reclassified to the statements of income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net other comprehensive income (loss) before tax&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(77&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(58&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corresponding income tax&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net other comprehensive income (loss) after tax*&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(62&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(47&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of June&#160;30, 2021, net of taxes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,981&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(349&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(116&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,446&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="width: 26%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;Amounts do not include a $68&#160;million loss from foreign currency translation adjustments attributable to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interests. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2021_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-2274000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2021_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-324000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2021_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-85000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-2683000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="P01_01_2022To06_30_2022_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-127000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="P01_01_2022To06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-127000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="P01_01_2022To06_30_2022_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-14000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="P01_01_2022To06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-14000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="P01_01_2022To06_30_2022_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-127000000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="P01_01_2022To06_30_2022_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">14000000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="P01_01_2022To06_30_2022_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="P01_01_2022To06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-113000000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="P01_01_2022To06_30_2022_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">5000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="P01_01_2022To06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">5000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2022To06_30_2022_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_52307826"
      unitRef="Unit_USD">-132000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2022To06_30_2022_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_52307827"
      unitRef="Unit_USD">14000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2022To06_30_2022_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_52307828"
      unitRef="Unit_USD">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2022To06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_52307829"
      unitRef="Unit_USD">-118000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn06_30_2022_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-2406000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn06_30_2022_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-310000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn06_30_2022_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-85000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-2801000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2022To06_30_2022_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">150000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2020_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-1919000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2020_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-363000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2020_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-117000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-2399000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="P01_01_2021To06_30_2021_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-77000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="P01_01_2021To06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-77000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="P01_01_2021To06_30_2021_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-18000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="P01_01_2021To06_30_2021_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-1000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="P01_01_2021To06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-19000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="P01_01_2021To06_30_2021_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-77000000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="P01_01_2021To06_30_2021_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">18000000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="P01_01_2021To06_30_2021_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="P01_01_2021To06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-58000000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="P01_01_2021To06_30_2021_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-15000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="P01_01_2021To06_30_2021_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">4000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="P01_01_2021To06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-11000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2021To06_30_2021_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_52307781"
      unitRef="Unit_USD">-62000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2021To06_30_2021_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_52307780"
      unitRef="Unit_USD">14000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2021To06_30_2021_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_52307958"
      unitRef="Unit_USD">1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2021To06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_52307779"
      unitRef="Unit_USD">-47000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn06_30_2021_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-1981000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn06_30_2021_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-349000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn06_30_2021_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-116000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-2446000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2021To06_30_2021_AccountingStandardsUpdate201601MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis"
      decimals="-6"
      unitRef="Unit_USD">68000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="P01_01_2022To06_30_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 15 &#x2013; Segments: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva operates its business and reports its financial results in three segments: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;(a)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;North America segment, which includes the United States and Canada. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;(b)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Europe segment, which includes the European Union, the United Kingdom and certain other European countries. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;(c)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;International Markets segment, which includes all countries other than those in the North America and Europe segments. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In addition to these three segments, Teva has other sources of revenues, primarily the sale of APIs to third parties, certain contract manufacturing services and an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;out-licensing&lt;/div&gt; platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva&#x2019;s&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Chief Executive Officer (&#x201c;CEO&#x201d;), who is the chief operating decision maker (&#x201c;CODM&#x201d;), reviews financial information prepared on a consolidated basis, accompanied by disaggregated information about revenues and contributed profit by the &lt;/div&gt;three&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; identified reportable segments, namely North America, Europe and International Markets, to make decisions about resources to be allocated to the segments and assess their performance.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Segment profit is comprised of gross profit for the segment less R&amp;amp;D expenses, S&amp;amp;M expenses, G&amp;amp;A expenses and other income related to the segment. Segment profit does not include amortization and certain other items. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva manages its assets on a company basis, not by segments, as many of its assets are shared or commingled. Teva&#x2019;s CODM does not regularly review asset information by reportable segment and, therefore, Teva does not report asset information by reportable segment. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;Teva&#x2019;s&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;CEO may review its strategy and organizational structure from time to time. Any changes in strategy may lead to a reevaluation of the Company&#x2019;s segments and goodwill allocation to reporting units, as well as fair value attributable to its reporting units. See note 3 and note 6. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;a.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;Seg&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;information:&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 59%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three months ended June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&#160;America&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&#160;Markets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenues&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,904&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,171&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;454&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross profit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,010&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;703&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;242&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&amp;amp;D expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;147&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;56&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&amp;amp;M expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;256&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;196&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;99&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;G&amp;amp;A expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;127&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Segment profit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;481&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;389&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;95&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three months ended June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&#160;America&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&#160;Markets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenues&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,943&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,184&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;485&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross profit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,040&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;661&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;270&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&amp;amp;D expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;162&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&amp;amp;M expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;255&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;209&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;105&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;G&amp;amp;A expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;106&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;47&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Segment profit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;521&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;343&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;123&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xa7; Represents an amount less than $0.5&#160;million. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 59%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six months ended June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&#160;America&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&#160;Markets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenues&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,641&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,327&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;946&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross profit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,899&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,397&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;528&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&amp;amp;D expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;289&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;114&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;39&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&amp;amp;M expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;501&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;393&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;196&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;G&amp;amp;A expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;239&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;122&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;60&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(41&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Segment profit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;883&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;769&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;274&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 59%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six months ended June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&#160;America&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&#160;Markets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenues&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,932&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,398&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;975&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross profit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,114&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,349&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;530&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&amp;amp;D expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;322&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;129&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&amp;amp;M expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;483&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;424&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;201&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;G&amp;amp;A expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;218&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;117&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;51&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Segment profit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,098&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;680&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;245&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents a reconciliation of Teva&#x2019;s segment profits to its consolidated operating income (loss) and to consolidated income (loss) before income taxes for the three and six months ended June&#160;30, 2022 and 2021: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three months ended &lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June 30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six months ended &lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June 30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $&#160;in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $&#160;in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 82%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0.5%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0.25%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0.125%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0.0625%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0.03125%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0.015625%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0.015625%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;North America profit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;481&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;521&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;883&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,098&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Europe profit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;389&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;343&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;769&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;680&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;International Markets profit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;95&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;123&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;274&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;245&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total reportable segments profit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;964&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;987&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,926&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,023&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Profit of other activities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;55&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;47&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;107&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;87&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total segments profit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;1,019&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,034&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,032&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,111&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amounts not allocated to segments:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; padding: 0px;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; padding: 0px;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; padding: 0px;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; padding: 0px;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; padding: 0px;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; padding: 0px;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; padding: 0px;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; padding: 0px;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;212&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;173&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;412&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;414&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other assets impairments, restructuring and other items&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;118&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;28&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;246&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;165&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill impairment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;745&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; width: 4%;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;745&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets impairments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;51&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;195&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;274&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Legal settlements and loss contingencies&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;729&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,854&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;110&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other unallocated amounts&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;113&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;50&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;240&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;132&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Consolidated operating income (loss)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(949&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;582&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,662&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,015&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial expenses, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;211&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;274&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;468&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;564&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Consolidated income (loss) before income taxes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,160&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;308&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,131&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;451&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 1.25pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 1.25pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 1.25pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 1.25pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 1.25pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;b. Segment revenues by major products and activities: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following tables present revenues by major products and activities for the three and six months ended June&#160;30, 2022 and 2021: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 81%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North America&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;months&#160;ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 81%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Generic products&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;1,026&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;951&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AJOVY&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;49&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;46&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AUSTEDO&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;204&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;174&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;BENDEKA&#xae;/TREANDA&#xae;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;83&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;106&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COPAXONE&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;152&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Anda&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;308&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;316&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;139&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,904&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,943&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North America&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six&#160;months&#160;ended&lt;br/&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Generic products&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,925&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,004&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AJOVY&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;86&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;77&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AUSTEDO&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;358&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;320&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;BENDEKA/TREANDA&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;165&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;197&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COPAXONE&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;180&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;315&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Anda&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;650&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;605&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;278&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;414&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,641&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,932&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td/&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 82%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;months&#160;ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 82%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Generic products&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;873&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;878&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AJOVY&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COPAXONE&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;72&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Respiratory products&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;65&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;85&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;131&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;102&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,171&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,184&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six&#160;months&#160;ended&lt;br/&gt; June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom; width: 80%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Generic products&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,749&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,742&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 80%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AJOVY&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;60&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 80%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COPAXONE&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;144&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;201&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 80%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Respiratory products&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;137&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;179&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 80%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;238&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;242&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 80%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; width: 80%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,327&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,398&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 80%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International markets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;months&#160;ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$&#160;in&#160;millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom; width: 84%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Generic products&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;394&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;407&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 84%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AJOVY&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 84%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COPAXONE&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 84%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;65&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 84%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom; width: 84%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;454&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;485&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 84%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International markets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six&#160;months&#160;ended&lt;br/&gt; June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$&#160;in&#160;millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom; width: 84%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Generic products&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;782&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;799&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 84%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AJOVY&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 84%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COPAXONE&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 84%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;128&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;150&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 84%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 84%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;946&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;975&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 84%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  </us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="P01_01_2022To06_30_2022"
      decimals="0"
      unitRef="Unit_Segment">3</us-gaap:NumberOfReportableSegments>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock contextRef="P01_01_2022To06_30_2022">&lt;div style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;a.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;Seg&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;information:&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 59%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three months ended June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&#160;America&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&#160;Markets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenues&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,904&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,171&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;454&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross profit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,010&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;703&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;242&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&amp;amp;D expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;147&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;56&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&amp;amp;M expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;256&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;196&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;99&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;G&amp;amp;A expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;127&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Segment profit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;481&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;389&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;95&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three months ended June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&#160;America&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&#160;Markets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenues&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,943&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,184&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;485&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross profit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,040&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;661&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;270&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&amp;amp;D expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;162&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&amp;amp;M expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;255&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;209&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;105&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;G&amp;amp;A expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;106&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;47&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Segment profit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;521&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;343&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;123&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xa7; Represents an amount less than $0.5&#160;million. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 59%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six months ended June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&#160;America&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&#160;Markets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenues&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,641&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,327&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;946&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross profit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,899&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,397&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;528&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&amp;amp;D expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;289&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;114&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;39&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&amp;amp;M expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;501&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;393&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;196&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;G&amp;amp;A expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;239&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;122&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;60&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(41&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Segment profit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;883&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;769&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;274&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 59%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six months ended June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&#160;America&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&#160;Markets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenues&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,932&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,398&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;975&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross profit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,114&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,349&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;530&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&amp;amp;D expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;322&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;129&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&amp;amp;M expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;483&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;424&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;201&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;G&amp;amp;A expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;218&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;117&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;51&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Segment profit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,098&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;680&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;245&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1904000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1171000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">454000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:GrossProfit
      contextRef="P04_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1010000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P04_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">703000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P04_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">242000000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P04_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">147000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P04_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">56000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P04_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">19000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P04_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">256000000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P04_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">196000000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P04_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">99000000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P04_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">127000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P04_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">63000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P04_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">30000000</us-gaap:GeneralAndAdministrativeExpense>
    <teva:OtherOperatingIncomeExpense
      contextRef="P04_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-1000000</teva:OtherOperatingIncomeExpense>
    <teva:OtherOperatingIncomeExpense
      contextRef="P04_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-1000000</teva:OtherOperatingIncomeExpense>
    <teva:OtherOperatingIncomeExpense
      contextRef="P04_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-1000000</teva:OtherOperatingIncomeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="P04_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">481000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P04_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">389000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P04_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">95000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1943000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1184000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">485000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:GrossProfit
      contextRef="P04_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1040000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P04_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">661000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P04_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">270000000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P04_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">162000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P04_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">63000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P04_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">18000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P04_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">255000000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P04_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">209000000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P04_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">105000000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P04_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">106000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P04_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">47000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P04_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">25000000</us-gaap:GeneralAndAdministrativeExpense>
    <teva:OtherOperatingIncomeExpense
      contextRef="P04_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-5000000</teva:OtherOperatingIncomeExpense>
    <teva:OtherOperatingIncomeExpense
      contextRef="P04_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-1000000</teva:OtherOperatingIncomeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="P04_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">521000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P04_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">343000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P04_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">123000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">3641000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">2327000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">946000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:GrossProfit
      contextRef="P01_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1899000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P01_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1397000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P01_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">528000000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">289000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">114000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">39000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P01_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">501000000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P01_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">393000000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P01_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">196000000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">239000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">122000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">60000000</us-gaap:GeneralAndAdministrativeExpense>
    <teva:OtherOperatingIncomeExpense
      contextRef="P01_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-12000000</teva:OtherOperatingIncomeExpense>
    <teva:OtherOperatingIncomeExpense
      contextRef="P01_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-1000000</teva:OtherOperatingIncomeExpense>
    <teva:OtherOperatingIncomeExpense
      contextRef="P01_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-41000000</teva:OtherOperatingIncomeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">883000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">769000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">274000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">3932000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">2398000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">975000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:GrossProfit
      contextRef="P01_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">2114000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P01_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1349000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P01_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">530000000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">322000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">129000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">35000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P01_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">483000000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P01_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">424000000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P01_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">201000000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">218000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">117000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">51000000</us-gaap:GeneralAndAdministrativeExpense>
    <teva:OtherOperatingIncomeExpense
      contextRef="P01_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-7000000</teva:OtherOperatingIncomeExpense>
    <teva:OtherOperatingIncomeExpense
      contextRef="P01_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-1000000</teva:OtherOperatingIncomeExpense>
    <teva:OtherOperatingIncomeExpense
      contextRef="P01_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-3000000</teva:OtherOperatingIncomeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1098000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">680000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">245000000</us-gaap:OperatingIncomeLoss>
    <teva:ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock contextRef="P01_01_2022To06_30_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents a reconciliation of Teva&#x2019;s segment profits to its consolidated operating income (loss) and to consolidated income (loss) before income taxes for the three and six months ended June&#160;30, 2022 and 2021: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three months ended &lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June 30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six months ended &lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June 30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $&#160;in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $&#160;in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 82%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0.5%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0.25%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0.125%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0.0625%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0.03125%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0.015625%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0.015625%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;North America profit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;481&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;521&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;883&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,098&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Europe profit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;389&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;343&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;769&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;680&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;International Markets profit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;95&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;123&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;274&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;245&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total reportable segments profit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;964&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;987&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,926&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,023&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Profit of other activities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;55&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;47&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;107&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;87&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total segments profit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;1,019&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,034&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,032&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,111&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amounts not allocated to segments:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; padding: 0px;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; padding: 0px;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; padding: 0px;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; padding: 0px;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; padding: 0px;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; padding: 0px;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; padding: 0px;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; padding: 0px;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;212&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;173&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;412&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;414&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other assets impairments, restructuring and other items&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;118&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;28&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;246&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;165&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill impairment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;745&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; width: 4%;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;745&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets impairments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;51&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;195&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;274&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Legal settlements and loss contingencies&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;729&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,854&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;110&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other unallocated amounts&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;113&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;50&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;240&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;132&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Consolidated operating income (loss)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(949&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;582&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,662&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,015&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial expenses, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;211&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;274&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;468&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;564&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.375pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Consolidated income (loss) before income taxes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,160&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;308&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,131&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;451&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 1.25pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 1.25pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 1.25pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 1.25pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 1.25pt; line-height: 1pt; font-size: 1pt;;text-align:right;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"&gt;&lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </teva:ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock>
    <us-gaap:OperatingIncomeLoss
      contextRef="P04_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">481000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P04_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">521000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">883000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1098000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P04_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">389000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P04_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">343000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">769000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">680000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P04_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">95000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P04_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">123000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">274000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">245000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P04_01_2022To06_30_2022_CorporateMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">964000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P04_01_2021To06_30_2021_CorporateMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">987000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To06_30_2022_CorporateMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1926000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2021To06_30_2021_CorporateMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">2023000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P04_01_2022To06_30_2022_AllOtherSegmentsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">55000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P04_01_2021To06_30_2021_AllOtherSegmentsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">47000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To06_30_2022_AllOtherSegmentsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">107000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2021To06_30_2021_AllOtherSegmentsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">87000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P04_01_2022To06_30_2022_SegmentsAndOtherActivitiesMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1019000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P04_01_2021To06_30_2021_SegmentsAndOtherActivitiesMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1034000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To06_30_2022_SegmentsAndOtherActivitiesMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">2032000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2021To06_30_2021_SegmentsAndOtherActivitiesMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">2111000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:AdjustmentForAmortization
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">212000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">173000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">412000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">414000000</us-gaap:AdjustmentForAmortization>
    <teva:ImpairmentsRestructuringAndOthers
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">118000000</teva:ImpairmentsRestructuringAndOthers>
    <teva:ImpairmentsRestructuringAndOthers
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">28000000</teva:ImpairmentsRestructuringAndOthers>
    <teva:ImpairmentsRestructuringAndOthers
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">246000000</teva:ImpairmentsRestructuringAndOthers>
    <teva:ImpairmentsRestructuringAndOthers
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">165000000</teva:ImpairmentsRestructuringAndOthers>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">745000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">745000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">51000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">195000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">199000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">274000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <teva:LegalSettlementsAndLossContingencies
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">729000000</teva:LegalSettlementsAndLossContingencies>
    <teva:LegalSettlementsAndLossContingencies
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">6000000</teva:LegalSettlementsAndLossContingencies>
    <teva:LegalSettlementsAndLossContingencies
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">1854000000</teva:LegalSettlementsAndLossContingencies>
    <teva:LegalSettlementsAndLossContingencies
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">110000000</teva:LegalSettlementsAndLossContingencies>
    <teva:OtherUnallocatedAmounts
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">113000000</teva:OtherUnallocatedAmounts>
    <teva:OtherUnallocatedAmounts
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">50000000</teva:OtherUnallocatedAmounts>
    <teva:OtherUnallocatedAmounts
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">240000000</teva:OtherUnallocatedAmounts>
    <teva:OtherUnallocatedAmounts
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">132000000</teva:OtherUnallocatedAmounts>
    <us-gaap:OperatingIncomeLoss
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-949000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">582000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-1662000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">1015000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-211000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">-274000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-468000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">-564000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-1160000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">308000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">-2131000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">451000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock contextRef="P01_01_2022To06_30_2022"> &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 81%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North America&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;months&#160;ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 81%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Generic products&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;1,026&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;951&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AJOVY&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;49&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;46&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AUSTEDO&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;204&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;174&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;BENDEKA&#xae;/TREANDA&#xae;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;83&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;106&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COPAXONE&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;152&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Anda&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;308&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;316&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;139&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,904&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,943&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North America&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six&#160;months&#160;ended&lt;br/&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Generic products&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,925&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,004&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AJOVY&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;86&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;77&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AUSTEDO&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;358&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;320&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;BENDEKA/TREANDA&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;165&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;197&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COPAXONE&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;180&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;315&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Anda&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;650&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;605&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;278&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;414&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,641&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,932&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td/&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 82%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;months&#160;ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 82%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Generic products&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;873&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;878&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AJOVY&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COPAXONE&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;72&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Respiratory products&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;65&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;85&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;131&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;102&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,171&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,184&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six&#160;months&#160;ended&lt;br/&gt; June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom; width: 80%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Generic products&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,749&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,742&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 80%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AJOVY&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;60&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 80%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COPAXONE&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;144&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;201&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 80%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Respiratory products&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;137&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;179&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 80%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;238&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;242&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 80%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; width: 80%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,327&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,398&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 80%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International markets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;months&#160;ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$&#160;in&#160;millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom; width: 84%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Generic products&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;394&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;407&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 84%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AJOVY&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 84%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COPAXONE&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 84%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;65&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 84%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom; width: 84%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;454&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;485&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 84%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International markets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six&#160;months&#160;ended&lt;br/&gt; June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$&#160;in&#160;millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom; width: 84%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Generic products&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;782&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;799&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 84%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AJOVY&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 84%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COPAXONE&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 84%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;128&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;150&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 84%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 84%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;946&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;975&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 84%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_GenericsMediciansMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1026000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_GenericsMediciansMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">951000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_AjovyMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">49000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_AjovyMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">46000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_AustedoMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">204000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_AustedoMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">174000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_BendekaAndTreandaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">83000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_BendekaAndTreandaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">106000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_COPAXONEMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">94000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_COPAXONEMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">152000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_AndaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">308000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_AndaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">316000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">139000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">199000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1904000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1943000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_GenericsMediciansMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1925000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_GenericsMediciansMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">2004000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_AjovyMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">86000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_AjovyMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">77000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_AustedoMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">358000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_AustedoMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">320000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_BendekaAndTreandaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">165000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_BendekaAndTreandaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">197000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_COPAXONEMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">180000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_COPAXONEMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">315000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_AndaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">650000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_AndaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">605000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">278000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">414000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">3641000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">3932000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_GenericsMediciansMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">873000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_GenericsMediciansMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">878000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_AjovyMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">29000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_AjovyMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">19000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_COPAXONEMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">72000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_COPAXONEMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">100000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_RespiratoryProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">65000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_RespiratoryProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">85000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">131000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">102000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1171000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1184000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_GenericsMediciansMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">1749000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_GenericsMediciansMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">1742000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_AjovyMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">60000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_AjovyMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">35000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_COPAXONEMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">144000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_COPAXONEMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">201000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_RespiratoryProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">137000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_RespiratoryProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">179000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">238000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">242000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">2327000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">2398000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_GenericsMediciansMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">394000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_GenericsMediciansMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">407000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_AjovyMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_AjovyMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_COPAXONEMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_COPAXONEMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">40000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">65000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">454000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">485000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_GenericsMediciansMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">782000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_GenericsMediciansMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">799000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_AjovyMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">16000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_AjovyMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_COPAXONEMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_COPAXONEMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">19000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">128000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">150000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To06_30_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">946000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To06_30_2021_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">975000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2022To06_30_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 16 &#x2013; Fair value measurement: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial items carried at fair value on a recurring basis as of June&#160;30, 2022 and December&#160;31, 2021 are classified in the tables below in one of the three categories of fair value levels: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money markets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;451&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;451&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash, deposits and other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,607&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,607&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment in securities:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted cash&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;33&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;33&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivatives:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Asset derivatives&#x2014;options and forward contracts&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;69&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;69&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liability derivatives:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Options and forward contracts&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(37&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(37&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bifurcated embedded derivatives&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent consideration*&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(205&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(205&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,106&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(204&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,934&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 71%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money markets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;220&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;220&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash, deposits and other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,945&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,945&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment in securities:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted cash&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;33&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;33&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivatives:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Asset derivatives&#x2014;options and forward contracts&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liability derivatives:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Options and forward contracts&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(23&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(23&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bifurcated embedded derivatives&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent consideration*&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(176&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(176&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,222&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(175&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,054&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="width: 26%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xa7;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Represents an amount less than $0.5&#160;million. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;*&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent consideration represents liabilities recorded at fair value in connection with acquisitions. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva determined the fair value of the liabilities for the contingent consideration based on a probability-weighted discounted cash flow analysis. This fair value measurement is based on significant unobservable inputs in the market and thus represents a Level&#160;3 measurement within the fair value hierarchy. The fair value of the contingent consideration is based on several factors, such as: the cash flows projected from the success of unapproved product candidates; the probability of success of product candidates, including risks associated with uncertainty regarding achievement and payment of milestone events; the time and resources needed to complete the development and approval of product candidates; the life of the potential commercialized products and associated risks of obtaining regulatory approvals in the United States and Europe, and the risk adjusted discount rate for fair value measurement. A probability of success factor of 100% was used in the fair value calculation to reflect inherent regulatory and commercial risk of the contingent payments and IPR&amp;amp;D. The discount rate applied ranged from 8.3% to 11.2%. The weighted average discount rate, calculated based on the relative fair value of Teva&#x2019;s contingent consideration liabilities, was 8.8%. The contingent&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;consideration is evaluated quarterly, or more frequently, if circumstances dictate. Changes in the fair value of contingent consideration are recorded in consolidated statements of income. Significant changes in unobservable inputs, mainly the probability of success and cash flows projected, could result in material changes to the contingent consideration liabilities. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt; &lt;div style="top: 0px; letter-spacing: 0px; font-family: 'Times New Roman'; font-size: 10pt; display: inline;"&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the activity for those financial assets and liabilities where fair value measurements are estimated utilizing Level&#160;3 inputs: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six&#160;months&lt;br/&gt;ended&#160;June&#160;30,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six&#160;months&lt;br/&gt;ended&lt;br/&gt;June&#160;30,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value at the beginning of the period&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(175&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(258&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Redemption of debt securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bifurcated embedded derivatives&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Adjustments to provisions for contingent consideration:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Actavis Generics transaction&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(92&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;22&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Eagle transaction&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Settlement of contingent consideration:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Actavis Generics transaction&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Eagle transaction&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;46&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 75%; white-space: nowrap;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;Additional contingent consideration resulting from Novetide acquisition*&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 75%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value at the end of the period&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(204&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(204&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 75%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;/div&gt; &lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="width: 26%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xa7;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Represents an amount less than $0.5&#160;million. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;In January 2022, Teva acquired 100% ownership of Novetide Ltd. (&#x201c;Novetide&#x201d;), which was previously accounted for as &#x201c;investment in associated &lt;div style="display:inline;"&gt;companies.&#x201d; This&lt;/div&gt;&#160;transaction was accounted for as a business combination. Total consideration for the transaction included cash and certain contingent royalty payments through 2034. As part of the transaction, Teva recognized a gain under &#x201c;Share in (profits) losses of associated companies, net&#x201d;, reflecting the difference between the book value of its investment in Novetide and its fair value as of the date Teva completed its acquisition. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments not measured at fair value &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments measured on a basis other than fair value mostly consist of senior notes and convertible senior debentures (see note 7) and are presented in the table below in terms of fair value (level 1 inputs): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated fair value*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes and sustainability-linked senior notes included under senior notes and loans&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,481&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,477&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes and convertible senior debentures included under short-term debt&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,702&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,426&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,183&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;22,903&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;div style="width: 26%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value was estimated based on quoted market prices. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; </us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="P01_01_2022To06_30_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial items carried at fair value on a recurring basis as of June&#160;30, 2022 and December&#160;31, 2021 are classified in the tables below in one of the three categories of fair value levels: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money markets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;451&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;451&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash, deposits and other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,607&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,607&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment in securities:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted cash&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;33&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;33&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivatives:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Asset derivatives&#x2014;options and forward contracts&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;69&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;69&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liability derivatives:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Options and forward contracts&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(37&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(37&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bifurcated embedded derivatives&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent consideration*&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(205&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(205&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,106&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(204&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,934&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 71%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money markets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;220&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;220&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash, deposits and other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,945&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,945&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment in securities:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted cash&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;33&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;33&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivatives:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Asset derivatives&#x2014;options and forward contracts&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liability derivatives:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Options and forward contracts&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(23&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(23&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bifurcated embedded derivatives&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent consideration*&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(176&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(176&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,222&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(175&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,054&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="width: 26%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xa7;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Represents an amount less than $0.5&#160;million. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;*&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent consideration represents liabilities recorded at fair value in connection with acquisitions. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn06_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">451000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn06_30_2022_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">451000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn06_30_2022_DemandDepositsMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      unitRef="Unit_USD">1607000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn06_30_2022_DemandDepositsMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">1607000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn06_30_2022_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      unitRef="Unit_USD">10000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn06_30_2022_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">10000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn06_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">5000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn06_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn06_30_2022_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">6000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:RestrictedCash
      contextRef="PAsOn06_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      unitRef="Unit_USD">33000000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">33000000</us-gaap:RestrictedCash>
    <us-gaap:DerivativeAssets
      contextRef="PAsOn06_30_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_InterestRateSwapMemberusgaapFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">69000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="PAsOn06_30_2022_InterestRateSwapMemberusgaapFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">69000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn06_30_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-6"
      unitRef="Unit_USD">37000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn06_30_2022_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-6"
      unitRef="Unit_USD">37000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn06_30_2022_CrossCurrencyInterestRateContractMemberusgaapFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:DerivativeLiabilities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn06_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      id="Fact_52307481"
      unitRef="Unit_USD">205000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      id="Fact_52307482"
      unitRef="Unit_USD">205000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="PAsOn06_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      unitRef="Unit_USD">2106000000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="PAsOn06_30_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      unitRef="Unit_USD">32000000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="PAsOn06_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      unitRef="Unit_USD">-204000000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">1934000000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">220000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2021_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">220000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2021_DemandDepositsMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      unitRef="Unit_USD">1945000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2021_DemandDepositsMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">1945000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn12_31_2021_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      unitRef="Unit_USD">18000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn12_31_2021_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">18000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">6000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn12_31_2021_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">7000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:RestrictedCash
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      unitRef="Unit_USD">33000000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">33000000</us-gaap:RestrictedCash>
    <us-gaap:DerivativeAssets
      contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_InterestRateSwapMemberusgaapFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">30000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="PAsOn12_31_2021_InterestRateSwapMemberusgaapFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">30000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-6"
      unitRef="Unit_USD">23000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2021_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-6"
      unitRef="Unit_USD">23000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2021_CrossCurrencyInterestRateContractMemberusgaapFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:DerivativeLiabilities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      id="Fact_52308001"
      unitRef="Unit_USD">176000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      id="Fact_52308002"
      unitRef="Unit_USD">176000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      unitRef="Unit_USD">2222000000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      unitRef="Unit_USD">7000000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      unitRef="Unit_USD">-175000000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">2054000000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="PAsOn06_30_2022_MeasurementInputProbabilityOfSuccessMemberusgaapMeasurementInputTypeAxis"
      decimals="0"
      unitRef="Unit_pure">100</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="PAsOn06_30_2022_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis"
      decimals="1"
      unitRef="Unit_pure">8.3</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="PAsOn06_30_2022_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis"
      decimals="1"
      unitRef="Unit_pure">11.2</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="PAsOn06_30_2022_WeightedAverageMembersrtRangeAxis"
      decimals="1"
      unitRef="Unit_pure">8.8</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="P01_01_2022To06_30_2022">The following table summarizes the activity for those financial assets and liabilities where fair value measurements are estimated utilizing Level&#160;3 inputs:
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six&#160;months&lt;br/&gt;ended&#160;June&#160;30,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six&#160;months&lt;br/&gt;ended&lt;br/&gt;June&#160;30,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value at the beginning of the period&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(175&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(258&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Redemption of debt securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bifurcated embedded derivatives&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Adjustments to provisions for contingent consideration:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Actavis Generics transaction&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(92&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;22&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Eagle transaction&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Settlement of contingent consideration:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Actavis Generics transaction&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Eagle transaction&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;46&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 75%; white-space: nowrap;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;Additional contingent consideration resulting from Novetide acquisition*&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 75%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value at the end of the period&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(204&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(204&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 75%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xa7;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Represents an amount less than $0.5&#160;million. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;In January 2022, Teva acquired 100% ownership of Novetide Ltd. (&#x201c;Novetide&#x201d;), which was previously accounted for as &#x201c;investment in associated &lt;div style="display:inline;"&gt;companies.&#x201d; This&lt;/div&gt;&#160;transaction was accounted for as a business combination. Total consideration for the transaction included cash and certain contingent royalty payments through 2034. As part of the transaction, Teva recognized a gain under &#x201c;Share in (profits) losses of associated companies, net&#x201d;, reflecting the difference between the book value of its investment in Novetide and its fair value as of the date Teva completed its acquisition. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">175000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">258000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="P01_01_2022To06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">-9000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <teva:BifurcatedEmbeddedDerivatives
      contextRef="P01_01_2021To06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">0</teva:BifurcatedEmbeddedDerivatives>
    <teva:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod
      contextRef="P01_01_2022To06_30_2022_ActavisGenericsMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">-92000000</teva:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod>
    <teva:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod
      contextRef="P01_01_2021To06_30_2021_ActavisGenericsMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">22000000</teva:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod>
    <teva:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease
      contextRef="P01_01_2022To06_30_2022_EagleTransactionMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">-2000000</teva:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease>
    <teva:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease
      contextRef="P01_01_2021To06_30_2021_EagleTransactionMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">-7000000</teva:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="P01_01_2022To06_30_2022_ActavisGenericsMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">30000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="P01_01_2021To06_30_2021_ActavisGenericsMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="P01_01_2022To06_30_2022_EagleTransactionMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">46000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="P01_01_2021To06_30_2021_EagleTransactionMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">48000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="P01_01_2022To06_30_2022_NoveTideAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">-11000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="P01_01_2021To06_30_2021_NoveTideAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">204000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn06_30_2021"
      decimals="-6"
      unitRef="Unit_USD">204000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="PAsOn01_01_2022_NoveTideAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="2"
      unitRef="Unit_pure">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="P01_01_2022To06_30_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments measured on a basis other than fair value mostly consist of senior notes and convertible senior debentures (see note 7) and are presented in the table below in terms of fair value (level 1 inputs): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated fair value*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes and sustainability-linked senior notes included under senior notes and loans&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,481&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,477&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes and convertible senior debentures included under short-term debt&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,702&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,426&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,183&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;22,903&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;div style="width: 26%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value was estimated based on quoted market prices. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn06_30_2022_SeniorNotesAndSustainabilityLinkedSeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">17481000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn12_31_2021_SeniorNotesAndSustainabilityLinkedSeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">21477000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn06_30_2022_SeniornotesandconvertibleseniordebenturesMemberusgaapLongtermDebtTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">1702000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn12_31_2021_SeniornotesandconvertibleseniordebenturesMemberusgaapLongtermDebtTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">1426000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn06_30_2022"
      decimals="-6"
      unitRef="Unit_USD">19183000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">22903000000</us-gaap:DebtInstrumentFairValue>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact_52307110"
          xlink:label="Fact_52307110"
          xlink:type="locator"/>
        <link:footnote id="FN_170208" xlink:label="FN_170208" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents an amount less than $0.5 million.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307110"
          xlink:to="FN_170208"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307132"
          xlink:label="Fact_52307132"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307132"
          xlink:to="FN_170208"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307165"
          xlink:label="Fact_52307165"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307165"
          xlink:to="FN_170208"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307391"
          xlink:label="Fact_52307391"
          xlink:type="locator"/>
        <link:footnote id="FN_170214" xlink:label="FN_170214" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Accumulated goodwill impairment as of June 30, 2022 and December 31, 2021 was approximately $26.3 billion and $25.6 billion, respectively.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307391"
          xlink:to="FN_170214"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307392"
          xlink:label="Fact_52307392"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307392"
          xlink:to="FN_170214"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307393"
          xlink:label="Fact_52307393"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307393"
          xlink:to="FN_170214"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307394"
          xlink:label="Fact_52307394"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307394"
          xlink:to="FN_170214"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307395"
          xlink:label="Fact_52307395"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307395"
          xlink:to="FN_170214"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307401"
          xlink:label="Fact_52307401"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307401"
          xlink:to="FN_170214"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307402"
          xlink:label="Fact_52307402"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307402"
          xlink:to="FN_170214"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307403"
          xlink:label="Fact_52307403"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307403"
          xlink:to="FN_170214"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307404"
          xlink:label="Fact_52307404"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307404"
          xlink:to="FN_170214"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307405"
          xlink:label="Fact_52307405"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307405"
          xlink:to="FN_170214"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307410"
          xlink:label="Fact_52307410"
          xlink:type="locator"/>
        <link:footnote id="FN_170217" xlink:label="FN_170217" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In April 2022, Teva repaid $296 million of its 3.25% senior notes at maturity.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307410"
          xlink:to="FN_170217"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307411"
          xlink:label="Fact_52307411"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307411"
          xlink:to="FN_170217"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307419"
          xlink:label="Fact_52307419"
          xlink:type="locator"/>
        <link:footnote id="FN_170218" xlink:label="FN_170218" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.125%-0.375% per annum, from and including May 9, 2026.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307419"
          xlink:to="FN_170218"
          xlink:type="arc"/>
        <link:footnote id="FN_170219" xlink:label="FN_170219" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Interest rate adjustments and a potential one-time premium payment related to the sustainability-linked bonds are treated as bifurcated embedded derivatives. See note 8d.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307419"
          xlink:to="FN_170219"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307420"
          xlink:label="Fact_52307420"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307420"
          xlink:to="FN_170219"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307420"
          xlink:to="FN_170218"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307421"
          xlink:label="Fact_52307421"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307421"
          xlink:to="FN_170218"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307421"
          xlink:to="FN_170219"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307425"
          xlink:label="Fact_52307425"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307425"
          xlink:to="FN_170219"
          xlink:type="arc"/>
        <link:footnote id="FN_170220" xlink:label="FN_170220" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">If Teva fails to achieve certain sustainability performance targets, a one-time premium payment of 0.15%-0.45% out of the principal amount will be paid at maturity or upon earlier redemption, if such redemption is on or after May 9, 2026.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307425"
          xlink:to="FN_170220"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307426"
          xlink:label="Fact_52307426"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307426"
          xlink:to="FN_170220"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307426"
          xlink:to="FN_170219"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307427"
          xlink:label="Fact_52307427"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307427"
          xlink:to="FN_170219"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307427"
          xlink:to="FN_170220"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307452"
          xlink:label="Fact_52307452"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307452"
          xlink:to="FN_170220"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307452"
          xlink:to="FN_170219"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307453"
          xlink:label="Fact_52307453"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307453"
          xlink:to="FN_170219"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307453"
          xlink:to="FN_170220"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307454"
          xlink:label="Fact_52307454"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307454"
          xlink:to="FN_170220"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307454"
          xlink:to="FN_170219"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307455"
          xlink:label="Fact_52307455"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307455"
          xlink:to="FN_170219"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307455"
          xlink:to="FN_170218"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307456"
          xlink:label="Fact_52307456"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307456"
          xlink:to="FN_170218"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307456"
          xlink:to="FN_170219"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307457"
          xlink:label="Fact_52307457"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307457"
          xlink:to="FN_170219"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307457"
          xlink:to="FN_170218"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307481"
          xlink:label="Fact_52307481"
          xlink:type="locator"/>
        <link:footnote id="FN_170209" xlink:label="FN_170209" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Contingent consideration represents liabilities recorded at fair value in connection with acquisitions.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307481"
          xlink:to="FN_170209"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307482"
          xlink:label="Fact_52307482"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307482"
          xlink:to="FN_170209"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307503"
          xlink:label="Fact_52307503"
          xlink:type="locator"/>
        <link:footnote id="FN_170215" xlink:label="FN_170215" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Teva uses foreign exchange contracts (mainly option and forward contracts) to hedge balance sheet items from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, Teva recognizes gains or losses that offset the revaluation of the balance sheet items also recorded under financial expenses, net. [Ruble -to check 10K language]</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307503"
          xlink:to="FN_170215"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307504"
          xlink:label="Fact_52307504"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307504"
          xlink:to="FN_170215"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307505"
          xlink:label="Fact_52307505"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307505"
          xlink:to="FN_170215"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307506"
          xlink:label="Fact_52307506"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307506"
          xlink:to="FN_170215"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307507"
          xlink:label="Fact_52307507"
          xlink:type="locator"/>
        <link:footnote id="FN_170216" xlink:label="FN_170216" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on projected revenues and expenses recorded in euro, the Swiss franc, the Japanese yen, the British pound, the Russian ruble, the Canadian dollar and some other currencies to protect its projected operating results for 2021 and 2022. These derivative instruments do not meet the criteria for hedge accounting, however, they are accounted for as an economic hedge. These derivative instruments, which may include hedging transactions against future projected revenues and expenses, are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. In the first six months of 2022, the positive impact from these derivatives recognized under revenues was $35 million. In the first six months of 2021, the positive impact from these derivatives recognized under revenues was $13 million. Changes in the fair value of the derivative instruments are recognized in the same line item in the statements of income as the underlying exposure being hedged. The cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307507"
          xlink:to="FN_170216"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307508"
          xlink:label="Fact_52307508"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307508"
          xlink:to="FN_170216"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307509"
          xlink:label="Fact_52307509"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307509"
          xlink:to="FN_170216"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307510"
          xlink:label="Fact_52307510"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307510"
          xlink:to="FN_170216"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307515"
          xlink:label="Fact_52307515"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307515"
          xlink:to="FN_170215"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307516"
          xlink:label="Fact_52307516"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307516"
          xlink:to="FN_170215"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307517"
          xlink:label="Fact_52307517"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307517"
          xlink:to="FN_170215"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307518"
          xlink:label="Fact_52307518"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307518"
          xlink:to="FN_170215"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307519"
          xlink:label="Fact_52307519"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307519"
          xlink:to="FN_170216"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307520"
          xlink:label="Fact_52307520"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307520"
          xlink:to="FN_170216"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307521"
          xlink:label="Fact_52307521"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307521"
          xlink:to="FN_170216"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307522"
          xlink:label="Fact_52307522"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307522"
          xlink:to="FN_170216"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307555"
          xlink:label="Fact_52307555"
          xlink:type="locator"/>
        <link:footnote id="FN_170213" xlink:label="FN_170213" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Including impairments related to exit and disposal activities.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307555"
          xlink:to="FN_170213"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307556"
          xlink:label="Fact_52307556"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307556"
          xlink:to="FN_170213"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307557"
          xlink:label="Fact_52307557"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307557"
          xlink:to="FN_170213"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307558"
          xlink:label="Fact_52307558"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307558"
          xlink:to="FN_170213"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307612"
          xlink:label="Fact_52307612"
          xlink:type="locator"/>
        <link:footnote id="FN_170212" xlink:label="FN_170212" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes adjustments for foreign currency translation.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307612"
          xlink:to="FN_170212"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307613"
          xlink:label="Fact_52307613"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307613"
          xlink:to="FN_170212"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307614"
          xlink:label="Fact_52307614"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307614"
          xlink:to="FN_170212"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307617"
          xlink:label="Fact_52307617"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307617"
          xlink:to="FN_170217"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307618"
          xlink:label="Fact_52307618"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307618"
          xlink:to="FN_170217"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307619"
          xlink:label="Fact_52307619"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307619"
          xlink:to="FN_170217"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307779"
          xlink:label="Fact_52307779"
          xlink:type="locator"/>
        <link:footnote id="FN_170211" xlink:label="FN_170211" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Amounts do not include a $68 million loss from foreign currency translation adjustments attributable to non-controlling interests.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307779"
          xlink:to="FN_170211"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307780"
          xlink:label="Fact_52307780"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307780"
          xlink:to="FN_170211"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307781"
          xlink:label="Fact_52307781"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307781"
          xlink:to="FN_170211"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307826"
          xlink:label="Fact_52307826"
          xlink:type="locator"/>
        <link:footnote id="FN_170210" xlink:label="FN_170210" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Amounts do not include a $150 million loss from foreign currency translation adjustments attributable to non-controlling interests.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307826"
          xlink:to="FN_170210"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307827"
          xlink:label="Fact_52307827"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307827"
          xlink:to="FN_170210"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307828"
          xlink:label="Fact_52307828"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307828"
          xlink:to="FN_170210"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307829"
          xlink:label="Fact_52307829"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307829"
          xlink:to="FN_170210"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307908"
          xlink:label="Fact_52307908"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307908"
          xlink:to="FN_170212"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52307958"
          xlink:label="Fact_52307958"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52307958"
          xlink:to="FN_170211"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52308001"
          xlink:label="Fact_52308001"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52308001"
          xlink:to="FN_170209"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52308002"
          xlink:label="Fact_52308002"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52308002"
          xlink:to="FN_170209"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52308225"
          xlink:label="Fact_52308225"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52308225"
          xlink:to="FN_170212"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52308226"
          xlink:label="Fact_52308226"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52308226"
          xlink:to="FN_170212"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52308383"
          xlink:label="Fact_52308383"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52308383"
          xlink:to="FN_170218"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52308383"
          xlink:to="FN_170219"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52308385"
          xlink:label="Fact_52308385"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52308385"
          xlink:to="FN_170219"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52308385"
          xlink:to="FN_170220"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52308389"
          xlink:label="Fact_52308389"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52308389"
          xlink:to="FN_170217"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52308397"
          xlink:label="Fact_52308397"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52308397"
          xlink:to="FN_170219"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52308397"
          xlink:to="FN_170220"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_52308398"
          xlink:label="Fact_52308398"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52308398"
          xlink:to="FN_170218"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_52308398"
          xlink:to="FN_170219"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>84
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M[0B+R@N3%9EIKJM7Q0G%-[0U4NOZ%+?M'=DX@351;)%,OO@>M9(,5SQ!9OL
MQ<U[GS,9Q^"W,RV]]PLRRS<%Y'NF4\T3'U)825@HMW-ELS'=]"FE3MMMN6VH
MM4T5EVT&%'?P>:@C0>224/;3XF<R$UZF +22 U>"EJM"CR?D#NH!^@ILBW<#
MO""">P%L>_/M1I*7BDP$^:Y@R.5K6)IM'Z&X_4-/\_-*_(P7,JH<Q0D!\!Z,
MQ+8-BCO]/I-D].$%/%F)XVZ("SV]S4;8=M0V#88;?;DX/*E@Q7+3^2_R-0L%
MH* T,S!!4Z)^)>8)]4D3@[1-A)W51.Y#J,JG+%X(5<F"BS@.K5.77K4P)-LC
MV%D]8N#[4+Y0S+L+,@E-#2?5R<(E*6N1NPW, 7G@3V(3?OW28?3J&X?9N,28
M;?=@N-WOF.?\@XQ]L^26L#3SK1Z25%S2<>I.\8,1VB;"SFHB95:'Y@[*<"ZW
M224=+C<7$1ELP@W&9ML(.ZN-E&Q3"?X<D3_"]?'5@2NZUZV6P]#,V5;"SFHE
M-G/%PJVDPI7&$PS(]A"&.W\^=0,E^/'LX *H=5CO9[AU3V2^/P],:T&J'!>Y
MIJTZK$64R/8 AEOW@9F!OX+/KN21><)U)EQ!_QAXG@ AD/$+2>PTP7:%)N[;
MLYA'!L_NXF"/LN9))><)K5/_#C9M&VB>U09&L*=8&:9?0$$'*!HN>!+-MH/F
M6>U@%H@H0H%PF:- C8/S+S/\_)0O)9Y9Y<516/FT/$D<%.=G]O7B&/*1F^RE
M)!)+"'4NK\"D5'&R5]QHN<Y/TQ92:QGGEX'@OE#F!?A\*:7>WY@O*,]7^_\
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M0SU54=][U@^*;ZN+O3E7BA?5QPVCNG\:@/Y]Q;DZ/)@!CK?/DW\ 4$L#!!0
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MM,OXZE]O5O\$XI(K+]B)0<2ZS#U=E\E U+%TL2Z3K7A=9MM"A> #9M04J[<
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M&UK&_I7U)Y816+H=)S5\TJ7UJ;0=6MU0.?:OKA]H3--\5S=A\;J!\L. HX#
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M4=-"1ATN[<T[ZN)YR7B5U3[]BILLN[]?B"KZ8)M.&1XTRN1_>=OE84OAJ'Q
M8=(I3)+?V5#R\HT,<GKB[(UP+ TT7J10DS:<4X:+<A4<;A7TPO1,>N6%70B4
MU),)DG-U,@J 9H%1U<&<99C) S"'XH,U8>7%'Z:F^O_Z([C4^S6Y\^ML\BC@
MG]$,Q7XY$)-R,GD$;[^/<S_A[3\5Y\56G.*?V=P'!V;\NRODC'BP&Y&[Y=BW
MLJ+3(N7.K:F8OG@^/BQ?/^+O0>_OP6/HOUZ7QV$^VD!B+%X\/YJ,QZ_%3M3C
M9W*X^T9\61'ZIK)-*\U&F:6(1L9:!:I%98VW6M62-PMEI*F4U,)#D]"TP8N5
M7).8$QG&;*6#'" #(+ULB'L)%J5/)]*8".TG08?B?8:PK3+L(3QNI,'XX.M!
MNMKI#'J=!X&06@O#[:QAL\9Q%9WCR&3]'=V6A0U5Y#UFE A6+*1R>I.Q?L)O
MK5=YMB0HCTF0<HB1Z5("T^X+K9%@3J4R>8JRBC*5CN@5+("*3'R.T@5B4Y?4
M6A<X63QXQ+C<^\P_?XD-2;='L-4EH766'>W*AA1S('SQ9!X'6UG#\IJ\(!\4
M?"/<?8_U,F>" Y,>$[O-X8259/F-D(L%IY.-N>0N#,G&1I,S !UB*UK)N=)(
M$L/2CZC"9@"%-9E(&9UN\7WQW<:13B[7RE?:^NB(P1!-0&3L:L9-LEO0=]EM
M(^Z40=$XYXGTKU[[G\+IXP07O$VI4C6Y% IA9QM5"=6T6E7W->3+\T_?WK_9
M&_^^8X%ZO*6YBTP9'E@#<1F]5U)H&0V^H\@-5WPM?<?9K]<.'TP:BED/S\7*
MZZ?(,$CA[N8;");0PLH1I7B]NA5-'L[$PUE@M%(_6@7Z$@T1>LXKV%2F3L&O
MDT-WAE+M*QMUC:Y.=:L2O3J+2+!RW!V^ M68JD-Q3BX@SIX9ROP:/>]X9W'.
M,G 0]6+>L:NRKD5L11V)^],!N@8]D$OT-C)1\?A:TO8 @D=5S-2*/L^QI'9/
MVN&S^5!<J:51"X3.3,/8BXEW:'-P 31#+1@;"9*U;1/CMX0<J(-B=P& $;.X
MQ$3A+)=Y,+V=79T)A6Z"YNSJ:[K9*P_%P:MR;U+^QCH?I*M63ZH<W'O2W3WH
MR"!E;$.A]QE6/MHU-7-P'G#C!PV-]\8E2W^J@OT%X?)HUV=OM/4T:<@MTP/,
MB^1M?J7TI_T;;Y:?-O?B^8&(W"P5**YI =5R^.IE(5Q^=.5-L&UZZ,QMP+,I
M+5=XIY)C =PO+&C4;=A __*=_@=02P,$%     @ IX#[5)<'26GE"0  >AD
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M83U46/#$/(J--4AGPYV .=X$+/96+*45S,XYE*1B@5PMR1Z6:(O]&LRO+,"
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M*%?^6;38)#;>!?Q@T.FC/;&9[*1\M,9UL?)#*P@XY,8R4%R>X!PXMT0HX]?
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MS.C5OS)5!?%0#I]&7\8RU *0/!M'!\2=CW<O/F!!"\Z.3X1](17O2FD]NBY
M!AOMS>*T<R2/'^XNQ</6P"D9[;EKJ=HAO!%ED89A115VM<R+JJ MK:1->;\
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M5$\2Q(/D@P\0!PK^'':()YE7BLS0P4.F!&@H.96A^\HWB=(FM86*-LAT.6
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M0ZU>43;$]TK41Z*NRER1-A+,K5F\=43(H@3E&1)K0OW/SP]-I E?X,TZGWA
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M9R<]# ?\<2O>!%OR!Z69#<$6_'.I)'B;-N#YW")K]0T=T'YAO/D/4$L#!!0
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MX4'3G9#*%XW"?.3@LGUD-VREHONTH/JE).P5%?!;@XWH3YE-B1TT"L*0^6K
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M%*4-^#XS %-\( ;MWU)>_0U02P,$%     @ IX#[5*O/DAH] P  \0<  !D
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M0$1 9&K'&&UAX2,N.:5V.=7IKG@10!YP62A%3RX+76 ?(F$(K8*.1NE$Y)_
MLRCI@3:"T"VEWCWV"9Q MVL[1X$O"EH=,3DC#^Y%A 2))8P38,@4GW[QIGBR
MTA?E'Q-X +(DYB#*V _UE[JYKC. MFW3&<RU9VZSA0B5QL $FPA*!$-33*W7
MP'*Q=P(S4S4+1-FV$/*)QU9C3*]=$+AW0"V8GPV65E#R80K .:X(73<M($6
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MI?F;"G07KBPK.[F'.MD\$>?*6N.Z8%HCO=[#HI)\G-;T#R--YRH'MY--,?C
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MRYTTS"R8,GKYHT)HE<QSO91S);+<)Z,'V#PZP\]D3#]#_,R&O6<0!L*# BM
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M3^9ES?"-8_C2Y((:PTN>4_=P8) DGB&8KV'\?+^VUX.+6C6N.!_T,#N85I=
M8[$F=5>[WEROC[0@J4_KTS7K?,.(>V]Z4GE'B(OP4FDL('*EX'+3ZWN-R6/>
MX^5_-$Y+BQ*(] Q-)?%'QC-X6#/L4K;OTL?JE4;3KEXD>EBO+"((^ SZQ!8*
MI++.)]$4: %.R"3JZ0+.12BUJJ'L2)<WF >9OP>KD8N"MJ]_\2<^IFTI'C:
M5/*'')\IK1!2;OXW3(\^SAP9S<F\R]PT:3>$S/K4)?/Y5U)]=LAT?_H*@F=
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M[A,+1+M &+_M1L;+2]G(\[.JO&,5S88U^F)"-:OAG"XH*;=-A:<:ZYKS6[4
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M;KXN<7U7%4W \WF)^W'[@S;H_]]R_E]02P,$%     @ IX#[5$U<[C"="
M-!<  !D   !X;"]W;W)K<VAE971S+W-H965T,C0N>&ULO5A9<]NV%G[7K\"H
M24;.J!))K5YG;,?I32=M,G9R[S-$0A)JDF  T(KZZ^]W (JBM7BZ3/O"!<#9
MOW-P@(N5TH]F*81EW[,T-Y?MI;7%6;]OXJ7(N.FI0N28F2N=<8M?O>B;0@N>
M.*(L[4=!,.YG7.;MJPLW]EE?7:C2IC(7GS4S999QO;X1J5I=ML/V9N!>+I:6
M!OI7%P5?B =AOQ:?-?[Z-9=$9B(W4N5,B_EE^SH\NQG0>K?@OU*L3..;D24S
MI1[IYT-RV0Y((9&*V!('CM>3N!5I2HR@QK>*9[L6283-[PWW]\YVV#+C1MRJ
M]'\RL<O+]K3-$C'G96KOU>H_HK)G1/QBE1KW9"N_-AJT65P:J[**&!ID,O=O
M_KWR0X-@&APAB"J"R.GM!3DMWW'+KRZT6C%-J\&-/IRICAK*R9R"\F U9B7H
M[-5[+C5[XFDI6":X*;6 Q^U%WX(WK>C'%9\;SR<ZPF?,?E&Y71IVER<B>4[?
MATZU8M%&L9OH188_EWF/#8(NBX(H>H'?H#9TX/@-_[:A+_*A)#DS!8_%91M9
M8(1^$NVK7S]]N6/AF+WY81J%X3D[+.R,O9<YSV/)4R:MR R+N=92)(Q;-M^2
M$%@!^+C$9+X@T$G#N&%JSN 547N%\3QA[T0LLIG0;!"ZT9!Q+5B<<F/DG'C+
MG-FE8);/4F'8C-*0QA08@:&;6FH!$F[%0D$=)ZBA3BJ>1&K.6L]DMS[2* N9
M?T?5>\"^*,O35N=K[Z''7I&@3*8I\L^<M&ZY63J=8_H0WTH) ? +> ,\8@U<
MZT=A#>B&HQ!/Y\[H_-D79ARC+G*O4$9B.;%4,$2SL#L.)O7BS=N-MC[D3\)8
MB@-I9<B]TL+:L]8=-+'KQA +@WTF0>N3DS':#K%QZQX\M8RMJ*P:#/8H!X/6
M.Z%A*]4?B+LV!L4VV0Y5"U5!=<J;@VJ[XAH\D50:E<O4W,:GC<_61\EG,B7M
MDZ:(3W^(56<P82?/_UHW<EYJ@D+""%8)DKG)>L^X-S^$XTG]V[J%$&"6G QY
M1H*4DRIO]P@[43""=/]J.=0@NE$W#,9X#R(\,#?$DE<(X.E@V-I#^C^,P2@*
MCF 0,R]A\'0X.H!!C/XY#$[WF4PK#(X;&)S\^Q@<!(W/OXG!:-#$(/W]<QA\
MM8_"<#(F%+I7A<*H&T4$OPE!,)R,' 2C;C :MBI)]\*5_MS%G?%,E9"%ZFI0
M2C'P*NB--I#KM=ZR8PJAQM=\TLJ)%'F4?J63O6T!B %Y7K4S*VD!Y!BP ?[(
MT3WV13QQ.,H*C48!Y%3;F]N*K_9-28B+&XN/:4@-3^(WI$*K617H'U>NV:&P
M2!.3]1OHS6EWX3E/U]BSH-$2.]?\X&;(,%-S-W*18[>*.<;+7,UH6Z7]"C87
M);Q3[6$^-QVB[+(T3?_Q.OF;,LA)%6U#BZ6$>3I>KDG!0RXZZHYG.D.>!ESF
MP+/2IHN^-D9$S)EGL?&&(<?])EQVSK7*W"R6Q@07R"MS7F#%$Z;Q2LH8,F&@
M3(!_<^Y6-SQ/% WB?8HN?!6G94*-@Y;FD1H'H]!RD'R'F3*/A;9HU\%-BP72
MDM;R&%YY\EXC_Q9\[;XA!$A&@:%^ 0O@:Z^416ON5B(""ND*-.5"$&JM@M>R
M(@40W<J$ J.*FK6W%YX[:,!Y!=)Y'8U"69!2TP2VF=#4/\G?M_[R):9AIK<;
MU&I&=CI7B$69<L1I78NO4?4UET3U8$F\XW57:IQZNA70A&/(>/(;VO$&YAE
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M:(V+B1R'B=*#+%=VDVB[S>AA@GJQZQC]Q84_%3E?-?-7&11:'UKC4 472]@
MF=4NC#GL*%:Z$N(GD4V0 PF&=8P0;C&;G/@&0%/Q<Y':N?787GI0:[Q[O=%)
MJU.DKQ(G.(O5I62[[.WV^J-Y#FVY>QAW&#U81AYVC3+(8!3K32.=ROR1=H#F
M,M_ 42'+ ?I]OZ0*:4.GXDEW.*5KDBCL#B>3?5DO.W!7S%)I^R,YR->LL#L)
M(CR'T;@^G8>GW7 Z< ?@[FDP -IW^F="Y[80U]O]MU+1?]6^%Z@,M%4<NM3K
M-VXRT<@LW'TM]0$ N;_4K$?K*^%K?Q.Z7>[ODW_A&@4;)RLQ!VG0FXS:Z(G<
M':W_L:IP]Z(S9:W*W.=2</B"%F!^KJ!U]4,"ZHORJ_\#4$L#!!0    ( *>
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M>P!9!\BB[K905/F%>SX96;,&&[*)+02QU8@F<5*'C[+PEDXEX?QDQIUT8%9
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M#N%70@&X#3=^@1[+=^AEC^B)=(/>B!_!2"%X!90EE!OTI(CH*<)-H@Z('FI
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M ^Z--:#=IAJYX\&3V@]VZ]=F&NK4>U/5,UU78>/KI;8+_&/VD3;XM>W</K_
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MI K#)3ZAC:4-^/^\QZ_NS80NV#W*S_\&4$L#!!0    ( *> ^U1$_30B=P(
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M60"Z:[9N857M"WRO++6+GY;T/J%V#K1?*&6/"W? \.*M_P)02P,$%     @
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MAWF2>8.%29X,1IKD9&1A'L]HG85'Q7QR97B%H'B#%K)Y#%D1 TL22(H<TJR
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M[6B*A>6!/AMHO ,]WVOM+AL?H/L0K?\#4$L#!!0    ( *> ^U3@E:7%:00
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MP*3R0-5%83TP<NL*L;DT6-:Y[@;K:*[L IQ?232B&=@-VLI\^@]02P,$%
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M#@D</;E"TXY#YUSSC,8R'#"X#;Z=*8&]M7>F=-1#B,#J@17DNA9N? ]8'D2
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M;EI!J\DT7H#SE5)VNT #??.Z_ =02P,$%     @ IX#[5(L"8Q[: P  ;PH
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MUT^G S'H!NZR^<+PP.CL9)G.U;TRWY:W%:Y&O95I5JBRSG1)E9J=#L;BTWG
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M-O788T3@]LZAM6\ZUETR.-KX](#JG-L/++Q?0/Z;KQ#]:/\-9]Q\NEA/;SX
M8?^?9V6-EYL9EKI'$:2O:CZJ-!=&+^V'C$=MC"[LZ4*E4U7Q!-R?:6VZ"WY
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MJ;)6I6XX%QR^H /8GREH74Y(0/4'Z/1O4$L#!!0    ( *> ^U0][4.I" H
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M&4C3)9C.1)8GQ6F.)%^DQ+'G.22FDYA!8B:)621FDY@S>/.CQR7'\TC,)[&
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MZG9T37XS[H-N]28WCDXFM-T<U0Q4,U'-0C6[TIJ_Z-><)#OHB"ZJ>:CFHUJ
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MEM>=XFSO:Y+GR7SU<"+BD4C+%Q3??TB2?/VD'. Y2;^M-O_F_U!+ P04
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MW%"+A]H9T/>54O8P<1LT36/Z#5!+ P04    " "G@/M4CZGCCF0"  "(!0
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MYMWER[+YUWO9:B<C[^ZIK/+5MG%]!*LTV_R?_+8]$7L-:@[=@&T;,+M!T-&
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M:J=O>ALD9?Z8W1?R._233G,^WLC-O51@D QW-#1*QM+6=\L)J'%T2AQ4QG)
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MR3""9S1-4AZ,S#2ATU9@9XJ,KU%.E_<C)SCC:) *9G$XP/&D2X"C'/_B*,.
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M%E#OUXS)IXG^#M!\]TE^ %!+ P04    " "G@/M4*C&I;R '   Y/P  &0
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M[^EPNC/JFN^,\T!G)?:P2* LZDY7<PW8/M>@[<3<-.L#_.7U 3OVX%X!.M$
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M$D*&N7$,Q"X[7"!CCLBF\;OG#(9?.N"Q?6#_Z+5;+1NB<2'9#UJ8:AJ\#Z#
M+6F8N9?M9^SU7#N^7#+MO]#VL5$ >:.-Y#W89L"IZ%;RU-?A"#"^>@$0]X#X
M7P%)#_"5"[O,O*PE,21+E6Q!N6C+Y@Q?&X^V:JAPM[@VRIY2BS/9)RF+EC(&
ME[#N+A+D%A85$25JH ),A; @2NVI*&'&92.,BQAPFSVLL;3W:N!\191=*S0T
M)^P"SI=H"+7&)3RLEW!^=@%GCG)N<?8*=1H:J\#E$>9]MO,NV_B%;+\T8@1)
M] [B*(Y/P!>OPY>86_C8P\?/X:&MVU"\>"A>[/F2OQ7OYU=[ G<&N?YU2E5'
M<W6:QC7JK:Y)CM/ =J)&M<,@>_MF/(D^G-+XG\B>*4X&Q<EK[-DLSQO>,&*P
M@/*@GO*:4.6>P"GM'>&-)W0S99?%DU&2AKMC32>"KD>3(:C+-3QZYF[$?".J
MI$(#PZV%1:.;ZP!4U[:=8V3M7_Y&&MM'WJSLI$/E NSY5DIS<%PS#;,S^P-0
M2P,$%     @ IX#[5-I+*P(N!P  ^$0  !D   !X;"]W;W)K<VAE971S+W-H
M965T-#<N>&ULQ9QK;YM(&(7_RL@;K5JI&W/Q+=G$4AHSLZG6JRAM=S]$_3"Q
M)S$J%Q?&<2+MC]\!$_ 0,H7MB?HEL8'W.0,'7N-CX&0;)U_3E1"2/(1!E)[V
M5E*NC_O]=+$2(4\/X[6(U)S;. FY5&^3NWZZ3@1?YD5AT'<L:]0/N1_UIB?Y
MM,MD>A)O9.!'XC(AZ28,>?+X7@3Q]K1G]YXF7/EW*YE-Z$]/UOQ.?!3R\_HR
M4>_Z)67IAR)*_3@BB;@][9W9Q\R=9 7Y$G_[8IONO2;9JMS$\=?LS<7RM&=E
M(Q*!6,@,P=6_>W$N@B CJ7%\*Z"]4C,KW'_]1*?YRJN5N>&I.(^#?_RE7)WV
M)CVR%+=\$\BK>/N'*%9HF/$6<9#F?\FV6-;JD<4FE7%8%*L1A'ZT^\\?B@VQ
M5V"[+Q0X18%3+QB^4. 6!6Z]8/!"P: H&+15&!8%P[8*HZ)@U+9@7!2,<[-V
M6S>W9L8EGYXD\98DV=**EKW(_<VKE2-^E.V*'V6BYOJJ3DY9'"^W?A"0W\C9
M<NEGNP</R$6TV\FSG>7-3$CN!V_5$I\_SLB;@[?D@/@1F:LJ-3\]Z4LUCHS6
M7Q2:YSM-YP5-E\SC2*Y2XD5+L6RH]\SU(T-]7ZU_N1&<IXUP[AB!'S;1(7&M
M=\2Q'*=A/+/VY7;3ZOR8.OTQ=68NGXF%*K>;RK5MZ98[E)OSW._M4-=_JCGD
M0HHP_=*TC^PP@V9,UH&/TS5?B-.>:K&I2.Y%;_KK+_;(^KW)("3,0\(H$L9
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MBV6;_]Q@*0[:!>#X2J'-JN$FJ(O[\;]02P,$%     @ IX#[5*YKR#-U#
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M+A==K^$M']RQ:6;L S_NS.@41F#N9T.%,[]625D.0C,IB())U^LUSOIMBW>
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M'I1NF.&O#"@+P/6)E&8YL:=E_7,4_P%02P,$%     @ IX#[5)?@B@._!P
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M?T ^[9EQ_C!#.Z<9D^:ATGQ46H!*"[%H=>DXE70<K'FD)&'I!9/FH=)\5%J
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M,U_.&B=E=+,9JJFHIJ&:CFK&\.4NHJN+IN\!-]'K6JAFHYJ#:BZJ>:CFHUJ
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MJV:/)W!;QD5T)1RJJ:BFH9J.:@:JF:AFH9J-:L[HY9J_8>/0[Z+7]5#-1[4
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MSC%9+N_+A;(I%[N)N-PJVR^5LIW?5LKJT[-]=DWC<3O<=SQ&-175-%334<U
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MM=H^_6!_@6^K]3\>OOSW_Q]02P,$%     @ IX#[5(>I\=Z:!   YAH  !D
M  !X;"]W;W)K<VAE971S+W-H965T-3<N>&ULK9EK3^,X%(;_BI4=K4 :R*TM
M+=M6 I)J60T:-,Q%J]%^<)-3:I'$'=NE(.V/7]L):=-D#)WUE^;F\YSX?5W'
ME_&&L@>^!!#H*<\*/G&60JS.79<G2\@Q/Z4K*.23!64Y%O*2W;M\Q0"G.BC/
MW,#S!FZ.2>%,Q_K>+9N.Z5IDI(!;AO@ZSS%[OH2,;B:.[[S<^$3NET+=<*?C
M%;Z'.Q!?5K=,7KDU)24Y%)S0 C%83)P+_WSF]U2 +O&5P(;OG"-5E3FE#^KB
M.ITXGGHCR" 1"H'EX1&N(,L42;['CPKJU#E5X.[Y"WVF*R\K,\<<KFCVC:1B
M.7&&#DIA@=>9^$0W?T)5H;[B)33C^A=MRK)G,F.RYH+F5;"\SDE1'O%3)<1.
M@.1T!P150/#6@+ *"/<#>C\)Z%4!O;=FZ%<!_;=F&%0! ZU]*996.L("3\>,
M;A!3I25-G6B[=+04F!2J9=T))I\2&2>FUT5"<T"?\1-P=((NTI0HQW&&KHNR
MW2K_CR(0F&3'LL27NP@=O3M&[Q IT W),OF<CUTAWT41W:3*>UGF#7Z2UT<W
MM!!+CN(BA;0C_LH<'[X6'YOC!X9X5VI8"QF\"'D9&($?$W&*0O\]"KS [ZJ/
M.?RO=2'#/1T>=(1';P_ORA[_O^RS7\[>T#*L&V6H>>&KC1)]_R"?H6L!.?^G
MJY65H%XW2'7+YWR%$Y@XLM_EP![!F?[^FS_P_NBRR"8LL@F+;<)FEF -:WNU
MM3T3?1H_K>0W!5)$\A4F3'ZC!*(+V9=HQX5T? X%+(CH,MN(/M1LF[#()BPN
M80,-4R.#QZD?AF/W<==#2PD;'O9K#_M&#Z^W9H&TL^" CBK7CKML,](.M:W?
M$N=DY'E-=:)VH=&P620NB_1W.</1:$_E-L?O;\LTQ!O4X@V,XMTR.%'*52W^
M**.<=ZIFQ!RJVJ!=6U^6W9-MT*INZ.WKUBYS$OBAOR=<NU2O[W<+=U8+=V84
M[N.<TPP$(#DF2A[0AA$AH)"=QZ)+/2/K4/7.6NKU@E:;LYDQM@F;68(U7!O6
MK@W-_?UB 7KRL-O%,TAHD9",E*-+G-.U_ R0XE%^#2A[?LU;8\9#O1VV6NJP
MOV^MS82Q3=C,$JQA[:BV=F3^#'"&(=.CM(NU6%)IVC/Z?@/Y'%CG6,V(.]0W
MF[#()BRV"9M9@C4,]KWMY-"S-1"O2);<M4J+K-)BJ[29+5K3X9WIOV_\$]\)
M+-:ZT]4=,Q:JHT;E7[O39B/N8)MMTB*KM+BBC7:^#-YIL#\.MY6S:5^PM2_X
M]3X8_:L?_ V8R9FY-T2?J3SZOK&3-B<\V&";M,@J+;9*F]FB-1O"=L7$M[9D
MXEM=,[%*BZS28JNTF2U:T^'MPHEO7CG9<3A^PCDI].#Y/8JY(+GJM^D"W<K)
M))EG@#[(DT[OVVL+X?YP]\K\(@=;:G5MQ"IM9HM66NKN+,/GP.[UA@E'B9K=
ME(N?]=UZ4^9";T7LW;_RSR._XWZL-G'TLO\67^X W6!V3PJ.,EC(5-[IF9RL
MLG)3I;P0=*4W >94")KKTR7@%)@J()\O*!4O%RI!O;4U_0]02P,$%     @
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M#<UHTU]?F*ZR,[[PITO?,K[2_;AE_'PR74ULX[XW754-O/LRH:K]OX)\BZD
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M=(/-1(O*MCMKH:%YLL,"&F@BC0'L;X30+Q,3H&O)XW\ 4$L#!!0    ( *>
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M)Y[C>8;UK*XW=TWA_#?OP;_V?B9&OZF+?LG7?X5OP50:I5FAMS'90%@(+ 5
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MN\5UBJH=J@:*[\O[_I8K[![*QP0[2! :@.]CSM7S0#MH>M+Y/U!+ P04
M" "G@/M4$?:Z>E(&   1)   &0   'AL+W=O<FMS:&5E=',O<VAE970V,RYX
M;6R]6MMRVS80_16,FNDX,XU) -2ULF9TR]2=N/$D3?O@R0-$018;DE  R$[^
MON!%A$B"D)2R?K%%:O=@=[' .0(Y?F;\B]A2*L&W*(S%36<KY6[D.,+?THB(
M:[:CL?IFPWA$I+KDCX[8<4K6J5,4.LAU>TY$@K@S&:?W[OEDS/8R#&)ZSX'8
M1Q'AWV<T9,\W'=@YW/@0/&YE<L.9C'?DD7ZD\M/NGJLKIT!9!Q&-1<!BP.GF
MIC.%HR4>)@ZIQ5\!?19'GT&2RHJQ+\G%[?JFXR81T9#Z,H$@ZM\3G=,P3)!4
M'%]ST$XQ9N)X_/F _C9-7B6S(H+.6?AWL);;F\Z@ ]9T0_:A_,">?Z-Y0MT$
MSV>A2/^"Y]S6[0!_+R2+<F<5013$V7_R+2_$D8/",3N@W %5'7"# \X=<-7!
M:W#P<@?OW!&ZN4.:NI/EGA9N0229C#E[!CRQ5FC)A[3ZJ;>J5Q GC?)1<O5M
MH/SD9.K[^V@?$DG7X+W<4@[F+%(MMTUZX8F"V]AG$057[Y@0K\'5@DH2A*_!
M&_#IXP)<O7H-7H$@!G=!&*II%V-'JI@29,?/QY]EXZ.&\7O@CL5R*\ R7M-U
MV=]1N10)H4-",V0%_'T?7P/L_@*0BY AGL7Y[M 2#B[JBU,\W$I]']XI=W K
M:20^FVJ9C>69QTKVE)'8$9_>=-0(@O(GVIG\_!/LN;^:"M$26*DL7E$6SX8^
MF=''((Z#^!',2$ABGYJRS2!Z*42RX3U-WJ#> (^=I^,TK /]8!K=(HVN-0W5
MM"=RR/R[I1P&+JSD8!WE!W/H%3GTK#FH_5;MIC&8[SFGL?\=_,E)+%3')OOX
M=/V/VH,4,4@!'NYHM*+<V)C6(2YMS); 2M7H%]7HO^!Z[;=9EI; 2F49%&49
M_/?U.C#T.NI[E5X?U%<U',)A856*;UC$-[3&ETV57YJJ()^J,)VJ%56JBBIM
MXX=$B& 3^&F'&REK6$\$HGXE#X-1OV_. KJ:C5UK'G\H:<C.S462;T;"=<\)
MWV35&/^1FH#6^.=,;2)BQ[)],8^Z*4Y8CZ!;C;)N [L-02(=)&JAR&0CE453
M[,A08XS*T<]/Q/$ 39O&PH3=JT O3T&CSY95#[5Z@585< ;!Y0#E5>^YO>I$
M&LS@<  ;YE+K"&@7$@O*@R>2_-@ ;X-8!1F04&W20O+]:=:R8U^Z/[>%5JZ$
MEB*P^X+,!5N2)'EI_@^! [7"@7:)<Q9[Y1BE#L6HREY&JQYN:&.M.J"5O2?3
MB.V3;M7TI&91,J#F$0BIYC1K9K;)-REC OWZ7ED+WV S: A>:P-H%P>MD%9=
M/-2#-]@T!:^% [0KAXL8RPIU\:(P* C/G [2 @*U(2"LW(;JRJ Z%?,3430P
MVQG(RU/(5F)#6J@@NU Y36S(($\P="L]:;3R&M0LTA(%V?E[1F.Z"22X5^'9
M.<P.=&E/MH563EO+#?22IR6HU>.2MM#*I=%"![5P8I)CE+IQ4-74)B,(&Z0_
MTOH#V<]"VJ P^Q 7SUC]\*5!;R(M)9!=2K3!=:BN(6K;2MVD*72M,9!=8[1!
M#77YX%:9P1Y$$S,8=$F5&$X VXE!BQED%S-G$(/AG*.^R Q&$/8:YE"K%617
M*]/W\ULPE9('J[TDJY F*^R><+6T["S1JG)I"ZU\HJXU#G9?\DS=*C@N/E1O
M":U<&BUKL%W6G,42V*!9# ?K1C,\;- V6&L;;-<V[9[58=-)3.VTRV35=-J%
MCY[MV$]'VJ \7#\8J?WP,=DT38,6%-@N*-I@,FR4$K5&,EAU&WZX8:TWL%UO
M7/+##1L>PU1W;(,-;.!<K.4";D,N6#D7&TX<X-'OWHQV3\310+LF;*^R=I:G
MH*W$B[4\P78"/TV\.4#Y@6#]89K1S/,:N!<GRJ!\1[,QMK.QJNIA"U@S$#.9
MS&NX7U- P"O8=4&4/1<'R32##6<1V.1/V_S#TS9Y]+2-'#UM(Q62CUG\QF>Q
MY$Q!I@VO>H8**:[5!#1'T1N\3!"F%G".7DN(*'],WP<1:B6H6+/GD\7=XIV3
M:?JF1>7^#(Z6T'0?C>8F^P4:+4WWIW@P6JH)-WTS/+SNXNA0LY=E[@A7I"I
M2#<J;/>ZKY8+S]X_R2XDVZ4O6*R8E"Q*/VXI65.>&*CO-XS)PT4R0/$6T.1?
M4$L#!!0    ( *> ^U0@IB &#P,  )(*   9    >&PO=V]R:W-H965T<R]S
M:&5E=#8T+GAM;,5686_:,!#]*Z>LFEII;4*@%'6 1.FF,;5;U:[;AVH?3'*
MM\1F]@7:?[^S QET%+42VKZ [?@]WWOVV=>>:_/33A )[O-,V4XP(9J>AJ%-
M)I@+>Z2GJ/C+2)M<$'?-.+13@R+UH#P+XRAJAKF0*NBV_=B5Z;9U09E4>&7
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M1>VJ*/F60K>(1JDJE@?B#B9R!KQVV$KUW'H<ZJB*DJ:KF$1XDU'H4A6Y+GP
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M?]1L_JC9@K&R]=\\=Y3/]>OH.OYK0ONOHN!J'B9RX9,S(O),,!T'F,@9>%'
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MX?&*%Q5 _7XOA'PZJ$[0;D:=_P]02P,$%     @ IX#[5'_:#X/."   358
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M<VAE971S+W-H965T-S N>&ULS5=M3]LP$/XK5B9-F]0U;VTIK(W4@J8QP81
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M(UW0%*8>2EZ#VH"7O'\7CH+/'03BAD#LO,==J;^VJ>^1F=9@-*$B(V>LXL!
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M<FMS:&5E=',O<VAE970W,BYX;6RU5%%/VS 0_BNG3)I 8B1-"]M8&XF"T$"
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M+R-:G\#K"V-H$_AN[=_:[#=02P,$%     @ IX#[5+:@&$<M P  80L  !D
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M[$8<P12 !@P)@O(^>' _\K;W*:_Y>W_\!U!+ P04    " "G@/M4EXJ[',
M   3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!
M5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]I
MSI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z
M3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=
MQ_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( *>
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M15:#(FN%(FN%(FN%(FOUE;+>.;?_S_'3L^QM.[SDL^E_I.L_4$L! A0#%
M  @ IX#[5 =!36*!    L0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    " "G@/M4EZ0GT>\    K @  $0
M    @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " "G@/M4F5R<
M(Q &  "<)P  $P              @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM
M;%!+ 0(4 Q0    ( *> ^U14/.+O104  &L5   8              " @0X(
M  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " "G@/M4.)+C
M;0\(  #R(@  &               @(&)#0  >&PO=V]R:W-H965T<R]S:&5E
M=#(N>&UL4$L! A0#%     @ IX#[5.<?ENQ] @  N@8  !@
M ("!SA4  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( *>
M^U1(E#T8N@8  (D>   8              " @8$8  !X;"]W;W)K<VAE971S
M+W-H965T-"YX;6Q02P$"% ,4    " "G@/M4<39Y&0,$  #W#@  &
M        @(%Q'P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%
M  @ IX#[5*F'$HUI"0  >T\  !@              ("!JB,  'AL+W=O<FMS
M:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( *> ^U3F6*;+M (   ((   8
M              " @4DM  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"
M% ,4    " "G@/M4U7:,[C@'  #Q'P  &               @($S,   >&PO
M=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ IX#[5#4.D\NU!
M!0L  !@              ("!H3<  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM
M;%!+ 0(4 Q0    ( *> ^U27!TEIY0D  'H9   9              " @8P\
M  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ IX#[5'ZW
MZ&BP!@  X1   !D              ("!J$8  'AL+W=O<FMS:&5E=',O<VAE
M970Q,2YX;6Q02P$"% ,4    " "G@/M4[QP(-7@"   %!0  &0
M    @(&/30  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (
M *> ^U04437MN@8  &,5   9              " @3Y0  !X;"]W;W)K<VAE
M971S+W-H965T,3,N>&UL4$L! A0#%     @ IX#[5.%.X!@T"   ;10  !D
M             ("!+U<  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"
M% ,4    " "G@/M4U@4X+&,(  #@%0  &0              @(&:7P  >&PO
M=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( *> ^U2D/Y+$(PL
M *(B   9              " @31H  !X;"]W;W)K<VAE971S+W-H965T,38N
M>&UL4$L! A0#%     @ IX#[5*O/DAH] P  \0<  !D              ("!
MCG,  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " "G@/M4
M^#Y6S7HK   0AP  &0              @($"=P  >&PO=V]R:W-H965T<R]S
M:&5E=#$X+GAM;%!+ 0(4 Q0    ( *> ^U149- =/08  )H/   9
M      " @;.B  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%
M  @ IX#[5+K%IXB'"P  '2$  !D              ("!)ZD  'AL+W=O<FMS
M:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " "G@/M4T1E\U:H#  "H"P
M&0              @('EM   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+
M 0(4 Q0    ( *> ^U3#>'"[S@,  )@*   9              " @<:X  !X
M;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ IX#[5$S0T-1=
M"0  >QD  !D              ("!R[P  'AL+W=O<FMS:&5E=',O<VAE970R
M,RYX;6Q02P$"% ,4    " "G@/M435SN,)T(   T%P  &0
M@(%?Q@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( *>
M^U3/#X.X8 (  /8%   9              " @3//  !X;"]W;W)K<VAE971S
M+W-H965T,C4N>&UL4$L! A0#%     @ IX#[5*,\26X1 P  G 8  !D
M         ("!RM$  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
M    " "G@/M4#M9W/0(&  "@#P  &0              @($2U0  >&PO=V]R
M:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( *> ^U1$_30B=P(  /T$
M   9              " @4O;  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL
M4$L! A0#%     @ IX#[5!S.@[#9 @  ]P4  !D              ("!^=T
M 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " "G@/M4P1%:
M-B\#  "4!@  &0              @($)X0  >&PO=V]R:W-H965T<R]S:&5E
M=#,P+GAM;%!+ 0(4 Q0    ( *> ^U3@E:7%:00  *4+   9
M  " @6_D  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @
MIX#[5!PU9]E#!@  YA   !D              ("!#^D  'AL+W=O<FMS:&5E
M=',O<VAE970S,BYX;6Q02P$"% ,4    " "G@/M4L%P,U",$  #("@  &0
M            @(&)[P  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4
M Q0    ( *> ^U2+ F,>V@,  &\*   9              " @>/S  !X;"]W
M;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ IX#[5#"DO<3I!@
MY1(  !D              ("!]/<  'AL+W=O<FMS:&5E=',O<VAE970S-2YX
M;6Q02P$"% ,4    " "G@/M4I3!6"XH&   -$@  &0              @($4
M_P  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( *> ^U0]
M[4.I" H  +V7   9              " @=4% 0!X;"]W;W)K<VAE971S+W-H
M965T,S<N>&UL4$L! A0#%     @ IX#[5$(8(625 P  0 H  !D
M     ("!%! ! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *> ^U3[C<Y5U@,   ,2   9              "
M@<,K 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ IX#[
M5"HQJ6\@!P  .3\  !D              ("!T"\! 'AL+W=O<FMS:&5E=',O
M<VAE970T-"YX;6Q02P$"% ,4    " "G@/M4M:-MB& &  "1,0  &0
M        @($G-P$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0
M   ( *> ^U2DK"A!4 (  $<%   9              " @;X] 0!X;"]W;W)K
M<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ IX#[5-I+*P(N!P  ^$0
M !D              ("!14 ! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q0
M2P$"% ,4    " "G@/M40J^65(\#  #H"P  &0              @(&J1P$
M>&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( *> ^U2N:\@S
M=0P  'EL   9              " @7!+ 0!X;"]W;W)K<VAE971S+W-H965T
M-#DN>&UL4$L! A0#%     @ IX#[5&S0;UP#"P  _HH  !D
M ("!'%@! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " "G
M@/M4Q;?)<7D(  "@50  &0              @(%68P$ >&PO=V]R:W-H965T
M<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( *> ^U188DK#X@(  "@)   9
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M970U-BYX;6Q02P$"% ,4    " "G@/M4AZGQWIH$  #F&@  &0
M    @(':K0$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    (
M *> ^U0#J>'RL ,  .,,   9              " @:NR 0!X;"]W;W)K<VAE
M971S+W-H965T-3@N>&UL4$L! A0#%     @ IX#[5,1&Q/9O P  G@L  !D
M             ("!DK8! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"
M% ,4    " "G@/M4EFVX=)L#  "$$   &0              @($XN@$ >&PO
M=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( *> ^U2L9=$&0@0
M %D2   9              " @0J^ 0!X;"]W;W)K<VAE971S+W-H965T-C$N
M>&UL4$L! A0#%     @ IX#[5'Y+\3>C P  GPX  !D              ("!
M@\(! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4    " "G@/M4
M$?:Z>E(&   1)   &0              @(%=Q@$ >&PO=V]R:W-H965T<R]S
M:&5E=#8S+GAM;%!+ 0(4 Q0    ( *> ^U0@IB &#P,  )(*   9
M      " @>;, 0!X;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%
M  @ IX#[5'@$UJ_C!@  $RH  !D              ("!+- ! 'AL+W=O<FMS
M:&5E=',O<VAE970V-2YX;6Q02P$"% ,4    " "G@/M4PA[CE\4'  "8.@
M&0              @(%&UP$ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+
M 0(4 Q0    ( *> ^U1_V@^#S@@  $U6   9              " @4+? 0!X
M;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @ IX#[5.SM+"8I
M @  MP0  !D              ("!1^@! 'AL+W=O<FMS:&5E=',O<VAE970V
M."YX;6Q02P$"% ,4    " "G@/M4CY":%($'  #C.@  &0
M@(&GZ@$ >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( *>
M^U0>^8RF#P,  * ,   9              " @5_R 0!X;"]W;W)K<VAE971S
M+W-H965T-S N>&UL4$L! A0#%     @ IX#[5#8DVY-!!   C!(  !D
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M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "G@/M4EXJ[',     3 @  "P
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52P4&     %$ 40 N%@  (@\"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>620</ContextCount>
  <ElementCount>306</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>150</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - Consolidated Statements of Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss</Role>
      <ShortName>Consolidated Statements of Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - Consolidated Statements of Changes in Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity</Role>
      <ShortName>Consolidated Statements of Changes in Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Statement - Consolidated Statements of Changes in Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Changes in Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Basis of presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/BasisOfPresentation</Role>
      <ShortName>Basis of presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Certain transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/CertainTransactions</Role>
      <ShortName>Certain transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Revenue from contracts with customers</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/RevenueFromContractsWithCustomers</Role>
      <ShortName>Revenue from contracts with customers</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Identifiable Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/IdentifiableIntangibleAssets</Role>
      <ShortName>Identifiable Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/Goodwill</Role>
      <ShortName>Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Debt obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/DebtObligations</Role>
      <ShortName>Debt obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Derivative instruments and hedging activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities</Role>
      <ShortName>Derivative instruments and hedging activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Legal Settlements and Loss Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies</Role>
      <ShortName>Legal Settlements and Loss Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Commitments and contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/IncomeTaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Other assets impairments, restructuring and other items</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems</Role>
      <ShortName>Other assets impairments, restructuring and other items</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Earnings (Loss) per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/EarningsLossPerShare</Role>
      <ShortName>Earnings (Loss) per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Accumulated other comprehensive income (loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLoss</Role>
      <ShortName>Accumulated other comprehensive income (loss)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/Segments</Role>
      <ShortName>Segments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Fair value measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/FairValueMeasurement</Role>
      <ShortName>Fair value measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Basis of presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/BasisOfPresentationPolicies</Role>
      <ShortName>Basis of presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Certain transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/CertainTransactionsTables</Role>
      <ShortName>Certain transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/CertainTransactions</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Revenue from contracts with customers (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables</Role>
      <ShortName>Revenue from contracts with customers (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/RevenueFromContractsWithCustomers</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/Inventories</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Identifiable Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables</Role>
      <ShortName>Identifiable Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/IdentifiableIntangibleAssets</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/GoodwillTables</Role>
      <ShortName>Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/Goodwill</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Debt obligations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/DebtObligationsTables</Role>
      <ShortName>Debt obligations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/DebtObligations</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Derivative instruments and hedging activities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables</Role>
      <ShortName>Derivative instruments and hedging activities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Other assets impairments, restructuring and other items (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables</Role>
      <ShortName>Other assets impairments, restructuring and other items (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Accumulated other comprehensive income (loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossTables</Role>
      <ShortName>Accumulated other comprehensive income (loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLoss</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Segments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/SegmentsTables</Role>
      <ShortName>Segments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/Segments</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/FairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Certain Transactions - Other Transactions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail</Role>
      <ShortName>Certain Transactions - Other Transactions - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Certain Transactions - Business Acquisitions - Summary of Major Classes of Assets and Liabilities Included as Held for Sale (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail</Role>
      <ShortName>Certain Transactions - Business Acquisitions - Summary of Major Classes of Assets and Liabilities Included as Held for Sale (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Revenue from Contracts with Customers - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail</Role>
      <ShortName>Revenue from Contracts with Customers - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Revenue from Contracts with Customers - Summary of Disaggregation of Revenues by Major Revenue Streams (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail</Role>
      <ShortName>Revenue from Contracts with Customers - Summary of Disaggregation of Revenues by Major Revenue Streams (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Revenue from Contracts with Customers - Schedule of Sales Reserves and Allowances (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail</Role>
      <ShortName>Revenue from Contracts with Customers - Schedule of Sales Reserves and Allowances (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Inventories - Summary of Inventories (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail</Role>
      <ShortName>Inventories - Summary of Inventories (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - Identifiable Intangible Assets - Summary of Identifiable Intangible Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail</Role>
      <ShortName>Identifiable Intangible Assets - Summary of Identifiable Intangible Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - Identifiable Intangible Assets - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail</Role>
      <ShortName>Identifiable Intangible Assets - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure - Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail</Role>
      <ShortName>Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure - Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail</Role>
      <ShortName>Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1047 - Disclosure - Goodwill - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail</Role>
      <ShortName>Goodwill - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1048 - Disclosure - Debt Obligations - Schedule of Short-term Debt (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail</Role>
      <ShortName>Debt Obligations - Schedule of Short-term Debt (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>1049 - Disclosure - Debt Obligations - Schedule of Senior Notes and Loans (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail</Role>
      <ShortName>Debt Obligations - Schedule of Senior Notes and Loans (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>1050 - Disclosure - Debt Obligations - Schedule of Senior Notes and Loans (Parenthetical) (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail</Role>
      <ShortName>Debt Obligations - Schedule of Senior Notes and Loans (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>1051 - Disclosure - Debt Obligations - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail</Role>
      <ShortName>Debt Obligations - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>1052 - Disclosure - Derivative Instruments and Hedging Activities - Summary of Classification and Fair Values of Derivative Instruments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail</Role>
      <ShortName>Derivative Instruments and Hedging Activities - Summary of Classification and Fair Values of Derivative Instruments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>1053 - Disclosure - Derivative Instruments and Hedging Activities - Schedule Of Other Derivatives Not Designated As Hedging Instruments Statements OfFinancial Performance And Financial Position Location (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails</Role>
      <ShortName>Derivative Instruments and Hedging Activities - Schedule Of Other Derivatives Not Designated As Hedging Instruments Statements OfFinancial Performance And Financial Position Location (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>1054 - Disclosure - Derivative Instruments and Hedging Activities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail</Role>
      <ShortName>Derivative Instruments and Hedging Activities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>1055 - Disclosure - Legal Settlements and Loss Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail</Role>
      <ShortName>Legal Settlements and Loss Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>1056 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>1057 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>1058 - Disclosure - Other assets impairments, restructuring and other items - Schedule of Other Assets Impairments, Restructuring and Other Items (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail</Role>
      <ShortName>Other assets impairments, restructuring and other items - Schedule of Other Assets Impairments, Restructuring and Other Items (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>1059 - Disclosure - Other assets impairments, restructuring and other items - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail</Role>
      <ShortName>Other assets impairments, restructuring and other items - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>1060 - Disclosure - Other assets impairments, restructuring and other items - Components of costs associated with restructuring plan including costs related to exit and disposal activities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail</Role>
      <ShortName>Other assets impairments, restructuring and other items - Components of costs associated with restructuring plan including costs related to exit and disposal activities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>1061 - Disclosure - Other assets impairments, restructuring and other items - Summary of Restructuring Accruals (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail</Role>
      <ShortName>Other assets impairments, restructuring and other items - Summary of Restructuring Accruals (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>1062 - Disclosure - Earnings (Loss) per Share - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail</Role>
      <ShortName>Earnings (Loss) per Share - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/EarningsLossPerShare</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>1063 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>1064 - Disclosure - Accumulated Other Comprehensive Income (Loss)  (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss)  (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>1065 - Disclosure - Segments - Summary of Segment Profit (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail</Role>
      <ShortName>Segments - Summary of Segment Profit (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>1066 - Disclosure - Segments - Summary of Profit by Segments and Reconciliation of Segments Profit to Consolidated Income Before Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail</Role>
      <ShortName>Segments - Summary of Profit by Segments and Reconciliation of Segments Profit to Consolidated Income Before Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>1067 - Disclosure - Segments - Schedule of Revenues by Major Products and Activities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail</Role>
      <ShortName>Segments - Schedule of Revenues by Major Products and Activities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>1068 - Disclosure - Segments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail</Role>
      <ShortName>Segments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>1069 - Disclosure - Fair Value Measurement - Summary of Financial Items Carried at Fair Value (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail</Role>
      <ShortName>Fair Value Measurement - Summary of Financial Items Carried at Fair Value (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>1070 - Disclosure - Fair value measurement - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail</Role>
      <ShortName>Fair value measurement - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>1071 - Disclosure - Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail</Role>
      <ShortName>Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>1072 - Disclosure - Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail</Role>
      <ShortName>Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="d360666d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>1073 - Disclosure - Fair Value Measurement - Summary of Financial Instrument Measured on a Basis Other Than Fair Value (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail</Role>
      <ShortName>Fair Value Measurement - Summary of Financial Instrument Measured on a Basis Other Than Fair Value (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="d360666d10q.htm">d360666d10q.htm</File>
    <File>d360666dex311.htm</File>
    <File>d360666dex312.htm</File>
    <File>d360666dex32.htm</File>
    <File>teva-20220630.xsd</File>
    <File>teva-20220630_cal.xml</File>
    <File>teva-20220630_def.xml</File>
    <File>teva-20220630_lab.xml</File>
    <File>teva-20220630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="1196">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>90
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d360666d10q.htm": {
   "axisCustom": 3,
   "axisStandard": 31,
   "contextCount": 620,
   "dts": {
    "calculationLink": {
     "local": [
      "teva-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "teva-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "d360666d10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "teva-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "teva-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "teva-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 648,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 1,
    "http://xbrl.sec.gov/dei/2022": 6,
    "total": 7
   },
   "keyCustom": 78,
   "keyStandard": 228,
   "memberCustom": 97,
   "memberStandard": 52,
   "nsprefix": "teva",
   "nsuri": "http://www.tevapharm.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "1001 - Document - Cover Page",
     "role": "http://www.tevapharm.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "teva:CertainTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1010 - Disclosure - Certain transactions",
     "role": "http://www.tevapharm.com/role/CertainTransactions",
     "shortName": "Certain transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "teva:CertainTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1011 - Disclosure - Revenue from contracts with customers",
     "role": "http://www.tevapharm.com/role/RevenueFromContractsWithCustomers",
     "shortName": "Revenue from contracts with customers",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1012 - Disclosure - Inventories",
     "role": "http://www.tevapharm.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1013 - Disclosure - Identifiable Intangible Assets",
     "role": "http://www.tevapharm.com/role/IdentifiableIntangibleAssets",
     "shortName": "Identifiable Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1014 - Disclosure - Goodwill",
     "role": "http://www.tevapharm.com/role/Goodwill",
     "shortName": "Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1015 - Disclosure - Debt obligations",
     "role": "http://www.tevapharm.com/role/DebtObligations",
     "shortName": "Debt obligations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1016 - Disclosure - Derivative instruments and hedging activities",
     "role": "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities",
     "shortName": "Derivative instruments and hedging activities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1017 - Disclosure - Legal Settlements and Loss Contingencies",
     "role": "http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies",
     "shortName": "Legal Settlements and Loss Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1018 - Disclosure - Commitments and contingencies",
     "role": "http://www.tevapharm.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1019 - Disclosure - Income taxes",
     "role": "http://www.tevapharm.com/role/IncomeTaxes",
     "shortName": "Income taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn06_30_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002 - Statement - Consolidated Balance Sheets",
     "role": "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn06_30_2022",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "teva:OtherExpensesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1020 - Disclosure - Other assets impairments, restructuring and other items",
     "role": "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems",
     "shortName": "Other assets impairments, restructuring and other items",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "teva:OtherExpensesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1021 - Disclosure - Earnings (Loss) per Share",
     "role": "http://www.tevapharm.com/role/EarningsLossPerShare",
     "shortName": "Earnings (Loss) per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1022 - Disclosure - Accumulated other comprehensive income (loss)",
     "role": "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLoss",
     "shortName": "Accumulated other comprehensive income (loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1023 - Disclosure - Segments",
     "role": "http://www.tevapharm.com/role/Segments",
     "shortName": "Segments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1024 - Disclosure - Fair value measurement",
     "role": "http://www.tevapharm.com/role/FairValueMeasurement",
     "shortName": "Fair value measurement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1025 - Disclosure - Basis of presentation (Policies)",
     "role": "http://www.tevapharm.com/role/BasisOfPresentationPolicies",
     "shortName": "Basis of presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "teva:ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1026 - Disclosure - Certain transactions (Tables)",
     "role": "http://www.tevapharm.com/role/CertainTransactionsTables",
     "shortName": "Certain transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "teva:ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1027 - Disclosure - Revenue from contracts with customers (Tables)",
     "role": "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables",
     "shortName": "Revenue from contracts with customers (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1028 - Disclosure - Inventories (Tables)",
     "role": "http://www.tevapharm.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1029 - Disclosure - Identifiable Intangible Assets (Tables)",
     "role": "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables",
     "shortName": "Identifiable Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn06_30_2022",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn06_30_2022",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1030 - Disclosure - Goodwill (Tables)",
     "role": "http://www.tevapharm.com/role/GoodwillTables",
     "shortName": "Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShortTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1031 - Disclosure - Debt obligations (Tables)",
     "role": "http://www.tevapharm.com/role/DebtObligationsTables",
     "shortName": "Debt obligations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShortTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1032 - Disclosure - Derivative instruments and hedging activities (Tables)",
     "role": "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables",
     "shortName": "Derivative instruments and hedging activities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "teva:OtherExpensesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1033 - Disclosure - Other assets impairments, restructuring and other items (Tables)",
     "role": "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables",
     "shortName": "Other assets impairments, restructuring and other items (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "teva:OtherExpensesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1034 - Disclosure - Accumulated other comprehensive income (loss) (Tables)",
     "role": "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossTables",
     "shortName": "Accumulated other comprehensive income (loss) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1035 - Disclosure - Segments (Tables)",
     "role": "http://www.tevapharm.com/role/SegmentsTables",
     "shortName": "Segments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1036 - Disclosure - Fair Value Measurement (Tables)",
     "role": "http://www.tevapharm.com/role/FairValueMeasurementTables",
     "shortName": "Fair Value Measurement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_08_2018To01_08_2018_AlderMemberusgaapBusinessAcquisitionAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "teva:UpfrontPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1037 - Disclosure - Certain Transactions - Other Transactions - Additional Information (Detail)",
     "role": "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
     "shortName": "Certain Transactions - Other Transactions - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_08_2018To01_08_2018_AlderMemberusgaapBusinessAcquisitionAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "teva:UpfrontPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn06_30_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1038 - Disclosure - Certain Transactions - Business Acquisitions - Summary of Major Classes of Assets and Liabilities Included as Held for Sale (Detail)",
     "role": "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail",
     "shortName": "Certain Transactions - Business Acquisitions - Summary of Major Classes of Assets and Liabilities Included as Held for Sale (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn06_30_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022_USsrtStatementGeographicalAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "teva:SalesReservesAndAllowancesToCustomersPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1039 - Disclosure - Revenue from Contracts with Customers - Additional Information (Detail)",
     "role": "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail",
     "shortName": "Revenue from Contracts with Customers - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022_USsrtStatementGeographicalAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "teva:SalesReservesAndAllowancesToCustomersPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P04_01_2022To06_30_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004 - Statement - Consolidated Statements of Income (Loss)",
     "role": "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
     "shortName": "Consolidated Statements of Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P04_01_2022To06_30_2022",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P04_01_2022To06_30_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1040 - Disclosure - Revenue from Contracts with Customers - Summary of Disaggregation of Revenues by Major Revenue Streams (Detail)",
     "role": "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
     "shortName": "Revenue from Contracts with Customers - Summary of Disaggregation of Revenues by Major Revenue Streams (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P04_01_2022To06_30_2022_ProductMembersrtProductOrServiceAxis",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1041 - Disclosure - Revenue from Contracts with Customers - Schedule of Sales Reserves and Allowances (Detail)",
     "role": "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail",
     "shortName": "Revenue from Contracts with Customers - Schedule of Sales Reserves and Allowances (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn06_30_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1042 - Disclosure - Inventories - Summary of Inventories (Detail)",
     "role": "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail",
     "shortName": "Inventories - Summary of Inventories (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn06_30_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn06_30_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1043 - Disclosure - Identifiable Intangible Assets - Summary of Identifiable Intangible Assets (Detail)",
     "role": "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail",
     "shortName": "Identifiable Intangible Assets - Summary of Identifiable Intangible Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn06_30_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1044 - Disclosure - Identifiable Intangible Assets - Additional Information (Detail)",
     "role": "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
     "shortName": "Identifiable Intangible Assets - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1045 - Disclosure - Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Detail)",
     "role": "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
     "shortName": "Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn06_30_2022",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1046 - Disclosure - Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Parenthetical) (Detail)",
     "role": "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail",
     "shortName": "Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Parenthetical) (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn06_30_2022",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn06_30_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1047 - Disclosure - Goodwill - Additional Information (Detail)",
     "role": "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
     "shortName": "Goodwill - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShortTermDebtTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn06_30_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtCurrent",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1048 - Disclosure - Debt Obligations - Schedule of Short-term Debt (Detail)",
     "role": "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail",
     "shortName": "Debt Obligations - Schedule of Short-term Debt (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShortTermDebtTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn06_30_2022_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis",
      "decimals": "4",
      "lang": null,
      "name": "us-gaap:DebtInstrumentInterestRateEffectivePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn06_30_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:SeniorNotes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1049 - Disclosure - Debt Obligations - Schedule of Senior Notes and Loans (Detail)",
     "role": "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
     "shortName": "Debt Obligations - Schedule of Senior Notes and Loans (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn06_30_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:SeniorNotes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P04_01_2022To06_30_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005 - Statement - Consolidated Statements of Comprehensive Income (Loss)",
     "role": "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
     "shortName": "Consolidated Statements of Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P04_01_2022To06_30_2022",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn04_30_2022_SeniorNotesMemberusgaapLongtermDebtTypeAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "teva:SeniorNotesRepaidAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1050 - Disclosure - Debt Obligations - Schedule of Senior Notes and Loans (Parenthetical) (Detail)",
     "role": "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail",
     "shortName": "Debt Obligations - Schedule of Senior Notes and Loans (Parenthetical) (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn04_30_2022_SeniorNotesMemberusgaapLongtermDebtTypeAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "teva:SeniorNotesRepaidAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn06_30_2022",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "teva:LongTermDebtCurrencyPortionUSD",
      "reportCount": 1,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1051 - Disclosure - Debt Obligations - Additional Information (Detail)",
     "role": "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
     "shortName": "Debt Obligations - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtInstrumentCarryingAmount",
       "div",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn12_31_2021_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn06_30_2022_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_SeniorNotesAndLoansMemberusgaapBalanceSheetLocationAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeFairValueOfDerivativeLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1052 - Disclosure - Derivative Instruments and Hedging Activities - Summary of Classification and Fair Values of Derivative Instruments (Detail)",
     "role": "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail",
     "shortName": "Derivative Instruments and Hedging Activities - Summary of Classification and Fair Values of Derivative Instruments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn06_30_2022_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_SeniorNotesAndLoansMemberusgaapBalanceSheetLocationAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeFairValueOfDerivativeLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P04_01_2022To06_30_2022_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:GainLossOnDerivativeInstrumentsNetPretax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1053 - Disclosure - Derivative Instruments and Hedging Activities - Schedule Of Other Derivatives Not Designated As Hedging Instruments Statements OfFinancial Performance And Financial Position Location (Details)",
     "role": "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails",
     "shortName": "Derivative Instruments and Hedging Activities - Schedule Of Other Derivatives Not Designated As Hedging Instruments Statements OfFinancial Performance And Financial Position Location (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P04_01_2022To06_30_2022_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:GainLossOnDerivativeInstrumentsNetPretax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn06_30_2022",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "teva:RevenuesOtherThanUsd",
      "reportCount": 1,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1054 - Disclosure - Derivative Instruments and Hedging Activities - Additional Information (Detail)",
     "role": "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
     "shortName": "Derivative Instruments and Hedging Activities - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:DerivativeLossOnDerivative",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P06_02_2022To06_02_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:LitigationSettlementExpense",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1055 - Disclosure - Legal Settlements and Loss Contingencies - Additional Information (Detail)",
     "role": "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail",
     "shortName": "Legal Settlements and Loss Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:LegalMattersAndContingenciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2021To06_30_2021",
      "decimals": null,
      "lang": "en-US",
      "name": "teva:RestructuringExpenseAndIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn06_30_2022",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "teva:DamagesAssessment",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1056 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "role": "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn09_01_2020",
      "decimals": "-6",
      "lang": null,
      "name": "teva:AnnualSalesAtTimeOfSettlement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "teva:ExpectedImpairmentOfIncomeTaxBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1057 - Disclosure - Income Taxes - Additional Information (Detail)",
     "role": "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "teva:ExpectedImpairmentOfIncomeTaxBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "teva:OtherExpensesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P04_01_2022To06_30_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1058 - Disclosure - Other assets impairments, restructuring and other items - Schedule of Other Assets Impairments, Restructuring and Other Items (Detail)",
     "role": "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail",
     "shortName": "Other assets impairments, restructuring and other items - Schedule of Other Assets Impairments, Restructuring and Other Items (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "teva:OtherExpensesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P04_01_2022To06_30_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "teva:OtherExpensesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P04_01_2022To06_30_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:TangibleAssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1059 - Disclosure - Other assets impairments, restructuring and other items - Additional Information (Detail)",
     "role": "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
     "shortName": "Other assets impairments, restructuring and other items - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "teva:OtherExpensesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P04_01_2022To06_30_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:TangibleAssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006 - Statement - Consolidated Statements of Changes in Equity",
     "role": "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity",
     "shortName": "Consolidated Statements of Changes in Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "teva:OtherExpensesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P04_01_2022To06_30_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1060 - Disclosure - Other assets impairments, restructuring and other items - Components of costs associated with restructuring plan including costs related to exit and disposal activities (Detail)",
     "role": "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail",
     "shortName": "Other assets impairments, restructuring and other items - Components of costs associated with restructuring plan including costs related to exit and disposal activities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:ScheduleOfRestructuringChargesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P04_01_2022To06_30_2022_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1061 - Disclosure - Other assets impairments, restructuring and other items - Summary of Restructuring Accruals (Detail)",
     "role": "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail",
     "shortName": "Other assets impairments, restructuring and other items - Summary of Restructuring Accruals (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareDiluted",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P04_01_2022To06_30_2022",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EarningsPerShareBasic",
      "reportCount": 1,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1062 - Disclosure - Earnings (Loss) per Share - Additional Information (Detail)",
     "role": "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail",
     "shortName": "Earnings (Loss) per Share - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P04_01_2022To06_30_2022_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1063 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Detail)",
     "role": "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn12_31_2021_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2021To06_30_2021_AccountingStandardsUpdate201601MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1064 - Disclosure - Accumulated Other Comprehensive Income (Loss)  (Parenthetical) (Detail)",
     "role": "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail",
     "shortName": "Accumulated Other Comprehensive Income (Loss)  (Parenthetical) (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2021To06_30_2021_AccountingStandardsUpdate201601MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P04_01_2022To06_30_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1065 - Disclosure - Segments - Summary of Segment Profit (Detail)",
     "role": "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail",
     "shortName": "Segments - Summary of Segment Profit (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P04_01_2022To06_30_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:GrossProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P04_01_2022To06_30_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1066 - Disclosure - Segments - Summary of Profit by Segments and Reconciliation of Segments Profit to Consolidated Income Before Income Taxes (Detail)",
     "role": "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail",
     "shortName": "Segments - Summary of Profit by Segments and Reconciliation of Segments Profit to Consolidated Income Before Income Taxes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P04_01_2022To06_30_2022",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:AdjustmentForAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P04_01_2022To06_30_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1067 - Disclosure - Segments - Schedule of Revenues by Major Products and Activities (Detail)",
     "role": "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail",
     "shortName": "Segments - Schedule of Revenues by Major Products and Activities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P04_01_2022To06_30_2022_GenericsMediciansMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1068 - Disclosure - Segments - Additional Information (Detail)",
     "role": "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail",
     "shortName": "Segments - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Segment",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn06_30_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1069 - Disclosure - Fair Value Measurement - Summary of Financial Items Carried at Fair Value (Detail)",
     "role": "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail",
     "shortName": "Fair Value Measurement - Summary of Financial Items Carried at Fair Value (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn06_30_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P04_01_2022To06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007 - Statement - Consolidated Statements of Changes in Equity (Parenthetical)",
     "role": "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical",
     "shortName": "Consolidated Statements of Changes in Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P04_01_2022To06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn06_30_2022_MeasurementInputProbabilityOfSuccessMemberusgaapMeasurementInputTypeAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1070 - Disclosure - Fair value measurement - Additional Information (Detail)",
     "role": "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail",
     "shortName": "Fair value measurement - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn06_30_2022_MeasurementInputProbabilityOfSuccessMemberusgaapMeasurementInputTypeAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1071 - Disclosure - Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Detail)",
     "role": "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail",
     "shortName": "Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn01_01_2022_NoveTideAcquisitionMemberusgaapBusinessAcquisitionAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1072 - Disclosure - Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Parenthetical) (Detail)",
     "role": "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail",
     "shortName": "Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Parenthetical) (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn01_01_2022_NoveTideAcquisitionMemberusgaapBusinessAcquisitionAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn06_30_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1073 - Disclosure - Fair Value Measurement - Summary of Financial Instrument Measured on a Basis Other Than Fair Value (Detail)",
     "role": "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail",
     "shortName": "Fair Value Measurement - Summary of Financial Instrument Measured on a Basis Other Than Fair Value (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "PAsOn06_30_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1008 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1009 - Disclosure - Basis of presentation",
     "role": "http://www.tevapharm.com/role/BasisOfPresentation",
     "shortName": "Basis of presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d360666d10q.htm",
      "contextRef": "P01_01_2022To06_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 150,
   "tag": {
    "country_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States [Member]"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]",
        "terseLabel": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLoss",
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail",
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail",
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossTables",
      "http://www.tevapharm.com/role/BasisOfPresentationPolicies",
      "http://www.tevapharm.com/role/CertainTransactions",
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CertainTransactionsTables",
      "http://www.tevapharm.com/role/CommitmentsAndContingencies",
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/DebtObligations",
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail",
      "http://www.tevapharm.com/role/DebtObligationsTables",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables",
      "http://www.tevapharm.com/role/EarningsLossPerShare",
      "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail",
      "http://www.tevapharm.com/role/FairValueMeasurement",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementTables",
      "http://www.tevapharm.com/role/Goodwill",
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail",
      "http://www.tevapharm.com/role/GoodwillTables",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssets",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables",
      "http://www.tevapharm.com/role/IncomeTaxes",
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/Inventories",
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail",
      "http://www.tevapharm.com/role/InventoriesTables",
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies",
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomers",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables",
      "http://www.tevapharm.com/role/Segments",
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail",
      "http://www.tevapharm.com/role/SegmentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Smaller Reporting Company"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLoss",
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail",
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail",
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossTables",
      "http://www.tevapharm.com/role/BasisOfPresentationPolicies",
      "http://www.tevapharm.com/role/CertainTransactions",
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CertainTransactionsTables",
      "http://www.tevapharm.com/role/CommitmentsAndContingencies",
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/DebtObligations",
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail",
      "http://www.tevapharm.com/role/DebtObligationsTables",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables",
      "http://www.tevapharm.com/role/EarningsLossPerShare",
      "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail",
      "http://www.tevapharm.com/role/FairValueMeasurement",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementTables",
      "http://www.tevapharm.com/role/Goodwill",
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail",
      "http://www.tevapharm.com/role/GoodwillTables",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssets",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables",
      "http://www.tevapharm.com/role/IncomeTaxes",
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/Inventories",
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail",
      "http://www.tevapharm.com/role/InventoriesTables",
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies",
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomers",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables",
      "http://www.tevapharm.com/role/Segments",
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail",
      "http://www.tevapharm.com/role/SegmentsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r131",
      "r175",
      "r188",
      "r189",
      "r190",
      "r191",
      "r193",
      "r195",
      "r199",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r317",
      "r318",
      "r320",
      "r322",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r131",
      "r175",
      "r188",
      "r189",
      "r190",
      "r191",
      "r193",
      "r195",
      "r199",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r317",
      "r318",
      "r320",
      "r322",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r71",
      "r73",
      "r129",
      "r130",
      "r330",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]",
        "terseLabel": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe [Member]"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r299",
      "r301",
      "r303",
      "r304",
      "r329",
      "r363",
      "r417",
      "r420",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r613",
      "r674",
      "r677",
      "r706",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r299",
      "r301",
      "r303",
      "r304",
      "r329",
      "r363",
      "r417",
      "r420",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r613",
      "r674",
      "r677",
      "r706",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NorthAmericaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "North America [Member]",
        "terseLabel": "North America [Member]"
       }
      }
     },
     "localname": "NorthAmericaMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r201",
      "r301",
      "r303",
      "r395",
      "r397",
      "r615",
      "r673",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r201",
      "r301",
      "r303",
      "r395",
      "r397",
      "r615",
      "r673",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r275",
      "r299",
      "r301",
      "r303",
      "r304",
      "r329",
      "r363",
      "r405",
      "r417",
      "r420",
      "r422",
      "r423",
      "r424",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r613",
      "r674",
      "r677",
      "r706",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail",
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical",
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r275",
      "r299",
      "r301",
      "r303",
      "r304",
      "r329",
      "r363",
      "r405",
      "r417",
      "r420",
      "r422",
      "r423",
      "r424",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r613",
      "r674",
      "r677",
      "r706",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail",
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical",
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r72",
      "r73",
      "r129",
      "r130",
      "r330",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r148",
      "r153",
      "r297",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r202",
      "r203",
      "r395",
      "r398",
      "r676",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r202",
      "r203",
      "r395",
      "r398",
      "r676",
      "r694",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r148",
      "r153",
      "r297",
      "r418",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r588",
      "r590",
      "r593",
      "r706",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average [Member]"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_LA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LOUISIANA",
        "terseLabel": "Laos [Member]"
       }
      }
     },
     "localname": "LA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_AccruedExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses.",
        "label": "Accrued Expenses",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedExpenses",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_ActavisGenericsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Actavis Generics [Member]",
        "label": "Actavis Generics [Member]",
        "terseLabel": "Actavis Generics [Member]"
       }
      }
     },
     "localname": "ActavisGenericsMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_ActavisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Actavis [Member]",
        "label": "Actavis [Member]",
        "terseLabel": "Actavis [Member]"
       }
      }
     },
     "localname": "ActavisMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_AgreementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement.",
        "label": "Agreement [Axis]"
       }
      }
     },
     "localname": "AgreementAxis",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_AgreementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement.",
        "label": "Agreement [Domain]"
       }
      }
     },
     "localname": "AgreementDomain",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_AjovyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AJOVY [Member]"
       }
      }
     },
     "localname": "AjovyMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_AlderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alder [Member]",
        "label": "Alder [Member]",
        "terseLabel": "Alder [Member]"
       }
      }
     },
     "localname": "AlderMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_AlvotechMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alvotech.",
        "label": "Alvotech [Member]",
        "terseLabel": "Alvotech [Member]"
       }
      }
     },
     "localname": "AlvotechMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_AmountsAllocatedToSegmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts allocated to segments.",
        "label": "Amounts Allocated To Segments [Abstract]",
        "terseLabel": "Amounts allocated to segments:"
       }
      }
     },
     "localname": "AmountsAllocatedToSegmentsAbstract",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_AmountsNotAllocatedToSegmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts not allocated to segments.",
        "label": "Amounts Not Allocated To Segments [Abstract]",
        "terseLabel": "Amounts not allocated to segments:"
       }
      }
     },
     "localname": "AmountsNotAllocatedToSegmentsAbstract",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_AndaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Anda [Member]",
        "label": "Anda [Member]",
        "terseLabel": "Anda [Member]"
       }
      }
     },
     "localname": "AndaMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_AndroGelRateAtOnePercentageMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Andro gel rate at one percentage.",
        "label": "Andro Gel Rate At One Percentage [Member]",
        "terseLabel": "AndroGel Rate at 1% [Member]"
       }
      }
     },
     "localname": "AndroGelRateAtOnePercentageMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_AnnualSalesAtTheTimeOfLaunchOfProduct": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual sales at the time of launch of product.",
        "label": "Annual Sales At The Time Of Launch Of Product"
       }
      }
     },
     "localname": "AnnualSalesAtTheTimeOfLaunchOfProduct",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AnnualSalesAtTimeOfSettlement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual sales at time of settlement.",
        "label": "Annual Sales At Time Of Settlement",
        "terseLabel": "Annual sales at the time of settlement"
       }
      }
     },
     "localname": "AnnualSalesAtTimeOfSettlement",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AnnualSalesOfActoplus": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual sales of Acto plus.",
        "label": "Annual Sales Of Actoplus",
        "terseLabel": "Annual sales of Acto plus"
       }
      }
     },
     "localname": "AnnualSalesOfActoplus",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AnnualSalesOfActos": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual sales of Actos.",
        "label": "Annual Sales Of Actos",
        "terseLabel": "Annual sales of Actos"
       }
      }
     },
     "localname": "AnnualSalesOfActos",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AnnualSalesOfCopaxone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Sales Of Copaxone.",
        "label": "Annual Sales Of Copaxone",
        "terseLabel": "Annual sales of Copaxone"
       }
      }
     },
     "localname": "AnnualSalesOfCopaxone",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AnnualSalesOfEffexor": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual sales of effexor.",
        "label": "Annual Sales Of Effexor",
        "terseLabel": "Annual sales of Effexor"
       }
      }
     },
     "localname": "AnnualSalesOfEffexor",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AnnualSalesOfLamictal": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual sales of Lamictal.",
        "label": "Annual Sales Of Lamictal",
        "terseLabel": "Annual sales of Lamictal"
       }
      }
     },
     "localname": "AnnualSalesOfLamictal",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AnnualSalesOfNarcan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual sales of narcan.",
        "label": "Annual sales of Narcan",
        "terseLabel": "Annual sales of Narcan"
       }
      }
     },
     "localname": "AnnualSalesOfNarcan",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AnnualSalesOfNiaspan": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual sales of Niaspan.",
        "label": "Annual Sales Of Niaspan",
        "terseLabel": "Annual sales of Niaspan"
       }
      }
     },
     "localname": "AnnualSalesOfNiaspan",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AnnualSalesOfSensipar": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Annual Sales Of Sensipar.",
        "label": "Annual Sales Of Sensipar"
       }
      }
     },
     "localname": "AnnualSalesOfSensipar",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AtripalaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Atripala [Member]"
       }
      }
     },
     "localname": "AtripalaMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_AttorneyGeneralOfFloridaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Attorney General of Florida",
        "label": "Attorney General of Florida [Member]"
       }
      }
     },
     "localname": "AttorneyGeneralOfFloridaMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_AttorneyGeneralOfLouisanaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Attorney general of louisana.",
        "label": "Attorney General Of Louisana [Member]",
        "terseLabel": "Attorney General Of Louisana [Member]"
       }
      }
     },
     "localname": "AttorneyGeneralOfLouisanaMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_AttorneyGeneralOfRhodeIslandMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Attorney General of Rhode Island",
        "label": "Attorney General of Rhode Island [Member]"
       }
      }
     },
     "localname": "AttorneyGeneralOfRhodeIslandMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_AttorneyGeneralOfWestVirginiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Attorney General of West Virginia [Member]"
       }
      }
     },
     "localname": "AttorneyGeneralOfWestVirginiaMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_AustedoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Austedo [Member]",
        "label": "Austedo [Member]",
        "terseLabel": "AUSTEDO [Member]"
       }
      }
     },
     "localname": "AustedoMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_BasisOfPresentationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation [Abstract]"
       }
      }
     },
     "localname": "BasisOfPresentationAbstract",
     "nsuri": "http://www.tevapharm.com/20220630",
     "xbrltype": "stringItemType"
    },
    "teva_BendekaAndTreandaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BENDEKA and TREANDA.",
        "label": "BENDEKA and TREANDA [Member]",
        "verboseLabel": "BENDEKA and TREANDA [Member]"
       }
      }
     },
     "localname": "BendekaAndTreandaMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beneficial Interest Obtained in Exchange for Securitized Trade Receivables",
        "label": "Beneficial Interest Obtained in Exchange for Securitized Trade Receivables",
        "terseLabel": "Beneficial interest obtained in exchange for securitized accounts receivables"
       }
      }
     },
     "localname": "BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_BifurcatedEmbeddedDerivatives": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bifurcated embedded derivatives.",
        "label": "Bifurcated Embedded Derivatives",
        "terseLabel": "Bifurcated embedded derivatives"
       }
      }
     },
     "localname": "BifurcatedEmbeddedDerivatives",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_COPAXONEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COPAXONE.",
        "label": "COPAXONE [Member]",
        "terseLabel": "COPAXONE [Member]"
       }
      }
     },
     "localname": "COPAXONEMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_CashReceivedOnSettlementOfPosition": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notional amount hedge debt.",
        "label": "Cash Received On Settlement Of Position",
        "terseLabel": "Cash received on settlement of position"
       }
      }
     },
     "localname": "CashReceivedOnSettlementOfPosition",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_CertainTransactionsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element may be used for the entire related party transactions disclosure as a single block of text. Disclosure may include: business acquisitions, agreements with related parties, significant cooperation agreements, the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Certain Transactions Disclosure [Text Block]",
        "terseLabel": "Certain transactions"
       }
      }
     },
     "localname": "CertainTransactionsDisclosureTextBlock",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_ChargebacksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chargebacks.",
        "label": "Chargebacks [Member]",
        "terseLabel": "Chargebacks [Member]"
       }
      }
     },
     "localname": "ChargebacksMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_ColcysMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Colcys [Member]"
       }
      }
     },
     "localname": "ColcysMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_CollaborativeAgreementMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement Milestone Payments",
        "label": "Collaborative Agreement Milestone Payments",
        "terseLabel": "Collaborative agreement milestone payments"
       }
      }
     },
     "localname": "CollaborativeAgreementMilestonePayments",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_CommitmentAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment And Contingencies [Line Items]",
        "label": "Commitment And Contingencies [Line Items]",
        "terseLabel": "Commitment And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentAndContingenciesLineItems",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_CommitmentAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment And Contingencies [Table]",
        "label": "Commitment And Contingencies [Table]",
        "terseLabel": "Commitment And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentAndContingenciesTable",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_CompaniesShareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Companies share.",
        "label": "Companies Share [Member]"
       }
      }
     },
     "localname": "CompaniesShareMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_DamagesAssessment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Damages assessment.",
        "label": "Damages Assessment",
        "terseLabel": "Damages assessment"
       }
      }
     },
     "localname": "DamagesAssessment",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_DebtInstrumentMaturityYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Maturity Year",
        "label": "Debt Instrument Maturity Year",
        "terseLabel": "Maturity"
       }
      }
     },
     "localname": "DebtInstrumentMaturityYear",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "teva_DefendantsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defendants.",
        "label": "Defendants [Axis]"
       }
      }
     },
     "localname": "DefendantsAxis",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_DefendantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defendants.",
        "label": "Defendants [Member]"
       }
      }
     },
     "localname": "DefendantsMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_DeferredIncomeTaxesNetAndUncertainTaxPositions": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred income taxes net and uncertain tax positions.",
        "label": "Deferred Income Taxes Net And Uncertain Tax Positions",
        "terseLabel": "Deferred income taxes \u2013 net and uncertain tax positions"
       }
      }
     },
     "localname": "DeferredIncomeTaxesNetAndUncertainTaxPositions",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_DiscontinuationOfBusinessAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinuation Of Business [Axis]"
       }
      }
     },
     "localname": "DiscontinuationOfBusinessAxis",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_DiscontinuationOfBusinessDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinuation Of Business [Domain]"
       }
      }
     },
     "localname": "DiscontinuationOfBusinessDomain",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_EagleTransactionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eagle transaction.",
        "label": "Eagle Transaction [Member]",
        "terseLabel": "Eagle Transaction [Member]"
       }
      }
     },
     "localname": "EagleTransactionMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_EffectiveIncomeTaxReconciliationAmountInventoryWrittenOff": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax reconciliation amount inventory written off.",
        "label": "Effective Income Tax Reconciliation Amount Inventory Written Off",
        "terseLabel": "Effective income tax reconciliation amount inventory written off"
       }
      }
     },
     "localname": "EffectiveIncomeTaxReconciliationAmountInventoryWrittenOff",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_EmployeeTerminationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee termination.",
        "label": "Employee Termination [Member]",
        "terseLabel": "Employee termination costs [Member]"
       }
      }
     },
     "localname": "EmployeeTerminationMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_EosinophilicEsophagitisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eosinophilic Esophagitis [Member]",
        "label": "Eosinophilic Esophagitis [Member]",
        "terseLabel": "Eosinophilic Esophagitis [Member]"
       }
      }
     },
     "localname": "EosinophilicEsophagitisMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_EuropeSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Europe segment.",
        "label": "Europe Segment [Member]",
        "terseLabel": "Europe [Member]"
       }
      }
     },
     "localname": "EuropeSegmentMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_ExitAndDisposalAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exit And Disposal [Axis]",
        "label": "Exit And Disposal [Axis]",
        "terseLabel": "Exit And Disposal [Axis]"
       }
      }
     },
     "localname": "ExitAndDisposalAxis",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_ExitAndDisposalDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exit And Disposal [Domain]",
        "label": "Exit And Disposal [Domain]",
        "terseLabel": "Exit And Disposal [Domain]"
       }
      }
     },
     "localname": "ExitAndDisposalDomain",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_ExpectedImpairmentOfIncomeTaxBenefit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected impairment of income tax benefit.",
        "label": "Expected Impairment OF Income Tax Benefit",
        "terseLabel": "Expected impairment of income tax benefit"
       }
      }
     },
     "localname": "ExpectedImpairmentOfIncomeTaxBenefit",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability contingent consideration arising during period.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Contingent Consideration Arising During Period",
        "terseLabel": "Actavis Generics transaction"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability contingent consideration increase decrease.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Contingent Consideration Increase Decrease",
        "terseLabel": "Adjustments to provisions for contingent consideration"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_FinancialExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial expenses [Member]",
        "terseLabel": "Financial expenses [Member]"
       }
      }
     },
     "localname": "FinancialExpensesMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward starting interest rate swaps and treasury lock agreements losses.",
        "label": "Forward Starting Interest Rate Swaps And Treasury Lock Agreements Losses",
        "terseLabel": "Forward starting interest rate swaps and treasury lock agreements losses"
       }
      }
     },
     "localname": "ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_FourOtherDefendantsOtherThanTevaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four other defendants other than teva.",
        "label": "Four Other Defendants Other Than Teva [Member]",
        "terseLabel": "Four Other Defendants Other Than Teva [Member]"
       }
      }
     },
     "localname": "FourOtherDefendantsOtherThanTevaMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_GenericPipelineProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Generic Pipeline Products [Member]"
       }
      }
     },
     "localname": "GenericPipelineProductsMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_GenericsMediciansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generics Medicians.",
        "label": "Generics Medicians [Member]",
        "terseLabel": "Generic products [Member]"
       }
      }
     },
     "localname": "GenericsMediciansMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_ImpairmentAndRestructuring": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment and restructuring.",
        "label": "Impairment And Restructuring",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "ImpairmentAndRestructuring",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment Of Intangible Assets Reasons For Impairment.",
        "label": "Impairment Of Intangible Assets Reasons For Impairment [Axis]"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment Of Intangible Assets Reasons For Impairment.",
        "label": "Impairment Of Intangible Assets Reasons For Impairment [Domain]"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_ImpairmentsRestructuringAndOthers": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 10.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairments restructuring and others.",
        "label": "Impairments Restructuring And Others",
        "verboseLabel": "Other asset impairments, restructuring and other items"
       }
      }
     },
     "localname": "ImpairmentsRestructuringAndOthers",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_IncomeTaxLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax [Line Items]",
        "label": "Income Tax [Line Items]",
        "terseLabel": "Income Tax [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxLineItems",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_IncomeTaxTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax [Table]",
        "label": "Income Tax [Table]",
        "terseLabel": "Income Tax [Table]"
       }
      }
     },
     "localname": "IncomeTaxTable",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_InprocessresearchandDevelopmenttoProductRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In Process Research And Development To Product Rights [Member]",
        "label": "In Process Research And Development To Product Rights [Member]",
        "terseLabel": "In Process Research And Development To Product Rights [Member]"
       }
      }
     },
     "localname": "InprocessresearchandDevelopmenttoProductRightsMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_IntangibleAssetsImpairments": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 7.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible Assets Impairments",
        "label": "Intangible Assets Impairments",
        "terseLabel": "Intangible assets impairments"
       }
      }
     },
     "localname": "IntangibleAssetsImpairments",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_InterestRateIncreaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate increase.",
        "label": "Interest Rate Increase [Member]"
       }
      }
     },
     "localname": "InterestRateIncreaseMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_InterestRateSwapLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate swap loss.",
        "label": "Interest Rate Swap Loss"
       }
      }
     },
     "localname": "InterestRateSwapLoss",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_InternationalMarketsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "International markets.",
        "label": "International Markets [Member]",
        "terseLabel": "International Markets [Member]"
       }
      }
     },
     "localname": "InternationalMarketsMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_InternationalMarketsReportingUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "International markets reporting unit.",
        "label": "International Markets Reporting Unit [Member]"
       }
      }
     },
     "localname": "InternationalMarketsReportingUnitMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_InventoriesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories [Line Items]",
        "label": "Inventories [Line Items]",
        "terseLabel": "Inventories [Line Items]"
       }
      }
     },
     "localname": "InventoriesLineItems",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_InventoriesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories [Table]",
        "label": "Inventories [Table]",
        "terseLabel": "Inventories [Table]"
       }
      }
     },
     "localname": "InventoriesTable",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_LegalSettlementsAndLossContingencies": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 11.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net proceeds or assets obtained in excess of (less than) the net carrying amount of assets recorded, or assets distributed and liabilities assumed less than (in excess of) litigation reserves extinguished, in settlement of a litigation matter. Represents (for other than an insurance entity in its normal claims settlement process), the amount of income (expense) recognized in the period to settle pending or threatened litigation and insurance claims and the aggregate amount provided for estimated restructuring charges, remediation costs, and asset impairment loss during an accounting period. Generally, these items are either unusual or infrequent, but not both (in which case they would be extraordinary items).",
        "label": "Legal Settlements And Loss Contingencies",
        "terseLabel": "Legal settlements and loss contingencies"
       }
      }
     },
     "localname": "LegalSettlementsAndLossContingencies",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail": {
       "order": 4.0,
       "parentTag": "teva_ImpairmentAndRestructuring",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal settlements loss contingencies impairments other expenses.",
        "label": "Legal Settlements Loss Contingencies Impairments Other Expenses",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "LegalSettlementsLossContingenciesImpairmentsOtherExpenses",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_LeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leverage ratio.",
        "label": "Leverage Ratio"
       }
      }
     },
     "localname": "LeverageRatio",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement potential aggregate milestone payments amount.",
        "label": "License Agreement Potential Aggregate Milestone Payments Amount",
        "verboseLabel": "License agreement potential aggregate milestone payments amount"
       }
      }
     },
     "localname": "LicenseAgreementPotentialAggregateMilestonePaymentsAmount",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_LineOfCreditExtentionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of credit extention period.",
        "label": "Line Of Credit Extention Period"
       }
      }
     },
     "localname": "LineOfCreditExtentionPeriod",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_LitigationAmountIncludingAlreadyPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation amount including already paid.",
        "label": "Litigation Amount Including Already Paid",
        "terseLabel": "Litigation amount including already paid"
       }
      }
     },
     "localname": "LitigationAmountIncludingAlreadyPaid",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_LitigationAmountToBePaidToTribes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation amount to be paid to tribes.",
        "label": "Litigation Amount To Be Paid To Tribes",
        "terseLabel": "Litigation amount to be paid to tribes"
       }
      }
     },
     "localname": "LitigationAmountToBePaidToTribes",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_LitigationSettlementAmountAwardedCashAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation settlement amount awarded cash amount.",
        "label": "Litigation Settlement Amount Awarded Cash Amount",
        "terseLabel": "Litigation settlement amount awarded cash amount"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedCashAmount",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_LitigationSettlementAmountAwardedCashAmountDistributionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation settlement amount awarded cash amount distribution period.",
        "label": "Litigation Settlement Amount Awarded Cash Amount Distribution Period",
        "terseLabel": "Litigation settlement amount awarded cash amount distribution period"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedCashAmountDistributionPeriod",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "teva_LitigationSettlementAmountAwardedDistributionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation settlement amount awarded distribution period.",
        "label": "Litigation Settlement Amount Awarded Distribution Period",
        "terseLabel": "Litigation settlement amount awarded distribution period"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedDistributionPeriod",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "teva_LitigationSettlementAmountDistributableinKind": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation settlement amount distributableIn kind.",
        "label": "Litigation Settlement Amount DistributableIn Kind",
        "terseLabel": "Litigation Settlement Amount DistributableIn Kind"
       }
      }
     },
     "localname": "LitigationSettlementAmountDistributableinKind",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_LitigationSettlementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation settlement term.",
        "label": "Litigation Settlement Term",
        "terseLabel": "Litigation settlement term"
       }
      }
     },
     "localname": "LitigationSettlementTerm",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "teva_LongTermDebtCurrencyPortionCHF": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term debt currency portion C H F.",
        "label": "Long Term Debt Currency Portion C H F",
        "terseLabel": "Long term debt currency portion CHF"
       }
      }
     },
     "localname": "LongTermDebtCurrencyPortionCHF",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "teva_LongTermDebtCurrencyPortionEUR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term debt currency portion E U R.",
        "label": "Long Term Debt Currency Portion E U R",
        "terseLabel": "Long term debt currency portion EUR"
       }
      }
     },
     "localname": "LongTermDebtCurrencyPortionEUR",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "teva_LongTermDebtCurrencyPortionUSD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term debt currency portion U S D.",
        "label": "Long Term Debt Currency Portion U S D",
        "terseLabel": "Long term debt currency portion USD"
       }
      }
     },
     "localname": "LongTermDebtCurrencyPortionUSD",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "teva_LossContingenciesOnEnvironmentalLawsPenalty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss contingencies on environmental laws penalty.",
        "label": "Loss Contingencies On Environmental Laws Penalty",
        "terseLabel": "Loss Contingencies On Environmental Laws Penalty"
       }
      }
     },
     "localname": "LossContingenciesOnEnvironmentalLawsPenalty",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_LossContingencyClaimsDismissedValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss contingency claims dismissed value.",
        "label": "Loss Contingency Claims Dismissed Value",
        "terseLabel": "Loss Contingency Claims Dismissed Value"
       }
      }
     },
     "localname": "LossContingencyClaimsDismissedValue",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_MeasurementInputProbabilityOfSuccessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input probability of success.",
        "label": "Measurement Input Probability Of Success [Member]",
        "terseLabel": "Measurement input probability of success [Member]"
       }
      }
     },
     "localname": "MeasurementInputProbabilityOfSuccessMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_MeasurementInputTerminalGrowthRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input terminal growth rate.",
        "label": "Measurement Input Terminal Growth Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputTerminalGrowthRateMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_MedicaidAndOtherGovernmentalAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicaid and other governmental allowances.",
        "label": "Medicaid And Other Governmental Allowances [Member]",
        "terseLabel": "Medicaid and Other Governmental Allowances [Member]"
       }
      }
     },
     "localname": "MedicaidAndOtherGovernmentalAllowancesMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_MedincellMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MedinCell [ Member].",
        "label": "MedinCell [Member]"
       }
      }
     },
     "localname": "MedincellMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_MilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment.",
        "label": "Milestone Payment",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "MilestonePayment",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_ModagMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Modag .",
        "label": "Modag [Member]",
        "terseLabel": "MODAG [Member]"
       }
      }
     },
     "localname": "ModagMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_NationwideSettlementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nationwide Settlement [Member]",
        "terseLabel": "Nationwide Settlement [Member]"
       }
      }
     },
     "localname": "NationwideSettlementMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_NetRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Revenues [Member]",
        "terseLabel": "Net Revenues [Member]"
       }
      }
     },
     "localname": "NetRevenuesMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_NorthAmericaAndMedisReportingUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "North america and medis reporting units.",
        "label": "North America and Medis Reporting Units [Member]"
       }
      }
     },
     "localname": "NorthAmericaAndMedisReportingUnitsMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_NorthAmericaSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "North America segment.",
        "label": "North America Segment [Member]",
        "terseLabel": "North America [Member]"
       }
      }
     },
     "localname": "NorthAmericaSegmentMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_NotionalAmountHedgeDebt": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notional amount hedge debt.",
        "label": "Notional Amount Hedge Debt",
        "terseLabel": "Notional amount hedge debt"
       }
      }
     },
     "localname": "NotionalAmountHedgeDebt",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_NoveTideAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nove tide Acquisition.",
        "label": "Nove tide Acquisition [Member]"
       }
      }
     },
     "localname": "NoveTideAcquisitionMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_OneTimePremiumPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One time\u00a0premium payment.",
        "label": "One Time Premium Payment [Member]"
       }
      }
     },
     "localname": "OneTimePremiumPaymentMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_OpioidLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Opioid Litigation [Member]"
       }
      }
     },
     "localname": "OpioidLitigationMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_OptionsAndForwardContractsDerivativeLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options and forward contracts derivative liabilities.",
        "label": "Options And Forward Contracts Derivative Liabilities [Member]",
        "terseLabel": "Liability Derivatives Options and Forward Contracts [Member]"
       }
      }
     },
     "localname": "OptionsAndForwardContractsDerivativeLiabilitiesMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_OtherActivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Activities [Member]",
        "label": "Other Activities [Member]",
        "terseLabel": "Other activities [Member]"
       }
      }
     },
     "localname": "OtherActivitiesMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_OtherCountriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other countries.",
        "label": "Other Countries [Member]",
        "terseLabel": "Other [Member]"
       }
      }
     },
     "localname": "OtherCountriesMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_OtherDebentures2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other debentures 2026.",
        "label": "Other Debentures 2026 [Member]",
        "terseLabel": "Other Debentures [Member]"
       }
      }
     },
     "localname": "OtherDebentures2026Member",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_OtherExitAndDisposalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other exit and disposal.",
        "label": "Other Exit And Disposal [Member]",
        "terseLabel": "Other Exit and Disposal [Member]"
       }
      }
     },
     "localname": "OtherExitAndDisposalMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_OtherExpensesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Expenses [Text Block]",
        "label": "Other Expenses [Text Block]",
        "terseLabel": "Other assets impairments, restructuring and other items"
       }
      }
     },
     "localname": "OtherExpensesTextBlock",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_OtherOperatingIncomeExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Operating Income (Expense)",
        "label": "Other Operating Income (Expense)",
        "verboseLabel": "Other (income) expense"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpense",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_OtherProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products [Member]",
        "label": "Other Products [Member]",
        "terseLabel": "Other [Member]"
       }
      }
     },
     "localname": "OtherProductsMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_OtherRestrictedCashMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other restricted cash.",
        "label": "Other Restricted Cash [Member]",
        "terseLabel": "Other [Member]"
       }
      }
     },
     "localname": "OtherRestrictedCashMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_OtherSalesReservesAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other sales reserves and allowances.",
        "label": "Other Sales Reserves And Allowances [Member]",
        "terseLabel": "Other [Member]"
       }
      }
     },
     "localname": "OtherSalesReservesAndAllowancesMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_OtherUnallocatedAmounts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other unallocated amounts.",
        "label": "Other Unallocated Amounts",
        "terseLabel": "Other unallocated amounts"
       }
      }
     },
     "localname": "OtherUnallocatedAmounts",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_OtsukaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Otsuka [Member]",
        "label": "Otsuka [Member]",
        "terseLabel": "Otsuka [Member]"
       }
      }
     },
     "localname": "OtsukaMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from purchase of available for sales securities and other assets.",
        "label": "Payment To Acquire Marketable Securities And Other Assets",
        "negatedLabel": "Purchases of investments and other assets"
       }
      }
     },
     "localname": "PaymentToAcquireMarketableSecuritiesAndOtherAssets",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_PercentageOfPopulationOfSubdivisionsWillFormallyReleaseAsAPartOfSettlement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of population of subdivisions will formally release as a part of settlement",
        "label": "Percentage of population of subdivisions will formally release as a part of settlement",
        "terseLabel": "Percentage of population of subdivisions will formally release as a part of settlement"
       }
      }
     },
     "localname": "PercentageOfPopulationOfSubdivisionsWillFormallyReleaseAsAPartOfSettlement",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "teva_PercentageOfWholesaleAcquisitionCostValueInCashInLieuOfProductToBePaidUnderSettlementAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of wholesale acquisition cost value in cash in lieu of product to be paid under settlement agreement.",
        "label": "Percentage Of Wholesale Acquisition Cost Value In Cash In Lieu Of Product To Be Paid Under Settlement Agreement",
        "terseLabel": "Percentage of wholesale acquisition cost value in cash in lieu of product to be paid under settlement agreement"
       }
      }
     },
     "localname": "PercentageOfWholesaleAcquisitionCostValueInCashInLieuOfProductToBePaidUnderSettlementAgreement",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "teva_PreviouslyHedgeDebtRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Previously hedge debt rate.",
        "label": "Previously Hedge Debt Rate",
        "terseLabel": "Previously hedge debt rate"
       }
      }
     },
     "localname": "PreviouslyHedgeDebtRate",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from beneficial interest in exchange for securitized trade receivables",
        "label": "Proceeds from beneficial interest in exchange for securitized trade receivables",
        "terseLabel": "Beneficial interest collected in exchange for securitized trade receivables"
       }
      }
     },
     "localname": "ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_ProductOfferingSettlementAtWholesaleAcquisitionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product offering settlement at wholesale acquisition costs.",
        "label": "Product Offering Settlement At Wholesale Acquisition Costs",
        "terseLabel": "Product offering in settlement at wholesale acquistion costs"
       }
      }
     },
     "localname": "ProductOfferingSettlementAtWholesaleAcquisitionCosts",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_ProductRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Rights [Member]",
        "label": "Product Rights [Member]",
        "terseLabel": "Identifiable product rights [Member]",
        "verboseLabel": "Product rights"
       }
      }
     },
     "localname": "ProductRightsMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_ProductToBeSettledValuationTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product settlement term.",
        "label": "Product To Be Settled Valuation Term",
        "terseLabel": "Product to be settled valuation term"
       }
      }
     },
     "localname": "ProductToBeSettledValuationTerm",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "teva_ProfitFromSaleOfLongLivedAssetsAndInvestment": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profit from sale of long lived assets and investment.",
        "label": "Profit From Sale Of Long Lived Assets And Investment",
        "negatedLabel": "Net loss (gain) from investments and from sale of long lived assets"
       }
      }
     },
     "localname": "ProfitFromSaleOfLongLivedAssetsAndInvestment",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_RebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rebates.",
        "label": "Rebates [Member]",
        "terseLabel": "Rebates [Member]"
       }
      }
     },
     "localname": "RebatesMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recently issued accounting pronouncements not yet adopted.",
        "label": "Recently Issued Accounting Pronouncements Not Yet Adopted [Policy Text Block]",
        "terseLabel": "Recently issued accounting pronouncements, not yet adopted"
       }
      }
     },
     "localname": "RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/BasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_RegeneronMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regeneron [Member]",
        "label": "Regeneron [Member]",
        "terseLabel": "Regeneron [Member]"
       }
      }
     },
     "localname": "RegeneronMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_ResearchAndDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Costs",
        "label": "Research And Development Costs",
        "terseLabel": "Research and development costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentCosts",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_ReservesIncludedInAccountsReceivableNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserves included in accounts receivable net.",
        "label": "Reserves Included In Accounts Receivable Net [Member]",
        "terseLabel": "Reserves Included in Accounts Receivable, Net [Member]"
       }
      }
     },
     "localname": "ReservesIncludedInAccountsReceivableNetMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_RespiratoryProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Respiratory product.",
        "label": "Respiratory Product [Member]",
        "terseLabel": "Respiratory Product [Member]"
       }
      }
     },
     "localname": "RespiratoryProductMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_RestructuringAccrualProvision": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring Accrual Provision",
        "label": "Restructuring Accrual Provision",
        "negatedLabel": "Provision"
       }
      }
     },
     "localname": "RestructuringAccrualProvision",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_RestructuringAndImpairmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and impairment.",
        "label": "Restructuring And Impairment [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndImpairmentAbstract",
     "nsuri": "http://www.tevapharm.com/20220630",
     "xbrltype": "stringItemType"
    },
    "teva_RestructuringAndImpairmentCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and impairment costs.",
        "label": "Restructuring And Impairment Costs [Line Items]",
        "terseLabel": "Restructuring and Impairment Costs [Line Items]"
       }
      }
     },
     "localname": "RestructuringAndImpairmentCostsLineItems",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_RestructuringAndImpairmentCostsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring And Impairment Costs [Table]",
        "label": "Restructuring And Impairment Costs [Table]",
        "terseLabel": "Restructuring And Impairment Costs [Table]"
       }
      }
     },
     "localname": "RestructuringAndImpairmentCostsTable",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_RestructuringExpenseAndIncome": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring expense and income",
        "label": "Restructuring expense and income",
        "terseLabel": "Restructuring expense and income"
       }
      }
     },
     "localname": "RestructuringExpenseAndIncome",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_ReturnsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Returns.",
        "label": "Returns [Member]",
        "terseLabel": "Returns [Member]"
       }
      }
     },
     "localname": "ReturnsMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_RevenueRecognitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition [Line Items]",
        "label": "Revenue Recognition [Line Items]",
        "terseLabel": "Revenue Recognition [Line Items]"
       }
      }
     },
     "localname": "RevenueRecognitionLineItems",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_RevenueRecognitionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition [Table]",
        "label": "Revenue Recognition [Table]",
        "terseLabel": "Revenue Recognition [Table]"
       }
      }
     },
     "localname": "RevenueRecognitionTable",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_RevenueTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Type [Axis]"
       }
      }
     },
     "localname": "RevenueTypeAxis",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_RevenueTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Type [Domain]"
       }
      }
     },
     "localname": "RevenueTypeDomain",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_RevenuesOtherThanUsd": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues other than US Dollar.",
        "label": "Revenues Other Than Usd",
        "terseLabel": "Revenues other than USD"
       }
      }
     },
     "localname": "RevenuesOtherThanUsd",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "teva_SalesReservesAndAllowances": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the balance sheet amounts of the allowances for chargebacks, returns, rebates, other promotional items and price protection.",
        "label": "Sales Reserves And Allowances",
        "terseLabel": "Sales reserves and allowances"
       }
      }
     },
     "localname": "SalesReservesAndAllowances",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_SalesReservesAndAllowancesCurrentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of sales reserves and allowances current.",
        "label": "Sales Reserves And Allowances Current [Table Text Block]",
        "terseLabel": "Summary of Sales Reserves and Allowances"
       }
      }
     },
     "localname": "SalesReservesAndAllowancesCurrentTableTextBlock",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_SalesReservesAndAllowancesToCustomersPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales reserves and allowances to customers percentage.",
        "label": "Sales Reserves and Allowances to Customers Percentage",
        "terseLabel": "Percentage sales reserves and allowances to U.S. customers"
       }
      }
     },
     "localname": "SalesReservesAndAllowancesToCustomersPercentage",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Assets And Liabilities Held For Sale [Table Text Block]",
        "label": "Schedule Of Assets And Liabilities Held For Sale [Table Text Block]",
        "terseLabel": "Summary of Major Classes of Assets and Liabilities Included as Held for Sale"
       }
      }
     },
     "localname": "ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of consolidated income before income tax.",
        "label": "Schedule Of Consolidated Income Before Income Tax [Table Text Block]",
        "terseLabel": "Schedule Of Consolidated Income Before Income Tax"
       }
      }
     },
     "localname": "ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_ScheduleOfRestructuringChargesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Restructuring Charges [Table Text Block]",
        "label": "Schedule of Restructuring Charges [Table Text Block]",
        "terseLabel": "Summary of Restructuring Plan Including Costs Related to Exit and Disposal"
       }
      }
     },
     "localname": "ScheduleOfRestructuringChargesTableTextBlock",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_SegmentsAndOtherActivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Segments and other activities.",
        "label": "Segments And Other Activities [Member]",
        "terseLabel": "Segments and Other Activities [Member]"
       }
      }
     },
     "localname": "SegmentsAndOtherActivitiesMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SeniorNotesAndLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior notes and loans.",
        "label": "Senior Notes And Loans [Member]",
        "terseLabel": "Accounts Payable [Member]"
       }
      }
     },
     "localname": "SeniorNotesAndLoansMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SeniorNotesAndSustainabilityLinkedSeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior notes and sustainability linked senior notes.",
        "label": "Senior Notes And Sustainability Linked Senior Notes [Member]",
        "terseLabel": "Senior Notes And Sustainability Linked Senior Notes [Member]"
       }
      }
     },
     "localname": "SeniorNotesAndSustainabilityLinkedSeniorNotesMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SeniorNotesDue2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Due 2021 [Member]",
        "label": "Senior Notes Due 2021 [Member]",
        "terseLabel": "Senior Notes Due 2021 [Member]"
       }
      }
     },
     "localname": "SeniorNotesDue2021Member",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SeniorNotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior notes due 2022.",
        "label": "Senior Notes Due 2022 [Member]",
        "terseLabel": "Senior Notes Due 2022 [Member]"
       }
      }
     },
     "localname": "SeniorNotesDue2022Member",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SeniorNotesDue2023TwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior notes due 2023 two.",
        "label": "Senior Notes Due 2023 Two [Member]",
        "terseLabel": "Senior Notes Due 2023 Two [Member]"
       }
      }
     },
     "localname": "SeniorNotesDue2023TwoMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SeniorNotesMaturityPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior notes maturity percentage.",
        "label": "Senior Notes Maturity Percentage",
        "verboseLabel": "Senior notes maturity percentage"
       }
      }
     },
     "localname": "SeniorNotesMaturityPercentage",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "teva_SeniorNotesRepaidAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior notes repaid amount.",
        "label": "Senior Notes Repaid Amount",
        "verboseLabel": "Senior notes repaid amount"
       }
      }
     },
     "localname": "SeniorNotesRepaidAmount",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_SeniornotesandconvertibleseniordebenturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior notes and convertible senior debentures.",
        "label": "Seniornotesandconvertibleseniordebentures [Member]",
        "terseLabel": "Senior Notes and Convertible Senior Debentures Included Under Short-Term Debt [Member]"
       }
      }
     },
     "localname": "SeniornotesandconvertibleseniordebenturesMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SettlementOnAccountOfProductLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement On Account Of Product Liability.",
        "label": "Settlement On Account Of Product Liability [Member]"
       }
      }
     },
     "localname": "SettlementOnAccountOfProductLiabilityMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_ShortCreditAgreement2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short credit agreement 2026.",
        "label": "Short Credit Agreement 2026 [Member]",
        "terseLabel": "Convertible senior debentures [Member]"
       }
      }
     },
     "localname": "ShortCreditAgreement2026Member",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_StatesPoliticalSubdivisionsAndTribesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "States political subdivisions and tribes.",
        "label": "States Political Subdivisions And Tribes [Member]",
        "terseLabel": "States Political Subdivisions and Tribes [Member]"
       }
      }
     },
     "localname": "StatesPoliticalSubdivisionsAndTribesMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2022OneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary senior notes due 2022 one.",
        "label": "Subsidiary Senior Notes Due 2022 One [Member]",
        "terseLabel": "Senior notes EUR 700 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2022OneMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2022ThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary Senior Notes Due 2022 Three [Member]",
        "label": "Subsidiary Senior Notes Due 2022 Three [Member]",
        "terseLabel": "Senior notes CHF 350 Million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2022ThreeMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2022TwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary senior notes due 2022 two.",
        "label": "Subsidiary Senior Notes Due 2022 Two [Member]",
        "terseLabel": "Senior notes USD 844 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2022TwoMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2023OneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary senior notes due 2023 one.",
        "label": "Subsidiary Senior Notes Due 2023 One [Member]",
        "terseLabel": "Senior notes EUR 1,300 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2023OneMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2023TwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary senior notes due 2023 two.",
        "label": "Subsidiary Senior Notes Due 2023 Two [Member]",
        "terseLabel": "Senior notes USD 3,000 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2023TwoMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary senior notes due 2024.",
        "label": "Subsidiary Senior Notes Due 2024 [Member]",
        "terseLabel": "Senior notes EUR 1,500 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2024Member",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2024OneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary Senior Notes Due 2024 One [Member]",
        "label": "Subsidiary Senior Notes Due 2024 One [Member]",
        "terseLabel": "Senior notes USD 1,250 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2024OneMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary Senior Notes Due 2025 Member",
        "label": "Subsidiary Senior Notes Due 2025 [Member]",
        "terseLabel": "Senior notes EUR 900 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2025Member",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2025OneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary Senior Notes Due 2025 One [Member]",
        "label": "Subsidiary Senior Notes Due 2025 One [Member]",
        "terseLabel": "Senior notes EUR 1,000 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2025OneMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2025ThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary senior notes due 2025 three.",
        "label": "Subsidiary Senior Notes Due 2025 Three [Member]",
        "terseLabel": "Senior notes CHF 350 Million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2025ThreeMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2025TwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary senior notes due 2025 two.",
        "label": "Subsidiary Senior Notes Due 2025 Two [Member]",
        "terseLabel": "Senior notes USD 1,000 million [Member]",
        "verboseLabel": "Senior notes USD 1,000 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2025TwoMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2026OneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary senior notes due 2026 one.",
        "label": "Subsidiary Senior Notes Due 2026 One [Member]",
        "terseLabel": "Senior notes USD 3,500 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2026OneMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary senior notes due 2027.",
        "label": "Subsidiary Senior Notes Due 2027 [Member]",
        "terseLabel": "Senior notes EUR 700 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2027Member",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary senior notes due 2028.",
        "label": "Subsidiary Senior Notes Due 2028 [Member]",
        "terseLabel": "Senior notes EUR 750 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2028Member",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2028OneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary Senior Notes Due 2028 One [Member]",
        "label": "Subsidiary Senior Notes Due 2028 One [Member]",
        "terseLabel": "Senior notes USD 1,250 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2028OneMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary senior notes due 2030.",
        "label": "Subsidiary Senior Notes Due 2030 [Member]",
        "terseLabel": "Sustainability-linked senior notes EUR 1,500 million"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2030Member",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary senior notes due 2036.",
        "label": "Subsidiary Senior Notes Due 2036 [Member]",
        "terseLabel": "Senior notes USD 789 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2036Member",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2046Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary senior notes due 2046.",
        "label": "Subsidiary Senior Notes Due 2046 [Member]",
        "terseLabel": "Senior notes USD 2,000 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2046Member",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SustainabilityLinkedSeniorNotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sustainability linked senior notes due 2027.",
        "label": "Sustainability Linked Senior Notes Due 2027 [Member]",
        "terseLabel": "Sustainability-linked senior notes EUR 1,100\u00a0million [Member]"
       }
      }
     },
     "localname": "SustainabilityLinkedSeniorNotesDue2027Member",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SustainabilityLinkedSeniorNotesDue2027TwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sustainability linked senior notes due 2027 two.",
        "label": "Sustainability Linked Senior Notes Due 2027 Two [Member]",
        "terseLabel": "Sustainability-linked senior notes USD 1,000\u00a0million [Member]"
       }
      }
     },
     "localname": "SustainabilityLinkedSeniorNotesDue2027TwoMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SustainabilityLinkedSeniorNotesDue2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sustainability linked senior notes due 2029.",
        "label": "Sustainability Linked Senior Notes Due 2029 [Member]",
        "terseLabel": "Sustainability-linked senior notes USD 1,000\u00a0million [Member]"
       }
      }
     },
     "localname": "SustainabilityLinkedSeniorNotesDue2029Member",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SustainabilityLinkedSeniorNotesDue2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sustainability linked senior notes due 2030.",
        "label": "Sustainability Linked Senior Notes Due 2030 [Member]",
        "terseLabel": "Sustainability-linked senior notes EUR 1,500\u00a0million [Member]"
       }
      }
     },
     "localname": "SustainabilityLinkedSeniorNotesDue2030Member",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_TakedaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Takeda.",
        "label": "Takeda [Member]",
        "terseLabel": "Takeda [Member]"
       }
      }
     },
     "localname": "TakedaMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_TaxYear2008To2011Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2008 To 2011 [Member]"
       }
      }
     },
     "localname": "TaxYear2008To2011Member",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_TevasApiReportingUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Teva's API reporting unit.",
        "label": "Tevas API Reporting Unit [Member]"
       }
      }
     },
     "localname": "TevasApiReportingUnitMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_TevasEuropeReportingUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Teva's europe reporting unit.",
        "label": "Tevas Europe Reporting Unit [Member]"
       }
      }
     },
     "localname": "TevasEuropeReportingUnitMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_TiruvadaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tiruvada [Member]"
       }
      }
     },
     "localname": "TiruvadaMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_TotalReservesIncludedInSalesReservesAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total reserves included in sales reserves and allowances.",
        "label": "Total Reserves Included In Sales Reserves And Allowances [Member]",
        "terseLabel": "Total Reserves Included in Sales Reserves and Allowances [Member]"
       }
      }
     },
     "localname": "TotalReservesIncludedInSalesReservesAndAllowancesMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_TrancheAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche.",
        "label": "Tranche [Axis]"
       }
      }
     },
     "localname": "TrancheAxis",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_TrancheDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche.",
        "label": "Tranche [Domain]"
       }
      }
     },
     "localname": "TrancheDomain",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_UnrealizedGainLossOnDerivativeNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrealized gain (loss) on derivative net of tax.",
        "label": "Unrealized gain (loss) on derivative net of tax",
        "terseLabel": "Unrealized gain (loss) from derivative financial instruments, net"
       }
      }
     },
     "localname": "UnrealizedGainLossOnDerivativeNetOfTax",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_UnsecuredSyndicatedRevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unsecured Syndicated Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "UnsecuredSyndicatedRevolvingCreditFacilityMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_UpfrontPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payments",
        "label": "Upfront Payments",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "UpfrontPayments",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_UtilizationAndOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Utilization and other.",
        "label": "Utilization And Other",
        "terseLabel": "Utilization and other"
       }
      }
     },
     "localname": "UtilizationAndOther",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_ValuationAllowancesAndReservesForeignCurrencyTranslation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation allowances and reserves foreign currency translation.",
        "label": "Valuation Allowances And Reserves Foreign Currency Translation",
        "terseLabel": "Translation differences"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesForeignCurrencyTranslation",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation allowances and reserves related to current period sales.",
        "label": "Valuation Allowances And Reserves Related To Current Period Sales",
        "terseLabel": "Provisions related to sales made in current year"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesRelatedToCurrentPeriodSales",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation allowances and reserves related to prior period sales.",
        "label": "Valuation Allowances And Reserves Related To Prior Period Sales",
        "terseLabel": "Provisions related to sales made in prior periods"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesRelatedToPriorPeriodSales",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_VireadMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Viread [Member]"
       }
      }
     },
     "localname": "VireadMember",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_WholesaleAcquisitionCostValueInCashAmountInLieuOfProductToBePaidUnderSettlementAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wholesale acquisition cost value in cash amount in lieu of product to be paid under settlement agreement.",
        "label": "Wholesale Acquisition Cost Value In Cash Amount In Lieu Of Product To Be Paid Under Settlement Agreement",
        "terseLabel": "Wholesale acquisition cost value in cash amount in lieu of product to be paid under settlement agreement"
       }
      }
     },
     "localname": "WholesaleAcquisitionCostValueInCashAmountInLieuOfProductToBePaidUnderSettlementAgreement",
     "nsuri": "http://www.tevapharm.com/20220630",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201601Member": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-01 Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.",
        "label": "Accounting Standards Update 2016-01 [Member]",
        "terseLabel": "Accounting Standards Update 2016-01 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201601Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "auth_ref": [
      "r18",
      "r53"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Trade, Current",
        "verboseLabel": "Accounts payables"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r207",
      "r208"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 24.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Accounts receivables, net of allowance for credit losses of $95 million and $90 million as of June 30, 2022 and December 31, 2021"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccrualForEnvironmentalLossContingencies": {
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r279",
      "r296",
      "r302"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs accrued as of the balance sheet date for environmental loss contingencies.",
        "label": "Accrual for Environmental Loss Contingencies",
        "terseLabel": "Accrual for Environmental Loss Contingencies"
       }
      }
     },
     "localname": "AccrualForEnvironmentalLossContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r77",
      "r81",
      "r89",
      "r90",
      "r91",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Benefit Plans [Member]"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r76",
      "r81",
      "r89",
      "r90",
      "r91",
      "r477",
      "r546",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the noncontrolling interest.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Foreign Currency Translation Adjustments Attributable to Non-controlling Interests [Member]"
       }
      }
     },
     "localname": "AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r81",
      "r89",
      "r90",
      "r91",
      "r92",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Derivative Financial Instruments [Member]"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail",
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r38",
      "r79",
      "r80",
      "r81",
      "r658",
      "r685",
      "r689"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 19.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail",
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r78",
      "r81",
      "r89",
      "r90",
      "r91",
      "r138",
      "r139",
      "r140",
      "r477",
      "r573",
      "r680",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "AOCI Attributable to Parent [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r76",
      "r81",
      "r89",
      "r90",
      "r91",
      "r477",
      "r547",
      "r548",
      "r549",
      "r550",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign Currency Translation Adjustments [Member]"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r36",
      "r579"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 17.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "verboseLabel": "Additional\u00a0paid-in\u00a0capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r425",
      "r426",
      "r427",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r116",
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r141",
      "r142",
      "r143",
      "r144",
      "r153",
      "r211",
      "r212",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r425",
      "r426",
      "r427",
      "r441",
      "r442",
      "r443",
      "r444",
      "r459",
      "r460",
      "r461",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r554",
      "r555",
      "r561",
      "r562",
      "r563",
      "r564",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r617",
      "r618",
      "r619",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r421",
      "r428",
      "r429"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by operations:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllOtherSegmentsMember": {
     "auth_ref": [
      "r170",
      "r188",
      "r189",
      "r190",
      "r191",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.",
        "label": "Other Segments [Member]",
        "terseLabel": "Other Segments [Member]"
       }
      }
     },
     "localname": "AllOtherSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r42",
      "r209",
      "r227"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "verboseLabel": "Allowance for credit losses"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r116",
      "r258",
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Weighted average shares with anti-dilutive effect on earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r116",
      "r267"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Impairment of goodwill long-lived assets and assets held for sale"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r27",
      "r126",
      "r183",
      "r190",
      "r197",
      "r220",
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r321",
      "r323",
      "r324",
      "r471",
      "r478",
      "r535",
      "r577",
      "r579",
      "r635",
      "r655"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r16",
      "r52",
      "r126",
      "r220",
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r321",
      "r323",
      "r324",
      "r471",
      "r478",
      "r535",
      "r577",
      "r579"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 22.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueAdjustment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of addition (reduction) to the amount at which an asset could be incurred (settled) in a current transaction between willing parties.",
        "label": "Assets, Fair Value Adjustment",
        "terseLabel": "Adjustments of assets held for sale to fair value"
       }
      }
     },
     "localname": "AssetsFairValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r10",
      "r11",
      "r12",
      "r268",
      "r273"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 28.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "terseLabel": "Assets held for sale",
        "verboseLabel": "Total assets of the disposal group classified as held for sale in the consolidated balance sheets"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail",
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r490",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "verboseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/BasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r416",
      "r419",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r416",
      "r419",
      "r454",
      "r455",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Business acquisition, Percentage of voting interests acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Consideration Transferred [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r115",
      "r465"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail": {
       "order": 2.0,
       "parentTag": "teva_ImpairmentAndRestructuring",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Business combination contingent consideration arrangements change in amount of contingent consideration liability",
        "verboseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r462",
      "r463",
      "r464"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "negatedLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Business combination, contingent consideration, liability, measurement input"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r456"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "terseLabel": "Business combination recognized identifiable assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r13",
      "r23",
      "r118"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 23.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 23.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r113",
      "r118",
      "r122"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Balance of cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Balance of cash, cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash shown in the statement of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash reported in the consolidated balance sheets:"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r113",
      "r545"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r64",
      "r641",
      "r663"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies, see note 10"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r305",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r138",
      "r139",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Ordinary Shares [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par or stated value per share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Ordinary shares, authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Ordinary shares, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r35",
      "r579"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 16.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Ordinary shares of NIS 0.10 par value per share; June 30, 2022 and December 31, 2021: authorized 2,495 million shares; issued 1,216 million shares and 1,209 million shares, respectively."
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r85",
      "r87",
      "r88",
      "r98",
      "r647",
      "r670"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss) attributable to Teva"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r85",
      "r87",
      "r97",
      "r469",
      "r470",
      "r482",
      "r646",
      "r669"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 7.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive income (loss) attributable to non-controlling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r85",
      "r87",
      "r96",
      "r468",
      "r482",
      "r645",
      "r668"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Total comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r168",
      "r169",
      "r205",
      "r533",
      "r534",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r168",
      "r169",
      "r205",
      "r533",
      "r534",
      "r690",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r168",
      "r169",
      "r205",
      "r533",
      "r534",
      "r690",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r168",
      "r169",
      "r205",
      "r533",
      "r534",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r329",
      "r339",
      "r340",
      "r341",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r356",
      "r357",
      "r358",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt [Member]"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r361",
      "r362",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateMember": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items.",
        "label": "Corporate Segment [Member]",
        "terseLabel": "Corporate Segment [Member]"
       }
      }
     },
     "localname": "CorporateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r101",
      "r615"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 14.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of sales [Member]"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CrossCurrencyInterestRateContractMember": {
     "auth_ref": [
      "r406",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates.",
        "label": "Cross Currency Interest Rate Contract [Member]",
        "verboseLabel": "Liabilities Derivatives - Interest Rate and Cross Currency Swaps [Member]"
       }
      }
     },
     "localname": "CrossCurrencyInterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r119",
      "r121"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "negatedLabel": "Redemption of convertible senior notes"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Total short term debt",
        "documentation": "Amount of debt and lease obligation, classified as current.",
        "label": "Debt, Current",
        "terseLabel": "Short-term debt"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r123",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r343",
      "r350",
      "r351",
      "r353",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt obligations"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r29",
      "r30",
      "r32",
      "r125",
      "r131",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r339",
      "r340",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r356",
      "r357",
      "r358",
      "r359",
      "r559",
      "r636",
      "r637",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r32",
      "r354",
      "r637",
      "r653"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Principal amount currently outstanding on the debt instruments"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentCovenantDescription": {
     "auth_ref": [
      "r32",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of minimum financial levels (for example, tangible net worth and working capital) and achievement of certain financial ratios (for example, working capital ratio and debt service coverage ratio), and adherence to certain clauses which generally require or restrict certain actions (for example, entering into a debt arrangement with equal or greater seniority, and selling or discontinuing a certain business segment or material subsidiary) to be in compliance with the covenant clauses of the debt agreement. May also include a discussion of the adverse consequences that would result if the entity violates or fails to satisfy the covenants.",
        "label": "Debt Instrument, Covenant Description"
       }
      }
     },
     "localname": "DebtInstrumentCovenantDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r326",
      "r356",
      "r357",
      "r557",
      "r559",
      "r560"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r341",
      "r356",
      "r357",
      "r532"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r60",
      "r355",
      "r557",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Weighted average interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument.",
        "label": "Debt Instrument, Interest Rate, Increase (Decrease)",
        "terseLabel": "Debt Instrument, Interest Rate, Increase (Decrease)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r61",
      "r329",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Debt Instrument, Maturity Date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r62",
      "r125",
      "r131",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r339",
      "r340",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r356",
      "r357",
      "r358",
      "r359",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r62",
      "r125",
      "r131",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r339",
      "r340",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r352",
      "r356",
      "r357",
      "r358",
      "r359",
      "r378",
      "r379",
      "r380",
      "r381",
      "r556",
      "r557",
      "r559",
      "r560",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFinanceCostsNoncurrentNet": {
     "auth_ref": [
      "r558"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Noncurrent, Net",
        "negatedLabel": "Less debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNoncurrentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r431",
      "r432"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 29.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.",
        "label": "Deferred Tax and Other Liabilities, Noncurrent",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredTaxAndOtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DemandDepositsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts that may or may not bear interest and that depositor is entitled to withdraw at anytime without prior notice. Checking and negotiable order of withdrawal (NOW) accounts are the most common forms of demand deposits.",
        "label": "Demand Deposits [Member]",
        "terseLabel": "Cash, Deposits and Other [Member]"
       }
      }
     },
     "localname": "DemandDepositsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r116",
      "r269"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r69",
      "r70",
      "r73",
      "r532"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Derivatives"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss": {
     "auth_ref": [
      "r507"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on derivative instrument designated and qualifying as fair value hedge included in assessment of hedge effectiveness, recognized in earnings.",
        "label": "Derivative, Fair Value Hedge, Included in Effectiveness, Gain (Loss)",
        "terseLabel": "Derivative, Fair Value Hedge, Included in Effectiveness, Gain (Loss)"
       }
      }
     },
     "localname": "DerivativeFairValueHedgeIncludedInEffectivenessGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r68",
      "r73",
      "r74",
      "r493",
      "r595"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Asset derivatives"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r68",
      "r73",
      "r74",
      "r493",
      "r595"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "negatedLabel": "Liability derivatives"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainOnDerivative": {
     "auth_ref": [
      "r492"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain on Derivative"
       }
      }
     },
     "localname": "DerivativeGainOnDerivative",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentDetailAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument Detail [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentDetailAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r73",
      "r491",
      "r494",
      "r498",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r509",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Derivative Instruments and Hedging Activities"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r488",
      "r491",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r69",
      "r70",
      "r73",
      "r532"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "negatedLabel": "Derivatives"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLossOnDerivative": {
     "auth_ref": [
      "r492"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Loss on Derivative",
        "terseLabel": "Teva other comprehensive loss"
       }
      }
     },
     "localname": "DerivativeLossOnDerivative",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r483",
      "r484",
      "r485",
      "r488",
      "r489",
      "r496",
      "r498",
      "r504",
      "r505",
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Abstract]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r395",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Summary of disaggregates revenues by major revenue streams"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r10",
      "r268",
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Goodwill, Current",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r10",
      "r268",
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Inventory, Current",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r10",
      "r268",
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current",
        "terseLabel": "Property, plant and equipment, net and others"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DistributionServiceMember": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Distribution assistance, including, but not limited to, marketing and selling fund shares, advertising, printing and mailing of prospectus and sale literature to investor.",
        "label": "Distribution Service [Member]",
        "terseLabel": "Distribution [Member]"
       }
      }
     },
     "localname": "DistributionServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings (loss) per share attributable to ordinary shareholders:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r99",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r154",
      "r156",
      "r158",
      "r159",
      "r160",
      "r164",
      "r165",
      "r520",
      "r521",
      "r648",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic",
        "verboseLabel": "Earnings per share, Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r99",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r156",
      "r158",
      "r159",
      "r160",
      "r164",
      "r165",
      "r520",
      "r521",
      "r648",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted",
        "verboseLabel": "Earnings per share, Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings (Loss) per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/EarningsLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r545"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Translation adjustment on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r127",
      "r434",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory tax rate in Israel"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee-related obligations"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Employee termination [Member]"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r89",
      "r90",
      "r91",
      "r138",
      "r139",
      "r140",
      "r142",
      "r150",
      "r152",
      "r167",
      "r224",
      "r377",
      "r382",
      "r425",
      "r426",
      "r427",
      "r443",
      "r444",
      "r519",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r552",
      "r573",
      "r680",
      "r681",
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail",
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r215",
      "r654",
      "r691",
      "r692",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Equity Securities [Member]"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r524",
      "r525",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.",
        "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]",
        "terseLabel": "Summary of Financial Instrument Measured on a Basis Other Than Fair Value"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r524",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r341",
      "r356",
      "r357",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r415",
      "r525",
      "r585",
      "r586",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r530",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair value measurement"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r341",
      "r406",
      "r407",
      "r412",
      "r415",
      "r525",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r341",
      "r356",
      "r357",
      "r406",
      "r407",
      "r412",
      "r415",
      "r525",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r341",
      "r356",
      "r357",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r415",
      "r525",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r528",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "auth_ref": [
      "r529"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "verboseLabel": "Redemption of debt securities"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r529"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "terseLabel": "Settlement of contingent consideration"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r528"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "negatedPeriodEndLabel": "Fair value at the end of the period",
        "negatedPeriodStartLabel": "Fair value at the beginning of the period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r341",
      "r356",
      "r357",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r415",
      "r585",
      "r586",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetAssetLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of asset after deduction of liability.",
        "label": "Fair Value, Net Asset (Liability)",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "FairValueNetAssetLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r213",
      "r214",
      "r216",
      "r217",
      "r218",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r352",
      "r375",
      "r509",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Amortization of intangible assets useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r25",
      "r262"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r259",
      "r260",
      "r262",
      "r264",
      "r616",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r262",
      "r620"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross carrying amount net of impairment"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r259",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r262",
      "r616"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 32.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Identifiable intangible assets, net",
        "totalLabel": "Net carrying amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r73",
      "r406",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign Exchange Contract [Member]"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis": {
     "auth_ref": [
      "r577",
      "r578",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by adjustment for effect of reorganization under Chapter 11 of Bankruptcy Code. Includes, but is not limited to, adjustment for reorganization plan effect and adoption of fresh-start reporting.",
        "label": "Fresh-Start Adjustments [Axis]",
        "terseLabel": "Fresh-Start Adjustments [Axis]"
       }
      }
     },
     "localname": "FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "auth_ref": [
      "r491"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.",
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "terseLabel": "Gain (Loss) on Derivative Instruments, Net, Pretax"
       }
      }
     },
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "G&amp;A expenses",
        "verboseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r24",
      "r242",
      "r244",
      "r251",
      "r256",
      "r579",
      "r634"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 33.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r245",
      "r256"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill acquired"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillDisclosureTextBlock": {
     "auth_ref": [
      "r252",
      "r254",
      "r256",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill.",
        "label": "Goodwill Disclosure [Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/Goodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "negatedLabel": "Translation differences"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r244",
      "r251",
      "r256"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Accumulated goodwill impairment"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r116",
      "r243",
      "r248",
      "r255",
      "r256"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 8.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "negatedLabel": "Goodwill impairment",
        "terseLabel": "Goodwill impairment"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r100",
      "r126",
      "r183",
      "r189",
      "r193",
      "r196",
      "r199",
      "r220",
      "r310",
      "r311",
      "r312",
      "r315",
      "r316",
      "r317",
      "r319",
      "r321",
      "r323",
      "r324",
      "r535"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 12.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "terseLabel": "Gross profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r488",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r116",
      "r265"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Impairment of intangible assets excluding goodwill",
        "verboseLabel": "Intangible assets impairments"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r116",
      "r267",
      "r271"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail": {
       "order": 1.0,
       "parentTag": "teva_ImpairmentAndRestructuring",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment of Long-Lived Assets Held-for-use",
        "terseLabel": "Impairments of long-lived tangible assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In Process Research and Development [Member]",
        "verboseLabel": "In process research and development [Member]"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r183",
      "r189",
      "r193",
      "r196",
      "r199"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Pre-tax income (loss)",
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r93",
      "r116",
      "r180",
      "r219",
      "r642",
      "r665"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 17.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Share in (profits) losses of associated companies, net"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r272",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r127",
      "r435",
      "r438",
      "r439",
      "r445",
      "r448",
      "r450",
      "r451",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss": {
     "auth_ref": [
      "r436"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated amount of loss resulting from an adverse tax position.",
        "label": "Income Tax Examination, Estimate of Possible Loss",
        "terseLabel": "Income Tax Examination, Estimate of Possible Loss"
       }
      }
     },
     "localname": "IncomeTaxExaminationEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r128",
      "r151",
      "r152",
      "r181",
      "r433",
      "r446",
      "r449",
      "r672"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 16.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income taxes (benefit)",
        "verboseLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapital": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.",
        "label": "Increase (Decrease) in Operating Capital",
        "negatedLabel": "Net change in operating assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Identifiable Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Asset Derivatives - Options and Forward Contracts [Member]"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r43",
      "r238"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished products"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r14",
      "r49",
      "r579"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 25.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r45",
      "r238"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw and packaging materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r44",
      "r238"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Products in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r237"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Obsolete stock written off"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r524"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Investment in securities"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IsraelTaxAuthorityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of Israel.",
        "label": "Israel Tax Authority [Member]",
        "terseLabel": "Israel Tax Authority [Member]"
       }
      }
     },
     "localname": "IsraelTaxAuthorityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "terseLabel": "Legal Settlements and Loss Contingencies"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r57",
      "r126",
      "r191",
      "r220",
      "r310",
      "r311",
      "r312",
      "r315",
      "r316",
      "r317",
      "r319",
      "r321",
      "r323",
      "r324",
      "r472",
      "r478",
      "r479",
      "r535",
      "r577",
      "r578"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r41",
      "r126",
      "r220",
      "r535",
      "r579",
      "r639",
      "r661"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r17",
      "r59",
      "r126",
      "r220",
      "r310",
      "r311",
      "r312",
      "r315",
      "r316",
      "r317",
      "r319",
      "r321",
      "r323",
      "r324",
      "r472",
      "r478",
      "r479",
      "r535",
      "r577",
      "r578",
      "r579"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r32",
      "r33",
      "r126",
      "r220",
      "r310",
      "r311",
      "r312",
      "r315",
      "r316",
      "r317",
      "r319",
      "r321",
      "r323",
      "r324",
      "r472",
      "r478",
      "r479",
      "r535",
      "r577",
      "r578"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 9.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long-term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Long-term liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r10",
      "r11",
      "r12",
      "r268",
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current",
        "negatedLabel": "Total liabilities of the disposal group classified as held for sale in the consolidated balance sheets, recorded under accrued expenses and other long-term liabilities"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "Licensing Arrangements [Member]"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r54",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r54",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Litigation settlement amount"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Legal settlements and loss contingencies, expense",
        "verboseLabel": "Litigation Settlement, Expense"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "negatedLabel": "Less current maturities",
        "terseLabel": "Current maturities of long-term liabilities"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermNotesAndLoans": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 12.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Notes and Loans, Noncurrent",
        "terseLabel": "Senior notes and loans",
        "verboseLabel": "Total senior notes and loans"
       }
      }
     },
     "localname": "LongTermNotesAndLoans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of items purchased under a long-term purchase commitment.",
        "label": "Category of Item Purchased [Axis]",
        "terseLabel": "Category of Item Purchased [Axis]"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment.",
        "label": "Long-term Purchase Commitment, Category of Item Purchased [Domain]",
        "terseLabel": "Long-term Purchase Commitment, Category of Item Purchased [Domain]"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r62",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongtermDebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of long-term debt outstanding calculated at point in time.",
        "label": "Long-term Debt, Weighted Average Interest Rate, at Point in Time",
        "verboseLabel": "Weighted average interest rate"
       }
      }
     },
     "localname": "LongtermDebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r296",
      "r298",
      "r299",
      "r300",
      "r301",
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r296",
      "r298",
      "r299",
      "r300",
      "r301",
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r296",
      "r297"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Accrued amount for legal settlements and loss contingencies",
        "verboseLabel": "Generic modafinil, and imposed fines amount"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualProvision": {
     "auth_ref": [
      "r296"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.",
        "label": "Loss Contingency Accrual, Provision",
        "terseLabel": "Loss Contingency Accrual, Provision"
       }
      }
     },
     "localname": "LossContingencyAccrualProvision",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesPaidValue": {
     "auth_ref": [
      "r296",
      "r298",
      "r300"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of damages paid to the plaintiff in the legal matter.",
        "label": "Loss Contingency, Damages Paid, Value",
        "terseLabel": "Loss contingency payment"
       }
      }
     },
     "localname": "LossContingencyDamagesPaidValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r296",
      "r298",
      "r300"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Damage claimed"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r296",
      "r298",
      "r299",
      "r300",
      "r301",
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement input, discount rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r67",
      "r126",
      "r220",
      "r310",
      "r315",
      "r316",
      "r317",
      "r323",
      "r324",
      "r535",
      "r638",
      "r660"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 21.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Non-controlling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Markets [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r113",
      "r114",
      "r117"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r12",
      "r83",
      "r86",
      "r91",
      "r94",
      "r117",
      "r126",
      "r141",
      "r145",
      "r146",
      "r147",
      "r148",
      "r151",
      "r152",
      "r157",
      "r183",
      "r189",
      "r193",
      "r196",
      "r199",
      "r220",
      "r310",
      "r311",
      "r312",
      "r315",
      "r316",
      "r317",
      "r319",
      "r321",
      "r323",
      "r324",
      "r521",
      "r535",
      "r643",
      "r666"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income (loss) attributable to Teva"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r83",
      "r86",
      "r91",
      "r151",
      "r152",
      "r474",
      "r481"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 18.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss) attributable to non-controlling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Recently adopted and issued accounting pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/BasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Noncash or Part Noncash Acquisitions [Line Items]",
        "terseLabel": "Noncash or Part Noncash Acquisitions [Line Items]"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionsTable": {
     "auth_ref": [
      "r119",
      "r120",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The process of acquiring assets or a business through noncash (or part noncash) transactions. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisitions [Table]",
        "terseLabel": "Noncash or Part Noncash Acquisitions [Table]"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r382",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non-controlling Interests [Member]"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument [Member]"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 15.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "negatedLabel": "Financial expenses, net",
        "negatedTerseLabel": "Financial expenses, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument, not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP), used as economic hedge for exposure to risk.",
        "label": "Not Designated as Hedging Instrument, Economic Hedge [Member]",
        "terseLabel": "Not Designated as Hedging Instrument, Economic Hedge [Member]"
       }
      }
     },
     "localname": "NotDesignatedAsHedgingInstrumentEconomicHedgeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotDesignatedAsHedgingInstrumentTradingMember": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument, not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP), used for trading purposes for exposure to risk.",
        "label": "Not Designated as Hedging Instrument, Trading [Member]",
        "terseLabel": "Not Designated as Hedging Instrument, Trading [Member]"
       }
      }
     },
     "localname": "NotDesignatedAsHedgingInstrumentTradingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent": {
     "auth_ref": [
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "OCI, before Reclassifications, before Tax, Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss) before reclassifications"
       }
      }
     },
     "localname": "OciBeforeReclassificationsBeforeTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r183",
      "r189",
      "r193",
      "r196",
      "r199"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "presentationGuidance": "Segments profit",
        "terseLabel": "Segment profit",
        "totalLabel": "Operating income (loss)",
        "verboseLabel": "Consolidated operating income (loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r566"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 13.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r565"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 34.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r51",
      "r579"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 27.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 30.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other\u00a0non-current\u00a0assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent": {
     "auth_ref": [
      "r468",
      "r469",
      "r476"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent",
        "terseLabel": "Net other comprehensive income (loss) before tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax": {
     "auth_ref": [
      "r79",
      "r82",
      "r413"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of increase (decrease) to other comprehensive income from settlement and curtailment gain (loss) of defined benefit plan.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement and Curtailment Gain (Loss), after Tax",
        "verboseLabel": "Unrealized loss on defined benefit plans"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r84",
      "r87",
      "r89",
      "r90",
      "r92",
      "r95",
      "r377",
      "r546",
      "r551",
      "r552",
      "r644",
      "r667"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss)",
        "totalLabel": "Total other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss), net of tax:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r84",
      "r87",
      "r468",
      "r469",
      "r476"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Foreign currency translation attributable to non-controlling interests"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r84",
      "r87",
      "r468",
      "r469",
      "r476"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Net other comprehensive income (loss) after tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": {
     "auth_ref": [
      "r468",
      "r469",
      "r476"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent",
        "negatedLabel": "Corresponding income tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r490",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherInventoryInTransit": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of merchandise or supplies to which the entity holds the title but does not hold physical possession because the goods are currently being transported.",
        "label": "Other Inventory, in Transit, Gross",
        "terseLabel": "Materials in transit and payments on account"
       }
      }
     },
     "localname": "OtherInventoryInTransit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r58",
      "r579"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 11.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other taxes and long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other items"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 9.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "negatedLabel": "Other income"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherRestructuringMember": {
     "auth_ref": [
      "r281",
      "r282",
      "r290",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and related activities classified as other.",
        "label": "Other Restructuring [Member]",
        "terseLabel": "Other [Member]"
       }
      }
     },
     "localname": "OtherRestructuringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Total Teva Shareholders' Equity [Member]"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r105",
      "r108"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other investing activities"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisition of businesses, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r15",
      "r50",
      "r240",
      "r241"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 26.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Proceeds from sale of business and long lived assets"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r109",
      "r111"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other financing activities"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Proceeds from sale of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other [Member]"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Product Information [Line Items]",
        "terseLabel": "Product Information [Line Items]"
       }
      }
     },
     "localname": "ProductInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Sale of Goods [Member]"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r12",
      "r83",
      "r86",
      "r91",
      "r112",
      "r126",
      "r141",
      "r151",
      "r152",
      "r183",
      "r189",
      "r193",
      "r196",
      "r199",
      "r220",
      "r310",
      "r311",
      "r312",
      "r315",
      "r316",
      "r317",
      "r319",
      "r321",
      "r323",
      "r324",
      "r468",
      "r473",
      "r475",
      "r481",
      "r482",
      "r521",
      "r535",
      "r649"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 6.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net Income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r270",
      "r579",
      "r650",
      "r662"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 31.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": {
     "auth_ref": [
      "r81"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "Reclassification from AOCI, Current Period, before Tax, Attributable to Parent",
        "negatedLabel": "Amounts reclassified to the statements of income"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationTypeAxis": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of reclassification adjustment affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Type [Axis]"
       }
      }
     },
     "localname": "ReclassificationTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationTypeDomain": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of reclassification adjustment affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Type [Domain]"
       }
      }
     },
     "localname": "ReclassificationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {
     "auth_ref": [
      "r189",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r189",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Summary of Segment Profit"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r414",
      "r574",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r414",
      "r574",
      "r576",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfSeniorDebt": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.",
        "label": "Repayments of Senior Debt",
        "negatedLabel": "Repayment of senior notes and loans"
       }
      }
     },
     "localname": "RepaymentsOfSeniorDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReportingUnitAxis": {
     "auth_ref": [
      "r253",
      "r255",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by reporting unit.",
        "label": "Reporting Unit [Axis]"
       }
      }
     },
     "localname": "ReportingUnitAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReportingUnitDomain": {
     "auth_ref": [
      "r253",
      "r255",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Level of reporting at which goodwill is tested for impairment.",
        "label": "Reporting Unit [Domain]"
       }
      }
     },
     "localname": "ReportingUnitDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of fair value of reporting unit in excess of carrying amount.",
        "label": "Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount",
        "verboseLabel": "Reporting unit percentage of fair value in excess of carrying amount"
       }
      }
     },
     "localname": "ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r430",
      "r614",
      "r708"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r430"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "R&amp;D expenses",
        "verboseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r23",
      "r122",
      "r633",
      "r657"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r23",
      "r118",
      "r122"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 24.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Restricted cash included in other current assets"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r116",
      "r280",
      "r287",
      "r290"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail": {
       "order": 3.0,
       "parentTag": "teva_ImpairmentAndRestructuring",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Restructuring costs",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring",
        "verboseLabel": "Restructuring charges"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r281",
      "r282",
      "r290",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r282",
      "r288"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "negatedPeriodEndLabel": "Ending balance",
        "negatedPeriodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r37",
      "r382",
      "r579",
      "r659",
      "r684",
      "r689"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 18.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r138",
      "r139",
      "r140",
      "r142",
      "r150",
      "r152",
      "r224",
      "r425",
      "r426",
      "r427",
      "r443",
      "r444",
      "r519",
      "r680",
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r174",
      "r175",
      "r188",
      "r194",
      "r195",
      "r201",
      "r202",
      "r205",
      "r394",
      "r395",
      "r615"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 13.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "positiveLabel": "Revenues",
        "positiveTerseLabel": "Total revenue",
        "verboseLabel": "Net revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r396",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue from contracts with customers"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomers"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition [Abstract]"
       }
      }
     },
     "localname": "RevenueRecognitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r81",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Accumulated Other Comprehensive Income/(Loss) (Net of Tax)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for cash flow hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Cash Flow Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Information Regarding The Location And Amount Of Pretax (Gains) Losses Of Derivatives Designated In Fair Value Or Cash Flow Hedging Relationships"
       }
      }
     },
     "localname": "ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "terseLabel": "Summary of Classification and Fair Values of Derivative Instruments"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Schedule of Net Sales by Product Line"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Financial Items Carried at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r259",
      "r261",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r259",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Summary of Identifiable Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Summary of Changes in the Carrying Amount of Goodwill by Segment"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r19",
      "r46",
      "r47",
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Summary of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Required Annual Principal Payments of Long-term Debt, Excluding Debt Issuance Cost"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.",
        "label": "Schedule of Product Information [Table]",
        "terseLabel": "Schedule of Product Information [Table]"
       }
      }
     },
     "localname": "ScheduleOfProductInformationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r290",
      "r291",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r285",
      "r286",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Summary of Restructuring Accruals"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r282",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Other Assets Impairments, Restructuring and Other Items"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r183",
      "r186",
      "r192",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTextBlock": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Short-term Debt"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r170",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r188",
      "r189",
      "r190",
      "r191",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r199",
      "r205",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r256",
      "r284",
      "r292",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r170",
      "r172",
      "r173",
      "r183",
      "r187",
      "r193",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r204",
      "r205",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/Segments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "terseLabel": "S&amp;M expenses",
        "verboseLabel": "Selling and marketing expenses"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeniorNotes": {
     "auth_ref": [
      "r640",
      "r664"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.",
        "label": "Senior Notes",
        "verboseLabel": "Total senior notes"
       }
      }
     },
     "localname": "SeniorNotes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermBorrowings": {
     "auth_ref": [
      "r28",
      "r579",
      "r636",
      "r656"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
        "label": "Short-term Debt",
        "terseLabel": "Convertible senior debentures"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r9",
      "r170",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r188",
      "r189",
      "r190",
      "r191",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r199",
      "r205",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r256",
      "r274",
      "r284",
      "r292",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r66",
      "r89",
      "r90",
      "r91",
      "r138",
      "r139",
      "r140",
      "r142",
      "r150",
      "r152",
      "r167",
      "r224",
      "r377",
      "r382",
      "r425",
      "r426",
      "r427",
      "r443",
      "r444",
      "r519",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r552",
      "r573",
      "r680",
      "r681",
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail",
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLoss",
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossTables",
      "http://www.tevapharm.com/role/BasisOfPresentationPolicies",
      "http://www.tevapharm.com/role/CertainTransactions",
      "http://www.tevapharm.com/role/CertainTransactionsTables",
      "http://www.tevapharm.com/role/CommitmentsAndContingencies",
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/DebtObligations",
      "http://www.tevapharm.com/role/DebtObligationsTables",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables",
      "http://www.tevapharm.com/role/EarningsLossPerShare",
      "http://www.tevapharm.com/role/FairValueMeasurement",
      "http://www.tevapharm.com/role/FairValueMeasurementTables",
      "http://www.tevapharm.com/role/Goodwill",
      "http://www.tevapharm.com/role/GoodwillTables",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssets",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables",
      "http://www.tevapharm.com/role/IncomeTaxes",
      "http://www.tevapharm.com/role/Inventories",
      "http://www.tevapharm.com/role/InventoriesTables",
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomers",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables",
      "http://www.tevapharm.com/role/Segments",
      "http://www.tevapharm.com/role/SegmentsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r167",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLoss",
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail",
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail",
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossTables",
      "http://www.tevapharm.com/role/BasisOfPresentationPolicies",
      "http://www.tevapharm.com/role/CertainTransactions",
      "http://www.tevapharm.com/role/CertainTransactionsTables",
      "http://www.tevapharm.com/role/CommitmentsAndContingencies",
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/DebtObligations",
      "http://www.tevapharm.com/role/DebtObligationsTables",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables",
      "http://www.tevapharm.com/role/EarningsLossPerShare",
      "http://www.tevapharm.com/role/FairValueMeasurement",
      "http://www.tevapharm.com/role/FairValueMeasurementTables",
      "http://www.tevapharm.com/role/Goodwill",
      "http://www.tevapharm.com/role/GoodwillTables",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssets",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables",
      "http://www.tevapharm.com/role/IncomeTaxes",
      "http://www.tevapharm.com/role/Inventories",
      "http://www.tevapharm.com/role/InventoriesTables",
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomers",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables",
      "http://www.tevapharm.com/role/Segments",
      "http://www.tevapharm.com/role/SegmentsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r34",
      "r35",
      "r377",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of Shares, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r34",
      "r35",
      "r377",
      "r382"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of Shares, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r66",
      "r377",
      "r382"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of options by employees and vested RSUs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r35",
      "r39",
      "r40",
      "r126",
      "r210",
      "r220",
      "r535",
      "r579"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 15.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Stockholders' equity attributable to Teva shareholders"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Teva shareholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r2",
      "r3",
      "r90",
      "r126",
      "r138",
      "r139",
      "r140",
      "r142",
      "r150",
      "r220",
      "r224",
      "r382",
      "r425",
      "r426",
      "r427",
      "r443",
      "r444",
      "r466",
      "r467",
      "r480",
      "r519",
      "r535",
      "r546",
      "r547",
      "r552",
      "r573",
      "r681",
      "r682"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 14.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r124",
      "r362",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r376",
      "r382",
      "r385",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r553",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r553",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail",
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r553",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail",
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Non-cash\u00a0financing and investing activities:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TangibleAssetImpairmentCharges": {
     "auth_ref": [
      "r8",
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.",
        "label": "Tangible Asset Impairment Charges",
        "verboseLabel": "Impairments of property, plant and equipment"
       }
      }
     },
     "localname": "TangibleAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Text Block [Abstract]"
       }
      }
     },
     "localname": "TextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Trade names [Member]"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r213",
      "r214",
      "r216",
      "r217",
      "r218",
      "r352",
      "r375",
      "r509",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r65",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Shares [Member]"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r65",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury shares"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r65",
      "r383",
      "r384"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury shares as of June 30, 2022 and December 31, 2021: 106 million ordinary shares"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r141",
      "r142",
      "r143",
      "r144",
      "r153",
      "r211",
      "r212",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r425",
      "r426",
      "r427",
      "r441",
      "r442",
      "r443",
      "r444",
      "r459",
      "r460",
      "r461",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r554",
      "r555",
      "r561",
      "r562",
      "r563",
      "r564",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r617",
      "r618",
      "r619",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfFreshStartAdjustmentDomain": {
     "auth_ref": [
      "r577",
      "r578",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment for effect of reorganization under Chapter 11 of Bankruptcy Code. Includes, but is not limited to, adjustment for reorganization plan effect and adoption of fresh-start reporting.",
        "label": "Type of Fresh-Start Adjustment [Domain]",
        "terseLabel": "Type of Fresh-Start Adjustment [Domain]"
       }
      }
     },
     "localname": "TypeOfFreshStartAdjustmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r281",
      "r282",
      "r290",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r132",
      "r136"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r135"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedLabel": "Credits and payments"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r155",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted Average Number of Shares Outstanding, Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted average number of shares (in millions):"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r154",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144439"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2473-110228"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)(1)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)(3)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13207-110859"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6571209&loc=d3e13703-110860"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q1)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(21))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613674-111683"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(6)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061172-113977"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "https://asc.fasb.org/topic&trid=2229140"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL75039408-165497"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.16)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(g)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.16(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r709": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r710": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r711": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r712": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r713": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r714": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r715": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r716": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r717": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r718": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r719": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r720": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r721": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>91
<FILENAME>0001193125-22-203392-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-22-203392-xbrl.zip
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M_?2I51>?#[Z\()/A7SY%'KGZ#=>V[HH7$*8C\Q%^M8T;^(XE?-N_FHE?U;%
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M"K,OO_!0X)*)+#A$[IK(G5\ZTS'^]8 !TTR>\!/?#2D/['G&_S!(]!^],>-
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M#WSW41<SAQ*^?>$*L6&ER%!TZ\)7UUZN!*$ZW&PI;F9'AGP5HU5F;BI.5<#
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M*>7M9,VF\MLF4=V@XU)[C*M> V!]5\L)WSUT8]@>P0-TU+:,[]@@T;H&K()
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M-Z5JDL6&.)>BD&5#^1UN2O51+E?-@/KQ4[TA$.[;D2)@HY%M]1Q;_QG&N.>
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MUX/'>N.I+O8Q-/OV?)W/P9=&_?!?PLF:/] 7M:94I[*J4T0(_^?_^,7AYV^
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MULFY=!!: JLC03V,#)<*XEDV.9ZZ#@#2DY<J,P_"J,Y0O#0\SQE8AD]-\1K
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M>XFL2,R_!)N05(XXA05EO^*[6QH[:K!&1 (B 9& 2$ D(!(0"8@$1 (B 9&
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MP_Y42AI4+C6HLX4(MG6J*3@4"I@Z:W2:+02+>NU4BBY^F[J94[>KUR8SOIZ
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MB2PTSK\$FR!JC"^4*=]L0=FOO/:6QHX:K!&1@$A )" 2$ F(!$0"(@&1@$A
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M>:9U.\"_,S_?A:=]JPZP%(W4T2U>Z:%4GEL]AU)Y;O4<2N6YU7,HO-<0@8C
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M;*T8=I7AI9'Y9*8J,N,?LYS!A3,>3PV3V3\^'C6/^&OY>/XZ9(4\\H,/$Z9
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M TCF&RLP9[2Y6X0PJ;B5OXO^J6J88<J%TXC!AULS #ZRBVE"FU"1.<9JU\H
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M>T[2^%?",=G,XY_P27T0MO\<:+ZXKWFVZBRP;YA(K2/W=.I2C[=U,VQB3)S
M]N%9GD?\Z,02W1'&L=[I<%>$_(<?Q"WG,8)A?VJ>=I:WOICQ94':4S$^B;/O
M=3C8]H@6U$,MJP,OE\V8'38OB]]M<MYG&C8OJ]FC5UFLL-$2-B]3L7F9ACT#
ME%FGZF<*VVQ@\S*$%38O4VDJB")L6X9,JA!X8?,R1%9.B@HV+TOK_,#F9=6#
M=U6;EZ7W4ZS$=>'5/'>S_^9;:*@8=PSV3,LA=%*+A$YJJO=,Z^H*Q>\C>!;
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M]0;Y8?DC_@27,C[+N-.3,68[ P"&T5V+LUYR:=B&:?!3\3N%J=IOIT3N]TW
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M545-U+0;>EM#W"B FRQIVFJ>EU/Z/0-;56H;+!JBUAJB(N4U7#KFF7"^(U/
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MB0<%<F_;>3=R0"RDPX+"D45:8AUJQ$CA&%$MZF=3R\$>XD8%W&1:<J2=L^R
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M(F871/*\L^XBX+;#@[SSX*%C8^K!V^%?LX]BVY!$AY5F_,C'Y@*K/NN]X_?
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MJ_PT&>79#]Y3*J@WRL,D[UMJE<Z#C9#D>RJV!SR092(N$!>("\0%X@)Q@;A
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MC:LNS[$:R\3$#I&QMV+,E<3/V5XJ)Z>="I'532RB+C)V!<NO7OK %/]V*]7
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M01['K[BD[\V[IM5'#3)HK+F*F^_?JEI%=QHCFU;!X\ GH;_>"JAY<44K*%[
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M.D-AW\*1I7D"?X=)#-<&H]9CPA9.$B34EZXS<B*R62BVY!!Z 3[@.C" S*I
M+9?W/01!P@]&#&U8PCS C5:O&A , OJ> GQA9CCD#SH0L%OH3GC@XJ$&IBO:
M0ZO';1_%P\B'&Q.M8U@KJKP6S#T@8[MIP8E7]KW(6<+5@IDN3S ZGH!=EHE8
M'SD2MP#?8@N70W*[W_T?-AJ__6K=W/UAW=DX'USSD:-^ T<$=@X7[H$L"_A#
M[++(#R;H"AF!TD2D1,KZ3X):P.LN!^F(*[3(5X'.DG3#A'B#_TW2C"L_P.,J
M_M[G: TB%7U/=Y(D,YZ]Y*82V'FWPHQ\M*4R*J<5L8WO/&WTLM(>=^,WV3]%
MH--:<+=G[F,L LRO'#_3G/@]#MR'3GSWB4W"Q&63^7,8Y#PP(@BAW-U=G+.6
MI=L^[38L]<?KMZ]^VY&79[?NL)+9ZTD0N^>[_=HPX_W-7U?6US^OOGVZNK[Y
M?G][??71NOW\_OO=_;?;FSOKX^VGV_N;]T4,N_J9-QNTQ@91R!6OVFNXY3 %
MGE3J#\G-?P>Z!!<!*;-)N]JDH^\> [4+=N;U4KMPH K RC[YSKR2^PW][+7S
M:'V'=06D3J+/*HG=@4(JE.NLGBXK CP_ M/#QH#='"M*_O(;_C!O-YUK=M/E
M9AZC'W=Q+^3_CF%[;AYSR6FYKY)DD'G&W[QIGQ2:>VO:=B?-T]:T79?]][-R
M[X-!Z7LB@!@-G:!O_3MF 6P9[9CP?:RWIG8K75-2R5;E5IQHZ313RQ[X<1 -
MU6(W76MBKG=A_[IRK=WZL]VY-FUU6O9@VB?:M,]V,.V39FOA 9O->4Z >06+
MSEUWXW/7U<Y=E=3I-L]7/'==/92U[M$[T99[4NERIZ4M+1?G00OSO2<6],-\
MOMZV(NZ=V:K \@G=U]*I]YZ'=N"0#W Y%^6:=U;B760>9K+'(:@ 8.>K'!D8
M.AC[E)0VCN%O(<^X_S#WE=)DDM 7NA2;UE42L+*2H#D%O!)]1'F3X0R&UO\*
MKG0GUC<.HT7H$/O@!R.@\O'_-D [45D_UA,/.*;WA!$3KK,X47=@%4WK=X8+
M@)^K?D<X*OHM;!9&% X(8U?51JJD)/X\!L41S)\ABRQ'IO5K*I&0'LH44FY7
M^!C>-@0#(02A$N$HT5 =-R0I>KKAGSX0 3V^HIPM67OVI6%J7U%LD;*T9J?0
M5\_"0JT,@5#.P &:V$Y@QR/<!CO+$J6[]8$ Q^C+=1T<2U) !">\B6*GQ!<.
M#(@'IX>Y693U)00]<+8GHZU)] =__L0<$'$-X"^P&$1.&@A'ZC [\ONP5%O8
M&/@)C_PLWR1\TL,4,Y>C_=RCP%">+:^2_#4,YSXZOJM<\[GI-[1?TOR/1R):
M,4WR)S]V%4,CV\$!YH\RJZ[/!TQ]C"4J*EH59B=F4=CZ:<@]ZX'R-O$;> _3
M-CKA<E7TPG+LSID]A$]4HN 4;E=Q7"[S&-:_I&>Z@<YT&,_EC+S_10M+ES'E
M-%]C_'Y,>V<'?DBI?6!(!DSF_/F/#KG^FSN\/G:7&U$L&U6&&Q)MR!XQ*W@
M1\7!3:+<!V 9F4$18>1F3$+=B62O#6"61\?F*@U4YD+ >\7!2Z6BWW.=!WE2
M%DE3%BTC4IM95: @+7/^5:VRE],+&X%$_N1]V+6'*PQM4?;&>R>T73^, XZ.
MB=]=W_ZYU"W^R@+IQ<;(6D',YZ422N_&Q5EI[)%AQHOEF;&.GK+/7^YOK N+
MA$+[K97N&PBL9..([89BZRR6[-V; M_:-,[#>H?\K ;.2]9$W0J>\%"_&6(-
MIA4XX4^8EP>Z/I+FS2R/XB8S2Z%J4!> K]^NP3X2I47635A3[Q11H#[8>$*
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M HXH/+%XPFG+Q"U/=IT?/PR%;1R2+V;JA\*98TXZY7#90]\/>7I,V0-FXT7
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MK>]L=YW@;M!R3$+U>JAQ2B\0U%7-81KBGQZ/:I]=;;CR\+CR,[:>E&TP:\^
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MC>D$^FFP?+-#T5"A\]E<&H$T>2,%\YT<YU8.\PU&N<-!KKS^O1P"--6?5\D
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MP\CC#Y;X Q9,^T$:0Z<I)==;#&^SAW!V.6(MBPN('I"WGDRBL7F?CG$H:BM
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M+%/MWDG$A9)H,AM,;9L>GR\@;)(N@$D ).FRN DHX[2CY[+8LX>\GXDC[91
MT[*YM99L9@,0.2.I=P@'>RYVJPA,HJV0O&ANZ*3\Q":Z;K'F=9$=2J6Q#"@]
M,[E(\"$9^1[*3LW^> PF"5ZP$R$(^4]K $,/13]M!PZ':K]=<,D ZXES9J$2
MAT%I%YL5AC+4@3>)EC+;HWHF+K-B;3*.M,0 &:T)P$#W9 !;'M>LK1.IXJDQ
M2Q0U?"&N#DP(SXO3EU7$;"JVAP2BY'7*Y'E6%)EG)(CY4B/Q+P,QV3E 2-O
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M*Y1B'*2>TT?C90R4D6T R;FM[)T9:HUPK\&KX!ZR$XM(?J> %7H3&@PW6/Z
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M3Q[./9QQ!1/IV1/63='>\4"8)S+_A>MG7G#+,+DD1#;M2(-Z)[,[HXI@5DU
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MLY8U3/5U([;L$T63J#6-S!T *@0Q^=/D*^ZIVU^"?"A7(@U"F0B[8"B5T1
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MLG'H )>(S HU8GKNDJ8'E)R;I(9DK-MVDH*1/Z]4WY;/ZFW UA"B+IK=$1X
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MGQVS01DG+H7DQA3*RLT_R>E2H5_&+:(V6E%IJ=5=9D]'0"N1"+HI@1FY5LJ
M-%:2#SUVI2[@0C7,C*^^%\6:%9CA?$RC\_U'H7T21FNT+&[6F0DK5=(5S$CN
M(M+G[EYDM,MT.>U6TAZ8DV*6XQRKF3_EO AAF06=JR[WGTWO&=C_&!K"PU^V
M"&JY\AN^PIY(4"D-!:W,=@V[]0FS >%_HY%'"6+3TJ4^AG%\06(1%J;[S-[W
M]PJ+]9^NG^1KO"EIZI@[VK=;,S*>FCKAJ3DCX>FL?=1HEL!W4JHO; G7K.-.
M%"?\,4R\V',#MZKI=B3<Q*S6G/-/M]4X/&I.G+ &1V@?.%^RX:DX@PC8H'Z
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M&@H?F2&R[JK5'U/&F0_"YBV34S40K3T?&SIN9CUU\9!ZMG'0C&W'!$^V-<Q
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M N*^YS#"%SAO96"XS1-F'.T66"[Z\_</,'42$N_UQ.G/VX$;X(R9J:"3*[V
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MF"YH@'%,L:&,J%1<77KZPSY<@>Q4I@'"2<8[1$\Z_W5(X/K\*HT'D&B^$_=
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M_,.1]OJLWPL%8W_+/$#2.QYU>A4>8><>;#.D/O8D"%F6#2. '4L3 7$N\-A
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MP60X@OW.%-O,P9K+_[G)8S57VE<5Q%?YL9JK \?*,RLV4[''JICZ@9L](3*
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M?=C2!/%R?#$%T3##.S/-J[(9"F>)<7%Y#4NNJ0O)-1YC'LG],S.=Z-X-)+\
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MG97@UB&P.8= KJ#Y1<OZKR(6;M0=G >]]Z#@^^&(.OWQTJ0Z????B1>)WE4
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M3],SNCQSU+4<A9NB'L? )UZ1)U\N@2Y2D1%]E!&L+6.S_*.UPEENZ36K?86
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MUVA#*K(+B&+@;RNJ-)NOMLH[*HK"J+8Q\>'CZ*?X3ZE59U$Y[=.OG6)5*^C
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M>L@8#I'*QBV8?Y,,S5B8UA!I3\4; ^&(6RN0*.R6X[CW$H<.OVN-)YY[+W!
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M!IBMFH#EHLN'9%M G3V KY7RU!#UCM@$GU)+0/]0KDFRMQ09TR6/9FH0@+-
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M?Z2;8";Z(<.S[5<S;3'A*YWT5Y8WQMQ_%7@9MDI.C S7]BU,81NZ[:/FS,[
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MLDU-72^7R\S[[Y:M=P[V7N<*MZ"DMR3KPGC'A\IWZ&T6?FT[MX%XOS H8%W
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M(,>+4E"=N:@1P4<S=97M O\J);7$AV4HSH50G,JZ:Y^2P<-7:R+( C#\9I\
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M'QQ@<H>RO=5X_"^@RN-&8DKG!,"RV'4,F".^[VQ@V!9^"K,J-A(.,=[MI[M
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M,@B,< )OM)J]\SUP.X/0SH^W#(16PTG&8"6'QY]=T;[EXSS<I9:C 6%>JL^
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MS[?V,QP1N=9$+NX75N\&27>KCUB&P6G#77D/7/ @U88+*U3\+K];H$3N@<F
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M6#2E26)PZ\2H_E:&0[L(SM;O&OJ7:IBUW+O@23:Z#-7:&V?W;:R/@D]M-#'
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MH/7;M"A1;(G 5887C*5E(CTWT%KZ&;HOE^C9% CZ49X 5$&C@6\DWSQO@BH
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M_;K7;U_U+S,W#R+QD XP\^"RN8!'2IDC69R> %U"V[6U]:7W(X.V%((AI;+
MP9)Y#^:2/8,3^^4I".74N U];S9Y2EGBRVW"$$BT3P)#F8'G)GL'SX-G4]54
M3T1 <\Q 5KCX!,@20XE74XZM?%%]F1,_A$K.=_'.8"2U18R<!<,2%C6<\ !#
M=S#PK?/71,*Y\8MS-XU;8S9!Z] <&A:0!=&P80JRCX.X[@8K;R4%]!+T/YQZ
M?_L1[WA<%PZ"$,[=G(M!IVHJ"+O0B&9@:::B3%UX%E+!@(AT?/0)U37?5"F#
MMX!N(J=T#5)3?QUCGK 7$@0O"6E<O:Y\UEQ"4\(T8'I[KLP(64K*40AH($=
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M\NVT@Z<T#P51YUQ&-&?5M3 %BN"L2=\>H9+YX_9N'P'/?[_N]ENM5AQI#:(
M7;@8QCV(AE84"E>"&X.WOHNCD@&H[K^\V004F"T(6#&-CIB-6'I3*N*,4ES(
M'7LT1GYTKV*-VKZ*PY@?WJ9A3)RQ0(<&IO\J3T+%$3M*5RAW[=$S9O8#E4@$
M(=A3B?.,%%?QSB3H6-S7C&E,=\F!THP+X@1+/,*,/9?L:3/#4(N">HM-'16A
M71F&2\T-TVS/W=3C$^NDS +]FIF8A' "2D+*/&-BE2"!L1@A!<Q,"\+3;;6#
M(**;BS<Z4(N0>D@KF(O8,=G6-Y__2+85[3="KJ9Q8,,7;;1^4"!JG).+YU7%
MH)3I@'/#Y@@[2 L]81IUCH4!;O(C_@83#893^#:9N"_GS/Q'(7VK*S.=[07$
M)U2&A.H8=7]T*1-W7/Z1_P8_?#WQ'AN:"GBK1I.A:>T@8+$5WQ#JF(3.%/%]
M3%'1T18*4GCJ2B[&FU!7EAF7 ]Y#+AMA<0QFMR G*@,;08%AHU'?"/5!DJP1
MSQI+2[*;5595LL/IQ2!Q98!@OI:Z<22DJ3@X1,G$,>:&'N/&2)9D92\I*7]:
M&Z_D-%#DZ$'X&,+10ZF!P$^3<J0<BCB:=(HA\"+(5[QSN?"ICI92L)$@Y6'T
MAI:U@<0XD%:HV2@T94'Y#S9Q8K+7"5"^CP4].B$3"3QU[?$3(3='+LH\78-,
MKJ%FB811/7T_E;E:3FI4P&5]C5]\BB-N*KRFQ,Z%K=M5V^X8O4GMJ0*+V)Z3
M: #T92BQBY+9-683?DMQG';]D=_Q*9273%/>X)<N['B2D9B*>_6\H';]I"56
M[*.EML2[[ZA5U2$)+-\>JF/BY<J%4_R-A(C(R>)1]_C :P@,"- =''E_.M.*
M,&T)@B!.DX_/($4@I)\AK(J'9BA+5,21:+'Q3FEESYDQZXX8I<C=QJ$.;,R7
MYF-\S.1C5")K!DQ:/Y,X13&"'%=E"OJH;H/B [$%F7YK3<Z)G:)8898BV PA
M<I9QA[?A@[@&YU85A7RFCAMHQ?SJ^=/R5:G9>OV_FN"Q74Q%:JK;T>HR[THS
M_!<4VG2(Q1Y"41\\]_5OM[>?DOMV N-_BQ;\"S,QF&=1:%,P.%9F>PG$95:?
MRFA=KJ2P$+%\$MW!#&RB;DW@_AFY&:6K]$H677$J0]^V@F*M)DIZ^5V@B4[:
M!$Q 5 7Q>I%Y][W6>(4_K8GC]7>(>65&*"&.APW-%5H7:/49QH7=^W^\:KVB
MUWI@>JT?035DIPGB/!:*0]T8N4#5#N==MWPG>VD6P-OQ7\E'N?6^4FM(XF69
MZ!H8/6":_V2(!\\>Q5\<%8(^O?,,8>9:V>LO=9;=;&5B110JPJ' _^NO&,M<
M,M:*I]APZJ51+Q7%*DD&+V-5 YDL;G(/!PH.JP,/I;(MTX)04'._>. 8$P #
MV+A6Z/DJ\G+( YH30;D>.*I$,Q5)5%A+Y5&)'8VN.H&4*JT]C$;W,G89,4*F
M+YZR4Y"%GA%A9!'$1+E)@Y>X]?"O3__BN<QOJN6 ]OT)\1!NIN)[3.Q\')0E
M#DN<DY<XNFA:'TU#9;S(?3;D*@@:@F^X(9' AYL/-Q_ND@ZWKOU(E6>2RJ*/
M/"IKZ08Z_0QC1@@4,2+? D,Y#2,*=% ^.)R]@;A V%WIO_"(=JB2=K 8 6T?
ME!%_@J!2]A'>5BA<I42(>6Z41'Y3/-__8AI9/);4S0ITZ&HDL5 &T2%UU([B
M4WH@I$K6%@F!^"@D0SOM>I^8.$E[BR"]DCJ$H3;#X*D;J@6D@9"A!&>ON2^1
M^@(![7W$&Q9XW#IL95"_:[R6PMI;^-2U=1?Q3)]5]67'GMIA"F*B>H@!^XPC
MQZ7+*4_7Q'IX._ ?F13E$*OMFSWH-G2H^]!FW O@#\RQTO<U]"CTU?CAU +@
MR8G[X\32S$+^Z3TB\&0C?4_=9XD(OZRS#$&&P'-]DXLHG9@9&I+ ']$AHU &
M)2?B*AJ'<W0PKJWBE=J/(?6<)!UEVYJCG-"9I,G/QTED7R7SVSK?_@"R<P%Q
MM1V'D@'1OSU'^UDSE'9A9L_@O:GGQYW<J:B06)^"0EEW5"5Q!>0#9H2BSF#(
MG &\BB;%\1++#@KQKPPYB-%A@YX2'M>7PDG#YZ1Y=@:6"/??B\)L'0.F[S_(
M3+-2$5\OJJLMQ4;I)!ENRLZ7TRQ>D7=B!54H% &9&P6A__2,:\8=@LE;7#FN
M#";?)6P7 %$=JCQ%4W$/M5SK><7.5=FJH 3=A!'>M@.S)QFI#;J&C&B7??IR
M,@H5WL1C9[=TE7C#!ZM$.K7PP>8C%E;=M ]IK-#UHTITQGX*<JIUD;3I)"B,
MK_T\D8^X&GAT]6/ENW;JEL#)12EN/MEVC?A0)D:H/LJIG&SH[A#Q:AKQ<D3:
M_%A?X(*5X I*Z4'F@NW#BF@X% V5K4R2"OD192D52T0P6E*>B75#I--SHAP8
M!XB"E] R:8V:X4G*BE*X:70?398JY4W$)T'=":-I'>^,1LS,>0M)BS2L3E<M
M(R@#&UO+8Y9/JD:H&F%<N(+6DK:A41(>96R-9(P172"E7!-X7C!JL1@$M6Q^
M=)V"AI@,<W?=L4A/>JXH7R9Y_)&G3KR&K$-L5HV,DE$!L4="WW0<I0FP=*N1
MNT110ZN=U[7O?+G!T0B.1E TXH7R)L04VQ.D69FSR+<F&I<6!(A*O%280#?%
MU'4.0O*QYV-_E,=^'C51>68ZLRA3=CN6*L/U1[ K"*<^ :6Q",1-0S-2J-!&
M>. (LTDI)Q5K 4-M@8 M%ZK\-BH+M\!Z8'G"\H3E23WD"?J'MI\4=E)1CX.7
M)0EH8AH>2@T+:N.WJE4KOKKWO!'FFA].7'!IY(N41O:X-'+3XD!6(ZQ&ZJA&
M$.W7QZY =&L01Z&RRB.@7FZ43N?+N!2>X!H:23X\5A/B01#IA[D:K:3- ZBG
M4;8U=Q+V2IK+9I'&J:1$)_9E/&:ZJ4#=1=BFF..7*P4C."1YCWA/&>CC&/=-
ME:G0AL?ATK@@;.Q949!6P\37:>DH;#^SX&/!5[+@RT"JOJ:F+'8,UOTZD044
MPLX*I6S_K12R-;ZZTW<Y6.UV[XNLP,(FY7CSD2",(Y26I,);<,)CSYLN,%RJ
MLR[]K@=Q2%Y'LYNBS<6BA$4)BY*CM*$2(R9CNF0:^V6O*=F"X&//Q[[LM&)X
M BK<!A.@='WMP8S822^?M$/ SV11%*_S$/.#$AM2+RA.YR7GQ[<?=&=0%SVO
M#&"% B"@DQ(W62$+)S:'#%6/A/-0+=./>#F0.B4L3%B8L# Y5ALB<J, ZP5"
M\5UY.VPI\.'FPUV/PZTAJAZ%/PH4>E"<!9#" .F<3(7MY.N.:H@'Q6* Q0"+
M@?J( 4F(6"K@F$DQSV0<8[IV$.G&W]AIQL$BOR1;V/:792(74I_=^:3G-5G)
MZ36)2C\/XF2C3+Q5-WTDH+2LYZ7\'8))E A*GB8XTE5-9N@DN/KHHX.&+1V5
MR(L;*+GX,!D?*[F2B:TD5>N2K=!F^<CRD>7C<<M'R_,5CJTJH@!/2%(51 (O
MB$DEJH, "<YBN=)Q%A1CATFI0DJT1AL$]L*>SZY'65[23^I@[CZE300UYF0>
MX#('BZI;U1Z@I&J^LJUI?/"V?=Q<+S*ML3)UB_&<B^KH8KR[96W/[^9&>X%B
MO^0A[>_&%)AG$FAHOM\C5VI8OI:"Y<O6I8V,LT)OY;5TI1+O&%432"J".$GX
ML%  6ZQ8UV$1G.[HSTA'0#56;L;L2)8V%0J!F9J&J7;5^AHF]PC[P"S>"#./
MZML>9-ROB?@.+;6G.*/EH#M!R35>0%A6VU7Y*C,T0W&1),JD9%=6:G;&;"L@
M/<%"2?>26,5Y1,)0M3/7BU!(P7L#G5R D$"5G00Z,$)C"GM7QNVJ$D\AM?:#
MQ>;^)(-40KJ4/L@4%39U0TF$<!,J03A3 AOF,1I5K&)="2$G\[Y(,F^?DWG+
M[_11OLF]+3[! J$4RR25S$@V4*QI&HD7O6\1E6KEN)89]5K6@-_[$RAQE%@5
MNE4'$4CAX?]D+!4'M7#LU3,JQUZQ^SY=_:L2//W,<)F/B^YVNW-.8F8;UUYM
M5/YGF_S-0_/0/#0/_<RA5;AI7L9M8E620-TX]KGT83<.0:[X!4AQD-ON/U[U
M4NVRY.?9(&9BIV45X[:*<%M[R)?2>*^B!^\61P_:^9X3SR/,B^^LH2V U 9I
M]F;A,S9\BX&VX(-8WZN7KS.&/FP"_G=9_$IL@F3L"/T)S?038L(!>5Z8P<CE
M/E-%\]@IEP(B.M064!M<;&B#2$6JD:XV0R^?QW,;[<UILV*[6IRH/) ]++A\
MRG4K1KIW<00;7;8#@6BBAWHDVU6QW=HSTFW=9&3)AMA:9BAGOGT^X4*NNLWD
MR_]]Z/_X<Q8"B]Y(T2KHI8*S.+)5_H%H/_3X&<0?M1RP*S!QGU[DD'V.;(F_
M:900M6<)&LF1K6*[.X*M0F4OF8#QK!N4NW03]<'$? /ZFY!EGG^W4BK=S*K1
M+990<[DH1W,*/F=1(+1D"HY.Z+ZA9\:G3PLQ]<NX;[82P=2@3GTS%-\D]J.F
M%_HZ]?AD\3NJ--4;EU:;'MDJWB25_+%R3*OYCVPI'S&G@E:Q9S=':5_,AOOA
MR$ATFV+"T"+>9G!ACFPIZ6[33E3WZ7>=;W].EC$4UK=[WXO<4=:O;;>Z#:/=
MN8)_>KW+M:Z8RLE=?K__FO(=]FS2Y5(.:,(J&2L?)*8 /D@WDH<S68Q%DJ^D
M8;(GDE(_8.!.8W#5/_CC/6-!S]IW=7-^FK,PC9G&=9B%:<PTKL,L3&.F<1UF
M81HSC>LP"].8:5R'64XQQO!R*0P<-UL;-\/+)6JR*YP:!\[,QO5U^Q@"9X>F
MR[5Y#%2ID0*HK)JIT>J9QG69A6E<21H?VB0]!AUU8)KP-6 =9ZD^WW6ZQ\!X
MAR;*4?@6-3HG?!ICOW;0/DRP1N.!+  W.+(M>K4<-69I"$>7&"EHF=EW55U4
M*%!:']0I _GGY)9YD&J@>I#J1);)',$<P1S!',$<P1S!',$<P1S!',$<P1S!
M',$<P1Q1(5*=R#*9(Y@CF".8(Y@CF".>R1'[RY!F_($#Y5'_YGL!=E7QQG98
MXS3JP37G?W :]:G,PC1F&M=A%J9Q)6G,:=0O3A-.HZ[C+-7G.TZCYC3J4YFE
M^HS7;K1ZUP=)H^::]XK%:O2CUC9DTQTT=U<UYRQ6JS<+TYAI7(=9F,9,XSK,
MPC1F&M=A%J8QT[@.LS"-F<9UF*7Z,89>M^P8 R=$'7V0[?/?Q'1V\]:0W[%O
M5XVQ)=OM*[ZVJ.$L3&.F<1UF81HSC>LP"].XDC0^M*_!ME8-9V$:,XWK, O3
MN)(T/GA$H-Q$1DXFJW"<ZPO%N=[7/\[5X]*_16>=*__J. O3F&E<AUF8QDSC
M.LQ2?4.@W/H1YKMJS%)]OFLQW]5P%J9Q)6E\:)>[7V[-/J=5'7VXZ3<*-]W6
M/]S4,8\"KZ)&\K"R4K=&JV<:UV46IC'3N ZS,(TK2>-#(UAR#GL=9ZD^XW4&
MS'@UG(5I7$D:'SHYHE>N6N%$J I'ICZ&$^D;MFMY4UG;J-1%"<"-EZRPJC<+
MTYAI7(=9F,9,XSK,PC1F&M=A%J9Q)6E\<+=A]S(!=ALJ. O3N)(T/OCQ+O=T
M<Y[6T4?#_I#WPC$"^)4CIT"4P!#NR' 0>-Z"H6$,Z5IVC?.W!FW.B*_C+,QY
MS'E'PWDU6CW3N"ZS,(V9QG68A6G,-*[#+$QCIG$=9JF^9_:W_[EJF^T;-?X>
M'I;SPRH<$5/Y82((9!@8]G0F;)\"8PW#ET'H1U88^3 0Q<D\E4L6RFE] V0F
MY]S7<A:F,=.X#K,<@01E0,(%!36,D%W'69C&E:3Q@0]W_RC01@],%#:CZS@+
MT[B2-.:($6=:52NN=.>&PKVWAXY<$%RJ;?2H=Q260(UD964E<HU6SS2NRRPL
M0)GQCH7Q:K1ZIG%=9F$:,XWK, O3F&E<AUFJ;] >;ZB,@V [!\%^\[S1H^TX
MQET2^ZIMZ&O0Y2ON.L["-*XDC?ETUYPG*LMY-5H]T[@NLS"-F<9UF(5IS#2N
MPRQ,8Z9QU6=9%CI3WS3IFQ5:\',<J%QT;J. VM#S1])77P(2&('GV"/*D6LU
M#/SO<I,0V[:!LGAESXR-U6.9!W"0ZT*J$UDF<P1S!',$<P1S!',$<P1S!',$
M<P1S!',$<P1S!'-$A4AU(LMDCF".8(Y@CF".8(YX)D?L+U^=H1T.!1DZD[[
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MF/1T%*8;$^DZ\_PT$3W$NA#K*ELOP!@8V] +, ;&-O0"C(&Q#;T 8V!L0R_
MV$B,"X]UU4\0ZYH7Z\KWEB0=ZZ)_Y;5^TY$GUQ<\^DA-#3X-^<,X_B-#1'M/
M(9=%@:KFNQDFOQHSFPQ--1:$IO9^NQF(J4[G";AR2"D(@_=?VNUOF5 ]'5MB
M]TI@^H,3O/Q.L" =WHJ(A7T6#WA$XMSSF#D5QSG4B)*DOA<&)%K$$AIH[#VP
M(8DYB)D@7'KL?]) Z*\V:A56K]7K5;8M)'-'\6(:Q>SRR(0_T&A70(1@CP1S
M&N\8(9G[($>1>$]#F@/Z)IBD,7B:8[EDU>V9KO#]$>_UJ,U?]VI[ZG76AWJ=
M#4EGCJJ^F)M&$?%!)5'2NO9ZR> C<VJU67:L%'O-4E.I49^/8GIW_-?31U.2
M[\T$Q9<.<V?#E52>%_&>5'0RZDR__V4));?@IR^74O9]]?FF@^?S0^671/YH
M\W1+Q#"6I//3GF"AZE,\N&*4D%;B?O9Y,N )+3)V*WQ/_!",-!F+TW[?<STB
MF/_(?!)+Z*]1$YYJPT]CJ=D\:GXX"J.$!XF\ [9/ _6]A"?43,!26M)13)])
M8DLUF1!E>W)$+$PCUO<"'K@>#81T9^HG<87Z=0>,E*A+4\OI:]REI4#*5FK=
MGJ#%2E^7@Z<AC$00TRQ1X]3>#QII&#VR^XADHI[ZU-8H\FA":%JI>5^U0 .4
M2B?B6G[OO[HM&I@<#D$9)+I!#54:I'%*HQ.R]?A9,^>P3V+E+[_R+5OZVSDE
MZVHE0/1F<KEFM%>K04RM!'FW,WUM8LG00I8++$Z&Q#JU=@,Q7C/?J]=56K2W
M-.4>K379/EE!Q&&UB$,B:CP*]?*G79:)?E^XM,:HJ[&JTDIHO+AR7&(O<%YQ
M^N;,U!KXSZN^6,!-EV 6T0I&GE-;0Z95V:<[6U7\HY/9"9[ZWX(2&G76/"N&
M?&]"W=P*LB6ENO'O^6,\,?V#:$;G:!4Y7H\-.>*)$A2GU:BP\3\'G_8^O#I!
M,^HEZ^6XVO)H>EXJFTR.2'?/TR2<.5E7;^VMOC?H1O3>H)LU;;?X-.7 S-L_
M7H0NYNX:C<:[^5&-\>=S=I4G3WZRV&F)O]$TFD;3!C2]O>2KF<&^R1R9I_I>
MW0.MW6SR<SBP8:!I-(VF5]@P)I7/.KM!'H=(I.Q(O06_[C7K>Z_\?#*L\;09
MK',1P L74)]KT/;E]UY^^_K5"+TSZ=F]%9;-3AK+=K9G+[+:4N[PRN=RRS>T
MPA2/=SS]<O)BA.<+(::_,MY:)W;2[!/5TT?]<+=M<T=%AWY2$=7L@,P+6'8H
M%K-]'8IF(Q'ICQD?AFF0Q =O(]12<V,QSPRCF3Z'V(# ^2/7:)H%7>=!!6M[
MZIATTX=$0\'C-!(RN%N2Z3*,Z!L^."^5 LS9.GIUIHM(Z5EOA',ITQ[*,QA]
MZ/+WV^C#;V&?C=+('?!8]-0;7I#PX,XCSUR]Y'$LDKAD4IZ+.^ZKX=/@$U^I
MF%B+0Q:!/&A2+URB'[%6!*XGRB;BVJ=,RQX2KG/T-QQQ+U+Z/:.:'Y*24"]\
M[\=LT=P: CG%"#1># 65^FV -E<B3J+43=*(!,X605RZ]7VJQBQ'_WQ:G+V\
M2^F-,'K4J]V5>DY_,^%_"'F>K%YDV2+E6_:=/U,O><PF;B@S4;0J+Y<4IV/%
MFXSUL-SQHS**HO*IE!0;-I?UYBQ3%I9)2S$3(C5\<T>_;G]OM' +OYJRL#+\
M-9_Z'LG\MU186UI_5#DNQY.&7YQYE;&%<HX:<D-NR VY(3?DAMR[9L]M*&9N
MF:\@PT&J%I+[HKCH7-'L:E:<IE,&;Z%@7/)^)#QT,.2&W&59_4XI%G_1H""J
MA!4R)L-)*8P& Z9R%\C0J!SF;"[]M8OBS"F1, C^=9^B1N+I!"V['Q9GBIA@
M!!@!1H 18 08 4: $6 $& %&@!%@!!@!1A@$U8Z("4: $6 $&+$T(]Z8SX,*
M@3FP?XG".&:C*.Q[B;5)/XW*40M/VD323\E.-0T8->2V]Q0;23](^L$*0=*/
M$2V83X9FI5X_+C#I!W4)+SV4; #6.BK-HVIK[=&]@\Z!W) ;<D/N,HX:<D-N
MR&V'/==J5 _SM>=P]I&?9W'U,Q^./IT]/8S06K>B54,@PV"E9,"H(3?DAMQV
M:'NG%$?=!DSE+I!A_7 BN& +%YK'1SB_*-S+N%9>QE?[O0RG4J^58NLI6@4C
MI<!@'6S J"$WY+9-Z3GYIDJ #) ;<I=F\5><1KX19QQ[Y)A0I1R2MOT.2:L!
MR]M@I63 J"$WY(;<=FC[.LZX088Q&7[^VW'=J7_2[6]IL.6<VUU@1ROG(U(<
MA"SC=Z@G&+)]+W##H3@8NQ_6>A_[S?5#8 ?0.9 ;<D-NR%W&44-N>VW(_<;Z
MR338WNVA@[-^^&&*#CCQR,_S.!=WW&<Q_<H70Q(@9CSH,5_6E;O4-+4A M>S
M^"3$04XP=!784 XV&#!JR VY(3?DAMSEV]TW??2%PX[E#SMX3$Y'S+SAB'N1
M\CPJ+!)Q$J5NDD;4D')$0O5=PGUHL0=RB$HT@W64 :/>!=U\7 K'JV!0#D_*
M (H!_(9FL%<S[#OK7Q14Q'%"T3?4E^*.:@,8O@MKQ%#/!D<N<_R?;I#PX,Z[
M]<5+)\A:)Z=^U(2Z,E==&3#J75#36 5&L\& 44-NR VY(7>9=[GM.B..0M78
MR;#EL9,[(B88 4: $6 $& %&@!%@!!@!1H 18 08 4: $09!M2-B@A%@!!@!
M1BS-B#=F[NQ83L[E2$1<5CLS?0<3VY<ET ?6IN,XE9I3BJJ#HI\#XY0B00-5
MT0:@TFB!*V4M62AZ 94B5[MHID"IH-AA25A.2G%=O65Y-G:@5*\X.5Q A6*(
MS3A>G[V !Z['_:=G;E18(.RM@V@=EL)H-"#/$1FBD!MR0V[(#;DAM]E6S4DI
M'FE9="SYL,AGBJ/L 4>(.%0&(\"(K4.U(V*"$6 $& %&@!%@!!@!1H 18 08
M 4: $6 $&&$05#LB)LH>WG 5Z42Q [L5_3 2XPJ(A#]8_-BW9BO?G#!+4$'Y
M \H?4/Z \H><%Q#*'U#^@/('E#\@Z6CSA;V'S7SWY3=Z4JAV6.QOV>U:.:U2
MV$ &)'8B)19R0V[(#;DA-^0VVZK9=^KK.^P6NJ;UG!_<BH.;91R)ZP%7)S5,
MGMR(F(5]^2RYT/5X(GJ,G(P1#SQZ7UT1X'RRNJ1Z/X=#BR(6I@%J%AL4Y(;<
MD!MR0V[(;;I94PJKIG!4UC]+GH+EK_T-5%4C0Q$YJV $&+%UJ'9$3# "C  C
MP @P HP (\ (, *, "/ "# "C  C#()J1\1$+<"&4G@N1#+]L#G&DR3R;M.$
MW_J"?LENQ ]N;=9.H[9^I9=]QULHP$8!-@JPUT$%!=@HP$8!]AKY%2C 1@'V
MDERIER/QNO 2[,91D4]^*'--Q.M.T.3HYB&ULM\5A $YH4$2A3Z]<Y>Y5EY
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MGV!M@3[5<LGEDK;K!5A'BB$E>5ZNF92,>F=LJ,Z1Y+E*%@CPFF2@P%4SGC:
M;*[GS/742F\THOP%"9532X(:&*L%GNL,R3VL1ZI_,]7?OT"J3W):O/JE\?ZW
M,YT2.<T7:5M4KBMQ:?@R8#P4AI:@F9QB=< @)B"&J2?UG,S)S$=,H+A UX[4
MMJ=T'(IRB<)%J+R$H(M0V<)!NV:O04E'@. )[ZP[>\Z#F6!=;,3CV(/%TQG,
M.UYKG+X6;[(TAH9XNM>ID_3:ZB8IR0\2H1%>1KM_07^))&ARAP(OEYZ&[OY'
MT-T<.CV*+9W##66)K6.:=HAT-Y/*19K>/'U4U_P%ZMH16LZ(E";[R27('E!@
ME3(SF\?Z\"Z4(4VAZ<U02=*EXA >$$Z64IL(!3,1&$=4>^:QK1@@0^%QHZ<T
MZTH97$TC)]V1"') HI4G'1X9F%,\3LFI((%ADAB:>!V0FUA3LF8V,VTR.Q//
ME!9 $R%X4J<%RB5IQQZG&(Q)&01YTH<>20I93'WQ;2I@6"XA5,+!L0KZP?*:
MOGAY'1PN[JGLB9[E4AYIC-K8 6*#0I=X#AB5:Q5PBM%<0W]4&:%QQD,GXSED
M)_E4>C):4XZX+\"1YHTD#-D3M6Z9%BHKDPK<I3-:Q.$":M,FI[5M%3H&@*FQ
M9B) JNI!=+@C%J1F,D$!F0H+LI<+1,^CM'ZHM.P7*"VQY%YL-GBBG7!=U#]R
M"<+HW3HF2U@/"%7)Y4YEDZG+J @]$6ET4CU-51P]//PAT91OK 75AN[39PEL
MFE6=9F=(EP%XSI)T\%A]_4 A."]0""G-[E7BYJPM+3/,G7N".+Q\H8RL7%*V
M'8?$R$(*M./25SI"/_KY XXT'0>GA\WL=1))9E)'B#%1UL.%JK#5[QAG@,%U
M<SQ()X=!O,'T)LD1YUQO\D0*$D:%PC'ATZQ#&MG6S)-?A9<>%>[85Q];FDTI
M^N#:/":[8_@Y],SC] 4*Z_EG'N:GEHT>J_E639&C*(U\UX:'<ND9B>%VX9/A
MXJA](A7J31IF&LC*EU$DQ ,1<:J0Y-$]1P*8<? :TD'\T13?\)]*KTSJXL]8
M K>1=AS8Y@3QS4-G!L>(\[][:$!'SU1>2' ?.[DYV+*E %?3%&I3NZ^P,I02
M)>F]28I,86)^W\F.H8F >Q50+NV+14FIG1PO[MG?N8.>6FRV][UR26L9F(/W
M*#FJ25*FD9'IV,=R86',3-)0NO>X_IAP_7\6]917N2%VV"JX*$Q$ )W-;X0I
M[ZM)>B*#I?*6@G*4 "N5_-89ID%$^ M/K07NKN8JB1Q\2U50 25NY=*W9&YO
MG\Y,OON;)7VL0HO]/?;6R4-O_JW*FB?-)MM]IZ7@M?E,99B7H;9?1\K%LLOA
M78YGM 2EBU+XKAKKT*M;B5XZZ9?^MICRAY*;9A@>$!9[)H9TV(>4\OCK80UJ
MFF)S%&'>=,?,P2K[Y<3\/9,9=5W?\]+1-D-_VD+L _+30=R$@AP&D8DEO;D4
M+K/NA!W380(;)=EED2F9@-MU*&!_@='XO? P'W[WKR@G\DO^VO7T9<.$D'5Z
M*Q&-YF7&?P-02P,$%     @ J(#[5  ]O+[7!P  Q"@  !$   !D,S8P-C8V
M9&5X,S$R+FAT;>U:[W/BMA;]S@S_@X9..[LSL 1VTW8(88: LZ'EA930;?>C
ML&70K&U1RX;0O_Z=*]O8D)"0MS\FKR4?"):OKJ[D<W3/%6Y?3?XS[+2OK&Z_
M4RZU)X/)T.I8?];>-MXTV_7D$NWUU("U+T;]C^SB?6\T'(W/*W]<#296I</*
M)1CU1!")L-/N#SZPV\G'H75>64DGFK=^?G,J@PKCGIP%YQ5/N%'%^+K)S'P>
MSF10B]2B=;*(SEAZ/551I/RDR55!5-/R;]%JY-<N]Z6W;DVD+S2[%BLV5C['
M2-WAX/WU>264LSF&:E]TK+NYG,J(T;18NW[1:==O:%X/1=!\]P5#L,V:F!AZ
MUG@RN!STNI/!Z)J-+EGO:F!=LLO!=?>Z-^@.T82[UOBI^!K-KQ/?S>_CV]^[
MUQ,V&;%;JV>B?'O2I$@G5Q:[[8XONM?6;6WTY]#ZR+J]R3<)M#.H,LN3[%>@
MQZTR6X21=-<LFO.HQ6CP HQROS_"[0ZH[L51Z?P03/7BS#@A['<OAE;FZF(T
M[EOC&F ^[-[<6JWLRZ/![LZLPA(WYY63"NM9P^%-M]\?7+_?7-_>='O9]1^#
M_N3JO-(X.?F^DL0S9CI:>X*=L\J"ST1M&@K^J28#+1W1XDLEG=2PGW5^]WV%
M?4B?+.:]><H)Y1IOP.A^UJ5X:ZM3<479]B*RSWV<9VPGI@&;\Z5@H5A*L1(.
MGJO4[*^8AT"EMT;[0H414P&[5*'/VI<CX#/;6^8R$C6]X+9H!6H5<H3>.*G]
MUJZ358<IETW$DI=+-W,>^K"*(VESCPT")]91*!'74/KPX9P9()G%P<>8/@@+
M1V@=#*WF"X36!=< %*#CK]DG ,03SDQ4$X2EN'(4/ 0J8C;\<ADP'JQ9'$1A
M++! /!(^MD<"$D=P0*0$?%QNHRED"M!AD4KL&&"V;1$(6VC-PS79^/R3P, %
MIQIM#J+!F!YE*1J$#&P9VK$/LP#=$8HC0@:@VW.F8_K(^Z]$*%(G- -?:D]P
M1P8SMI+1'#/4"V&;",GO J$I!_-<HIO#INOB.NS#?W%?/Q+@40*\_7\B@&"N
M#( P FN.J"K0#W/<#@OW9>!BY^61A!\9V%[LP"=06X!/M5QRN:3M>@'4$6.(
M29Z7<R8%H]X9&ZQS)'FNDD7LP0 T4,"J&4^;@&RNY\SUU$IO.*+\!1&54TL2
M-6*L%G"NLTCNQ7J$^F=#_=T+A/HDA\4/WS7>_7BF4R"G>I&V1>6Z$I<&+P/&
M0V%@"9C)*58'"&("9)AZ4L_)G,Q\Y 3*"W3M2&U[2L>A*)<H783*2P"Z")4M
M'+1K]@J0= 0 GN#.NK/G/)@)UL5&/(X]6#RM8-[R6N/TE7B=R1@:XNE>IT[2
M:ZN;)&T?)$2C>!GM_@7^)92@R1T:>+GT=.CN_Q2ZFX=.CV*+YW!#*K%UE&F'
M4'<SJ9RDZ<W31WG-7R"O':'EC$!IU$].0;:'@5529C:/]>%=2"%-P>G-4(GH
M4G$(#T@G2ZE-AH*9"(PCJCWSW%9,D*'PN.%3JKI2!%?3S$EW))(<(M'*DPZ/
M3)A3/$[)J2"!82(,3;X.R$VL2:R9S4P;96?RF=("T41(GM1I@7))VK''*0=C
M4B:"7/2A1R(AB](7WZ8"AN424B4<'*N@KTROZ8NGU\'IXA[+GNA9+N69QK"-
M'4 V,'2)YX!1N58!IQS--?A'E1$:9SQT,IR#=I)/I2>C-6G$AQ(<<=Y0PH ]
M8>N6::&R,E+@+IW1(@X78)LVFM:V5>B8 $R--1,!I*H'TN&.6!";R00%9$HL
MT%XND#V/U/JJU+)?(+7$DGNQV> )=L)U4?_()0"C=^N83+ >D*J2RYW*)F.7
M81%Z(M/HI'J:JCC:/_PAV91OK 75AN[39PELFE6=9F=(EP'QG"5R\%A]?44B
M."^0""G,[E7BYJPM+3/,G7N$.+Q\(456+BG;CD-"9$$"[;CTE8[0CW[U@"--
MQ\'I83-[E622F=01<DR4]7#!*FSU.\99P,"Z.1ZDD\,@WL3T.M&(<ZXW.I&2
MA&&A<$SZ-.N09K8U\^0GX:5'A3OVU<>69E.*[EV;QVAW3#^'GGF<OD!B/?_,
MP_S4LN%C-=^J*7,4J9'OVO!0+CU#&&X7/EE<'+5/I$*]D6&F@:Q\&45"[,F(
M4P611_<<B<",@U>@#O*/IOR&_U1Z9507?\42<1MJQX%M3A!?[SLS.&:<?^ZA
M 1T]4WDA@7WLY.9@RY8"6$TEU*9V7V%E2!(E\MZ((E.8F-]WLF-H N"##"B7
M'LI%2:F='"\^L+]S!SVUV&SO#](EK65@#MRCY*@FHDQ#D>G8QW)A8<Q,TE3Z
MX'']47#].XMZTE5NB!VV"BP*DQ$ 9_,;88K[:B)/9+!4WE*01@FP4LEOG6&:
M1(2_\-1:X.YJKI+,P;=8!1:0<"N7/D>YO7E:F7SQ%TKZ6(46^R7VULE#;_Y4
M9<V39I/MOLI2\-I\)C/,.U#;;R'E9-G%\"[&,U@"TD4J?%&.=>B-K80OG?1+
M?YM,^4/)3;,8]A"+/3.&=-A]3'G\K; &-4VQ.8HP;[ICYF"5?7=B_IZ)C+JN
MY^\:;0/SF\V_,/ZW'_M.V#$=$[ /4(WL)A3D/T )TIM+X;++#8%'B:XL8B2C
M;KL.[#]<6C1^+CS&_2_[%8E$?LE?NYZ^79A L4ZO(:+1O+WX7U!+ P04
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M7",WV[OZBQ?N8@W:' 3JT7*NL3W_I)!5IXKZ]H"-Z0>+/P%02P,$%     @
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MQ@V$U9<E'<PX]J&M&LWX\0AQG[,0*ZZ^/,0OLQ!1)!E?7*N_,YY<5M&I'\O
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MGE(>3RB$.='G U^MWHBLE<:<*<Z)8*O8]R9CTVFU/D0-(J[=;(6L+6!T$SG
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M$D^[%:F/2)#N3WYA<]7O0@$UK=N.5W:#9&.G)S55=6VG$L_NH.'J3;S=E6E
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M,%]C86PN>&UL[5WK<]LV$O]^,_<_Z'R?9?F1MHFG:4=^I;JQ(X]DIYVYN>G
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M/-J& OZ56L3[HQXHX@3?4%Z,2-U0KT3M!9U,&1[CD),9+I%T[;BOQ0?BX^N
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M-0EA"Y::YPDR(P(6+H-\\@RRK;5=MLDF8E[R)/BXH[*;1YI%BPZ7*Y <K4U
M8Y/^(T8G]0*Y8(P6%U?$@7\ZE;PAF/.4^9C!2?J@]8S)TUBHCQ6JRR5^%+!$
M+([T\2<AB9>+E5PJNA,:A>+8H"SV0]2J*ODGQC;,]HRF@WRR KE=+<K M(>Q
MSZ]!*G=HKK: :\K4%I1O9<@]4L,QS\UO.O2G=<WO 9XNJ.Z/AC@DE$DM-@"L
MZ]!P''5LI</UIK:9&F\T_='ZYM,/]]KF#&"_RM.^'PA>1Z[IJOI#72N+9D[V
MI]+KM^=!,W60[WJ52USIZO)C7>JB[.&5.7P!5NJ3435T'5S<B Q*OPVACJUT
MN'ZJSRZ8,NR16,*A#R=;)L@7]=5H"AAZ-1PX(V_IZ+VM"[W=I6;)Z 6:$B%I
MU()HT[GA6-JPF [INZ(GPUW/I_P%M&J$&9/D2T_]/7K!'-@#_7H(/; N$0GA
MMSO*B0J(I:!V?_6IFWN4AL)7B%>-P^6HX-S4X C<C(B05N(021_P#0V?;L@,
M^[$?&,B3(0,NY)JO0S'?&$W&,!^G&@2/ZW2G /EQ6,WD*5DV:BA6::QHP#BI
M:ZL;P@$*G\,:[LO()PYYUAE%UZ'A&.G8TN!5FT-*><Y2^$KB4<L8E0'"'&,T
M'-4<G&J ?N.8?R!>V/?T#Z0.\MT_D$M<&GTIZD_2GXN6_O-S'.(1 1,JZ(4"
M,R"I%R:\75,VQ%[$@+@OV+]GR,<#[&&0T&.0JB').:*4T5U<)0P39?LL58H,
M-/I0F\-HG:]+HF0A(@:'Q?.(DQ##0=$V3J7MW5#8<_&H@;4VQU(21+NG70]6
M0(:!"]C?Q/PN0*$TX^2Z.,TX .09I.D@YV!5@_5;)^+.TM*[13+]2<R![ L:
M!+"321L]3J>+K3W;.6T]6M/A+\*S1@_>E;RUQYJY5,Q;Q#YC(7>39)_!/,ES
MB^UZ[39>8*2&XEJ87TU*R5%]<WM[85KM.B">.,%P\1<_SU)N'*:AJ!=C5@-Y
MC7ZO50+,^KH49[+FLNMRC_25 &_-KP;[M!2RSE;*\/<LXF+),&6DO50G 7D
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M<2CGV8W3I0IEXUA!S6:]@[NB4T;V6[QKNQ5AD,#K&2'?G-&QCY&1]D[*-#=
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M"@QS#,0%_G%2A?5A2?BFBNL\E+R' 4J?XPW;L8(Z>3/+;VLDUC(."A=(R?]
MA&<*+>;O*/%7Z#XG\!^6I1OXD&=IYD?DFEU@]Y']E#=SS>&"+=D(FPL4YZ*"
M\W8QJ>]XO9[52=K(6NT,?X3;A1@#(':U-]2DES<\]"6L JN^IG[3LY$KB&4
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MO@L>CJY7?0T]G/HS,D#F+G@XT[&;'HZ@DMWR</:[H.S;5K@;0>E<V0W&)B"
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ME>Q.XM03>D=1CKY@7(3@*,'N3?I'F*VO\C2+MRCIH*,SO9 :JY"C@S=D0D6
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M#2\&DZ&F4YS&^SPV&!4<7,K,)6 :/!RM9I\T,D$IM#Y2K@:J/F1("=YVGW;
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M[U'ZAH)P&:(%.S(&M2^AV P9L#5,L0@7BKX$4L-6L;UFZ3"/VN*M3A'\]C#
MF:8#A.YC'1^4$\FGJKEA2W2V[FK$E2]NM'-@^BK)VC>;[?51O_VXA<>DSO+
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M<:$:S;F$W-E%[U"!TL1;)KP8LO4M9J-S0"Y4IU%L)5<60/7F<HN'X^CT"EZ
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M1L!^9H-(-"G[C>S7WV-SXW&'#ON=8 3L9S9F0Y.RU\A^O3TV-Y[*ZK#?"4;
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M<!]$-+NC&4V?Q)G:JKR3;K0,&P>4D5BE5MPS)R8E-6'DI*9',)X!PJ>E\/S
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MQ<WYE>%V)/E5<B'9!K16H%L(?;&H[ 7T!2+4HP&:\S"G5=G98)\.L,FO>3U
M=SR,;#?]E7BITR);A*'X($I3C]\))Z =?>T>G7N6L?.![J7;-5 WPEL[WR_K
MG6_LR61^16"WH#V0I>X?>\ **M'ID,1BZ>\T!@TM;#*2(JDFC8;1R)0#9)C[
MB'M35J&5&TB+P+,1$)K4'#T:@.KGRCK3ET'*C[8S)WA-#*!5< TRJS5%BR+:
M)24REF<0'+8\J@TK:@54&U!@WBT1RR,GI-MDD&^7M.53JK(M8<WJD%'>P>=5
M>J3S51+4%H!;'0R4%S4T& #!Z ._:'M*G_U"!RTU(&+UTBJ@**@6$4#T%7DY
M(80%&EWX6G !G>GU/DD_T2^KZDV"VS2)V7^NBY<Q["=./=O!R<'RTM"64,4?
M@^#GM743I-W& LY[!HVH);_'?SAAW"YK^V:[VB1'OGYT^UTM.:3CU<NKN#%&
MQD_22\)%G*K8^EIQ9):.'@Z,+,T;H&#_J@'!_O&/.]:%U."9.K\##'E7(F5Q
MP']#.<\>(QD$X+1C62),.Y#S0LKH5A0*2%B95YUR^%".C\=*!PHOO0LS#.IL
M$/L8? T/IX,59!T:()AU)>L.9?$[TL)@"@FAX*8=XR;@M .,GITI?KL14WAV
M^96FZS"S7Z7JW]9"LC9-F@[(X)0D15ND:FQYZ9R^.I>_\8 T*=1Z?";T<(R2
M9TKELWF\"#[KDKO[STM,GG:CN4_VIQ7*T'=KSX-L_SY*OF3]KM1JV'!NTNKD
MM]?P9PQ$<"SOVJQQ,"RW98TC 9-0N=W2-9/B\NMZSX.>.R;73<QEXO^?[_X^
M!1%?VM_QMR[#-3-R_L,JWK3_T*"T '"6KT$F<\[26XK#%5_A6"^_0_B'>($5
MSGPF3:#1!K^B5S8O?^0NN?NW!@-23BE([SUHJVWQSEN7/2/^@YJ[ S17=3X#
M5#)=Y[,^F"0^FO//WQ:/\;Y[_LSFW:NX>,DGWJW6>?@DWD#VF N'- :9\#=$
M5]U#J<+TRV9XW/:"MT3"^#M2-4;JUM#+!T^B>*U94)&C5@4>#ETEAW P;N%K
M!?![O/$ZC'B1FKK\U4,RG17/\SFLF@#3]9>C#D#U(5%DJOUN(?OY6_,9.)V8
M5IW(Z^BVBU3QNE3LCR+0.#8Z,JE>G4-U1W-:J;4XP,0F.J*0^07=TC2EF\:[
M?TPF%NM\9CW(RSS&O)RZ>#N;C9;&!0UJ!:JP>6_MNE@O&VB]1"J\!6N$5*V(
M%P>J=A#*G$^G:/,14?+/__3SF]>O_R*,F*\83I7"_'W-HTEAL%+GP]#;*GF.
M"%VOTN<SC:QC1'L70C>X%^;,MF'.'PN]9RNEF^UU$N^NPR>ZX2_%YYEX4K1\
M.-3D7/JU >5:>FJFOE'+V0GG)[P!<K,EO DBVB"R$>%DZF:F\RN_2 5CNN,7
MU*R>9:2>W%6*LK@O>/W]XOV$L'XL5H!0_#'CO9!L&37KA4CT0B ^@>9=AH"W
MY5O0D.OE6:9!L'WLQ/#6PPW_OL(%/;( -0R*4NJK W\]ZC^T_=((#*U<@,LB
MN_2JIZ^I>2GO8T2K9PB:K.(E=1:.;TYKO)IEPU43^@0->LPEA >^NBL!#W#!
M[%%P"[TZ'(,PY;9YO@_2G;4"D8D!<I_ )+.R2.6$I*8D!2G2RMQ7[(; S)WN
MDF3S)8PBX5=?*GZU^,\]C38B"9=[8=3EM!50RH+8BB80"^@^$-98;!=W+RW6
MX,,,:!E>NBAP*YC(BY+M.UX,L][=*EBA(\]12O&0LS@O9+HD]1YX;3E1&#R&
MD=A+P308?_QUC<<??'#OPF@VJLI#_>J<WV)//=J ?J?%4S/]>RNZK>*S.GV#
M5"T@O@,U2L&0_8[_NDD?]&E?*>D#/;C"[>^ZI6)M>4T&!NAB[CJ9M67=-666
MD?(#O<4VE#U&+YINQ(FV?+H1) M+8)@D<6&A"0O3)"K@O(8^6DOE1/#%J=0R
MT20M?!LY"^-S%99@AG+3;Z(\(FMC^&9IU[6G>5:-+2DG8!+%:\V6G4?D 5U/
MV_3 +5#-C^?ROC$3<4WI)N,;]B)@U<AH,=#>+8%6#NFKI5I<Y+F^C/ZB;$0<
M3K!Y4RQ3=.:)M:\Q7N%BZ:4Q3-S:)(/@JI8O&8154(M\2%;KWT\ABZ5/61C3
M+!/G\O(>0_&+[8Y8OV80;-%3/Z,A\F=V)!FI6ZA><Q33:-D,MA4.5%7\)/,E
MN$J/#2V+%^5EIKU!2PR[[ -:DU'V02R.13*?P4+K_)D_&,LS97BB_M&Q^]BG
M$4QKM.GF8XLE_YEXVCD_$]OA52.+L<1>:C*A]@&#(3>Y8Z4??W19YCA1DWJH
M)NA$J=, G1"%,;_&#'T1BLDY/Z7T9EO[!YO=^7!#&IR7-II<F#K@) T^#LF:
M$ZGFW00JE0D^Y20G3]&6D*DU (:*8?EC<$PJI#3?RGH_!NEO5-2^OZ?K4RK7
MF+&L%B\SL#1F,[@EL+3((5H:)B[R4,];=3ND;DCD1\J5T$H+P+GGKPE5;DYB
MW?S(1*B(G0TY&+_MG$A<\/IE1DXQH@][*A< R2G?\H->X4B/Q3CS80Z>@C 2
MD"ZS=S*2U>#NCCQ\\J3_YM@D.\,+W1&>9B=X40<U_EI:#FJ6MOG4'ZW#-X.G
MB <:4<<[&M-MN Z#J'P-XRHNKZ>_3]+2Z_P'W3RDP8;>T34-G[CG,,<($[4.
M>)UBFMZPQ[&/5=,,OL5K,"%_M+A(&!..N&Z?Y/P#_(IC^06$NUVS=<T[36>L
MDRBBHEC&J&Z!O*,QH15U;V\LS81\[W5\<Z8$OE/!K[Q\#'(NW3,+Y<XE[/G5
MMYMM?>W%=^?"NS6DG0Q_;>UCSMLY(V5+(D*MV^(A;:,Q_,V.J;0N-S]"LW)8
M.QT]86S;^>B)89AWB&8JP/7ME-J:NBS44BMG'>7[['F0YBX3G[I+W@51^63W
M6O1.MRZ6Z(RT[@QYK)>S&7 7QOPU&''P(!28J5\N8^<1RF)ZA?)MB]GZPVO5
M.WDM-?$L3(]NR/;)EYA'0_F>DJQ9ME'\S+>#4*>06>JJ?3L5U$9)*BN@JA=P
MUM%IPWQ!LZJ<K#0WUSPT0)!O9>(:TL<SS71G16%CHKDK=T8JD3HU*J54WZ#W
MFZ+GVQ?P_-WF-^L1![N$25WH8'^P?)_KD8 ^4?O?BH>T9&M/Y/C04]?GZI^R
M^%I13:)?@)O28Y(6VZ,\N&--94D4;O@I,7DL8N9L3VF.FR$_J;E-ZJ90\N@5
M\;I"Y>=!FCXS-RE*VUO\3.^60)^2[:NE:ANJCU ]R?DI3=$N+$^JI+#I4$R1
MTJ;E@?M:*KB M*:!P%6?KQV$6LPL@_=AS)SI1/?0K(WA9QW8=>V9?5 U]@W<
M0^NG>*W9LN^A>4#7,_7  [<+L]%);'.A-CF-+2XJ$\A?2S%5ZC.!MAJ[_#;,
M<KPYHN7:-R[)B43$?K;8NR6DDVL_+>WGMR^:MT/+ZZ PEMGWR'J8NE*CI5GA
M0+#:SJA[(!6HNNAC?I[$3VR8PR26_Y5S1\&F:)&HLSKP!Z)?6PS1OPG0NJ/>
M>JF5.A_9C%CQGI&*F]3L9T0V@'7?;(1^=W1##\=JYTBRACR).Z-QF*0D3G)<
MN^L+2K4^:3]$ FW@' O;O]G>BX[F8EKW:?0,H-LQ!IE53)6$'%.2E'!:+/OH
M+SD7O&D Q06Q .=Q #_4J)LD-LC U'P['8^12!8((AZ \NIS5S$+6PZR7+#'
MXY:^+4!6A?/62JFWUN!LU$QL,*/O; Q7[E,2O^2KJG_^I]=_?/671OA6U4Q?
MT%9'3V0J9>?ZP7+$O0HUY?GFD3]PP6>P<7<JIF@9ZC[%)+U@N3!0MDK*9OGF
M^64S][O1-!%MDSO4:Q1S]TB5!)\T>L28#1^LUSR(RA9QB6(ZDVE=H%B8O7A=
MGOB&[&:,CPRRD 4YMTR2LD,LH86;!<RK6>564U@9-0],F_3(KV7[=G_;D-Q]
M#Q*=ZN2(-_?A+@X9O'D1$NG5^#OQ2<0 3[,'^C5_QZ3YS1*RCFL6,(X=J;\?
M/GGTUVB2U&V2LE'R*V^6B':GCWK9<O\Q<<>]<W7&L=$@9L [!=B[4? 42 >Q
M].JK'BM.#2V@3>HD5?+W*VM!]O[.[NT"QMBW(R;_\^+90/Y ?"!O>%V$V3I*
MLE-*;?ZZ%S=42."MC9(F63[=V> D->N\/M:]7!FM5][@1(MT^F&M%?0@ ,UK
MA3!X8![V;(*C<A.$'()G\DB).$+G43_/)65_YZ6.4AJ);-)CD.;/K6$DFQJ>
M048"DK&)(J+D4;@V-G?F[//?-T',/U.DM_VY4;RKKER9G9%@EU(J=Y^_A/F^
M]7WQ5DG6B$;62?5V<X/Q3,@?!V7),_XOT0S_PCX\OLB^8]\A&YJMT[ Z/.%4
M3?5D*X$X73#_3D7NN@@5@OBY<=& _WB@^3X1]\_8&HNMF$+V=18XB99H>L@T
MS<HS8OY'%GD\A<DI*^ZNG<F;6YMZ9<_TIF=L37\,BQ[8B#_(EGG<=@CBF*9R
M+SS/BZ%FK4G%RNZ2W5SU43G49^7#=F)?8'.BO&XC@X:0KS,HWY.K;869XB9V
M$E-.?DCX&(@38?&C*"7$_G2*-SRS,3D<>.]_87+RD1$<01SLI&3,IG-F"J*]
MG..U^D/1Z_R;=85^UBNGB(]%=?K,EKCE([)G3;@6(,PT0"D_T00,H4\T)J$@
MX&!G_S].VK;P2/,OE,9U+XANZ6 _B+*D_'8Q"&P4^!E( V=5MB=3>E.^ELN?
MPV4C3>-,+LMIL-ZWK_+1(.67/[,R8F5,7X2TC7$)N94>Z.%1HB(@NS0Y'1E%
MD+,>XP6?@G8*.?]L2EGWQ%UKX&"7OT;-9',%*6RD1&X[;[O".V]<RMS50AVW
M6I^SPBQ8!X9'3L'383+1^T6[A;T]/C/5P_5>38GOT<N\KR(1R/ ?DJ)]WG75
MYV3O27!6,!(E/@4\VSXADTZ!];24\GMR^34X'"-98\WB92N\Z.#V(OB.C1GC
MDN9R./(/BAU[9@?9Z3$+-V&0/O^%O'C\KOYW*#\:E/8G^1G1^CLI?VW&O)VZ
MRZ6A_D7\\F+S76-TX<N!W7&C/%&>B''.;99US=^9)SL_97ERH*G'4L&[!=!3
M6E^MU,-/P2G-KN25SKWD7LAZH^?(J0>CO89M"6#TV7?R;V(Y<+0%F%YX1%O5
M3*W@NF NHM9UP8^<;] /E#T-#6<OB!=_B5FSSW5LY>'JK5R@[Z+:I->]=".H
M6SL!B_#A'L.@OA+J' ,L!/GX9SL;+H9L;DH/(G3'.U +]#=RW=CQP#V.Z_Q0
M/."]BC=7<<YZER>*RHK!O9QISW8 3:.OAEV4E?QB@5.W4-3S7IX7'C2B77P.
M&DX@3VT2Q\]A>W"#^FT?;53'9T/A MSX(*4V?(MA&XIRXXJ&N [>&W*JG_?&
M&ZB[[V<U5BX$5^X'J,IQ+\HXANFPA FE!^P]  -V^ZE7&&-B +[9Y!68B'M,
MBPL_[%VNN\F#'%"T1?!QAT8.-)387(@"$W07V%/VY#$*=P%:EH G3NS(QG)_
M:?C$>NZ)UE?C^+,P?Z6;7>M*:D\?.:)54!,9H[T*Q;*UQBU1>:9>--@L9K)
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MF[H)@4;10,;+KA]$/%3\A61Y2@.<3-E!R%2N/?>!)4P*0!7 5$4E?6?Y_DU
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M/DS27F%5I)P \IZ6[8-W8.MN%- 2PW#>+)\E:\CR5>* ?9:!+:-8_=!>L%E
MLS291'BK55(4%RY*/B[/$TS5)W[]\$/1#R\^4;%'_A!\Q:W7-HV%F!W#*/,
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M3V[ "Z96E'0NE\X/$<^+I1-W^:1F=FTID>!FP3.W:TMU &T_7F/5.P!0 -$
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MT@WM;%#[E*3Y?G6@:;@.K(#3$0+!3BNC^M(D(R(%%2(&)Q06"I!F##1A:08
MR 3-K]S+=\2K?&P6UY;)WKS\N.,PTK<!P"G=6R=E%KT\)_?K/=V<(K:N>OWF
MY:M?SDC56O/:!5^ 55<R>(NH)YH+4A@RQ.B'W6[LT0^X"S!&Y[&I'_MB#-%\
M>CD,E;A'LLO0=3GF9S_N[0/5$0=1HK)=V:HL$$$W5['Y0I/]J&IP<U"'6</U
MU=<$K/!6ML7^@W0N)*[:%Q(1C\7FUSY4M _\M <[8!N)^-81W!+@[G5(-_7
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MA<DG$Q<C=E/08(K<%"B @M;\M/P'9D?7]I+%?1I!@+F7;B9 G9&"G93\I-$
MX2V0%[R-"9/8?I'ZQ73'BUC[FL<@-9NZ;,+MEG)>]9TS#,OQAZ3)I/SQ"&IK
M9;KWQ2D-XYU\(-W#NO1L"/9DD-]L0=55"<E!) ON9-)3"1(4]$NP#!N 3+9@
M0\^(TUCQ)MDYWXKBCR;;[YOJ::%.4@V2ZE^_J^@P;Z'VDAC]*JH-":UCV-EA
MX'7(VJMSUR4=_-EH:;_R?)9N&J];U$>VGO&91QL(TXF/9N:YI>1NO^'2./F^
M1GMN8HR"367*VP,+>6^B-R)-4Y(W'($*_!QY_F2\^QR'.9L?U]R#[/AC:DRB
MOP71B5[%EU]Y78>;[7GQ'LA*/ =BL;PQC8(6"!JANUI J&B,\-;.2-V>>(B/
MM4A$D_QQ5MDH_WO9+)'M8MV4F:DG3JPU<FQUQ)9WQ%/9$;3JB,Y;,[CUEL::
MA%J/::P]S+:]>\_B!7' >L^$"EAX;-GE-] ";>R:)%7/?>3/R!O[UHYM[N):
M>W6^<2\^]CG.CG0=;D.V1K+MZUOHH<;?(K$) V>D08V^M^_L\Q8L7!T^8OFJ
MI"31]!#&0?0A3;[D>VM&4$]^J&5N#XT\DLT*9B*Y[=E!8"O-OH/66GVBC)C7
MBG2BD1/93R0O1VXG1X[G0,$O7EO3O;.\JD*+%0$;"ZHV ]L%Y.X:N]<:=B&4
M3FU\W:-FJH8:"PF6*JEM+"P@(=?2S58\3#:9?F)M[E<'7A\^6,6;CW039JTO
M.?:'_?FA)M,>&G4!(EA)P2MJ1 ENT@;. DH(]AVUUFR*,F1>L^GHH0L:0W<0
M0Y>VEO/]]X*-98399"UOCP?1QR#]35SS:4CJJASLR0Y7+-A7'TV9D9J3%*RD
MZVJQ#:;G>'4JX<(/EF?QVVD&[5 ,6MM6IC*5!_9_LLM3FAQI#PMQ<4$9AE-Z
M)3F#,Q#)L3@S\!N+%OH!!\(+](,&Y%\R0N6(S(CQU3'L"W 3"RBZC7+KH;VZ
MO5HFKNW]KX(:H//]$=UK$/Y%CL)(+(]>(U[0Q_PJSO)4Z.BZ.Z*E!EPCZJ6U
MW;NX3N+=2[XI0S@OJ9DSW%LD$)I +H(M..HN@BT@ H'\><I6%?G[8"T*0SEV
MQW3$@(#7RJK<(A!$I*0R;)#!X'I"@2'A:\9$%[UF0"" U[FIIR=' [#Y(DP7
M$89]/0P0CQ8:#\CVW4@;..:[S54DA=ON\K5(H&YMM>52QKJ\A(#A7,?+!W9Y
M3#.ZK0MCFJ'M#;6,KK_?)4\_K(O&)-S*?]5P*__RCU44%1\.J?GRH)T< (8.
M>954Q2@B-1F2RYQ'9@BX^J"CA*X/-!"6:X[854>,ME@SO<7;7LN@QJX3"HRW
M]++%KF9 ((#W4W!PUXXRLZ !N26W QUGA%,C1[.SB8\'<A4[=JBKP!FQ47R_
M3])<QLZK74I%]@^C^J-]K]C%!;5=[)1>V8/B#*18ZU0LA/-@7M+JK<=Y$C_1
M-!=U&#,:ATE*-O21<9U2RW4SL.UO/U2U=L !(>6U"3X06FL)K: %+>R=\&N/
M8A)&#K2YZ=I2J4$)7*ZQZTO,(SO>K*1@QCXI*8 !@3D_1N 9KEP6N92QW:/2
M4@/"6R]M%Q[MHY&S8H69DX\!<^[B33<<@/M)7TI[J*3EQSU1I5-4/TV'5>K"
M<QC$JR6*-I@&:D%[US@M4(>IY,<G0R[ NR1-DR]AO+/-/5IJR I^6FFU$WQM
MF4@%^[Q$M8:'J-7ZS+A0*O6903%BO=.>M0J?^OQO-#"N=6P<4.L<J]2N^*(D
M)YP>87'32_CR9[2EBQL@K64+$#J\EBSSH 1AO2*R06DF"A-?;K=TG8=/M+[H
MZ[V*<;:#MK9Q:^C<S2J;$/?ISDC52N.J_!)60OTU_3L-=WM>LB)@<QB_YQZ6
MFO+[9\M9(7FBU+YN\H0HB!'^+4C%>])<%L=IC$H*:$H:.;L8*DF*RZ:(YS 3
M"0L)<Q,.ND@V@0 <K,Z3%QTQ$F"-QQ4=%*">LDPH,!9P[2<J9D",.4LY/6;A
M)@S2YWNQYOJ4Y#2[.-$WKWYTG:=X<(*=J?AHH:R-*R8BN8A@(XR/<$;4PY5!
M"DDM8J'%Y_L+\N;LU:M7Y!!&$:]RBG_"XHVU]BD++-#\3EI& BYK#M6F -Q4
M%VG,PKWY^29V%/;P9,:W[+8N_8S[S<^$,2_3P!UZ=6W\]=F;G[X)&]=@S]/,
MYP+>2$N?"8!C:])>5)NF[IP("P-H=5J#S/J:I#4Q>@[$*.'1;=4)%[5Z[>Q8
M\2]AVZO;-VW, ,RT?QPST_YQ63/M'T<XNC\N>*:UZ]6=:=^>_?1M1-,:[/G.
MM#,!;^Q,ZPM 35C- )C$_2N ]3?XGQX8YW"3;[,OP.@[^O0T^Y^(8%^HX;MT
M:\+H_*_OR5L68G_\!@Q?AT%?TY\-@&.-WQ^(.O/_B>2<'< !O!TSX[]=UHS_
M=L2,_W;!,[Y=KR9\+C_?L;7UVV]DQE>QYVOV,P%OK-'[ E!G\F]A9ORW@S?(
MWRYH@_SMT WRMPO=(+<IU WI__3S+]^">7>1YFG;L\!LI&'[P4UCU6\A%NT_
M/7Q)1D3P-3.^7;=UZ1^]?TF6:=X.O=3M<9\CL-$:.1[9P-!I 7Y+8T_^JY%9
MC&G\6L3/J PKD2\)@!/[<<PZY,=EK4-^'+$.^7'!ZQ"[7M_N&9^*/5^#GPEX
M8PU^'@#.9/C#K7Y))C^\NQ=JZWTV'+Z5(X8?!UKY$DU\Z(3^(\!D_J?!-OVG
M!=GTGX;:])\6:M,6A;HV_:=OQ*+_-,RBYX#96(OV@IO.HO\$8-%OQH3G;Y85
MGK\9$1V]67!X;M?K6[5P%7F^1CX3[,;:N2_\=*;^!B@MX.V8+<6WR]I2?#MB
M2_'M@K<4[7JI>4#?RO:;BCWO4\%E;K_Y E!_*CCI]EN6!V$LZX(\7S-ZNE&.
M.EZY[+Y/&W#FWTLS=1":[$3R:X\/7^$Z@PFU?!E)+;-N8""6\__\3Z__^.HO
M"W(7_9';\1I(L/5T'E/"5S>PQ7'D*XC;.L.OZBPH:OAY:,CP\T+#!8M"RM+@
M&]FW_WE8F# 'S$;?RAD:(/P,L?@?LQIXLZS5P)L1JX$W"UX-V/7JK@9^_O''
M;\+"5>1Y+_Z7N1;PA9]^\0]S%/]FW)V -TN[$_!FU)V -XN^$^#2[5N]$Z##
MH+_I+_1.P'Q G"FQ<'A6X8+,_Z>A'?[30FW>HE WDO_E&]GS^VF8I<\!L]')
M=L/A)CD!['K,8=Y/RSK,^VG$8=Y/"S[,L^NE[ME]*[O[*O:\C7V9QWGS '#F
M77YWADZ?-I:TRV]-H_#<Y<=.X)E02\LN_^MO<I??D?&#!-O)=OG]X6O>Y9\R
M(<A'8H_=P9[-+,NAV+=L_'T*^N;AM,IJ74MUT^>;="VNW48\&$_H8'K V>9C
MH!,3WOPR@9/Y99$>YI<)W,LOBW<MOEK^Y_,KOXQU*G/ =CJ/X@U?BSOY!?[E
MMH8>&I^BI8)\*:<EG6$#0/P,?2W83\*') ^BUE"COH:CCK7R"HXZT$ /<FQI
MFM+->V8G3)?S),NS3TPK^9;4)VI[9\V#%_3A#;<F^L<VLNS$.8A@.2,U$_MO
M.N'[3_V>+QNBCWC,;,.5"DNEUIP/]S$-3X2I#VAXP@OL"<*\>&FM?+ED)1\N
M:;[M83$7[Q: GRKTT\KU?&'UFDO!WGVW)LC);1+&#)DQ>0@/T[]9XSEO#-=X
MN>_5],2F[A'!'L $-[<']AW'.S5Z<B1#:LCKLAI.BOILS?1R8P&_BQ(;RKL0
M08&T\S4;$P,BK(V/Q.@!@OJXS3RR8\+;_M:-'2[0BUKC=IF%%F>!ZSKGEAM=
MF'L]SNZUK";;?8OPR./[8$U7A^1D?;+;S(+V=&-+;N<KC9R:2/(EO,;H%CZL
MGP3=<MD#K>QXKRZJL+$_L*AB!OE!TZMXG=(@HQ=4_J\W^NV-+.(I4XUN?=\Q
M+9L@+\I&OEN"X<!KN8R'34UH]7_5U 15!#,LWSB^L&_(V)C0S*PCNQ-PU7O.
M%YI-" P+FE0!/./08<AN##H C3F5KF.X.WH,PHTQB+*3@YTU&^6UQM62=J[0
MR:O&;%_!Y=%A*@7'BYM\4-(^[ 6 B-^Y[@0]/EGR1V.I5!BP]05Z'R8$D]/*
M;C6\RN_.^(Y\3_/KHX2$Q*%4XFA4 L,4S4@R&>3,,.IKEI.,!,!S$LYR,6Y.
M_%LDUMH:UN<DD.O!#%+(OPI,>:-D@1=)'-5>0%$W]G4)+_3-6LY%MXRT&[:-
M \J@K5)WN[*U+U!O"Z!G$+J[O@5MH'[W@O2P_N=G]20LR*<"\$U,>4[#;4H/
MX>EP&SR+]: 5P586L(>$K7(KS\+&5*1ND(*>% SX*/;H__:[O$"=[_<R;^]!
MR!FYS$0^%B-QE%P(::QLBJ"_G]BW+Y]LF'?00Y[\&23637Z2C@C"99P VKI;
M.06T]35,RD,8TYOM>4HW(3^@$3&?*Y/'R *9]F"66TVYC#>4A>7!81$),8X.
M5W(&'+V-AA+9K>X4&2<K,FHZ>BCH82PDV1+)1$JN,U+ :A%9*)[#XX,MW=B,
MB+MXRLM#D?)R+O*"U\^W2<IGV_._OC>%7BXNJ.C+*;TN48D\E(E*I.0A!1,Y
M)W\E[Q%V H8I(C*N1++ZNE3D6"KR5T4-L%C2#U.M<!(04%X1Y?3CP8$UU6+)
M(MWEY[L!1BNX%F"T4OJ^1GM)/I.[91FM11$+2!C7$HVV@2E?HYT:4&.-=N!X
M<&#!KPC;A^+G09H^A_&N9P9@EPTM'4.1WY4\_"%-LNDO10[(PW!*?IN&\3H\
M!E%QHEH@*(^>27+*LSR(-XR=,"3E>UK<*JM:1[Y2YH:8/5=#CZ]Y)K7/]Q<#
M)C7!M8!)34K?=U+[3.[)Q;(F-8LB%B?*N)8XJ34PY3NI30VHL9/:P/'@P$*?
MU)(G&@=Q?D&S=1H>=1U@]E8Z7KSI3:N),V>O9",-O@5-".;A<<P*YK%!VPC[
M&'P-#Z?#NR1-DR]LQCH/CNR7_+GGIIBY&>0-,HM^WIME11ND:H24K2QMW\PU
MFCY[:*ZA'!/%-#YW^35G)L%,X):F8;(QAC V%K#XQ2JW%D<W%8XJ!B(Y\.9[
M=^^W)WN@KO>;Z?L/ 3/EM1P"6@W!47!,MM5$Y37V.RZZ$<%M(C#,=F13#Y:*
M,@."  ^4NBYLPW"V_O,#GF\_IIP X81\ST+7,@;V*&5@H(<\(3=(K)R0<[I%
M53.80W+0XWT;5I3C?1M0<*#M/*\U<F#"VW@Z:X ):E6#N:1'A;G](-D!&A"H
MGR<QFT;R\#&B7 IGGI.!'A#F)HF[,&G0R<T\G)3RV<2&!+85)5U86R$" NH[
M^I1$3WP)V5Y@NL#MX ,$N4N#+FHJ^NXF C+JY]<#T@R\<-4U!R]0C5@+?HXS
MNCZQMN^?XTVXYB48^^)_8#M0*\H!&G9Q535!ZC;(,L$V:E!;"]BA(SH"C*M=
M2BE?VAH6@SHB*!AU9>MBI/H=<<%D[L36R,[7@UY;$]X].=5^5]6@<2&F)P.'
MEG'1T@ 7XD+%UIEZ@,W0D_T@YN[1J4#VD ;Q>F_:QE))H,#5EDNI""Y_Q?99
MFLYK 6JNGO,"DU</3@PCNZ?J$ %#R6A3%9BP?92V$W6 PO)/GCV)D=&1AD],
M]"=:G_]?T#P(H]4C^W>PMB<KNIE!<SH\=%&3.DJF1FH'D6S,2Q:,J.M(_S%2
M\SI\!P@8; _!8V2O2=:A1(%1*:4%,[\*&J3MDBDDQ0%R:_S-J&T-/C!$K\.8
M7N7T8#NDU%*C0+4IK0T$G(X(0G3,3B R#G@59)@!K, "&,3O@S#]6Q"=Z,VV
M*511=\8+V:XF4.#NU,L"J(J,ERL.4R+:*6XLU#_BO7<S6,?J-[*IZ)$O*/3#
MH=F._$"X!.-:99GCM2@?]N485:F/Q: $B<Z8Q _8TTPOK<3?OQ'S:2&MI^FT
M8(:VT,P^L-7P-4/*N^>_TLTNC'=W-!+KZ&P?'AT)8D,;1%Z0>NG<A65!29JD
MJ!EF&)IA+[G]T>JS#/>'*HAY:F1P9K%9> "-S":Y']I0$]EF$Q_27)SHZ5J$
M$SIH<])=F/TV8.:IV9#GEX;\?EN=2YM&)E( >[;HXLAG3NB""-@(SI-8[ E[
MI3#;V5",0"N_!4,E/?(,,*,".$9@QI'9",P@ C&"]TE*PUU\^76]9WU=2>-,
M 77P 9J!2X,NC IZ4C(TP(2: CJ_'I!&X86KKE5X@0IR57!!,R:/B-0<H9&)
M 7X]H,ILBJ8;E*C!T R"(ZP!#%@Q+  ,0$$"M^^*5\.""G#G@K&%E"4L=Z<6
M'A?H7FM=(VA P/XIB3>% '3C#&NTU( 0UTO;!<BG)*_ P=^CST@)F>;J$#6:
M 5 $$OH6%'51;X$0".#?!:R+U_1^3VE^S;_@#E[,+(#0M\C=A4U!2@0M*8E1
M8YBYI(<$N0LY7:2[8(,&=V<X8V-"AKPQ*C#!!C6JF5,#;.C;@QLWA*9YE' 5
M;ZZ3(,[LEQ(M# B/$2HR6Q\B9-1$D*,^9M9#^M5ZS:N&9OS]&YZGB7\-THD7
MT[.#,X*E[Y.#OJ"13Y %##01)X>_.7"3[VDJBUGF(IW$;)MN%L#9QB*W\L@0
M)RVJNN8RF\ELG9!^VM7W72_MZO@1/OH3S>_H$XU/U.&;-810/EDGH[(&8W-Q
M283I@2>3%<SK&A'0\K;&X1^!O?=AS(*/,(@NOQYIG+D0:"2'PJ%97N54HZ0D
MM"#%Q.0L<H/ATX&2%DH=$ ':JLOKS:!55FP%U3M!#VG *])[;.+U:@=T>Z^?
MAD/VR\Y(T0KZ#N 2=(7=)!R 7W7[< !X%V&>EZR;DD.XYC^8G^\=U=J"3%6O
M[3 0EVV)'\W+R678+8+B2S)B"\K[FK(%XB &729BW\3:/&T6N-ZF- ^^6JS8
MOPE T^VA5Q>VG)6\X,S?\8=OM'F7V1GYQ*_]R$9PC!1514AS[(O1K@WV!2A0
M,=$LO]G>!Y%EX6:A!2TBJDJJ5N+,<E[+/>-4B_#AQOY52W :.G>:O?N+$V6_
MOWWXDGCOWJLL"/OW&KFM._B,GG &PC@6LHD_BPH8^_DF#)EV]&<%4-\]??]1
MD+OZFW(4\B_]*_7[VN.;GL;X!MT2W_3"\)M%F>!4LN/9WIL^AC<'6(99G;/C
M6R;W9C9S>]W3W%ZCF]OK7I!]O2ASFTIV/'-[W<?<Y@#+,'.;HN-'F%UYQ"0.
M/!_V0?PY,S[9I:>%,C>#I)H*Y_*83YY%<T+"*!%LK*_ B1 X%P(COAYJ0T3+
MJ&:'@Y=!C>IE<I%$49!.-8?=IO0I3$Y9)"H4B-<9[H)<5[;/3@YE4F9YU3>?
M2\IBRU4\G<&)$0QKD-A[(;9X'#;5B UF7@Z,M"P, B!>1C9%CT]E9&P^9)(&
MD7R"NY+'9&1&<K!<&J.\FK,/04DD:</2,-)J^HM=/ =?CSM>AHT=(^T\&P"
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M2PLEJX$QD9*+W,2DYB,W6U)R(DS%P]5)2W68O6:U.LF6' WJ@$VF_DAKS9?
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M^IQF7W/3I2-'><CP2$>+E(C)3E"J.)D4HJ24)5SXPS[-/IQRBA1).=NRO'Q
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M^$#"K-5D?HPS7OR]^H29.OKR<&M+K<;J$K,IVFP7(3)I(<T!U\AFK/26R@!
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M &[MM+X\DEF>4&2=[O-3D(70+EDM5AHK'. -[#C DIUFEJ?$9T/L\7WU'(<
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M\D\_S,E7XC-T#'2+*M_V\SOYI@IJGZB:UQE=C-U0_48=Y$<Y%>2HIOX52#Z
M^C>ZL&49VQ>\@OI7=/RLU;]1!\FH ,M;IOX57?[@ZM^H8]M3WPJW'M7^NZW^
M\78!%<5/6(])QA;?ERI=?'95X+BM['WRTR"]6]SOM7L?AT'+N5BFLUF<%_')
MFX\K:'QP):\SW)XM+-?WAD-DN[=4BFK:7H'C VA[PZ%E>U,A> 5MK^CX66M[
MPR'2Y@++6Z;M%5W^X-K><(A\XE684=+^NZWM?2/?][:!)([HC[,RQV^Q*;R7
M_ZNB .HVQ>1GR_5)E53^&*B)T)":.">+( I8*U_R8.[3+QN(P7D@,]K]\/TF
M37,RA]!]B[/_(MET3D&0N7Q$&&K9&W3ZD[Z%QP;.$#$-F3]FAHX<+2Y)DM%=
M[BGQHY2JD[39M%AA'8K+'KGR#,T(^QD:2'B*MN(/\KC,R+;'94:*C\N,SOYQ
MF9%5C\N,5!Z7&?WUN R5@2VJ 3RCI/VW,2[[<?9"YGE([A9EQA7VV$?@/P=A
M\<3)/T@X_QPGCWY("MQ21;!F<TQ MOB"5%GCZ'[-4+IM27X@;R3*R6<J0)9K
MDND Z>]!]G*9IUF\HGUJ7?GC]&B_0PHJH6(+7F>\W=@M5Q3'6-M</9&JJ8]C
M>",\*_5Q;-MF5PA>07T<P[O<F:B/8ZQM"I:W3'T<PWO.AU$?Q]CG9H49)>V_
MV\;GJR#UE\N$#F$&X&ZQWB"D:J56?28I[)@*B#X^VSJP3J4X-CH_4"V7Y68D
MR1MA>O T#./OS%Z=7N9)LAGP\G.#7C-,(+;$XXIY;H#.;;/P340',AU%[%FC
MMD\$FV^_:V9J!VO1DUM_Z(;F/\)^^4PN1D5C,?P$VEEI^Z.^+3O6ON!5C,5]
M<$\Z$VU_A/6T*BQOJ;$8?C+UPVC[(]N>4^7,*&G_W=;V=Q;2[7:@J@_J-L'&
MO"VN1542 <[UD+EM+[Z9T^:"1<"0W="&HV5 ?RKMYJTKAE_B>/X]"$.J@U?[
MHJ4J:K5#:1R[$I8V09Y)=02KJ$Y./DB<VMBV.+6)8IS:^.SCU"96Q:F-5>+4
M)G_%J8TFEL4"<&:4M/_GHDY^9FZQY#9X(T<;1 W-4KDU)D5;+N6JU,J43%V0
M;NN;&PWBP^B6(T>R78VPD_W6$:RB;@DG_STOW1+[!0*NX%5T2_C1@7/1+4<V
MI< :\=\:X'3YH^N66$\1:,PH:?_/1;?<J@Y:.N11+2856\[@5:IDNB($QFV=
M\(H\9W?/85 Z6;1O=F3?U](!^16\SMB5!R3'V ]("B6HIM6-/\@KDF/;7I$<
M*[XB.3[[5R3'5KTB.59Y17+\URN25 :VV(K@&27M_[EH=8\O<9(]D63%M@0]
MU8Y?E<G'%JV]2II,OQ,B0O4O-<CX5Y^]$LY"L>X6MW&TW.+5-Q"K->4-!L.>
M-1F#=,>$)D:WW5*O2!*\T>;8BU;L0?DB2\,TFO^#S)<L _Z,_JF0!<(A0;%G
MFB>)VJUZG8DKZ70GV.ETFXM9[4PR^2#9=B>V9=N=*&;;G9Q]MMV)5=EV)RK9
M=B=_9=NE,K!%/X%GE+3_YW(FX6X7-]$6=W%I[T>SP _OX[3( [;-4:NGP!KY
M$I.^+0&4U2$ATVY-"N!<#DB7?OKR.8R_K[63/<%LQ9+NRX4DBSA9L8 UJM(<
MB>N6]9;^M\;QJHV.L'?9NEU7AV^K$G+[:%<\6ESZ<]RL7ND<+H3S0)C$9NR(
M2_7PJ'S:N&# M2QUDYXKI[$^\FD,$I[B&:O_0<Y8/=O.6'W%,U;O[,]8?:O.
M6#V5,U;_KS/6I&_;&>MX1DG[?RYGK(.-?YU\X=/[$_TVU:KB5/,J2+DU)D5;
M;O^JU,J435V05B8DX:.YI+KBDLAC!+3;8**P\7!QS'==:*<Z%: N"/0D\$!"
M*K<Y&]A*CQYIML2D9XN[=*.%0 *0/SQ&CAP:I[-9OLH+=,7)\#)>T6^\D"@M
M+$:T'+F-T_;/BN53\PH'Q<."["C?<20BI.@J\@P!I*=T4-STW]!1,;3RE%B
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M\-Y*7>L)\SNJ.<WRA+F;?/+3H%8NU^;?H9+OVN+!61T.,G74''RWHYRV<E"
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MSX:8U#@Y/Y!7EO L6OX6!5!F<;"LUZ'X)SUW#E\*2"Q[F;$NE0J9?H]*KX6
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M?/)#/YJ1QQ="LMMXIJ)'0U68)!TXI"K"<#P[! ^==.&&*S&A(-]\2/A2)_D
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MAC?H##I89^"Z?"G L3(O4'$\3._CD&*FV_5C_CP/WH*4]K%,2Q4\"W+T:[;
M]OEAOXOH9E*'V3KX'$\:1#&FY,^<>?&_T?]A<I+</@ UBK'OFF>?*B9W<P9Q
MD$FO%< ZI3R0,R#(N%)FN(+)5'X?=(ZE[ZQPRY=R0 X]D[.DQ&X%T2ER C79
MB*_H1Z.YSYS+^4LMIQ3+AW31&3EV72 $ M!R>M\;*2UB+:A:;HT(T[4&$K&0
MC6KO 3Y.;Y$!,]+F29'(>M?E;5[K)UI S)):[35Z3"<)F! .>[JH ,?VEMQE
MX*BA5S^BZ\;C"Q6/S.OPN.Q:^4;R;] G38P!H C-#K-UPQ)M3@>%2O!8#RTV
MVIL '  G:#:7;3=!W9U7C.'I7'0P>0'D*V*BVG> "VU;BC$N,EHR(N]?2$02
M/[Q;W,9YD/J1-,9#6*V4#=;SSV(&>&RIH@'8PX[*J?3^X26>DYLT]"-)-(*\
M9G'Y.,)ZG+ YD0)  )=HT3Q'??\<QDD@B^X1UUJCQ=0M&M$'@ &H0XO\.>KW
M[R3-_ADDRR *=/D[KEK>,F-EV&A.H@@1P"1BZ!"D>=T*$B&I5J6*FXLF#V5D
M )NXKV9=^2M_2=(I>Y$D92! 2TBUH#?I8&HPRF+GV47X6 ""<)_-FD91[H?%
MP]+3["E8D;O%[BH27#=%E2A8),?5QL0IX (BPW&M('O]OENPIP=^Q/">QRGK
M3;IV+HU:E%7@ $SAIHPZZ.ZMOPIF&>N< E6;PA2<J^NB  ] %F[HS4%_OP5^
M^NK#]A).60K-SB!93:H.X !,82<XV>ON=);%L+7QJ"2%A7E$,\;2'AB (V1+
M2;6SKV&N3A,K3,'9Z112@ZD='H LC- 84PE-R]=(I^SY0C)_BHMKI7L6@BWP
M)-!JQYM@I:!N,A(:0 4&"6JP3OV8Y/4!Z=X/YIHY4*LUJ720LND8&0@JX #J
M,8* S%'_&.?+EZP>^7MUJ83L3$K0@/XC>,  P#7L'&QHCR1* RHOI=U\4[CP
MGNV?A>IU! F@#,W_1;KC7 5IE@3/.2MR3Y(@!M^VK]%4Z3WGX#K=&#"0LP[7
M6B0%Q-ZY+7]1>Q#LFB@#&5PU6=0!"I".:WC2 &)P+1 U6LKK;%<%)>C 4+'(
M['49O_H_X@C,O\TM7"9\/X-;  XD@#+4)#/6O4DQ[HQ''9=/Z%HH@2&A;6Y[
M(\ES;,^@N$_B,F)->SAL:WJ=[F@R&3NX^VL#! 9!2V8\I1L,*C75"XRB: EN
M@A2D9?@.HX((H OW"?;*8+L,_6#%7HE8!6E*0%.9:M72DQ(K^W1SC4L'(4!O
M2T8S;1U\JR(R5Z @^I]!5$/GYC2R=IZUTYV^B9(MQ J0CY&JQY(GXJADNI8&
M5->^,3D"!]"N;71#4\/6RL7G.+F.WH(DCAA,/SS*?BH8!:I-E%)ST5&K/E+@
MQ0)D8URUOW?1(1[_>WI/:(>YEZ>Z393"Z)Z'"J"(%* =UQRW>W;F;G$?O^9A
MP<'=8C]/R.]!R(;WR@_#]P<2$I:H*9VR2V$5'TUS7V"B[/>P,L0U'C2G$ 0P
MIJRQVTVSIQ=2.K#>^GDT>]F^9J[FT@M47J?<<U6=U,0(D(P6+;A3@DH=^"::
MA?F<XI^&[%V8=^8W(#\UP'7+..*>J^SJ003(Q761XZFY3R19Z9P%6?EU1+BK
M/MUR6 ![N,:VS2.""]H!BG;OR)K]_D*_EM*%9SK[,Z=;3I%++$XST/^Q3EMK
M\3B[3S>"#(P(7'O>&M)3_&F=WZ\P4Q6,B*:UI-H:M(/7*WKH $IQ;7C[VB0T
M+ M;Y U+%OAR$]T&)-\J%PPTVX=^BRB6O1&^B?!44>;-?Y6)?#S 2D=K5,$_
MI7" \8CKAU?5>C9PGN(RQZ2J0EBM5\ >8Z5K-ZX,PO  5G&C,A6&\4;)-;*^
MG.I[:S$[:'EN22S XYW-;9*_[LN:(OVC*G_VNP,"R(^,T/YNY7A$ 1/)ZXN?
MK/XVBU?E9^D9*UZ1)_\'/5'/YT$)XR9:,%,*^\<5R?P@_+D]$_JV0U=!.@OC
M-$_(]#G-$I]K^5"HY75V%R=-9O3V$T6T/S0/#TO1;V,EM%:7#&?:<%$ CS0@
M/I\Q)T$YI.@/NY%$_^'=DJ4?7M.E(H/>3^248C@QSUY<J1^R _<:2-AH)3ME
MY\'T9=4B%&$?Z:P$R_N8%TZ7@801%C_0].#3S57PI,GV[TP,F+JEPF3A]1>(
MZ["=$>&+67LE&$K$%]&KT@;X..@K<.GOB*L''8"7M(M!Z5A*U2;F.RY)F@_6
M81+!U+05YI0J!N!0YC*KP@>Y%6LRZ2"GS)<QI\'W$2[@,.0(Z]OA/\VSES@)
M=N^5JYP\CBHQ]1K3\U9C-DM!\(EUQ1^/#T\ZET75F%R0WT>0DJ;#]0$J/MLM
M&=2:LYTF/@GW 4H?P8"J4'E@W<%JT 7P+,8$G.9;\J4SL4.7D7AR76M7CJV!
MF'<D>OK54;\!RC L,(TH4U&B]DLR^$A^KB(Z),0=]!V@#M?=C';UOXB?T-;'
M3W'WHM,1Y]H%BJ_]-/&U6H[8.:9-*0J JM,[C1D( HR6[ +^/D]F+WY*=A<G
MG]XO_8PLX^3];L$N3#8E9*MGS1:9]#&=&S36V68(@;'BRGM_,'@ NG3EKMDB
M$R>22[N9@: [N%2D 0PN5RQC!A^3''=&J($N&NN)# - JGL/"^Z>X]-C=/.$
M'Y4']M%*QI4RPQ5, ,>GS\I?ZWZA>.>6K4F/,Q+Y5(42W/YPRWK#46^,FL1/
M\2Y(W'N M=._0%B/M36$WZ+TE<R"12#8G(7E2_Q(-WER5C@L2I$ 3*+E;ML.
MSUO9(QC')9F)Q_*M3]QSP"_!%3L32T@_RX(WL@7X0(?K YG%T2P(@Y*+[#.9
ML\=:V%#.:1_>#PH+]D<#K3-SGA4#I$H\?_<TAQ@86+A1H2RD?9:1^<WJU0\2
MMJI1#7_3^4\D(HL =.%4J5OJ)E;8,,5\ZR,"^,3P8&ITQ[3.:@"3+:E!M['.
M9&*%&X#:E);A (C5-JBA974H ;+0]<]44*4'<AY$R[M7ND@Q6.DGLHB3W9)&
MTJ]!5%RYW$1T.)*4>2X?MG+]9U[<R&0O,?W+&RW"IH?\HKF57E#JNA=V6/!T
MAF"[L@&&M;;M;TXG2U0X7G_)@[D?S0C6NN6O@JB0UG6:!2NZT[)P^S0-J.+'
MA**VE$D:6=O9W5S>E+$!8\,5TQT;[A'3NWZG,X1<Q=_%7A+5PF4 8-\*BX J
MQS &@$O<N%2.&GVH0J^#6O9@922Z6RQ Y;-N@VM!6>$*K**2-L<)#(CF7F[M
M1/P4#Y.PEPVS=*>7IP]T?TOR69:SR&VZ%Q:E"ED^SE[(/ _I6J=;4S=V"!CK
MU0_LOBT(#%*LZ75ZDPL#\Q'^4A'E+@P94JG+^HFYGBI+DC/E-/!]@!"C'NJS
M[AI<'#()8SGKP*/>!&EC@^5]S NGRZB!1_762*EQ7+4^$P'FV;7V'*N#TL)X
M)IV#QIYAD#E+W%+%;%YJ&/\@X?QSG/PF3)FJ5)])"O.1(DU&@1.*!E*W(ZH^
MY2F5"$L3N7I>'[>W0?]48E$:S-=&G6F2L&BR0@N]?&$_WJSU=_;J [?*;> _
M4U4_>^\(1E5+/6!L8=I!C(S+=F5E**H,S9)\('(JA&0IS 7,*\XD@7G_8V34
M"("AAI!!*7J8(K;+ I(>9;'=.PX7Q]_U30B<NZ=N@UZG?X&9%+ 1^T:@HT:B
M00X>N]-P-#\0$>CH =9@,"T^(2HP+,5F*KPL+A)&VVX_,Y)6!\4TUM^^^&BW
M::R/>E6I+,G:IK&^(-3 2C-+3=-8'_6!"PTN%$QC??@]BS,QC?6Q4E7 \I:9
MQOIP9@J;<_)L\NHFCR1Y"V:B]#R\HDPXF'D(:D\L"2 +35]J1*94"&LXJ=!I
M&RS/)(!T")20 C((@G#;6E5>(V]]V&_91Q@1*DE#N+685# OTVO/5G5L;N<&
M O I9A,!ZC')(-FHU7G3XOL EX5Y@52CHKZ0>)G0,V P\T.5R*AJ>397G)S/
M*J@L3 LDXY4LJWC$<5-0>28!)(\,%68X7$J06)CTY^21BX/.H-=W\M IQV0J
MP8]K\8P%?J3SCIP5#HM2)*;R_IB*9VS/D:./FH^Y]N2L@Q(W0Y"!Y$[1DOG!
M%X;Q/:C2.TYQ128<S.A&31+Y&K(21%-IA]#NMC^.W\9H,.[U+-8:U$9EV])R
M/%>2$=<-W+?=C P; 3!3"8N0(^(H0D*E^D(E=$7>2!B_,A')WV\7UBON $?N
MKQJ*($VE.0*'@IUW_70M?8VCPG5E40B5UHUG 3T0S'\/LI>#BO>A'VU?."T*
M/Y"0E7R*KW\$S'?B*DA?XY0>ZUG $A4"T8ZH,;OJ%>X<11=W/5)XFT>Y#3I\
M>IU6I_HNM@GHI-!%H48K#"*RG5>7#OXZH(_Y(S@P]) <4>JSHN+*T(.CW:UD
M3]^5H8=D+X+E+75EZ(&&(517AMH:=9RNW05)\B9+%"FIR:2#G$VTZ4340VJA
M)X2.Z8BV79&3/$,X5(=)!$G)UN,,,!5)<+GM+'&]>@WC=T(>Z<DA8<J\]&$&
MH :3!G9&> E3?'[%>-QVC"B.00<"D=(+5:'RZ",GAZW'KP20A7X0J+Y.O<E%
MMX_\C(ZIK5H%IR%_"4-7LNA.3TPL RO>UQ'3ID5X!9LAMXKV*1>H,:(;7IWJ
M;#XA^4:UJ*A7X3K^\I*9BY >\JJOP9?6/4C/X#M-G*M<.\W>C_EJY;/'+ Z+
MS&9)[H?G;[3>/DY]OD9K+(>JNG28,%H+7*^L-'O6-5KWD2\D]%E1,5KWP2N'
M<S%:8VG.L+RE1FM8(<9-356]<.5/'Z@H0^^4O?EX#DF@H1J8U3@#9PY<F('#
M#,V Y2TGYP !JE48HF=MZ63OGZW=R\3/2X(5&$C,C#<BR?.(DN! -?("9*T3
MK1S@%+,%UV P,5UV->F2 G';9MN.%0<KAL;4]E<#KH6A;W6'Q1JAZC!8%V?J
M')(W:PVZ%/@^Q-74;CLI^8VHHDS'7_DV\6/F)]EITJF6MI;[)'X+4MIE:-D6
M5F+(D1V8:C.JC*ZQ]?606%-L_I8%8?#O4MQKTQK$(:<HPX9\ FG&'(S)\4?O
M#2VTR+<D)UMHX>L0=2L-;Z6]C@YF9CMF\VL_B2B\(J4A[<8C_2LQDOVMN>/-
MNF?;7LD-X% 5KS.88#EI3Z,LF =ASM[O>"0S.IB8Z??Z!W.B)_/RZ:?5:UY2
M>K>H0E WB9OX$!,4LEHLX5!F)#<HA0]@1Q]@)1D_*7$*IO8!G'/\3$SMPPLD
MY0J6M\S47G39;?_PAJ/XTSN_ 8F[V@F_RJBS)D#D9&M$>X)TV^V=#^^;OR)2
MKSI9528?Y!/#Z=G7&75'HG';C_XRCMY(DK&<$O>;_CYF\>P/J<.UI";;-Y!M
M>HH$\ME7@^>VFWW#F:5B]3?U"<:5-1?CMF]X5:FY?>_44!AE>I'3#=&R?29I
M9,<VPX/F)"/S0%ANWWL=Z1E^&LP$PXQ;WAMUQ@.LY(^M#APQ?$.A#6@9JZKH
MKI@X=R9?A>&PKE%*Q&V-N]Z J K 5&P#VICXG03+%^99S.(SE^1;SO3&N\4:
M9X$YO<NS-/.C.?]]GYHM%5EWNL./L!W5ELS)[@+;N1^:SF;Y*B_\48H;3B;*
MA+R0*-V^1\ZNCMJ_'?HS9\9%A3NA@X(LQ.VB.VCW+F@3;2>]RSDH6'85>6X!
MT@-N8?C]-W2/TBR:\%17* 5([&A@OMSEUR";SANZ"#DU0[IW( 4\)+=.D;@E
M]R";;ANZ"6D_"G<['LO58Y=@3G*-(:Q7B&6 ?5VI,M/TX!BZ$&B?Y0HJZ04
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M)U^)G^9)L59NW^3<QM47<KKTDR0@\VFVK=/ZO=3VRV42.I:F+/"?@W"=++]
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M^JHW=<!=4F*LJA9"B9U.7YTBG7F%:#=):4[8[O35QSC:PE>_WY.U3LU1WN,
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M-C V-C9D,3!Q+FAT;5!+ 0(4 Q0    ( *B ^U1.,8S!W0<  -,H   1
M          "  >7/ @!D,S8P-C8V9&5X,S$Q+FAT;5!+ 0(4 Q0    ( *B
M^U0 /;R^UP<  ,0H   1              "  ?'7 @!D,S8P-C8V9&5X,S$R
M+FAT;5!+ 0(4 Q0    ( *B ^U0)(Z8VCP0  +<0   0              "
M ??? @!D,S8P-C8V9&5X,S(N:'1M4$L! A0#%     @ J(#[5 ,2;_/^&P
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M,#(R,#8S,%]L86(N>&UL4$L! A0#%     @ J(#[5'IU_\TG?P  P),( !4
M             ( !\1X$ '1E=F$M,C R,C V,S!?<')E+GAM;%!+!08
.."0 ) $0"  !+G@0    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
